

Pancreatitis

NICE guideline NG104

Appendices A – Q

September 2018

Final

*Developed by the National Guideline Centre,
hosted by the Royal College of Physicians*

Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and, where appropriate, their carer or guardian.

Local commissioners and providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

Copyright

© NICE 2018. All rights reserved. Subject to [Notice of rights](#).

ISBN
978-1-4731-3083-8

Contents

Appendices.....	5
Appendix A: Scope.....	5
Appendix B: Declarations of interest	17
Appendix C: Clinical review protocols.....	40
Appendix D: Health economic review protocol	77
Appendix E: Clinical study selection.....	79
Appendix F: Health economic study selection.....	103
Appendix G: Literature search strategies	104
Appendix H: Clinical evidence tables.....	178
Appendix I: Health economic evidence tables.....	383
Appendix J: GRADE tables	393
Appendix K: Forest plots	463
Appendix L: Excluded clinical studies	516
Appendix M: Excluded health economic studies.....	577
Appendix N: Unit costs	580
Appendix O: Research Recommendations	585
Appendix P: NICE technical team.....	598
Appendix Q: References	599

Appendices

Appendix A: Scope

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Guideline scope

Pancreatitis: diagnosis and management

Topic

The Department of Health in England has asked NICE to develop a clinical guideline on the diagnosis and management of pancreatitis.

This guideline will also be used to develop the NICE quality standard for pancreatitis (including acute pancreatitis).

The guideline will be developed using the methods and processes outlined in [Developing NICE guidelines: the manual](#).

For more information about why this guideline is being developed, and how the guideline will fit into current practice, see the [context](#) section.

Who the guideline is for

- People using services, families, carers and the public.
- Healthcare professionals.
- Clinical commissioning groups.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK provinces are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#).

Equality considerations

NICE has carried out [an equality impact assessment](#) during scoping. The assessment identified no equality issues relevant to the scope.

1 What the guideline is about

1.1 Who is the focus?

Groups that will be covered

- Children, young people and adults with acute or chronic pancreatitis.

Groups that will not be covered

- Children, young people and adults with pancreatic cancer.

1.2 Settings

Settings that will be covered

- All settings in which NHS-commissioned care is provided.

1.3 Activities, services or aspects of care

We will look at evidence on the areas listed below when developing the guideline, but it may not be possible to make recommendations on all the areas.

Key areas that will be covered

- 1 Fluid resuscitation for people with acute pancreatitis.
- 2 Using antibiotics to prevent infection in people with acute pancreatitis (including who should be offered antibiotics and which type of antibiotic they should be offered).
- 3 Referring people with acute pancreatitis to specialist centres.
- 4 Managing necrosis in people with acute pancreatitis.
- 5 Managing nutrition in acute pancreatitis.
- 6 Assessing aetiology of acute pancreatitis.
- 7 Diagnosing chronic pancreatitis.
- 8 Assessing aetiology of chronic pancreatitis.
- 9 Managing pain in people with chronic pancreatitis.
- 10 Managing biliary obstruction in people with chronic pancreatitis.
- 11 Managing malabsorption or malnutrition in people with chronic pancreatitis.

- 12 Follow-up for people with chronic pancreatitis.
- 13 Surveillance for pancreatic cancer in people with chronic pancreatitis.
- 14 Managing pancreatic ascites and pleural effusion secondary to acute or chronic pancreatitis.
- 15 Managing diabetes secondary to pancreatitis (type 3c diabetes).
- 16 Lifestyle interventions for people with acute or chronic pancreatitis.
- 17 Information and support for people with acute or chronic pancreatitis, their families and carers.

Areas that will not be covered

- 1 Diagnosing and managing pancreatic cancer.
- 2 Diagnosing acute pancreatitis.
- 3 Managing gallstones.
- 4 Duodenal obstruction.
- 5 Managing haemorrhage secondary to pancreatitis.

1.4 Economic aspects

We will take economic aspects into account when making recommendations. We will develop an economic plan that states for each review question (or key area in the scope) whether economic considerations are relevant, and if so whether this is an area that should be prioritised for economic modelling and analysis. We will review the economic evidence and carry out economic analyses, using an NHS and personal social services (PSS) perspective, as appropriate.

1.5 Key issues and questions

While writing this scope, we have identified the following key issues and draft review questions related to them:

- 1 Fluid resuscitation for people with acute pancreatitis
 - 1.1 What is the most clinically and cost-effective type of intravenous fluid for resuscitation in people with acute pancreatitis?
 - 1.2 What is the most clinically and cost-effective speed of administration of intravenous fluid for resuscitation in people with acute pancreatitis?

- 2 Using antibiotics to prevent infection in acute pancreatitis (including who should be offered antibiotics and which type of antibiotic they should be offered)
 - 2.1 What is the clinical and cost effectiveness of prophylactic antibiotics to prevent infection in people with acute pancreatitis?
- 3 Referring people with acute pancreatitis to specialist centres
 - 3.1 What are the indications for referring people with acute pancreatitis for specialist input or to a specialist centre?
- 4 Managing necrosis in people with acute pancreatitis
 - 4.1 What is the most clinically and cost-effective method for managing necrosis in people with acute pancreatitis?
- 5 Managing nutrition in acute pancreatitis
 - 5.1 What is the most clinically and cost-effective route of feeding for people with acute pancreatitis?
- 6 Assessing aetiology of acute pancreatitis
 - 6.1 What is the clinical and cost effectiveness of assessing the aetiology of acute pancreatitis to prevent recurrent attacks?
- 7 Diagnosing chronic pancreatitis
 - 7.1 What is the most clinically and cost-effective method for diagnosing chronic pancreatitis?
- 8 Assessing aetiology of chronic pancreatitis
 - 8.1 What is the most clinically and cost-effective investigative pathway (including testing for genetic markers and auto-antibodies) for identifying the aetiology of chronic pancreatitis?
- 9 Managing pain in people with chronic pancreatitis
 - 9.1 What is the most clinically and cost-effective strategy for managing pain in people with chronic pancreatitis secondary to pancreatic duct obstruction, with or without an inflammatory mass?
 - 9.2 What is the most clinically and cost-effective strategy for managing pain in people with chronic pancreatitis secondary to pseudocysts?
 - 9.3 What is the most clinically and cost-effective strategy for managing pain in people with chronic pancreatitis secondary to small-duct disease?
- 10 Managing biliary obstruction in people with chronic pancreatitis

- 10.1 What is the most clinically and cost-effective intervention for treating biliary obstruction in people with chronic pancreatitis?
- 11 Managing malabsorption or malnutrition in people with chronic pancreatitis
 - 11.1 What is the most clinically and cost-effective intervention (including dietary advice) for managing malabsorption or malnutrition in people with chronic pancreatitis?
- 12 Follow-up for people with chronic pancreatitis
 - 12.1 What investigations should be conducted during follow-up for people with chronic pancreatitis?
 - 12.2 Where should follow-up for people with chronic pancreatitis take place – primary, secondary or tertiary care?
- 13 Surveillance for pancreatic cancer in people with chronic pancreatitis
 - 13.1 What is the best assessment for surveillance for pancreatic cancer in people with chronic pancreatitis?
 - 13.2 What is the clinical and cost effectiveness of routine surveillance for pancreatic cancer in people with chronic pancreatitis?
- 14 Managing pancreatic ascites and pleural effusion secondary to acute or chronic pancreatitis
 - 14.1 What are the most clinically and cost-effective interventions for treating pancreatic ascites and pleural effusion secondary to acute or chronic pancreatitis?
- 15 Managing diabetes secondary to pancreatitis (type 3c diabetes)
 - 15.1 What are the most clinically and cost-effective management strategies specifically for diabetes secondary to pancreatitis (type 3c diabetes) that is difficult to control?
- 16 Lifestyle interventions for people with pancreatitis
 - 16.1 What is the effectiveness of stopping or reducing alcohol consumption in reducing recurrent episodes of acute pancreatitis and improving quality of life in people with both chronic and acute pancreatitis?
- 17 Information and support for people with acute or chronic pancreatitis, their families and carers

17.1 What information and support should people with acute or chronic pancreatitis, their family and carers receive after diagnosis?

1.6 Main outcomes

The main outcomes that will be considered when searching for and assessing the evidence are:

- 1 Health-related quality of life.
- 2 Mortality.
- 3 Pain.

2 Links with other NICE guidance, NICE quality standards, and NICE Pathways

2.1 NICE guidance

NICE has produced the following guidance on the experience of people using the NHS. This guideline will not include additional recommendations on these topics unless there are specific issues related to the diagnosis and management of pancreatitis.

- [Patient experience in adult NHS services](#) (2012) NICE guideline CG138
- [Medicines adherence](#) (2009) NICE guideline CG76
- [Medicines optimisation](#) (2015) NICE guideline NG5
- [Antimicrobial stewardship](#) (2015) NICE guideline NG15

NICE guidance that is closely related to this guideline

Published

NICE has published the following guidance that is closely related to this guideline:

- [Intravenous fluid therapy in children and young people in hospital](#) (2015) NICE guideline NG29
- [Gallstone disease: diagnosis and initial management](#) (2014) NICE guideline CG188

- [Intravenous fluid therapy in adults in hospital](#) (2013) NICE guideline CG174
- [Alcohol-use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence](#) (2011) NICE guideline CG115
- [Alcohol-use disorders: diagnosis and management of physical complications](#) (2010) NICE guideline CG100
- [Alcohol-use disorders: prevention](#) (2010) NICE guideline PH24
- [Nutrition support for adults: oral nutrition support, enteral tube feeding and parenteral nutrition](#) (2006) NICE guideline CG32
- [Endoscopic transluminal pancreatic necrosectomy](#) (2011) NICE interventional procedure guidance IPG411
- [Percutaneous retroperitoneal endoscopic necrosectomy](#) (2011) NICE interventional procedure guidance IPG384
<https://guidance.nice.org.uk/IPG384>
- [Autologous pancreatic islet cell transplantation for improved glycaemic control after pancreatectomy](#) (2008) NICE interventional procedure guidance
- [Laparoscopic distal pancreatectomy](#) (2007) NICE interventional procedure guidance IPG204

In development

NICE is currently developing the following guidance that is closely related to this guideline:

- [Pancreatic cancer](#) NICE guideline. Publication expected January 2018
- [Endoscopic transluminal pancreatic necrosectomy](#) NICE interventional procedure. Publication expected November 2016

2.2 NICE quality standards

NICE quality standards that may use this guideline as an evidence source when they are being developed


Pancreatitis (including acute pancreatitis) NICE quality standard. Publication date to be confirmed.

2.3 NICE Pathways

NICE Pathways bring together all NICE guidance and associated products on a topic in an interactive flow chart.

When this guideline is published, the recommendations will be incorporated into a new pathway on pancreatitis.

An outline of the new pathway, based on the scope, is included below. It will be adapted and more detail added as the recommendations are written during guideline development.



3 Context

3.1 Key facts and figures

Acute pancreatitis

Acute pancreatitis is acute inflammation of the pancreas and a common cause of acute abdominal pain. The incidence in the UK is approximately 56 cases per 100,000 people per year. In the UK approximately 50% of cases are caused by gallstones, 25% by alcohol and 25% by other factors. In 25% of cases acute pancreatitis is severe and associated with complications such as respiratory or kidney failure, or the development of abdominal fluid collections. In these more severe cases people often need intensive care and a prolonged hospital stay, and the mortality rate is 25%, giving an overall mortality rate in acute pancreatitis of approximately 5%.

A small proportion of people with severe acute pancreatitis will develop pancreatic necrosis, and some of these people will need treatment for infected necrosis. Treatment may be by surgery, endoscopy or interventional radiology. Acute pancreatitis is a self-limiting condition and the majority of people who recover will return to normal activities. They will then need treatment, often cholecystectomy, to eradicate the cause of the pancreatitis. If the cause can be found then appropriate treatment can prevent recurrent attacks.

Chronic pancreatitis

Chronic pancreatitis is a continuous prolonged inflammatory process of the pancreas that results in fibrosis, cyst formation and stricturing of the pancreatic duct. It usually presents with chronic abdominal pain but may be painless. The clinical course is variable but most people with chronic pancreatitis have had one or more attacks of acute pancreatitis that has resulted in inflammatory change and fibrosis. In some people, however, chronic pancreatitis has a more insidious onset. The intensity of pain can range from mild to severe, even in people with little evidence of pancreatic disease on imaging.

The annual incidence of chronic pancreatitis in western Europe is about 5 new cases per 100,000 people, although this is probably an underestimate. The male to female ratio is 7:1 and the average age of onset is between 36 and 55 years. Alcohol is responsible for 70–80% of cases of chronic pancreatitis. Although cigarette smoking is not thought to be a primary cause in itself, it is strongly associated with chronic pancreatitis and is thought to exacerbate the condition. Chronic pancreatitis may be idiopathic or, in about 5% of cases, caused by hereditary factors (in these cases there is usually a positive family history). Other causes include hypercalcaemia, hyperlipidaemia or autoimmune disease.

Chronic pancreatitis causes a significant reduction in pancreatic function and the majority of people have reduced exocrine (digestive) function and reduced endocrine function (diabetes). They usually need expert dietary advice and medication. Chronic pancreatitis can also give rise to specific complications including painful inflammatory mass and obstructed pancreatic duct, biliary or duodenal obstruction, haemorrhage, or accumulation of fluid in the abdomen (ascites) or chest (pleural effusion). Managing these complications may be difficult because of ongoing comorbidities and social problems such as alcohol or opiate dependence. Chronic pancreatitis significantly increases the risk of pancreatic cancer. This risk is much higher in people with hereditary pancreatitis.

3.2 Current practice

People with acute pancreatitis usually present to their local hospital as an emergency with acute abdominal pain. If organ failure (usually respiratory or kidney failure) occurs, then admission to intensive care is necessary. About 75% of people recover quickly; the remainder develop severe acute pancreatitis that is associated with organ failure, or with intra-abdominal fluid collections or pancreatic necrosis. The amount and type of fluid resuscitation varies. The use of prophylactic antibiotics also varies.

Interventions such as drainage of necrotic collections are offered locally or by referral to a pancreatic centre. There is uncertainty about where these interventions are best offered. Techniques used to treat infected necrosis

vary. Open surgery is the conventional technique but percutaneous (radiological) and endoscopic techniques have been developed and are in widespread use. These less invasive techniques are not used in all hospitals managing acute pancreatitis because of limited availability of expertise.

Variation also exists in the care of people with chronic pancreatitis. Newer techniques for the diagnosis and assessment of chronic pancreatitis are available but are not in widespread use. There is uncertainty about using tests for hereditary pancreatitis and autoimmune pancreatitis. This is of particular concern in children with pancreatitis.

The indications for referral to specialist centres vary significantly in chronic pancreatitis. Surgical and endoscopic management of complications is very well developed in some specialist centres and less so in others. Use of enzyme replacement therapy and specialist advice also varies.

There are many interventional treatments available for pain caused by pancreatic duct obstruction associated with chronic calcific pancreatitis. These include surgery, endoscopy and extracorporeal shockwave lithotripsy for pancreatic stone destruction. Availability of these treatments varies from hospital to hospital and region to region. For people whose only treatment option is total pancreatectomy, islet auto-transplant is available.

Support for people with pancreatitis, their families and carers also varies widely. In some regions there are specific pancreatitis nurse specialists and patient support groups.

3.3 Policy, legislation, regulation and commissioning

Policy

Service specifications for adults are set out in the [NHS England 2013/14 standard contract for hepatobiliary and pancreas \(adult\)](#). The Association of Upper Gastrointestinal Surgeons' [provision of services document](#) also provides guidance on service configuration.

Legislation, regulation and guidance

The British Society of Gastroenterology's [UK guidelines for the management of acute pancreatitis](#) (2005) have been used extensively but are now out of date. The American College of Gastroenterology published a comprehensive guideline on the [management of acute pancreatitis](#) in 2013. However, this guideline is mainly written by and for US physicians, whereas the majority of people with pancreatitis in the UK are cared for by gastrointestinal surgeons.

Guidelines on chronic pancreatitis sponsored by [United European Gastroenterology](#) are in preparation, with publication expected in late 2016 or early 2017.

Commissioning

Services for pancreatitis are commissioned by clinical commissioning groups unless tertiary care is provided by pancreatic centres, in which case specialised commissioning is responsible.

4 Further information

This is the final scope, incorporating comments from registered stakeholders during consultation.

The guideline is expected to be published in September 2018.

You can follow progress of the [guideline](#).

Our website has information about how [NICE guidelines](#) are developed.

Appendix B: Declarations of interest

B.1 Richard Charnley (chair)

Meeting	Declaration	Classification	Action taken
Initial application	None	-	-
GC 01	None	-	-
GC 02	None	-	-
GC 03	None	-	-
GC 04	None	-	-
GC 05	None	-	-
GC 06	None	-	-
GC 07	None	-	-
GC 08	None	-	-
GC 09	None	-	-
GC 10	None	-	-
GC 11	None	-	-
GC 12	None	-	-
GC 13	None	-	-

B.2 Alex Horton (radiologist)

Meeting	Declaration	Classification	Action taken
Initial application	Local radiologist for the following trials: <ul style="list-style-type: none"> • Epock and STOP HCC, both commercial trials funded by BTG UK. • TACE2 trial: Closed prior to recruitment at local site. • Sillajen (PHOCUS) study: Funded by Sillajen, San Francisco, USA 	Non-specific non-personal non-financial	Declare and participate
GC 01	None	-	-
GC 02	HCC Round table meeting in London 22/3/16. Paid honorarium by Bayer. Not related to pancreatitis	Non-specific Personal Financial	Withdraw from the nutritional intervention protocol discussions because it was initially thought to be Specific personal financial classification. Bayer previously involved in enzyme replacement

Meeting	Declaration	Classification	Action taken
			therapy. However, have not been involved with this for some time. ^a
	BTG Rep training event DC Beads in TACE 5/3/15. Paid attendance. (entry left in register as in GC minutes on NICE website)	Non-specific Personal Financial (item over 1 year old)	Declare and Participate
GC 03	None	-	-
GC 04	None	-	-
GC 05	None	-	-
GC 06	HCC round table meeting in London, April 2017. Paid honorarium by Bayer. Not related to pancreatitis	Non-specific Personal Financial	Withdraw from the nutritional intervention protocol discussions because it was initially thought to be Specific personal financial classification. Bayer previously involved in enzyme replacement therapy. However, have not been involved with this for some time. ^b
GC 07	None	-	-
GC 08	None	-	-
GC 09	None	-	-
GC 10	None	-	-
GC 11	None	-	-
GC 12	None	-	-
GC 13	None	-	-

^a Later found to not be a conflict.

^b Later found to not be a conflict.

B.3 Amy Lucas (lay member)

Meeting	Declaration	Classification	Action taken
Initial application	None	-	-
GC 01	None	-	-
GC 02	None	-	-
GC 03	None	-	-
GC 04	Liverpool patient group member for pancreatitis, delivered talk on NICE guideline experience. February 2016.	Specific personal non-financial	Declare and participate
GC 05	None	-	-
GC 06	Will be doing a talk about the scope of this guideline at the Liverpool National Pancreatic Patients Forum – 5 May 2017. Will only mention what is available online.	Specific personal non-financial	Declare and participate
GC 07	None	-	-
GC 08	None	-	-
GC 09	None	-	-
GC 10	None	-	-
GC 11	None	-	-
GC 12	None	-	-
GC 13	None	-	-

B.4 Ashraf Rasheed (upper GI surgeon)

Meeting	Declaration	Classification	Action taken
Initial application	None	-	-
GC 01	None	-	-
GC 02	None	-	-
GC 03	None	-	-
GC 04	None	-	-
GC 05	None	-	-
GC 06	None	-	-
GC 07	None	-	-
GC 08	None	-	-

Meeting	Declaration	Classification	Action taken
GC 09	None	-	-
GC 10	None	-	-
GC 11	None	-	-
GC 12	None	-	-
GC 13	None	-	-

B.5 Ganesan Baranidharan (pain specialist)

Meeting	Declaration	Classification	Action taken
Initial application	My special interest is in Neuromodulation for Pain Management. I am considered an International Key Opinion Leader in this field.	Non-specific personal non-financial	Declare and participate
	Have been on the Advisory Board of various Neuromodulation Companies.	Non-specific personal financial	
	In 2016 I attended a Neuromodulation training weekend with Boston Scientific in Budapest at their cost.	Non-specific personal financial	
	21st April 2015 Lecturing at a GP education meeting sponsored by Grunenthal specifically educating regarding Palexia: fee for the event was £200. Other drugs produced by Grunenthal are Arcoxia(R) Tramacet (R) Versatis (R) Zydol (R)	Specific personal financial – over one year ago	
	In 2014 I attended 2 Neuromodulation training weekends paid completely by Medtronic both in Europe. On 27th June 2015 I attended a Neuromodulation training weekend with NEVRO Corp in Budapest at their cost.		
Initial application	International Advisory Board for St Jude Medical and Nevro Corporation. Advisory Board member of a new start-up company Nalu Medical (paid for number of hours' advice). (develop neurostimulation for chronic pain management, not an intervention considered in guideline).	Non-specific personal financial	Declare and participate
	Un Restricted Educational Grant Nevro Corporation – Currently running a study on managing Low back pain using neurostimulation (NHS portfolio study)	Non-specific Non-personal financial	
	St Jude Medical – Have been offered an Educational Grant to do a Pilot RCT on use of Dorsal Root Ganglion Stimulation for managing Pain secondary to Pancreatitis (develop neurostimulation for chronic pain management, not an intervention considered in guideline).	Non-specific Non-Personal financial	

Meeting	Declaration	Classification	Action taken
	St Jude Medical and Nevro – Grant for a Research Nurse organised by the Trust (develop neurostimulation for chronic pain management, not an intervention considered in guideline).	Non-specific Non-personal Financial	
	Secretary, Neuromodulation Society of the UK and Ireland	Non-specific personal Non-financial	
GC 01	None	-	-
GC 02	None	-	-
GC 03	Dec 2016 - Cadaver Workshop in Barcelona organised by ECMT (http://ecmt-training.com/) Attended as an invited Faculty with Honorarium	Non-specific personal financial	Declare and participate
	Dec 2016 – European Advisory Board for Boston Scientific as a Consultant (Paid Personal)	Non-specific personal financial	Declare and participate
	Nov 2016 – Represented Nevro Corporation as a Clinical Expert (paid Personal) for a Court Hearing on Patent	Non-specific personal non- financial	Declare and participate
GC 04	Had an advisory board meeting on 20th January 2017 at North American Neuromodulation Society Meeting, Las Vegas. This is for advice on their development of the neuromodulation device and plans for their clinical study looking at back pain.	Specific personal non-financial	Declare and participate
GC 05	Two day International Executive Advisory Board meeting Abbott (previous St Jude Medical). Financial as per previous declarations – ongoing consultancy agreement. Invited article on abdominal pain by Mundipharma.	Non-Specific personal financial	Declare and participate
GC 06	Conducted a course on Neuromodulation aimed at advanced pain trainees, sponsored by Industry and approved by Royal College of Anaesthetists in March 2017.	Non-specific personal financial	Declare and participate
GC 07	Attended International Neuromodulation Society Meeting in Edinburgh as a Faculty. This waived my registration fee and my stay. Attended International Advisory Board on Peripheral Nerve Stimulation for treating Chronic Pain. This meeting was to advice on development of a new product (30/05/2017). Paid role, not related to Pancreatitis.	Non-specific personal non- financial Non-specific personal financial	Declare and participate
GC 08	None	-	-
GC 09	None	-	-

Meeting	Declaration	Classification	Action taken
GC 10	None	-	-
GC 11	None	-	-
GC 12	Attended user roundtable conference on improving outcomes in Neuromodulation - Sponsored to travel and stay for the meeting in New York as an Expert in Neuromodulation (2 nd December 2017).	Non-specific, personal non-financial	Declare and participate
GC 13	None	-	-

B.6 James Shaw (diabetes specialist) – co-opted member

Meeting	Declaration	Classification	Action taken
Initial application	Member of the Medtronic UK Scientific Advisory Board	Non-specific personal financial	Declare and participate
	Received travel support from Novo Nordisk to attend and present data at the American Diabetes Association Annual Scientific Sessions, New Orleans, June 2016	Non-specific personal non-financial	
GC 01	None	-	-
GC 02	None	-	-
GC 03	None	-	-
GC 04	None	-	-
GC 05	None	-	-
GC 06	None	-	-
GC 07	None	-	-
GC 08	None	-	-
GC 09	None	-	-
GC 10	None	-	-
GC 11	None	-	-
GC 12	None	-	-
GC 13	None	-	-

B.7 Jonathan Booth (non-specialist gastroenterologist)

Meeting	Declaration	Classification	Action taken
Initial application	Annual meeting sponsored by Mylan - they make creon, does not get paid but the company helps to organise the event.	Specific personal non-financial	Declare and participate

Meeting	Declaration	Classification	Action taken
	Creon is an enzyme replacement therapy		
	I also own a few shares in Advanced Medical Solutions [advanced wound care, surgical and wound closure] - personal investment choice	Non-specific personal financial	
GC 01	None	-	-
GC 02	None	-	-
GC 03	None	-	-
GC 04	None	-	-
GC 05	None	-	-
GC 06	None	-	-
GC 07	None	-	-
GC 08	None	-	-
GC 09	None	-	-
GC 10	None	-	-
GC 11	None	-	-
GC 12	Attended a regional pancreatitis meeting that was sponsored by Mylan. No personal payment received.	Specific personal non-financial	Declare and participate
GC 13	None	-	-

B.8 Louise Carr (lay member)

Meeting	Declaration	Classification	Action taken
Initial application	None	-	-
GC 01	None	-	-
GC 02	None	-	-
GC 03	None	-	-
GC 04	None	-	-
GC 05	None	-	-
GC 06	None	-	-
GC 07	None	-	-
GC 08	None	-	-
GC 09	None	-	-

Meeting	Declaration	Classification	Action taken
GC 10	None	-	-
GC 11	None	-	-
GC 12	None	-	-
GC 13	None	-	-

B.9 Manu Nayar (specialist gastroenterologist)

Meeting	Declaration	Classification	Action taken
Initial application	European Group for Endoscopic Ultrasonography meeting; Edinburgh, October 2015 - 300 euros by Medtronic U.K.	Non-specific Personal financial	Declare and participate
	LEEDS Endoscopic retrograde cholangio-pancreatography (ERCP) MASTERCALSS – JULY 2016 - £1500/- by Olympus U.K. Paid speaking arrangement.	Specific Personal Financial	Declare and withdraw for discussions on Diagnosing Chronic Pancreatitis
GC 01	None	-	-
GC 02	None	-	-
GC 03	Declared during initial interviews: Leeds: ERCP Master class, July 2016, £1500 – by Olympus UK.	Specific personal financial	Declare and withdraw for discussions on Diagnosing Chronic Pancreatitis
GC 04	None	-	-
GC 05	None	-	-
GC 06	None	-	-
GC 07	I was invited faculty for the International ERCP symposium in Stoke on Trent on 28/04/2017. Aquilant UK paid for my travel and accommodation expenses. No personal honorariums received.	Personal non-financial non-specific	Declare and participate
GC 08	None	-	-
GC 09	None	-	-
GC 10	None	-	-
GC 11	None	-	-

Meeting	Declaration	Classification	Action taken
GC 12	None	-	-
GC 13	None	-	-

B.10 Mary Phillips (dietitian)

Meeting	Declaration	Classification	Action taken
Initial application	The course I ran in September in Guildford was the same PEI course mentioned below (on pancreatic enzyme replacement therapy). Delivered to a group of 20 Dietitians, as previously there was no attendance by industry, and they have no input into the content of the course. It is funded by an unconditional educational grant that includes an honorarium for the trainer.	Specific Personal Financial	Declare and withdraw for reviews including enzyme replacement therapy
	<p>Mylan Pharmaceuticals</p> <p>I have received honoraria and travel expenses for speaking at educational meetings:</p> <p>The Nutrition Interest Group of the Pancreatic Society of Great Britain and Ireland (NIGPS) run a course for Dietitians on the identification and management of pancreatic exocrine insufficiency; this is funded by an unconditional education grant from Mylan. Mylan have not had any input to the content of the course, and we do not encourage trade-stands at the meetings. For each course I run I submit a budget request to Mylan, and this is paid to NIGPS to allow us to run the course. This includes a honoraria for the speakers. I have run 13 courses to date, and have a financial commitment from Mylan to continue running them over the next 2 years. Mylan produce an enzyme replacement therapy product.</p>	Specific Personal Financial	Declare and withdraw for reviews including enzyme replacement therapy
	I have spoken at various nutrition and dietetic department journal clubs on nutritional management of patients with pancreatic exocrine insufficiency, and received honoraria from Mylan for doing so, Mylan have had no input to the content of my presentation. Mylan produce an enzyme replacement therapy product.	Specific Personal Financial	Declare and withdraw for reviews including enzyme replacement therapy
	Conference attendance sponsorship (registration and accommodation only) for Pancreatic Society Meetings 2015 and 2016 and HPBSurg 2016 (registration, travel and accommodation).	Specific Personal Non financial	Declare and participate
	Site PI on a European commercial trial September 2015- June 2016. This was a non-intervention validation of a patient questionnaire with the aim of developing and validating a screening tool for chronic pancreatitis patients with pancreatic exocrine insufficiency, this trial is completed. My Trust received a payment for each patient recruited (n=10); this was part of a bank contract I hold with the trust, and I did not receive any payment other	Non-specific Non-Personal Financial	Declare and participate

Meeting	Declaration	Classification	Action taken
	than my usual hourly rate for the time taken to complete the patient questionnaire.		
	<p>Nutricia Clinical Care</p> <p>Site PI on a commercial multicentre clinical trial on the efficacy of an enteral feed – due to commence October 2016. This is a trial to evaluate a new peptide enteral feeding product licensed for use in patients with intractable malabsorption, with the aim of assessing tolerance of a product compared to other commercially available products. The sample group will be patients already receiving peptide based enteral feeds. We have been asked to recruit 6 patients. The contracts are not yet finalised for this trial, and I am prepared to withdraw if this is deemed a conflict of interest by NICE.</p> <p>Comparison of enteral feeds not an intervention in guideline. Nutricia makes oral feeds too. There is a question comparing oral to enteral feeding.</p>	<p>Specific</p> <p>Non-personal</p> <p>Financial</p>	Declare and participate
	<p>Vitaflo International</p> <p>Honoria for speaking at an educational event: Vitaflo sponsored a British Dietetic association study day in January 2016 in Birmingham on the management of pancreatic and liver disease. I spoke on the nutritional management of pancreatic disease, and received travel and accommodation reimbursement and an honoraria. Vitaflo did not have any input to the content of my presentation, and I did not include any reference to their products within the presentation.</p> <p>Vitaflo make oral supplements that could be used for nutrition support in pancreatitis. Not comparing oral supplements in guideline.</p>	<p>Non-specific</p> <p>Personal</p> <p>Financial</p>	Declare and participate
	<p>MERCK</p> <p>I received honoraria for speaking at an Enhanced Recovery Study day funded by MERCK in Guildford in June, and this is being repeated in September 2016. My session is part of a surgical and anaesthetic study day, and my presentation is on the implementation of an enhanced recovery programme in pancreatico-duodenectomy. MERCK have not had any input into the content of my presentation.</p>	<p>Non-specific</p> <p>Personal</p> <p>Financial</p>	Declare and participate
GC 01	No change	-	-
GC 02	Pancreatic exocrine insufficiency (PEI) course taught in Guildford (Sept 2016): Honoria received. National Course (previously declared) sponsored by an unconditional educational grant from Mylan. Mylan had no input to the content of the course and were not in attendance. Mylan produce an enzyme replacement therapy product.	Specific personal financial	Declare and participate for this meeting. Withdraw for reviews including enzyme

Meeting	Declaration	Classification	Action taken
			replacement therapy discussed at other meetings.
	CECOG (Central European Cooperative Oncology Group) conference in Vienna (12.11.16) – speaking on Pancreatic Cancer and Nutrition. Honoria, travel and accommodation paid for by conference organiser	Non specific Personal Financial	Declare and participate
GC 03	None	-	-
GC 04	None	-	-
GC 05	None	-	-
GC 06	None	-	-
GC 07	None	-	-
GC 08	Honoria received from Northern Ireland Health Board for presentation at Dietitians education meeting on pancreatic exocrine insufficiency. Honoria received from Mylan for presenting at Diabetes Nurse Study day (TREND) on pancreatic exocrine insufficiency.	Non-specific personal financial Specific personal financial	Declare and participate Declare and participate for this meeting. Withdraw for reviews including enzyme replacement therapy discussed at other meetings.
GC 09	None		
GC 10	None	-	-
GC 11	None	-	-
GC 12	Co-authored article: "Nutritional Therapy in Chronic Pancreatitis" for a special issue of Gastroenterology Clinics on Nutritional Management of Gastrointestinal Diseases review on nutrition support in chronic pancreatitis	Specific personal non-financial	Withdraw during discussion of recommendation related to Nutrition in Chronic Pancreatitis.
GC 13	None	-	Withdraw during discussion of recommendation related

Meeting	Declaration	Classification	Action taken
			to Nutrition in Chronic Pancreatitis.

B.11 Peter Hampshire (critical care specialist) – co-opted member

Meeting	Declaration	Classification	Action taken
Initial application	None	-	-
GC 01	None	-	-
GC 02	None	-	-
GC 03	None	-	-
GC 04	None	-	-
GC 05	None	-	-
GC 06	None	-	-
GC 07	None	-	-
GC 08	None	-	-
GC 09	None	-	-
GC 10	None	-	-
GC 11	None	-	-
GC 12	None	-	-
GC 13	None	-	-

B.12 Robert Sutton (pancreatic surgeon)

Meeting	Declaration	Classification	Action taken
Initial application	I have an over-riding, specific interest in the prevention, diagnosis and treatment of acute and chronic pancreatitis. Specifically I am interested in the research development of new and personalised approaches to the management of pancreatitis, to reduce death, to prolong survival and to alleviate human suffering from pancreatitis, over and above what can be achieved through the fullest implementation of optimal guidelines. This is my over-riding professional concern alongside making every endeavour to provide optimal care for all patients with pancreatic digestive diseases at a leading regional specialist unit in Liverpool. Institutional research grant income is essential to this objective, guided by the Nolan Principles of Public Life: selflessness, integrity, objectivity, accountability, openness, honesty and leadership.	Specific personal non-financial	Declare and participate

Meeting	Declaration	Classification	Action taken
	<p>Importantly, there are no drugs available for the treatment of pancreatitis to modify the disease, and much of my research is directed at development of new and/or repositioned drugs to treat the disease. This is to achieve the aims of reducing death, prolonging survival and alleviating human suffering.</p> <p>[PUBLICLY HELD VIEW]</p>		
	<p>I have spent many years unravelling critical mechanisms and encouraging development of new drugs for acute pancreatitis, one of which is intended to enter phase I studies (CalciMedica's CM 4620, safety and pharmacokinetic studies; n.b. CalciMedica do not market any approved product for any disease) within six months, but which will have to go through years of development (phase IIa, then phase IIb and then phase III 'pivotal' regulatory trials) before it might be considered to be clinically applicable; many drugs fail these steps.</p> <p>[RESEARCH]</p>	<p>Non specific Personal Non financial</p>	<p>Declare and participate</p>
	<p>I am the principal investigator on an Efficacy and Mechanism Evaluation (MRC/NIHR) application to conduct a multicentre phase IIb (efficacy not effectiveness) randomised study of infliximab (from Merck/MSD who market this as Remicade®) in acute pancreatitis, that has reached 'intent to fund' status. Infliximab is not used in the treatment of acute pancreatitis, nor are there sufficient data and there is no regulatory approval for the use of infliximab in acute pancreatitis. There is no reason whatsoever for investigation of the potential effects of these drugs to influence the current management of acute pancreatitis, as all these compounds have no current role at all in the treatment of acute pancreatitis. There are no data within the evidence base from which the guidelines are to be compiled for the use of any of these drugs in the management of pancreatitis, and there is no reason to modify any guideline on pancreatitis as a result of the research that I am undertaking on drug discovery and development described above.</p>	<p>Non specific Personal Non financial</p>	<p>Declare and participate</p>
	<p>Other than occasional medicolegal expert witness (I have a current instruction relating to a bile duct injury and undertaken at the request of a senior physician but my last case was over 5 years ago)</p>	<p>Specific non-personal non financial:</p>	<p>Declare and participate</p>
	<p>[Additionally] a small number of holiday lettings on a privately owned property My sole source of income is paid by salary from the University of Liverpool, through my employment as a Professor of Surgery and Honorary Consultant Surgeon.</p> <p>I hold this honorary position at the Royal Liverpool and Broadgreen University Hospitals NHS Trust. I do not undertake private practice.</p>		<p>Declare and participate</p>

Meeting	Declaration	Classification	Action taken
	[EMPLOYMENT/INCOME – NOT RELEVANT TO THE GUIDELINE’S WORK]		
	My principal non-personal financial interest is to secure and develop innovative programmes of research at the University of Liverpool and Royal Liverpool and Broadgreen University Hospitals NHS Trust, endeavouring to maintain the highest ethical standards to advance the management of pancreatitis. Much of this research is preclinical (funded by the Medical Research Council and members of the Association of Medical Research Charities) or early stage translational (proof of principle, funded by the National Institute for Health Research) and has unfortunately yet to achieve late stage translation that would enter the realm of the evidence base that will inform guidelines for the management of pancreatitis. The number and size of the grants are commensurate with what is necessary to have a significant likelihood of reducing death, prolonging survival and/or alleviating human suffering from pancreatitis through research, over and above what can be achieved through the fullest implementation of optimal guidelines from the current evidence base.	Non-specific Financial Non-Personal	Declare and participate
	I am chief/principal/co- investigator on the following research grants awarded to the University of Liverpool and/or Royal Liverpool and Broadgreen University Hospitals NHS Trust that are current or have expired within the last 12 months: The role of IP3 receptors and Orai channels in the physiology and pathophysiology of pancreatic acinar cells (Col). Liverpool-RIKEN PhD Studentship for David Collier: 1 October 2011 to 30 September 2015: £75,000	Non-specific non-personal Financial	Declare and participate
	(2) Preclinical testing of agents for acute pancreatitis (PI). China Scholarship Council: Research Fellowship for Li Wen: 1 October 2011 to 30 September 2015; £100,000	Non-specific Non-personal Financial	Declare and participate
	(3) Pancreatic Digestive Diseases Biomedical Research Unit (PI). NIHR: BRU Revenue Funding: 1 April 2012 to 31 March 2017: £6,500,000	Non-specific Non personal Financial	Declare and participate
	(4) Chemical synthesis of novel cyclophilin D inhibitors (Col). EPSRC 50% PhD Studentship for Emma Shore: 1 October 2012 to 30 September 2016: £70,000	Non specific Non personal Financial	Declare and participate
	(5) Interaction of endocytic vacuoles with cellular organelles as a trigger for the cell damage in acute pancreatitis (Col). MRC Research Grant: 1 April 2013 to 31 March 2016: £509,047	Non specific Non personal Financial	Declare and participate

Meeting	Declaration	Classification	Action taken
	(6) Liverpool Imaging Partnership: Molecular physiology and drug response (CoI). MRC Infrastructure Award: 1 April 2013 to 31 March 2017: £1,025,736	Non specific Non personal Financial	Declare and participate
	(7) Liverpool Biomedical Research Centre in Personalised Health (CI). Liverpool Health Partners (non-NIHR): 1 October 2014 to 31 March 2017: £1,500,000 (2014-17)	Non specific Non personal Financial	Declare and participate
	(8) Preclinical drug testing for acute pancreatitis (PI). China Scholarship Council: Research Studentship for Stephanie Zhang: 1 October 2014 to 30 September 2018: £100,000	Non Specific Non personal Financial	Declare and participate
	(9) Preclinical development of cyclophilin inhibitors in acute pancreatitis (PI). Cypralis Research Grant: 1 January 2015 to 31 December 2016: £84,000	Non specific Non personal financial	Declare and participate
	(10) TNF alpha signaling in acute pancreatitis (PI): Mersey Deanery: Madel Research Fellowship for Ajay Sud: 1 April 2015 to 31 March 2017: £90,000	Non specific Non personal Financial	Declare and participate
	(11) Neutrophil-acinar cell interactions in acute pancreatitis (PI). Royal College of Surgeons of England: Research Fellowship for Peter Szatmary; 1 August 2015 to 31 July 2016: £50,000	Non specific Non personal Financial	Declare and participate
	(12) Chemical synthesis of novel inhibitors of cyclophilin D (Co-I). EPSRC 50% PhD Studentship for Michael Rogers: 1 October 2015 to 30 September 2019: £70,000	Non specific Non personal Financial	Declare and participate
	(13) The role of the mitochondrial Ca ²⁺ uniporter in initiation and development of acute pancreatitis (Co-I). MRC: Research Grant: 1 April 2016 to 31 March 2019: £403,000	Non specific Non personal Financial	Declare and participate
	(14) NIHR Senior Investigator (PI). NIHR: Investigator Award: 1 April 2016 to 31 March 2012: £450,000 (£375,000 to Research Capability Funding at RLBUHT)	Non specific Non personal Financial	Declare and participate
	(15) TNF alpha signaling in acute pancreatitis (PI). Royal College of Surgeons of England: Research Fellowship for Ajay Sud: 1 April 2017 to 31 March 2018: £50,000	Non specific Non personal financial	Declare and participate
	The University of Liverpool offers a consultancy service by means of which external organisations, public and private, can obtain expert advice from senior academic staff	Non specific Non personal	Declare and participate

Meeting	Declaration	Classification	Action taken
	(please see: https://www.liverpool.ac.uk/business/services/research-and-consultancy/). I am registered on this service to provide advice and collaborate to develop new treatments for pancreatitis, including a contract with Cypralis Ltd (http://www.cypralis.com) that begun on 1 August 2016 at £10,000 p.a..	Financial	
	Currently the work with Cypralis is entirely preclinical in nature (see also grant 9 above); if there is a promising lead candidate identified, Cypralis intend to undertake a full, regulatory preclinical toxicology work package. If approved by the regulatory bodies (including the Medicines and Healthcare products Regulatory Agency), this will be a prelude to first-in-man phase I studies of single and multiple ascending doses of their chosen compound, again years away from clinical application other than in phase I, phase IIa, phase IIb and phase III clinical trials. This work has no bearing on the evidence base for pancreatitis guidelines, and Cypralis do not market any approved product for the management of any disease.	Non specific Non personal Financial	Declare and participate
	Director, NIHR Liverpool Pancreas Biomedical Research Unit, 2008-2017 Co-opted member of Executive Committee, Pancreatic Society of Great Britain and Ireland (as Chair of Guideline Development Committee; previously member 1998-2001 and 2005-2014, President 2012-2013), 2014 et seq Faculty, American Pancreatic Association, 2004 et seq Member of Council, International Association of Pancreatology, 2008-2016 [MEMBERSHIPS]	Specific personal non-financial:	Declare and participate
	Director of Research, Development and Innovation, Royal Liverpool and Broadgreen University Hospital NHS Trust, 2009 et seq Director of Research, Liverpool Health Partners, 2013 et seq Research Awards Committee, CORE (Digestive Disorders Foundation), 2003 et seq Member, Association of UK University Hospitals Research Directors, 2011 et seq	Non-specific personal non-financial	Declare and participate
	Previously contributed to editorship within the Cochrane Collaboration as Joint Editor Cochrane Hepatobiliary Collaborative Review Group, 1996-2012; I have also contributed to peer reviewing for public funding organisation and peer-reviewed journals for 30 years.	Non-specific personal non-financial	Declare and participate
	Has published the following original articles in 2015 and 2016:	Non-specific personal non-	Declare and participate

Meeting	Declaration	Classification	Action taken
	<p>(1) Chvanov M, Huang W, Jin T, Wen L, Armstrong J, Elliot V, Alston B, Burdyga A, Criddle DN, Sutton R, Tepikin AV. Novel lipophilic probe for detecting near-membrane reactive oxygen species responses and its application for studies of pancreatic acinar cells: effects of pyocyanin and L-ornithine. <i>Antioxid Redox Signal</i> 2015; 22: 451-464.</p> <p>(2) Jenkinson C, Elliott V, Menon U, Apostolidou S, Fourkala OE, Gentry-Maharaj A, Pereira SP, Jacobs I, Cox TF, Greenhalf W, Timms JF, Sutton R, Neoptolemos JP, Costello E. Evaluation in pre-diagnosis samples discounts ICAM-1 and TIMP-1 as biomarkers for earlier diagnosis of pancreatic cancer. <i>J Proteomics</i> 2015; 113: 400-402.</p> <p>(3) Voronina S, Collier D, Chvanov M, Middlehurst B, Beckett AJ, Prior IA, Criddle DN, Begg M, Mikoshiba K, Sutton R, Tepikin AV. The role of Ca²⁺ influx in endocytic vacuole formation in pancreatic acinar cells. <i>Biochem J</i> 2015; 465: 405-412.</p> <p>(4) Wang YC, Szatmary P, Zhu JQ, Xiong JJ, Huang W, Gomatos I, Nunes QM, Sutton R, Liu XB. Prophylactic intra-peritoneal drain placement following pancreaticoduodenectomy: a systematic review and meta-analysis. <i>World J Gastroenterol</i> 2015; 21: 2510-2521.</p> <p>(5) Nicholson JA, Greenhalf W, Jackson R, Cox TF, Butler JV, Hanna T, Harrison S, Grocock CJ, Halloran CM, Howes NR, Raraty MG, Ghaneh P, Johnstone M, Sarkar S, Smart HL, Evans JC, Aithal GP, Sutton R, Neoptolemos JP, Lombard MG. Incidence of post-ERCP pancreatitis from direct pancreatic juice collection in hereditary pancreatitis and familial pancreatic cancer before and after the introduction of prophylactic pancreatic stents and rectal diclofenac. <i>Pancreas</i> 2015; 44: 260-265.</p> <p>(6) Huang W, Cash N, Wen L, Szatmary P, Mukherjee R, Armstrong J, Chvanov M, Tepikin AV, Murphy MP, Sutton R, Criddle DN. Effects of the mitochondria-targeted antioxidant mitoquinone in murine acute pancreatitis. <i>Mediators Inflamm</i> 2015; 2015:901780.</p> <p>(7) Huang W, Xiong JJ, Wan MH, Szatmary P, Bharucha S, Gomatos I, Nunes QM, Xia Q, Sutton R, Liu XB. Meta-analysis of subtotal stomach-preserving pancreaticoduodenectomy vs pylorus preserving pancreaticoduodenectomy. <i>World J Gastroenterol</i> 2015; 21: 6361-6373.</p> <p>(8) Wen L, Voronina S, Javed MA, Awais M, Szatmary P, Latawiec D, Chvanov M, Collier D, Huang W, Barrett J, Begg M, Stauderman K, Roos J, Grigoryev S, Ramos S, Rogers E, Whitten J, Velicelebi G, Dunn M, Tepikin AV, Criddle DN, Sutton R. Inhibitors of ORAI1 Prevent Cytosolic Calcium-Associated Injury of Human Pancreatic Acinar Cells and Acute Pancreatitis in 3 Mouse Models.</p>	financial	

Meeting	Declaration	Classification	Action taken
	<p>Gastroenterology 2015; 149: 481-492.</p> <p>(9) Ou X, Cheng Z, Liu T, Tang Z, Huang W, Szatmary P, Zheng S, Sutton R, Toh CH, Zhang N, Wang G. Circulating histone levels reflect disease severity in animal models of acute pancreatitis. <i>Pancreas</i> 2015; 44: 1089-1095.</p> <p>(10) Gomatos IP, Halloran CM, Ghaneh P, Raraty MG, Polydoros F, Evans JC, Smart HL, Yagati-Satchidanand R, Garry JM, Whelan PA, Hughes FE, Sutton R, Neoptolemos JP. Outcomes from minimal access retroperitoneal and open pancreatic necrosectomy in 394 patients with necrotizing pancreatitis. <i>Ann Surg</i> 2015 Oct 22. [Epub ahead of print]</p> <p>(11) Huang W, Cane MC, Mukherjee R, Szatmary P, Zhang X, Elliott V, Ouyang Y, Chvanov M, Latawiec D, Wen L, Booth D, Haynes AC, Petersen OH, Tepikin AV, Criddle DN, Sutton R. Caffeine protects against experimental acute pancreatitis by inhibition of inositol 1,4,5-trisphosphate receptor-mediated Ca²⁺ release. <i>Gut</i> 2015 Dec 7. [Epub ahead of print]</p> <p>(12) Sultana A, Jackson R, Tim G, Bostock E, Psarelli EE, Cox TF, Sutton R, Ghaneh P, Raraty MG, Neoptolemos JP, Halloran CM. What is the best way to identify malignant transformation within pancreatic IPMN: a systematic review and meta-analyses. <i>Clin Transl Gastroenterol</i> 2015 Dec 10;6:e130. doi:10.1038/ctg.2015.60.</p> <p>(13) Okeke E, Parker T, Dingsdale H, Concannon M, Awais M, Voronina S, Molgo J, Begg M, Metcalf D, Knight AE, Sutton R, Haynes L, Tepikin AV. Epithelial- mesenchymal transition, IP3 receptors and ER-PM junctions: translocation of Ca²⁺ signalling complexes and regulation of migration. <i>Biochem J</i> 2016 Jan 12 [Epub ahead of print]</p> <p>(14) Gomatos IP, Halloran C, Ghaneh P, Raraty M, Polydoros F, Campbell F, Evans J, Sutton R, Garry J, Whelan P, Neoptolemos JP. Management and outcome of 64 patients with pancreatic serous cystic neoplasms. <i>Dig Surg</i> 2016; 33: 203-212.</p> <p>(15) Shore E, Awais M, Kershaw N, Gibson R, Pandalaneni S, Latawiec D, Wen L, Javed M, Criddle D, Berry N, O'Neill P, Lian L-Y, Sutton R. Small molecule inhibitors of cyclophilin D to protect mitochondrial function as a potential treatment for acute pancreatitis. <i>J Med Chem</i> 2016; 59: 2596-2611.</p> <p>(16) Xiong JJ, Szatmary P, Huang W, Iglesia-Garcia D, Nunes QM, Xia Q, Hu WM, Sutton R, Liu XB, Raraty MG. Enhanced recovery after surgery program in patients undergoing pancreaticoduodenectomy: A PRISMA-compliant systematic review and meta-analysis. <i>Medicine</i> 2016; 95: e3497.</p> <p>(17) Mukherjee R, Mareninova OA, Odinkova IV, Huang</p>		

Meeting	Declaration	Classification	Action taken
	W, Murphy J, Chvanov M, Javed MA, Wen L, Booth DM, Cane MC, Awais M, Gavillet B, Pruss RM, Schaller S, Molkentin JD, Tepikin AV, Petersen OH, Pandol SJ, Gukovsky I, Criddle DN, Gukovskaya AS, Sutton R; and NIHR Pancreas Biomedical Research Unit. Mechanism of mitochondrial permeability transition pore induction and damage in the pancreas: inhibition prevents acute pancreatitis by protecting production of ATP. <i>Gut</i> 2016; 65: 1333-1346.		
	Has published the following review articles and book chapters in 2015 and 2016:		
	(1) Awais M, Voronina SG, Sutton R. An efficient method is required to transfect non-dividing cells with genetically encoded optical probes for molecular imaging. <i>Anal Sci</i> 2015; 31: 293-298.	Non-specific personal non-financial	Declare and participate
	(2) Afghani E, Pandol S, Shimosegawa T, Sutton R, Wu B, Vege SS, Gorelick F, Hirota M, Windsor J, Lo SK, Freeman M, Lerch MM, Tsuji Y, Melmed GY, Wassef W, Mayerle J. Acute pancreatitis: progress and challenges. A report on an international symposium. <i>Pancreas</i> 2015; 44: 1195-210.	Specific personal non-financial	Declare and participate
	(3) Cummings M, Bodansky J, Hicks D, Hopkins D, Kirby M, Sutton R. Pancreatic exocrine insufficiency in diabetes: why it is important and what are the practicalities in diagnosis and management. <i>Diabetes Digest</i> 2015; 13 (Suppl 3):2-8.	Non-specific personal non-financial	Declare and participate
	(4) Huang W, Szatmary P, Wan M, Bharucha S, Awais M, Tang W, Criddle DN, Xia Q, Sutton R. Translational insights into peroxisome proliferator-activated receptors in experimental acute pancreatitis. <i>Pancreas</i> 2015 Nov 17. [Epub ahead of print]	Non-specific personal non-financial	Declare and participate
	(5) Wen L, Javed MA, Altaf K, Szatmary P and Sutton R. Specific treatment for acute pancreatitis. In: Adams DB, Cotton PB, Zyromski NJ, Windsor J, eds. <i>Pancreatitis: medical and surgical management</i> . Oxford: Wiley, in press.	Specific personal Non-financial	Declare and participate
	(6) Mukherjee R, Sutton R. Pharmaceutical developments for chronic pancreatitis: pipelines and future options. <i>Pancreapedia: Exocrine Pancreas Knowledge Base</i> , DOI: 10.3998/panc.2016.12.	Non-specific personal financial	Declare and participate
	(7) Wen L, Mukherjee R, Huang W, Sutton R. Calcium signaling, mitochondria and acute pancreatitis: avenues for therapy. <i>Pancreapedia: Exocrine Pancreas Knowledge Base</i> , DOI: 10.3998/panc.2016.15.	Non-specific personal financial	Declare and participate
GC 01	None		
GC 02	None	-	-
GC 03	None	-	-

Meeting	Declaration	Classification	Action taken
GC 04	<p>International Chair of the West China Pancreas International Forum 15th – 16th October 2016 held at the Ritz Carlton Hotel, Chengdu, China with expenses paid by West China Hospital.</p> <p>Member of the NHS England Hepato-Pancreato-Biliary Clinical Reference Group as representative of the Pancreatic Society of Great Britain and Ireland from 6th October 2016.</p>	Non Specific personal financial	Declare and participate.
GC 05	None	-	-
GC 06	None	-	-
GC 07	None	-	-
GC 08	None	-	-
GC 09	A new grant from Innovate UK (£300,000) with Cypralis PLC on testing molecules that inhibit cyclophilin D for the treatment of chronic pancreatitis (preclinical). 01/08/17 – 31/07/18.	Personal Non specific financial	Declare and participate
GC 10	None	-	-
GC 11	None	-	-
GC 12	None	-	-
GC 13	None	-	-

B.13 Stacey Munnely (nurse)

Meeting	Declaration	Classification	Action taken
Initial application	<p>I am currently working as part of a project team to develop and launch a virtual internet based clinic for patients with stable chronic pancreatitis to access follow up care in place of their traditional face to face outpatient clinic appointment for my employer (CMFT NHS Trust).</p> <p>The work involves collaborating with a commercial sector IT company who will provide a bespoke computer package which will help clinicians to perform health consultations and assess patients remotely by asking a series of set questions related to symptoms. Decisions regarding further investigations required or changes to treatment will then be made and communicated to the patients and their GPs by the responsible clinician via telephone/letter. The computer package simply allows patients to submit data related to their condition and does not make clinical decisions or replace the clinical expertise/judgement of the reviewing clinician.</p> <p>The aim of the virtual clinic is to use technology to facilitate a new innovative way to access healthcare that is convenient and safe and will free up traditional clinic</p>	<p>Non-specific</p> <p>Personal</p> <p>Non-financial</p>	Declare and participate

Meeting	Declaration	Classification	Action taken
	spaces for new patients, consequently reducing waiting times for new referrals in line with new 2015 British Society of Gastroenterology targets for referral to consultation and improving patient engagement and satisfaction. There will be no personal financial rewards. The Trust will incur a financial recompense from local commissioners in the same way that it does for traditional outpatient clinic appointments. I have made no publications or public statements regarding the project but may do so in the future if the project aims are achieved.		
GC 01	None	-	-
GC 02	None	-	-
GC 03	None	-	-
GC 04	None	-	-
GC 05	None	-	-
GC 06	From March 2017, I have been recruited to contribute to and deliver the content of a degree level module for post registration Nurses/Allied Health Care Professionals by the University of Manchester. Topics will include the anatomy, physiology, pathophysiology, management and evidence/research to support management of GI diseases including liver diseases, pancreatic and biliary diseases. I will not receive financial payment for this work.	Specific personal non-financial	Declare and participate.
GC 07	None	-	-
GC 08	None	-	-
GC 09	None	-	-
GC 10	None	-	-
GC 11	None	-	-
GC 12	None	-	-
GC 13	None	-	-

B.14 Stuart Wood (lay member)

Meeting	Declaration	Classification	Action taken
Initial application	None	-	-
GC 01	None	-	-
GC 02	None	-	-

Meeting	Declaration	Classification	Action taken
GC 03	None	-	-
GC 04	None	-	-
GC 05	None	-	-
GC 06	Attended a meeting of the Liverpool Clinical Trial Unit PPI Group on 28th April 2017. The only payment that I received was for travel expenses. I have been invited to join the committee for which I will, on future occasions, receive a fee as well as expenses.	Non-specific personal financial	Declare and participate
GC 07	None	-	-
GC 08	None	-	-
GC 09	None	-	-
GC 10	None	-	-
GC 11	None	-	-
GC 12	None	-	-
GC 13	None	-	-

B.15 Tassos Grammatikopoulos (paediatrician)

Meeting	Declaration	Classification	Action taken
Initial application	Children's Liver Disease Foundation research grants in portal hypertension (x2)	Non-specific non-personal financial	Declare and participate
	<p>Papers:</p> <p>Mutations in DCDC2 (doublecortin domain containing protein 2) in neonatal sclerosing cholangitis.</p> <p>Grammatikopoulos T, Sambrotta M, Strautnieks S, Foskett P, Knisely AS, Wagner B, Deheragoda M, Starling C, Mieli-Vergani G, Smith J; University of Washington Center for Mendelian Genomics, Bull L, Thompson RJ.</p> <p>J Hepatol. 2016 Jul 25. pii: S0168-8278(16)30342-7. doi: 10.1016/j.jhep.2016.07.017. [Epub ahead of print]. PMID: 27469900. Financial support for above work(non-personal). Funding for this project included NIH R01 DK094828 to L.N.B. and R.J.T., the UCSF-King's. College Health Partners Faculty Fellowship Travel Grant (UCSF Academic Senate) to L.N.B., and NIH U01 DK062500 to P. Rosenthal, as well as a gift of funds from A.S. Knisely. WES was undertaken by the University of Washington Center for Mendelian. Genomics (UW CMG) and was funded by the National Human Genome Research Institute and the National Heart, Lung, and Blood Institute grant 1U54HG006493 to Drs. Debbie Nickerson, Jay Shendure,</p>	Non-specific Personal Non-financial	Declare and participate

Pancreatitis
Declarations of interest

Meeting	Declaration	Classification	Action taken
	and Michael Bamshad.		
GC 01	None	-	-
GC 02	None	-	-
GC 03	None	-	-
GC 04	Travel sponsored by Nutricia for lecturing on neonatal cholestasis in December 2016.	Non-specific personal financial	Declare and Participate
GC 05	None	-	-
GC 06	The department was sponsored for organising an international symposium in paediatric liver transplantation at King's College Hospital, London by the International Liver Transplantation Society and pharmaceutical companies Alexion, Intercept and Gilead. I was the symposium organiser.	Non-specific non-personal financial	Declare and participate.
GC 07	None	-	-
GC 08	None	-	-
GC 09	None	-	-
GC 10	None	-	-
GC 11	None	-	-
GC 12	None	-	-
GC 13	None	-	-

Appendix C: Clinical review protocols

C.1 Patient information

Review question	What information and support should people with acute or chronic pancreatitis, their family and carers receive after diagnosis?
Guideline condition and its definition/method of assessment	Acute or chronic pancreatitis, including hereditary
Objective	To determine what type of information and support should be provided to people with acute or chronic pancreatitis, their family and carers after diagnosis. Patient support refers here to direct patient or carer interaction or engagement designed to help management of medication or disease outcomes (for example, adherence, awareness and education), or to provide healthcare professionals with support for their patients.
Population and setting	People with acute or chronic pancreatitis Adults (>16 years) Children (≤ 16 years) Family and carers of people with acute or chronic pancreatitis. Including young carers (<18 years)
Context	Any type of information and support of people with acute or chronic pancreatitis, their family and carers after diagnosis described by studies. For example: Content of information and support required and how this information and support is delivered Information and support to include pain relief, dietary advice Timing of information and support Information for family and carers
Exclusions	Papers that do not report a qualitative analysis
Search strategy	The databases to be searched are Medline, Embase, The Cochrane Library, CINAHL, PsychINFO Studies will be restricted to English language only.
Search terms	
The review strategy	Study designs to be considered: Qualitative studies (e.g., interviews, focus groups, observations) Appraisal of methodological quality The methodological quality of each study will be assessed using NCGC modified NICE checklists and the quality of the body of evidence as a whole will be assessed by a GRADE CerQual approach for each review finding. Data synthesis Synthesis of qualitative research: Thematic analysis - information synthesised into main review findings. Results presented in a detailed narrative with accompanying diagrams and in table format with summary statements of main review findings. Note: extract any themes around concerns about incorrect GP diagnosis.

Review question	What information and support should people with acute or chronic pancreatitis, their family and carers receive after diagnosis?
	For full details of the review methods please refer to chapter 4 of the full guideline.
Quality assurance measures	Quality assurance will be undertaken by a senior research fellow prior to completion. 10% of papers will be double reviewed (sift and quality assessment)

C.2 Lifestyle interventions: stopping or reducing alcohol consumption

Review question	What is the clinical effectiveness and cost effectiveness of stopping or reducing alcohol consumption in reducing recurrent episodes of acute pancreatitis and improving quality of life in people with either chronic or acute pancreatitis?
Guideline condition and its definition/method of assessment	Pancreatitis
Objectives	To identify the most clinical and cost-effective method to support people with both chronic and acute pancreatitis in stopping or reducing alcohol consumption
Review population	People with acute or chronic pancreatitis
Major age categories	All age categories: Adults (>16) Young people (<16)
Setting	Primary, secondary and tertiary care
Intervention	Structured program to support people with both chronic and acute pancreatitis in stopping or reducing alcohol consumption
Comparator	No structured program/usual care (e.g. general advice)
Outcomes	Critical Quality of life (continuous) (no time cutoff) Mortality (dichotomous) (no time cutoff) Recurrent episodes of pancreatitis (dichotomous) (no time cutoff) Alcohol consumption (dichotomous or continuous) (no time cutoff) Important Nutritional status (continuous or dichotomous) (no time cutoff) Admissions to hospital (dichotomous) (no time cutoff) Morbidity (e.g. pancreatic function, pain) (continuous or dichotomous) (no time cutoff)
Study design	RCTs, systematic reviews of RCTs. If insufficient RCT evidence to form a recommendation is found, non-randomised comparative studies will be included.
Unit of randomisation	Patient or hospital randomised
Population stratification	None (young adults will be considered together with adults)
Review strategy/other analysis	Studies will only be included if they reported one of more of the outcomes listed above. For full details of the review methods please refer to chapter 4 of the full guideline.
Subgroup analyses if there is heterogeneity	Subgroup analyses will be conducted on the following if there is heterogeneity: Severity of pancreatitis (mild, moderate, severe)

Review question	What is the clinical effectiveness and cost effectiveness of stopping or reducing alcohol consumption in reducing recurrent episodes of acute pancreatitis and improving quality of life in people with either chronic or acute pancreatitis?
	Aetiology of pancreatitis (alcohol-related, other) Amount of alcohol consumed (high or low, as defined by national guidelines) Previous pancreatic surgery (previous surgery, no previous surgery) Type of program
Search criteria	Databases: Medline, Embase, the Cochrane Library Date limits for search: 1990 Language: Restrict to English only
Quality assurance measures	Quality assurance will be undertaken by a senior research fellow prior to completion. 10% of papers will be double reviewed (sift and quality assessment).

C.3 Aetiology of acute pancreatitis

Review question	What is the clinical effectiveness and cost effectiveness of assessing the aetiology of acute pancreatitis to prevent recurrent attacks in people in whom the aetiology is unconfirmed by first-line test results within normal ranges?
Guideline condition and its definition/method of assessment	Acute pancreatitis
Objectives	To identify what is the clinical and cost effectiveness of assessing the aetiology of acute pancreatitis to prevent recurrent attacks in people in which the aetiology is unconfirmed by first line test results within normal range (i.e. patient enquiry for alcohol and ultrasound (US) for gallstones, with or without patient enquiry for genetic causes, blood tests for hypercalcemia, hyperlipidemia).
Review population	People with a diagnosis of acute pancreatitis and aetiology unconfirmed by normal first line tests (i.e. patient enquiry for alcohol and genetic causes, US for gallstones and blood tests for metabolic causes).
Major age categories	Adults (>16 years old) Children (<16 years old)
Setting	All settings
Line of therapy	Not applicable
Interventions: generic/class; specific/drug	Testing for aetiology of acute pancreatitis with any of the following tests: History: drug history, specific questioning for Sphincter of Oddi dysfunction Blood tests: autoantibodies, antibodies, serological tests, tests for hypercalcaemia and hyperlipidaemia DNA test Endoscopic US of gall bladder and bile duct, EUS with duodenoscopy MRCP, secretin-MRCP Combinations of tests
Comparator	No test
Outcomes	Critical outcomes Quality of life (continuous)

Review question	What is the clinical effectiveness and cost effectiveness of assessing the aetiology of acute pancreatitis to prevent recurrent attacks in people in whom the aetiology is unconfirmed by first-line test results within normal ranges?
	Pancreatitis-related mortality (dichotomous) Number of repeated tests (dichotomous) Important outcomes Any pancreatitis-related admissions (including recurrent attacks) (dichotomous) Confirmation of aetiology/identification of a cause (dichotomous) Adverse events following investigations (dichotomous)
Study design	RCTs, systematic reviews of RCTs. If insufficient RCT evidence to form a recommendation is found, non-randomised controlled studies will be included.
Unit of randomisation	Patient or hospital randomised
Crossover study	Not permitted
Other inclusions	Only studies reporting one or more of the outcomes listed above will be included.
Other exclusions	Abstracts
Population stratification	Cause of acute pancreatitis Acute pancreatitis due to a genetic cause Gallstone-related (microlithiasis) acute pancreatitis Autoimmune acute pancreatitis Tumour-related pancreatitis Anatomical anomalies (pancreas divisum) Sphincter of Oddi dysfunction Infectious causes Drug-related pancreatitis Metabolic causes
Reasons for stratification	Different causes of acute pancreatitis are investigated with different tests
Review strategy/other analysis	Paper will only be included if they reported one or more of the outcomes listed above No time cut-off for outcomes was specified a priori. The GC felt it was not appropriate to impose a limit on outcomes for this review question, because consequences of testing could have a long-term effect. For full details of the review methods please refer to chapter 4 of the full guideline.
Subgroup analyses if there is heterogeneity	Causes (see above) Age (children/adults)
Search criteria	Databases: Medline, Embase, the Cochrane Library Date limits for search: 1990 Language: English only
Quality assurance measures	Quality assurance will be undertaken by a senior research fellow prior to completion. 10% of papers will be double reviewed (sift and quality assessment).

C.4 Aetiology of chronic pancreatitis

Review question	What is the clinical effectiveness and cost effectiveness of performing genetic marker and autoantibody tests for identifying the aetiology of chronic pancreatitis in people with no known family history of pancreatitis, no significant alcohol history, and normal serum calcium and lipid levels?
Guideline condition and its definition/method of assessment	Chronic pancreatitis
Objectives	To identify what is the clinical and cost effectiveness of performing genetic markers and autoantibodies tests for identifying the aetiology of chronic pancreatitis in people with no known family history of pancreatitis, no significant alcohol history, and normal serum calcium and lipids
Review population	People with a diagnosis of chronic pancreatitis and no known family history of pancreatitis, no significant alcohol history, and normal serum calcium and lipids
Major age categories	Adults (>16 years old) Children (<16 years old)
Setting	All settings
Line of therapy	Not applicable
Interventions: generic/class; specific/drug	For the identification of autoimmune chronic pancreatitis Autoantibodies (for example, IgG4, ANA) For the identification of hereditary chronic pancreatitis (including CFTR) Genetic markers (for example, PRSS1, SPINK1, CFTR)
Comparator	No test
Outcomes	Critical outcomes Quality of life (continuous) Mortality (dichotomous) Number of repeated tests/any pancreatitis-related admissions (dichotomous) Important outcomes Early detection of cancer (for hereditary pancreatitis) (dichotomous) Early detection of extra-pancreatic involvement (for IgG4 related pancreatitis) (dichotomous) Confirmation of etiology/identification of a cause (dichotomous)
Study design	RCTs, systematic reviews of RCTs. If insufficient RCT evidence to form a recommendation is found, non-randomised comparative studies will be included.
Unit of randomisation	Patient or hospital randomised
Crossover study	Not permitted
Other inclusions	Only studies reporting one or more of the outcomes listed above will be included.
Other exclusions	Abstracts
Population stratification	Age: Adults and young people >16 years old children <16 years old
Reasons for stratification	The diagnosis of hereditary pancreatitis is more common in childhood.
Review strategy/other analysis	Paper will only be included if they reported one or more of the outcomes listed above

Review question	What is the clinical effectiveness and cost effectiveness of performing genetic marker and autoantibody tests for identifying the aetiology of chronic pancreatitis in people with no known family history of pancreatitis, no significant alcohol history, and normal serum calcium and lipid levels?
	No cut-off for outcomes was established. The GC felt it was not appropriate to impose a limit on outcomes for this review question, as consequences of testing could have a long-term effect. For full details of the review methods please refer to chapter 4 of the full guideline.
Subgroup analyses if there is heterogeneity	None
Search criteria	Databases: Medline, Embase, the Cochrane Library Date limits for search: 1990 Language: English only
Quality assurance measures	Quality assurance will be undertaken by a senior research fellow prior to completion. 10% of papers will be double reviewed (sift and quality assessment).

C.5 Diagnosing chronic pancreatitis

Review question	In people with suspected (or under investigation for) chronic pancreatitis, whose diagnosis has not been confirmed by any of CT scan, ultrasound scan or upper GI endoscopy, what is the most accurate diagnostic test to identify whether chronic pancreatitis is present (as indicated by the reference standards: biopsy, clinical follow-up or subsequent CT scan)?
Objectives	To evaluate and compare the accuracy of diagnostic tests to identify whether chronic pancreatitis is present, in people with suspected (or under investigation for) chronic pancreatitis whose diagnosis has not been confirmed by any of CT scan, US scan and/or upper GI endoscopy
Study design	Prospective and retrospective cohort studies, in which the index tests and the reference standard test are applied to the same patients in a cross-sectional design
Population	All people with suspected (or under investigation for) chronic pancreatitis whose diagnosis has not been confirmed by CT scan, US scan and/or upper GI endoscopy
Major age categories	Adults (>16 years old) Children (<16 years old)
Target condition	Chronic pancreatitis in people presenting with chronic abdominal pain, and normal or uncertain CT and/or US scan and/or upper GI endoscopy
Setting	All care settings (for example GP, hospital)
Index test	Breath tests (C13 mixed tryglicerides test) Endoscopic-based pancreatic function tests Faecal tests (stool tests): Faecal elastase (monoclonal or polyclonal tests) (<200 micrograms per gram) Faecal tests (stool tests): Faecal fat/coefficient of fat absorption (>7 gr per day, when people are on a 100 gr fat intake) Radiological imaging: MRI Radiological imaging: MRCP (= magnetic resonance cholangiopancreatography) Radiological imaging: Secretin-MRCP Endoscopic imaging: ERCP (= endoscopic retrograde cholangiopancreatography)

Review question	In people with suspected (or under investigation for) chronic pancreatitis, whose diagnosis has not been confirmed by any of CT scan, ultrasound scan or upper GI endoscopy, what is the most accurate diagnostic test to identify whether chronic pancreatitis is present (as indicated by the reference standards: biopsy, clinical follow-up or subsequent CT scan)?
	<p>Endoscopic imaging: Endoscopic US (cut-off: Rosemont criteria: presence of chronic pancreatitis if >5) (including elastography)</p> <p>Combinations of the tests above</p> <p>Where a cut-off is not indicated, the GC was not able to indicate one a priori.</p>
Reference standard	<p>Biopsy</p> <p>Clinical follow-up</p> <p>Subsequent CT scan</p>
Statistical measures	<p>Specificity</p> <p>Sensitivity</p> <p>Positive and / or Negative predictive value (influenced by prevalence of a condition)</p> <p>Positive and / or negative likelihood ratio (less dependent on the prevalence of the condition)</p> <p>ROC curve or Area under Curve</p> <p>The committee agreed that sensitivity would be the primary measure for decision making.</p>
Other exclusions	Two-gate studies
Search Strategy	<p>Databases: Cochrane, Medline</p> <p>Date limits for search: 1990</p> <p>Language: English only</p>
Review Strategy	<p>Prospective diagnostic cohorts; if none identified, retrospective diagnostic cohorts</p> <p>Stratum: Age (Children; adults) – children rarely undergo invasive procedures for diagnosis. There is also an issue with radiation protection for imaging.</p> <p>Subgroups (to be investigated if heterogeneity is identified): none identified.</p> <p>Appraisal of methodological quality: The methodological quality of each study will be assessed using the QUADAS-2 checklist (per target condition).</p> <p>Synthesis of data: Diagnostic meta-analysis will be conducted where appropriate and if sufficient data available (when there are 3 or more studies where 2x2 data are available for the same threshold, or agreed similar threshold) using hierarchical methods.</p> <p>For full details of the review methods please refer to chapter 4 of the full guideline.</p>
Quality assurance measures	<p>Quality assurance will be undertaken by a senior research fellow prior to completion.</p> <p>10% of papers will be double reviewed (sift and quality assessment).</p>

Review question	In people with suspected (or under investigation for) chronic pancreatitis, in whom other causes have not been excluded by the use of CT scan, ultrasound scan or upper GI endoscopy, what is the most clinically effective and cost effective test to identify whether chronic pancreatitis is present, when each is followed by the appropriate treatment, in order to improve patient outcomes?
Objectives	To evaluate the clinical effectiveness of different tests in improving patients' outcomes when followed up by appropriate treatment for chronic pancreatitis, in people with suspected (or under investigation for) chronic pancreatitis whose diagnosis has not been confirmed by CT scan, US scan and/or upper GI endoscopy
Population and target condition	People with suspected (or under investigation for) chronic pancreatitis whose diagnosis has not been confirmed by CT scan, US scan and/or upper GI endoscopy
Major age categories	Adults (>16 years old) Children (<16 years old)
Index diagnostic test + treatment	<p>Tests</p> <p>Breath tests (C13 mixed tryglicerides test)</p> <p>Endoscopic-based pancreatic function tests</p> <p>Faecal tests (stool tests): Faecal elastase (monoclonal or polyclonal tests) (<200 micrograms per gram)</p> <p>Faecal tests (stool tests): Faecal fat/coefficient of fat absorption (>7 gr per day, when people are on a 100 gr fat intake)</p> <p>Radiological imaging: MRI</p> <p>Radiological imaging: MRCP (= magnetic resonance cholangiopancreatography)</p> <p>Radiological imaging: Secretin-MRCP</p> <p>Endoscopic imaging: ERCP (= endoscopic retrograde cholangiopancreatography)</p> <p>Endoscopic imaging: Endoscopic US (cut-off: Rosemont criteria: presence of chronic pancreatitis if >5) (including elastography)</p> <p>Combinations of the above tests</p> <p>Where a cut-off is not indicated, the GC was not able to indicate one a priori.</p> <p>Treatment</p> <p>Pancreatic enzyme replacement (PERT) and/or insulin; pain control; management of complications</p>
Comparator index diagnostic tests + treatment or treatment alone (no test)	<p>Tests</p> <p>Biopsy</p> <p>Clinical follow-up</p> <p>Subsequent CT scan</p> <p>Treatment</p> <p>Pancreatic enzyme replacement (PERT) and/or insulin; pain control; management of complications</p>
Outcomes	<p>Critical</p> <p>Quality of life</p> <p>Mortality</p> <p>Adverse events related to test (endoscopic complications)</p> <p>Adverse events related to treatment</p> <p>Important</p> <p>Hospital admission</p> <p>Number of people receiving treatment (i.e. including people who may not have needed it, such as those with false positive results)</p> <p>Patient/physician confidence in test</p>

Review question	In people with suspected (or under investigation for) chronic pancreatitis, in whom other causes have not been excluded by the use of CT scan, ultrasound scan or upper GI endoscopy, what is the most clinically effective and cost effective test to identify whether chronic pancreatitis is present, when each is followed by the appropriate treatment, in order to improve patient outcomes?
	Repeat testing/additional testing
Study design	Diagnostic RCTs Systematic reviews of diagnostic RCTs
Unit of randomisation	Patient or hospital randomised
Review strategy	Stratification – groups that cannot be combined: Age (children; adults) Subgroups: N/A For full details of the review methods please refer to chapter 4 of the full guideline.
Search Strategy	Databases: Cochrane library, Medline, Date limits for search: 1990 Language: English only
Key paper	
Quality assurance measures	Quality assurance will be undertaken by a senior research fellow prior to completion. 10% of papers will be double reviewed (sift and quality assessment).

C.6 Type of intravenous fluid for resuscitation in people with acute pancreatitis

Review question	What is the most clinically effective and cost-effective type of intravenous fluid for resuscitation in people with acute pancreatitis?
Guideline condition and its definition/method of assessment	Acute pancreatitis
Objectives	To identify what type of intravenous fluid is most clinically and cost-effective for people with acute pancreatitis who require fluid resuscitation.
Review population	Those admitted to hospital and receiving treatment for acute pancreatitis
Major age categories	All age categories: Adults and young people (>16) Children (<16)
Setting	Secondary care, tertiary care
Line of therapy	N/A
Interventions and comparators: generic/class; specific/drug	The following types of intravenous fluid: Albumin Synthetic colloids Balanced crystalloids (eg Ringer) Saline
Outcomes	Critical Quality of life (continuous) (<1 year) Mortality (dichotomous) (<1 year) Length of stay (in critical care or hospital) (continuous or dichotomous) Important

Review question	What is the most clinically effective and cost-effective type of intravenous fluid for resuscitation in people with acute pancreatitis?
	Local complications (fluid collection; cystic collection; pancreas necrosis; peri-pancreatic necrosis; local infection) (dichotomous) (<6 months) Systemic complications (persistent organ failure; fluid overload) (dichotomous) (during admission) Serious adverse events (dichotomous) (during admission)
Key confounders	Severity of AP Aetiology Age
Study design	RCTs, systematic reviews of RCTs. If insufficient RCT evidence to form a recommendation is found, non-randomised comparative studies will be included.
Other exclusions	Abstracts Hydroxyethyl starches, as they are not recommended for use by the Medicines and Healthcare products Regulatory Agency due to significant risk of acute kidney injury
Unit of randomisation	Patient or hospital randomised
Population stratification	Age: Adults and young people >16 years old Children <16 years old
Reasons for stratification	Different strategies of fluid resuscitation are used in children
Other stratifications	None
Review strategy/other analysis	Studies will only be included if they reported one of more of the outcomes listed above. For full details of the review methods please refer to chapter 4 of the full guideline.
Subgroup analyses if there is heterogeneity	Elderly (>75) Severity of pancreatitis (as defined by studies; information on the classification of severity used by single studies will be extracted) Type of fluid within class
Search criteria	Databases: Medline, Embase, the Cochrane Library Date limits for search: 1990 Language: Restrict to English only
Quality assurance measures	Quality assurance will be undertaken by a senior research fellow prior to completion. 10% of papers will be double reviewed (sift and quality assessment).

C.7 Speed of intravenous fluid for resuscitation in people with acute pancreatitis

Review question	What is the most clinically effective and cost-effective speed of administration of intravenous fluid for resuscitation in people with acute pancreatitis?
Guideline condition and its definition/method of assessment	Acute pancreatitis

Review question	What is the most clinically effective and cost-effective speed of administration of intravenous fluid for resuscitation in people with acute pancreatitis?
Objectives	To identify what speed of administration of intravenous fluid is most clinically and cost-effective for people with acute pancreatitis who require fluid resuscitation.
Review population	Those admitted to hospital and receiving treatment for acute pancreatitis who require fluid resuscitation
Major age categories	All age categories: Adults and young people (>16) Children (<16)
Setting	Secondary care, tertiary care
Interventions and comparators: generic/class; specific/drug	'Aggressive' fluid administration (as defined by studies, including goal-directed therapies; for example: 15 ml/kg body weight per hour, ≥ 33% of total volume in 72h of infusion performed in the first 24 hrs., >3.1 L given in first 24hrs) 'Conservative' fluid administration (as defined by studies, including goal-directed therapies; for example, 5-10 ml/kg body weight per hour) Studies in the following fluids will be considered: albumin, synthetic colloids, balanced crystalloids (e.g. Ringer), saline. Only studies where both arms use the same type of fluid will be included.
Outcomes	Critical Quality of life (continuous) (<1 year) Mortality (dichotomous) (<1 year) Length of stay (in critical care or hospital) (continuous or dichotomous) Achievement of pre-specified target for resuscitation (for example, target central venous pressure, urine output, lactate levels, PiCCO measurement) Important Local complications (fluid collection; cystic collection; pancreas necrosis; peri-pancreatic necrosis; local infection) (dichotomous) (<6 months) Systemic complications (persistent organ failure; fluid overload) (dichotomous) (during admission) Serious adverse events (dichotomous) (during admission)
Key confounders	Severity of AP Aetiology Age
Study design	RCTs, systematic reviews of RCTs. If insufficient RCT evidence to form a recommendation is found, non-randomised comparative studies will be included.
Other exclusions	Abstracts Studies where arms use different types of fluids Maintenance fluid administration. For studies in patients receiving fluids for resuscitation and then maintenance (for example, bolus plus maintenance strategies), only outcomes at a time-point that is relevant to the resuscitation therapy given (i.e. after 24hrs) will be extracted. In such studies, outcomes reported at one time point (e.g. CCU or hospital mortality) rather than after the "resuscitation" period (e.g. 24hrs) will not be extracted. Hydroxyethyl starches, as they are not recommended for use by the Medicines and Healthcare products Regulatory Agency due to significant risk of acute kidney injury

Review question	What is the most clinically effective and cost-effective speed of administration of intravenous fluid for resuscitation in people with acute pancreatitis?
Unit of randomisation	Patient or hospital randomised
Population stratification	Age: Adults and young people >16 years old Children <16 years old
Reasons for stratification	Different strategies of fluid resuscitation are used in children
Other stratifications	None
Review strategy/other analysis	As there is no universally accepted definition of 'aggressive' or 'conservative' fluid management, the definition given by the studies will be used. For full details of the review methods please refer to chapter 4 of the full guideline.
Subgroup analyses if there is heterogeneity	Age (Elderly >75 years; <75 years) Severity of pancreatitis (as defined by studies; information on the classification of severity used by single studies will be extracted)
Search criteria	Databases: Medline, Embase, the Cochrane Library Date limits for search: 1990 Language: Restrict to English only
Quality assurance measures	Quality assurance will be undertaken by a senior research fellow prior to completion. 10% of papers will be double reviewed (sift and quality assessment).

C.8 Route of feeding in people with severe acute pancreatitis

Review question	What is the most clinically effective and cost effective route of feeding at time of admission to the hospital in people with severe acute pancreatitis?
Guideline condition and its definition/method of assessment	Acute pancreatitis
Objectives	To identify the most clinically and cost-effective route of feeding in people with acute pancreatitis
Review population	People with severe or moderately severe acute pancreatitis admitted to hospital
Major age categories	Adults (>16 years old) Children (<16 years old)
Setting	Secondary and tertiary care
Interventions and comparators: generic/class; specific/drug	The following routes of administration will be considered: Oral feeding Enteral feeding (+/- oral feeding), where separate data are available this will be stratified as: Gastric, or jejunal/duodenal Parenteral feeding (+/- oral feeding) Compared to each other Early versus late
Outcomes	Critical

Review question	What is the most clinically effective and cost effective route of feeding at time of admission to the hospital in people with severe acute pancreatitis?
	<p>Quality of life (continuous) (≤ 1 year)</p> <p>Mortality (dichotomous) (≤ 1 year)</p> <p>Length of stay (in critical care or hospital) (continuous or dichotomous) (≤ 1 year)</p> <p>Achieving nutrition (meeting nutritional requirements; at least 20-25 kcal/kg (dichotomous) (≤ 1 year)</p> <p>Requiring total parenteral nutrition (dichotomous) (≤ 1 year)</p> <p>Important</p> <p>Infections (dichotomous) (≤ 1 year)</p> <p>Serious adverse events (dichotomous) (≤ 1 year)</p> <p>Adverse events (dichotomous) (eg tube displacements, aspirational pneumonia, ischemic gut and central line infections – in PN group)</p> <p>Weight loss (continuous or dichotomous) (≤ 1 year)</p>
Key confounders	<p>Predicted severity on admission</p> <p>Presence of organ failure</p> <p>Vomiting</p>
Study design	<p>RCTs, systematic reviews of RCTs. If insufficient RCT evidence to form a recommendation is found, non-randomised controlled studies will be included.</p>
Other exclusions	<p>Mild acute pancreatitis</p>
Unit of randomisation	<p>Patient or hospital randomised</p>
Population stratification	<p>Age:</p> <p>Adults and young people >16 years old</p> <p>Children <16 years old</p>
Reasons for stratification	<p>Children do not tolerate prolonged periods of nil by mouth in the way adults do and so the routes of feeding routinely used differ from those in adults.</p>
Review strategy/other analysis	<p>Studies will only be included if they reported one of more of the outcomes listed above.</p> <p>Regarding enteral feeding, gastric and jejunal/duodenal will be considered as two different interventions where they are clearly defined in the studies, and comparisons between these two enteral routes will be included. However, if studies describe an intervention as enteral (including a combination of both gastric and jejunal/duodenal) compared with a different feeding route this will also be included.</p> <p>We will accept 'severe' as defined by the author, but acknowledge that there is also a moderately severe category, which will also be included.</p> <p>A network meta-analysis will be considered if sufficient data are available.</p> <p>For full details of the review methods please refer to chapter 4 of the full guideline.</p>
Subgroup analyses if there is heterogeneity	<p>Subgroup analyses will be conducted on the following if there is heterogeneity:</p> <p>Patients in critical care</p>
Search criteria	<p>Databases: Medline, Embase, the Cochrane Library</p> <p>Date limits for search: 1990</p> <p>Language: Restrict to English only</p>
Quality assurance measures	<p>Quality assurance will be undertaken by a senior research fellow prior to</p>

Review question	What is the most clinically effective and cost effective route of feeding at time of admission to the hospital in people with severe acute pancreatitis?
	completion. 10% of papers will be double reviewed (sift and quality assessment)

C.9 Early versus late nutritional intervention in people with chronic pancreatitis

Review question	What is the clinical effectiveness and cost-effectiveness of early compared with late nutritional intervention (for example, food supplements, enzyme supplements) in people with chronic pancreatitis and signs of malnutrition or malabsorption?
Guideline condition and its definition/method of assessment	Chronic pancreatitis
Objectives	To identify the most clinical and cost-effective timing of nutritional intervention in people with chronic pancreatitis and signs of malnutrition or malabsorption.
Review population	Individuals with chronic pancreatitis
Major age categories	All age categories: Adults and young people (>16) Children (<16)
Setting	Primary, secondary and tertiary care
Interventions and comparators: generic/class; specific/drug	Early intervention (as defined by studies, e.g. <5% weight loss) Late intervention (as defined by studies, e.g. ≥5% weight loss) The following interventions will be considered: Nutrition advice Food supplements Enzyme supplements
Outcomes	Critical Quality of life (continuous) (≤ 1 year) Mortality (dichotomous) (≤1 year) Weight loss/BMI (change from baseline or final score; continuous or dichotomous) (≤1 year) Osteoporosis or biochemical deficiencies (dichotomous) (≤1 year) Hospital admissions (dichotomous) (≤1 year) Important Signs of vitamin and mineral deficiency (e.g. skin problems, swollen tongue, poor vision at night, breathlessness, bone and joint pain) (dichotomous) (≤1 year)
Study design	RCTs, systematic reviews of RCTs. If insufficient RCT evidence to form a recommendation is found, non-randomised comparative studies will be included.
Minimum duration of study	1 month
Other exclusions	People with no signs of malnutrition.
Unit of randomisation	Patient or hospital randomised

Review question	What is the clinical effectiveness and cost-effectiveness of early compared with late nutritional intervention (for example, food supplements, enzyme supplements) in people with chronic pancreatitis and signs of malnutrition or malabsorption?
Population stratification	Age: Adults and young people >16 years old Children <16 years old
Reasons for stratification	There may be more long term effects of malnourishment in children undergoing development.
Review strategy/other analysis	Studies will only be included if they reported one of more of the outcomes listed above. For full details of the review methods please refer to chapter 4 of the full guideline.
Subgroup analyses if there is heterogeneity	Subgroup analyses will be conducted on the following if there is heterogeneity: Nutrition advice Food supplements Enzyme supplements
Search criteria	Databases: Medline, Embase, the Cochrane Library Date limits for search: 1990 Language: Restrict to English only
Quality assurance measures	Quality assurance will be undertaken by a senior research fellow prior to completion. 10% of papers will be double reviewed (sift and quality assessment)

C.10 Specialist versus non-specialist nutritional assessment in people with chronic pancreatitis

Review question	What is the clinical effectiveness and cost-effectiveness of a specialist nutritional assessment compared with a non-specialist assessment for managing malabsorption or malnutrition in people with chronic pancreatitis?
Guideline condition and its definition/method of assessment	Chronic pancreatitis
Objectives	To identify what is the clinical and cost effectiveness of a specialist nutritional assessment compared to a non-specialist assessment for managing malabsorption or malnutrition in people with chronic pancreatitis
Review population	Individuals with chronic pancreatitis
Major age categories	Adults (>16 years old) Children (<16 years old)
Setting	All settings (primary, secondary and tertiary care)
Interventions: generic/class; specific/drug	Specialist nutritional assessment
Comparator	Non-specialist nutritional assessment
Outcomes	Critical Quality of life (continuous) (≤ 1 year)

Review question	What is the clinical effectiveness and cost-effectiveness of a specialist nutritional assessment compared with a non-specialist assessment for managing malabsorption or malnutrition in people with chronic pancreatitis?
	<p>Mortality (dichotomous) (≤ 1 year)</p> <p>Weight loss/BMI (change from baseline or final score; continuous or dichotomous) (≤ 1 year)</p> <p>Osteoporosis or biochemical deficiencies (dichotomous) (≤ 1 year)</p> <p>Hospital admissions (dichotomous) (≤ 1 year)</p> <p>Unnecessary dietary restriction (low fat diets) (dichotomous) (≤ 1 year)</p> <p>Important</p> <p>Signs of vitamin and mineral deficiency (e.g. skin problems, swollen tongue, poor vision at night, breathlessness, bone and joint pain) (dichotomous) (≤ 1 year)</p>
Study design	RCTs, systematic reviews of RCTs. If insufficient RCT evidence to form a recommendation is found, non-randomised comparative studies will be included.
Unit of randomisation	Patient or hospital randomised
Crossover study	Not permitted
Other inclusions	Only studies reporting one or more of the outcomes listed above will be included.
Other exclusions	Abstracts
Population stratification	<p>Age:</p> <p>Adults and young people >16 years old</p> <p>Children <16 years old</p>
Reasons for stratification	There may be more long term effects of malnourishment in children undergoing development so they may require specialist assessment to a different extent from adults.
Review strategy/other analysis	<p>Paper will only be included if they reported one or more of the outcomes listed above</p> <p>For some outcomes, no time cut-off was specified a priori. The GC felt it was not appropriate to impose a limit on some outcomes for this review question, because consequences of testing could have a long-term effect.</p> <p>For full details of the review methods please refer to chapter 4 of the full guideline.</p>
Subgroup analyses if there is heterogeneity	<p>Subgroup analyses will be conducted on the following if there is heterogeneity:</p> <p>Pancreatic exocrine insufficiency / no pancreatic exocrine insufficiency</p> <p>Requiring enteral nutrition / not requiring enteral nutrition</p>
Search criteria	<p>Databases: Medline, Embase, the Cochrane Library</p> <p>Date limits for search: 1990</p> <p>Language: English only</p>
Quality assurance measures	<p>Quality assurance will be undertaken by a senior research fellow prior to completion.</p> <p>10% of papers will be double reviewed (sift and quality assessment)</p>

C.11 Prophylactic antimicrobial agents to prevent infection in people with acute pancreatitis

Review question	What is the clinical effectiveness and cost effectiveness of prophylactic antimicrobial agents to prevent infection in people with acute pancreatitis?
Guideline condition and its definition/method of assessment	Acute pancreatitis
Objectives	To identify whether or not the use of prophylactic antimicrobial agents to prevent infection in people with acute pancreatitis is clinically and cost effective.
Review population	Those admitted to hospital with acute pancreatitis.
Major age categories	All age categories: Adults and young people (>16) Children (<16)
Setting	Secondary care, tertiary care
Interventions and comparators: generic/class; specific/drug	<p>Intervention: Any antimicrobial therapy administered prophylactically, including antifungals, for example:</p> <p>Antibiotics</p> <p>Penicillins (Ampicillin, Amoxicillin, Amoxicillin/Clavulanic acid, Piperacillin/Tazobactam)</p> <p>Cephalosporins (Cefuroxime, Ceftriaxone, Cefalexin, Ceftazidime, Cefotaxime)</p> <p>Carbapenems (Meropenem, Imipenem/cilastatin, Ertapenem)</p> <p>Fluoroquinolones (Ciprofloxacin, Ofloxacin, Levofloxacin, Pefloxacin)</p> <p>Imidazole (Metronidazole)</p> <p>Oxazolidinones (Linezolid)</p> <p>Tetracyclines (Tigecycline)</p> <p>Other antibiotics (Vancomycin, Teicoplanin, Clindamycin, Aztreonam)</p> <p>Antifungals:</p> <p>Azoles (Caspofungin, Anidulafungin, Micafungin)</p> <p>Azoles (Fluconazole, Miconazole, Econazole, Clotrimazole, Tioconazole, Omoconazole, Ketoconazole, Voriconazole, Posaconazole, Epoxiconazole)</p> <p>Other antifungals (Amphoterecin)</p> <p>Comparison:</p> <p>No antimicrobial therapy (usual care)</p> <p>Placebo</p> <p>Any antimicrobial therapy</p>
Outcomes	<p>Critical</p> <p>Quality of life (continuous) (≤ 1 year)</p> <p>Mortality (dichotomous) (≤ 1 year)</p> <p>Length of stay (in critical care or hospital) (continuous or dichotomous)</p> <p>Infected necrosis (dichotomous) (≤ 1 year)</p> <p>Important</p> <p>Extra-pancreatic infection (dichotomous) (≤ 1 year)</p> <p>Colonisation of resistant organisms (≤ 6 months, >6 months)</p> <p>Serious adverse events (≤ 6 months, >6 months)</p>
Study design	RCTs, systematic reviews of RCTs.

Review question	What is the clinical effectiveness and cost effectiveness of prophylactic antimicrobial agents to prevent infection in people with acute pancreatitis?
	If insufficient RCT evidence to form a recommendation is found, non-randomised comparative studies will be included for the children strata only.
Other exclusions	People with known infection or already on antibiotics People who are immunosuppressed Abstracts
Unit of randomisation	Patient or hospital randomised
Reasons for stratification	Children with pancreatitis show lower mortality and morbidity rates, lower risk of complications, and lower risk of pancreatic necrosis
Review strategy/other analysis	Antimicrobial agents will be pooled across drug classes and doses. Both inter-class and intra-class comparison allowed For full details of the review methods please refer to chapter 4 of the full guideline.
Subgroup analyses if there is heterogeneity	Subgroup analyses will be conducted on the following if there is heterogeneity: Severity of pancreatitis (as defined by studies; information on the classification of severity used by single studies will be extracted) Drug class / dose / route / duration of therapy
Search criteria	Databases: Medline, Embase, the Cochrane Library Date limits for search: 1990 Language: Restrict to English only
Quality assurance measures	Quality assurance will be undertaken by a senior research fellow prior to completion. This question will be double reviewed in full including double sift and quality assessment.

C.12 Methods of management of infected necrosis in people with acute pancreatitis

Review question	What is the most clinically effective and cost-effective method for managing (suspected) infected necrosis in people with acute pancreatitis?
Guideline condition and its definition/method of assessment	Acute pancreatitis
Objectives	To identify what method is the most clinical and cost-effective type of intervention for managing (suspected) infected necrosis in people with acute pancreatitis.
Review population	Individuals with (suspected) infected necrosis in acute pancreatitis.
Major age categories	All age categories: Adults and young people (>16) Children (<16)
Setting	Secondary care, tertiary care
Interventions and comparators: generic/class; specific/drug	Any of the following interventions: Minimally invasive surgery: percutaneous Minimally invasive surgery: endoscopic

Review question	What is the most clinically effective and cost-effective method for managing (suspected) infected necrosis in people with acute pancreatitis?
	Open surgery Percutaneous drainage (radiological) Antibiotic treatment Combination of intervention techniques: combined approach upfront Combination of intervention techniques: step-up approach No treatment
Outcomes	Critical Quality of life (continuous) (≤ 1 year) Mortality (dichotomous) (≤ 1 year) Length of stay (in critical care or hospital) (continuous or dichotomous) (≤ 1 year) Important Number of procedures (repeated procedures) (≤ 1 year) Recurrence of infection (≤ 1 year) Complications (for example bleeding, fistulae) (≤ 1 year) Pancreatic function (for example development of diabetes) (≤ 1 year)
Key confounders	Percentage necrosis Positive bacteriology Presence of organ failure
Study design	RCTs, systematic reviews of RCTs. If insufficient RCT evidence to form a recommendation is found, non-randomised comparative studies will be included.
Other exclusions	None
Unit of randomisation	Patient or hospital randomised
Review strategy/other analysis	Studies will only be included if they reported one of more of the outcomes listed above. For full details of the review methods please refer to chapter 4 of the full guideline.
Subgroup analyses if there is heterogeneity	Subgroup analysis will be conducted on the following if there is heterogeneity: Severity of infection Severity of pancreatitis Type of minimally invasive surgery Procalcitonin-led antibiotic treatment
Search criteria	Databases: Medline, Embase, the Cochrane Library Date limits for search: 1990 Language: Restrict to English only
Quality assurance measures	Quality assurance will be undertaken by a senior research fellow prior to completion. 10% of papers will be double reviewed (sift and quality assessment).

C.13 Timing of management of infected necrosis in people with acute pancreatitis

Review question	What is the most clinically effective and cost-effective timing of intervention for managing (suspected) infected necrosis in people with acute pancreatitis?
Guideline condition and its definition/method of assessment	Acute pancreatitis
Objectives	To identify what timing of intervention is the most clinical and cost-effective method for managing (suspected) infected necrosis in people with acute pancreatitis.
Review population	Individuals with (suspected) infected necrosis in acute pancreatitis.
Major age categories	All age categories: Adults and young people (>16) Children (<16)
Setting	Secondary care, tertiary care
Interventions and comparators: generic/class; specific/drug	<p>Early intervention (as defined by studies) Late intervention (as defined by studies)</p> <p>The following interventions will be considered: No treatment Minimally invasive surgery: percutaneous Minimally invasive surgery: endoscopic Open surgery Percutaneous drainage (radiological) Antibiotic treatment Combination of intervention techniques: combined approach upfront Combination of intervention techniques: step-up approach</p> <p>Only studies where both arms use the same type of intervention will be included.</p>
Outcomes	<p>Critical Quality of life (continuous) (≤ 1 year) Mortality (dichotomous) (≤ 1 year) Length of stay (in critical care or hospital) (continuous or dichotomous) (≤ 1 year)</p> <p>Important Number of procedures (repeated procedures) (≤ 1 year) Recurrence of infection (≤ 1 year) Complications (for example bleeding, fistulae) (≤ 1 year) Pancreatic function (for example development of diabetes) (≤ 1 year)</p>
Key confounders	Percentage necrosis Positive bacteriology Presence of organ failure
Study design	RCTs, systematic reviews of RCTs. If insufficient RCT evidence to form a recommendation is found, non-randomised comparative studies will be included.
Other exclusions	None

Review question	What is the most clinically effective and cost-effective timing of intervention for managing (suspected) infected necrosis in people with acute pancreatitis?
Unit of randomisation	Patient or hospital randomised
Review strategy/other analysis	Studies will only be included if they reported one of more of the outcomes listed above For full details of the review methods please refer to chapter 4 of the full guideline.
Subgroup analyses if there is heterogeneity	Subgroup analysis will be conducted on the following if there is heterogeneity: Severity of infection Severity of pancreatitis Type of intervention Procalcitonin-led antibiotic treatment
Search criteria	Databases: Medline, Embase, the Cochrane Library Date limits for search: 1990 Language: Restrict to English only
Quality assurance measures	Quality assurance will be undertaken by a senior research fellow prior to completion. 10% of papers will be double reviewed (sift and quality assessment).

C.14 Management of pain in people with chronic pancreatitis

Review question	What is the most clinically effective and cost-effective intervention for managing chronic pain in people with chronic pancreatitis?
Guideline condition and its definition/method of assessment	Chronic pancreatitis
Objectives	To identify what type of intervention is most clinically and cost-effective for managing pain in people with chronic pancreatitis.
Review population	People with chronic pancreatitis presenting with chronic pain
Major age categories	All age categories: Adults and young people (>16) Children (<16)
Setting	Primary care, secondary care, tertiary care
Line of therapy	N/A
Interventions	Nerve blocks Opioids Pharmacological therapies (excluding opioids) Antioxidants Psychological interventions e.g. Psychotherapy Enzyme replacement therapy Surgery Endoscopic treatment Combinations of the above
Comparator	Standard treatment Placebo To each other

Review question	What is the most clinically effective and cost-effective intervention for managing chronic pain in people with chronic pancreatitis?
	No pain relief
Outcomes	<p>Critical</p> <p>Quality of life (continuous) (no time cutoff)</p> <p>Mortality (dichotomous) (no time cutoff)</p> <p>Pain – acute or chronic (duration of pain, reduction in pain, medication reduction) (continuous or dichotomous) (no time cutoff)</p> <p>Important</p> <p>Serious adverse events (dichotomous) (≤ 1 year)</p> <p>Adverse events (dichotomous) (≤ 1 year)</p> <p>Return to usual activities (continuous or dichotomous) (no time cutoff)</p> <p>Pancreatic function (endocrine and exocrine) (no time cutoff)</p>
Study design	<p>RCTs, systematic reviews of RCTs</p> <p>If insufficient RCT evidence to form a recommendation is found, non-randomised comparative studies will be included.</p>
Other exclusions	<p>Abstracts</p> <p>Pharmacological treatment for neuropathic pain (for example, gabapentin). The Pancreatitis guideline will cross-refer to the Neuropathic pain guideline CG173.</p>
Unit of randomisation	Patient or hospital randomised
Population stratification	<p>Age:</p> <p>Adults and young people >16 years old</p> <p>Children <16 years old</p>
Review strategy/other analysis	<p>Studies will only be included if they reported one of more of the outcomes listed above.</p> <p>Where not specified above, a time cut off for outcomes was not defined a priori. For this review question the GC felt it was not appropriate to impose a limit on some outcomes, because consequences of pain relief could have long-term effects.</p> <p>Acute and chronic pain outcomes will be analysed separately.</p> <p>Note: Presentation with chronic pain is the area where the difficulty of pain control exists (although patients with CP occasionally get acute episodes). A network meta-analysis will be considered if sufficient data are available. For full details of the review methods please refer to chapter 4 of the full guideline.</p>
Subgroup analyses if there is heterogeneity	<p>Severity of pain</p> <p>Types of surgery</p> <p>Types of nerve blocks</p> <p>Drug class</p> <p>Types of psychological therapies</p>
Search criteria	<p>Databases: Medline, Embase, the Cochrane Library</p> <p>Date limits for search: 1990</p> <p>Language: Restrict to English only</p>
Quality assurance measures	<p>Quality assurance will be undertaken by a senior research fellow prior to completion.</p> <p>10% of papers will be double reviewed (sift and quality assessment)</p>

C.15 Management of pancreatic duct obstruction in people with chronic pancreatitis

Review question	What is the most clinically effective and cost-effective intervention for managing pancreatic duct obstruction, with or without an inflammatory mass, in people with chronic pancreatitis presenting with chronic pain?
Guideline condition and its definition/method of assessment	Chronic pancreatitis
Objectives	To identify what type of intervention is most clinically and cost-effective for managing pancreatic duct obstruction, with or without an inflammatory mass, in people with chronic pancreatitis presenting with chronic pain.
Review population	People with chronic pancreatitis and pancreatic duct obstruction, with or without an inflammatory mass, presenting with pain
Major age categories	All age categories: Adults and young people (>16) Children (<16)
Setting	Secondary care, tertiary care
Line of therapy	N/A
Interventions	Pancreatic endotherapy (endoscopic techniques – pancreatic stent (plastic or metal), pancreatic sphincterotomy, drainage) Pancreatic ESWL (extracorporeal shock wave lithotripsy [ESWL]) – with or without ERCP Surgery (Resection and/or surgical drainage procedure) Combination of techniques (eg ESWL + pancreatic endotherapy)
Comparator	Standard treatment / no treatment To each other
Outcomes	Critical Quality of life (continuous) no time cutoff) Mortality (dichotomous) (no time cutoff) Complications (dichotomous) (≤ 1 year) Pain – acute or chronic (duration of pain, reduction in pain, medication reduction) (continuous or dichotomous) (no time cutoff) Important Length of stay (in critical care or hospital) (continuous) (≤ 1 year) Repeated procedures (dichotomous) (no time cutoff) Pancreatic function (endocrine and exocrine) (no time cutoff)
Study design	RCTs, systematic reviews of RCTs If insufficient RCT evidence to form a recommendation is found, non-randomised comparative studies will be included.
Other exclusions	Abstracts
Unit of randomisation	Patient or hospital randomised
Population stratification	Age: adults >16 years old children and young people <16 years old
Review strategy/other analysis	Studies will only be included if they reported one of more of the outcomes listed above. Where not specified above, a time cut off for outcomes was not defined a priori. For this review question the GC felt it was not appropriate to impose a limit on some outcomes, because consequences of surgery (for example,

Review question	What is the most clinically effective and cost-effective intervention for managing pancreatic duct obstruction, with or without an inflammatory mass, in people with chronic pancreatitis presenting with chronic pain?
	stents) could and have long-term effects. Acute and chronic pain outcomes will be analysed separately. Note: Presentation with chronic pain is the area where the difficulty of pain control exists (although patients with CP occasionally get acute episodes). A network meta-analysis will be considered if sufficient data are available. For full details of the review methods please refer to chapter 4 of the full guideline.
Subgroup analyses if there is heterogeneity	Presence of an inflammatory mass (yes/no) Type of surgery (resection/surgical drainage) Types of endotherapy
Search criteria	Databases: Medline, Embase, the Cochrane Library Date limits for search: 1990 Language: Restrict to English only
Quality assurance measures	Quality assurance will be undertaken by a senior research fellow prior to completion. 10% of papers will be double reviewed (sift and quality assessment).

C.16 Management of small-duct disease in people with chronic pancreatitis

Review question	What is the most clinically effective and cost-effective intervention for managing small-duct disease (in the absence of pancreatic duct obstruction, inflammatory mass or pseudocyst) in people with chronic pancreatitis presenting with chronic pain?
Guideline condition and its definition/method of assessment	Chronic pancreatitis
Objectives	To identify what type of intervention is most clinically and cost-effective for managing small-duct disease in people with chronic pancreatitis presenting with chronic pain.
Review population	People with chronic pancreatitis and small-duct disease presenting with pain
Major age categories	All age categories: Adults and young people (>16) Children (<16)
Setting	Secondary care, tertiary care
Line of therapy	N/A
Interventions	Surgery (partial or total resection, resection and drainage operation,) Endoscopic treatment
Comparator	Standard care treatment (for example, pharmacological treatment only/enzyme replacement therapy/nerve blocks) / no treatment To each other
Outcomes	Critical Quality of life (continuous) (no time cutoff) Mortality (dichotomous) (no time cutoff)

Review question	What is the most clinically effective and cost-effective intervention for managing small-duct disease (in the absence of pancreatic duct obstruction, inflammatory mass or pseudocyst) in people with chronic pancreatitis presenting with chronic pain?
	<p>Complications (dichotomous) (≤ 1 year)</p> <p>Pain – acute or chronic (duration of pain, reduction in pain, medication reduction) (continuous or dichotomous) (no time cutoff)</p> <p>Important</p> <p>Length of stay (in critical care or hospital) (continuous) (≤ 1 year)</p> <p>Repeated procedures (dichotomous) (no time cutoff)</p> <p>Pancreatic function (endocrine and exocrine) (no time cutoff)</p>
Key confounders	<p>Presence of diabetes;</p> <p>Opiates for pain;</p> <p>Presence of pancreatic calcification;</p> <p>Continued alcohol consumption;</p> <p>Continued smoking.</p>
Study design	<p>RCTs, systematic reviews of RCTs</p> <p>If insufficient RCT evidence to form a recommendation is found, non-randomised comparative studies will be included.</p>
Other exclusions	Abstracts
Unit of randomisation	Patient or hospital randomised
Population stratification	<p>Age:</p> <p>Adults and young people >16 years old</p> <p>Children <16 years old</p>
Review strategy/other analysis	<p>Studies will only be included if they reported one of more of the outcomes listed above.</p> <p>Where not specified above, a time cut off for outcomes was not defined a priori. For this review question the GC felt it was not appropriate to impose a limit on some outcomes, because consequences of treatment could have long-term effects.</p> <p>Acute and chronic pain outcomes will be analysed separately.</p> <p>Note: Presentation with chronic pain is the area where the difficulty of pain control exists (although patients with CP occasionally get acute episodes).</p> <p>A network meta-analysis will be considered if sufficient data are available.</p> <p>For full details of the review methods please refer to chapter 4 of the full guideline.</p>
Subgroup analyses if there is heterogeneity	<p>Type of surgery</p> <p>Type of endotherapy</p>
Search criteria	<p>Databases: Medline, Embase, the Cochrane Library</p> <p>Date limits for search: 1990</p> <p>Language: Restrict to English only</p>
Quality assurance measures	<p>Quality assurance will be undertaken by a senior research fellow prior to completion.</p> <p>10% of papers will be double reviewed (sift and quality assessment).</p>

C.17 Management of pseudocysts

Review question	What is the most clinically effective and cost-effective intervention for managing pseudocysts in people with pancreatitis presenting with or without pain?
Guideline condition and its definition/method of assessment	Acute or chronic pancreatitis
Objectives	To identify what type of intervention is most clinically and cost-effective for managing pseudocysts in people with acute or chronic pancreatitis with or without pain.
Review population	People with acute or chronic pancreatitis and pseudocysts presenting with or without pain
Major age categories	All age categories: Adults and young people (>16) Children (<16)
Setting	Secondary care, tertiary care
Line of therapy	N/A
Interventions	Pancreatic endoscopic stent Endoscopic drainage (EUS-guided) Laparoscopic drainage Percutaneous drainage Open surgery (resection/drainage) Combination of techniques
Comparator	Standard treatment/no treatment To each other
Outcomes	Critical Quality of life (continuous) no time cutoff) Mortality (dichotomous) (≤ 1 year) Complications – bleeding, perforation and infection or overall rate of complications (dichotomous) (no time cutoff) Resolution of presenting symptoms (e.g Pain, nutritional status, gastric outlet obstruction) (continuous or dichotomous) (no time cutoff) Resolution or recurrence of pseudocysts (dichotomous) (no time cutoff) Important Length of stay (in critical care or hospital) (continuous or dichotomous) (≤ 1 year) Repeated procedures (dichotomous) (no time cutoff)
Study design	RCTs, systematic reviews of RCTs If insufficient RCT evidence to form a recommendation is found, non-randomised comparative studies will be included.
Other exclusions	Abstracts
Unit of randomisation	Patient or hospital randomised
Population stratification	Age: Adults and young people >16 years old Children <16 years old
Review strategy/other analysis	Studies will only be included if they reported one of more of the outcomes listed above. Where not specified above, a time cut off for outcomes was not defined a priori. For this review question the GC felt it was not appropriate to impose a limit on some outcomes, because consequences of surgery (for example,

Review question	What is the most clinically effective and cost-effective intervention for managing pseudocysts in people with pancreatitis presenting with or without pain?
	stents) could have long-term effects A network meta-analysis will be considered if sufficient data are available. For full details of the review methods please refer to chapter 4 of the full guideline.
Subgroup analyses if there is heterogeneity	Presence of pain (people presenting with pain; people presenting without pain) Pancreatitis (acute pancreatitis; chronic pancreatitis) Type of stent Type of surgery
Search criteria	Databases: Medline, Embase, the Cochrane Library Date limits for search: 1990 Language: Restrict to English only
Quality assurance measures	Quality assurance will be undertaken by a senior research fellow prior to completion. 10% of papers will be double reviewed (sift and quality assessment)

C.18 Management of pancreatic ascites and pleural effusion secondary to pancreatitis

Review question	What are the most clinically effective and cost-effective interventions for treating pancreatic ascites and pleural effusion secondary to acute or chronic pancreatitis?
Guideline condition and its definition/method of assessment	Acute or chronic pancreatitis
Objectives	To identify what method is the most clinical and cost-effective type of intervention for treating pancreatic ascites and pleural effusion secondary to acute or chronic pancreatitis
Review population	People with ascites and pleural effusion, including fistulae and intra-abdominal collections, secondary to acute or chronic pancreatitis
Major age categories	All age categories: Adults and young people (>16) Children (<16)
Setting	Secondary care, tertiary care
Interventions and comparators: generic/class; specific/drug	Percutaneous intervention (e.g. aspiration and/or drainage) Surgery (e.g. resection or drainage procedure) Pharmacological treatment (e.g. somatostatin analogue, for example octreotide, lanreotide; diuretics e.g. spironolactone) Nutritional supplements (enteral or parenteral) Pancreatic endotherapy Combinations
Comparator	To each other No treatment

Review question	What are the most clinically effective and cost-effective interventions for treating pancreatic ascites and pleural effusion secondary to acute or chronic pancreatitis?
	Usual care
Outcomes	<p>Critical</p> <p>Quality of life (continuous) (no time cutoff)</p> <p>Mortality (dichotomous) (no time cutoff)</p> <p>Length of stay (in critical care or hospital) (continuous or dichotomous) (no time cutoff)</p> <p>Resolution (e.g. resolution of fluid collection, resolution of fistulae) (no time cutoff)</p> <p>Important</p> <p>Number of procedures (repeated procedures) (time cutoff)</p> <p>Recurrence (time cutoff)</p> <p>Complications (no time cutoff)</p>
Study design	RCTs, systematic reviews of RCTs. If insufficient RCT evidence to form a recommendation is found, non-randomised comparative studies will be included.
Other exclusions	None
Unit of randomisation	Patient or hospital randomised
Review strategy/other analysis	<p>Studies will only be included if they reported one of more of the outcomes listed above.</p> <p>No time cutoff – this is a recurrent condition</p> <p>For full details of the review methods please refer to chapter 4 of the full guideline.</p>
Subgroup analyses if there is heterogeneity	<p>Subgroup analysis will be conducted on the following if there is heterogeneity:</p> <p>Acute or chronic pancreatitis (Ascites and pleural effusion related to chronic pancreatitis are more likely to be associated with pancreatic duct disruption and so may influence the definitive treatment required.)</p>
Search criteria	<p>Databases: Medline, Embase, the Cochrane Library</p> <p>Date limits for search: 1990</p> <p>Language: Restrict to English only</p>
Quality assurance measures	<p>Quality assurance will be undertaken by a senior research fellow prior to completion.</p> <p>10% of papers will be double reviewed (sift and quality assessment).</p>

C.19 Management of biliary obstruction in people with chronic pancreatitis

Review question	What is the most clinically effective and cost-effective intervention for treating biliary obstruction in people with chronic pancreatitis?
Guideline condition and its definition/method of assessment	Chronic pancreatitis
Objectives	To identify what method is the most clinical and cost-effective type of intervention for treating biliary obstruction in people with chronic pancreatitis.

Review question	What is the most clinically effective and cost-effective intervention for treating biliary obstruction in people with chronic pancreatitis?
Review population	People with biliary obstruction and chronic pancreatitis
Major age categories	All age categories: Adults and young people (>16) Children (<16)
Setting	Secondary care, tertiary care
Interventions	Plastic stents (single, multiple) Metal stents (uncovered, partially covered, fully covered) Surgery (for example, hepatojejunostomy, choledocho-jejunostomy, biliary-enteric anastomosis) Combination stent + surgery (eg step-up approach as defined by studies)
Comparator	To each other
Outcomes	Critical Quality of life (continuous) Mortality (dichotomous) (≤ 1 year) Recurrence of biliary obstruction (including failed stent, both removal and additional stents) (dichotomous) Biliary infections (dichotomous) Important Number of procedures (repeated procedures) (dichotomous) Length of stay (in critical care or hospital) (continuous or dichotomous) Complications (for example, bleeding, fistulae) (dichotomous)
Key confounders	Presence of pancreatic head mass Portal hypertension or portal vein thrombosis Previous biliary stent
Study design	RCTs, systematic reviews of RCTs. If insufficient RCT evidence to form a recommendation is found, non-randomised controlled studies will be included.
Other exclusions	None
Unit of randomisation	Patient or hospital randomised
Reasons for stratification	Treatment modalities are different in children.
Review strategy/other analysis	Studies will only be included if they reported one of more of the outcomes listed above. Where not specified above, a time cut off for outcomes was not defined a priori. For this review question the GC felt it was not appropriate to impose a limit on some outcomes, because consequences of surgery (for example, stents) could have long-term effects A network meta-analysis will be considered if sufficient data are available. For full details of the review methods please refer to chapter 4 of the full guideline.
Subgroup analyses if there is heterogeneity	Subgroup analysis will be conducted on the following if there is heterogeneity: Timing of intervention (prophylactic surgery/on demand surgery) Type of stent (endoscopic vs percutaneous insertion of stent; single/multiple; uncovered/partially covered/fully covered) Type of surgery
Search criteria	Databases: Medline, Embase, the Cochrane Library Date limits for search: 1990

Review question	What is the most clinically effective and cost-effective intervention for treating biliary obstruction in people with chronic pancreatitis?
	Language: Restrict to English only
Quality assurance measures	Quality assurance will be undertaken by a senior research fellow prior to completion. 10% of papers will be double reviewed (sift and quality assessment)

C.20 Management of type 3c diabetes secondary to pancreatitis

Review question	What is the most clinically effective and cost-effective insulin regimen strategy specifically for type 3c diabetes secondary to pancreatitis?
Guideline condition and its definition/method of assessment	People with acute and chronic pancreatitis
Objectives	To identify the most clinically and cost-effective insulin regimen strategy for diabetes secondary to pancreatitis (type 3c diabetes)
Review population	Individuals diagnosed with diabetes secondary to pancreatitis C peptide-positive people only Includes chronic pancreatitis in people with Cystic fibrosis mutations
Major age categories	All age categories: Adults and young people (>16 years) Children (<16 years)
Setting	Primary, secondary and tertiary care
Interventions: generic/class; specific/drug	Multiple daily injection therapy (basal-bolus)
Comparator	Twice daily insulin regimen Insulin pump
Outcomes	<p>Critical</p> <p>Quality of life (continuous) (≤ 1 year)</p> <p>HbA1c levels (continuous) (no time cutoff)</p> <p>Hospital admissions (for example related to diabetic ketoacidosis or decompensated high glucose levels) (dichotomous)(no time cutoff)</p> <p>Severe hypoglycemia (as defined by the American Diabetes association: an event requiring assistance of another person to actively administer carbohydrates, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration) (dichotomous) (no time cutoff)</p> <p>Important</p> <p>Mortality (dichotomous) (≤ 1 year)</p> <p>Hyperglycaemic hyperosmolar nonketotic coma (HONK) (dichotomous) (≤ 1 year)</p> <p>Fear of hypoglycemia according to known validated scoring systems (for example, Hypoglycemia fear survey) (no time cutoff)</p> <p>Impaired awareness of hypoglycemia according to known validated scoring systems (for example, Gold score, Clarke score, Ryan score (Hypoglycaemia burden score) , Pedersen-Bjergaard score) (dichotomous) (no time cutoff)</p>
Study design	RCTs, systematic reviews of RCTs. If insufficient RCT evidence to form a

Review question	What is the most clinically effective and cost-effective insulin regimen strategy specifically for type 3c diabetes secondary to pancreatitis?
	recommendation is found, non-randomised comparative studies will be included.
Unit of randomisation	Patient or hospital randomised
Other exclusions	Abstracts Type 3c diabetes secondary to pancreatic cancer C-peptide negative patients Once-daily insulin therapy (\pm oral glucose lowering agents) Comparisons of insulin with oral agents (this would not be of value as likely to reflect different severity of disease, eg C-peptide insufficiency) Management of decompensated glucose levels during acute pancreatitis hospital admission Studies comparing specific types of insulin against each other (for example, different types of long-acting insulin compared to each other)
Population stratification	All age categories: Adults and young people (>16 years) Children (<16 years)
Reasons for stratification	Treatment modalities are different in children.
Review strategy/other analysis	Studies will only be included if they reported one of more of the outcomes listed above. For full details of the review methods please refer to chapter 4 of the full guideline.
Subgroup analyses if there is heterogeneity	Severity of disease (as assessed by presence of calcification in pancreas) Complications of chronic pancreatitis Previous pancreatic surgery Current insulin therapy (yes/no)
Search criteria	Databases: Medline, Embase, the Cochrane Library Date limits for search: 1990 Language: Restrict to English only
Quality assurance measures	Quality assurance will be undertaken by a senior research fellow prior to completion. 10% of papers will be double reviewed (sift and quality assessment)

C.21 Receiving specialist input in people with acute pancreatitis

Review question	What is the clinical effective and cost-effectiveness of receiving specialist input in people with acute pancreatitis?
Guideline condition and its definition/method of assessment	Pancreatitis
Objectives	To determine the clinical and cost-effectiveness of receiving specialist input in people with acute pancreatitis
Review population	People with acute pancreatitis
Major age categories	All age categories: Adults and young people (>16 years) Children (<16 years)
Setting	Primary, secondary and tertiary care

Review question	What is the clinical effective and cost-effectiveness of receiving specialist input in people with acute pancreatitis?
Interventions: generic/class; specific/drug	Specialist input in the diagnosis, management or follow-up of acute pancreatitis (regardless of setting; e.g., specialist consultation in a secondary setting)
Comparator	No specialist input in the diagnosis, management or follow-up of acute pancreatitis
Outcomes	<p>Critical</p> <p>Quality of life (continuous) (no time cutoff)</p> <p>Mortality (dichotomous) (no time cutoff)</p> <p>Length of stay (continuous) (no time cutoff)</p> <p>Important</p> <p>Hospital admissions (dichotomous) (no time cutoff)</p> <p>Complications (dichotomous) (no time cutoff)</p>
Study design	RCTs, systematic reviews of RCTs. If insufficient RCT evidence to form a recommendation is found, non-randomised comparative studies will be included.
Other exclusions	Abstracts
Unit of randomisation	Patient or hospital randomised
Population stratification	<p>Age:</p> <p>Adults and young people (>16 years)</p> <p>Children (<16 years)</p>
Reasons for stratification	Treatment modalities are different in children.
Review strategy/other analysis	<p>Studies will only be included if they reported one of more of the outcomes listed above.</p> <p>Specialist input was defined as:</p> <p>A tertiary centre; or</p> <p>Consultation with a pancreatitis specialist (either in person or by teleconference); or</p> <p>Consultation in person with a GI specialist</p> <p>For full details of the review methods please refer to chapter 4 of the full guideline.</p>
Subgroup analyses if there is heterogeneity	<p>Severity of disease, as assessed by the revised Atlanta criteria 2012:</p> <p>Mild: no organ failure; no local complications;</p> <p>Moderate: transient organ failure <48h with or without local complications</p> <p>Severe: persistent organ failure >48h</p> <p>Previous pancreatic surgery</p> <p>Presence of necrosis</p> <p>Presence of recurrent acute pancreatitis</p> <p>Aetiology</p> <p>Worsening or persistent organ failure (>48 hours)</p> <p>Presence of ductal changes</p> <p>Age at diagnosis</p>
Search criteria	<p>Databases: Medline, Embase, the Cochrane Library</p> <p>Date limits for search: 1990</p> <p>Language: Restrict to English only</p>
Quality assurance measures	<p>Quality assurance will be undertaken by a senior research fellow prior to completion.</p> <p>10% of papers will be double reviewed (sift and quality assessment)</p>

C.22 Follow-up of pancreatic exocrine function in people with chronic pancreatitis

Review question	How often should follow up to assess pancreatic exocrine function and any secondary health issues, if any, be carried out in people with chronic pancreatitis?
Guideline condition and its definition/method of assessment	Chronic pancreatitis
Objectives	To identify the frequency that investigations should be conducted during follow-up in people with chronic pancreatitis
Review population	People with a diagnosis of chronic pancreatitis
Major age categories	All age categories: Adults and young people (>16 years) Children (<16 years)
Setting	Primary, secondary, tertiary settings
Interventions: generic/class; specific/drug	Follow up (with any of the following tests, alone or in combination: faecal elastase; assessment of nutritional status (for example, measurement of fat-soluble vitamins ADEK; iron; body weight; anthropometrics (for example Z scores); PTH); bone density (DEXA scan)) 6-monthly (or at intervals of ≤ 6 months) Yearly (or at intervals of 6 months - 1 year) At intervals >1 year No follow-up
Comparison	Follow-up versus no follow-up (or follow-up on demand) Different frequency of same follow up investigation
Outcomes	Critical Quality of life (continuous) Mortality (dichotomous) Exocrine function (as measured by for example faecal elastase) Low impact fractures (dichotomous) Changes in nutritional status Important Hospital admissions (dichotomous) Return to usual activities (dichotomous)
Study design	RCTs, systematic reviews of RCTs. If insufficient RCT evidence to form a recommendation is found, non-randomised comparative studies will be included.
Unit of randomisation	Patient or hospital randomised
Other exclusions	Abstracts
Population stratification	Etiology of pancreatitis: hereditary pancreatitis any other etiology Age: Adults and young people >16 years old Children <16 years old
Reasons for stratification	People with hereditary pancreatitis are at higher risk of developing pancreatic cancer; they are also currently followed up as per EUROPAC

Review question	How often should follow up to assess pancreatic exocrine function and any secondary health issues, if any, be carried out in people with chronic pancreatitis?
	guidance Hereditary pancreatitis is more common as aetiology in children
Review strategy/other analysis	Papers will only be included if they reported one or more of the outcomes above. No cut-off for outcomes was established. The GC felt it was not appropriate to impose a limit on outcomes for this review question, as consequences of testing could have a long-term effect. For full details of the review methods please refer to chapter 4 of the full guideline.
Subgroup analyses if there is heterogeneity	Type of investigation (eg imaging) Type of genetic mutation (in hereditary pancreatitis)
Search criteria	Databases: Medline, Embase, the Cochrane Library Date limits for search: 1990 Language: Restrict to English only
Quality assurance measures	Quality assurance will be undertaken by a senior research fellow prior to completion. 10% of papers will be double reviewed (sift and quality assessment).

C.23 Follow-up to identify diabetes in people with chronic pancreatitis

Review question	How often should follow up to identify the development of diabetes be carried out in people with chronic pancreatitis?
Guideline condition and its definition/method of assessment	Chronic pancreatitis
Objectives	To identify the frequency that investigations should be conducted during follow-up in people with chronic pancreatitis
Review population	People with a diagnosis of chronic pancreatitis
Major age categories	All age categories: Adults and young people (>16 years) Children (<16 years)
Setting	Primary, secondary, tertiary settings
Interventions: generic/class; specific/drug	Surveillance (with HbA1c; fasting glucose; OGTT) 6-monthly (or at intervals of ≤ 6 months) Yearly (or at intervals of 6 months - 1 year) At intervals >1 year No surveillance
Comparison	Follow-up versus no follow-up (or follow-up on demand) Different frequency of same follow up investigation
Outcomes	Critical Quality of life (continuous) Mortality (dichotomous) Important People requiring insulin (dichotomous) Diabetic complications (for example, retinopathy, peripheral neuropathy, CKD) (dichotomous)

Review question	How often should follow up to identify the development of diabetes be carried out in people with chronic pancreatitis?
	Diagnosis of diabetes (dichotomous)
Study design	RCTs, systematic reviews of RCTs. If insufficient RCT evidence to form a recommendation is found, non-randomised comparative studies will be included.
Unit of randomisation	Patient or hospital randomised
Other inclusions	Define
Other exclusions	Abstracts
Population stratification	Etiology of pancreatitis: hereditary pancreatitis any other etiology Age: Adults and young people >16 years old Children <16 years old
Reasons for stratification	People with hereditary pancreatitis are at higher risk of developing pancreatic cancer; they are also currently followed up as per EUROPAC guidance Hereditary pancreatitis is more common as aetiology in children
Review strategy/other analysis	Papers will only be included if they reported one or more of the outcomes above. No cut-off for outcomes was established. The GC felt it was not appropriate to impose a limit on outcomes for this review question, as consequences of testing could have a long-term effect. For full details of the review methods please refer to chapter 4 of the full guideline.
Subgroup analyses if there is heterogeneity	Type of investigation (eg imaging) Type of genetic mutation (in hereditary pancreatitis)
Search criteria	Databases: Medline, Embase, the Cochrane Library Date limits for search: 1990 Language: Restrict to English only
Quality assurance measures	Quality assurance will be undertaken by a senior research fellow prior to completion. 10% of papers will be double reviewed (sift and quality assessment).

C.24 Follow-up to identify pancreatic cancer in people with chronic pancreatitis

Review question	How often should follow up to identify the development of pancreatic cancer be carried out in people with chronic pancreatitis?
Guideline condition and its definition/method of assessment	Chronic pancreatitis
Objectives	To identify the frequency that investigations should be conducted during follow-up in people with chronic pancreatitis
Review population	People with a diagnosis of chronic pancreatitis
Major age categories	All age categories: Adults and young people (>16 years)

Review question	How often should follow up to identify the development of pancreatic cancer be carried out in people with chronic pancreatitis?
	Children (<16 years)
Setting	Primary, secondary, tertiary settings
Interventions: generic/class; specific/drug	Surveillance (with any of the following tests, alone or in combination: tumour markers (eg CA19.9); MRI; EUS; CT) 6-monthly (or at intervals of ≤ 6 months) Yearly (or at intervals of 6 months - 1 year) At intervals >1 year No surveillance
Comparison	Follow-up versus no follow-up (or follow-up on demand) Different frequency of same follow up investigation
Outcomes	Critical Quality of life (continuous) Mortality (dichotomous) Cancer-related mortality (dichotomous) Important Stage of cancer at diagnosis Serious adverse events (dichotomous)
Study design	RCTs, systematic reviews of RCTs. If insufficient RCT evidence to form a recommendation is found, non-randomised comparative studies will be included.
Unit of randomisation	Patient or hospital randomised
Other exclusions	Abstracts
Population stratification	Etiology of pancreatitis: hereditary pancreatitis any other etiology Age: Adults and young people >16 years old Children <16 years old
Reasons for stratification	People with hereditary pancreatitis are at higher risk of developing pancreatic cancer; they are also currently followed up as per EUROPAC guidance Hereditary pancreatitis is more common as aetiology in children
Review strategy/other analysis	Papers will only be included if they reported one or more of the outcomes above. No cut-off for outcomes was established. The GC felt it was not appropriate to impose a limit on outcomes for this review question, as consequences of testing could have a long-term effect. For full details of the review methods please refer to chapter 4 of the full guideline.
Subgroup analyses if there is heterogeneity	Type of investigation (eg imaging) Type of genetic mutation (in hereditary pancreatitis)
Search criteria	Databases: Medline, Embase, the Cochrane Library Date limits for search: 1990 Language: Restrict to English only
Quality assurance measures	Quality assurance will be undertaken by a senior research fellow prior to completion. 10% of papers will be double reviewed (sift and quality assessment).

Appendix D: Health economic review protocol


Review question	All questions – health economic evidence
Objectives	To identify health economic studies relevant to any of the review questions.
Search criteria	<p>Populations, interventions and comparators must be as specified in the clinical review protocols in appendix D above.</p> <p>Studies must be of a relevant health economic study design (cost–utility analysis, cost-effectiveness analysis, cost–benefit analysis, cost–consequences analysis, comparative cost analysis).</p> <p>Studies must not be a letter, editorial or commentary, or a review of health economic evaluations. (Recent reviews will be ordered although not reviewed. The bibliographies will be checked for relevant studies, which will then be ordered.)</p> <p>Unpublished reports will not be considered unless submitted as part of a call for evidence.</p> <p>Studies must be in English.</p>
Search strategy	A health economic study search will be undertaken using population-specific terms and a health economic study filter – see appendix G.
Review strategy	<p>Studies not meeting any of the search criteria above will be excluded. Studies published before 2001, abstract-only studies and studies from non-OECD countries or the USA will also be excluded.</p> <p>Each remaining study will be assessed for applicability and methodological limitations using the NICE economic evaluation checklist which can be found in appendix H of Developing NICE guidelines: the manual (2014).⁷⁸⁷</p> <p>Inclusion and exclusion criteria</p> <ul style="list-style-type: none"> • If a study is rated as both ‘Directly applicable’ and with ‘Minor limitations’ then it will be included in the guideline. A health economic evidence table will be completed and it will be included in the health economic evidence profile. • If a study is rated as either ‘Not applicable’ or with ‘Very serious limitations’ then it will usually be excluded from the guideline. If it is excluded then a health economic evidence table will not be completed and it will not be included in the health economic evidence profile. • If a study is rated as ‘Partially applicable’, with ‘Potentially serious limitations’ or both then there is discretion over whether it should be included. <p>Where there is discretion</p> <p>The health economist will make a decision based on the relative applicability and quality of the available evidence for that question, in discussion with the guideline committee if required. The ultimate aim is to include health economic studies that are helpful for decision-making in the context of the guideline and the current NHS setting. If several studies are considered of sufficiently high applicability and methodological quality that they could all be included, then the health economist, in discussion with the committee if required, may decide to include only the most applicable studies and to selectively exclude the remaining studies. All studies excluded on the basis of applicability or methodological limitations will be listed with explanation as excluded health economic studies in appendix M.</p> <p>The health economist will be guided by the following hierarchies.</p> <p><i>Setting:</i></p> <ul style="list-style-type: none"> • UK NHS (most applicable). • OECD countries with predominantly public health insurance systems (for example, France,

Review question	All questions – health economic evidence
	<p>Germany, Sweden).</p> <ul style="list-style-type: none"> • OECD countries with predominantly private health insurance systems (for example, Switzerland). • Studies set in non-OECD countries or in the USA will be excluded before being assessed for applicability and methodological limitations. <p><i>Health economic study type:</i></p> <ul style="list-style-type: none"> • Cost–utility analysis (most applicable). • Other type of full economic evaluation (cost–benefit analysis, cost-effectiveness analysis, cost–consequences analysis). • Comparative cost analysis. • Non-comparative cost analyses including cost-of-illness studies will be excluded before being assessed for applicability and methodological limitations. <p><i>Year of analysis:</i></p> <ul style="list-style-type: none"> • The more recent the study, the more applicable it will be. • Studies published in 2001 or later but that depend on unit costs and resource data entirely or predominantly from before 2001 will be rated as ‘Not applicable’. • Studies published before 2001 will be excluded before being assessed for applicability and methodological limitations. <p><i>Quality and relevance of effectiveness data used in the health economic analysis:</i></p> <p>The more closely the clinical effectiveness data used in the health economic analysis match with the outcomes of the studies included in the clinical review the more useful the analysis will be for decision-making in the guideline.</p>

Appendix E: Clinical study selection


E.1 Patient information (qualitative study selection)

Figure 1: Flow chart of qualitative study selection for the review of information and support




E.2 Aetiology of acute pancreatitis

Figure 2: Flow chart of clinical study selection for the review of aetiology of acute pancreatitis




E.3 Aetiology of chronic pancreatitis

Figure 3: Flow chart of clinical study selection for the review of aetiology of chronic pancreatitis




E.4 Diagnosing chronic pancreatitis

Figure 4: Flow chart of clinical study selection for the review of Diagnosis of chronic pancreatitis




E.5 Lifestyle interventions: stopping or reducing alcohol consumption

Figure 5: Flow chart of clinical study selection for the review of lifestyle intervention (alcohol consumption)




E.6 Fluid Resuscitation - Type

Figure 6: Flow chart of clinical study selection for the reviews of IV fluid for resuscitation in acute pancreatitis




E.7 Speed of intravenous fluid for resuscitation in people with acute pancreatitis

Figure 7: Flow chart of clinical study selection for the review of IV fluid resuscitation in acute pancreatitis




E.8 Route of feeding in people with severe acute pancreatitis

Figure 8: Flow chart of clinical study selection for the review of route of feeding for severe acute pancreatitis




E.9 Early versus late nutritional intervention in people with chronic pancreatitis

Figure 9: Flow chart of clinical study selection for the review of the timing of nutritional intervention




E.10 Specialist versus non-specialist nutritional assessment in people with chronic pancreatitis

Figure 10: Flow chart of clinical study selection for the review of specialist versus non-specialist nutritional assessment




E.11 Prophylactic antimicrobial agents to prevent infection in people with acute pancreatitis

Figure 11: Flow chart of clinical study selection for the review of antimicrobial prophylaxis for acute pancreatitis




E.12 Methods of management of infected necrosis in people with acute pancreatitis

Figure 12: Flow chart of clinical study selection for the review of what is the most clinical and cost-effective method for managing (suspected) infected necrosis in people with acute pancreatitis?




E.13 Timing of management of infected necrosis in people with acute pancreatitis

Figure 13: Flow chart of clinical study selection for the review of the timing of intervention for managing infected necrosis in people with acute pancreatitis




E.14 Management of pain in people with chronic pancreatitis

Figure 14: Flow chart of clinical study selection for the review of management of pain in people with chronic pancreatitis




E.15 Management of pancreatic duct obstruction in people with chronic pancreatitis

Figure 15: Flow chart of clinical study selection for the review of what is the most clinically and cost-effective intervention for managing pancreatic duct obstruction, with or without an inflammatory mass, in people with chronic pancreatitis presenting with pain?




E.16 Management of small-duct disease in people with chronic pancreatitis

Figure 16: Flow chart of clinical study selection for the review of pain management in small duct disease




E.17 Management of pseudocysts

Figure 17: Flow chart of clinical study selection for the review of pseudocysts




E.18 Management of pancreatic ascites and pleural effusion secondary to pancreatitis

Figure 18: Flow chart of clinical study selection for the review of managing pancreatic ascites and pleural effusion




E.19 Management of biliary obstruction in people with chronic pancreatitis

Figure 19: Flow chart of clinical study selection for the review of interventions for treating biliary obstruction in people with chronic pancreatitis




E.20 Management of type 3c diabetes secondary to pancreatitis

Figure 20: Flow chart of clinical study selection for the review of insulin management for type 3c diabetes




E.21 Receiving specialist input in people with acute pancreatitis

Figure 21: Flow chart of clinical study selection for the review of receiving specialist input




E.22 Follow-up of pancreatic exocrine function in people with chronic pancreatitis

Figure 22: Flow chart of clinical study selection for the review of follow-up to assess pancreatic exocrine function




E.23 Follow-up to identify diabetes in people with chronic pancreatitis

Figure 23: Flow chart of clinical study selection for the review of follow-up of diabetes




E.24 Follow-up to identify pancreatic cancer in people with chronic pancreatitis

Figure 24: Flow chart of clinical study selection for the review of follow-up of pancreatic cancer



Appendix F: Health economic study selection

Figure 25: Flow chart of health economic study selection for the guideline



Appendix G: Literature search strategies

G.1 Contents

Introduction	Search methodology
Section G.2	Population search strategies
G.2.1	Standard pancreatitis population
G.2.2	Chronic pancreatitis population
Section 0	Study filter search terms
G.3.1	Excluded study designs and publication types
G.3.2	Randomised controlled trials (RCT)
G.3.3	Systematic reviews (SR)
G.3.4	Health economic studies (HE)
G.3.5	Quality of life studies (QoL)
G.3.6	Diagnostic test accuracy studies (DIAG)
G.3.7	Observational studies (OBS)
G.3.8	Qualitative reviews (QUAL)
Section G.4	Searches for specific questions with intervention
G.4.1	Information and support
0	Acute aetiology
0	Chronic aetiology
0	Chronic diagnosis
0	Lifestyle: alcohol
G.4.6	IV fluid management
0	Nutrition support
0	Antimicrobial prophylaxis
0	Necrosis
0	Pain management
0	Pancreatic ascites and pleural effusion
0	Biliary obstruction
0	Diabetes
0	Specialist assessment
0	Follow up: pancreatic function
0	Follow up: pancreatic cancer
Section 0	Health economics search terms
G.5.1	Health economic reviews
G.5.2	Quality of life reviews

Search strategies used for the pancreatitis guideline are outlined below and were run in accordance with the methodology in the NICE guidelines manual 2014, available from <https://www.nice.org.uk/article/pmg20/>. All searches were run up to 28 September 2017 unless otherwise stated. Any studies added to the databases after this date (even those published prior to

this date) were not included unless specifically stated in the text. Where possible searches were limited to retrieve material published in English.

Table 1: Database date parameters

Database	Dates searched
Medline	1990 – 28 September 2017
Embase	1990 – 28 September 2017
The Cochrane Library	Cochrane Reviews from 1990 to 2017 Issue 10 of 12 CENTRAL from 1990 to 2017 Issue 9 of 12 DARE and NHSEED to from 1990 to 2015 Issue 2 of 4 HTA from 1990 to 2016 Issue 4 of 4
CINAHL	1990– 28 September 2017
PsycINFO	1990– 28 September 2017

Searches for the **clinical reviews** were run in Medline (OVID), Embase (OVID) and the Cochrane Library (Wiley). Additional searches were run in CINAHL, Current Nursing and Allied Health Literature (EBSCO)and PsycINFO (ProQuest). Searches for **intervention and diagnostic studies** were usually constructed using a PICO format where population (P) terms were combined with Intervention (I) and sometimes Comparison (C) terms. An intervention can be a drug, a procedure or a diagnostic test. Outcomes (O) are rarely used in search strategies for interventions. Search filters were also added to the search where appropriate.

Searches for **patient views** were run in Medline, Embase, CINAHL and PsycINFO. Searches were constructed by adding a patient views search filter to the population terms.

Table 2: Databases searched

Question	Question number	Databases
Acute aetiology	0	Medline, Embase, The Cochrane Library, PsycINFO
Antimicrobial prophylaxis	0	Medline, Embase, The Cochrane Library, PsycINFO
Biliary obstruction	0	Medline, Embase, The Cochrane Library, PsycINFO
Chronic aetiology	0	Medline, Embase, The Cochrane Library, PsycINFO
Chronic diagnosis	0	Medline, Embase, The Cochrane Library, PsycINFO
Diabetes	0	Medline, Embase, The Cochrane Library, PsycINFO
Follow up: pancreatic cancer	0	Medline, Embase, The Cochrane Library, PsycINFO
Follow up: pancreatic function	0	Medline, Embase, The Cochrane Library, PsycINFO
Information and support	G.4.1	Medline, Embase, CINAHL, PsycINFO
IV fluid management	G.4.6	Medline, Embase, The Cochrane Library, PsycINFO
Lifestyle: alcohol	0	Medline, Embase, The Cochrane Library, PsycINFO
Necrosis	0	Medline, Embase, The Cochrane

Question	Question number	Databases
		Library, PsycINFO
Nutrition support	0	Medline, Embase, The Cochrane Library, PsycINFO
Pain management	0	Medline, Embase, The Cochrane Library, PsycINFO
Pancreatic ascites and pleural effusion	0	Medline, Embase, The Cochrane Library, PsycINFO
Specialist assessment	0	Medline, Embase, The Cochrane Library, PsycINFO

Searches for the health economic reviews were run in Medline, Embase, the NHS Economic Evaluations Database (NHS EED) and the Health Technology Assessment (HTA) database. NHS EED and HTA databases are hosted by the Centre for Research and Dissemination (CRD). The NHS EED database has not been updated since 2015.

For Medline and Embase an economic filter (instead of a study type filter) was added to the same clinical search strategy. Searches in CRD were constructed using population terms only.

G.2 Population search strategies

G.2.1 Standard pancreatitis population

The standard population was not used in questions 0 and 0. Question 0 used both the standard population and the chronic pancreatitis population.

Medline and Embase search terms

1.	exp pancreatitis/
2.	exp pancreas/
3.	inflammation/
4.	2 and 3
5.	pancreatitis.ti,ab.
6.	(pancrea* adj3 inflam*).ti,ab.
7.	or/1,4-6

Cochrane search terms

#1.	MeSH descriptor: (pancreatitis) explode all trees
#2.	MeSH descriptor: (pancreas) explode all trees
#3.	MeSH descriptor: (inflammation) this term only
#4.	#2 and #3
#5.	pancreatitis:ti,ab
#6.	(pancrea* near/3 inflam*):ti,ab
#7.	#1 or #4 or #5 or #6

CINAHL search terms

S1.	(MH "pancreatitis+")
S2.	(MH "pancreas+")
S3.	(MH "inflammation+")
S4.	S2 and S3
S5.	T1 pancreatitis or AB pancreatitis

S6.	AB (pancrea* n3 inflam*) or TI (pancrea* n3 inflam*)
S7.	S1 or S4 or S5 or S6

PsycINFO search terms

1.	pancrea*
----	----------

CRD search terms

1.	MeSH descriptor pancreatitis explode all trees
2.	MeSH descriptor pancreas explode all trees
3.	MeSH descriptor inflammation explode all trees
4.	#2 and #3
5.	(pancreatitis)
6.	((pancrea* adj3 inflam*))
7.	#1 or #4 or #5 or #6

G.2.2 Chronic pancreatitis population

This population was used in questions 0, 0 and 0

Medline search terms

1.	exp pancreatitis, chronic/ or exp pancreatitis, alcoholic/
2.	exp pancreas/
3.	inflammation/
4.	2 and 3
5.	chronic pancreatitis.ti,ab.
6.	(pancrea* adj3 (autoimmun* or heredit* or inflam*).ti,ab.
7.	or/1,4-6

Embase search terms

1.	exp alcoholic pancreatitis/ or exp chronic pancreatitis/
2.	exp autoimmune pancreatitis/
3.	exp pancreas/
4.	inflammation/
5.	3 and 4
6.	chronic pancreatitis.ti,ab.
7.	(pancrea* adj3 (heredit* or inflam*).ti,ab.
8.	1 or 2 or 5 or 6 or 7

Cochrane search terms

#1.	MeSH descriptor: (pancreatitis, chronic) explode all trees
#2.	MeSH descriptor: (pancreatitis, alcoholic) explode all trees
#3.	MeSH descriptor: (pancreas) explode all trees
#4.	MeSH descriptor: (inflammation) explode all trees
#5.	#3 and #4
#6.	chronic pancreatitis:ti,ab
#7.	(pancrea* near/3 (autoimmun* or heredit* or inflam*)):ti,ab
#8.	#1 or #2 or #5 or #6 or #7

G.3 Study filter search terms

G.3.1 Excluded study designs and publication types

The following study designs and publication types were removed from retrieved results using the NOT operator.

Medline search terms

1.	letter/
2.	editorial/
3.	news/
4.	exp historical article/
5.	anecdotes as topic/
6.	comment/
7.	case report/
8.	(letter or comment*).ti.
9.	or/1-8
10.	randomized controlled trial/ or random*.ti,ab.
11.	9 not 10
12.	animals/ not humans/
13.	exp animals, laboratory/
14.	exp animal experimentation/
15.	exp models, animal/
16.	exp rodentia/
17.	(rat or rats or mouse or mice).ti.
18.	or/11-17

Embase search terms

1.	letter.pt. or letter/
2.	note.pt.
3.	editorial.pt.
4.	case report/ or case study/
5.	(letter or comment*).ti.
6.	or/1-5
7.	randomized controlled trial/ or random*.ti,ab.
8.	6 not 7
9.	animal/ not human/
10.	nonhuman/
11.	exp animal experiment/
12.	exp experimental animal/
13.	animal model/
14.	exp rodent/
15.	(rat or rats or mouse or mice).ti.
16.	or/8-15

CINAHL search terms

S1.	pt anecdote or pt audiovisual or pt bibliography or pt biography or pt book or pt book review
-----	---

	or pt brief item or pt cartoon or pt commentary or pt computer program or pt editorial or pt games or pt glossary or pt historical material or pt interview or pt letter or pt listservs or pt masters thesis or pt obituary or pt pamphlet or pt pamphlet chapter or pt pictorial or pt poetry or pt proceedings or pt "questions and answers" or pt response or pt software or pt teaching materials or pt website
--	--

PsycINFO (ProQUEST) search terms

1.	(su.exact.explode("rodents") or su.exact.explode("mice") or (su.exact("animals") not (su.exact("human males") or su.exact("human females")))) or ti(rat or rats or mouse or mice))
2.	Limits applied: Books, Letter; Dissertation Abstract; Comment/Reply; Obituary; Editorial

G.3.2 Randomised controlled trials (RCT)

Medline search terms

(Based on the sensitivity and precision maximising version reported in the Cochrane Handbook (<http://handbook.cochrane.org/>)).

1.	randomized controlled trial.pt.
2.	controlled clinical trial.pt.
3.	randomi#ed.ti,ab.
4.	placebo.ab.
5.	randomly.ab.ti
6.	clinical trials as topic.sh.
7.	trial.ti.
8.	or/1-7

Embase search terms

1.	random*.ti,ab.
2.	factorial*.ti,ab.
3.	(crossover* or cross over*).ti,ab.
4.	((doubl* or singl*) adj blind*).ti,ab.
5.	(assign* or allocat* or volunteer* or placebo*).ti,ab.
6.	crossover procedure/
7.	double blind procedure/
8.	single blind procedure/
9.	randomized controlled trial/
10.	or/1-9

G.3.3 Systematic reviews (SR)

Medline search terms

1.	meta-analysis/
2.	meta-analysis as topic/
3.	(meta analy* or metanaly* or metaanaly*).ti,ab.
4.	((systematic* or evidence*) adj3 (review* or overview*)).ti,ab.
5.	(reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab.
6.	(search strategy or search criteria or systematic search or study selection or data extraction).ab.
7.	(search* adj4 literature).ab.

8.	(medline or pubmed or cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or science citation index or bids or cancerlit).ab.
9.	cochrane.jw.
10.	((multiple treatment* or indirect or mixed) adj2 comparison*).ti,ab.
11.	or/1-10

Embase search terms

1.	systematic review/
2.	meta-analysis/
3.	(meta analy* or metanaly* or metaanaly*).ti,ab.
4.	((systematic or evidence) adj3 (review* or overview*)).ti,ab.
5.	(reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab.
6.	(search strategy or search criteria or systematic search or study selection or data extraction).ab.
7.	(search* adj4 literature).ab.
8.	(medline or pubmed or cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or science citation index or bids or cancerlit).ab.
9.	cochrane.jw.
10.	((multiple treatment* or indirect or mixed) adj2 comparison*).ti,ab.
11.	or/1-10

G.3.4 Health economic studies (HE)

Medline search terms

1.	economics/
2.	value of life/
3.	exp "costs and cost analysis"/
4.	exp economics, hospital/
5.	exp economics, medical/
6.	economics, nursing/
7.	economics, pharmaceutical/
8.	exp "fees and charges"/
9.	exp budgets/
10.	budget*.ti,ab.
11.	cost*.ti.
12.	(economic* or pharmaco?economic*).ti.
13.	(price* or pricing*).ti,ab.
14.	(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.
15.	(financ* or fee or fees).ti,ab.
16.	(value adj2 (money or monetary)).ti,ab.
17.	or/1-16

Embase search terms

1.	health economics/
2.	exp economic evaluation/
3.	exp health care cost/
4.	exp fee/
5.	budget/

6.	funding/
7.	budget*.ti,ab.
8.	cost*.ti.
9.	(economic* or pharmaco?economic*).ti.
10.	(price* or pricing*).ti,ab.
11.	(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.
12.	(financ* or fee or fees).ti,ab.
13.	(value adj2 (money or monetary)).ti,ab.
14.	or/1-13

G.3.5 Quality of life studies (QoL)

Medline search terms

1.	quality-adjusted life years/
2.	sickness impact profile/
3.	(quality adj2 (wellbeing or well-being)).ti,ab.
4.	sickness impact profile.ti,ab.
5.	disability adjusted life.ti,ab.
6.	(qal* or qtime* or qwb* or daly*).ti,ab.
7.	(euroqol* or eq5d* or eq 5d*).ti,ab.
8.	(qol* or hql* or hqol* or h qol* or hrqol* or hr qol*).ti,ab.
9.	(health utility* or utility score* or disutilit*).ti,ab.
10.	(hui or hui1 or hui2 or hui3).ti,ab.
11.	health* year* equivalent*.ti,ab.
12.	(hye or hyes).ti,ab.
13.	rosser.ti,ab.
14.	(willingness to pay or time tradeoff or time trade off or tto or standard gamble*).ti,ab.
15.	(sf36 or sf 36 or short form 36 or shortform 36 or shortform36).ti,ab.
16.	(sf20 or sf 20 or short form 20 or shortform 20 or shortform20).ti,ab.
17.	(sf12 or sf 12 or short form 12 or shortform 12 or shortform12).ti,ab.
18.	(sf8 or sf 8 or short form 8 or shortform 8 or shortform8).ti,ab.
19.	(sf6 or sf 6 or short form 6 or shortform 6 or shortform6).ti,ab.
20.	or/1-19

Embase search terms

1.	quality adjusted life year/
2.	"quality of life index"/
3.	short form 12/ or short form 20/ or short form 36/ or short form 8/
4.	sickness impact profile/
5.	(quality adj2 (wellbeing or well-being)).ti,ab.
6.	sickness impact profile.ti,ab.
7.	disability adjusted life.ti,ab.
8.	(qal* or qtime* or qwb* or daly*).ti,ab.
9.	(euroqol* or eq5d* or eq 5d*).ti,ab.
10.	(qol* or hql* or hqol* or h qol* or hrqol* or hr qol*).ti,ab.
11.	(health utility* or utility score* or disutilit*).ti,ab.

12.	(hui or hui1 or hui2 or hui3).ti,ab.
13.	health* year* equivalent*.ti,ab.
14.	(hye or hyes).ti,ab.
15.	rosser.ti,ab.
16.	(willingness to pay or time tradeoff or time trade off or tto or standard gamble*).ti,ab.
17.	(sf36 or sf 36 or short form 36 or shortform 36 or shortform36).ti,ab.
18.	(sf20 or sf 20 or short form 20 or shortform 20 or shortform20).ti,ab.
19.	(sf12 or sf 12 or short form 12 or shortform 12 or shortform12).ti,ab.
20.	(sf8 or sf 8 or short form 8 or shortform 8 or shortform8).ti,ab.
21.	(sf6 or sf 6 or short form 6 or shortform 6 or shortform6).ti,ab.
22.	or/1-21

G.3.6 Diagnostic test accuracy studies (DIAG)

Medline search terms

1.	exp "sensitivity and specificity"/
2.	(sensitivity or specificity).ti,ab.
3.	((pre test or pretest or post test) adj probability).ti,ab.
4.	(predictive value* or ppv or npv).ti,ab.
5.	likelihood ratio*.ti,ab.
6.	likelihood function/
7.	(roc curve* or auc).ti,ab.
8.	(diagnos* adj3 (performance* or accurac* or utilit* or value* or efficien* or effectiveness)).ti,ab.
9.	gold standard.ab.
10.	or/1-9

Embase search terms

1.	exp "sensitivity and specificity"/
2.	(sensitivity or specificity).ti,ab.
3.	((pre test or pretest or post test) adj probability).ti,ab.
4.	(predictive value* or ppv or npv).ti,ab.
5.	likelihood ratio*.ti,ab.
6.	(roc curve* or auc).ti,ab.
7.	(diagnos* adj3 (performance* or accurac* or utilit* or value* or efficien* or effectiveness)).ti,ab.
8.	diagnostic accuracy/
9.	diagnostic test accuracy study/
10.	gold standard.ab.
11.	or/1-10

G.3.7 Observational studies (OBS)

Medline search terms

1.	epidemiologic studies/
2.	observational study/
3.	exp cohort studies/

4.	(cohort adj (study or studies or analys* or data)).ti,ab.
5.	((follow up or observational or uncontrolled or non randomi#ed or epidemiologic*) adj (study or studies or data)).ti,ab.
6.	((longitudinal or retrospective or prospective or cross sectional) and (study or studies or review or analys* or cohort* or data)).ti,ab.
7.	controlled before-after studies/
8.	historically controlled study/
9.	interrupted time series analysis/
10.	(before adj2 after adj2 (study or studies or data)).ti,ab.
11.	or/1-10
12.	exp case control study/
13.	case control*.ti,ab.
14.	or/12-13
15.	11 or 14
16.	cross-sectional studies/
17.	(cross sectional and (study or studies or review or analys* or cohort* or data)).ti,ab.
18.	or/16-17
19.	11 or 18
20.	11 or 15 or 18

Embase search terms

1.	Clinical study/
2.	Observational study/
3.	family study/
4.	longitudinal study/
5.	retrospective study/
6.	prospective study/
7.	cohort analysis/
8.	follow-up/
9.	cohort*.ti,ab.
10.	88 and 89
11.	(cohort adj (study or studies or analys* or data)).ti,ab.
12.	((follow up or observational or uncontrolled or non randomi#ed or epidemiologic*) adj (study or studies or data)).ti,ab.
13.	((longitudinal or retrospective or prospective or cross sectional) and (study or studies or review or analys* or cohort* or data)).ti,ab.
14.	(before adj2 after adj2 (study or studies or data)).ti,ab.
15.	or/1-7,10-14
16.	exp case control study/
17.	case control*.ti,ab.
18.	or/16-17
19.	15 or 18
20.	cross-sectional study/
21.	(cross sectional and (study or studies or review or analys* or cohort* or data)).ti,ab.
22.	or/20-21
23.	15 or 22

24.	15 or 18 or 22
-----	----------------

G.3.8 Qualitative reviews (QUAL)

Medline search terms

1.	qualitative research/ or narration/ or exp interviews as topic/ or exp questionnaires/ or health care surveys/
2.	(qualitative or interview* or focus group* or theme* or questionnaire* or survey*).ti,ab.
3.	(metasynthes* or meta-synthes* or metasummar* or meta-summar* or metastud* or meta-stud* or metathem* or meta-them* or ethno* or emic or etic or phenomenolog* or grounded theory or constant compar* or (thematic* adj3 analys*) or theoretical sampl* or purposive sampl* or hermeneutic* or heidegger* or husserl* or colaizzi* or van kaam* or van manen* or giorgi* or glaser* or strauss* or ricoeur* or spiegelberg* or merleau*).ti,ab.
4.	or/1-3

Embase search terms

1.	health survey/ or exp questionnaire/ or exp interview/ or qualitative research/ or narrative/
2.	(qualitative or interview* or focus group* or theme* or questionnaire* or survey*).ti,ab.
3.	(metasynthes* or meta-synthes* or metasummar* or meta-summar* or metastud* or meta-stud* or metathem* or meta-them* or ethno* or emic or etic or phenomenolog* or grounded theory or constant compar* or (thematic* adj3 analys*) or theoretical sampl* or purposive sampl* or hermeneutic* or heidegger* or husserl* or colaizzi* or van kaam* or van manen* or giorgi* or glaser* or strauss* or ricoeur* or spiegelberg* or merleau*).ti,ab.
4.	or/1-3

CINAHL search terms

S1.	(mh "qualitative studies+")
S2.	(mh "qualitative validity+")
S3.	(mh "interviews+") or (mh "focus groups") or (mh "surveys") or (mh "questionnaires+")
S4.	(qualitative or interview* or focus group* or theme* or questionnaire* or survey*)
S5.	(metasynthes* or meta-synthes* or metasummar* or meta-summar* or metastud* or meta-stud* or metathem* or meta-them* or ethno* or emic or etic or phenomenolog* or grounded theory or constant compar* or (thematic* adj3 analys*) or theoretical sampl* or purposive sampl* or hermeneutic* or heidegger* or husserl* or colaizzi* or van kaam* or van manen* or giorgi* or glaser* or strauss* or ricoeur* or spiegelberg* or merleau*)
S6.	S1 or s2 or S3 or S4 or S5

G.4 Searches for specific questions

G.4.1 Information and support

What information and support should people with acute or chronic pancreatitis, their family and carers receive after diagnosis?

Medline search terms

1.	Standard population (G.2.1)
2.	Excluded study designs and publication types (G.3.1)
3.	1 not 2
4.	Limit 3 to English language
5.	caregivers/ or exp family/ or exp parents/ or exp legal-guardians/
6.	patients/ or inpatients/ or outpatients/

7.	or/5-6
8.	popular-works-publication-type/ or exp information-services/ or publications/ or books/ or pamphlets/ or counseling/ or directive-counseling/
9.	7 and 8
10.	patient education as topic/
11.	consumer health information/
12.	patient satisfaction/
13.	exp consumer-satisfaction/
14.	personal-satisfaction/
15.	patient participation/
16.	decision making/
17.	access to information/
18.	exp patient-acceptance-of-health-care/
19.	((caregiver* or carer* or client* or customer* or famil* or father* or guardian* or mother* or next of kin or parent* or patient* or relatives or spouse or user*) adj6 (attitude* or belief* or believe* or choice* or choos* or decid* or decision* or expectation* or feeling* or interpret* or involvement or misconception* or misconception* or mis-conception* or misunderstand* or mis-understand* or need or needs or opinion* or perception* or perspective* or preferen* or priorit* or satisfact* or understand* or view*)).ti,ab.
20.	((caregiver* or carer* or client* or customer* or famil* or father* or guardian* or mother* or next of kin or parent* or patient* or relatives or spouse or user*) adj6 (advi?e* or communicat* or consult* or convers* or counsel* or discuss* or educat* or inform* or involve* or knowledge or learn* or psycholog* or support*)).ti,ab.
21.	((advi?e* or communicat* or consult* or convers* or counsel* or discuss* or educat* facilitat* or inform* or involve* or knowledge or learn* or psycholog* or support*) adj6 (access* or arrang* or barrier* or deliver* or disseminat* or establish* or facilitat* or need or needs or offer* or provide* or provision* or requirement* or seek* or support)).ti,ab.
22.	((caregiver* or carer* or client* or customer* or famil* or father* or guardian* or mother* or next of kin or parent* or patient* or relatives or spouse or user*) adj6 (bluetooth or booklet* or brochure* or computer* or digital* or dvd* or email* or e-mail* or handout* or interactive* or internet or leaflet* or literature or manual* or mobile health or pamphlet* or phone* or program* or publication* or resource* or smartphone* or social media or social network* or sms or telephone* or text* or video* or web page* or web site* or webpage* or website* or wireless)).ti,ab.
23.	or/9-22
24.	Study filter QUAL (G.3.8)
25.	4 and 23 and 24
	Date parameters: 1946-28 September 2017

Embase search terms

1.	Standard population (G.2.1)
2.	Excluded study designs and publication types (G.3.1)
3.	1 not 2
4.	Limit 3 to English language
5.	patient/ or hospital patient/ or outpatient/
6.	caregiver/ or exp family/ or exp parent/
7.	5 or 6
8.	information service/ or information center/ or publication/ or book/ or counseling/ or directive counseling/
9.	7 and 8

10.	patient education/
11.	consumer health information/
12.	patient satisfaction/
13.	patient participation/
14.	decision making/
15.	patient preference/
16.	patient attitude/
17.	patient information/
18.	((caregiver* or carer* or client* or customer* or famil* or father* or guardian* or mother* or next of kin or parent* or patient* or relatives or spouse or user*) adj6 (attitude* or belief* or believe* or choice* or choos* or decid* or decision* or expectation* or feeling* or interpret* or involvement or misconception* or misconception* or mis-conception* or misunderstand* or mis-understand* or need or needs or opinion* or perception* or perspective* or preferen* or priorit* or satisfact* or understand* or view*)).ti,ab.
19.	((advi?e* or communicat* or consult* or convers* or counsel* or discuss* or educat* or inform* or involve* or knowledge or learn* or psycholog* or support*) adj6 (access* or arrang* or barrier* or deliver* or disseminat* or establish* or facilitat* or need or needs or offer* or provide* or provision* or requirement* or seek* or support)).ti,ab.
20.	((caregiver* or carer* or client* or customer* or famil* or father* or guardian* or mother* or next of kin or parent* or patient* or relatives or spouse or user*) adj6 (advi?e* or communicat* or consult* or convers* or counsel* or discuss* or educat* or inform* or involve* or knowledge or learn* or psycholog* or support*)).ti,ab.
21.	((caregiver* or carer* or client* or customer* or famil* or father* or guardian* or mother* or next of kin or parent* or patient* or relatives or spouse or user*) adj6 (bluetooth or booklet* or brochure* or computer* or digital* or dvd* or email* or e-mail* or handout* or interactive* or internet or leaflet* or literature or manual* or mobile health or pamphlet* or phone* or program* or publication* or resource* or smartphone* or social media or social network* or sms or telephone* or text* or video* or web page* or web site* or webpage* or website* or wireless)).ti,ab.
22.	or/9-21
23.	Study filter QUAL (G.3.8)
24.	4 and 22 and 23
	Date parameters: 1974-28 September 2017

CINAHL search terms

S1.	Standard population (G.2.1)
S2.	Excluded study designs and publication types (G.3.1)
S3.	1 not 2
S4.	Limit 3 to English language
S5.	(MH "caregivers")
S6.	(MH "family+")
S7.	(MH "parents+")
S8.	(MH "guardianship, legal+")
S9.	(MH "patients+")
S10.	(MH "inpatients")
S11.	(MH "outpatients")
S12.	S5 or S6 or S7 or S8 or S9 or S10 or S11
S13.	(MH "information services+")
S14.	(MH "books") or (MH "reference books") or (MH "literature") or (MH "pamphlets")

S15.	(MH "counseling")
S16.	S13 or S14 or S15
S17.	S12 and S16
S18.	(MH "patient education")
S19.	(MH "consumer health information")
S20.	(MH "patient satisfaction")
S21.	(MH "consumer satisfaction+")
S22.	(MH "personal satisfaction")
S23.	(MH "consumer participation")
S24.	(MH "decision making")
S25.	(MH "access to information")
S26.	TI (((caregiver* or carer* or client* or customer* or famil* or father* or guardian* or mother* or next of kin or parent* or patient* or relatives or spouse or user*) n6 (attitude* or belief* or believe* or choice* or choos* or decid* or decision* or expectation* or feeling* or interpret* or involvement or misconception* or misconception* or mis-conception* or misunderstand* or mis-understand* or need or needs or opinion* or perception* or perspective* or preferen* or priorit* or satisfact* or understand* or view*))) or AB (((caregiver* or carer* or client* or customer* or famil* or father* or guardian* or mother* or next of kin or parent* or patient* or relatives or spouse or user*) n6 (attitude* or belief* or believe* or choice* or choos* or decid* or decision* or expectation* or feeling* or interpret* or involvement or misconception* or misconception* or mis-conception* or misunderstand* or mis-understand* or need or needs or opinion* or perception* or perspective* or preferen* or priorit* or satisfact* or understand* or view*))
S27.	TI (((caregiver* or carer* or client* or customer* or famil* or father* or guardian* or mother* or next of kin or parent* or patient* or relatives or spouse or user*) n6 (advi?e* or communicat* or consult* or convers* or counsel* or discuss* or educat* or inform* or involve* or knowledge or learn* or psycholog* or support*))) or AB (((caregiver* or carer* or client* or customer* or famil* or father* or guardian* or mother* or next of kin or parent* or patient* or relatives or spouse or user*) n6 (advi?e* or communicat* or consult* or convers* or counsel* or discuss* or educat* or inform* or involve* or knowledge or learn* or psycholog* or support*))
S28.	TI (((advi?e* or communicat* or consult* or convers* or counsel* or discuss* or educat* or facilitat* or inform* or involve* or knowledge or learn* or psycholog* or support*) n6 (access* or arrang* or barrier* or deliver* or disseminat* or establish* or facilitat* or need or needs or offer* or provide* or provision* or requirement* or seek* or support))) or AB (((advi?e* or communicat* or consult* or convers* or counsel* or discuss* or educat* or facilitat* or inform* or involve* or knowledge or learn* or psycholog* or support*) n6 (access* or arrang* or barrier* or deliver* or disseminat* or establish* or facilitat* or need or needs or offer* or provide* or provision* or requirement* or seek* or support))
S29.	TI (((caregiver* or carer* or client* or customer* or famil* or father* or guardian* or mother* or next of kin or parent* or patient* or relatives or spouse or user*) n6 (bluetooth or booklet* or brochure* or computer* or digital* or dvd* or education sheet* or email* or e-mail* or handout* or information sheet* or interactive* or internet or leaflet* or literature or manual* or mobile health or pamphlet* or phone* or program* or publication* or resource* or smartphone* or social media or social network* or SMS or telephone* or text* or video* or web page* or web site* or webpage* or website* or wireless))) or AB ((caregiver* or carer* or client* or customer* or famil* or father* or guardian* or mother* or next of kin or parent* or patient* or relatives or spouse or user*) n6 (bluetooth or booklet* or brochure* or computer* or digital* or dvd* or email* or e-mail* or handout* or interactive* or internet or leaflet* or literature or manual* or mobile health or pamphlet* or phone* or program* or publication* or resource* or smartphone* or social media or social network* or SMS or telephone* or text* or video* or web page* or web site* or webpage* or website* or wireless))

S30.	S18 or S19 or S20 or S21 or S22 or S23 or S24 or S25 or S26 or S27 or S28 or S9
S31.	S17 or S30
S32.	Study filter QUAL (G.3.8)
S33.	S4 or S31 or S32
	Date parameters: 1981-28 September 2017

PsycINFO search terms

1.	Standard population (A.2.1)
2.	Excluded study designs and publication types (A.3.1)
3.	1 not 2
4.	Limit 3 to English language
	Date parameters: see Table 1

G.4.2 Acute aetiology

- What is the clinical and cost effectiveness of assessing the aetiology of acute pancreatitis to prevent recurrent attacks in people in which the aetiology is unconfirmed by first line test results within normal ranges?

Medline search terms

1.	Standard population (G.2.1)
2.	Excluded study designs and publication types (G.3.1)
3.	1 not 2
4.	Limit 3 to English language
5.	((medic* or drug* or clinical or patient*) adj3 (history or record* or antecedent*)).ti,ab.
6.	medical history taking/
7.	5 or 7
8.	"sphincter of oddi"/
9.	((sphincter of oddi or hepatopancreatic sphincter or glisson's sphincter) adj3 (dysfunction* or failure* or disorder*)).ti,ab.
10.	cholangiopancreatography, endoscopic retrograde/
11.	(endoscopic retrograde cholangiopancreatograph* or ercp).ti,ab.
12.	10 or 11
13.	9 or (8 and 12)
14.	exp immunoglobulins/
15.	immunoglobulin*.ti,ab.
16.	igg*.ti,ab.
17.	exp antibodies, antinuclear/
18.	(autoantibod* or auto-antibod*).ti,ab.
19.	(anti-nuclear antibod* or antinuclear antibod* or ana).ti,ab.
20.	(antinuclear factor* or anti-nuclear factor* or anf).ti,ab.
21.	or/14-20
22.	serologic tests/
23.	hypercalcemia/
24.	hyperlipidemias/
25.	((test* or analysis) adj3 (hypercalc?emia or hyperlipid?emia or serolog* or blood)).ti,ab.
26.	or/22-25

27.	genetic markers/ or genetic testing/
28.	genetic predisposition to disease/
29.	(genetic* adj3 (marker* or test* or predisposition*)).ti,ab.
30.	trypsin/
31.	trypsinogen/
32.	(trypsinogen or trypsin or prss1).ti,ab.
33.	(tati or psti).ti,ab.
34.	chymotrypsin/
35.	(chymotrypsin* or ctrc or cldn2).ti,ab.
36.	cystic fibrosis transmembrane conductance regulator/
37.	(cystic fibrosis transmembrane conductance regulator or cftr).ti,ab.
38.	trypsin inhibitor, kazal pancreatic/
39.	(serine protease inhibitor kazal-type 1 or spink1).ti,ab.
40.	or/27-39
41.	endosonography/
42.	cholangiopancreatography, endoscopic retrograde/
43.	41 or 42
44.	exp biliary tract/
45.	43 and 44
46.	((endoscopic retrograde cholangiopancreatograph* or ercp or endoscopic ultraso* or eus or echo-endoscop* or endosonograph*) adj3 (gall bladder or gallbladder or bil* duct* or gallstone* or cbd or choledoch* or biliary)).ti,ab.
47.	45 or 46
48.	duodenoscopy/
49.	((endoscopic ultraso* or eus or echo-endoscop* or endosonograph*) adj3 ((endoscop* adj3 duodenum) or duodenoscop*)).ti,ab.
50.	or/47-49
51.	cholangiopancreatography, magnetic resonance/
52.	secretin/
53.	51 and 52
54.	(magnetic resonance cholangiopancreatograph* or mrcp or secretin-mrcp).ti,ab.
55.	smrcp.ti,ab.
56.	or/53-55
57.	pancreatitis, acute necrotizing/et (etiology)
58.	(pancrea* adj3 ?etiology).ti,ab.
59.	4 and (7 or 13 or 21 or 26 or 40 or 50 or 56 or 57 or 58)
60.	Study filters RCT (G.3.2) or SR (G.3.3) or OBS (G.3.7)
61.	59 and 60
	Date parameters: see Table 1

Embase search terms

1.	Standard population (G.2.1)
2.	Excluded study designs and publication types (G.3.1)
3.	1 not 2
4.	Limit 3 to English language
5.	((medic* or drug* or clinical or patient*) adj3 (history or record* or antecedent*)).ti,ab.

6.	anamnesis/
7.	5 or 6
8.	oddi sphincter/
9.	((sphincter of oddi or hepatopancreatic sphincter or glisson's sphincter) adj3 (dysfunction* or failure* or disorder*)).ti,ab.
10.	endoscopic retrograde cholangiopancreatography/
11.	(endoscopic retrograde cholangiopancreatograph* or ercp).ti,ab.
12.	10 or 11
13.	9 or (8 and 12)
14.	exp immunoglobulin/
15.	immunoglobulin*.ti,ab.
16.	igg*.ti,ab.
17.	exp antinuclear antibody/
18.	(anti-nuclear antibod* or antinuclear antibod* or ana).ti,ab.
19.	(antinuclear factor* or anti-nuclear factor* or anf).ti,ab.
20.	(autoantibod* or auto-antibod*).ti,ab.
21.	autoantibody/
22.	or/14-21
23.	serology/ or serodiagnosis/
24.	hypercalcemia/
25.	hyperlipidemia/
26.	((test* or analysis) adj3 (hypercalc?emia or hyperlipid?emia or serolog* or blood)).ti,ab.
27.	or/23-26
28.	genetic predisposition/ or disease predisposition/
29.	genetic marker/
30.	genetic screening/
31.	(genetic* adj3 (marker* or test* or predisposition*)).ti,ab.
32.	trypsin/ or trypsin inhibitor/
33.	trypsinogen/
34.	(trypsinogen or trypsin or prss1).ti,ab.
35.	(tati or psti).ti,ab.
36.	chymotrypsin/ or chymotrypsin inhibitor/
37.	(chymotrypsin* or ctrc or cldn2).ti,ab.
38.	cystic fibrosis transmembrane conductance regulator/
39.	(cystic fibrosis transmembrane conductance regulator or cftr).ti,ab.
40.	(serine protease inhibitor kazal-type 1 or spink1).ti,ab.
41.	or/8-40
42.	endoscopic ultrasonography/
43.	endoscopic retrograde cholangiopancreatography/
44.	42 or 43
45.	bile duct/
46.	gallbladder/
47.	common bile duct/
48.	or/45-47
49.	44 and 48

50.	((endoscopic retrograde cholangiopancreatograph* or ercp or endoscopic ultraso* or eus or echo-endoscop* or endosonograph*) adj3 (gall bladder or gallbladder or bil* duct* or gallstone* or biliary or cbd or choledoch*)).ti,ab.
51.	duodenoscopy/
52.	((endoscopic ultraso* or eus or echo-endoscop* or endosonograph*) adj3 ((endoscop* adj3 duodenum) or duodenoscop*)).ti,ab.
53.	or/49-52
54.	endoscopic retrograde cholangiopancreatography/
55.	secretin/
56.	54 and 55
57.	(magnetic resonance cholangiopancreatograph* or mrcp or secretin-mrcp).ti,ab.
58.	smrcp.ti,ab.
59.	or/56-58
60.	acute pancreatitis/et (etiology)
61.	(pancrea* adj3 ?etiology).ti,ab.
62.	4 and (7 or 13 or 22 or 27 or 41 or 53 or 59 or 60 or 61)
63.	Study filters RCT (G.3.2) or SR (G.3.3) or OBS (G.3.7)
64.	62 and 63
	Date parameters: see Table 1

Cochrane search terms

#1.	Standard population (G.2.1)
#2.	((medic* or drug* or clinical or patient*) near/3 (history or record* or antecedent*)):ti,ab
#3.	MeSH descriptor: (medical history taking) this term only
#4.	#2 or #3
#5.	MeSH descriptor: (sphincter of oddi) this term only
#6.	((sphincter of oddi or hepatopancreatic sphincter or glisson's sphincter) near/3 (dysfunction* or failure* or disorder*)):ti,ab
#7.	MeSH descriptor: (cholangiopancreatography, endoscopic retrograde) this term only
#8.	(endoscopic retrograde cholangiopancreatograph* or ercp):ti,ab
#9.	#7 or #8
#10.	#5 and #9
#11.	#6 or #10
#12.	MeSH descriptor: (immunoglobulins) explode all trees
#13.	immunoglobulin*:ti,ab
#14.	igg*:ti,ab
#15.	MeSH descriptor: (antibodies, antinuclear) explode all trees
#16.	(autoantibod* or auto-antibod*):ti,ab
#17.	(anti-nuclear antibod* or antinuclear antibod* or ana):ti,ab
#18.	(antinuclear factor* or anti-nuclear factor* or anf):ti,ab
#19.	(or #12-#18)
#20.	MeSH descriptor: (serologic tests) this term only
#21.	MeSH descriptor: (hypercalcemia) this term only
#22.	MeSH descriptor: (hyperlipidemias) this term only
#23.	((test* or analysis) near/3 (hypercalc?emia or hyperlipid?emia or serolog* or blood)):ti,ab
#24.	(or #20-#23)

#25.	MeSH descriptor: (genetic markers) this term only
#26.	MeSH descriptor: (genetic testing) this term only
#27.	MeSH descriptor: (genetic predisposition to disease) this term only
#28.	(genetic* near/3 (marker* or test* or predisposition*)):ti,ab
#29.	MeSH descriptor: (trypsin) this term only
#30.	MeSH descriptor: (trypsinogen) this term only
#31.	(trypsinogen or trypsin or prss1):ti,ab
#32.	(tati or psti):ti,ab
#33.	MeSH descriptor: (chymotrypsin) this term only
#34.	(chymotrypsin* or ctrc or cldn2):ti,ab
#35.	MeSH descriptor: (cystic fibrosis transmembrane conductance regulator) this term only
#36.	(cystic fibrosis transmembrane conductance regulator or cftr):ti,ab
#37.	MeSH descriptor: (trypsin inhibitor, kazal pancreatic) this term only
#38.	(serine protease inhibitor kazal-type 1 or spink1):ti,ab
#39.	(or #25-#38)
#40.	MeSH descriptor: (endosonography) this term only
#41.	MeSH descriptor: (cholangiopancreatography, endoscopic retrograde) explode all trees
#42.	(or #40-#41)
#43.	MeSH descriptor: (biliary tract) explode all trees
#44.	#42 and #43
#45.	((endoscopic retrograde cholangiopancreatograph* or ercp or endoscopic ultraso* or eus or echo-endoscop* or endosonograph*) near/3 (gall bladder or gallbladder or bil* duct* or gallstone* or cbd or choledoch* or biliary)):ti,ab
#46.	MeSH descriptor: (duodenoscopy) this term only
#47.	((endoscopic retrograde cholangiopancreatograph* or ercp or endoscopic ultraso* or eus or echo-endoscop* or endosonograph*) near/3 ((endoscop* near/3 duodenum) or duodenoscop*)):ti,ab
#48.	(or #44-#47)
#49.	MeSH descriptor: (cholangiopancreatography, magnetic resonance) this term only
#50.	MeSH descriptor: (secretin) this term only
#51.	#49 and #50
#52.	(magnetic resonance cholangiopancreatograph* or mrcp or secretin-mrcp):ti,ab
#53.	smrcp:ti,ab
#54.	(or #51-#53)
#55.	(pancrea* near/3 ?etiology):ti,ab
#56.	(or #4, #11, #19, #24, #39, #48, #54-#58)
#57.	#1 and #56
	Date parameters: see Table 1

PsycINFO search terms

1.	Standard population (A.2.1)
2.	Excluded study designs and publication types (A.3.1)
3.	1 not 2
4.	Limit 3 to English language
	Date parameters: see Table 1

G.4.3 Chronic aetiology

- What is the clinical and cost effectiveness of performing genetic markers and autoantibodies tests for identifying the aetiology of chronic pancreatitis in people with no known family history of pancreatitis, no significant alcohol history, and normal serum calcium and lipids?

Medline search terms

1.	Standard population (G.2.1)
2.	Excluded study designs and publication types (G.3.1)
3.	1 not 2
4.	Limit 3 to English language
5.	exp immunoglobulins/
6.	immunoglobulin*.ti,ab.
7.	igg*.ti,ab.
8.	exp antibodies, antinuclear/
9.	(autoantibod* or auto-antibod*).ti,ab.
10.	(anti-nuclear antibod* or antinuclear antibod* or ana).ti,ab.
11.	(antinuclear factor* or anti-nuclear factor* or anf).ti,ab.
12.	pancreatitis, chronic/et (etiology)
13.	genetic predisposition to disease/
14.	genetic markers/ or genetic testing/
15.	(genetic* adj3 (marker* or test* or predisposition*)).ti,ab.
16.	trypsin/
17.	trypsinogen/
18.	(trypsinogen or trypsin or prss1).ti,ab.
19.	(tati or psti).ti,ab.
20.	chymotrypsin/
21.	(chymotrypsin* or ctrc or cldn2).ti,ab.
22.	cystic fibrosis transmembrane conductance regulator/
23.	(cystic fibrosis transmembrane conductance regulator or cftr).ti,ab.
24.	trypsin inhibitor, kazal pancreatic/
25.	(serine protease inhibitor kazal-type 1 or spink1).ti,ab.
26.	or/5-25
27.	4 and 26
	Date parameters: see Table 1

Embase search terms

1.	Chronic pancreatitis population (G.2.2)
2.	Excluded study designs and publication types (G.3.1)
3.	1 not 2
4.	Limit 3 to English language
5.	exp immunoglobulin/
6.	immunoglobulin*.ti,ab.
7.	igg*.ti,ab.
8.	exp antinuclear antibody/
9.	(anti-nuclear antibod* or antinuclear antibod* or ana).ti,ab.
10.	(antinuclear factor* or anti-nuclear factor* or anf).ti,ab.

11.	(autoantibod* or auto-antibod*).ti,ab.
12.	autoantibody/
13.	chronic pancreatitis/et (etiology)
14.	autoimmune pancreatitis/et (etiology)
15.	genetic predisposition/ or disease predisposition/
16.	genetic marker/
17.	genetic screening/
18.	(genetic* adj3 (marker* or test* or predisposition*)).ti,ab.
19.	trypsin/ or trypsin inhibitor/
20.	trypsinogen/
21.	(trypsinogen or trypsin or prss1).ti,ab.
22.	(tati or psti).ti,ab.
23.	chymotrypsin/ or chymotrypsin inhibitor/
24.	(chymotrypsin* or ctrc or cldn2).ti,ab.
25.	cystic fibrosis transmembrane conductance regulator/
26.	(cystic fibrosis transmembrane conductance regulator or cftr).ti,ab.
27.	(serine protease inhibitor kazal-type 1 or spink1).ti,ab.
28.	or/5-27
29.	4 and 28
	Date parameters: see Table 1

Cochrane search terms

#1.	Chronic pancreatitis population (G.2.2)
#2.	MeSH descriptor: (immunoglobulins) explode all trees
#3.	immunoglobulin*:ti,ab
#4.	igg*:ti,ab
#5.	MeSH descriptor: (antibodies, antinuclear) explode all trees
#6.	(autoantibod* or auto-antibod*):ti,ab
#7.	(anti-nuclear antibod* or antinuclear antibod* or ana):ti,ab
#8.	(antinuclear factor* or anti-nuclear factor* or anf):ti,ab
#9.	MeSH descriptor: (genetic predisposition to disease) this term only
#10.	MeSH descriptor: (genetic markers) this term only
#11.	MeSH descriptor: (genetic testing) this term only
#12.	(genetic* near/3 (marker* or test* or predisposition*)).ti,ab
#13.	MeSH descriptor: (trypsin) this term only
#14.	MeSH descriptor: (trypsinogen) this term only
#15.	(trypsinogen or trypsin or prss1):ti,ab
#16.	(tati or psti):ti,ab
#17.	MeSH descriptor: (chymotrypsin) this term only
#18.	(chymotrypsin* or ctrc or cldn2):ti,ab
#19.	MeSH descriptor: (cystic fibrosis transmembrane conductance regulator) this term only
#20.	(cystic fibrosis transmembrane conductance regulator or cftr):ti,ab
#21.	MeSH descriptor: (trypsin inhibitor, kazal pancreatic) this term only
#22.	(serine protease inhibitor kazal-type 1 or spink1):ti,ab
#23.	(or #2-#22)

#24.	#1 and #23
	Date parameters: see Table 1

PsycINFO search terms

1.	Standard population (A.2.1)
2.	Excluded study designs and publication types (A.3.1)
3.	1 not 2
4.	Limit 3 to English language
	Date parameters: see Table 1

G.4.4 Chronic diagnosis

Searches for the following two questions were run as one search:

- In people with suspected (or under investigation for) chronic pancreatitis, in whom other causes have not been excluded by the use of CT scan, US scan and/or upper GI endoscopy, what is the most accurate diagnostic test to identify whether chronic pancreatitis is present (as indicated by the reference standards biopsy, clinical follow-up or subsequent CT scan)?
- In people with suspected (or under investigation for) chronic pancreatitis in whom other causes have not been excluded by the use of CT scan, US scan and/or upper GI endoscopy, what is the most clinically and cost effective test to identify whether chronic pancreatitis is present, when each is followed by the appropriate treatment, in order to improve patient outcomes?

• **Medline search terms**

1.	Chronic pancreatitis population (G.2.2)
2.	Excluded study designs and publication types (G.3.1)
3.	1 not 2
4.	Limit 3 to English language
5.	breath tests/
6.	breath test*.ti,ab.
7.	(triglyceride* adj3 test*).ti,ab.
8.	pancreatic function tests/
9.	(pancrea* adj3 function adj3 test*).ti,ab.
10.	feces/di (diagnosis)
11.	((f?ecal or stool* or f?ece* or monoclonal or polyclonal or chymotrypsin or fat) adj3 test*).ti,ab.
12.	((f?ecal or stool* or f?ece*) adj3 (fat or elast*)).ti,ab.
13.	magnetic resonance imaging/
14.	(mri* or magnetic resonance imag* or mr imag*).ti,ab.
15.	cholangiopancreatography, magnetic resonance/
16.	cholangiopancreatography, endoscopic retrograde/
17.	(cholangiopancreatograph* or mrcp or ercp).ti,ab.
18.	endoscopic ultrasound-guided fine needle aspiration/
19.	ultrasonography/ or elasticity imaging techniques/
20.	endoscopy, digestive system/ or endoscopy, gastrointestinal/
21.	(endoscop* adj3 (ultrasound or elastograph* or imag* or eus)).ti,ab.
22.	(secretin-cholecystokinin or secretin-cck or cck).ti,ab.
23.	(secretin adj3 (stimulation or test*)).ti,ab.
24.	or/5-23

25.	Study filters RCT (G.3.2) or SR (G.3.3) or DIAG (G.3.6) or OBS (G.3.7)
26.	4 and 24 and 25
	Date parameters: see Table 1

Embase search terms

1.	Chronic pancreatitis population (G.2.2)
2.	Excluded study designs and publication types (G.3.1)
3.	1 not 2
4.	Limit 3 to English language
5.	breath analysis/
6.	breath test*.ti,ab.
7.	(triglyceride* adj3 test*).ti,ab.
8.	(pancrea* adj3 function test*).ti,ab.
9.	pancreas examination/ or pancreas function test/ or pancreatography/
10.	feces analysis/
11.	((f?ecal or stool* or f?ece* or monoclonal or polyclonal or Chymotrypsin or fat) adj3 test*).ti,ab.
12.	((f?ecal or stool* or f?ece*) adj3 (fat or elast*)).ti,ab.
13.	nuclear magnetic resonance imaging/ or magnetic resonance cholangiopancreatography/
14.	(MRI* or magnetic resonance imag* or MR imag*).ti,ab.
15.	endoscopic retrograde cholangiopancreatography/
16.	(cholangiopancreatograph* or MRCP or ERCP).ti,ab.
17.	endoscopic ultrasound guided fine needle biopsy/
18.	elastography/
19.	digestive tract endoscopy/
20.	(endoscop* adj3 (ultrasound or elastograph* or imag* or EUS)).ti,ab.
21.	(secretin-cholecystokinin or Secretin-CCK or CCK).ti,ab.
22.	(secretin adj3 (stimulation or test*)).ti,ab.
23.	or/5-22
24.	Study filters RCT (A.3.2) or SR (A.3.3) or DIAG (A.3.6) or OBS (A.3.7)
25.	4 and 23 and 24
	Date parameters: see Table 1

Cochrane search terms

#1.	Chronic pancreatitis population (G.2.2)
#2.	MeSH descriptor: (breath tests) this term only
#3.	breath test*:ti,ab
#4.	(triglyceride* near/3 test*):ti,ab
#5.	MeSH descriptor: (pancreatic function tests) this term only
#6.	(pancrea* near/3 function near/3 test*):ti,ab
#7.	((f?ecal or stool* or f?ece* or monoclonal or polyclonal or chymotrypsin or fat) near/3 test*):ti,ab
#8.	((f?ecal or stool* or f?ece*) near/3 (fat or elast*)):ti,ab
#9.	MeSH descriptor: (magnetic resonance imaging) this term only
#10.	(mri* or magnetic resonance imag* or mr imag*):ti,ab
#11.	MeSH descriptor: (cholangiopancreatography, magnetic resonance) this term only

#12.	MeSH descriptor: (cholangiopancreatography, endoscopic retrograde) this term only
#13.	MeSH descriptor: (endoscopic ultrasound-guided fine needle aspiration) this term only
#14.	MeSH descriptor: (ultrasonography) this term only
#15.	MeSH descriptor: (elasticity imaging techniques) this term only
#16.	MeSH descriptor: (endoscopy, gastrointestinal) this term only
#17.	MeSH descriptor: (endoscopy, digestive system) this term only
#18.	(endoscop* near/3 (ultrasound or elastograph* or imag* or eus)):ti,ab
#19.	(secretin-cholecystokinin or secretin-cck or cck):ti,ab
#20.	(secretin near/3 (stimulation or test*)):ti,ab
#21.	(or #2-#20)
#22.	#1 and #21
	Date parameters: see Table 1

PsycINFO search terms

1.	Standard population (A.2.1)
2.	Excluded study designs and publication types (A.3.1)
3.	1 not 2
4.	Limit 3 to English language
	Date parameters: 1806-28 September 2017

G.4.5 Lifestyle: alcohol

- What is the effectiveness of stopping or reducing alcohol consumption in reducing recurrent episodes of acute pancreatitis and improving quality of life in people with both chronic and acute pancreatitis?

Medline search terms

1.	Standard population (G.2.1)
2.	Excluded study designs and publication types (G.3.1)
3.	1 not 2
4.	Limit 3 to English language
5.	temperance/ or alcohol abstinence/
6.	(alcohol* adj3 (cessat* or ceas* or reduc* or restrict* or avoid* or abstem* or control* or stop* or quit* or giv* up or withdraw* or low* or drop* or fall* or decreas* or less* or moderat* or cut* or regulat* or abstin* or abstain* or discontinu* or chang* or alter* or modif* or adjust* or amend*)):ti,ab.
7.	(alcohol* adj6 (program* or interven* or prevent* or help* or manag* or motivat* or educat* or mentor* or inform* or support* or advice or advis* or counsel* or therap* or strateg* or policy or policies)):ti,ab.
8.	(temperate or temper or tempers or teetotal* or sober* or sobriety).ti,ab.
9.	or/5-8
10.	drinking behavior/ or alcohol drinking/ or alcoholic beverages/
11.	alcohol-related disorders/ or alcohol-induced disorders/ or alcoholic intoxication/ or alcoholism/ or binge drinking/
12.	(alcohol* adj3 "use").ti,ab.
13.	(alcohol* adj3 (addict* or abus* or depend* or overdos* or disorder* or misus* or using or user or drink* or consume* or consumption or risk* or intak* or exposure or excess* or problem* or unit*)):ti,ab.
14.	(intoxicat* or drunken*).ti,ab.

15.	(drink* adj3 (behaviour* or behavior* or binge* or problem* or excess*)).ti,ab.
16.	or/10-15
17.	4 and (9 or 16)
	Date parameters: see Table 1

Embase search terms

1.	Standard population (G.2.1)
2.	Excluded study designs and publication types (G.3.1)
3.	1 not 2
4.	Limit 3 to English language
5.	temperance/ or alcohol abstinence/
6.	(alcohol* adj3 (cessat* or ceas* or reduc* or restrict* or avoid* or abstem* or control* or stop* or quit* or giv* up or withdraw* or low* or drop* or fall* or decreas* or less* or moderat* or cut* or regulat* or abstin* or abstain* or discontinu* or chang* or alter* or modif* or adjust* or amend*)).ti,ab.
7.	(alcohol* adj6 (program* or interven* or prevent* or help* or manag* or motivat* or educat* or mentor* or inform* or support* or advice or advis* or counsel* or therap* or strateg* or policy or policies)).ti,ab.
8.	(temperate or temper or tempers or teetotal* or sober* or sobriety).ti,ab.
9.	or/5-8
10.	drinking behavior/ or alcohol drinking/ or alcoholic beverages/
11.	alcohol-related disorders/ or alcohol-induced disorders/ or alcoholic intoxication/ or alcoholism/ or binge drinking/
12.	(alcohol* adj3 "use").ti,ab.
13.	(alcohol* adj3 (addict* or abus* or depend* or overdos* or disorder* or misus* or using or user or drink* or consume* or consumption or risk* or intak* or exposure or excess* or problem* or unit*)).ti,ab.
14.	(intoxicat* or drunken*).ti,ab.
15.	(drink* adj3 (behaviour* or behavior* or binge* or problem* or excess*)).ti,ab.
16.	or/10-15
17.	4 and (9 or 16)
	Date parameters: see Table 1

Cochrane search terms

#1.	Standard population (G.2.1)
#2.	MeSH descriptor: (temperance) this term only
#3.	MeSH descriptor: (alcohol abstinence) this term only
#4.	(alcohol* near/3 (cessat* or ceas* or reduc* or restrict* or avoid* or abstem* or control* or stop* or quit* or giv* next up or withdraw* or low* or drop* or fall* or decreas* or less* or moderat* or cut* or regulat* or abstin* or abstain* or discontinu* or chang* or alter* or modif* or adjust* or amend*)).ti,ab
#5.	(alcohol* near/6 (program* or interven* or prevent* or help or support* or advice or advise* or counsel* or therap* or strateg* or policy or policies)).ti,ab
#6.	(temperate or temper or tempers or teetotal* or sober* or sobriety):ti,ab
#7.	#2 or #3or #4 or #5 or #6
#8.	MeSH descriptor: (drinking behavior) this term only
#9.	MeSH descriptor: (alcohol drinking) this term only
#10.	MeSH descriptor: (alcoholic beverages) this term only
#11.	MeSH descriptor: (alcohol-related disorders) this term only

#12.	MeSH descriptor: (alcohol-induced disorders) this term only
#13.	MeSH descriptor: (alcoholic intoxication) this term only
#14.	MeSH descriptor: (alcoholism) this term only
#15.	MeSH descriptor: (binge drinking) this term only
#16.	alcohol* near/3 use:ti,ab
#17.	(alcohol* near/3 (addict* or abus* or depend* or overdos* or disorder* or misus* or using or user or drink* or consume* or consumption or risk* or intak* or exposure or excess* or problem* or unit*)):ti,ab
#18.	(intoxicat* or drunken*):ti,ab
#19.	(drink* near/3 (behaviour* or behavior* or binge* or problem* or excess*)):ti,ab
#20.	#8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19
#21.	#7 or #20
#22.	#1 and #21
	Date parameters: see Table 1

PsycINFO search terms

1.	Standard population (A.2.1)
2.	Excluded study designs and publication types (A.3.1)
3.	1 not 2
4.	Limit 3 to English language
	Date parameters: see Table 1

G.4.6 IV fluid management

Searches for the following two questions were run as one search:

- What is the most clinically and cost-effective type of intravenous fluid for resuscitation in people with acute pancreatitis?
- What is the most clinically and cost-effective speed of administration of intravenous fluid for resuscitation in people with acute pancreatitis?

Medline search terms

1.	Standard population (G.2.1)
2.	Excluded study designs and publication types (G.3.1)
3.	1 not 2
4.	Limit 3 to English language
5.	exp fluid therapy/
6.	((fluid* or volum*) adj3 (restor* or resuscita* or replac* or deplet* or deficien*)):ti,ab.
7.	(fluid* adj3 (challenge or bolus)):ti,ab.
8.	colloids/
9.	exp plasma substitutes/
10.	albumins/ or exp serum albumin/
11.	dextrans/
12.	hydroxyethyl starch derivatives/
13.	exp hypertonic solutions/ or isotonic solutions/
14.	gelatin/
15.	(crystalloid* or colloid* or isotonic).ti,ab.
16.	(albumin* or albumex or albumorm or octalbin or zenalb or flexbumin).ti,ab.

17.	(dextran or rescueflow).ti,ab.
18.	(gelatin or gelospan or gelofusine or geloplasma or isoplex or volplex).ti,ab.
19.	(starch* or hetastarch* or pentastarch* or pentaspan* or haemaccel or haes-steril or hemohe or tetrastarch* or tetraspan or venofundin or volulyte or voluven).ti,ab.
20.	(hypertonic or hyperhaes or hypotonic).ti,ab.
21.	potassium chloride/ or sodium chloride/ or sodium bicarbonate/
22.	(sodium or salin* or hartman* or ringer* or glucose or lactate* or acetate*).ti,ab.
23.	(dextrose or potassium or bicarbonate).ti,ab.
24.	(goal adj1 (direct* or orient*) adj1 therap*).ti,ab.
25.	(plasmalyte or plasma-lyte).ti,ab.
26.	or/5-25
27.	4 and 26
	Date parameters: see Table 1

Embase search terms

1.	Standard population (G.2.1)
2.	Excluded study designs and publication types (G.3.1)
3.	1 not 2
4.	Limit 3 to English language
5.	exp fluid therapy/
6.	fluid resuscitation/
7.	fluid balance/
8.	((fluid* or volum*) adj3 (restor* or resuscita* or replac* or deplet* or deficien*)).ti,ab.
9.	(fluid* adj3 (challenge or bolus)).ti,ab.
10.	colloid/
11.	plasma substitute/
12.	albumin/
13.	serum albumin/
14.	hypertonic solution/
15.	isotonic solution/
16.	dextran/
17.	hetastarch derivative/
18.	gelatin/
19.	(crystalloid* or colloid* or isotonic).ti,ab.
20.	(albumin* or albumex or albumorm or octalbin or zenalb or flexbumin).ti,ab.
21.	human serum albumin/
22.	human albumin/
23.	(dextran or rescueflow).ti,ab.
24.	dextran 70/
25.	(gelatin or gelospan or gelofusine or geloplasma or isoplex or volplex).ti,ab.
26.	gelatin succinate/
27.	crystalloid/
28.	(starch* or hetastarch* or pentastarch* or pentaspan* or haemaccel or haes-steril or hemohe or tetrastarch* or tetraspan or venofundin or volulyte or voluven).ti,ab.
29.	polygeline/
30.	(hypertonic or hyperhaes or hypotonic).ti,ab.

31.	potassium chloride/
32.	sodium chloride/
33.	bicarbonate/
34.	(sodium or salin* or hartman* or ringer* or glucose or lactate* or acetate*).ti,ab.
35.	hartmann solution/
36.	ringer lactate solution/ or ringer solution/
37.	(dextrose or potassium or bicarbonate).ti,ab.
38.	(goal adj1 (direct* or orient*) adj1 therap*).ti,ab.
39.	acetic acid plus gluconate sodium plus magnesium chloride plus potassium chloride plus sodium chloride/
40.	(plasmalyte or plasma-lyte).ti,ab.
41.	or/5-41
42.	4 and 42
	Date parameters: see Table 1

Cochrane search terms

#1.	Standard population (G.2.1)
#2.	MeSH descriptor: (fluid therapy) explode all trees
#3.	((fluid* or volum*) near/3 (restor* or resuscita* or replac* or deplet* or deficien*)):ti,ab
#4.	(fluid* near/3 (challenge or bolus)):ti,ab
#5.	MeSH descriptor: (colloids) explode all trees
#6.	MeSH descriptor: (plasma substitutes) explode all trees
#7.	MeSH descriptor: (albumins) explode all trees
#8.	MeSH descriptor: (serum albumin) explode all trees
#9.	MeSH descriptor: (dextrans) explode all trees
#10.	MeSH descriptor: (hydroxyethyl starch derivatives) explode all trees
#11.	(mh "hypertonic solutions")
#12.	(mh "isotonic solutions")
#13.	(mh gelatin)
#14.	(crystalloid* or colloid* or isotonic):ti,ab
#15.	(albumin* or albumex or alburnorm or octalbin or zenalb or flexbumin):ti,ab
#16.	(dextran or rescueflow):ti,ab
#17.	(gelatin or gelospan or gelofusine or geloplasma or isoplex or volplex):ti,ab
#18.	(starch* or hetastarch* or pentastarch* or pentaspan* or haemaccel or haes-steril or hemohees or tetrastarch* or tetraspan or venofundin or volulyte or voluven):ti,ab
#19.	(hypertonic or hyperhaes or hypotonic):ti,ab
#20.	(mh "potassium chloride")
#21.	(mh "sodium chloride")
#22.	(mh "sodium bicarbonate")
#23.	(sodium or salin* or hartman* or ringer* or glucose or lactate* or acetate*).ti,ab
#24.	(dextrose or potassium or bicarbonate):ti,ab
#25.	(goal next (direct* or orient*) next therap*):ti,ab
#26.	(plasmalyte or plasma-lyte):ti,ab
#27.	(or #4-#26)
#28.	#1 and #27
	Date parameters: see Table 1

PsycINFO search terms

1.	Standard population (A.2.1)
2.	Excluded study designs and publication types (A.3.1)
3.	1 not 2
4.	Limit 3 to English language
	Date parameters: see Table 1

G.4.7 Nutrition support

Searches for the following two questions were run as one search:

- What is the clinical and cost effectiveness of early versus late nutritional intervention (for example, food supplements, enzyme supplements) in people with chronic pancreatitis and signs of malnutrition or malabsorption?
- What is the most clinically and cost-effective route of feeding at time of admission to the hospital in people with acute pancreatitis?

Medline search terms

1.	Standard population (G.2.1)
2.	Excluded study designs and publication types (G.3.1)
3.	1 not 2
4.	Limit 3 to English language
5.	exp nutrition therapy/ or nutrition assessment/ or diet therapy/ or exp nutritional support/
6.	dietary supplements/ or exp enzyme therapy/
7.	feeding methods/ or enteral nutrition/ or parenteral nutrition/
8.	((diet* or nutrition* or nutrient* or food or feed*) adj4 (support* or assess* or advice or advise* or counsel* or therap* or intervention* or strateg* or protocol* or manage* or treat* or absorb* or absorption or supplement* or intak* or replace*)).ti,ab.
9.	((enteral or parenteral or gastric or nasogastric or nasojejunal or jejunal or duodenal or nasoduodenal or nasoenteric) adj4 (feed* or fed or food or nutrition* or nutrient* or diet*)).ti,ab.
10.	((enzyme* or calorie* or vitamin* or glutamine or probiotic* or omega-3) adj4 (supplement* or treat* or intervention* or therap* or replace* or absorb* or absorption)).ti,ab.
11.	(ert or pert or pancrease or pancrex or creon or kreon or pancreaze or pancreatin or nutrizym or pankreon or pankreatin).ti,ab.
12.	(pancreatic adj enzyme*).ti,ab.
13.	(tube adj3 (feed* or fed)).ti,ab.
14.	(oral* adj3 (fed or feed* or diet* or supplement*)).ti,ab.
15.	((liquid or soft) adj2 diet*).ti,ab.
16.	immunonutrition.ti,ab.
17.	(route adj2 feed*).ti,ab.
18.	or/5-18
19.	4 and 19
20.	malnutrition/ or malabsorption syndromes/ or nutritional status/
21.	(malnutrition or malabsorption or malnourish* or maldigestion or under-nutrition or undernutrition or under-nourish* or undernourish*).ti,ab.
22.	(nutrition* adj3 (status or deficient* or impair* or deplet* or risk*)).ti,ab.
23.	((micronutrient* or vitamin*) adj3 (deficien* or impair* or deplet*)).ti,ab.
24.	(weight adj2 (lost or loss*)).ti,ab.

25.	(skinfold* or skin fold*).ti,ab.
26.	body mass index/ or skinfold thickness/
27.	weight loss/
28.	or/20-27
29.	4 and 28
30.	Study filters RCT (G.3.2) or SR (G.3.3) or OBS (G.3.7)
31.	30 and (19 or 29)
	Date parameters: see Table 1

Embase search terms

1.	Standard population (G.2.1)
2.	Excluded study designs and publication types (G.3.1)
3.	1 not 2
4.	Limit 3 to English language
5.	diet therapy/ or nutritional assessment/ or nutritional support/
6.	dietary supplement/ or vitamin supplementation/ or diet supplementation/
7.	food intake/ or enteric feeding/ or exp parenteral nutrition/
8.	exp enzyme therapy/
9.	((diet* or nutrition* or nutrient* or food or feed*) adj4 (support* or assess* or advice or advise* or counsel* or therap* or intervention* or strateg* or protocol* or manage* or treat* or absorb* or absorption or supplement* or intak* or replace*)).ti,ab.
10.	((enteral or parenteral or gastric or nasogastric or nasojejunal or jejunal or duodenal or nasoduodenal or nasoenteric) adj4 (feed* or fed or food or nutrition* or nutrient* or diet*)).ti,ab.
11.	((enzyme* or calorie* or vitamin* or glutamine or probiotic* or omega-3) adj4 (supplement* or treat* or intervention* or therap* or replace* or absorb* or absorption)).ti,ab.
12.	(ert or pert or pancrease or pancrex or creon or kreon or pancreaze or pancreatin or nutrizym or pankreon or pankreatin).ti,ab.
13.	(pancreatic adj enzyme*).ti,ab.
14.	(tube adj3 (feed* or fed)).ti,ab.
15.	(oral* adj3 (fed or feed* or diet* or supplement*)).ti,ab.
16.	((liquid or soft) adj2 diet*).ti,ab.
17.	(route adj2 feed*).ti,ab.
18.	immunonutrition.ti,ab.
19.	or/5-18
20.	nutritional status/
21.	(nutrition* adj3 (status or deficien* or impair* or deplet* or risk*)).ti,ab.
22.	malnutrition/ or malabsorption/
23.	(malnutrition or malabsorption or malnourish* or maldigestion or under-nutrition or undernutrition or under-nourish* or undernourish*).ti,ab.
24.	vitamin deficiency/ or nutritional deficiency/
25.	((micronutrient* or vitamin*) adj3 (deficien* or impair* or deplet*)).ti,ab.
26.	weight reduction/ or body mass/ or skinfold thickness/
27.	(weight adj2 (lost or loss*)).ti,ab.
28.	(skinfold* or skin fold*).ti,ab.
29.	or/20-28
30.	4 and (19 or 29)

31.	Study filters RCT (G.3.2) or SR (G.3.3) or OBS (G.3.7)
32.	30 and 31
	Date parameters: see Table 1

Cochrane search terms

#1.	Standard population (G.2.1)
#2.	(mh "nutrition therapy")
#3.	(mh ^"nutrition assessment")
#4.	(mh ^"diet therapy")
#5.	(mh "nutritional support")
#6.	(mh ^"dietary supplements")
#7.	(mh "enzyme therapy")
#8.	(mh ^"feeding methods")
#9.	((diet* or nutrition* or nutrient* or food or feed*) near/4 (support* or assess* or advice or advise* or counsel* or therap* or intervention* or strateg* or protocol* or manage* or treat* or absorb* or absorption or supplement* or intak* or replace*)):ti,ab
#10.	((enteral or parenteral or gastric or nasogastric or nasojejunal or jejunal or duodenal or nasoduodenal or nasoenteric) near/4 (feed* or fed or food or nutrition* or nutrient* or diet*)):ti,ab
#11.	((enzyme* or calorie* or vitamin* or glutamine or probiotic* or omega-3) near/4 (supplement* or treat* or intervention* or therap* or replace* or absorb* or absorption)):ti,ab
#12.	(ert or pert or pancrease or pancrex or creon or kreon or pancreaze or pancreatin or nutrizym or pankreon or pankreatin):ti,ab
#13.	(pancreatic next enzyme*):ti,ab
#14.	(tube near/3 (feed* or fed)):ti,ab
#15.	(oral* near/3 (fed or feed* or diet* or supplement*)):ti,ab
#16.	((liquid or soft) near/2 diet*):ti,ab
#17.	immunonutrition:ti,ab
#18.	(route near/2 feed*):ti,ab
#19.	(or #2-#18)
#20.	#1and #19
#21.	(mh ^malnutrition)
#22.	(mh ^"malabsorption syndromes")
#23.	(mh ^"nutritional status")
#24.	(malnutrition or malabsorption or malnourish* or maldigestion or under-nutrition or undernutrition or under-nourish* or undernourish*):ti,ab
#25.	(nutrition* near/3 (status or deficien* or impair* or deplet* or risk*)):ti,ab
#26.	((micronutrient* or vitamin*) near/3 (deficien* or impair* or deplet*)):ti,ab
#27.	(weight near/2 (lost or loss*)):ti,ab
#28.	(skinfold* or skin fold*):ti,ab
#29.	(mh ^"body mass index")
#30.	(mh ^"skinfold thickness")
#31.	(mh ^"weight loss")
#32.	(or #21-#31)
#33.	#1 and #32
#34.	#19 or #33

	Date parameters: see Table 1
--	-------------------------------------

PsycINFO search terms

1.	Standard population (A.2.1)
2.	Excluded study designs and publication types (A.3.1)
3.	1 not 2
4.	Limit 3 to English language
	Date parameters: see Table 1

G.4.8 Antimicrobial prophylaxis

- What is the clinical and cost-effectiveness of prophylactic antimicrobial agents to prevent infection in people with acute pancreatitis?

Medline search terms

1.	Standard population (G.2.1)
2.	Excluded study designs and publication types (G.3.1)
3.	1 not 2
4.	Limit 3 to English language
5.	exp anti-infective agents/ or superinfection/ or exp bacterial infections/
6.	exp aminoglycosides/
7.	exp beta-lactams/
8.	exp glycopeptides/
9.	exp lincosamides/
10.	exp macrolides/
11.	exp nitroimidazoles/
12.	exp polymyxins/
13.	exp quinolones/
14.	exp sulfonamides/
15.	exp trimethoprim/
16.	exp tetracyclines/
17.	exp chloramphenicol/
18.	fusidic acid/
19.	daptomycin/
20.	linezolid/
21.	exp rifamycins/
22.	nitrofurantoin/
23.	methenamine/
24.	exp triazoles/ or exp imidazoles/
25.	exp polyenes/
26.	echinocandins/
27.	flucytosine/
28.	griseofulvin/
29.	(microb* or antimicrob* or anti-microb* or antiinfect* or anti-infect* or bacter* or antibacter* or anti-bacter* or antibiot* or anti-biot* or fung* or antifung* or anti-fung* or superbug* or super-bug*).ti,ab.
30.	beta-lactam*.mp,hw.

31.	(aminoglycoside* or amikacin or amikin or gentamicin or cidomycingenticin or neomycin or sulphate or nivemycin or streptomycin or tobramycin or nebcin or tobi or podhaler or tobi or tymbrineb or bramitob or tobravisc).mp,hw.
32.	(carbapen#m* or ertapenem or invanz or imipenem or cilastatin or primaxin or meropenem or meronem).mp,hw.
33.	(cephalosporin* or cefadroxil or cefalexin or ceporex or keflex or cefradine or nicef or cefaclor or distaclor or keftid or cefuroxime or zinnat or aprokam or zinacef or cefixime or suprax or cefotaxime or ceftazidime or fortum or kefadim or ceftriaxone or rocephin or ceftaroline or fosamil or zinforo).mp,hw.
34.	(glycopeptide* or teicoplanin or targocid or telavancin or vibativ or vancomycin or vancocin).mp,hw.
35.	(lincosamide* or clindamycin or dalacin or zindaclin).mp,hw.
36.	(macrolide* or azithromycin or zithromax or zedbac or ayter or clarithromycin or clarie or klaricid or erythromycin or erythrocin or erythrolar or erythroped or erymax or primacine or tiloryth or ofthalmolosa cusi eritromicina or telithromycin or ketek).mp,hw.
37.	(monobactam* or aztreonam or azactam or cayston).mp,hw.
38.	(nitroimidazole* or metronidazole or flagyl or vaginyl or norzol or metrolyl or tinidazole or fasigyn).mp,hw.
39.	(penicillin* or piperacillin or tazobactam or tazocin or ticarcillin or clavulanic acid or timentin or benzylpenicillin or crystapen or phenoxymethylpenicillin or amoxicillin or amoxil or amix or amoram or amoxient or galenamox or rimoxallin or ampicillin or penbritin or rimacillin or co-fluampicil or flu-amp or magnapen or co-amoxiclav or augmentin or pivmecillinam or selexid or flucloxacillin or floxapen or flucomix or ladropen or temocillin or negaban).mp,hw.
40.	(polymyxin* or colistimethate or colistin or sulfomethate or colomycin or promixin or colobreathe).mp,hw.
41.	(quinolone* or ciprofloxacin or ciproxin or levofloxacin or evoxil or tavanic or moxifloxacin or avelox or nalidixic acid or norfloxacin or ofloxacin or tarivid or perfloxacin).mp,hw.
42.	(sulfonamide* or co-trimoxazole or fectrim or septrin or sulfadiazine or trimethoprim or trimopan).mp,hw.
43.	(tetracycline* or demeclocycline or doxycycline or vibramycin-d or efracea or lymecycline or tetralysal or minocycline or aknemin or acnamino or minocin or sebomin or oxytetracycline or oxymycin or tigecycline or tygacil).mp,hw.
44.	(chloramphenicol or kemicetine or brochlor or brolene or chloromycetin or golden eye or optrex or klorafect or fosfomycin or fomicyt or fusidic acid or sodium fusidate or fucidin or daptomycin or cubicin or linezolid or zyvox or rifaximin or targaxan or xifaxanta or fidaxomicin or dificlir or tedizolid or sivextro).mp,hw.
45.	(nitrofurantoin or macrobid or methenamine hippurate or hexamine hippurate or hiprex).mp,hw.
46.	(triazole* or fluconazole or diflucan or itraconazole or sporanox or posaconazole or noxafil or voriconazole or vfend or omoconazole or epoxiconazole).mp,hw.
47.	(imidazole* or clotrimazole or econazole or tioconazole or ketoconazole or miconazole).mp,hw.
48.	(polyene* or amphotericin or fungizone or abelcet or ambisome).mp,hw.
49.	(echinocandin* or anidulafungin or ecalta or caspofungin or candidas or micafungin or mycamine).mp,hw.
50.	(flucytosine or ancotil or griseofulvin or terbinafine or lamisil).mp,hw.
51.	or/5-50
52.	4 and 51
	Date parameters: see Table 1

Embase search terms

1.	Standard population (G.2.1)
2.	Excluded study designs and publication types (G.3.1)
3.	1 not 2
4.	Limit 3 to English language
5.	exp antiinfective agent/
6.	exp bacterial infection/ or exp superinfection/
7.	exp *aminoglycoside antibiotic agent/
8.	*amikacin/ or *gentamicin/ or *neomycin/ or *streptomycin/ or *tobramycin/
9.	exp *beta lactam antibiotic/
10.	*carbapenem derivative/ or *carbapenem/ or *ertapenem/ or *cilastatin with imipenem/ or *imipenem/ or *meropenem/
11.	exp *cephalosporin derivative/ or exp *cephalosporin/
12.	*cefadroxil/ or *cefalexin/ or *cefradine/ or *cefaclor/ or *cefuroxime/ or *cefixime/ or *cefotaxime/ or *ceftazidime/ or *ceftriaxone/ or *ceftaroline fosamil/
13.	*glycopeptide/
14.	*teicoplanin/ or *telavancin/ or *vancomycin/
15.	*lincosamide/
16.	*clindamycin/
17.	exp *macrolide/
18.	*azithromycin/ or *clarithromycin/ or *erythromycin/ or *telithromycin/
19.	exp *monobactam derivative/
20.	*aztreonam/
21.	exp *nitroimidazole derivative/ or exp *nitroimidazole/
22.	*metronidazole/ or *tinidazole/
23.	exp *penicillin derivative/
24.	*piperacillin plus tazobactam/ or *ticarcillin/ or *clavulanic acid/ or *penicillin g/ or *penicillin v/ or *amoxicillin/ or *ampicillin/ or *ampicillin plus flucloxacillin/ or *amoxicillin plus clavulanic acid/ or *pivmecillinam/ or *flucloxacillin/
25.	*polymyxin/
26.	*colistin/ or *colistimethate/
27.	exp *quinolone derivative/ or exp *quinolone/
28.	*ciprofloxacin/ or *levofloxacin/ or *moxifloxacin/ or *nalidixic acid/ or *norfloxacin/ or *ofloxacin/ or *perfloxacin/
29.	exp *sulfonamide/ or exp *trimethoprim/ or exp *trimethoprim derivative/
30.	*cotrimoxazole/ or *sulfadiazine/
31.	exp *tetracycline derivative/ or exp *tetracycline/
32.	*demeclocycline/ or *doxycycline/ or *lymecycline/ or *minocycline/ or *oxytetracycline/ or *tigecycline/
33.	*chloramphenicol derivative/ or *chloramphenicol/
34.	*fosfomycin/
35.	*fusidic acid/
36.	*daptomycin/
37.	*linezolid/
38.	*rifaximin/
39.	*fidaxomicin/
40.	*tedizolid/

41.	exp *triazole derivative/
42.	*fluconazole/ or *itraconazole/ or *posaconazole/ or *voriconazole/ or *omoconazole/ or *epoxiconazole/
43.	exp *imidazole derivative/
44.	*clotrimazole/ or *econazole/ or *tioconazole/ or *ketoconazole/ or *miconazole/
45.	exp *polyene antibiotic agent/
46.	*amphotericin/
47.	exp *echinocandin/
48.	*anidulafungin/ or *caspofungin/ or *micafungin/
49.	*flucytosine/ or *griseofulvin/ or *terbinafine/
50.	(microb* or antimicrob* or anti-microb* or antiinfect* or anti-infect* or bacter* or antibacter* or anti-bacter* or antibiot* or anti-biot* or fung* or antifung* or anti-fung* or superbug* or super-bug*).ti,ab.
51.	beta-lactam*.mp,hw.
52.	(aminoglycoside* or amikacin or amikin or gentamicin or cidomyingenticin or neomycin or sulphate or nivemycin or streptomycin or tobramycin or nebcin or tobi or podhaler or tobi or tymbrineb or bramitob or tobravisc).mp,hw.
53.	(carbapen#m* or ertapenem or invanz or imipenem or cilastatin or primaxin or meropenem or meronem).mp,hw.
54.	(cephalosporin* or cefadroxil or cefalexin or ceporex or keflex or cefradine or nicef or cefaclor or distaclor or keftid or cefuroxime or zinnat or aprokam or zinacef or cefixime or suprax or cefotaxime or ceftazidime or fortum or kefadim or ceftriaxone or rocephin or ceftaroline or fosamil or zinforo).mp,hw.
55.	(glycopeptide* or teicoplanin or targocid or telavancin or vibativ or vancomycin or vancocin).mp,hw.
56.	(lincosamide* or clindamycin or dalacin or zindaclin).mp,hw.
57.	(macrolide* or azithromycin or zithromax or zedbac or ayter or clarithromycin or clarie or klaricid or erythromycin or erythrocin or erythrolar or erythroped or erymax or primacine or tiloryth or oftalmolosa cusi eritromicina or telithromycin or ketek).mp,hw.
58.	(monobactam* or aztreonam or azactam or cayston).mp,hw.
59.	(nitroimidazole* or metronidazole or flagyl or vaginyl or norzol or metrolyl or tinidazole or fasigyn).mp,hw.
60.	(penicillin* or piperacillin or tazobactam or tazocin or ticarcillin or clavulanic or timentin or benzylpenicillin or crystapen or phenoxymethylpenicillin or amoxicillin or amoxil or amix or amoram or amoxient or galenamox or rimoxallin or ampicillin or penbritin or rimacillin or co-fluampicil or flu-amp or magnapen or co-amoxiclav or augmentin or pivmecillinam or selexid or flucloxacillin or floxapen or flucomix or ladropen or temocillin or negaban).mp,hw.
61.	(polymyxin* or colistimethate or colistin or sulfomethate or colomycin or promixin or colobreathe).mp,hw.
62.	(quinolone* or ciprofloxacin or ciproxin or levofloxacin or evoxil or tavanic or moxifloxacin or avelox or nalidixic acid or norfloxacin or ofloxacin or tarivid or perfloxacin).mp,hw.
63.	(sulfonamide* or co-trimoxazole or cotrimoxazole or fectrim or septrin or sulfadiazine or trimethoprim or trimopan).mp,hw.
64.	(tetracycline* or demeclocycline or doxycycline or vibramycin-d or efracea or lymecycline or tetralysal or minocycline or aknemin or acnamino or minocin or sebomin or oxytetracycline or oxymycin or tigecycline or tygacil).mp,hw.
65.	(chloramphenicol or kemicetine or brochlor or brolene or chloromycetin or golden eye or optrex or klorafect or fosfomycin or fomicyt or fusidic acid or sodium fusidate or fucidin or daptomycin or cubicin or linezolid or zyvox or rifaximin or targaxan or xifaxanta or fidaxomicin or dificlir or tedizolid or sivextro).mp,hw.
66.	(nitrofurantoin or macrobid or methenamine hippurate or hexamine hippurate or

	hiprex).mp,hw.
67.	(triazole* or fluconazole or diflucan or itraconazole or sporanox or posaconazole or noxafil or voriconazole or v fend or omoconazole or epoxiconazole).mp,hw.
68.	(imidazole* or clotrimazole or econazole or tioconazole or ketoconazole or miconazole).mp,hw.
69.	(polyene* or amphotericin or fungizone or abelcet or ambisome).mp,hw.
70.	(echinocandin* or anidulafungin or ecalta or caspofungin or candidas or micafungin or mycamine).mp,hw.
71.	(flucytosine or ancotil or griseofulvin or terbinafine or lamisil).mp,hw.
72.	or/5-71
73.	4 and 72
	Date parameters: see Table 1

Cochrane search terms

#1.	Standard population (G.2.1)
#2.	MeSH descriptor: (anti-infective agents) explode all trees
#3.	MeSH descriptor: (superinfection) explode all trees
#4.	MeSH descriptor: (bacterial infections) explode all trees
#5.	MeSH descriptor: (aminoglycosides) explode all trees
#6.	MeSH descriptor: (beta-lactams) explode all trees
#7.	MeSH descriptor: (glycopeptides) explode all trees
#8.	MeSH descriptor: (lincosamides) explode all trees
#9.	MeSH descriptor: (macrolides) explode all trees
#10.	MeSH descriptor: (nitroimidazoles) explode all trees
#11.	MeSH descriptor: (polymyxins) explode all trees
#12.	MeSH descriptor: (quinolones) explode all trees
#13.	MeSH descriptor: (sulfonamides) explode all trees
#14.	MeSH descriptor: (trimethoprim) explode all trees
#15.	MeSH descriptor: (tetracyclines) explode all trees
#16.	MeSH descriptor: (chloramphenicol) explode all trees
#17.	MeSH descriptor: (fusidic acid) explode all trees
#18.	MeSH descriptor: (daptomycin) explode all trees
#19.	MeSH descriptor: (linezolid) explode all trees
#20.	MeSH descriptor: (rifamycins) explode all trees
#21.	MeSH descriptor: (nitrofurantoin) explode all trees
#22.	MeSH descriptor: (methenamine) explode all trees
#23.	MeSH descriptor: (azoles) explode all trees
#24.	MeSH descriptor: (polyenes) explode all trees
#25.	MeSH descriptor: (echinocandins) explode all trees
#26.	MeSH descriptor: (flucytosine) explode all trees
#27.	MeSH descriptor: (fosfomicin) explode all trees
#28.	MeSH descriptor: (griseofulvin) explode all trees
#29.	(microb* or antimicrob* or anti-microb* or (anti next microb*) or antiinfect* or anti-infect* or (anti next infect*) or bacter* or antibacter* or anti-bacter* or (anti next bacter*) or antibiot* or anti-biot* or (anti next biot*) or fung* or antifung* or anti-fung* or (anti next fung*) or superbug* or super-bug* or (super next bug*)):ti,ab,kw
#30.	(beta-lactam* or (beta next lactam*)):ti,ab,kw

#31.	(aminoglycoside* or amikacin or amikin or gentamicin or cidomycingenticin or neomycin or sulphate or nivemycin or streptomycin or tobramycin or nebcin or tobi or podhaler or tobi or tymbrineb or bramitob or tobravisc):ti,ab,kw
#32.	(carbapenem* or carbepenam* or ertapenem or invanz or imipenem or cilastatin or primaxin or meropenem or meronem):ti,ab,kw
#33.	(cephalosporin* or cefadroxil or cefalexin or ceporex or keflex or cefradine or nicef or cefaclor or distaclor or keftid or cefuroxime or zinnat or aprokam or zinacef or cefixime or suprax or cefotaxime or ceftazidime or fortum or kefadim or ceftriaxone or rocephin or ceftaroline or fosamil or zinforo):ti,ab,kw
#34.	(glycopeptide* or teicoplanin or targocid or telavancin or vibativ or vancomycin or vancocin):ti,ab,kw
#35.	(lincosamide* or clindamycin or dalacin or zindaclin):ti,ab,kw
#36.	(macrolide* or azithromycin or zithromax or zedbac or ayter or clarithromycin or clarie or klaricid or erythromycin or erythrocin or erythrolar or erythroped or erymax or primacine or tiloryth or ofthalmolosa or telithromycin or ketek):ti,ab,kw
#37.	(monobactam* or aztreonam or azactam or cayston):ti,ab,kw
#38.	(nitroimidazole* or metronidazole or flagyl or vaginyl or norzol or metrolyl or tinidazole or fasigyn):ti,ab,kw
#39.	(penicillin* or piperacillin or tazobactam or tazocin or ticarcillin or clavulanic or timentin or benzylpenicillin or crystapen or phenoxymethylpenicillin or amoxicillin or amoxil or amix or amoram or amoxient or galenamox or rimoxallin or ampicillin or penbritin or rimacillin or co-fluampicil or flu-amp or magnapen or co-amoxiclav or augmentin or pivmecillinam or selexid or flucloxacillin or floxapen or flucomix or ladropen or temocillin or negaban):ti,ab,kw
#40.	(polymyxin* or colistimethate or colistin or sulfomethate or colomycin or promixin or colobreathe):ti,ab,kw
#41.	(quinolone* or ciprofloxacin or ciproxin or levofloxacin or evoxil or tavanic or moxifloxacin or avelox or nalidixic acid or norfloxacin or ofloxacin or tarivid or perfloxacin):ti,ab,kw
#42.	(sulfonamide* or co-trimoxazole or fectrim or septrin or sulfadiazine or trimethoprim or trimopan):ti,ab,kw
#43.	(tetracycline* or demeclocycline or doxycycline or vibramycin-d or efracea or lymecycline or tetralysal or minocycline or aknemin or acnamino or minocin or sebomin or oxytetracycline or oxymycin or tigecycline or tygacil):ti,ab,kw
#44.	(chloramphenicol or kemicetine or brochlor or brolene or chloromycetin or golden eye or optrex or klorafect or fosfomycin or fomicyt or fusidic acid or sodium fusidate or fucidin or daptomycin or cubicin or linezolid or zyvox or rifaximin or targaxan or xifaxanta or fidaxomicin or dificlir or tedizolid or sivextro):ti,ab,kw
#45.	(nitrofurantoin or macrobid or methenamine hippurate or hexamine hippurate or hiprex):ti,ab,kw
#46.	(triazole* or fluconazole or diflucan or itraconazole or sporanox or posaconazole or noxafil or voriconazole or vfend or omoconazole or epoxiconazole):ti,ab,kw
#47.	(imidazole* or clotrimazole or econazole or tioconazole or ketoconazole or miconazole):ti,ab,kw
#48.	(polyene* or amphotericin or fungizone or abelcet or ambisome):ti,ab,kw
#49.	(echinocandin* or anidulafungin or ecalta or caspofungin or candidas or micafungin or mycamine):ti,ab,kw
#50.	(flucytosine or ancotil or griseofulvin or terbinafine or lamisil):ti,ab,kw
#51.	(or #2-#50)
#52.	#1 and #51
	Date parameters: see Table 1

PsycINFO search terms

1.	Standard population (A.2.1)
2.	Excluded study designs and publication types (A.3.1)
3.	1 not 2
4.	Limit 3 to English language
	Date parameters: see Table 1

G.4.9 Necrosis

Searches for the following two questions were run as one search:

- What is the most clinical and cost-effective method for managing (suspected) infected necrosis in people with acute pancreatitis?
- What is the most clinically and cost-effective timing of intervention for managing infected necrosis in people with acute pancreatitis?

Medline search terms

1.	Standard population (G.2.1)
2.	Excluded study designs and publication types (G.3.1)
3.	1 not 2
4.	Limit 3 to English language
5.	pancreatitis, acute necrotizing/
6.	5 not 22
7.	Limit 6 to English language
8.	necrosis/
9.	necro*.ti,ab.
10.	or/8-9
11.	4 and 10
12.	7 or 11
13.	surgical procedures, operative/ or minimally invasive surgical procedures/ or endoscopy/ or exp endoscopy, digestive system/ or exp laparoscopy/ or laparotomy/ or drainage/
14.	(surgery or surgical or drainage or endoscop* or laparotom* or laparoscop*).ti,ab.
15.	13 or 14
16.	exp anti-infective agents/ or superinfection/ or exp bacterial infections/
17.	exp aminoglycosides/
18.	exp beta-lactams/
19.	exp glycopeptides/
20.	exp lincosamides/
21.	exp macrolides/
22.	exp nitroimidazoles/
23.	exp polymyxins/
24.	exp quinolones/
25.	exp sulfonamides/
26.	exp trimethoprim/
27.	exp tetracyclines/
28.	exp chloramphenicol/
29.	fusidic acid/
30.	daptomycin/

31.	linezolid/
32.	exp rifamycins/
33.	nitrofurantoin/
34.	methenamine/
35.	exp triazoles/ or exp imidazoles/
36.	exp polyenes/
37.	echinocandins/
38.	flucytosine/
39.	griseofulvin/
40.	(microb* or antimicrob* or anti-microb* or antiinfect* or anti-infect* or bacter* or antibacter* or anti-bacter* or antibiot* or anti-biot* or fung* or antifung* or anti-fung* or superbug* or super-bug*).ti,ab.
41.	beta-lactam*.mp,hw.
42.	(aminoglycoside* or amikacin or amikin or gentamicin or cidomycingenticin or neomycin or sulphate or nivemycin or streptomycin or tobramycin or nebcin or tobi or podhaler or tobi or tymbrineb or bramitob or tobravisc).mp,hw.
43.	(carbapen#m* or ertapenem or invanz or imipenem or cilastatin or primaxin or meropenem or meronem).mp,hw.
44.	(cephalosporin* or cefadroxil or cefalexin or ceporex or keflex or cefradine or nicef or cefaclor or distaclor or keftid or cefuroxime or zinnat or aprokam or zinacef or cefixime or suprax or cefotaxime or ceftazidime or fortum or kefadim or ceftriaxone or rocephin or ceftaroline or fosamil or zinforo).mp,hw.
45.	(glycopeptide* or teicoplanin or targocid or telavancin or vibativ or vancomycin or vancocin).mp,hw.
46.	(lincosamide* or clindamycin or dalacin or zindaclin).mp,hw.
47.	(macrolide* or azithromycin or zithromax or zedbac or ayter or clarithromycin or clarie or klaricid or erythromycin or erythrocin or erythrolar or erythroped or erymax or primacine or tiloryth or oftalmolosa cusi eritromicina or telithromycin or ketek).mp,hw.
48.	(monobactam* or aztreonam or azactam or cayston).mp,hw.
49.	(nitroimidazole* or metronidazole or flagyl or vaginyl or norzol or metrolyl or tinidazole or fasigyn).mp,hw.
50.	(penicillin* or piperacillin or tazobactam or tazocin or ticarcillin or clavulanic acid or timentin or benzylpenicillin or crystapen or phenoxymethylpenicillin or amoxicillin or amoxil or amix or amoram or amoxient or galenamox or rimoxallin or ampicillin or penbritin or rimacillin or co-fluampicil or flu-amp or magnapen or co-amoxiclav or augmentin or pivmecillinam or selexid or flucloxacillin or floxapen or flucomix or ladropen or temocillin or negaban).mp,hw.
51.	(polymyxin* or colistimethate or colistin or sulfomethate or colomycin or promixin or colobreathe).mp,hw.
52.	(quinolone* or ciprofloxacin or ciproxin or levofloxacin or evoxil or tavanic or moxifloxacin or avelox or nalidixic acid or norfloxacin or ofloxacin or tarivid or perfloxacin).mp,hw.
53.	(sulfonamide* or co-trimoxazole or fectrim or septrin or sulfadiazine or trimethoprim or trimopan).mp,hw.
54.	(tetracycline* or demeclocycline or doxycycline or vibramycin-d or efracea or lymecycline or tetralysal or minocycline or aknemin or acnamino or minocin or sebomin or oxytetracycline or oxymycin or tigecycline or tygacil).mp,hw.
55.	(chloramphenicol or kemicetine or brochlor or brolene or chloromycetin or golden eye or optrex or klorafect or fosfomycin or fomicyt or fusidic acid or sodium fusidate or fucidin or daptomycin or cubicin or linezolid or zyvox or rifaximin or targaxan or xifaxanta or fidaxomicin or dificlir or tedizolid or sivextro).mp,hw.
56.	(nitrofurantoin or macrobid or methenamine hippurate or hexamine hippurate or hiprex).mp,hw.

57.	(triazole* or fluconazole or diflucan or itraconazole or sporanox or posaconazole or noxafil or voriconazole or v fend or omoconazole or epoxiconazole).mp,hw.
58.	(imidazole* or clotrimazole or econazole or tioconazole or ketoconazole or miconazole).mp,hw.
59.	(polyene* or amphotericin or fungizone or abelcet or ambisome).mp,hw.
60.	(echinocandin* or anidulafungin or ecalta or caspofungin or candidas or micafungin or mycamine).mp,hw.
61.	(flucytosine or ancotil or griseofulvin or terbinafine or lamisil).mp,hw.
62.	or/16-61
63.	15 or 62
64.	Study filters RCT (G.3.2) or SR (G.3.3) or OBS (G.3.7)
65.	12 and 63 and 64
	Date parameters: see Table 1

Embase search terms

1.	Standard population (G.2.1)
2.	Excluded study designs and publication types (G.3.1)
3.	1 not 2
4.	Limit 3 to English language
5.	acute hemorrhagic pancreatitis/
6.	5 not 2
7.	Limit 6 to English language
8.	necrosis/
9.	necro*.ti,ab.
10.	or/8-9
11.	4 and 10
12.	7 or 11
13.	*surgery/
14.	minimally invasive surgery/
15.	endoscopy/
16.	exp digestive tract endoscopy/
17.	exp laparoscopy/
18.	laparotomy/
19.	exp surgical drainage/
20.	(surgery or surgical or drainage or endoscop* or laparotom* or laparoscop*).ti,ab.
21.	or/13-20
22.	exp antiinfective agent/
23.	exp bacterial infection/ or exp superinfection/
24.	exp *aminoglycoside antibiotic agent/
25.	*amikacin/ or *gentamicin/ or *neomycin/ or *streptomycin/ or *tobramycin/
26.	exp *beta lactam antibiotic/
27.	*carbapenem derivative/ or *carbapenem/ or *ertapenem/ or *cilastatin with imipenem/ or *imipenem/ or *meropenem/
28.	exp *cephalosporin derivative/ or exp *cephalosporin/
29.	*cefadroxil/ or *cefalexin/ or *cefradine/ or *cefaclor/ or *cefuroxime/ or *cefixime/ or *cefotaxime/ or *ceftazidime/ or *ceftriaxone/ or *ceftaroline fosamil/
30.	*glycopeptide/

31.	*teicoplanin/ or *telavancin/ or *vancomycin/
32.	*lincosamide/
33.	*clindamycin/
34.	exp *macrolide/
35.	*azithromycin/ or *clarithromycin/ or *erythromycin/ or *telithromycin/
36.	exp *monobactam derivative/
37.	*aztreonam/
38.	exp *nitroimidazole derivative/ or exp *nitroimidazole/
39.	*metronidazole/ or *tinidazole/
40.	exp *penicillin derivative/
41.	*piperacillin plus tazobactam/ or *ticarcillin/ or *clavulanic acid/ or *penicillin g/ or *penicillin v/ or *amoxicillin/ or *ampicillin/ or *ampicillin plus flucloxacillin/ or *amoxicillin plus clavulanic acid/ or *pivmecillinam/ or *flucloxacillin/
42.	*polymyxin/
43.	*colistin/ or *colistimethate/
44.	exp *quinolone derivative/ or exp *quinolone/
45.	*ciprofloxacin/ or *levofloxacin/ or *moxifloxacin/ or *nalidixic acid/ or *norfloxacin/ or *ofloxacin/ or *perfloxacin/
46.	exp *sulfonamide/ or exp *trimethoprim/ or exp *trimethoprim derivative/
47.	*cotrimoxazole/ or *sulfadiazine/
48.	exp *tetracycline derivative/ or exp *tetracycline/
49.	*demeclocycline/ or *doxycycline/ or *lymecycline/ or *minocycline/ or *oxytetracycline/ or *tigecycline/
50.	*chloramphenicol derivative/ or *chloramphenicol/
51.	*fosfomycin/
52.	*fusidic acid/
53.	*daptomycin/
54.	*linezolid/
55.	*rifaximin/
56.	*fidaxomicin/
57.	*tedizolid/
58.	exp *triazole derivative/
59.	*fluconazole/ or *itraconazole/ or *posaconazole/ or *voriconazole/ or *omoconazole/ or *epoxiconazole/
60.	exp *imidazole derivative/
61.	*clotrimazole/ or *econazole/ or *tioconazole/ or *ketoconazole/ or *miconazole/
62.	exp *polyene antibiotic agent/
63.	*amphotericin/
64.	exp *echinocandin/
65.	*anidulafungin/ or *caspofungin/ or *micafungin/
66.	*flucytosine/ or *griseofulvin/ or *terbinafine/
67.	(microb* or antimicrob* or anti-microb* or antiinfect* or anti-infect* or bacter* or antibacter* or anti-bacter* or antibiot* or anti-biot* or fung* or antifung* or anti-fung* or superbug* or super-bug*).ti,ab.
68.	beta-lactam*.mp,hw.
69.	(aminoglycoside* or amikacin or amikin or gentamicin or cidomycingenticin or neomycin or sulphate or nivemycin or streptomycin or tobramycin or nebcin or tobi or podhaler or tobi or

	tymbrineb or bramitob or tobravisc).mp,hw.
70.	(carbapen#m* or ertapenem or invanz or imipenem or cilastatin or primaxin or meropenem or meronem).mp,hw.
71.	(cephalosporin* or cefadroxil or cefalexin or ceporex or keflex or cefradine or nicef or cefaclor or distaclor or keftid or cefuroxime or zinnat or aprokam or zinacef or cefixime or suprax or cefotaxime or ceftazidime or fortum or kefadim or ceftriaxone or rocephin or ceftaroline or fosamil or zinforo).mp,hw.
72.	(glycopeptide* or teicoplanin or targocid or telavancin or vibativ or vancomycin or vancocin).mp,hw.
73.	(lincosamide* or clindamycin or dalacin or zindaclin).mp,hw.
74.	(macrolide* or azithromycin or zithromax or zedbac or ayter or clarithromycin or clarie or klaricid or erythromycin or erythrocin or erythrolar or erythroped or erymax or primacine or tiloryth or oftalmolosa cusi eritromicina or telithromycin or ketek).mp,hw.
75.	(monobactam* or aztreonam or azactam or cayston).mp,hw.
76.	(nitroimidazole* or metronidazole or flagyl or vaginyl or norzol or metrolyl or tinidazole or fasigyn).mp,hw.
77.	(penicillin* or piperacillin or tazobactam or tazocin or ticarcillin or clavulanic or timentin or benzylpenicillin or crystapen or phenoxymethylpenicillin or amoxicillin or amoxil or amix or amoram or amoxient or galenamox or rimoxallin or ampicillin or penbritin or rimacillin or co-fluampicil or flu-amp or magnapen or co-amoxiclav or augmentin or pivmecillinam or selexid or flucloxacillin or floxapen or flucomix or ladropen or temocillin or negaban).mp,hw.
78.	(polymyxin* or colistimethate or colistin or sulfomethate or colomycin or promixin or colobreathe).mp,hw.
79.	(quinolone* or ciprofloxacin or ciproxin or levofloxacin or evoxil or tavanic or moxifloxacin or avelox or nalidixic acid or norfloxacin or ofloxacin or tarivid or perfloxacin).mp,hw.
80.	(sulfonamide* or co-trimoxazole or cotrimoxazole or fectrim or septrin or sulfadiazine or trimethoprim or trimopan).mp,hw.
81.	(tetracycline* or demeclocycline or doxycycline or vibramycin-d or efracea or lymecycline or tetralysal or minocycline or aknemin or acnamino or minocin or sebomin or oxytetracycline or oxymycin or tigecycline or tygacil).mp,hw.
82.	(chloramphenicol or kemeticine or brochlor or brolene or chloromycetin or golden eye or optrex or klorafect or fosfomycin or fomicyt or fusidic acid or sodium fusidate or fucidin or daptomycin or cubicin or linezolid or zyvox or rifaximin or targaxan or xifaxanta or fidaxomicin or dificlir or tedizolid or sivextro).mp,hw.
83.	(nitrofurantoin or macrobid or methenamine hippurate or hexamine hippurate or hiprex).mp,hw.
84.	(triazole* or fluconazole or diflucan or itraconazole or sporanox or posaconazole or noxafil or voriconazole or v fend or omoconazole or epoxiconazole).mp,hw.
85.	(imidazole* or clotrimazole or econazole or tioconazole or ketoconazole or miconazole).mp,hw.
86.	(polyene* or amphotericin or fungizone or abelcet or ambisome).mp,hw.
87.	(echinocandin* or anidulafungin or ecalta or caspofungin or candidas or micafungin or mycamine).mp,hw.
88.	(flucytosine or ancotil or griseofulvin or terbinafine or lamisil).mp,hw.
89.	or/22-88
90.	21 or 89
91.	Study filters RCT (G.3.2) or SR (G.3.3) or OBS (G.3.7)
92.	4 and 90 and 91
	Date parameters: see Table 1

Cochrane search terms

#1.	Standard population (G.2.1)
#2.	MeSH descriptor: (pancreatitis, acute necrotizing) explode all trees
#3.	MeSH descriptor: (necrosis) explode all trees
#4.	necro*:ti,ab
#5.	#3 or #4
#6.	#1 and #6
#7.	#2 or #6
#8.	MeSH descriptor: (surgical procedures, operative) explode all trees
#9.	MeSH descriptor: (minimally invasive surgical procedures) explode all trees
#10.	MeSH descriptor: (endoscopy) explode all trees
#11.	MeSH descriptor: (endoscopy, digestive system) explode all trees
#12.	MeSH descriptor: (laparoscopy) explode all trees
#13.	MeSH descriptor: (laparotomy) explode all trees
#14.	MeSH descriptor: (drainage) explode all trees
#15.	(surgery or surgical or drainage or endoscop* or laparotom* or laparoscop*):ti,ab
#16.	#8 or #9 or #10 or #11 or #12 or #13 or #14 or #15
#17.	MeSH descriptor: (anti-infective agents) explode all trees
#18.	MeSH descriptor: (superinfection) explode all trees
#19.	MeSH descriptor: (bacterial infections) explode all trees
#20.	MeSH descriptor: (aminoglycosides) explode all trees
#21.	MeSH descriptor: (beta-lactams) explode all trees
#22.	MeSH descriptor: (glycopeptides) explode all trees
#23.	MeSH descriptor: (lincosamides) explode all trees
#24.	MeSH descriptor: (macrolides) explode all trees
#25.	MeSH descriptor: (nitroimidazoles) explode all trees
#26.	MeSH descriptor: (polymyxins) explode all trees
#27.	MeSH descriptor: (quinolones) explode all trees
#28.	MeSH descriptor: (sulfonamides) explode all trees
#29.	MeSH descriptor: (trimethoprim) explode all trees
#30.	MeSH descriptor: (tetracyclines) explode all trees
#31.	MeSH descriptor: (chloramphenicol) explode all trees
#32.	MeSH descriptor: (fusidic acid) explode all trees
#33.	MeSH descriptor: (daptomycin) explode all trees
#34.	MeSH descriptor: (linezolid) explode all trees
#35.	MeSH descriptor: (rifamycins) explode all trees
#36.	MeSH descriptor: (nitrofurantoin) explode all trees
#37.	MeSH descriptor: (methenamine) explode all trees
#38.	MeSH descriptor: (azoles) explode all trees
#39.	MeSH descriptor: (polyenes) explode all trees
#40.	MeSH descriptor: (echinocandins) explode all trees
#41.	MeSH descriptor: (flucytosine) explode all trees
#42.	MeSH descriptor: (fosfomicin) explode all trees
#43.	MeSH descriptor: (griseofulvin) explode all trees
#44.	(microb* or antimicrob* or anti-microb* or (anti next microb*) or antiinfect* or anti-infect* or (anti next infect*) or bacter* or antibacter* or anti-bacter* or (anti next bacter*) or antibiot*

	or anti-biot* or (anti next biot*) or fung* or antifung* or anti-fung* or (anti next fung*) or superbug* or super-bug* or (super next bug*)):ti,ab,kw
#45.	(beta-lactam* or (beta next lactam*)):ti,ab,kw
#46.	(aminoglycoside* or amikacin or amikin or gentamicin or cidomycingenticin or neomycin or sulphate or nivemycin or streptomycin or tobramycin or nebcin or tobi or podhaler or tobi or tymbrineb or bramitob or tobravisc):ti,ab,kw
#47.	(carbapenem* or carbepenam* or ertapenem or invanz or imipenem or cilastatin or primaxin or meropenem or meronem):ti,ab,kw
#48.	(cephalosporin* or cefadroxil or cefalexin or ceporex or keflex or cefradine or nicef or cefaclor or distaclor or keftid or cefuroxime or zinnat or aprokam or zinacef or cefixime or suprax or cefotaxime or ceftazidime or fortum or kefadim or ceftriaxone or rocephin or ceftaroline or fosamil or zinforo):ti,ab,kw
#49.	(glycopeptide* or teicoplanin or targocid or telavancin or vibativ or vancomycin or vancocin):ti,ab,kw
#50.	(lincosamide* or clindamycin or dalacin or zindaclin):ti,ab,kw
#51.	(macrolide* or azithromycin or zithromax or zedbac or ayter or clarithromycin or clarie or klaricid or erythromycin or erythrocin or erythrolar or erythroped or erymax or primacine or tiloryth or oftalmolosa or telithromycin or ketek):ti,ab,kw
#52.	(monobactam* or aztreonam or azactam or cayston):ti,ab,kw
#53.	(nitroimidazole* or metronidazole or flagyl or vaginyl or norzol or metrolyl or tinidazole or fasigyn):ti,ab,kw
#54.	(penicillin* or piperacillin or tazobactam or tazocin or ticarcillin or clavulanic or timentin or benzylpenicillin or crystapen or phenoxymethylpenicillin or amoxicillin or amoxil or amix or amoram or amoxient or galenamox or rimoxallin or ampicillin or penbritin or rimacillin or co-fluampicil or flu-amp or magnapen or co-amoxiclav or augmentin or pivmecillinam or selexid or flucloxacillin or floxapen or flucomix or ladropen or temocillin or negaban):ti,ab,kw
#55.	(polymyxin* or colistimethate or colistin or sulfomethate or colomycin or promixin or colobreathe):ti,ab,kw
#56.	(quinolone* or ciprofloxacin or ciproxin or levofloxacin or evoxil or tavanic or moxifloxacin or avelox or nalidixic acid or norfloxacin or ofloxacin or tarivid or perfloxacin):ti,ab,kw
#57.	(sulfonamide* or co-trimoxazole or fectrim or septrin or sulfadiazine or trimethoprim or trimopan):ti,ab,kw
#58.	(tetracycline* or demeclocycline or doxycycline or vibramycin-d or efracea or lymecycline or tetralysal or minocycline or aknemin or acnamino or minocin or sebomin or oxytetracycline or oxymycin or tigecycline or tygacil):ti,ab,kw
#59.	(chloramphenicol or kemicetine or brochlor or brolene or chloromycetin or golden eye or optrex or klorafect or fosfomycin or fomicyt or fusidic acid or sodium fusidate or fucidin or daptomycin or cubicin or linezolid or zyvox or rifaximin or targaxan or xifaxanta or fidaxomicin or dificlir or tedizolid or sivextro):ti,ab,kw
#60.	(nitrofurantoin or macrobid or methenamine hippurate or hexamine hippurate or hiprex):ti,ab,kw
#61.	(triazole* or fluconazole or diflucan or itraconazole or sporanox or posaconazole or noxafil or voriconazole or vfeed or omoconazole or epoxiconazole):ti,ab,kw
#62.	(imidazole* or clotrimazole or econazole or tioconazole or ketoconazole or miconazole):ti,ab,kw
#63.	(polyene* or amphotericin or fungizone or abelcet or ambisome):ti,ab,kw
#64.	(echinocandin* or anidulafungin or ecalta or caspofungin or candidas or micafungin or mycamine):ti,ab,kw
#65.	(flucytosine or ancotil or griseofulvin or terbinafine or lamisil):ti,ab,kw
#66.	(or #17-#65)
#67.	#16 or #66

#68.	#7 and #67
	Date parameters: see Table 1

PsycINFO search terms

1.	Standard population (A.2.1)
2.	Excluded study designs and publication types (A.3.1)
3.	1 not 2
4.	Limit 3 to English language
	Date parameters: see Table 1

G.4.10 Pain management

Searches for the following four questions were run as one search:

- What is the most clinically and cost-effective intervention for managing pain in people with chronic pancreatitis?
- What is the most clinically and cost-effective intervention for managing pancreatic duct obstruction, with or without an inflammatory mass, in people with chronic pancreatitis presenting with pain?
- What is the most clinically and cost-effective intervention for managing pseudocysts in people with pancreatitis presenting with or without pain?
- What is the most clinically and cost-effective intervention for managing small-duct disease (in the absence of pancreatic duct obstruction, inflammatory mass or pseudocyst) in people with chronic pancreatitis presenting with pain?

Medline search terms

1.	Standard population (G.2.1)
2.	Excluded study designs and publication types (G.3.1)
3.	1 not 2
4.	Limit 3 to English language
5.	exp narcotics/
6.	(opioid* or opiate* or narcotic*).ti,ab.
7.	morphine/
8.	(morphine or astramorph or avinza or depodur or duramorph or embeda or infumorph or kadian or m-eslon or morcap or morphia or ms contin or msir or mst or nepenthe or oramorph or rescudose or rms or roxanol or sevredol or statex or zomorph).ti,ab.
9.	opium/
10.	(opium or omnopon or pantopon or papaveretum).ti,ab.
11.	hydromorphone/
12.	(hydromorphone or dihydromorphinone or dilaudid or dimorphone or exalgo or hydmrphn or hydromorph* or hydrostat or hymorphan or laudicon or novolauden or palladone).ti,ab.
13.	nicomorphine.ti,ab.
14.	exp oxycodone/
15.	(oxycodone or dazidox or dihydrohydroxycodone or dihydrone or dinarkon or endocodone or eth-oxydose or eucodal or hydroxycodone or m-oxy or oxiconum or oxycdn or oxycone or oxycontin or oxyfast or oxyir or pancodine or percocet or percolone or remoxy or roxicodone or theocodin).ti,ab.
16.	(dihydrocodeine or contugesic or dhc mundipharma or dicodin or dihydcdn or paracodin or paramol or parzone or rikodeine or tiamon or tosidrin or tuscodin).ti,ab.
17.	(diamorphine or acetomorphine or diacetylmorphine or diagesil or diamorf or heroin or min-i-

	jet morphine sulfate or skag).ti,ab.
18.	exp codeine/
19.	(codeine or ardinex or galcodine or isocodeine or methyl morphine or rx 336m or stanley-linctus or stanley-syrup).ti,ab.
20.	ketobemidone.ti,ab.
21.	exp meperidine/
22.	(pethidine or demerol or dolantin or dolargan or dolcontral or dolosal or dolsin or isonipeccain or isonipeccaine hydrochloride or lydol or meperidine or operidine epj or pethilorfan).ti,ab.
23.	exp fentanyl/
24.	(fentanyl or abstral or actiq or duragesic or fentanest or fentora or fentyl or ionsys or matrifen or nasalfent or onsolis or oralet or phentanyl or sublimaze).ti,ab.
25.	exp dextromoramide/
26.	dextromoramide.ti,ab.
27.	(piritramide or dipidolor or dipydolor or piridolan or pirium).ti,ab.
28.	exp dextropropoxyphene/
29.	(dextropropoxyphene or darvon or dolene or doloxene or levopropoxyphene or pp-cap or propoxyphene or proxyphen).ti,ab.
30.	(bezitramide or burgodin).ti,ab.
31.	exp methadone/
32.	(methadone or adanon or althose or amidines or amidone or biodone or diskets or dolophine or heptadon or metadol or metasedin or methaddict or metharose or methadose or methdn or methex or phy or phymet or physeptone or pinadone or symoron).ti,ab.
33.	exp benzomorphanes/
34.	exp pentazocine/
35.	(pentazocine or fortral or fortwin or lexir or talacen or talwin).ti,ab.
36.	exp phenazocine/
37.	(phenazocine or prinadol or narphen).ti,ab.
38.	oripavine.ti,ab.
39.	exp buprenorphine/
40.	(buprenorphine or '6029-m' or buprenex or buprex or prefin or suboxone or subutex or temgesic).ti,ab.
41.	exp etorphine/
42.	(etorphine or immobilon or m99).ti,ab.
43.	exp morphinans/
44.	exp butorphanol/
45.	(butorphanol or 'bc2627' or beforal or dolorex or moradol or stadol or torbugesic).ti,ab.
46.	exp tilidine/
47.	(tilidine or tilidate or valoron or valtran or tilidin).ti,ab.
48.	exp tramadol/
49.	(tramadol or 'k-315' or ralivia or ryzolt or tramahexal or tramake insts or tramal* or tramedo or ultram or zamadol or zydol).ti,ab.
50.	(dezocine or dalgan or 'wy-16225').ti,ab.
51.	exp meptazinol/
52.	(meptazinol or meptid).ti,ab.
53.	(tapentadol or cg5503 or nucynta).ti,ab.
54.	(remifentanil or 'gi 87084b' or remifentanyl or ultiva).ti,ab.
55.	exp procaine/

56.	(procaine or allocaine or anuject or gerokit or mericaine or novocaine or procaina serra).ti,ab.
57.	alfentanil.ti,ab.
58.	(alfenta or alfentanyl or fanaxal or limifen or rapifen).ti,ab.
59.	(dipipanone or co-dydramol or co-codamaol).ti,ab.
60.	analgesics/ or analgesics, non-narcotic/
61.	(non-steroid* or non-narcotic* or analgesic* or pharmacolog*).ti,ab.
62.	somatostatin/
63.	octreotide/
64.	(somatostatin* or octreotide or sandostatin or lanreotide or somatuline).ti,ab.
65.	acetaminophen/
66.	(aspirin or acetaminophen or paracetamol or panadol or perfalgan or nefopam or acupan).ti,ab.
67.	anti-inflammatory agents, non-steroidal/ or aspirin/ or diclofenac/ or flurbiprofen/ or ibuprofen/ or ketoprofen/ or ketorolac/ or ketorolac tromethamine/ or meclofenamic acid/ or mefenamic acid/ or naproxen/ or phenylbutazone/ or piroxicam/ or sulindac/
68.	ziconotide.ti,ab.
69.	(nsaid* or ibuprofen or aspirin or naproxen or fenoprofen or flurbiprofen or ketoprofen or dexketoprofen or dexibuprofen or tiaprofenic acid or diclofenac or aceclofenac or indometacin or mefenamic acid or meloxicam or nabumetone or phenylbutazone or piroxicam or sulindac or tenoxicam or tolfenamic acid or ketorolac or celecoxib or etoricoxib or aceclofenac or acemetacin or diclofenac or etodolac).ti,ab.
70.	nerve block/
71.	((nerve or percutaneous or splanchnic or subarachnoid or celiac or coeliac* or solar) adj1 block*).ti,ab.
72.	((celiac or coeliac* or solar) adj1 plexus).ti,ab.
73.	celiac plexus/
74.	splanchnic nerves/
75.	spinal cord stimulation/
76.	((spinal cord* or dorsal column) adj2 stimulation*).ti,ab.
77.	splanchnicectomy*.ti,ab.
78.	neurolysis/
79.	(neurolys* or neurolytic*).ti,ab.
80.	cholangiopancreatography, endoscopic retrograde/
81.	(endoscopic retrograde cholangiopancreatograph* or ercp).ti,ab.
82.	endoscopy, gastrointestinal/ or endoscopy, digestive system/
83.	(balloon adj dilatation*).ti,ab.
84.	dilatation/
85.	stents/ or self expandable metallic stents/
86.	(stent* or endoprothes* or wallstent*).ti,ab.
87.	sphincterotomy, endoscopic/
88.	sphincterotom*.ti,ab.
89.	drainage/
90.	lithotripsy/
91.	(extracorporeal shock wave lithotripsy* or eswl).ti,ab.
92.	(stone adj (extract* or remov*)).ti,ab.
93.	(endoscop* or endotherap* or minimally invasive).ti,ab.
94.	endoscopy/

95.	(pancreaticojejunosom* or pancreatico-jejunosom* or puestow).ti,ab.
96.	anastomosis, roux-en-y/ or pancreaticojejunosomy/
97.	roux-en-y.ti,ab.
98.	anastomos*.ti,ab.
99.	frey*.ti,ab.
100.	(partington adj rochelle).ti,ab.
101.	beger.ti,ab.
102.	pancreaticoduodenectomy/
103.	(pancreaticoduodenectom* or pancreatico-duodenectom* or pancreatoduodenectom* or pancreato-duodenectom* or whipple).ti,ab.
104.	surgical procedures, operative/
105.	pancreatectomy/
106.	(pancreatectom* or resect* or operat* or drain* or denervat* or decompress* or surg*).ti,ab.
107.	decompression, surgical/
108.	(cystogastrostom* or cysto gastrostom* or cyst-gastrostom*).ti,ab.
109.	(cystojejunostom* or cysto jejunosom* or cyst-jejunosom*).ti,ab.
110.	(cystoduodenostom* or cysto duodenostom* or cyst-duodenostom*).ti,ab.
111.	(pseudocystogastrostom* or pseudo cystogastrostom* or pseudocyst-gastrostom*).ti,ab.
112.	(pseudocystojejunostom* or pseudo cystojejunostom* or pseudocyst-jejunosom*).ti,ab.
113.	(pseudocystoduodenostom* or pseudo cystoduodenostom* or pseudocyst-duodenostom*).ti,ab.
114.	(hepatico-jejunosom* or hepaticojejunosom* or hepatojejunosom* or hepato-jejunosom* or hepat* jejunosom*).ti,ab.
115.	(pylorus preserving pancreatoduodectom* or pppd).ti,ab.
116.	v-shaped excision.ti,ab.
117.	sphincteroplast*.ti,ab.
118.	exp psychotherapy/
119.	biofeedback, psychology/
120.	(behavio?r* adj therap*).ti,ab.
121.	(cognitive adj2 therap*).ti,ab.
122.	(relax* adj2 (therap* or technique*).ti,ab.
123.	(meditat* or psychotherap*).ti,ab.
124.	(psychological adj (treatment* or therap*).ti,ab.
125.	(group* adj therap*).ti,ab.
126.	(self-regulat* adj train*).ti,ab.
127.	(coping adj skill*).ti,ab.
128.	(pain-related adj thought*).ti,ab.
129.	(behavio?r* adj2 rehabilitat*).ti,ab.
130.	((psychoeducation or psycho-education) adj1 group*).ti,ab.
131.	exp mind-body therapies/
132.	((mind and body) adj (relaxation or therap*).ti,ab.
133.	enzyme replacement therapy/
134.	exp pancreatic extracts/
135.	exp enzymes/tu (therapeutic use)
136.	(digest* adj2 enzyme*).ti,ab.
137.	(enzyme adj2 (replacement or therap*).ti,ab.

	linctus or stanley-syrup).ti,ab.
16.	ketobemidone.ti,ab.
17.	(pethidine or demerol or dolantin or dolargan or dolcontral or dolosal or dolsin or isonipeccain or isonipeccaine hydrochloride or lydol or meperidine or operidine epj or pethilorfan).ti,ab.
18.	(fentanyl or abstral or actiq or duragesic or fentanest or fentora or fentyl or ionsys or matrifen or nasalfent or onsolis or oralet or phentanyl or sublimaze).ti,ab.
19.	dextromoramide.ti,ab.
20.	(piritramide or dipidolor or dipydolor or piridolan or pirium).ti,ab.
21.	(dextropropoxyphene or darvon or dolene or doloxene or levopropoxyphene or pp-cap or propoxyphene or proxyphen).ti,ab.
22.	(bezitramide or burgodin).ti,ab.
23.	(methadone or adanon or althose or amidines or amidone or biodone or diskets or dolophine or heptadon or metadol or metasedin or methaddict or metharose or methadose or methdn or methex or phy or phymet or physeptone or pinadone or symoron).ti,ab.
24.	exp *benzomorphan derivative/
25.	exp *pentazocine lactate/ or exp *pentazocine/ or exp *paracetamol plus pentazocine/ or exp *naloxone plus pentazocine/
26.	(pentazocine or fortral or fortwin or lexic or talacen or talwin).ti,ab.
27.	exp *phenazocine/
28.	(phenazocine or prinadol or narphen).ti,ab.
29.	oripavine.ti,ab.
30.	(buprenorphine or '6029-m' or buprenex or buprex or prefin or suboxone or subutex or temgesic).ti,ab.
31.	(etorphine or immobilon or m99).ti,ab.
32.	exp *morphinan derivative/
33.	exp *butorphanol tartrate/ or exp *butorphanol/
34.	(butorphanol or 'bc2627' or beforal or dolorex or moradol or stadol or torbugesic).ti,ab.
35.	(tilidine or tilidate or valoron or valtran or tilidin).ti,ab.
36.	exp *tramadol/ or exp *paracetamol plus tramadol/
37.	(tramadol or 'k-315' or ralivia or ryzolt or tramahexal or tramake insts or tramal* or tramedo or ultram or zamadol or zydol).ti,ab.
38.	(dezocine or dalgan or 'wy-16225').ti,ab.
39.	exp *meptazinol/
40.	(meptazinol or meptid).ti,ab.
41.	(tapentadol or cg5503 or nucynta).ti,ab.
42.	(remifentanil or 'gi 87084b' or remifentanyl or ultiva).ti,ab.
43.	exp *penicillin g sodium plus procaine penicillin/ or exp *procaine/ or exp *adrenalin plus procaine/ or exp *penicillin g sodium plus procaine penicillin plus streptomycin sulfate/ or exp *penicillin g potassium plus procaine penicillin plus streptomycin sulfate/ or exp *procaine penicillin/ or exp *penicillin g potassium plus procaine penicillin/ or exp *benzathine penicillin plus procaine penicillin/ or exp *procaine penicillin plus streptomycin sulfate/
44.	(procaine or allocaine or anuject or gerokit or mericaine or novocaine or procaina serra).ti,ab.
45.	exp *cocodamol/
46.	alfentanil.ti,ab.
47.	(alfenta or alfentanyl or fanaxal or limifen or rapifen).ti,ab.
48.	(dipipanone or co-dydramol or co-codamaol).ti,ab.
49.	exp *paracetamol/ or exp *nonsteroid antiinflammatory agent/ or exp *analgesic agent/
50.	(non-steroid* or non-narcotic* or analgesic* or pharmacolog*).ti,ab.

51.	exp *somatostatin/
52.	exp *octreotide/
53.	(somatostatin* or octreotide or sandostatin or lanreotide or somatuline).ti,ab.
54.	(aspirin or acetaminophen or paracetamol or panadol or perfalgan or nefopam or acupan).ti,ab.
55.	ziconotide.ti,ab.
56.	(nsaid* or ibuprofen or aspirin or naproxen or fenoprofen or flurbiprofen or ketoprofen or dexketoprofen or dexibuprofen or tiaprofenic acid or diclofenac or aceclofenac or indometacin or mefenamic acid or meloxicam or nabumetone or phenylbutazone or piroxicam or sulindac or tenoxicam or tolfenamic acid or ketorolac or celecoxib or etoricoxib or aceclofenac or acemetacin or diclofenac or etodolac).ti,ab.
57.	exp nerve block/
58.	celiac plexus/
59.	splanchnic nerve/
60.	spinal cord stimulation/
61.	neurolysis/
62.	((nerve or percutaneous or splanchnic or subarachnoid or celiac or coeliac* or solar) adj1 block*).ti,ab.
63.	((celiac or coeliac* or solar) adj1 plexus).ti,ab.
64.	((spinal cord* or dorsal column) adj2 stimulation*).ti,ab.
65.	splanchnicectomy*.ti,ab.
66.	(neurolys* or neurolytic*).ti,ab.
67.	endoscopic retrograde cholangiopancreatography/
68.	(endoscopic retrograde cholangiopancreatograph* or ercp).ti,ab.
69.	digestive tract endoscopy/ or gastrointestinal endoscopy/
70.	(balloon adj dilatation*).ti,ab.
71.	dilatation/
72.	stent/
73.	self expandable metallic stent/
74.	(stent* or endoprothes* or wallstent*).ti,ab.
75.	endoscopic sphincterotomy/
76.	sphincterotom*.ti,ab.
77.	exp surgical drainage/
78.	exp lithotripsy/
79.	(extracorporeal shock wave lithotripsy* or eswl).ti,ab.
80.	(stone adj (extract* or remov*).ti,ab.
81.	(endoscop* or endotherap* or minimally invasive).ti,ab.
82.	endoscopy/
83.	(pancreaticojejunostom* or pancreatico-jejunostom* or puestow).ti,ab.
84.	pancreas surgery/ or pancreaticojejunostomy/
85.	roux y anastomosis/
86.	roux-en-y.ti,ab.
87.	anastomos*.ti,ab.
88.	frey*.ti,ab.
89.	(partington adj rochelle).ti,ab.
90.	beger.ti,ab.

91.	pancreaticoduodenectomy/
92.	(pancreaticoduodenectom* or pancreatico-duodenectom* or pancreatoduodenectom* or pancreato-duodenectom* or whipple).ti,ab.
93.	surgical technique/
94.	pancreas resection/
95.	(pancreatectom* or resect* or operat* or drain* or denervat* or decompress* or surg*).ti,ab.
96.	decompression surgery/
97.	(cystogastrostom* or cysto gastrostom* or cyst-gastrostom*).ti,ab.
98.	(cystojejunostom* or cysto jejunostom* or cyst-jejunosom*).ti,ab.
99.	(cystoduodenostom* or cysto duodenostom* or cyst-duodenostom*).ti,ab.
100.	(pseudocystogastrostom* or pseudo cystogastrostom* or pseudocyst-gastrostom*).ti,ab.
101.	(pseudocystojejunostom* or pseudo cystojejunostom* or pseudocyst-jejunosom*).ti,ab.
102.	(pseudocystoduodenostom* or pseudo cystoduodenostom* or pseudocyst-duodenostom*).ti,ab.
103.	(hepatico-jejunosom* or hepaticojejunosom* or hepatojejunosom* or hepato-jejunosom* or hepatic jejunosom*).ti,ab.
104.	(pylorus preserving pancreatoduodectom* or pppd).ti,ab.
105.	v-shaped excision.ti,ab.
106.	sphincteroplast*.ti,ab.
107.	exp psychotherapy/
108.	psychophysiology/
109.	(behavio?r* adj therap*).ti,ab.
110.	(cognitive adj2 therap*).ti,ab.
111.	(relax* adj2 (therap* or technique*)).ti,ab.
112.	(meditat* or psychotherap*).ti,ab.
113.	(psychological adj (treatment* or therap*)).ti,ab.
114.	(group* adj therap*).ti,ab.
115.	(self-regulat* adj train*).ti,ab.
116.	(coping adj skill*).ti,ab.
117.	(pain-related adj thought*).ti,ab.
118.	(behavio?r* adj2 rehabilitat*).ti,ab.
119.	((psychoeducation or psycho-education) adj1 group*).ti,ab.
120.	alternative medicine/
121.	((mind and body) adj (relaxation or therap*)).ti,ab.
122.	enzyme replacement/
123.	pancreas extract/
124.	exp enzyme/th (therapy)
125.	(digest* adj2 enzyme*).ti,ab.
126.	(enzyme adj2 (replacement or therap*)).ti,ab.
127.	ert.ti,ab.
128.	(creon or nutrizym or pancrease or pancrex or pankreon or viokase).ti,ab.
129.	(pancreatin or pancrelipase).ti,ab.
130.	oxidation reduction reaction/
131.	antioxidant activity/
132.	scavenger/
133.	ascorbic acid/ or bilirubin/ or butylated hydroxyanisole/ or butylcresol/ or canthaxanthin/ or

	carotenoid/ or catalase/ or thioneine/ or grape seed extract/ or melatonin/ or nordihydroguaiaretic acid/ or probucol/ or gallic acid propyl ester/ or pyrogallol/ or quercetin/ or flavonoid/ or selenium/ or silymarin/ or thiocctic acid/ or tocopherol/ or alpha tocotrienol/ or uric acid/ or urate/ or retinol/ or carotene/ or curcumin/ or methionine/ or flavone/ or beta carotene/ or allopurinol/ or glutathione/ or sodium selenite/ or acetylcysteine/ or riboflavin/ or zinc/ or magnesium/
134.	(antioxidant* or anti-oxidant* or micronutrient* or micro-nutrient*).ti,ab.
135.	(ascorbic acid or bilirubin or butylated hydroxyanisole or butylated hydroxytoluene or butylcresol or canthaxanthin or canthaxanthine or carotenoid* or catalase or ergothioneine or thioneine or grape seed extract or melatonin or nordihydroguaiaretic acid or masoprocol or probucol or superlipid or propyl gallate or pyrogallol or pyrogallic acid or gallic acid or quercetin or dikvertin or selenium or silymarin or milk thistle or silimarin or thiocctic acid or lipoic acid or tocopherol* or tocotrienol* or uric acid or trioxopurine or urate or vitamin e or vitamin c or vitamin a or retinol or carotene* or curcumin or methionine or allopurin* or glutathione or sodium selenite or acetylcysteine or zinc or magnesium or riboflavin or flavone* or flavonoid*).ti,ab.
136.	(free radical adj2 scaveng*).ti,ab.
137.	(reduct* adj2 oxidat*).ti,ab.
138.	or/5-137
139.	Study filters RCT (A.3.2) or SR (A.3.3) or OBS (A.3.7)
140.	4 and 138 and 139
	Date parameters: see Table 1

Cochrane search terms

#1.	Standard population (G.2.1)
#2.	(mh narcotics)
#3.	(opioid* or opiate* or narcotic*):ti,ab
#4.	(mh ^morphine)
#5.	(morphine or astramorph or avinza or depodur or duramorph or embeda or infumorph or kadian or m-eslon or morcap or morphia or ms contin or msir or mst or nepenthe or oramorph or rescudose or rms or roxanol or sevredol or statex or zomorph):ti,ab
#6.	(mh ^opium)
#7.	(opium or omnopon or pantopon or papaveretum):ti,ab
#8.	(mh ^hydromorphone)
#9.	(hydromorphone or dihydromorphinone or dilaudid or dimorphone or exalgo or hydmrphn or hydromorph* or hydrostat or hymorphan or laudicon or novolauden or palladone):ti,ab
#10.	nicomorphine:ti,ab
#11.	(mh oxycodone)
#12.	(oxycodone or dazidox or dihydrohydroxycodone or dihydrone or dinarkon or endocodone or eth-oxydose or eucodal or hydroxycodone or m-oxy or oxiconum or oxycdn or oxycone or oxycontin or oxyfast or oxyir or pancodine or percocet or percolone or remoxy or roxicodone or theocodin):ti,ab
#13.	(dihydrocodeine or contugesic or dhc mundipharma or dicodin or dihydcdn or paracodin or paramol or parzone or rikodeine or tiamon or tosidrin or tuscodin):ti,ab
#14.	(diamorphine or acetomorphine or diacetylmorphine or diagesil or diamorf or heroin or min-i-jet morphine sulfate or skag):ti,ab
#15.	(mh codeine)
#16.	(codeine or ardinex or galcodeine or isocodeine or methyl morphine or rx 336m or stanley-linctus or stanley-syrup):ti,ab
#17.	ketobemidone:ti,ab

#18.	(mh meperidine)
#19.	(pethidine or demerol or dolantin or dolargan or dolcontral or dolosal or dolsin or isonipeccain or isonipeccaine hydrochloride or lydol or meperidine or operidine epj or pethilorfan):ti,ab
#20.	(mh fentanyl)
#21.	(fentanyl or abstral or actiq or duragesic or fentanest or fentora or fentyl or ionsys or matrifen or nasalfent or onsolis or oralet or phentanyl or sublimaze):ti,ab
#22.	(mh dextromoramide)
#23.	dextromoramide:ti,ab
#24.	(piritramide or dipidolor or dipydolor or piridolan or pirium):ti,ab
#25.	(mh dextropropoxyphene)
#26.	(dextropropoxyphene or darvon or dolene or doloxene or levopropoxyphene or pp-cap or propoxyphene or proxyphen):ti,ab
#27.	(bezitramide or burgodin):ti,ab
#28.	(mh methadone)
#29.	(methadone or adanon or althose or amidines or amidone or biodone or diskets or dolophine or heptadon or metadol or metasedin or methaddict or metharose or methadose or methdn or methex or phy or phymet or physeptone or pinadone or symoron):ti,ab
#30.	(mh benzomorphans)
#31.	(mh pentazocine)
#32.	(pentazocine or fortral or fortwin or lexir or talacen or talwin):ti,ab
#33.	(mh phenazocine)
#34.	(phenazocine or prinadol or narphen):ti,ab
#35.	oripavine:ti,ab
#36.	(mh buprenorphine)
#37.	(buprenorphine or '6029-m' or buprenex or buprex or prefin or suboxone or subutex or temgesic):ti,ab
#38.	(mh etorphine)
#39.	(etorphine or immobilon or m99):ti,ab
#40.	(mh morphinans)
#41.	(mh butorphanol)
#42.	(butorphanol or 'bc2627' or beforal or dolorex or moradol or stadol or torbugesic):ti,ab
#43.	(mh tilidine)
#44.	(tilidine or tilidate or valoron or valtran or tilidin):ti,ab
#45.	(mh tramadol)
#46.	(tramadol or 'k-315' or ralivia or ryzolt or tramahexal or tramake insts or tramal* or tramedo or ultram or zamadol or zydol):ti,ab
#47.	(dezocine or dalgan or 'wy-16225'):ti,ab
#48.	(mh meptazinol)
#49.	(meptazinol or meptid):ti,ab
#50.	(tapentadol or cg5503 or nucynta):ti,ab
#51.	(remifentanil or 'gi 87084b' or remifentanyl or ultiva):ti,ab
#52.	(mh procaine)
#53.	(procaine or allocaine or anuject or gerokit or mericaine or novocaine or procaina serra):ti,ab
#54.	(alfenta or alfentanyl or fanaxal or limifen or rapifen):ti,ab
#55.	(dipipanone or co-dydramol or co-codamaol):ti,ab
#56.	(mh ^analgesics)
#57.	(mh ^"analgesics, non-narcotic")

#58.	(non-steroid* or non-narcotic* or analgesic* or pharmacolog*):ti,ab
#59.	(mh ^somatostatin)
#60.	(mh ^octreotide)
#61.	(somatostatin* or octreotide or sandostatin or lanreotide or somatuline):ti,ab
#62.	(mh acetaminophen)
#63.	(aspirin or acetaminophen or paracetamol or panadol or perfalgan or nefopam or acupan):ti,ab
#64.	(mh ^"anti-inflammatory agents, non-steroidal")
#65.	(mh ^aspirin)
#66.	(mh ^diclofenac)
#67.	(mh ^flurbiprofen)
#68.	(mh ^ibuprofen)
#69.	(mh ^ketoprofen)
#70.	(mh ^ketorolac)
#71.	(mh ^"ketorolac tromethamine")
#72.	(mh ^"meclofenamic acid")
#73.	(mh ^"mefenamic acid")
#74.	(mh ^naproxen)
#75.	(mh ^phenylbutazone)
#76.	(mh ^piroxicam)
#77.	(mh ^sulindac)
#78.	ziconotide:ti,ab
#79.	(nsaid* or ibuprofen or aspirin or naproxen or fenoprofen or flurbiprofen or ketoprofen or dexketoprofen or dexibuprofen or tiaprofenic acid or diclofenac or aceclofenac or indometacin or mefenamic acid or meloxicam or nabumetone or phenylbutazone or piroxicam or sulindac or tenoxicam or tolfenamic acid or ketorolac or celecoxib or etoricoxib or aceclofenac or acetaminophen or diclofenac or etodolac):ti,ab
#80.	(mh ^"nerve block")
#81.	((nerve or percutaneous or splanchnic or subarachnoid or celiac or coeliac* or solar) near/1 block*):ti,ab
#82.	((celiac or coeliac* or solar) near/1 plexus):ti,ab
#83.	(mh ^"celiac plexus")
#84.	(mh ^"splanchnic nerves")
#85.	(mh ^"spinal cord stimulation")
#86.	((spinal cord* or dorsal column) near/2 stimulation*):ti,ab
#87.	splanchnicectomy:ti,ab
#88.	(mh ^neurolysis)
#89.	(neurolysis* or neurolytic*):ti,ab
#90.	(mh ^"cholangiopancreatography, endoscopic retrograde")
#91.	(endoscopic retrograde cholangiopancreatograph* or ercp):ti,ab
#92.	(mh ^"endoscopy, gastrointestinal")
#93.	(mh ^"endoscopy, digestive system")
#94.	balloon dilatation*:ti,ab
#95.	(mh ^dilatation)
#96.	(mh ^stents)
#97.	(mh ^"self expandable metallic stents")

#98.	(stent* or endoprothes* or wallstent*):ti,ab
#99.	(mh ^"sphincterotomy, endoscopic")
#100.	sphincterotom*:ti,ab
#101.	(mh ^drainage)
#102.	(mh ^lithotripsy)
#103.	(extracorporeal shock wave lithotripsy* or eswl):ti,ab
#104.	(stone next (extract* or remov*)):ti,ab
#105.	(endoscop* or endotherap* or minimally invasive):ti,ab
#106.	(mh ^endoscopy)
#107.	(pancreaticojejunostom* or pancreatico-jejunostom* or puestow):ti,ab
#108.	(mh ^"anastomosis, roux-en-y")
#109.	(mh ^pancreaticojejunostomy)
#110.	roux-en-y:ti,ab
#111.	anastomos*:ti,ab
#112.	frey*:ti,ab
#113.	(partington next rochelle):ti,ab
#114.	beger:ti,ab
#115.	(mh ^pancreaticoduodenectomy)
#116.	(pancreaticoduodenectom* or pancreatico-duodenectom* or pancreatoduodenectom* or pancreato-duodenectom* or whipple):ti,ab
#117.	(mh ^"surgical procedures, operative")
#118.	(mh ^pancreatectomy)
#119.	(pancreatectom* or resect* or operat* or drain* or denervat* or decompress* or surg*):ti,ab
#120.	(mh ^"decompression, surgical")
#121.	(cystogastrostom* or cysto next gastrostom* or cyst-gastrostom*):ti,ab
#122.	(cystojejunostom* or cysto next jejunostom* or cyst-jejunostom*):ti,ab
#123.	(cystoduodenostom* or cysto next duodenostom* or cyst-duodenostom*):ti,ab
#124.	(pseudocystogastrostom* or pseudo next cystogastrostom* or pseudocyst-gastrostom*):ti,ab
#125.	(pseudocystojejunostom* or pseudo next cystojejunostom* or pseudocyst-jejunostom*):ti,ab
#126.	(pseudocystoduodenostom* or pseudo next cystoduodenostom* or pseudocyst-duodenostom*):ti,ab
#127.	(hepatico-jejunostom* or hepaticojejunostom* or hepatojejunostom* or hepato-jejunostom* or hepat* next jejunostom*):ti,ab
#128.	(pylorus next preserving next pancreatoduodectom* or pppd):ti,ab
#129.	"v-shaped excision":ti,ab
#130.	sphincteroplast*:ti,ab
#131.	(mh psychotherapy)
#132.	(mh ^"biofeedback, psychology")
#133.	(cognitive near/2 therap*):ti,ab
#134.	(relax* near/2 (therap* or technique*)):ti,ab
#135.	(meditat* or psychotherap*):ti,ab
#136.	(psychological next (treatment* or therap*)):ti,ab
#137.	(group* next therap*):ti,ab
#138.	(self-regulat* next train*):ti,ab
#139.	(coping next skill*):ti,ab
#140.	(pain-related next thought*):ti,ab

#141.	(behavio?r* near/2 rehabilitat*):ti,ab
#142.	((psychoeducation or psycho-education) near/1 group*):ti,ab
#143.	(mh "mind-body therapies")
#144.	((mind and body) next (relaxation or therap*)):ti,ab
#145.	(mh ^"enzyme replacement therapy")
#146.	(mh "pancreatic extracts")
#147.	MeSH descriptor: (enzymes) explode all trees and with qualifier(s): (therapeutic use - tu)
#148.	(digest* near/2 enzyme*):ti,ab
#149.	(enzyme near/2 (replacement or therap*)):ti,ab
#150.	ert:ti,ab
#151.	(creon or nutrizym or pancrease or pancrex or pankreon or viokase):ti,ab
#152.	(pancreatin or pancrelipase):ti,ab
#153.	(mh antioxidants)
#154.	(mh ^"beta carotene")
#155.	(mh ^curcumin)
#156.	(mh ^methionine)
#157.	(mh ^allopurinol)
#158.	(mh ^glutathione)
#159.	(mh ^"sodium selenite")
#160.	(mh ^acetylcysteine)
#161.	(mh ^flavonoids)
#162.	(mh ^riboflavin)
#163.	(mh ^zinc)
#164.	(mh magnesium)
#165.	(mh oxidation-reduction)
#166.	(mh "free radical scavengers")
#167.	(antioxidant* or anti-oxidant* or anti next oxidant* or micronutrient* or micro-nutrient* or micro next nutrient*):ti,ab
#168.	(ascorbic next acid or bilirubin or butylated next hydroxyanisole or butylated next hydroxytoluene or butylcresol or canthaxanthin or canthaxanthine or carotenoid* or catalase or ergothioneine or thioneine or grape next seed next extract or melatonin or nordihydroguaiaretic next acid or masoprocol or probucol or superlipid or propyl next gallate or pyrogallol or pyrogallic next acid or gallic next acid or quercetin or dikvertin or selenium or silymarin or milk next thistle or silimarin or thioctic next acid or lipoic next acid or tocopherol* or tocotrienol* or uric next acid or trioxopurine or urate or vitamin next e or vitamin next c or vitamin next a or retinol or carotene* or curcumin or methionine or allopurin* or glutathione or sodium next selenite or acetylcysteine or zinc or magnesium or riboflavin or flavone* or flavonoid*):ti,ab
#169.	(free radical near/2 scaveng*):ti,ab
#170.	(reduct* near/2 oxidat*):ti,ab
#171.	(or #2-#170)
#172.	#1 and #171
	Date parameters: see Table 1

PsycINFO search terms

1.	Standard population (A.2.1)
2.	Excluded study designs and publication types (A.3.1)
3.	1 not 2

4.	Limit 3 to English language
	Date parameters: see Table 1

G.4.11 Pancreatic ascites and pleural effusion

- What are the most clinically and cost-effective interventions for treating pancreatic ascites and pleural effusion secondary to acute or chronic pancreatitis?

Medline search terms

1.	Standard population (G.2.1)
2.	Excluded study designs and publication types (G.3.1)
3.	1 not 2
4.	Limit 3 to English language
5.	ascites/ or ascitic fluid/
6.	ascit*.ti,ab.
7.	(peritoneal adj2 fluid*).ti,ab.
8.	exp pleural effusion/
9.	((intrapleura* or intra-pleura* or pleura*) adj2 (effusion* or fluid*).ti,ab.
10.	pancreatic fistula/ or fistula/
11.	((pancrea* or pleura*) adj6 fistula*).ti,ab.
12.	(pancrea* adj3 leak*).ti,ab.
13.	(duct* adj3 disrupt*).ti,ab.
14.	((intra-abdominal or intraabdominal or intrapleura* or intra-pleura* or pleura*) adj2 collection*).ti,ab.
15.	or/5-14
16.	4 and 15
	Date parameters: see Table 1

Embase search terms

1.	Standard population (G.2.1)
2.	Excluded study designs and publication types (G.3.1)
3.	1 not 2
4.	Limit 3 to English language
5.	ascites fluid/
6.	ascites/
7.	ascit*.ti,ab.
8.	(peritoneal adj2 fluid*).ti,ab.
9.	pleura effusion/
10.	((intrapleura* or intra-pleura* or pleura*) adj2 (effusion* or fluid*).ti,ab.
11.	fistula/ or pancreas fistula/
12.	((pancrea* or pleura*) adj6 fistula*).ti,ab.
13.	(pancrea* adj3 leak*).ti,ab.
14.	(duct* adj3 disrupt*).ti,ab.
15.	((intra-abdominal or intraabdominal or intrapleura* or intra-pleura* or pleura*) adj2 collection*).ti,ab.
16.	or/5-15
17.	4 and 16

	Date parameters: see Table 1
--	-------------------------------------

Cochrane search terms

#1.	Standard population (G.2.1)
#2.	MeSH descriptor: (ascites) this term only
#3.	MeSH descriptor: (ascitic fluid) this term only
#4.	ascit*:ti,ab
#5.	(peritoneal near/2 fluid*):ti,ab
#6.	MeSH descriptor: (pleural effusion) explode all trees
#7.	((intrapleura* or intra-pleura* or pleura*) near/2 (effusion* or fluid*)):ti,ab
#8.	MeSH descriptor: (fistula) this term only
#9.	MeSH descriptor: (pancreatic fistula) this term only
#10.	((pancrea* or pleura*) near/6 fistula*):ti,ab
#11.	(pancrea* near/3 leak*):ti,ab
#12.	(duct* near/3 disrupt*):ti,ab
#13.	((intra-abdominal or intraabdominal or intrapleura* or intra-pleura* or pleura*) near/2 collection*):ti,ab
#14.	#2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13
#15.	#1 and #14
	Date parameters: see Table 1

PsycINFO search terms

1.	Standard population (A.2.1)
2.	Excluded study designs and publication types (A.3.1)
3.	1 not 2
4.	Limit 3 to English language
	Date parameters: see Table 1

G.4.12 Biliary obstruction

- What is the most clinically and cost-effective intervention for treating biliary obstruction in people with chronic pancreatitis?

Medline search terms

1.	Standard population (G.2.1)
2.	Chronic pancreatitis population (G.2.2)
3.	Excluded study designs and publication types (G.3.1)
4.	1 not 3
5.	2 not 3
6.	Limit 4 to English language
7.	Limit 5 to English language
8.	bile ducts/ or bile ducts, extrahepatic/ or bile ducts, intrahepatic/
9.	common bile duct/ or cystic duct/ or hepatic duct, common/
10.	biliary tract diseases/ or bile duct diseases/
11.	(biliary or bile or cbd or choledoch*).ti,ab.
12.	((cystic or hepatic) adj2 duct*).ti,ab.
13.	cholestasis/ or cholestasis, extrahepatic/ or cholestasis, intrahepatic/
14.	cholestasis.ti,ab.

15.	cholelithiasis/ or choledocholithiasis/
16.	(cholelithiasis or choledocholithiasis).ti,ab.
17.	gallstones/
18.	gallstone*.ti,ab.
19.	jaundice, obstructive/
20.	(jaundice* adj3 (obstruc* or block* or stricture*)).ti,ab.
21.	cholangitis/
22.	cholangitis.ti,ab.
23.	or/8-22
24.	(surger* or operation* or procedure* or bypass* or drain* or resect*).ti,ab.
25.	drainage/
26.	surgical procedures, operative/
27.	endoscopy, gastrointestinal/ or endoscopy, digestive system/
28.	biliary tract surgical procedures/
29.	anastomosis, roux-en-y/
30.	roux-en-y.ti,ab.
31.	biliary-enteric anastomosis.ti,ab.
32.	choledochostomy/
33.	(choledochoduodenostom* or choledocho-duodenostom*).ti,ab.
34.	(choledocho-jejunostom* or choledochojejunostom*).ti,ab.
35.	(hepatico-jejunostom* or hepaticojejunostom* or hepatojejunostom* or hepato-jejunostom* or hepatic jejunostom*).ti,ab.
36.	cholangiopancreatography, endoscopic retrograde/
37.	(endoscopic retrograde cholangiopancreatograph* or ercp).ti,ab.
38.	stents/ or self expandable metallic stents/
39.	(stent* or wallstent).ti,ab.
40.	or/24-39
41.	Study filters RCT (A.3.2) or SR (A.3.3)
42.	exp clinical trial/
43.	exp clinical trials as topic/
44.	exp evaluation studies/ or follow-up studies/ or prospective studies/
45.	exp epidemiological studies/
46.	cohort stud*.ti,ab.
47.	case control stud*.ti,ab.
48.	((crossover or cross-over or cross over) adj2 (design* or stud* or procedure* or trial*)).ti,ab.
49.	or/41-48
50.	41 or 49
51.	7 and 23
52.	6 and 23 and 40 and 50
53.	51 or 52
	Date parameters: see Table 1

Embase search terms

1.	Standard population (G.2.1)
2.	Chronic pancreatitis population (G.2.2)
3.	Excluded study designs and publication types (G.3.1)

4.	1 not 3
5.	2 not 3
6.	Limit 4 to English language
7.	Limit 5 to English language
8.	(biliary or bile or cbd or choledoch*).ti,ab.
9.	bile duct/ or extrahepatic bile duct/ or intrahepatic bile duct/
10.	common bile duct/ or common hepatic duct/ or cystic duct/
11.	biliary tract disease/ or bile duct disease/
12.	((cystic or hepatic) adj2 duct*).ti,ab.
13.	cholestasis/ or obstructive bile duct disease/
14.	cholestasis.ti,ab.
15.	cholelithiasis/
16.	bile duct stone/ or common bile duct stone/
17.	(cholelithiasis or choledocholithiasis).ti,ab.
18.	gallstone/
19.	obstructive jaundice/
20.	gallstone*.ti,ab.
21.	(jaundice* adj3 (obstruc* or block* or stricture*)).ti,ab.
22.	cholangitis/
23.	cholangitis.ti,ab.
24.	or/8-23
25.	(surger* or operation* or procedure* or bypass* or drain* or resect*).ti,ab.
26.	biliary tract drainage/ or biliary tract surgery/ or surgical drainage/
27.	surgery/
28.	gastrointestinal endoscopy/ or digestive tract endoscopy/
29.	roux y anastomosis/
30.	roux-en-y.ti,ab.
31.	biliary-enteric anastomosis.ti,ab.
32.	bile duct bypass/ or choledochojejunostomy/ or hepatojejunostomy/
33.	(choledochooduodenostom* or choledocho-duodenostom*).ti,ab.
34.	(choledocho-jejunostom* or choledochojejunostom*).ti,ab.
35.	(hepatico-jejunostom* or hepaticojejunostom* or hepatojejunostom* or hepato-jejunostom* or hepatic jejunostom*).ti,ab.
36.	endoscopic retrograde cholangiopancreatography/
37.	(endoscopic retrograde cholangiopancreatograph* or ercp).ti,ab.
38.	stent/ or metal stent/ or self expanding stent/
39.	(stent* or wallstent).ti,ab.
40.	or/25-39
41.	Study filters RCT (A.3.2) or SR (A.3.3) or OBS (A.3.7)
42.	7 and 24
43.	6 and 24 and 40 and 41
44.	42 or 43
	Date parameters: see Table 1

Cochrane search terms

#1.	Standard population (G.2.1)
-----	-----------------------------

#2.	Chronic pancreatitis population (G.2.2)
#3.	(biliary or bile or cbd or choledoch*):ti,ab
#4.	MeSH descriptor: (bile ducts) this term only
#5.	MeSH descriptor: (bile ducts, extrahepatic) this term only
#6.	MeSH descriptor: (bile ducts, intrahepatic) this term only
#7.	MeSH descriptor: (common bile duct) this term only
#8.	MeSH descriptor: (cystic duct) this term only
#9.	MeSH descriptor: (hepatic duct, common) this term only
#10.	MeSH descriptor: (biliary tract diseases) this term only
#11.	MeSH descriptor: (bile duct diseases) this term only
#12.	MeSH descriptor: (cholestasis) this term only
#13.	MeSH descriptor: (cholestasis, extrahepatic) this term only
#14.	MeSH descriptor: (cholestasis, intrahepatic) this term only
#15.	cholestasis:ti,ab
#16.	MeSH descriptor: (cholelithiasis) this term only
#17.	MeSH descriptor: (choledocholithiasis) this term only
#18.	(cholelithiasis or choledocholithiasis):ti,ab
#19.	MeSH descriptor: (gallstones) this term only
#20.	gallstone*:ti,ab
#21.	MeSH descriptor: (jaundice, obstructive) this term only
#22.	(jaundice* near/3 (obstruc* or block* or stricture*)):ti,ab
#23.	MeSH descriptor: (cholangitis) this term only
#24.	cholangitis:ti,ab
#25.	(or #3-#25)
#26.	(surger* or operation* or procedure* or bypass* or drain* or resect*):ti,ab
#27.	(mh ^drainage)
#28.	(mh ^"surgical procedures, operative")
#29.	(mh ^"endoscopy, gastrointestinal")
#30.	(mh ^"biliary tract surgical procedures")
#31.	(mh ^"anastomosis, roux-en-y")
#32.	roux-en-y:ti,ab
#33.	biliary-enteric anastomos?s:ti,ab
#34.	(mh ^choledochostomy)
#35.	(choledochoduodenostom* or choledocho-duodenostom*):ti,ab
#36.	(choledocho-jejunostom* or choledochojejunostom*):ti,ab
#37.	(hepatico-jejunostom* or hepaticojejunostom* or hepatojejunostom* or hepato-jejunostom* or hepatic jejunostom*):ti,ab
#38.	(mh ^"cholangiopancreatography, endoscopic retrograde")
#39.	(endoscopic retrograde cholangiopancreatograph* or ercp):ti,ab
#40.	(mh ^stents)
#41.	(mh ^"self expandable metallic stents")
#42.	(stent* or wallstent):ti,ab
#43.	(or #26-#42)
#44.	#1 and #25 and #43
#45.	#2 and #25

#46.	#44 or #45
	Date parameters: see Table 1

PsycINFO search terms

1.	Standard population (A.2.1)
2.	Excluded study designs and publication types (A.3.1)
3.	1 not 2
4.	Limit 3 to English language
	Date parameters: see Table 1

G.4.13 Diabetes

Searches for the following two questions were run as one search:

- How often should follow-up to identify the development of diabetes be carried out in people with chronic pancreatitis?
- What is the most clinically and cost-effective insulin regimen strategy specifically for type 3c diabetes secondary to pancreatitis?

Medline search terms

1.	Standard population (G.2.1)
2.	Excluded study designs and publication types (G.3.1)
3.	1 not 2
4.	Limit 3 to English language
5.	diabetes mellitus/
6.	diabet*.ti,ab.
7.	or/5-6
8.	4 and 7
9.	t3cdm.ti,ab.
10.	(diabet* and pancreatogenic).ti,ab.
11.	or/9-10
12.	8 or 11
13.	Study filters RCT (A.3.2) or SR (A.3.3) or OBS (A.3.7)
14.	12 and 13
	Date parameters: see Table 1

Embase search terms

1.	Standard population (G.2.1)
2.	Excluded study designs and publication types (G.3.1)
3.	1 not 2
4.	Limit 3 to English language
5.	diabetes mellitus/
6.	diabet*.ti,ab.
7.	or/5-6
8.	4 and 7
9.	t3cdm.ti,ab.
10.	(diabet* and pancreatogenic).ti,ab.
11.	or/9-10

12.	7 or 11
13.	Study filters RCT (A.3.2) or SR (A.3.3) or OBS (A.3.7)
14.	12 and 13
	Date parameters: see Table 1

Cochrane search terms

#1.	Standard population (G.2.1)
#2.	MeSH descriptor: (diabetes mellitus) this term only
#3.	diabet*:ti,ab
#4.	#2 or #3
#5.	#1 and #4
#6.	(diabet* and pancreatogenic):ti,ab
#7.	"t3cdm":ti,ab
#8.	#5 or #6 or #7
	Date parameters: see Table 1

PsycINFO search terms

1.	Standard population (A.2.1)
2.	Excluded study designs and publication types (A.3.1)
3.	1 not 2
4.	Limit 3 to English language
	Date parameters: see Table 1

G.4.14 Specialist assessment

Searches for the following two questions were run as one search:

- What is the clinical and cost effectiveness of receiving specialist input in people with acute pancreatitis?
- What is the clinical and cost effectiveness of a specialist nutritional assessment compared to a non-specialist assessment for managing malabsorption or malnutrition in people with chronic pancreatitis?

Medline search terms

1.	Standard population (G.2.1)
2.	Excluded study designs and publication types (G.3.1)
3.	1 not 2
4.	Limit 3 to English language
5.	tertiary care centers/
6.	(tertiary adj3 (unit* or center* or centre* or facilit* or team* or service*)):ti,ab.
7.	(specialis* or specializ* or expert* or consultant*):ti,ab.
8.	consultants/
9.	((pancreatitis or pancreas) adj4 (clinic* or unit* or centre* or center* or facilit* or team* or service*)):ti,ab.
10.	exp "referral and consultation"/
11.	decision making/
12.	((multidisciplin* or team* or interdisciplin* or mdt or idt or interprofessional* or multiprofessional* or inter-disciplin* or multi-disciplin* or inter-professional or multi-professional or multicenter* or multicentre* or multi-center* or multi-centre*) adj3 (support

	or liais* or co-operat* or cooperat* or contact* or relationship* or convers* or dialog* or talk* or exchange* or discuss* or advice or advis* or input or approach* or consult*).ti,ab.
13.	((surgeon* or surgical or surgery or endoscop* or gastroenterol* or diet* or nutrition* or radiolog*) adj3 (support or liais* or co-operat* or cooperat* or contact* or relationship* or convers* or dialog* or talk* or exchange* or discuss* or advice or advis* or input or consult*).ti,ab.
14.	telemedicine/
15.	remote consultation/
16.	(telemedicine or tele?consult*).ti,ab.
17.	nutrition therapy/ or diet therapy/ or nutritional support/ or nutrition assessment/
18.	((virtual or tele* or "face to face" or "in person" or remote) adj3 (consult* or refer* or refers or referral* or referring or centre* or center* or service* or input or meeting* or support* or advice or advis* or liais* or contact* or relationship* or convers* or dialog* or talk* or exchange* or discuss*).ti,ab.
19.	or/5-18
20.	Study filters RCT (A.3.2) or SR (A.3.3) or OBS (G.3.7)
21.	4 and 19 and 20
	Date parameters: see Table 1

Embase search terms

1.	Standard population (G.2.1)
2.	Excluded study designs and publication types (G.3.1)
3.	1 not 2
4.	Limit 3 to English language
5.	tertiary care center/
6.	(tertiary adj3 (unit* or center* or centre* or facilit* or team* or service*).ti,ab.
7.	(Specialis* or specializ* or expert* or consultant*).ti,ab.
8.	consultation/ or teleconsultation/
9.	((pancreatitis or pancreas) adj4 (clinic* or unit* or centre* or center* or facilit* or team* or service*).ti,ab.
10.	patient referral/
11.	decision making/
12.	((multidisciplin* or team* or interdisciplin* or MDT or IDT or interprofessional* or multiprofessional* or inter-disciplin* or multi-disciplin* or inter-professional or multi-professional or multicenter* or multicentre* or multi-center* or multi-centre*) adj3 (support or liais* or co-operat* or cooperat* or contact* or relationship* or convers* or dialog* or talk* or exchange* or discuss* or advice or advis* or input or approach* or consult*).ti,ab.
13.	((surgeon* or surgical or surgery or endoscop* or gastroenterol* or diet* or nutrition* or radiolog*) adj3 (support or liais* or co-operat* or cooperat* or contact* or relationship* or convers* or dialog* or talk* or exchange* or discuss* or advice or advis* or input or consult*).ti,ab.
14.	telemedicine/
15.	(telemedicine or tele?consult*).ti,ab.
16.	diet therapy/ or nutritional support/
17.	((virtual or tele* or "face to face" or "in person" or remote) adj3 (consult* or refer* or refers or referral* or referring or centre* or center* or service* or input or meeting* or support* or advice or advis* or liais* or contact* or relationship* or convers* or dialog* or talk* or exchange* or discuss*).ti,ab.
18.	or/5-17
19.	Study filters RCT (A.3.2) or SR (A.3.3) or OBS (G.3.7)

20.	4 and 18 and 19
	Date parameters: see Table 1

Cochrane search terms

#1.	Standard population (G.2.1)
#2.	(mh ^"tertiary care centers")
#3.	(tertiary near/3 (unit* or center* or centre* or facilit* or team* or service*)):ti,ab
#4.	(specialis* or specializ* or expert* or consultant*):ti,ab
#5.	(mh ^consultants)
#6.	((pancreatitis or pancreas) near/4 (clinic* or unit* or centre* or center* or facilit* or team* or service*)):ti,ab
#7.	(mh "referral and consultation")
#8.	(mh ^"decision making")
#9.	((multidisciplin* or team* or interdisciplin* or mdt or idt or interprofessional* or multiprofessional* or inter-disciplin* or multi-disciplin* or inter-professional or multi-professional or multicenter* or multicentre* or multi-center* or multi-centre*) near/3 (support or liais* or co-operat* or cooperat* or contact* or relationship* or convers* or dialog* or talk* or exchange* or discuss* or advice or advis* or input or approach* or consult*)):ti,ab
#10.	((surgeon* or surgical or surgery or endoscop* or gastroenterol* or diet* or nutrition* or radiolog*) near/3 (support or liais* or co-operat* or cooperat* or contact* or relationship* or convers* or dialog* or talk* or exchange* or discuss* or advice or advis* or input or consult*)):ti,ab
#11.	(mh ^telemedicine)
#12.	(mh ^"remote consultation")
#13.	(telemedicine or tele?consult*):ti,ab
#14.	(mh ^"nutrition therapy")
#15.	(mh ^"diet therapy")
#16.	(mh ^"nutritional support")
#17.	(mh ^"nutrition assessment")
#18.	((virtual or tele* or remote) near/3 (consult* or refer* or refers or referral* or referring or centre* or center* or service* or input or meeting* or support* or advice or advis* or liais* or contact* or relationship* or convers* or dialog* or talk* or exchange* or discuss*)):ti,ab
#19.	((face next to next face) near/3 (consult* or refer* or refers or referral* or referring or centre* or center* or service* or input or meeting* or support* or advice or advis* or liais* or contact* or relationship* or convers* or dialog* or talk* or exchange* or discuss*)):ti,ab
#20.	((in next person) near/3 (consult* or refer* or refers or referral* or referring or centre* or center* or service* or input or meeting* or support* or advice or advis* or liais* or contact* or relationship* or convers* or dialog* or talk* or exchange* or discuss*)):ti,ab
#21.	(or #2-#20)
#22.	#1 and #21
	Date parameters: see Table 1

PsycINFO search terms

1.	Standard population (A.2.1)
2.	Excluded study designs and publication types (A.3.1)
3.	1 not 2
4.	Limit 3 to English language
	Date parameters: see Table 1

G.4.15 Follow up: pancreatic function

- How often should follow-up to assess pancreatic exocrine function and any secondary health issues, if any, be carried out in people with chronic pancreatitis?

Medline search terms

1.	Standard population (G.2.1)
2.	Excluded study designs and publication types (G.3.1)
3.	1 not 2
4.	Limit 3 to English language
5.	pancreatic elastase/
6.	elastase.ti,ab.
7.	nutritional status/
8.	iron/ or iron, dietary/
9.	vitamins/ or vitamin d deficiency/ or vitamin a deficiency/ or vitamin d/ or vitamin a/ or vitamin e/
10.	((nutrition* or nutrient* or micronutrient* or micro-nutrient* or diet* or vitamin* or iron) adj6 (assess* or status or evaluat* or test* or screen* or investigat* or follow-up* or followup* or surveillance* or marker* or biomarker* or indicat* or parameter* or exam* or check-up* or checkup* or monitor* or measure*)).ti,ab.
11.	((vitamin* or iron or nutrition* or nutrient* or micronutrient* or micro-nutrient* or diet* or exocrine) adj3 (deficien* or insuffic*)).ti,ab.
12.	exocrine pancreatic insufficiency/
13.	(pancrea* adj2 (function or insuffic* or deficien*) adj6 (assess* or status or evaluat* or test* or screen* or investigat* or follow-up* or followup* or surveillance* or marker* or biomarker* or indicat* or parameter* or exam* or check-up* or checkup* or monitor* or measure*)).ti,ab.
14.	(exocrine adj6 (assess* or status or evaluat* or test* or screen* or investigat* or follow-up* or followup* or surveillance* or marker* or biomarker* or indicat* or parameter* or exam* or check-up* or checkup* or monitor* or measure*)).ti,ab.
15.	anthropometry/
16.	anthropometr*.ti,ab.
17.	z score*.ti,ab.
18.	bone density/
19.	dexa.ti,ab.
20.	(bone adj2 (density or mineral* or metabolism* or health)).ti,ab.
21.	body weight/ or body mass index/
22.	exp body composition/
23.	((body or muscle* or weight or bmi or metaboli*) adj6 (assess* or status or evaluat* or test* or screen* or investigat* or follow-up* or followup* or surveillance* or marker* or biomarker* or indicat* or parameter* or exam* or check-up* or checkup* or monitor* or measure*)).ti,ab.
24.	(body adj composition*).ti,ab.
25.	(primary hyperparathyroid* or parathyroid hormone* or pth).ti,ab.
26.	(biochemi* adj6 (assess* or status or evaluat* or test* or screen* or investigat* or follow-up* or followup* or surveillance* or marker* or biomarker* or indicat* or parameter* or exam* or check-up* or checkup* or monitor* or measure*)).ti,ab.
27.	(exocrine and ((assess* or evaluat* or test* or screen* or investigat* or follow-up or followup* or surveillance or marker* or biomarker* or monitor* or check-up* or checkup* or measure* or examin*) adj6 (interval* or frequen* or day* or week* or month* or year* or time* or timing* or regular* or ongoing or on-going or continu* or recurr* or repeat*))).ti,ab.

28.	((pancrea* adj2 function*) and ((assess* or evaluat* or test* or screen* or investigat* or follow-up or followup* or surveillance or marker* or biomarker* or monitor* or check-up* or checkup* or measure* or examin*) adj6 (interval* or frequen* or day* or week* or month* or year* or time* or timing* or regular* or ongoing or on-going or continu* or recurr* or repeat*))).ti,ab.
29.	or/5-28
30.	"pancreatic function tests"/
31.	time factors/
32.	30 and 31
33.	29 or 32
34.	Study filters RCT (A.3.2) or SR (A.3.3) or OBS (A.3.7)
35.	4 and 32 and 33
	Date parameters: see Table 1

Embase search terms

1.	Standard population (G.2.1)
2.	Excluded study designs and publication types (G.3.1)
3.	1 not 2
4.	Limit 3 to English language
5.	pancreatic elastase/
6.	elastase.ti,ab.
7.	nutritional status/ or nutritional parameters/
8.	iron/ or iron absorption/ or iron deficiency/
9.	vitamin/ or vitamin D/ or vitamin K group/ or vitamin D deficiency/ or retinol/ or alpha tocopherol/
10.	((nutrition* or nutrient* or micronutrient* or micro-nutrient* or diet* or vitamin* or iron) adj6 (assess* or status or evaluat* or test* or screen* or investigat* or follow-up* or followup* or surveillance* or marker* or biomarker* or indicat* or parameter* or exam* or check-up* or checkup* or monitor* or measure*)).ti,ab.
11.	((vitamin* or iron or nutrition* or nutrient* or micronutrient* or micro-nutrient* or diet* or exocrine) adj3 (deficien* or insuffic*)).ti,ab.
12.	exocrine pancreatic insufficiency/ or pancreatic insufficiency/ or pancreas function/
13.	(pancrea* adj2 (function or insuffic* or deficien*) adj6 (assess* or status or evaluat* or test* or screen* or investigat* or follow-up* or followup* or surveillance* or marker* or biomarker* or indicat* or parameter* or exam* or check-up* or checkup* or monitor* or measure*)).ti,ab.
14.	(exocrine adj6 (assess* or status or evaluat* or test* or screen* or investigat* or follow-up* or followup* or surveillance* or marker* or biomarker* or indicat* or parameter* or exam* or check-up* or checkup* or monitor* or measure*)).ti,ab.
15.	anthropometry/ or anthropometric parameters/
16.	anthropometr*.ti,ab.
17.	z score*.ti,ab.
18.	bone density/
19.	dexa.ti,ab.
20.	(bone adj2 (density or mineral* or metabolism* or health)).ti,ab.
21.	body weight/ or body composition/ or body distribution/ or body fat/ or body fat distribution/ or body mass/
22.	((body or muscle* or weight or BMI or metaboli*) adj6 (assess* or status or evaluat* or test* or screen* or investigat* or follow-up* or followup* or surveillance* or marker* or

	biomarker* or indicat* or parameter* or exam* or check-up* or checkup* or monitor* or measure*)):ti,ab.
23.	(body adj composition*).ti,ab.
24.	(primary hyperparathyroid* or parathyroid hormone* or PTH).ti,ab.
25.	(biochemi* adj6 (assess* or status or evaluat* or test* or screen* or investigat* or follow-up* or followup* or surveillance* or marker* or biomarker* or indicat* or parameter* or exam* or check-up* or checkup* or monitor* or measure*)):ti,ab.
26.	(exocrine and ((assess* or evaluat* or test* or screen* or investigat* or follow-up or followup* or surveillance or marker* or biomarker* or monitor* or check-up* or checkup* or measure* or examin*) adj6 (interval* or frequen* or day* or week* or month* or year* or time* or timing* or regular* or ongoing or on-going or continu* or recurr* or repeat*))).ti,ab.
27.	((pancrea* adj2 function*) and ((assess* or evaluat* or test* or screen* or investigat* or follow-up or followup* or surveillance or marker* or biomarker* or monitor* or check-up* or checkup* or measure* or examin*) adj6 (interval* or frequen* or day* or week* or month* or year* or time* or timing* or regular* or ongoing or on-going or continu* or recurr* or repeat*))).ti,ab.
28.	or/5-27
29.	pancreas function test/
30.	time/ or time factor/
31.	29 and 30
32.	28 or 31
33.	Study filters RCT (A.3.2) or SR (A.3.3) or OBS (A.3.7)
34.	4 and 32 and 33
	Date parameters: see Table 1

Cochrane search terms

#1.	Standard population (G.2.1)
#2.	(mh ^"pancreatic elastase")
#3.	elastase:ti,ab
#4.	(mh ^"nutritional status")
#5.	(mh ^iron)
#6.	(mh ^"iron, dietary")
#7.	(mh ^vitamins)
#8.	MeSH descriptor: (vitamin d deficiency) this term only
#9.	MeSH descriptor: (vitamin a deficiency) this term only
#10.	(mh ^"vitamin d")
#11.	(mh ^"vitamin a")
#12.	(mh ^"vitamin e")
#13.	((nutrition* or nutrient* or micronutrient* or micro next nutrient* or diet* or vitamin* or iron) next/6 (assess* or status or evaluat* or test* or screen* or investigat* or follow next up* or followup* or surveillance* or marker* or biomarker* or indicat* or parameter* or exam* or check next up* or checkup* or monitor* or measure*)):ti,ab
#14.	((vitamin* or iron or nutrition* or nutrient* or micronutrient* or micro next nutrient* or diet* or exocrine) next/3 (deficien* or insuffic*)):ti,ab
#15.	(mh ^"exocrine pancreatic insufficiency")
#16.	(pancrea* next/2 (function or insuffic* or deficien*) next/6 (assess* or status or evaluat* or test* or screen* or investigat* or follow next up* or followup* or surveillance* or marker* or biomarker* or indicat* or parameter* or exam* or check next up* or checkup* or monitor* or measure*)):ti,ab

#17.	(exocrine next/6 (assess* or status or evaluat* or test* or screen* or investigat* or follow-up* or followup* or surveillance* or marker* or biomarker* or indicat* or parameter* or exam* or check-up* or checkup* or monitor* or measure*)):ti,ab
#18.	(mh ^anthropometry)
#19.	anthropometr*:ti,ab
#20.	z score*:ti,ab
#21.	(mh ^"bone density")
#22.	dexa:ti,ab
#23.	(bone next/2 (density or mineral* or metabolism* or health)):ti,ab
#24.	(mh ^"body weight")
#25.	(mh ^"body mass index")
#26.	(mh "body composition")
#27.	((body or muscle* or weight or bmi or metaboli*) next/6 (assess* or status or evaluat* or test* or screen* or investigat* or follow next up* or followup* or surveillance* or marker* or biomarker* or indicat* or parameter* or exam* or check next up* or checkup* or monitor* or measure*)):ti,ab
#28.	body next composition*:ti,ab
#29.	(primary hyperparathyroid* or parathyroid hormone* or pth):ti,ab
#30.	(biochemi* next/6 (assess* or status or evaluat* or test* or screen* or investigat* or follow next up* or followup* or surveillance* or marker* or biomarker* or indicat* or parameter* or exam* or check next up* or checkup* or monitor* or measure*)):ti,ab
#31.	(exocrine and ((assess* or status or evaluat* or test* or screen* or investigat* or follow next up* or followup* or surveillance* or marker* or biomarker* or indicat* or parameter* or exam* or check next up* or checkup* or monitor* or measure*) next/6 (interval* or frequen* or day* or week* or month* or year* or time* or timing* or regular* or ongoing or on-going or continu* or recurr* or repeat*)):ti,ab
#32.	((pancrea* next/2 function*) and ((assess* or status or evaluat* or test* or screen* or investigat* or follow next up* or followup* or surveillance* or marker* or biomarker* or indicat* or parameter* or exam* or check next up* or checkup* or monitor* or measure*) next/6 (interval* or frequen* or day* or week* or month* or year* or time* or timing* or regular* or ongoing or on-going or continu* or recurr* or repeat*)):ti,ab
#33.	(or #2-#32)
#34.	(mh ^"pancreatic function tests")
#35.	(mh ^"time factors")
#36.	#34 and #35
#37.	#33 or #36
#38.	#1 and #37
	Date parameters: see Table 1

PsycINFO search terms

1.	Standard population (A.2.1)
2.	Excluded study designs and publication types (A.3.1)
3.	1 not 2
4.	Limit 3 to English language
	Date parameters: see Table 1

G.4.16 Follow up: pancreatic cancer

- How often should follow-up to identify development of pancreatic cancer be carried out in people with chronic pancreatitis?

Medline search terms

1.	Standard population (G.2.1)
2.	Excluded study designs and publication types (G.3.1)
3.	1 not 2
4.	Limit 3 to English language
5.	pancreas/
6.	neoplasms/
7.	(carcin* or cancer* or neoplas* or tumour* or tumor* or growth* or adenocarcin* or malig*).ti,ab.
8.	5 and (6 or 7)
9.	(pancrea* adj6 (carcin* or cancer* or neoplas* or tumour* or tumor* or growth* or adenocarcin* or malig*)).ti,ab.
10.	carcinoma, pancreatic ductal/ or pancreatic neoplasms/
11.	or/8-10
12.	((carcin* or cancer* or neoplas* or tumour* or tumor* or growth* or adenocarcin* or malig*) adj6 (assess* or status or evaluat* or test* or screen* or investigat* or follow-up* or followup* or surveillance* or marker* or biomarker* or indicat* or parameter* or exam* or check-up* or checkup* or monitor* or measure*)).ti,ab.
13.	(ca19-9 or ca-19* or muc1 or mucin* or muc* or antigen* or cea or heat shock protein* or hsp or microrna* or mrna* or mirna*).ti,ab.
14.	biomarkers, tumor/ or antigens, tumor-associated, carbohydrate/ or ca-19-9 antigen/ or antigens, neoplasm/
15.	((ercp or cholangiopancreatograph* or cholangio-pancreatograph*) and (carcin* or cancer* or neoplas* or tumour* or tumor* or growth* or adenocarcin* or malig*)).ti,ab.
16.	((eus or ultrasonic endoscop* or endoscopic ultrasonograph* or endosonograph* or ultrasound* or scan* or ct* or tomograph* or mri* or magnetic resonance or mrcp or pet-ct) and (carcin* or cancer* or neoplas* or tumour* or tumor* or growth* or adenocarcin* or malig*)).ti,ab.
17.	(methylat* and (carcin* or cancer* or neoplas* or tumour* or tumor* or growth* or adenocarcin* or malig*)).ti,ab.
18.	or/12-17
19.	biomarkers/
20.	cholangiopancreatography, endoscopic retrograde/
21.	tomography/ or magnetic resonance imaging/ or cholangiopancreatography, magnetic resonance/ or exp tomography, emission-computed/ or ultrasonography/
22.	tomography, x-ray computed/
23.	endosonography/
24.	or/19-23
25.	24 and (6 or 7)
26.	11 or 18 or 25
27.	Study filters RCT (A.3.2) or SR (A.3.3) or OBS (A.3.7)
28.	4 and 26 and 27
	Date parameters: see Table 1

Embase search terms

1.	Standard population (G.2.1)
2.	Excluded study designs and publication types (G.3.1)
3.	1 not 2

4.	Limit 3 to English language
5.	pancreas/
6.	neoplasm/ or malignant neoplasm/
7.	(carcin* or cancer* or neoplas* or tumour* or tumor* or growth* or adenocarcin* or malig*).ti,ab.
8.	5 and (6 or 7)
9.	(pancrea* adj6 (carcin* or cancer* or neoplas* or tumour* or tumor* or growth* or adenocarcin* or malig*).ti,ab.
10.	pancreas adenoma/ or pancreas tumor/ or pancreas adenocarcinoma/ or pancreas cancer/ or pancreas carcinoma/
11.	or/8-10
12.	((carcin* or cancer* or neoplas* or tumour* or tumor* or growth* or adenocarcin* or malig*) adj6 (assess* or status or evaluat* or test* or screen* or investigat* or follow-up* or followup* or surveillance* or marker* or biomarker* or indicat* or parameter* or exam* or check-up* or checkup* or monitor* or measure*).ti,ab.
13.	(ca19-9 or ca-19* or muc1 or mucin* or muc* or antigen* or cea or heat shock protein* or hsp or microrna* or mrna* or mirna*).ti,ab.
14.	tumor antigen/ or ca 19-9 antigen/ or carbohydrate antigen/
15.	((ercp or cholangiopancreatograph* or cholangio-pancreatograph*) and (carcin* or cancer* or neoplas* or tumour* or tumor* or growth* or adenocarcin* or malig*).ti,ab.
16.	((eus or ultrasonic endoscop* or endoscopic ultrasonograph* or endosonograph* or ultrasound* or scan* or ct* or tomograph* or mri* or magnetic resonance or mrcp or pet-ct) and (carcin* or cancer* or neoplas* or tumour* or tumor* or growth* or adenocarcin* or malig*).ti,ab.
17.	(methylat* and (carcin* or cancer* or neoplas* or tumour* or tumor* or growth* or adenocarcin* or malig*).ti,ab.
18.	or/12-17
19.	biological marker/
20.	endoscopic retrograde cholangiopancreatography/
21.	x-ray computed tomography/
22.	tomography/
23.	nuclear magnetic resonance/
24.	magnetic resonance cholangiopancreatography/
25.	exp computer assisted emission tomography/
26.	echography/ or endoscopic ultrasonography/
27.	or/19-26
28.	27 and (6 or 7)
29.	(11 or 18 or 28)
30.	Study filters RCT (A.3.2) or SR (A.3.3) or OBS (A.3.7)
31.	4 and 29 and 30
	Date parameters: see Table 1

Cochrane search terms

#1.	Standard population (G.2.1)
#2.	(mh ^pancreas)
#3.	(mh ^neoplasms)
#4.	(carcin* or cancer* or neoplas* or tumour* or tumor* or growth* or adenocarcin* or malig*).ti,ab

#5.	#2 and (#3 or #4)
#6.	(pancrea* next/6 (carcin* or cancer* or neoplas* or tumour* or tumor* or growth* or adenocarcin* or malig*)):ti,ab
#7.	(mh ^"carcinoma, pancreatic ductal")
#8.	(mh ^"pancreatic neoplasms")
#9.	(or #5-#8)
#10.	((carcin* or cancer* or neoplas* or tumour* or tumor* or growth* or adenocarcin* or malig*) next/6 (assess* or status or evaluat* or test* or screen* or investigat* or follow-up* or followup* or surveillance* or marker* or biomarker* or indicat* or parameter* or exam* or check-up* or checkup* or monitor* or measure*)):ti,ab
#11.	(ca19* or ca next 19* or muc1 or mucin* or muc* or antigen* or cea or heat shock protein* or hsp or microrna* or mrna* or mirna*):ti,ab
#12.	(mh ^"biomarkers, tumor")
#13.	(mh ^"antigens, tumor-associated, carbohydrate")
#14.	(mh ^"ca-19-9 antigen")
#15.	(mh ^"antigens, neoplasm")
#16.	((ercp or cholangiopancreatograph* or cholangio next pancreatograph*) and (carcin* or cancer* or neoplas* or tumour* or tumor* or growth* or adenocarcin* or malig*)):ti,ab
#17.	((eus or ultrasonic endoscop* or endoscopic ultrasonograph* or endosonograph* or ultrasound* or scan* or ct* or tomograph* or mri* or magnetic resonance or mrcp or pet-ct) and (carcin* or cancer* or neoplas* or tumour* or tumor* or growth* or adenocarcin* or malig*)):ti,ab
#18.	(methylat* and (carcin* or cancer* or neoplas* or tumour* or tumor* or growth* or adenocarcin* or malig*)):ti,ab
#19.	(or #10-#18)
#20.	(mh ^biomarkers)
#21.	(mh ^"cholangiopancreatography, endoscopic retrograde")
#22.	(mh ^tomography)
#23.	(mh ^"magnetic resonance imaging")
#24.	(mh ^"cholangiopancreatography, magnetic resonance")
#25.	(mh "tomography, emission-computed")
#26.	(mh ^ultrasonography)
#27.	(mh ^"tomography, x-ray computed")
#28.	(mh ^endosonography)
#29.	(or #20-#28)
#30.	#29 and (#3 or #4)
#31.	#1 and (#9 or #19 or #30)
	Date parameters: see Table 1

PsycINFO search terms

1.	Standard population (A.2.1)
2.	Excluded study designs and publication types (A.3.1)
3.	1 not 2
4.	Limit 3 to English language
	Date parameters: see Table 1

G.5 Health economics search terms

G.5.1 Health economic (HE) reviews

Economic searches were conducted in Medline, Embase and CRD

Medline & Embase search terms

1.	12.	Standard population (G.2.1)
2.	13.	Excluded study designs and publication types (G.3.1)
3.	14.	1 not 2
4.	15.	Limit 3 to English language
5.	16.	Study filter HE (G.3.4)
6.	17.	4 and 5
18.	19.	Date parameters: 2014 – 28 September 2017

CRD search terms

#1.	Standard population (G.2.1)
	Date parameters: Inception – 28 September 2017

G.5.2 Quality of life (QoL) reviews

Quality of life searches were conducted in Medline and Embase only

Medline & Embase search terms

1.	20.	Standard population (G.2.1)
2.	21.	Excluded study designs and publication types (G.3.1)
3.	22.	1 not 2
4.	23.	Limit 3 to English language
5.	24.	Study filter QOL (G.3.5)
6.	25.	4 and 5
26.	27.	Date parameters: 1946– 20 April 2016 (Medline)
28.	29.	Date parameters: 1974 – 20 April 2016 (Embase)

Appendix H: Clinical evidence tables

H.1 Patient information (qualitative evidence tables)

Study	Cronin 2012 ²⁵⁷
Aim	To develop an understanding and construct a meaning of living with chronic pancreatitis and, in so doing, to: illuminate the everyday contextualised and culturally situated lives of the participants, and explicate the meaning of living with chronic pancreatitis as a basis for understanding and interpretation by others.
Population	14 people living with chronic pancreatitis and 5 relatives Characteristics of those with pancreatitis: n= 14 ; male = 10/female = 4; age range 26 - 58 years. 7 participants had been living with chronic pancreatitis for 2 years or less, 4 for 2-5 years and 3 for more than 5 years.
Setting	All participants were under the care of a hospital-based pancreatic specialist in Ireland.
Study design	Qualitative unstructured interviews.
Methods and analysis	<p>Participants recruited through the clinical nurse specialist (CNS) or the pancreas data controller employed for the service. The CNS distributed 14 invitations to patients with a diagnosis of chronic pancreatitis over a period of 8 months. The data controller sent 33 invitations to patients identified from the hospital database as having a primary or secondary diagnosis of chronic pancreatitis.</p> <p>Multiple unstructured audiotaped conversations were conducted with each participant over a period of several months. Biographical and contextual data were also collected. In addition 5 close family members were interviewed. A total of 41 individual or joint interviews took place. Interviews and diary entries were transcribed and returned to the participants for comment.</p> <p>A 4 step data analysis cycle was undertaken including labelling of codes and themes that represented the experiences of the participants:</p> <ol style="list-style-type: none"> 1. gaining understanding of the whole text 2. Detailed analysis of text and identification of themes 3. Expansion of the unity of the understood sense 4. Representing shared understandings <p>A sample of texts were blind coded, compared and reviewed by 2 researchers.</p>
Findings	Most considered that the information with which they left the hospital with was inadequate in facilitating their understanding and management of the condition. It was only through attempting to assimilate chronic pancreatitis into their everyday lives that its implications became evident. Participants described this as ‘coming to know’ and marked the beginning of their health/illness transition. For example, despite following advice, most found that symptoms either did not resolve or recurred:

Study	Cronin 2012 ²⁵⁷
	<p><i>“ I pretty much thought that if I never drank again, then I’d never feel ill again... then it came around acutely the second time”</i></p>
	<p>Participants reported differences in the information with which they were provided. Most sought information from other sources such as the internet, family and friends, books/articles/mass media and fellow patients, but all reported that there was little ‘lay’ knowledge available about the condition:</p>
	<p><i>“I’m still caught between what I’ve read and what the specialists have told me”</i></p>
	<p>Although all knew that there was no cure for chronic pancreatitis and that the condition was a life-long one, few grasped fully the meaning of its progressive nature:</p>
	<p><i>“No one has told me exactly why my pancreas had decided to continue the progression of the disease even though I’m not drinking”</i></p>
	<p>Furthermore, most did not appear to have any knowledge of long-term complications associated with chronic pancreatitis</p>
	<p>Relationships with healthcare professionals were important mediators in facilitating or constraining their coping:</p>
	<p><i>“You go to casualty, you’ve got this triage battle... having to fight your case like a barrister for admittance into the hospital”</i></p>
	<p><i>“No matter what I said about he doesn’t drink... I always thought they didn’t believe me...”</i> Family member (wife)</p>
	<p>All participants made lifestyle modifications which included abstaining from alcohol, adjusting diet and ‘prioritising demands’ and ‘struggling to live well’. Continuous ‘self-monitoring’ provides participants with feedback on their body’s response to illness and contributes to how they make decisions:</p>
	<p><i>“I’ve sort of made up my own diet... I’ve been eliminating anything that caused me to get sick”</i></p>
	<p>Participants also used coping strategies including ‘emotional coping’ and ‘drawing on social resources’ such as family, friends and professional agencies:</p>
	<p><i>“When I go to [Alcoholics Anonymous] meeting, I don’t think I am going because I’m an alcoholic. I’m thinking of them as part and parcel of my daily routine of keeping well”</i></p>
	<p><i>“We’re both very much in tune with how each other is feeling... she’ll know when something is wrong’.</i></p>

Study	Cronin 2012 ²⁵⁷
	Participants also kept regular and necessary contact with the healthcare system for the purpose of ongoing monitoring and being treated including strategies for managing what they perceive as shortcomings in the system.
Limitations and applicability of evidence	This paper is applicable to this review question, but also includes other themes on suffering, and adjusting and managing, which do not detail anything on information or support. Unclear as to what exact questions were asked.

H.2 Lifestyle interventions: stopping or reducing alcohol consumption

Study	Nordback 2009 ⁸⁰³
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=120)
Countries and setting	Conducted in Finland; Setting: Tampere University Hospital
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 2 years
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients who had been admitted to the hospital for their first alcohol-associated acute pancreatitis (AP). The diagnosis of first AP was confirmed when the patient reported no previous symptoms, signs or findings of pancreatitis and now needed to be admitted to the hospital because of symptoms and signs consistent with AP together with serum amylase levels more than 3 times the upper normal range and/or AP in the abdominal imaging. Alcohol was considered a probable aetiology because of the association with alcohol consumption that was observed. Each patient or a family member reported heavy alcohol consumption, or heavy consumption was detected by the WHO-recommended Alcohol Use Disorder Identification Test (AUDIT) questionnaire. Lower consumption of alcohol still carries a risk of an association between alcohol consumption and AP, but was not accepted in this study for the association.
Exclusion criteria	Other possible aetiologies for AP were excluded by history, liver, chemistry, US, and serum calcium and lipids measurements

Study	Nordback 2009 ⁸⁰³
Recruitment/selection of patients	People admitted to hospital with first AP
Age, gender and ethnicity	Age - Mean (range): Control group 47 (18-73), intervention group 46 (25-71). Gender (M:F): 101/19. Ethnicity: not reported
Further population details	1. Aetiology of pancreatitis: Alcohol-related 2. Amount of alcohol consumed: High (as defined by national guidelines) (People with heavy consumption). 3. Previous pancreatic surgery: Not stated / Unclear 4. Severity of pancreatitis: Systematic review: mixed (Severe pancreatitis according to Atlanta criteria: control group n=15, intervention group n=18).
Extra comments	Baseline alcohol use in the control and intervention group, respectively: AUDIT scale (0-40) 20 (1-38), 22 (10-38); SADD scale (0-45) 13 (0-36), 15(0-36); self-reported alcohol consumption during past week, g of absolute ethanol 456 (72-2016), 590 (12-2184); calculated daily dose 65 (10-288), 84 (2-312); self-reported alcohol consumption during past 2 months, g of absolute ethanol 2880 (288-15456), 3372 (454-13248); calculated daily dose 48 (5-288), 56 (8-221)
Indirectness of population	No indirectness
Interventions	<p>(n=59) Intervention 1: Structured programme to support people with both chronic and acute pancreatitis in stopping or reducing alcohol consumption. Repeated intervention: initial in-hospital intervention plus repeated similar interventions at 6-months intervals in the gastrointestinal outpatient clinic. The intervention consisted of a 30-minute conversation, which consisted of 3 portions: a) information on the toxic effect of alcohol on the pancreas: the patient should not use any alcohol because that is the only way to guarantee avoidance of recurrent alcoholic pancreatitis, because no other safe limit exists. 2) the need for a change in drinking habits and the patient's responsibility for the change: one feature was to try to go through the situations associated with alcohol use and to offer other kinds of behaviour models for those situations. 3) focus on social problems, which were very common and included unemployment, economic and marital difficulties, etc. Help was searched for depending on the respective need. Duration 2 years. Concurrent medication/care: Not stated Further details: 1. Type of programme:</p> <p>(n=61) Intervention 2: No structured programme/usual care (for example, general advice) . Initial in-hospital intervention. The intervention consisted of a 30-minute conversation, which consisted of 3 portions: a) information on the toxic effect of alcohol on the pancreas: the patient should not use any alcohol because that is the only way to guarantee avoidance of recurrent alcoholic pancreatitis, because no other safe limit exists. 2) the need for a change in drinking habits and the patient's responsibility for the change: one feature was to try to go through the situations associated with alcohol use and to offer other kinds of behaviour models for those situations. 3) focus on social problems, which were very common and included unemployment, economic and marital difficulties, etc. Help was searched for depending on the respective need. Duration 1 initial session plus 2 years follow-up. Concurrent medication/care: Not stated</p>

Study	Nordback 2009⁸⁰³
	Further details: 1. Type of program:
Funding	Academic or government funding (The work was supported by the Pirkanmaa Hospital District Research Fund)
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: STRUCTURED PROGRAMME TO SUPPORT PEOPLE WITH BOTH CHRONIC AND ACUTE PANCREATITIS IN STOPPING OR REDUCING ALCOHOL CONSUMPTION versus NO STRUCTURED PROGRAMME/USUAL CARE (FOR EXAMPLE, GENERAL ADVICE)</p> <p>Protocol outcome 1: Admission to hospital at no time cut-off - Actual outcome: Admissions to hospital (n of patients admitted for abdominal complaints) - ITT at 2 years; Group 1: 7/59, Group 2: 16/61 Risk of bias: All domain - Very high, Selection - High, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments - No details on ITT imputation?; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing: - Actual outcome: Admissions to hospital (n of patients admitted for abdominal complaints fulfilling criteria of recurrent AP) - ITT at 2 years; Group 1: 5/59, Group 2: 13/61 Risk of bias: All domain - Very high, Selection - High, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments - No details on ITT imputation?; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing: - Actual outcome: Admissions to hospital (n of patients admitted for abdominal complaints fulfilling criteria of recurrent AP) - ACA at 2 years; Group 1: 3/39, Group 2: 9/45 Risk of bias: All domain - Very high, Selection - High, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments - No details on ITT imputation?; Indirectness of outcome: No indirectness ; Group 1 Number missing: 26, Reason: 1 died; 3 other possible etiology (gallstones) detected, 3 were revealed to have had AP before inclusion, 5 did not attend one or more visits during the 2 year period, 14 did not attend the 2-year visit as scheduled (6 were phone interviewed); Group 2 Number missing: 21, Reason: 3 died; 18 did not attend the 2-year visit as scheduled (5 were phone interviewed)</p> <p>Protocol outcome 2: Recurrent episodes of pancreatitis at no time cut-off - Actual outcome: Number of episodes of recurrent AP - ACA at 36 months; Group 1: 7/39, Group 2: 14/45 Risk of bias: All domain - Very high, Selection - High, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments - No details on ITT imputation?; Indirectness of outcome: No indirectness ; Group 1 Number missing: 26, Reason: 1 died; 3 other possible etiology (gallstones) detected, 3 were revealed to have had AP before inclusion, 5 did not attend one or more visits during the 2 year period, 14 did not attend the 2-year visit as scheduled (6 were phone interviewed); Group 2 Number missing: 21, Reason: 3 died; 18 did not attend the 2-year visit as scheduled (5 were phone interviewed) - Actual outcome: Number of episodes of recurrent AP - ITT at 36 months; Group 1: 9/59, Group 2: 20/61 Risk of bias: All domain - Very high, Selection - High, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments - No details on ITT imputation?; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 3: Alcohol consumption at no time cut-off - Actual outcome: Dependency on alcohol (SADD scale, 0-45) at 2 years; Mean; (median (range) for intervention and control group, respectively: 3 (0-28), 5 (0-26));</p>	

Study	Nordback 2009 ⁸⁰³
	<p>Risk of bias: All domain - Very high, Selection - High, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments - No details on ITT imputation?; Indirectness of outcome: No indirectness ; Group 1 Number missing: 26, Reason: 1 died; 3 other possible etiology (gallstones) detected, 3 were revealed to have had AP before inclusion, 5 did not attend one or more visits during the 2 year period, 14 did not attend the 2-year visit as scheduled (6 were phone interviewed); Group 2 Number missing: 21, Reason: 3 died; 18 did not attend the 2-year visit as scheduled (5 were phone interviewed) - Actual outcome: Self-reported alcohol consumption (g of absolute alcohol during past week) at 2 years; Mean; (median (range) for intervention and control group, respectively: 0 (0-1126), 0(0-912));</p> <p>Risk of bias: All domain - Very high, Selection - High, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments - No details on ITT imputation?; Indirectness of outcome: No indirectness ; Group 1 Number missing: 26, Reason: 1 died; 3 other possible etiology (gallstones) detected, 3 were revealed to have had AP before inclusion, 5 did not attend one or more visits during the 2 year period, 14 did not attend the 2-year visit as scheduled (6 were phone interviewed); Group 2 Number missing: 21, Reason: 3 died; 18 did not attend the 2-year visit as scheduled (5 were phone interviewed) - Actual outcome: Self-reported alcohol consumption (g of absolute alcohol during past 2 months) at 2 years; Mean; (median (range) for intervention and control group, respectively: 168(0-9408), 324(0-5880));</p> <p>Risk of bias: All domain - Very high, Selection - High, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments - No details on ITT imputation?; Indirectness of outcome: No indirectness ; Group 1 Number missing: 26, Reason: 1 died; 3 other possible etiology (gallstones) detected, 3 were revealed to have had AP before inclusion, 5 did not attend one or more visits during the 2 year period, 14 did not attend the 2-year visit as scheduled (6 were phone interviewed); Group 2 Number missing: 21, Reason: 3 died; 18 did not attend the 2-year visit as scheduled (5 were phone interviewed) - Actual outcome: Alcohol consumption (AUDIT scale, 0-40) at 2 years; Mean; (median (range) for intervention and control group, respectively: 12(0-35), 11(0-33));</p> <p>Risk of bias: All domain - Very high, Selection - High, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments - No details on ITT imputation?; Indirectness of outcome: No indirectness ; Group 1 Number missing: 26, Reason: 1 died; 3 other possible etiology (gallstones) detected, 3 were revealed to have had AP before inclusion, 5 did not attend one or more visits during the 2 year period, 14 did not attend the 2-year visit as scheduled (6 were phone interviewed); Group 2 Number missing: 21, Reason: 3 died; 18 did not attend the 2-year visit as scheduled (5 were phone interviewed)</p>
<p>Protocol outcomes not reported by the study</p>	<p>Quality of life at no time cut-off; Morbidity (for example, pancreatic function, pain) at no time cut-off; Mortality at no time cut-off; Alcohol consumption at no time cut-off; Nutritional status at no time cut-off; Morbidity at no time cut-off; Nutritional status at no time cut-off</p>

H.3 Aetiology of acute pancreatitis

None

H.4 Aetiology of chronic pancreatitis

None

H.5 Diagnosing chronic pancreatitis

Study	Ketwaroo 2013 ⁵⁹¹
Study type	Retrospective cohort
Number of studies (number of participants)	1 (n=116)
Country and setting	USA; Beth Israel Deaconess Medical Centre Boston, Massachusetts (tertiary referral centre)
Funding	No financial support
Duration of study	Data relative to 1995-2008 years
Age, gender, ethnicity	Characteristics of SPTF positive and negative groups, respectively: mean age (SD) 45.5 (13.3), 45.5 (11.1) years; males 20%, 32.9%; white ethnicity 70%, 77.1%.
Patient characteristics	Patients with a clinical history highly suggestive of chronic pancreatitis, that is, epigastric pain worse with eating, and radiating to the back, and with prior work-up that usually includes a negative esophagogastroduodenoscopy, gastric emptying study; abdominal ultrasound, and laboratory testing. All patients had normal cross-sectional or endoscopic pancreatic imaging before referral for SPFT. All patients were evaluated by a Pancreas specialist before performing SPFT.
Index test	Secretin pancreatic function test (SPFT): standard esophagogastroduodenoscopy was performed and a guidewire was placed through the endoscope under fluoroscopic guidance beyond the ligament of Treitz. The endoscope was removed keeping the guidewire in place, and a double-lumen gastroduodenal tube or Dreiling tube with gastric and duodenal ports was placed over the wire with the tip of the tube in the third to fourth portion of the duodenum. The guidewire was then removed after placement of the Dreiling tube was confirmed fluoroscopically. IV human secretin was administered to stimulate the secretion of bicarbonate. AN initial test dose of 0.1 ml was given and if there was no evidence of an adverse or allergic reaction, and the full dose of 0/2 mcg/kg was administered over 2 min. In the recovery room, the gastric port was attached to continuous suction and the gastric aspirate was discarded. The duodenal juice was continuously aspirated from the duodenal port of the Dreiling tube with collection representing 15, 30, 45 and 60 minute intervals after the secretin had been administered. Analysis for bicarbonate concentration was performed on all samples using the hospital autoanalyser. A positive test was defined as a peak bicarbonate

Study	Ketwaroo 2013 ⁵⁹¹
	level of <75 mEq/L in any of the duodenal fluid collections following administration of IV secretin. A pH of about 7 was required to ensure that the aspirated duodenal fluid was not contaminated by gastric contents.
Reference standard	Patient follow-up: medical records of patients who had undergone SPFT were reviewed for evidence of subsequent development of findings consistent with chronic pancreatitis by imaging or pathology from surgical specimens. In addition, records were also reviewed to determine if chronic pancreatitis had been conclusively ruled out, and if an alternative diagnosis had been made. Patients were contacted by telephone, if there was insufficient data based on medical record review, including outside record if available. All subsequent relevant radiology and endoscopy reports were reviewed for documentation of findings consistent with chronic pancreatitis. Imaging was read by gastrointestinal radiology attendings; positive findings were reviewed and confirmed by an independent gastrointestinal radiologist who was not blinded to the SPFT data. Imaging finding consistent with CP included the following: i) CT: findings of parenchymal and ductal calcifications, parenchymal atrophy, dilated main pancreatic duct, and dilated side branches; atrophy and hypertrophy were evaluated. Patients with only fullness of the pancreatic head were considered negative; ii) ERCP and MRI/MRCP: findings per Cambridge classification; iii)EUS, based on a 9-points based scoring system of pancreatic ductal and parenchymal changes; patients were considered to have CP with at least 5 criteria. Pathology confirmed changes consistent with CP such as periductal fibrosis, duct dilation, intralobular inflammation and atrophy; this was reviewed by a gastrointestinal pathologist who was not blinded to clinical data.
Target condition	Chronic pancreatitis in people presenting with chronic abdominal pain, and normal or uncertain CT or ultrasound scan or upper GI endoscopy
<p>Results: 2x2 table calculated using author-reported sens, spec and study prevalence</p> <p>Secretin pancreatic function test (SPFT): cut-off peak bicarbonate level of <75 mEq/L</p> <p>TP: 9 FP: 11 FN: 2 TN: 68</p> <p>Sensitivity: 0.82 Specificity: 0.86 Number of people analysed: 90</p> <p>Prevalence 0.12 PPV 0.45</p>	

Study	Ketwaroo 2013 ⁵⁹¹
NPV 0.97 Positive likelihood ratio 5.88 Negative likelihood ratio 0.21	
General limitations (according to QUADAS-2): patients were enrolled consecutively. It is unclear whether the index test results were interpreted without knowledge of the results of the reference test. The reference standard results were interpreted with knowledge of the results of the index test (non-blinded assessors). Duration of interval between index test and reference standard test is unclear. Not all patients received the same reference standard (clinical follow-up including a number of imaging test). Not all people were included in the final analysis (26 lost to follow-up, no further details).	

H.6 Type of intravenous fluid for resuscitation in people with acute pancreatitis

Study	Aboelsoud 2016 ⁴
Study type	Non-randomised comparative study
Number of studies (number of participants)	1 (n=198)
Countries and setting	Conducted in USA; Setting: Not reported
Line of therapy	Adjunctive to current care
Duration of study	Not clear:
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Diagnosis based on the ICD-9 code and confirmed by elevated serum amylase and/or lipase (>three times the upper limit of normal), and/or finding on CT abdomen consistent with AP.
Stratum	Adults (>16 years)
Subgroup analysis within study	Not applicable
Inclusion criteria	Diagnosis based on the ICD-9 code and confirmed by elevated serum amylase and/or lipase (>three times the upper limit of normal), and/or finding on CT abdomen consistent with AP.
Exclusion criteria	Patients who received colloids were excluded
Recruitment/selection of patients	Subjects were identified on the Multi-parameter Intelligent Monitoring in Intensive Care research database
Age, gender and ethnicity	Age - Range: 44-74. Gender (M:F): 100:98. Ethnicity: LR group: Caucasian: 78%, African American: 10%, Other: 12% IS group: Caucasian: 76%, African American: 13%, Other: 11%

Further population details	1. Age: <75 years 2. Severity of pancreatitis (as defined by study): Not stated / Unclear
Indirectness of population	No indirectness
Interventions	(n=68) Intervention 1: Balanced crystalloids. Patients received lactated Ringers solution. If a patient received both LR and IS, they were assigned to the group of predominant fluid amount. Duration 72 hours. Concurrent medication/care: Not reported (n=130) Intervention 2: Saline. Dose/quantity, brand name, extra details. Duration 72 hours. Concurrent medication/care: Not reported
Funding	Funding not stated
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: LACTATED RINGERS SOLUTION versus ISOTONIC SALINE</p> <p>Protocol outcome 1: Length of stay (in intensive therapy unit or hospital) at <1 year - Actual outcome for Adults (>16 years): Length of stay in CCU at During admission; Group 1: mean 6.2 days (SD 6.9); n=68, Group 2: mean 4.2 days (SD 4.49); n=130; Risk of bias: Very high; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 2: Mortality at <1 year - Actual outcome for Adults (>16 years): Mortality at During admission; Group 1: 39/68, Group 2: 21/130; Risk of bias: Very high; Indirectness of outcome: No indirectness</p>	
Protocol outcomes not reported by the study	Quality of life at <1 year; Systemic complications (persistent organ failure; fluid overload) at during admission; Serious adverse events at during admission; Length of stay (in intensive therapy unit or hospital) at <1 year; Local complications (fluid collection; cystic collection; pancreas necrosis; peri-pancreatic necrosis; local infection) at <6 months

Study	De-Madaria 2017 ²⁷¹
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=40)
Countries and setting	Conducted in Spain; Setting: Not reported
Line of therapy	Adjunctive to current care
Duration of study	Not clear
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: AP was defined as two of the following three criteria: (1) characteristic abdominal pain, (2) serum amylase and/or lipase greater than three times the upper limit of normal, and (3) cross-sectional abdominal imaging demonstrating changes consistent with AP
Stratum	Adults (>16 years)
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients aged 18 years or older who initially presented to the emergency room and were subsequently admitted to the center with a first episode of AP
Exclusion criteria	The exclusion criteria were: time from pain onset to randomization >24 hours, known history of renal disease (basal creatinine >2mg/dl, patient under chronic hemodialysis), greater than New York Heart Association class II heart failure, chronic lung disease requiring supplemental home oxygen, active acute infection (including acute cholecystitis and acute cholangitis), hypernatremia (serum sodium>145mEq/l) or hyponatremia (<135mEq/l), rhabdomyolysis, metastatic malignant disease, autoimmune diseases associated with inflammation (including inflammatory bowel disease), chronic infection (e.g. human immunodeficiency virus (HIV) and tuberculosis).
Recruitment/selection of patients	Patients who presented to the emergency room
Age, gender and ethnicity	Age – Mean (SD): Lactated Ringer’s group 63.8 (19.1), saline group 61.4 (15.5). Gender (M:F): 19:21. Ethnicity: Not reported
Further population details	1. Age: <75 years 2. Severity of pancreatitis (as defined by study): Not stated / Unclear
Indirectness of population	No indirectness
Interventions	(n=68) Intervention 1: Balanced crystalloids. Patients with hematocrit >44% and/or two or more SIRS criteria and/or blood urea nitrogen>20 mg/dl and/or signs of dehydration or hypovolemia received more vigorous resuscitation: 15 ml/kg of the study fluid in 60 minutes immediately after randomization, and then 1.2 ml/kg/hour of the study fluid for three days. All other patients received 10 ml/kg of the study fluid in 60 minutes immediately after randomization, and then 1 ml/kg/hour of the study fluid for three days. In patients with oliguria or hypotension. the attending

	<p>physician could administer boluses of 500 to 1000 ml of the study fluid in 30 to 60 minutes as needed. In case of fluid overload, the attending physician could decrease the study fluid volume rate and use diuretics as needed. Duration 3 days. Concurrent medication/care: All patients received 1000 ml of 10% dextrose solution in addition to the study fluid.</p> <p>(n=130) Intervention 2: Saline. Normal saline. Duration 3 days. Concurrent medication/care: All patients received 1000 ml of 10% dextrose solution in addition to the study fluid.</p>
Funding	The RCT was funded by AIGPA, an association of researchers in gastroenterology from the province of Alicante, Spain. In vitro experiments were supported by a national Spanish public grant from Instituto de Salud Carlos III; L.B. is supported by a predoctoral fellowship from Generalitat de Catalunya (AGAUR, FI DGR 2013).
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: LACTATED RINGERS SOLUTION versus ISOTONIC SALINE</p> <p>Protocol outcome 1: Persistent organ failure at <1 year - Actual outcome for Adults (>16 years): Systemic complications (persistent organ failure; fluid overload) at during admission; Group 1: 0/19, Group 2: 1/21 Risk of bias: Low; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 2: Mortality at <1 year - Actual outcome for Adults (>16 years): Mortality at During admission; Group 1: 0/19, Group 2: 1/21; Risk of bias: Very high; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 3: CCU admission at <1 year - Actual outcome for Adults (>16 years): Serious adverse events at during admission; Group 1: 0/19, Group 2: 1/21 Risk of bias: Low; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 3: (peri) pancreatic necrosis at <1 year - Actual outcome for Adults (>16 years): Local complications (fluid collection; cystic collection; pancreas necrosis; peri-pancreatic necrosis; local infection) at <6 months; Group 1: 0/19, Group 2: 1/21 Risk of bias: Low; Indirectness of outcome: No indirectness</p>	
Protocol outcomes not reported by the study	Quality of life at <1 year

Study	Wu 2011 ¹⁰⁴⁰
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=40)
Countries and setting	Conducted in USA; Setting: Brigham and Women's Hospital, Faulkner Hospital and Dartmouth-Hitchcock Medical Center
Line of therapy	Adjunctive to current care
Duration of study	Unclear
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Diagnosis was confirmed by the presence of 2 or more of the following criteria: epigastric abdominal pain, elevation in serum amylase and/or lipase level greater than 3 times the upper limit of normal, confirmatory findings on cross-sectional imaging.
Stratum	Adults (>16 years)
Subgroup analysis within study	Not applicable
Inclusion criteria	Not reported
Exclusion criteria	Patients were excluded from participation if they met any of the following criteria: known history of severe cardiovascular, respiratory, renal, hepatic, hematologic, or immunologic disease defined as greater than New York Heart Association class II heart failure, active myocardial ischaemia or cardiovascular intervention within previous 60 days, history of cirrhosis or chronic kidney disease with creatinine clearance <40 mL/min, or chronic obstructive pulmonary disease with requirement for home oxygen. Individuals were also excluded from participation if they had evidence of a concurrent metabolic or physiological derangement that required specific fluid management including sepsis (presence of suspected or confirmed infection in the setting of SIRS), hyponatremia (serum sodium <135 mEq/L), or rhabdomyolysis. Patients transferred from an outside hospital were excluded from participation. Patients with a history of metastatic malignancy, active inflammatory bowel disease, autoimmune conditions such as systemic lupus erythematosus, autoimmune pancreatitis, giant cell arteritis, rheumatoid arthritis, or chronic infectious disease including human immunodeficiency virus or tuberculosis were excluded because of potential confounding related to markers of systemic inflammation.
Recruitment/selection of patients	Eligible patients were identified in real time by a direct paging system from the clinical laboratory at each institution on the basis of lipase levels. Patients were approached either in the emergency department or on the general medical ward for study participation.
Age, gender and ethnicity	Age - Median (IQR): LR group: 50 (40, 73), NS group: 54 (40, 60). Gender (M:F): 22:18. Ethnicity: Not reported
Further population details	1. Age : <75 years 2. Severity of pancreatitis (as defined by study): Not stated / Unclear
Extra comments	LR group: Etiology - Biliary (42%), Alcohol (11%), Post-ERCP (11%), Other (36%); duration of symptoms (median, h): 8;

	SIRS: (32%), BISAP: (median): 0, APACHE II (median): 3 NS group: Etiology - Biliary (48%), Alcohol (19%), Post-ERCP (5%), Other (28%); duration of symptoms (median, h): 6; SIRS: (19%), BISAP: (median): 1, APACHE II (median): 3
Indirectness of population	No indirectness
Interventions	(n=19) Intervention 1: Balanced crystalloids. Patients received either 20 mL/kg or standard resuscitation of lactated Ringer's solution controlled by their treating physicians. Duration Unclear. Concurrent medication/care: Not reported (n=21) Intervention 2: Saline. Patients received either 20 mL/kg or standard resuscitation of normal saline controlled by their treating physicians. Duration Unclear. Concurrent medication/care: Not reported
Funding	Academic or government funding (Dr Wu is supported by a 2009 Junior Faculty Career Development Award from the American College of Gastroenterology)
RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: RINGERS LACTATED SOLUTION versus SALINE	
<p>Protocol outcome 1: Length of stay (in intensive therapy unit or hospital) at <1 year - Actual outcome for Adults (>16 years): Length of stay at Unclear; Risk of bias: ; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 2: Mortality at <1 year - Actual outcome for Adults (>16 years): Mortality at Unclear; Group 1: 0/19, Group 2: 0/21; Risk of bias: Very high; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 3: Local complications (fluid collection; cystic collection; pancreas necrosis; peri-pancreatic necrosis; local infection) at <6 months - Actual outcome for Adults (>16 years): Necrosis at Unclear; Group 1: 0/19, Group 2: 1/21; Risk of bias: Very high; Indirectness of outcome: No indirectness - Actual outcome for Adults (>16 years): Infection at Unclear; Group 1: 0/19, Group 2: 2/21; Risk of bias: Very high; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 4: Systemic complications (persistent organ failure; fluid overload) at during admission - Actual outcome for Adults (>16 years): Respiratory organ failure at Unclear; Group 1: 0/19, Group 2: 1/21; Risk of bias: Very high; Indirectness of outcome: No indirectness - Actual outcome for Adults (>16 years): Shock at Unclear; Group 1: 0/19, Group 2: 1/21; Risk of bias: Very high; Indirectness of outcome: No indirectness - Actual outcome for Adults (>16 years): Renal failure at Unclear; Group 1: 1/19, Group 2: 2/21; Risk of bias: Very high; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 5: Serious adverse events at during admission - Actual outcome for Adults (>16 years): Transfer to CCU at Unclear; Group 1: 1/19, Group 2: 3/21; Risk of bias: Very high; Indirectness of outcome: No indirectness</p>	
Protocol outcomes not reported by the study	Quality of life at <1 year; Length of stay (in intensive therapy unit or hospital) at <1 year

H.7 Speed of intravenous fluid for resuscitation in people with acute pancreatitis

Study	Buxbaum 2017 ¹⁷⁸
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=60)
Countries and setting	Conducted in USA; Setting: Emergency department
Line of therapy	Unclear
Duration of study	Intervention + follow up: 60 hours
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Adults (>16 years)
Subgroup analysis within study	Not applicable
Inclusion criteria	Acute pancreatitis, defined by two of three criteria: epigastric abdominal pain; elevated amylase or lipase >3 times the upper limit of normal; or imaging consistent with acute pancreatitis. Eligible patients were required to be evaluated, consented, and randomised within 4 hours of diagnosis.
Exclusion criteria	Systemic inflammatory response syndrome; New York Heart Associated Class II or greater heart failure; decompensated cirrhosis (Child's Class B or C); hypotension (systolic blood pressure <90mm Hg); renal insufficiency (Cr>2mg/dl at time of randomisation) or dialysis requirement; respiratory insufficiency (oxygen saturation <90% on room air); hyponatremia (sodium <135meq/l); clinical signs of volume overload (peripheral edema, pulmonary rales, and acites); gastrointestinal bleeding; pregnancy; and pancreatitis following an endoscopic, radiographic or surgical procedure. Also patients who had pancreatic abscess or necrosis on imaging
Recruitment/selection of patients	Not reported

Age, gender and ethnicity	Age - Mean (SD): Aggressive group: 44.4 (13.7); standard group: 45.3 (12.3). Gender (M:F): 45:15. Ethnicity: Hispanic 75.5%
Further population details	1. Age : <75 years 2. Severity of pancreatitis (as defined by study): Not stated / Unclear
Indirectness of population	No indirectness
Interventions	<p>(n=27) Intervention 1: 'Aggressive' fluid administration - 'Aggressive' as defined by studies. Aggressive intravenous hydration with Lactated Ringer's solution. Patients received a 20ml/kg bolus followed by infusion at 3ml/kg/h. This aggressive rate was based on a randomised trial of goal directed versus standard fluids for pancreatitis . Duration 12 hours. Concurrent medication/care: At 12 hours after randomisation, the patients were examined by the study team and laboratory testing was performed. This included a complete blood count, BUN, creatinine and electrolytes. If the hematocrit, BUN, or creatinine level had increased above its baseline value, the patient, regardless of study assignment was given a 20ml/kg LR bolus followed by LR at 3ml/kg/h; this was done if any one of the three laboratory tests increased even if the others stayed the same or decreased. If the laboratory tests did not increase and the abdominal pain decreased on the visual analogue scale, a clear liquid diet was also initiated. Patients were reassessed and fluid management was determined in the same way at subsequent checkpoints at 24 and 36 hours. . Indirectness: No indirectness</p> <p>(n=33) Intervention 2: 'Conservative' fluid administration - 'Conservative' as defined by studies. Patients randomised to standard hydration were given a 10ml/kg bolus followed by infusion at 1.5ml/kg/h. This rate was based on a discussion with the authors of a prior trial. . Duration 12 hours. Concurrent medication/care: At 12 hours after randomisation, the patients were examined by the study team and laboratory testing was performed. This included a complete blood count, BUN, creatinine and electrolytes. If the hematocrit, BUN, or creatinine level had increased above its baseline value, the patient, regardless of study assignment was given a 20ml/kg LR bolus followed by LR at 3ml/kg/h; this was done if any one of the three laboratory tests increased even if the others stayed the same or decreased. If the laboratory tests did not increase and the abdominal pain decreased on the visual analogue scale, a clear liquid diet was also initiated. Patients were reassessed and fluid management was determined in the same way at subsequent checkpoints at 24 and 36 hours. . Indirectness: No indirectness</p>
Funding	Academic or government funding (Supported by NIH/NCRR SC CTSI Grant)

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: 'AGGRESSIVE' AS DEFINED BY STUDIES versus 'CONSERVATIVE' AS DEFINED BY STUDIES

Protocol outcome 1: Mortality at <1 year

- Actual outcome for Adults (>16 years): Mortality at 3 days; Group 1: 0/27, Group 2: 1/33

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Baseline details: Difference in number of people with white blood cells >12x10⁹/l (44% versus 24%); Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 2: Local complications (fluid collection; cystic collection; pancreas necrosis; peri-pancreatic necrosis; local infection) at <6 months

- Actual outcome for Adults (>16 years): Hemoconcentration at 36 hours; Group 1: 3/27, Group 2: 12/33

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Baseline details: Difference in number of people with white blood cells >12x10⁹/l (44% versus 24%); Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 3: Systemic complications (persistent organ failure; fluid overload) at during admission

- Actual outcome for Adults (>16 years): Development of SIRS at 36 hours; Group 1: 4/27, Group 2: 9/33

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Baseline details: Difference in number of people with white blood cells >12x10⁹/l (44% versus 24%); Group 1 Number missing: ; Group 2 Number missing:

- Actual outcome for Adults (>16 years): Persistent SIRS at 36 hours; Group 1: 2/27, Group 2: 7/33

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Baseline details: Difference in number of people with white blood cells >12x10⁹/l (44% versus 24%); Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 4: Serious adverse events at during admission

- Actual outcome for Adults (>16 years): Severe pancreatitis at 36 hours; Group 1: 0/27, Group 2: 1/33

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Baseline details: Difference in number of people with white blood cells >12x10⁹/l (44% versus 24%); Group 1 Number missing: ; Group 2 Number missing:

Protocol outcomes not reported by the study

Quality of life at <1 year; Achievement of pre-specified target for resuscitation (eg target central venous pressure, urine output, lactate levels, PiCCO measurements) at <1 year; Length of stay (in intensive therapy unit or hospital) at <1 year; Length of stay (in intensive therapy unit or hospital) at <1 year

Study	De-Madaria 2011 ²⁷²
Study type	Non-randomised comparative study
Number of studies (number of participants)	1 (n=247)
Countries and setting	Conducted in Spain; Setting: The Pancreatic unit of Hospital General Universitario of Alicante
Line of therapy	Adjunctive to current care
Duration of study	Intervention time: 2.5 years
Method of assessment of guideline condition	Unclear method of assessment/diagnosis
Stratum	Adults (>16 years)
Subgroup analysis within study	Not applicable
Inclusion criteria	Adult patients (aged 18 and over) with AP admitted to the Pancreatic unit of Hospital General Universitario of Alicante
Exclusion criteria	Not reported
Recruitment/selection of patients	All patients admitted to the unit with AP were enrolled
Age, gender and ethnicity	Age - Range: 50-81. Gender (M:F): 135:112. Ethnicity: Not reported
Further population details	1. Age : Systematic review: mixed 2. Severity of pancreatitis (as defined by study): Systematic review: mixed

Extra comments	<p>Group A: Etiology - Gallstones: 33, Alcohol: 7, Idiopathic: 15, Other: 8, SIRS: 31, APACHE II >8: 25 Group B: Etiology - Gallstones: 71, Alcohol: 19, Idiopathic: 14, Other: 19, SIRS: 31, APACHE II >8: 44 Group C: Etiology - Gallstones: 30, Alcohol: 13, Idiopathic: 9, Other: 8, SIRS: 27, APACHE II >8: 24</p>
Indirectness of population	No indirectness
Interventions	<p>(n=61) Intervention 1: 'Aggressive' fluid administration - 'Aggressive' as defined by studies. Participants were given >4.1 L during the initial 24 hours of admission. Duration During admission. Concurrent medication/care: All other treatment followed the centers protocol for general management of AP.</p> <p>(n=123) Intervention 2: 'Aggressive' fluid administration - 'Aggressive' as defined by studies. Participants were given 3.1-4.1 L during the initial 24 hours of admission. Duration During admission. Concurrent medication/care: All other treatment followed the centers protocol for general management of AP.</p> <p>(n=63) Intervention 3: 'Conservative' fluid administration - 'Conservative' as defined by studies. Participants were given <3.1 L during the initial 24 hours of admission. Duration During admission. Concurrent medication/care: All other treatment followed the centers protocol for general management of AP.</p>
Funding	No funding
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: >4.1L versus 3.1-4.1 L</p> <p>Protocol outcome 1: Local complications (fluid collection; cystic collection; pancreas necrosis; peri-pancreatic necrosis; local infection) at <6 months - Actual outcome for Adults (>16 years): Necrosis at Unclear; Group 1: 12/61, Group 2: 13/123; Risk of bias: Very high ; Indirectness of outcome: No indirectness - Actual outcome for Adults (>16 years): Acute collections at Unclear; Group 1: 32/61, Group 2: 40/123; Risk of bias: Very high; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 2: Systemic complications (persistent organ failure; fluid overload) at during admission</p>	

- Actual outcome for Adults (>16 years): Persistent organ failure at Unclear; Group 1: 8/61, Group 2: 2/123; Risk of bias: Very high; Indirectness of outcome: No indirectness

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: >4.1L versus <3.1L

Protocol outcome 1: Local complications (fluid collection; cystic collection; pancreas necrosis; peri-pancreatic necrosis; local infection) at <6 months

- Actual outcome for Adults (>16 years): Necrosis at Unclear; Group 1: 12/61, Group 2: 7/62; Risk of bias: Very high; Indirectness of outcome: No indirectness

- Actual outcome for Adults (>16 years): Acute collections at Unclear; Group 1: 32/61, Group 2: 14/63; Risk of bias: Very high; Indirectness of outcome: No indirectness

Protocol outcome 2: Systemic complications (persistent organ failure; fluid overload) at during admission

- Actual outcome for Adults (>16 years): Persistent organ failure at Unclear; Group 1: 8/61, Group 2: 4/63; Risk of bias: Very high; Indirectness of outcome: No indirectness

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: 3.1-4.1 L versus <3.1L

Protocol outcome 1: Local complications (fluid collection; cystic collection; pancreas necrosis; peri-pancreatic necrosis; local infection) at <6 months

- Actual outcome for Adults (>16 years): Necrosis at Unclear; Group 1: 13/123, Group 2: 7/62; Risk of bias: Very high; Indirectness of outcome: No indirectness

- Actual outcome for Adults (>16 years): Acute collections at Unclear; Group 1: 40/123, Group 2: 14/63; Risk of bias: Very high; Indirectness of outcome: No indirectness

Protocol outcome 2: Systemic complications (persistent organ failure; fluid overload) at during admission

- Actual outcome for Adults (>16 years): Persistent organ failure at Unclear; Group 1: 2/123, Group 2: 8/61; Risk of bias: Very high; Indirectness of outcome: No indirectness

Protocol outcomes not reported by the study

Quality of life at <1 year; Mortality at <1 year; Achievement of pre-specified target for resuscitation (eg target central venous pressure, urine output, lactate levels, PiCCO measurements) at <1 year; Serious adverse events at during admission; Length of stay (in intensive therapy unit or hospital) at <1 year; Length of stay (in intensive therapy unit or hospital) at <1 year

Study	Eckerwall 2006 ³³¹
Study type	Non-randomised comparative study
Number of studies (number of participants)	1 (n=99)
Countries and setting	Conducted in Sweden; Setting: Lund University Hospital
Line of therapy	Adjunctive to current care
Duration of study	Other: 9 years
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Organ failure and/or local complications (necrosis, organ failure or pancreatic abscess) defined according to the Atlanta classification system.
Stratum	Adults (>16 years)
Subgroup analysis within study	Not applicable
Inclusion criteria	Organ failure and/or local complications (necrosis, organ failure or pancreatic abscess) defined according to the Atlanta classification system.
Exclusion criteria	Patients with pancreatic fluid collection alone were excluded.
Recruitment/selection of patients	Patients were identified from the hospital records by the aid of a computer search of the patient database.
Age, gender and ethnicity	Age - Mean (SD): 60 (18). Gender (M:F): 64:35. Ethnicity: Not reported
Further population details	1. Age : <75 years 2. Severity of pancreatitis (as defined by study): Severe pancreatitis
Extra comments	Weight - Male: 86 (17), Female: 77 (16) Etiology - Biliary: 31, Alcohol: 30, Other: 38

Indirectness of population	No indirectness
Interventions	<p>(n=32) Intervention 1: 'Aggressive' fluid administration - 'Aggressive' as defined by studies. Patients received 4000 mL or more during the first 24 hours of admission. Duration 24 hours. Concurrent medication/care: 69/95 of the patients received TPN</p> <p>(n=67) Intervention 2: 'Conservative' fluid administration - 'Conservative' as defined by studies. Patients received less than 4000 mL of fluid during the first 24 hours of admission. Duration 24 hours. Concurrent medication/care: 69/95 of the patients received TPN</p>
Funding	Funding not stated
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: 'AGGRESSIVE' AS DEFINED BY STUDIES versus 'CONSERVATIVE' AS DEFINED BY STUDIES</p> <p>Protocol outcome 1: Systemic complications (persistent organ failure; fluid overload) at during admission - Actual outcome for Adults (>16 years): Respiratory complications at During admission; Group 1: 21/32, Group 2: 36/67; Risk of bias: Very high; Indirectness of outcome: No indirectness - Actual outcome for Adults (>16 years): Pulmonary oedema at During admission; Group 1: 0/32, Group 2: 0/67; Risk of bias: Very high; Indirectness of outcome: No indirectness</p>	
Protocol outcomes not reported by the study	Quality of life at <1 year; Mortality at <1 year; Local complications (fluid collection; cystic collection; pancreas necrosis; peri-pancreatic necrosis; local infection) at <6 months; Achievement of pre-specified target for resuscitation (eg target central venous pressure, urine output, lactate levels, PiCCO measurements) at <1 year; Serious adverse events at during admission; Length of stay (in intensive therapy unit or hospital) at <1 year; Length of stay (in intensive therapy unit or hospital) at <1 year

Study	Gardner 2009 ³⁸⁹
Study type	Non-randomised comparative study
Number of studies (number of participants)	1 (n=45)
Countries and setting	Conducted in USA; Setting: Mayo Medical Center (Rochester, Minn., USA)
Line of therapy	Adjunctive to current care
Duration of study	Other: 15 years
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Diagnosis was based on at least two of the following: admitting serum amylase and/or lipase activity greater than three times the upper limit of normal, symptoms consistent with acute pancreatitis, or supporting cross-sectional imaging
Stratum	Adults (>16 years)
Subgroup analysis within study	Not applicable
Inclusion criteria	Age ≥ 18 years, acute pancreatitis as the primary admitting diagnosis, diagnosis of acute pancreatitis based on at least two of the following: admitting serum amylase and/or lipase activity greater than three times the upper limit of normal, symptoms consistent with acute pancreatitis, or supporting cross-sectional imaging, and diagnosis of severe acute pancreatitis as per the Atlanta Classification.
Exclusion criteria	All patients transferred from other institutions were excluded from the study. Patients in whom documentation of IV fluid volumes was incomplete from the time of presentation to the emergency room were also excluded.
Age, gender and ethnicity	Age - Mean (SD): Early group: 53 (13) Late group: 57 (17). Gender (M:F): 29:16. Ethnicity: Not reported

Further population details	1. Age : <75 years 2. Severity of pancreatitis (as defined by study): Severe pancreatitis
Extra comments	Early group - BMI: 28 (4), Charlson score: 2.2 (2.1), Etiology - Gallstone: 4, Alcoholic: 4, Post-ERCP: 5, Idiopathic: 2, Other: 2, Admission hematocrit: 35% Late group - BMI: 29 (6), Charlson score: 3.3 (2.6), Etiology - Gallstone: 14, Alcoholic: 5, Post-ERCP: 2, Idiopathic: 1, Medication: 2, Other: 4, Admission hematocrit: 39%
Indirectness of population	No indirectness
Interventions	(n=17) Intervention 1: 'Aggressive' fluid administration - 'Aggressive' as defined by studies. Participants received ≥33% of their cumulative 72-hour intravenous fluid within the first 24 hours after presentation to the emergency room. Total volume in the first 72 hours: 12, 190 mL. The mean rate of IV fluid resuscitation in the first 24 hours was 203 mL/h.. Duration 72 hours. Concurrent medication/care: All patients were given crystalloid solutions for their resuscitation fluids; 32 received 0.9% NaCl, 9 received 5% Dextrose with 0.45% NaCl, and 4 received lactated Ringer's solution. (n=28) Intervention 2: 'Conservative' fluid administration - 'Conservative' as defined by studies. Participants received <33% of their cumulative 72-hour intravenous fluid within the first 24 hours after presentation to the emergency room. Total volume in the first 72 hours: 7, 664 mL. The mean rate of IV fluid resuscitation in the first 24 hours was 71 mL/h.. Duration 72 hours. Concurrent medication/care: Participants received ≥33% of their cumulative 72-hour intravenous fluid within the first 24 hours after presentation to the emergency room.
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: EARLY RESUSCITATION versus LATE RESUSCITATION

Protocol outcome 1: Length of stay (in intensive therapy unit or hospital) at <1 year

- Actual outcome for Adults (>16 years): Duration of stay at During admission; Group 1: mean 40 days (SD 66); n=17, Group 2: mean 37 days (SD 70); n=28; Risk of bias: Very high; Indirectness of outcome: No indirectness

Protocol outcome 2: Mortality at <1 year

- Actual outcome for Adults (>16 years): Mortality at During admission; Group 1: 0/17, Group 2: 5/28; Risk of bias: Very high; Indirectness of outcome: No indirectness

Protocol outcome 3: Local complications (fluid collection; cystic collection; pancreas necrosis; peri-pancreatic necrosis; local infection) at <6 months

- Actual outcome for Adults (>16 years): Necrosis at During admission; Group 1: 8/17, Group 2: 11/28; Risk of bias: Very high; Indirectness of outcome: No indirectness

- Actual outcome for Adults (>16 years): Development of a pseudocyst or abscess at During admission; Group 1: 11/17, Group 2: 20/28; Risk of bias: Very high; Indirectness of outcome: No indirectness

Protocol outcome 4: Systemic complications (persistent organ failure; fluid overload) at during admission

- Actual outcome for Adults (>16 years): Persistent organ failure at During admission; Group 1: 6/17, Group 2: 12/28; Risk of bias: Very high; Indirectness of outcome: No indirectness

- Actual outcome for Adults (>16 years): SIRS at During admission; Group 1: 15/17, Group 2: 20/28; Risk of bias: Very high; Indirectness of outcome: No indirectness

Protocol outcomes not reported by the study

Quality of life at <1 year; Serious adverse events at during admission; Length of stay (in intensive therapy unit or hospital) at <1 year; Achievement of pre-specified target for resuscitation (eg target central venous pressure, urine output, lactate levels, PiCCO measurements) at <1 year

Study	Singh 2017 ⁹⁹⁹
Study type	Non-randomised comparative study
Number of studies (number of participants)	1 (n=1010)
Countries and setting	Conducted in Spain, USA; Setting: Four institutions
Line of therapy	Adjunctive to current care
Duration of study	Not clear:
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Defined according to the revised Atlanta classification
Stratum	Adults (>16 years)
Subgroup analysis within study	Not applicable
Inclusion criteria	Only adult (>18 years of age) patients with first or recurrent acute pancreatitis were included
Exclusion criteria	Patients with chronic pancreatitis, with missing or incomplete data regarding fluid administration in the ER, those undergoing chronic hemodialysis, and those transferred from outside institutions were excluded from the analysis
Recruitment/selection of patients	Consecutive patients
Age, gender and ethnicity	Age - Mean (SD): 53.6 (19.6). Gender (M:F): 508:502. Ethnicity: Not reported
Further population details	1. Age : <75 years 2. Severity of pancreatitis (as defined by study): Not stated / Unclear
Indirectness of population	No indirectness
Interventions	(n=314) Intervention 1: 'Aggressive' fluid administration - 'Aggressive' as defined by studies. Aggressive fluid volume administration in the emergency room. defined as >100ml from the time of arrival at the ER to 4 hours after diagnosis

	<p>of acute pancreatitis. Duration 4 hours. Concurrent medication/care: Not reported. Indirectness: No indirectness</p> <p>(n=427) Intervention 2: 'Conservative' fluid administration - 'Conservative' as defined by studies. Moderate fluid volume administered in emergency room, defined as 500-1000ml. Duration 4 hours. Concurrent medication/care: Not reported. Indirectness: No indirectness</p> <p>(n=269) Intervention 3: 'Conservative' fluid administration - 'Conservative' as defined by studies. Non-aggressive fluid volume administered in emergency room, defined as <500ml. Duration 4 hours. Concurrent medication/care: Not reported. Indirectness: No indirectness</p>
Funding	No funding
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: 'AGGRESSIVE' AS DEFINED BY STUDIES versus 'CONSERVATIVE' AS DEFINED BY STUDIES (MODERATE)</p> <p>Protocol outcome 1: Mortality at <1 year - Actual outcome for Adults (>16 years): Mortality at Not reported; Group 1: 8/314, Group 2: 7/427 Risk of bias: All domain - Very high, Selection - Very high, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 2: Local complications (fluid collection; cystic collection; pancreas necrosis; peri-pancreatic necrosis; local infection) at <6 months - Actual outcome for Adults (>16 years): Local complications at Not reported; Group 1: 50/314, Group 2: 19/427 Risk of bias: All domain - Very high, Selection - Very high, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 3: Systemic complications (persistent organ failure; fluid overload) at during admission - Actual outcome for Adults (>16 years): Persistent organ failure at Not reported; Group 1: 15/314, Group 2: 19/427 Risk of bias: All domain - Very high, Selection - Very high, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: 'AGGRESSIVE' AS DEFINED BY STUDIES versus 'CONSERVATIVE' AS DEFINED BY STUDIES (NON-AGGRESSIVE)</p>	

<p>Protocol outcome 1: Mortality at <1 year - Actual outcome for Adults (>16 years): Mortality at Not reported; Group 1: 8/314, Group 2: 8/269 Risk of bias: All domain - Very high, Selection - Very high, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 2: Local complications (fluid collection; cystic collection; pancreas necrosis; peri-pancreatic necrosis; local infection) at <6 months - Actual outcome for Adults (>16 years): Local complications at Not reported; Group 1: 50/314, Group 2: 51/269 Risk of bias: All domain - Very high, Selection - Very high, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 3: Systemic complications (persistent organ failure; fluid overload) at during admission - Actual outcome for Adults (>16 years): Persistent organ failure at Not reported; Group 1: 15/314, Group 2: 19/269 Risk of bias: All domain - Very high, Selection - Very high, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p>	
<p>Protocol outcomes not reported by the study</p>	<p>Quality of life at <1 year; Achievement of pre-specified target for resuscitation (eg target central venous pressure, urine output, lactate levels, PiCCO measurements) at <1 year; Serious adverse events at during admission; Length of stay (in intensive therapy unit or hospital) at <1 year; Length of stay (in intensive therapy unit or hospital) at <1 year</p>

Study	Szabo 2015 ¹⁰⁴⁹
Study type	Non-randomised comparative study
Number of studies (number of participants)	1 (n=201)
Countries and setting	Conducted in USA; Setting: Cincinnati Children's Hospital Medical Center
Line of therapy	Adjunctive to current care
Duration of study	Other: 5 years
Method of assessment of guideline condition	Unclear method of assessment/diagnosis
Stratum	Children (<16 years)
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients admitted to general paediatrics or the gastroenterology services, mild AP as defined by the Atlanta criteria (meeting 2 or 3 criteria: symptoms of pain, vomiting; elevated lipase and/or amylase at ≥ 3 times the normal upper limit; imaging findings of AP), or 0-21 years old at time of admission.
Exclusion criteria	Patients with AP and SAP on admission: multisystem organ failure, SIRS, local pancreatic complications (such as necrosis, hemorrhage, pseudocyst formation), or respiratory complications; and patients with pancreatitis related to trauma, gallstone pancreatitis, or postsurgery if they were admitted to the surgical service or CCU.
Recruitment/selection of patients	Identification of cases of AP was based on International Classification of Diseases, 9th Revision codes that started with 577 (AP)
Age, gender and ethnicity	Age - Range: 1-21. Gender (M:F): 94:107. Ethnicity: Not reported

Further population details	1. Age : <75 years 2. Severity of pancreatitis (as defined by study): Mild pancreatitis
Extra comments	<p>NPO + IVF lo: BMI – Mean (SD): 67.7 (28), Etiology – Viral: 0, Drug: 1, Trauma: 0, Gallstone: 4, Idiopathic: 8, Familial: 1, Systemic: 2, Post-ERCP:0, Hypertriglyceridemia: 1, Anatomic: 3, Alcohol: 0; Amylase – Mean (SD): 310 (259), Lipase – Mean (SD): 3139 (2982)</p> <p>NPO + IVF hi: BMI – Mean (SD): 60.9 (37.8), Etiology – Viral: 0, Drug: 5, Trauma: 0, Gallstone: 1, Idiopathic: 9, Familial: 8, Systemic: 2, Post-ERCP:1, Hypertriglyceridemia: 1, Anatomic: 3, Alcohol: 0; Amylase – Mean (SD): 596 (626), Lipase – Mean (SD): 5634 (6045)</p> <p>PO + IVF lo: BMI – Mean (SD): 65 (34.3), Etiology – Viral: 4, Drug: 6, Trauma: 1, Gallstone: 3, Idiopathic: 27, Familial: 0, Systemic: 6, Post-ERCP: 3, Hypertriglyceridemia: 2, Anatomic: 1, Alcohol: 2; Amylase – Mean (SD): 392 (434), Lipase – Mean (SD): 3926 (4963)</p> <p>PO + IVF hi: BMI – Mean (SD): 60.8 (34.4), Etiology – Viral: 3, Drug: 6, Trauma: 1, Gallstone: 8, Idiopathic: 41, Familial: 15, Systemic: 7, Post-ERCP: 7, Hypertriglyceridemia: 1, Anatomic: 7, Alcohol: 0; Amylase – Mean (SD): 594 (814), Lipase – Mean (SD): 5670 (7803)</p>
Indirectness of population	No indirectness
Interventions	<p>(n=126) Intervention 1: 'Aggressive' fluid administration - 'Aggressive' as defined by studies. Intravenous fluid was initiated at 1.5-2 times the maintenance rate of dextrose 5% normal saline on admission. Intravenous fluid was administered within 24 hours of admission.. Duration Unclear. Concurrent medication/care: 30 participants received enteral nutrition and 96 did not.</p> <p>(n=75) Intervention 2: 'Conservative' fluid administration - 'Conservative' as defined by studies. Intravenous fluid was initiated at the normal maintenance rate of dextrose 5% normal saline on admission. Intravenous fluid was administered within 24 hours of admission.. Duration Unclear. Concurrent medication/care: 20 participants received enteral nutrition and 55 did not.</p>
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: IVF HI versus IVF LO

Protocol outcome 1: Serious adverse events at during admission

- Actual outcome for Children (<16 years): Readmission rate at Unclear; Group 1: 5/126, Group 2: 5/75; Risk of bias: Very high; Indirectness of outcome: No indirectness

- Actual outcome for Children (<16 years): CCU transfer rate at Unclear; Group 1: 5/126, Group 2: 14/75; Risk of bias: Very high; Indirectness of outcome: No indirectness

- Actual outcome for Children (<16 years): Severe AP rate at Unclear; Group 1: 12/126, Group 2: 9/75; Risk of bias: Very high; Indirectness of outcome: No indirectness

Protocol outcome 2: Length of stay (in intensive therapy unit or hospital) at <1 year

- Actual outcome for Children (<16 years): Length of stay at During admission (NPO group); Group 1 : 5 (0.58), Group 2: 7.1 (1.01) ; Risk of bias: Very high; Indirectness of outcome: No indirectness

- Actual outcome for Children (<16 years): Length of stay at During admission (PO group); Group 1 : 3.2 (0.22), Group 2: 2.8 (0.24) ; Risk of bias: Very high; Indirectness of outcome: No indirectness

Protocol outcomes not reported by the study

Quality of life at <1 year; Mortality at <1 year; Local complications (fluid collection; cystic collection; pancreas necrosis; peri-pancreatic necrosis; local infection) at <6 months; Achievement of pre-specified target for resuscitation (eg target central venous pressure, urine output, lactate levels, PiCCO measurements) at <1 year; Systemic complications (persistent organ failure; fluid overload) at during admission; Length of stay (in intensive therapy unit or hospital) at <1 year; Length of stay (in intensive therapy unit or hospital) at <1 year

Study	Outcome	Intervention results	Intervention group (n)	Comparison results	Comparison group (n)	Risk of bias
Szabo 2015	Length of stay (in hospital), days, <1 year (NPO group)	Mean (SE): 5 (0.58)	30	Mean (SE): 7.1 (1.01)	20	Very high
Szabo 2015	Length of stay (in hospital), days, <1 year (PO group)	Mean (SE): 3.2 (0.22)	96	Mean (SE): 2.8 (0.24)	55	Very high

Study	Wall 2011 ¹¹²⁶
Study type	Non-randomised comparative study
Number of studies (number of participants)	1 (n=286)
Countries and setting	Conducted in USA; Setting:
Line of therapy	Adjunctive to current care
Duration of study	Other: 1 year per group
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Two of the following: abdominal pain typical of acute pancreatitis, elevation of amylase and/or lipase more than 3 times the upper normal limit, and/or findings consistent with acute pancreatitis on abdominal cross-sectional imaging.
Stratum	Adults (>16 years)
Subgroup analysis within study	Not applicable
Inclusion criteria	Diagnosis of AP based on having two of the following: abdominal pain typical of acute pancreatitis, elevation of amylase and/or lipase more than 3 times the upper normal limit, and/or findings consistent with acute pancreatitis on abdominal cross-sectional imaging.
Exclusion criteria	A known history of severe hepatic dysfunction (albumin <3 mg/dL), cardiovascular insufficiency (>NYHA Class II heart failure), respiratory insufficiency on admission defined by an oxygen saturation of less than 90% on room air, renal insufficiency or hematologic disease. Patients who were transferred after the diagnosis of acute pancreatitis was established were also not included.
Age, gender and ethnicity	Age - Mean (SD): 1998 group: 59.8 (17.1) 2008 group: 57.4 (19.4). Gender (M:F): 121:165. Ethnicity: Not reported

Further population details	1. Age : <75 years 2. Severity of pancreatitis (as defined by study): Not stated / Unclear
Extra comments	1998 group: BMI: 28.1 (3.3), Cause - biliary: 43%, alcohol: 19%, idiopathic: 16%, Post-ERCP: 14%, hypertriglyceridemia: 8% 2008 group: BMI: 28.8 (4.1), Cause - biliary: 43%, alcohol: 26%, idiopathic: 20%, Post-ERCP: 6%, hypertriglyceridemia: 6%
Indirectness of population	No indirectness
Interventions	(n=113) Intervention 1: 'Aggressive' fluid administration - 'Aggressive' as defined by studies. Hydration was provided at 284 mL/h during the first 6 hours and 221 mL/h during the first 12 hours. Duration Unclear. Concurrent medication/care: Not reported (n=173) Intervention 2: 'Conservative' fluid administration - 'Conservative' as defined by studies. Hydration was provided at 113 (80) mL/h during the first 6 hours and 152 (67) mL/h during the first 12 hours . Duration Unclear. Concurrent medication/care: Not reported
Funding	Funding not stated
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: 'AGGRESSIVE' AS DEFINED BY STUDIES versus 'CONSERVATIVE' AS DEFINED BY STUDIES</p> <p>Protocol outcome 1: Length of stay (in intensive therapy unit or hospital) at <1 year - Actual outcome for Adults (>16 years): Length of stay at During admission; Group1: 5.5, Group 2: 7.7; Risk of bias: Very high; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 2: Mortality at <1 year - Actual outcome for Adults (>16 years): Mortality at During admission; Group 1: 4/113, Group 2: 16/173; Risk of bias: Very high; Indirectness of outcome: No indirectness</p>	

Protocol outcome 3: Local complications (fluid collection; cystic collection; pancreas necrosis; peri-pancreatic necrosis; local infection) at <6 months
 - Actual outcome for Adults (>16 years): Pancreatic necrosis at During admission; Group 1: 8/113, Group 2: 26/173; Risk of bias: Very high; Indirectness of outcome: No indirectness

Protocol outcome 4: Systemic complications (persistent organ failure; fluid overload) at during admission
 - Actual outcome for Adults (>16 years): Renal failure at During admission; Group 1: 5/113, Group 2: 9/173; Risk of bias: Very high; Indirectness of outcome: No indirectness
 - Actual outcome for Adults (>16 years): Pulmonary failure at During admission; Group 1: 4/113, Group 2: 9/173; Risk of bias: Very high; Indirectness of outcome: No indirectness
 - Actual outcome for Adults (>16 years): Cardiovascular failure at During admission; Group 1: 4/113, Group 2: 7/173; Risk of bias: Very high; Indirectness of outcome: No indirectness
 - Actual outcome for Adults (>16 years): Multi organ failure at During admission; Group 1: 5/113, Group 2: 18/173; Risk of bias: Very high; Indirectness of outcome: No indirectness

Protocol outcomes not reported by the study

Quality of life at <1 year; Serious adverse events at during admission; Length of stay (in intensive therapy unit or hospital) at <1 year; Achievement of pre-specified target for resuscitation (eg target central venous pressure, urine output, lactate levels, PiCCO measurements) at <1 year

Study	Wang 2013 ¹¹³⁰
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=200)
Countries and setting	Conducted in China; Setting: The Intensive Care Unit in Wuxi Second People's Hospital
Line of therapy	Adjunctive to current care
Duration of study	Intervention time: 4 years
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Patients met Atlanta criteria for severe acute pancreatitis
Stratum	Adults (>16 years)
Subgroup analysis within study	Not applicable
Inclusion criteria	People admitted to hospital with severe acute pancreatitis were enrolled within 24 hours after onset of disease
Exclusion criteria	Any of the following: sepsis, less than 18 or more than 70 years of age, pregnant, chronic heart disease, pacemaker installed, chronic renal failure and SAP with unknown etiology
Age, gender and ethnicity	Age - Range: 18-70. Gender (M:F): Not reported. Ethnicity: Not reported
Further population details	1. Age : <75 years 2. Severity of pancreatitis (as defined by study): Severe pancreatitis
Indirectness of population	No indirectness
Interventions	(n=64) Intervention 1: 'Aggressive' fluid administration - 'Aggressive' as defined by studies. during the first six

	<p>hours of resuscitation, the goals of initial resuscitation should include all of the following: central venous pressure 8-12 mmHg, mean arterial pressure ≥ 65 mmHg, urine output ≥ 0.5 mL/kg/h and central venous or mixed venous oxygen saturation $\geq 70\%$. Duration Unclear. Concurrent medication/care: All patients were managed and cared for in the same manner according to Practice Guideline in Acute Pancreatitis, including supportive care, enteral feeding, treatment of sterile pancreatic necrosis, treatment of associated pancreatic duct disruptions, and use of antibiotics.</p> <p>(n=68) Intervention 2: 'Conservative' fluid administration - 'Conservative' as defined by studies. Patients fluid resuscitation was in line with the Practice Guidelines in Acute Pancreatitis. Duration Unclear. Concurrent medication/care: All patients were managed and cared for in the same manner according to Practice Guideline in Acute Pancreatitis, including supportive care, enteral feeding, treatment of sterile pancreatic necrosis, treatment of associated pancreatic duct disruptions, and use of antibiotics.</p>
Funding	Funding not stated
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: EARLY GOAL-DIRECTED FLUID THERAPY versus 'CONSERVATIVE' AS DEFINED BY STUDIES</p> <p>Protocol outcome 1: Length of stay (in intensive therapy unit or hospital) at <1 year - Actual outcome for Adults (>16 years): Length of time in CCU at During admission; Group 1: mean 18.6 days (SD 6.3); n=64, Group 2: mean 20.6 days (SD 6.8); n=68; Risk of bias: Very high; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 2: Mortality at <1 year - Actual outcome for Adults (>16 years): Mortality at During admission; Group 1: 14/64, Group 2: 16/68; Risk of bias: Very high; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 3: Systemic complications (persistent organ failure; fluid overload) at during admission - Actual outcome for Adults (>16 years): Abdominal compartment syndrome at During admission; Group 1: 14/64, Group 2: 20/68; Risk of bias: Very high; Indirectness of outcome: No indirectness - Actual outcome for Adults (>16 years): Multiple organ dysfunction syndrome at During admission; Group 1: 18/64, Group 2: 20/68; Risk of bias: Very</p>	

<p>high; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 4: Serious adverse events at during admission - Actual outcome for Adults (>16 years): Days on ventilation at During admission; Group 1: mean 12.3 days (SD 4.2); n=64, Group 2: mean 15.3 days (SD 5.2); n=68; Risk of bias: Very high; Indirectness of outcome: No indirectness</p>	
<p>Protocol outcomes not reported by the study</p>	<p>Quality of life at <1 year; Achievement of pre-specified target for resuscitation (eg target central venous pressure, urine output, lactate levels, PiCCO measurements) at <1 year; Length of stay (in intensive therapy unit or hospital) at <1 year; Local complications (fluid collection; cystic collection; pancreas necrosis; peri-pancreatic necrosis; local infection) at <6 months</p>

Study	Wu 2011 ¹¹⁶⁰
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=40)
Countries and setting	Conducted in USA
Line of therapy	Adjunctive to current care
Duration of study	--:
Method of assessment of guideline condition	--
Stratum	Adults (>16 years)
Subgroup analysis within study	Not applicable
Inclusion criteria	Define
Exclusion criteria	Define
Age, gender and ethnicity	Age - --: . Gender (M:F): Define. Ethnicity: Not reported
Further population details	1. Age : <75 years 2. Severity of pancreatitis (as defined by study): Not stated / Unclear
Indirectness of population	--
Interventions	(n=19) Intervention 1: 'Aggressive' fluid administration - 'Aggressive' as defined by studies. Each patient received an initial fluid challenge with 20 mL/kg of either LR solution or NS during a period of 30 minutes. Participants then received continuous infusion of 3 mL/kg/h of intravenous hydration for volume

	<p>maintenance. After 8-12 hours, study physicians reassessed patients with a bedside clinical examination as well as a BUN measurement. If refractory to initial volume challenge, participants received a second fluid challenge of 20 mL/kg to be administered during 30 minutes. They then continued to receive volume replacement at a rate of 3 mL/kg/h. An additional bolus of 20 mL/kg during a period of 30 minutes was initiated at 16-20 hours for patients who remained refractory to volume resuscitation.. Duration Unclear. Concurrent medication/care: Not reported</p> <p>(n=21) Intervention 2: 'Conservative' fluid administration - 'Conservative' as defined by studies. Patients randomised to standard fluid resuscitation had fluid adjustments managed by their treating physician.. Duration Unclear. Concurrent medication/care: Not reported</p>
Funding	Academic or government funding (Dr Wu is supported by a 2009 Junior Faculty Career Development Award from the American College of Gastroenterology)
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: GOAL DIRECTED RESUSCITATION versus STANDARD RESUSCITATION</p> <p>Protocol outcome 1: Length of stay (in intensive therapy unit or hospital) at <1 year - Actual outcome for Adults (>16 years): Length of stay at Unclear; Risk of bias: ; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 2: Mortality at <1 year - Actual outcome for Adults (>16 years): Mortality at Unclear; Group 1: 0/19, Group 2: 0/21; Risk of bias: Very high; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 3: Local complications (fluid collection; cystic collection; pancreas necrosis; peri-pancreatic necrosis; local infection) at <6 months - Actual outcome for Adults (>16 years): Necrosis at Unclear; Group 1: 1/19, Group 2: 0/21; Risk of bias: Very high; Indirectness of outcome: No indirectness - Actual outcome for Adults (>16 years): Infections at Unclear; Group 1: 2/19, Group 2: 0/21; Risk of bias: Very high; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 4: Systemic complications (persistent organ failure; fluid overload) at during admission</p>	

<p>- Actual outcome for Adults (>16 years): Respiratory organ failure at Unclear; Group 1: 1/19, Group 2: 0/21; Risk of bias: Very high; Indirectness of outcome: No indirectness</p> <p>- Actual outcome for Adults (>16 years): Shock at Unclear; Group 1: 1/19, Group 2: 0/21; Risk of bias: Very high; Indirectness of outcome: No indirectness</p> <p>- Actual outcome for Adults (>16 years): Renal failure at Unclear; Group 1: 2/19, Group 2: 1/21; Risk of bias: Very high; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 5: Serious adverse events at during admission</p> <p>- Actual outcome for Adults (>16 years): Transfer to CCU at Unclear; Group 1: 4/19, Group 2: 0/21; Risk of bias: Very high; Indirectness of outcome: No indirectness</p>	
<p>Protocol outcomes not reported by the study</p>	<p>Quality of life at <1 year; Length of stay (in intensive therapy unit or hospital) at <1 year; Achievement of pre-specified target for resuscitation (eg target central venous pressure, urine output, lactate levels, PiCCO measurements) at <1 year</p>

H.8 Route of feeding in people with severe acute pancreatitis

H.8.1 Randomised trials

Study (subsidiary papers)	Al-Omran 2010 ²² (Abou-Assi 2002 ⁵ ; Casas 2007 ¹⁹⁷ ; Gupta 2003 ⁴²⁵ ; Kalfarentzos 1997 ⁵⁶⁵ ; Louie 2005 ⁶⁷⁹ ; Petrov 2006 ⁸⁵³)
Study type	Systematic Review
Number of studies (number of participants)	8 (n=348)
Countries and setting	Conducted in Multiple countries; Setting: Systematic review: mixed
Line of therapy	1st line
Duration of study	Systematic review: mixed
Method of assessment of guideline condition	Systematic review: method of assessment mixed
Stratum	Adults >16 years
Subgroup analysis within study	Systematic review – pre-specified in protocol: Severe acute pancreatitis
Inclusion criteria	Randomised trials comparing TPN with EN in acute pancreatitis
Exclusion criteria	No assessment of severity
Recruitment/selection of patients	Systematic review: mixed
Age, gender and ethnicity	Age - Range: 21-91 years. Gender (M:F): Define. Ethnicity:
Further population details	1. Patients in critical care: Systematic review: mixed
Indirectness of population	Serious indirectness: Includes mild acute pancreatitis patients
Interventions	Systematic review: see study characteristics
Funding	Academic or government funding
RESULTS	
See published systematic review for mortality and length of hospital stay, and some infection results	
RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENTERAL versus PARENTERAL	
Abou-Assi 2002	
Protocol outcome 1: Serious adverse events at <1 year	

- Actual outcome: ARDS; Group 1: 5/27, Group 2: 3/26;
- Actual outcome: MODS; Group 1: 8/27, Group 2: 7/26
Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: 2 (switched – syndrome needed emergency surgery); Group 2 Number missing: 2 (switched – severe sepsis)

Protocol outcome 2: adverse events

- Actual outcome: necrosis or pseudocysts: Group 1: 3/26 Group 2: 4/27

- Actual outcome: hyperglycaemia: Group 1: 4/26, Group 2: 14/27

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 2 (switched – severe sepsis syndrome); Group 2 Number missing: 2 (switched – needed emergency surgery)

- Actual outcome: operative intervention: Group 1: 2/26, Group 2: 0/27

Risk of bias: All domain – Very high, Selection - High, Blinding - Low, Incomplete outcome data - high, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 2 (switched – severe sepsis syndrome); Group 2 Number missing: 2 (switched – needed emergency surgery)

Casas 2007

Protocol outcome 1: adverse events

- Actual outcome: necrosis: Group 1: 0/11, Group 2: 2/11

- Actual outcome: operative intervention: Group 1: 0/11, Group 2: 3/11

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0

Protocol outcome 2: achieving nutrition

- Actual outcome: kcal/kg/day at day 5: Group 1: mean 20.8 (SD 1.68) ; n=11, Group 2: mean 20.09 (SD 1.83); n=11

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0

Protocol outcome 3: infections

- Actual outcome: pancreatic infections: Group 1: 0/11, Group 2: 2/11

- Actual outcome: extra-pancreatic infections: Group 1: 1/11, Group 2: 0/11

- Actual outcome: systemic infections: Group 1: 0/11, Group 2: 5/11

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0

Protocol outcome 3: Serious adverse events

- Actual outcome: SIRS: Group 1: 2/11, Group 2: 2/11

- Actual outcome: MODS: Group 1: 0/11, Group 2: 2/11

- Actual outcome: svstemic infections: Group 1: 0/11. Group 2: 5/11

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0

Gupta 2003

Protocol outcome 1: adverse events

- Actual outcome: tube displacement: Group 1: 0/11, Group 2: 0/9

- Actual outcome: operative intervention: Group 1: 3/8, Group 2: 2/9

Risk of bias: All domain – Very high, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: 3 withdrew or improved; Group 2 Number missing: 2withdrew [available case analysis]

Protocol outcome 2: infections

- Actual outcome: extra-pancreatic infections (urinary or respiratory): Group 1: 1/8, Group 2: 1/9

- Actual outcome: systemic infections (central line infection): Group 1: 0/8, Group 2: 1/9

Risk of bias: All domain – Very high, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: 3 withdrew or improved; Group 2 Number missing: 2withdrew [available case analysis]

Protocol outcome 3: Serious adverse events

- Actual outcome: single organ failure: Group 1: 0/8, Group 2: 6/9

Risk of bias: All domain – Very high, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: 3 withdrew or improved; Group 2 Number missing: 2withdrew [available case analysis]

Protocol outcome 4: length of hospital stay

- Actual outcome: Median Length of hospital stay (range): : Group 1: 7 (4-14) days, Group 2: 10 (7-26) days

Risk of bias: All domain – Very high, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: 3 withdrew or improved; Group 2 Number missing: 2withdrew [available case analysis]

Kalfarentzos 1997

Protocol outcome 1: adverse events

- Actual outcome: operative intervention: Group 1: 3/18, Group 2: 11/20; Comments: 3 procedures in 2 patients and 11 procedures in 4 patients

- Actual outcome: hyperglycaemia >200 mg/dl: Group 1: 4/18, Group 2: 9/20

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: 2 (unsuccessful tube placement); Group 2 Number missing: 0

- Actual outcome: fistula or pseudocysts: Group 1: 0/18 Group 2: 3/20

Risk of bias: All domain – Very high, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: 2 (unsuccessful tube placement); Group 2 Number missing: 0

Protocol outcome 2: infections

- Actual outcome: pancreatic infections (infected necrosis or abscess): Group 1: 2/18, Group 2: 4/20

- Actual outcome: systemic infections (blood culture or catheter-related sepsis): Group 1: 1/18, Group 2: 5/20

Risk of bias: All domain – Very high, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;
Indirectness of outcome: No indirectness : Group 1 Number missing: 2 (unsuccessful tube placement): Group 2 Number missing: 0

- Actual outcome: extra-pancreatic infections (pneumonia or UTI): Group 1: 3/18, Group 2: 6/20
Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Louie 2005

Protocol outcome 1: achieving nutrition

- Actual outcome: days to goal: Group 1: mean 3.3 (SD 2.6) ; n=10, Group 2: mean 1.9 (SD 2.4); n=18

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 1 (switched because of failure); Group 2 Number missing: 0

Protocol outcome 2: infections

- Actual outcome: pancreatic infections (Infected fluid collections): Group 1: 1/10, Group 2: 4/18

- Actual outcome: systemic infections (infected central line): Group 1: 0/10, Group 2: 2/18

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 1 (switched because of failure); Group 2 Number missing: 0

Protocol outcome 3: Serious adverse events

- Actual outcome: single organ failure: Group 1: 7/10, Group 2: 13/18

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 1 (switched because of failure); Group 2 Number missing: 0

Protocol outcome 4: adverse events

- Actual outcome: tube displacement: Group 1: 9/10, Group 2: 0/18

- Actual outcome: acute fluid collections: Group 1: 3/10, Group 2: 9/18

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 1 (switched because of failure); Group 2 Number missing: 0

- Actual outcome: operative intervention: Group 1: 1/10, Group 2: 4/18

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 1 (switched because of failure); Group 2 Number missing: 0

Petrov 2006

Protocol outcome 1: adverse events

- Actual outcome: operative intervention: Group 1: 8/35, Group 2: 25/34;

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 1 (withdrew)

- Actual outcome: tube displacement: Group 1: 5/35, Group 2: 0/34;

- Actual outcome: hyperglycaemia : Group 1: 1/35, Group 2: 5/35

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness : Group 1 Number missing: 0: Group 2 Number missing: 1 (withdrew)

Protocol outcome 2: infections

- Actual outcome: pancreatic infections (infected necrosis or abscess): Group 1: 7/35, Group 2: 16/34;

- Actual outcome: extra-pancreatic infections (pneumonia or UTI): Group 1: 4/35, Group 2: 6/34;

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 1 (withdrew)

- Actual outcome: systemic infections (central line infection): Group 1: 0/35, Group 2: 5/34

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 1 (withdrew)

Protocol outcome 3: Serious adverse events

- Actual outcome: single organ failure: Group 1: 4/35, Group 2: 10/34;

- Actual outcome: multiple organ failure: Group 1: 7/35, Group 2: 17/34;

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 1 (withdrew)

Protocol outcomes not reported by the study

Quality of life at <1 year; Weight loss/BMI at <1 year; Achieving nutrition (meeting nutritional requirements; at least 20-25 kcal/kg) at <1 year; Requiring total parenteral nutrition at <1 year

Study	Doley 2009 ³⁰²
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=50)
Countries and setting	Conducted in India; Setting: Hospital
Line of therapy	1st line
Duration of study	Intervention time: 14 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: acute pancreatitis was defined using the Atlanta criteria: clinical features, hyperamylasemia (three times the normal upper limit), and radiological evidence of severe acute pancreatitis (contrast enhanced CT (CECT) scan evidence of pancreatic necrosis and a computed tomography severity index (CTSI) equal to, or greater than, 7).
Stratum	Adults >16 years
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients admitted with severe acute pancreatitis
Exclusion criteria	Acute or chronic pancreatitis, patients who had undergone intervention prior to admission, patients requiring inotropic support at inclusion, or complications requiring surgical intervention at the time of inclusion
Recruitment/selection of patients	Consecutive
Age, gender and ethnicity	Age - Mean (SD): Enteral: 38.4 (13.8); parenteral: 41.1 (11.3). Range 17-70 years. Gender (M:F): Not stated. Ethnicity: Not stated
Further population details	1. Patients in critical care: Not stated / Unclear
Indirectness of population	No indirectness
Interventions	(n=25) Intervention 1: Enteral feeding - Jejunal or duodenal. Placement of the enteral tube was done endoscopically and a 16F single lumen 125 cm long red rubber feeding tube was placed over a 400 cm long stainless steel guidewire beyond the ligament of Treitz using fluoroscopic control. Seven of 25 patients required a second attempt at placement of the tube in the desired position. A test feed with 500 ml of normal saline was administered over a period of 4-5 hours and jejunostomy feed was started subsequently. Jejunal feeding was started at low flow rates - an initial rate of 20–30 ml/hour until achievement of the full regime of EN. Minor complications such as diarrhoea and distension were managed by altering the infusion rate and adding an antimotility agent. Duration 14 days. Concurrent medication/care: All patients were managed routinely by gastrointestinal decompression, prophylactic antibiotics (ciprofloxacin/metronidazole or imipenem/cilastatin),

	<p>intravenous fluids and organ system support. Nutritional support was initiated within 72 hours of admission and was continued for a minimum of 14 days. The need for further continuation of nutritional support was decided on the basis of the patients' clinical status. Image-guided fine needle aspiration or percutaneous drainage of pancreatic or peripancreatic collection as a temporizing measure was resorted to in patients who continued to be toxic. Indirectness: No indirectness Comments: The targeted caloric and protein requirements were 2,500-2,700 kcal/day, and 120-130 g/day of protein.</p> <p>(n=25) Intervention 2: Parenteral feeding - Parenteral alone. A 16G central venous catheter was inserted through the subclavian or internal jugular vein. A chest X-ray was taken after insertion to check the catheter tip position and also to check for complications of central venous line placement. Commercially available parenteral nutrition formula (PNA: parenteral nutrition admixture) was administered. The target caloric and protein requirements were similar to the enteral group. Glycaemic control and metabolic parameters were monitored. All patients in the parenteral group could be weaned to oral diet (those managed conservatively) and feeding through a jejunostomy catheter placed intraoperatively (those operated on). Duration 14 days. Concurrent medication/care: All patients were managed routinely by gastrointestinal decompression, prophylactic antibiotics (ciprofloxacin/metronidazole or imipenem/cilastatin), intravenous fluids and organ system support. Nutritional support was initiated within 72 hours of admission and was continued for a minimum of 14 days. The need for further continuation of nutritional support was decided on the basis of the patients' clinical status. Image-guided fine needle aspiration or percutaneous drainage of pancreatic or peripancreatic collection as a temporizing measure was resorted to in patients who continued to be toxic. Indirectness: No indirectness Comments: The targeted caloric and protein requirements were 2,500-2,700 kcal/day, and 120-130 g/day of protein.</p>
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: JEJUNAL versus PARENTERAL ALONE

Protocol outcome 1: Mortality at <1 year

- Actual outcome: Mortality at 14 days; Group 1: 5/25, Group 2: 4/16; Comments: In the EN group, all 5 deaths occurred due to sepsis and multiorgan failure; 4 out of 5 deaths occurred in the post-operative period. In the TPN group, all 4 deaths occurred in the post-operative phase: 3 due to sepsis and multiorgan failure and one due to operative haemorrhage

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 2: Length of critical care or hospital stay at <1 year

- Actual outcome: Length of critical care stay at 14 days; ;

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:
 - Actual outcome: Length of hospital stay at 14 days; ;
 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 3: Infections at <1 year

- Actual outcome: Infection at 14 days; Group 1: 16/25, Group 2: 15/25
 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 4: Adverse events (for example, tube displacements, aspirational pneumonia, ischaemic gut and central line infections) at <1 year

- Actual outcome: Locoregional complications at 14 days; Group 1: 13/25, Group 2: 10/25
 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:
 - Actual outcome: Surgical intervention at 14 days; Group 1: 14/25, Group 2: 15/25
 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcomes not reported by the study	Quality of life at <1 year; Achieving nutrition (meeting nutritional requirements; at least 20-25 kcal/kg) at <1 year; Requiring total parenteral nutrition at <1 year; Serious adverse events at <1 year; Weight loss/BMI at <1 year
---	--

Study	Eatock 2005 ³²⁹
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=50)
Countries and setting	Conducted in United Kingdom; Setting: Glasgow Royal Infirmary
Line of therapy	1st line
Duration of study	Intervention + follow-up: Duration of hospitalisation
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Adults >16 years
Subgroup analysis within study	Not applicable
Inclusion criteria	Predicted severe acute pancreatitis; abdominal pain, amylase ≥ 3 -times ULN, onset of abdominal pain within 48h, APACHE II score ≥ 8 and/or CRP ≥ 150 mg/litre, and/or peripancreatic liquid shown on CT.
Exclusion criteria	AP due to surgery, IBD, stoma, short bowel, chronic pancreatitis with exacerbation.
Recruitment/selection of patients	Consecutive
Age, gender and ethnicity	Age - Median (IQR): NG: 63 (47-74); NJ: 58 (48-64). Gender (M:F): 53/47%. Ethnicity: Not stated
Further population details	1. Patients in critical care: Mixed (26% of NG and 36% of NJ group were admitted to CCU).
Extra comments	Feeding was started on average 72 hours from onset of pain
Indirectness of population	No indirectness
Interventions	<p>(n=27) Intervention 1: Enteral feeding - Gastric. Nasogastric tubes placed on the ward with position checked by aspiration and pH check or chest X-ray. Feeds were commenced at a full strength and rate of 30 ml/hour increasing to 100 ml/hour over 24–48 hours. The caloric target was 2000 kcal/day. Low fat semi-elemental feed was used (Pepti 2000 LF), which contains 1 kcal/ml and 40 g protein/litre (5.9 g nitrogen/litre). Carbohydrate provides 75% of energy, protein 16% and fat 9%. Duration Unclear. Concurrent medication/care: Unclear. Indirectness: No indirectness</p> <p>(n=22) Intervention 2: Enteral feeding - Jejunal or duodenal. Nasojejunal tubes placed under endoscopic guidance to the proximal jejunum. Feeds were commenced at a full strength and rate of 30 ml/hour increasing to 100 ml/hour over 24–48 hours. The caloric target was 2.000 kcal/day.</p>

	Low fat semi-elemental feed was used (Pepti 2000 LF), which contains 1 kcal/ml and 40 g protein/litre (5.9 g nitrogen/litre). Carbohydrate provides 75% of energy, protein 16% and fat 9%. Duration Unclear. Concurrent medication/care: Unclear. Indirectness: No indirectness
Funding	Funding not stated
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: GASTRIC versus JEJUNAL (PROXIMAL)</p> <p>Protocol outcome 1: Mortality at <1 year - Actual outcome for Adults >16 years: Mortality at During hospital stay; Group 1: 5/27, Group 2: 7/22; Comments: Mostly due to multiorgan failure. Only 2 of the deaths occurred within the first week of illness. Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: Numbers not equal; Group 1 Number missing: 0; Group 2 Number missing: 3, Reason: 1 Misdiagnosis excluded; 2 switched to NG because tube could not be passed into the jejunum</p> <p>Protocol outcome 2: Length of critical care or hospital stay at <1 year - Actual outcome for Adults >16 years: Length of hospital stay at During hospital stay ; Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: Numbers not equal; Group 1 Number missing: 0; Group 2 Number missing: 3, Reason: 1 Misdiagnosis excluded; 2 switched to NG because tube could not be passed into the jejunum</p> <p>Protocol outcome 3: Achieving nutrition (meeting nutritional requirements; at least 20-25 kcal/kg) at <1 year - Actual outcome for Adults >16 years: Tolerating administration of at least 75% of target at Within 48h of feed commencement; Group 1: 19/27, Group 2: 17/22 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: Numbers not equal; Group 1 Number missing: 0; Group 2 Number missing: 3, Reason: 1 Misdiagnosis excluded; 2 switched to NG because tube could not be passed into the jejunum - Actual outcome for Adults >16 years: Tolerating administration of at least 75% of target at Within 60h of feed commencement; Group 1: 21/27, Group 2: 17/22 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: Numbers not equal; Group 1 Number missing: 0; Group 2 Number missing: 3, Reason: 1 Misdiagnosis excluded; 2 switched to NG because tube could not be passed into the jejunum</p> <p>Protocol outcome 4: Requiring total parenteral nutrition at <1 year - Actual outcome for Adults >16 years: Converted to IV feeding at Unclear; Group 1: 0/27, Group 2: 1/22; Comments: Duodenal obstruction Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: Numbers not equal; Group 1 Number missing: 0; Group 2 Number missing: 3, Reason: 1 Misdiagnosis</p>	

excluded; 2 switched to NG because tube could not be passed into the jejunum

Protocol outcome 5: Adverse events (for example, tube displacements, aspirational pneumonia, ischaemic gut and central line infections) at <1 year

- Actual outcome for Adults >16 years: Tube displacement at During hospital stay; Group 1: 1/27, Group 2: 1/22

Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Baseline details: Numbers not equal; Group 1 Number missing: 0; Group 2 Number missing: 3, Reason: 1 Misdiagnosis
excluded; 2 switched to NG because tube could not be passed into the jejunum

Protocol outcomes not reported by the study

Quality of life at <1 year; Infections at <1 year; Serious adverse events at <1 year; Weight loss/BMI at <1 year

Study	Eckerwall 2006 ³³²
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=50)
Countries and setting	Conducted in Sweden; Setting: Lund University Hospital
Line of therapy	1st line
Duration of study	Intervention + follow-up: 10 days observation and 3-month follow-up
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Adults >16 years
Subgroup analysis within study	Not applicable
Inclusion criteria	Predicted severe acute pancreatitis; abdominal pain, amylase ≥ 3 -times ULN, onset of abdominal pain within 48h, APACHE II score ≥ 8 and/or CRP ≥ 150 mg/litre, and/or peripancreatic liquid shown on CT
Exclusion criteria	AP due to surgery, IBD, stoma, short bowel, chronic pancreatitis with exacerbation.
Recruitment/selection of patients	Unclear
Age, gender and ethnicity	Age - Median (IQR): TPN: 68 (60-80); EN: 71 (58-80). Gender (M:F): 48/52%. Ethnicity: Not stated
Further population details	1. Patients in critical care: Mixed (12% were admitted to CCU).
Extra comments	Median (IQR) APACHE II score TPN: 9 (8-10); EN: 10 (8-13)
Indirectness of population	No indirectness
Interventions	<p>(n=26) Intervention 1: Parenteral feeding - Parenteral alone. TPN (Kabiven PI) infused via central or peripheral venous catheter. Energy target of 25 kcal/kg per day based on admission weight. Duration 10 days. Concurrent medication/care: Fluids, such as crystalloids or colloids, were added in both groups to fulfil the individual's needs of fluid and energy (in case of reduced rate). Oral feeding was reintroduced when amylase and CRP levels had decreased and abdominal pain had resolved. Regular hospital diet was introduced gradually, in general initially starting with liquid and then solid food. Patients were treated according to clinical routine including pain control, symptomatic and organ supportive treatment and, when indicated, restrictive indications for surgery. Broad-spectrum antibiotic therapy was used according to current recommendations. Indirectness: No indirectness Comments: To maintain isocaloric groups, the TPN group did not receive Kabiven on day 1</p> <p>(n=24) Intervention 2: Enteral feeding - Gastric. Early nasogastric enteral nutrition with 'Fresubin original' infused at an initial rate of 25 ml/hour and gradually increased up to 100 ml/hour as tolerated and as needed.</p>

	Duration 10 days. Concurrent medication/care: Fluids, such as crystalloids or colloids, were added in both groups to fulfil the individual's needs of fluid and energy (in case of reduced rate). Oral feeding was reintroduced when amylase and CRP levels had decreased and abdominal pain had resolved. Regular hospital diet was introduced gradually, in general initially starting with liquid and then solid food. Patients were treated according to clinical routine including pain control, symptomatic and organ supportive treatment and, when indicated, restrictive indications for surgery. Broad-spectrum antibiotic therapy was used according to current recommendations. Indirectness: No indirectness
Funding	Academic or government funding

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: PARENTERAL ALONE versus GASTRIC

Protocol outcome 1: Mortality at <1 year

- Actual outcome for Adults >16 years: Mortality at 3 months; Group 1: 0/25, Group 2: 1/23

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Baseline details: Note: fixed block size and no blinding means investigators will know what the last patient in a block will receive personnel recruiting the patients would know the assignments for the patients at the end of a 'block'. ; Group 1 Number missing: 1, Reason: Protocol violation; Group 2 Number missing: 1, Reason: Protocol violation

Protocol outcome 2: Length of critical care or hospital stay at <1 year

- Actual outcome for Adults >16 years: Length of hospital stay at 3 months;

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Baseline details: Note: fixed block size and no blinding means investigators will know what the last patient in a block will receive personnel recruiting the patients would know the assignments for the patients at the end of a 'block'. Group 1 Number missing: 1, Reason: Protocol violation; Group 2 Number missing: 1, Reason: Protocol violation

Protocol outcome 3: Achieving nutrition (meeting nutritional requirements; at least 20-25 kcal/kg) at <1 year

- Actual outcome for Adults >16 years: Achieving nutrition (25 kcal/kg/day) at 10 days; Group 1: 17/26, Group 2: 16/24

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Baseline details: Note: fixed block size and no blinding means investigators will know what the last patient in a block will receive personnel recruiting the patients would know the assignments for the patients at the end of a 'block'. ; Group 1 Number missing: 1, Reason: Protocol violation; Group 2 Number missing: 1, Reason: Protocol violation

Protocol outcome 4: Infections at <1 year

- Actual outcome for Adults >16 years: Sepsis or infected pancreatic necrosis at 3 months; Group 1: 0/25, Group 2: 3/23

<p>Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: Note: fixed block size and no blinding means investigators will know what the last patient in a block will receive personnel recruiting the patients would know the assignments for the patients at the end of a 'block'. ; Group 1 Number missing: 1, Reason: Protocol violation; Group 2 Number missing: 1, Reason: Protocol violation</p> <p>Protocol outcome 5: Adverse events (for example, tube displacements, aspirational pneumonia, ischaemic gut and central line infections) at <1 year - Actual outcome for Adults >16 years: Surgical intervention at 3 months; Group 1: 1/26, Group 2: 1/24; Comments: Cholecystectomy and necrosectomy Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: Note: fixed block size and no blinding means investigators will know what the last patient in a block will receive personnel recruiting the patients would know the assignments for the patients at the end of a 'block'. ; Group 1 Number missing: 1, Reason: Protocol violation; Group 2 Number missing: 1, Reason: Protocol violation</p> <p>Protocol outcome 6: Serious adverse events at <1 year - Actual outcome for Adults >16 years: Multiple organ failure at 3 months; Group 1: 1/25, Group 2: 1/23 Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: Note: fixed block size and no blinding means investigators will know what the last patient in a block will receive personnel recruiting the patients would know the assignments for the patients at the end of a 'block'. ; Group 1 Number missing: 1, Reason: Protocol violation; Group 2 Number missing: 1, Reason: Protocol violation</p>	
Protocol outcomes not reported by the study	Quality of life at <1 year; Requiring total parenteral nutrition at <1 year; Weight loss/BMI at <1 year

Study	Kumar 2006⁶²¹
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=31)
Countries and setting	Conducted in India; Setting: Gastroenterology ward
Line of therapy	1st line
Duration of study	Intervention + follow-up: 7 day intervention plus follow-up to death, surgery or hospital discharge
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Adults >16 years
Subgroup analysis within study	Not applicable

Inclusion criteria	Severe acute pancreatitis; defined according to Atlanta criteria
Exclusion criteria	Delay of >4 weeks between onset of symptoms and presentation; already taking oral feeding; acute exacerbation of chronic pancreatitis; in shock (sBP <90mmHg)
Recruitment/selection of patients	Consecutive
Age, gender and ethnicity	Age - Mean (SD): NJ: 33.57 (12.53); NG: 43.25 (12.76). Gender (M:F): 25/5. Ethnicity:
Further population details	1. Patients in critical care: Not in critical care
Extra comments	Mean days from onset to admission to study hospital: NJ: 5.7; NG: 7.8 Mean APACHE II score: NJ: 9.64; NG: 10.50 87% had single or multiple organ failure at baseline
Indirectness of population	No indirectness
Interventions	(n=16) Intervention 1: Enteral feeding - Gastric. Tubes were placed under endoscopic guidance by the nasal route into the stomach. 'Re-feeding' started 48h after admission and used Paptamen, a semi-elemental formula through an enteral tube. Given as a slow infusion rate of 1-1.5 ml/min. Duration 7 days. Concurrent medication/care: Not stated Comments: After 7 days oral feeding was instituted (n=14) Intervention 2: Enteral feeding - Jejunal or duodenal. Tubes were placed under endoscopic guidance by the nasal route into the third part of the duodenum. 'Re-feeding' started 48h after admission and used Paptamen, a semi-elemental formula through an enteral tube. Given as a slow infusion rate of 1-1.5 ml/min and with an increase in caloric intake from 250 kcal to 1800 kcal over 7 days. Duration 7 days. Concurrent medication/care: Not stated. Indirectness: No indirectness Comments: After 7 days oral feeding was instituted
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: JEJUNAL OR DUODENAL (D3) versus GASTRIC

Protocol outcome 1: Mortality at <1 year

- Actual outcome for Adults >16 years: Mortality at Unclear; Group 1: 4/14, Group 2: 5/16

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 2: Length of critical care or hospital stay at <1 year

- Actual outcome for Adults >16 years: Length of hospital stay at 7 days; Group 1: mean 29.93 days (SD 25.54); n=14, Group 2: mean 24.06 days (SD 14.35); n=16

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 3: Achieving nutrition (meeting nutritional requirements; at least 20-25 kcal/kg) at <1 year

- Actual outcome for Adults >16 years: Partial parenteral nutrition at 7 days; Group 1: 4/14, Group 2: 6/16

Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 4: Infections at <1 year

- Actual outcome for Adults >16 years: Infection (blood or bile culture, tracheal or pancreatic aspirate) at 7 days; Group 1: 6/14, Group 2: 7/16

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 5: Adverse events (for example, tube displacements, aspirational pneumonia, ischaemic gut and central line infections) at <1 year

- Actual outcome for Adults >16 years: Tube displacement at 7 days; Group 1: 1/14, Group 2: 1/16

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

- Actual outcome for Adults >16 years: Surgical intervention at Unclear; Group 1: 2/14, Group 2: 1/16

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 6: Serious adverse events at <1 year

- Actual outcome for Adults >16 years: Serious complications requiring tube withdrawal at 7 days; Group 1: 0/14, Group 2: 0/16

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcomes not reported by the study	Quality of life at <1 year; Requiring total parenteral nutrition at <1 year; Weight loss/BMI at <1 year
---	---

Study (subsidiary papers)	PYTHON trial: Bakker 2014⁷¹ (Bakker 2011⁷³)
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=205)
Countries and setting	Conducted in Netherlands; Setting: 20 hospitals (Dutch Pancreatitis Study Group)

Line of therapy	1st line
Duration of study	Intervention plus 6 months follow-up
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Adults >16 years
Subgroup analysis within study	Not applicable
Inclusion criteria	<p>Diagnosis of acute pancreatitis if at least 2 of the 3 following features are present: 1) upper abdominal pain, 2) serum lipase or amylase levels above 3 times the upper level of normal and 3) characteristic findings of acute pancreatitis on cross-sectional abdominal imaging. Age \geq 18 years and written informed consent</p> <p>Predicted severe pancreatitis within 24 hours after admission defined as one or more of the following:</p> <p>APACHE-II score \geq 8 Imrie-score \geq 3 CRP level >150 mg/litre</p>
Exclusion criteria	<p>History of acute or chronic pancreatitis</p> <p>Identification of patients >24 hours after admission</p> <p>Onset of symptoms >96 hours (4 days) before admission</p> <p>Acute pancreatitis due to malignancy or post-ERCP pancreatitis</p> <p>Diagnosis of acute pancreatitis confirmed during laparotomy for acute abdomen</p> <p>Artificial nutrition at admission (EN or PN)</p> <p>Pregnancy</p>
Recruitment/selection of patients	Consecutive
Age, gender and ethnicity	Age - Mean (SD): 65 (15) years. Gender (M:F): 56/44%. Ethnicity: Not stated
Further population details	1. Patients in critical care: Mixed (19% had CCU admission after randomisation).
Extra comments	. Patients were stratified according to APACHE-II <13 or \geq 13 prior to randomisation
Indirectness of population	No indirectness
Interventions	<p>(n=104) Intervention 1: Enteral feeding - Jejunal or duodenal. A nasojejunal feeding tube was placed with the tip of the tube is beyond Treitz' ligament. If placed endoscopically, an abdominal X-ray is performed to check the tube's position and in case of radiological placement, fluoroscopy is used. After tube placement, EN started immediately using a very strict volume regimen: 20 ml/hour in the first 24 hours, 45 ml/hour, between 24–48 hour, 65 ml/hour, between 48–72 hours and, at 72 hours and thereafter: full nutrition, defined as an energy target of 25 kcal/kg/day (CCU patients) and 30 kcal/kg/day (non CCU patients). Nasoenteric feeding was administered as Nutrison Protein Plus. Per 100 ml this provided 125 kcal, 6.3 g protein, 4.9 g fat and 14.2 g carbohydrate. Standard amounts of minerals, vitamins and trace</p>

elements were included.

For both study groups, full nutrition was defined as an energy target of 25 kcal/kg/day for patients in the intensive care unit and 30 kcal/kg/day for patients in the ward.

At 3 and 7 days after admission a dietitian assessed nutritional status and nutritional requirements and made adjustments accordingly.

Duration Follow-up 3- and 6-months after discharge. Concurrent medication/care: All patients had contrast enhanced CT within 5-7 days after admission. Intravenous antibiotics were administered based on culture results and not as prophylaxis in case of necrotizing pancreatitis without documented infection. Invasive intervention for (suspected) infected necrosis was preferably postponed until the fluid collections are walled-off and demarcated on CT-scan. ERCP was performed in case of suspected cholangitis or in case of biliary pancreatitis with clinically important persistent cholestasis. . Indirectness: No indirectness

Comments: At 72 hours after the start of enteral feeding, the nutritional status will be evaluated and in case of intolerance, the type of EN will be changed accordingly (for example, additional proteins, calories, fibre). If feeding is not tolerated EN is reduced to 50% and stepwise rebuilt gradually until tolerated. If, after two of such attempts, full nutrition cannot be attained, PN will be started to reach the required energy target. Oral normal feeding is started, when abdominal pain has resolved and organ failure has subsided. In case of full tolerance of oral food nasojejunal feeding is gradually decreased. If pain relapses, EN is restarted. In case of nausea or vomiting, lowered consciousness (Glasgow Coma Score [GCS] 14 or lower in a non-intubated patient), or gastric residual volume (GRV) >250 ml/6 hours, the position of the feeding tube is checked.

In case of CCU admission, irrespective of time from admission, the patient is fed according to the attending intensivist's preference (nasogastric or nasojejunal; enteral or parenteral). These patients are analysed according to the treatment assigned.

(n=104) Intervention 2: Oral feeding. 'Nil by mouth' without any artificial nutrition during the first 72 hours after admission. If patients spontaneously request for oral food within these 72 hours, liquid and solid food are offered as requested and tolerated. If, at 72 hours after admission, patients develop organ failure, they will receive nasojejunal feeding with the same regimen as the intervention group. If, at 72 hours, there is no organ failure, patients are offered oral food ad libitum. If oral food is not tolerated, there is a re-challenge the next morning and if still not tolerated, EN is started through a nasojejunal feeding tube. Duration Follow-up 3- and 6-months after discharge. Concurrent medication/care: All patients had contrast enhanced CT within 5-7 days after admission. Intravenous antibiotics were administered based on culture results and not as prophylaxis in case of necrotizing pancreatitis without documented infection. Invasive intervention for (suspected) infected necrosis was preferably postponed until the fluid collections are walled-off and demarcated on CT-scan. ERCP was performed in case of suspected cholangitis or in case of biliary

	pancreatitis with clinically important persistent cholestasis. Indirectness: No indirectness Comments: 31% needed a nasoenteric feeding tube. 5% requested and received food within the first 72 h after presentation
--	--

Funding	Academic or government funding
---------	--------------------------------

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: JEJUNAL (EARLY) versus ORAL FEEDING

Protocol outcome 1: Mortality at <1 year

- Actual outcome for Adults >16 years: Mortality at 6 months; Group 1: 11/101, Group 2: 7/104

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Baseline details: Mean BMI 29 in early group and 27 in the on-demand group; Group 1 Number missing: 3, Reason: Incorrect diagnosis; Group 2 Number missing: 0

Protocol outcome 2: Length of critical care or hospital stay at <1 year

- Actual outcome for Adults >16 years: critical care admission at 6 months; Group 1: 18/101, Group 2: 20/103

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Baseline details: Mean BMI 29 in early group and 27 in the on-demand group; Group 1 Number missing: 3, Reason: Incorrect diagnosis; Group 2 Number missing: 0

Protocol outcome 3: Achieving nutrition (meeting nutritional requirements; at least 20-25 kcal/kg) at <1 year

- Actual outcome for Adults >16 years: Days from admission to full tolerance of oral diet at 6 months; ;

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Baseline details: Mean BMI 29 in early group and 27 in the on-demand group; Group 1 Number missing: 3, Reason: Incorrect diagnosis; Group 2 Number missing: 0

Protocol outcome 4: Requiring total parenteral nutrition at <1 year

- Actual outcome for Adults >16 years: Requiring parenteral nutrition at 6 months; Group 1: 5/101, Group 2: 10/103

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Baseline details: Mean BMI 29 in early group and 27 in the on-demand group; Group 1 Number missing: 3, Reason: Incorrect diagnosis; Group 2 Number missing: 0

Protocol outcome 5: Infections at <1 year

- Actual outcome for Adults >16 years: Infection at 6 months; Group 1: 25/101, Group 2: 27/104; Comments: Included infected pancreatic necrosis (9 versus 15); bacteraemia (17 versus 18); and pneumonia (12 versus 13)

<p>Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: Mean BMI 29 in early group and 27 in the on-demand group; Group 1 Number missing: 3, Reason: Incorrect diagnosis; Group 2 Number missing: 0</p> <p>Protocol outcome 6: Adverse events (for example, tube displacements, aspirational pneumonia, ischaemic gut and central line infections) at <1 year - Actual outcome for Adults >16 years: Nasoenteric tube displacement at 6 months; Group 1: 38/99, Group 2: 14/32; Comments: 2 patients in the early group declined tube insertion</p> <p>Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: Mean BMI 29 in early group and 27 in the on-demand group; Group 1 Number missing: 3, Reason: Incorrect diagnosis; Group 2 Number missing: 0 - Actual outcome for Adults >16 years: Ileus at 6 months; Group 1: 10/101, Group 2: 10/103</p> <p>Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: Mean BMI 29 in early group and 27 in the on-demand group; Group 1 Number missing: 3, Reason: Incorrect diagnosis; Group 2 Number missing: 0 - Actual outcome for Adults >16 years: Necrotising pancreatitis at 6 months; Group 1: 64/104, Group 2: 65/104</p> <p>Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: Mean BMI 29 in early group and 27 in the on-demand group; Group 1 Number missing: 3, Reason: Incorrect diagnosis; Group 2 Number missing: 0</p> <p>Protocol outcome 7: Serious adverse events at <1 year - Actual outcome for Adults >16 years: Multiple organ failure (among subset without organ failure at baseline) at 6 months; Group 1: 7/67, Group 2: 6/73</p> <p>Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: Mean BMI 29 in early group and 27 in the on-demand group; Group 1 Number missing: 3, Reason: Incorrect diagnosis; Group 2 Number missing: 0 - Actual outcome for Adults >16 years: Single organ failure (among subset without organ failure at baseline) at 6 months; Group 1: 26/67, Group 2: 31/73</p> <p>Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: Mean BMI 29 in early group and 27 in the on-demand group; Group 1 Number missing: 3, Reason: Incorrect diagnosis; Group 2 Number missing: 0</p>	
Protocol outcomes not reported by the study	Quality of life at <1 year; Weight loss/BMI at <1 year

Study	Singh 2012⁹⁹⁷
Study type	RCT (Patient randomised; Parallel)

Number of studies (number of participants)	1 (n=78)
Countries and setting	Conducted in India; Setting: Tertiary care academic centre (CCU initially)
Line of therapy	1st line
Duration of study	Not clear:
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Adults >16 years
Subgroup analysis within study	Not applicable
Inclusion criteria	<p>Patients with SAP admitted within 7 days of onset of pain AP diagnosis was based on clinical features, raised (>3 times the reference) amylase levels, and evidence of AP on imaging studies</p> <p>Severe AP was defined by at least 1 of the following criteria: (i) Presence of 1 or more organ failure as defined by the Atlanta classification. (ii) An APACHE II score of 8 or higher. (iii) CT severity index greater than 7.</p>
Exclusion criteria	Patient already on oral feeds at the time of presentation; patients in shock (that is, systolic blood pressure <90 mmHg at the time of randomisation); not willing to give consent to participate in the study.
Recruitment/selection of patients	Consecutive
Age, gender and ethnicity	Age - Mean (SD): NG: 39.1 (16.70); NJ: 39.7 (12.3). Gender (M:F): 68/32%. Ethnicity: Not stated
Further population details	1. Patients in critical care: In critical care (All in CCU initially).
Extra comments	Median (range) APACHE II score: NG 8.5 (2-19); NJ 8 (2-24)
Indirectness of population	No indirectness
Interventions	(n=39) Intervention 1: Enteral feeding - Gastric. Nasogastric tube placed in the ward with the position being confirmed at the bedside by air test and aspirating gastric contents. 'Refeeding' was attempted in all included patients 48 hours after admission. Novasource, a commercially available semielemental enteral formula, was used to reach the nutrient goal (25 kcal/kg per day) in 3 to 4 days. The composition of feed was similar in both groups and was aimed to be of equal energy value in both groups. If the elemental feed was tolerated well, with no postfeeding pain, distension, and vomiting for 7 days, it was switched to a polymeric feed and then from oral soft to solid hospital diet reintroduced gradually. Duration Unclear; minimum 7 days; tube removed once oral feeds were taken. Concurrent medication/care: All patients were treated in an intensive care unit initially with nil by mouth, analgesics, aggressive fluid resuscitation, and supportive

treatment. Antibiotics were prescribed if patients had infected pancreatic necrosis or if there was documented infection at the extrapancreatic sites. The antibiotics chosen were according to the culture and sensitivity report whenever available. In all patients with severe pancreatitis, enteral feeding was started early, unless the patient had persistent ileus or active gastrointestinal bleeding. In patients with organ failure, all possible organ support systems were used including ventilator support, vasopressors, and dialysis as and when required. Patients with biliary obstruction or cholangitis underwent an endoscopic retrograde cholangiography. All patients with infected pancreatic necrosis were treated initially with antibiotics, early EN, organ support, and percutaneous catheter drainage. Patients who did not improve despite maximal supportive management underwent open necrosectomy with lavage usually 4 weeks after the onset of pancreatitis. Indirectness: No indirectness

(n=39) Intervention 2: Enteral feeding - Jejunal or duodenal. Nasojejunal tube placed under endoscopic guidance. A commercially available single-port tube, 200 cm long was placed in the jejunum beyond the ligament of Trietz and confirmed radiologically.

'Refeeding' was attempted in all included patients 48 hours after admission. Novasource, a commercially available semielemental enteral formula, was used to reach the nutrient goal (25 kcal/kg per day) in 3 to 4 days. The composition of feed was similar in both groups and was aimed to be of equal energy value in both groups. If the elemental feed was tolerated well, with no postfeeding pain, distension, and vomiting for 7 days, it was switched to a polymeric feed and then from oral soft to solid hospital diet reintroduced gradually. Duration Unclear; minimum 7 days; tube removed once oral feeds were taken. Concurrent medication/care: All patients were treated in an intensive care unit initially with nil by mouth, analgesics, aggressive fluid resuscitation, and supportive treatment. Antibiotics were prescribed if patients had infected pancreatic necrosis or if there was documented infection at the extrapancreatic sites. The antibiotics chosen were according to the culture and sensitivity report whenever available. In all patients with severe pancreatitis, enteral feeding was started early, unless the patient had persistent ileus or active gastrointestinal bleeding. In patients with organ failure, all possible organ support systems were used including ventilator support, vasopressors, and dialysis as and when required. Patients with biliary obstruction or cholangitis underwent an endoscopic retrograde cholangiography. All patients with infected pancreatic necrosis were treated initially with antibiotics, early EN, organ support, and percutaneous catheter drainage. Patients who did not improve despite maximal supportive management underwent open necrosectomy with lavage usually 4 weeks after the onset of pancreatitis. Indirectness: No indirectness

Funding Academic or government funding

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: GASTRIC versus JEJUNAL

Protocol outcome 1: Mortality at <1 year
- Actual outcome for Adults >16 years: Mortality at Unclear; Group 1: 4/39, Group 2: 7/39

<p>Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 2, Reason: Inadvertent removal of NJ tube and refused re-insertion</p> <p>Protocol outcome 2: Length of critical care or hospital stay at <1 year - Actual outcome for Adults >16 years: Length of hospital stay at unclear; ; Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 2, Reason: Inadvertent removal of NJ tube and refused re-insertion</p> <p>Protocol outcome 3: Achieving nutrition (meeting nutritional requirements; at least 20-25 kcal/kg) at <1 year - Actual outcome for Adults >16 years: Achieving goal nutrient requirements at within 3 days; Group 1: 39/39, Group 2: 39/39 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 2, Reason: Inadvertent removal of NJ tube and refused re-insertion</p> <p>Protocol outcome 4: Infections at <1 year - Actual outcome for Adults >16 years: Infection: any positive culture (blood or bile culture; tracheal or pancreatic aspirate) at Unclear; Group 1: 9/39, Group 2: 14/39 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 2, Reason: Inadvertent removal of NJ tube and refused re-insertion</p> <p>Protocol outcome 5: Adverse events (for example, tube displacements, aspirational pneumonia, ischaemic gut and central line infections) at <1 year - Actual outcome for Adults >16 years: Surgical intervention at Unclear; Group 1: 4/39, Group 2: 2/39 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 2, Reason: Inadvertent removal of NJ tube and refused re-insertion</p>	
Protocol outcomes not reported by the study	Quality of life at <1 year; Requiring total parenteral nutrition at <1 year; Serious adverse events at <1 year; Weight loss/BMI at <1 year

Study	Wu 2010¹¹⁶¹
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=107)
Countries and setting	Conducted in China; Setting: CCU
Line of therapy	1st line
Duration of study	Not clear:

Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Mean APACHE II score for TPN 16 (4.4); TEN 14 (2.1)
Stratum	Adults >16 years
Subgroup analysis within study	Not applicable
Inclusion criteria	Severe acute pancreatitis with pancreatic necrosis (determined by dynamic spiral CT and confirmed by CRP >19.5mg/dl, 48h after onset of disease) and sufficient prophylactic antibiotics with concomitant parenteral or enteral nutrition within the first 7 days of hospitalisation.
Exclusion criteria	Not stated
Recruitment/selection of patients	Consecutive
Age, gender and ethnicity	Age - Mean (SD): TPN: 54 (11.2); TEN: 52 (12.1). Gender (M:F): 58/42%. Ethnicity: Not stated
Further population details	1. Patients in critical care: In critical care
Indirectness of population	No indirectness
Interventions	<p>(n=53) Intervention 1: Enteral feeding - Jejunal or duodenal. Total enteral nutrition. An 8F or 12F nasojejunal-gastric feeding tube was placed by endoscopy, which confirmed the feeding port position to be distal to the ligament of Treitz. (NJ) Enteral feeding with an elemental formula TEN, peptide enteral nutritional formulae was given at 20 ml/hour for 20 hours with feeding rates that provided 1.5 g of protein per kilogram per day and 105 to 126 kJ of energy intake per kilogram per day. The feeding was gradually increased in volume according to patient's condition</p> <p>Duration Not stated. Concurrent medication/care: Prophylactic antibiotics (IV metronidazol/ciprofloxacin). Indirectness: No indirectness</p> <p>(n=54) Intervention 2: Parenteral feeding - Parenteral alone. Total parenteral nutrition solution, containing nitrogen, glucose, calcium, magnesium, potassium, trace elements, and multiple vitamins in a volume of 2000 ml, was continuously infused within 24 hours, along with 250 ml of 20% introlipid, with infusion rates that provided 1.2 g of protein per kilogram per day and 105 to 126 kJ of energy intake per kilogram per day. Total parenteral nutrition was infused by single lumen polyurethane catheters through the anterior chests.</p> <p>Duration Not stated. Concurrent medication/care: Prophylactic antibiotics (IV metronidazol/ciprofloxacin). Indirectness: No indirectness</p>
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: PARENTERAL ALONE versus JEJUNAL

<p>Protocol outcome 1: Mortality at <1 year - Actual outcome for Adults >16 years: Mortality at Unclear; Group 1: 23/54, Group 2: 6/53; Comments: TPN group: 70% of deaths were due to septic shock; TEN group: 4 aspiration pneumonia; 2 multiple organ failure Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p>	
<p>Protocol outcome 2: Adverse events (for example, tube displacements, aspirational pneumonia, ischaemic gut and central line infections) at <1 year - Actual outcome for Adults >16 years: Surgical intervention at Unclear; Group 1: 43/54, Group 2: 12/53 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing: - Actual outcome for Adults >16 years: Infected pancreatic necrosis at Unclear; Group 1: 39/54, Group 2: 12/53 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p>	
<p>Protocol outcome 3: Serious adverse events at <1 year - Actual outcome for Adults >16 years: Single organ failure at Unclear; Group 1: 9/54, Group 2: 3/53 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing: - Actual outcome for Adults >16 years: Multiple organ failure at Unclear; Group 1: 35/54, Group 2: 8/53 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p>	
Protocol outcomes not reported by the study	Quality of life at <1 year; Length of critical care or hospital stay at <1 year; Achieving nutrition (meeting nutritional requirements; at least 20-25 kcal/kg) at <1 year; Requiring total parenteral nutrition at <1 year; Infections at <1 year; Weight loss/BMI at <1 year

Study	Zhao 2015¹¹⁸⁹
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=146)
Countries and setting	Conducted in China; Setting: National research centre for pancreatic disease
Line of therapy	1st line

Duration of study	Not clear:
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: The diagnosis and severity of AP were established according to the 2012 revision of the Atlanta classification
Stratum	Adults >16 years
Subgroup analysis within study	Not applicable
Inclusion criteria	Acute abdominal pain accompanied by elevated serum amylase and/or lipase levels (>3-fold above the upper reference limit) and unequivocal evidence of AP on ultrasound and CT.
Exclusion criteria	<ol style="list-style-type: none"> 1. Age <18 y or >70 y; 2. Abdominal pain lasting >72 h before admission; 3. Mild AP; 4. Pregnant or breastfeeding; 5. Pancreatic neoplasm, ERCP, or trauma aetiology; 6. The possibility of poor oral intake or prolonged hospitalisation for reasons other than pancreatitis, such as gastroparesis or surgical intervention; 7. Admission to the intensive care unit for intubation; and 8. Surgical intervention for infected pancreatic necrosis or pancreatic haemorrhage
Recruitment/selection of patients	Consecutive
Age, gender and ethnicity	Age - Median (range): Early group: 51 (24-72); Conventional group: 48 (21-74). Gender (M:F): 62/38%. Ethnicity: Not reported
Further population details	1. Patients in critical care: Not stated / Unclear
Extra comments	Mean Ranson score: Early - 3.4 (1.8); conventional - 3.9 (1.1) Moderate severity: Early - 67.2%; conventional - 78.9%
Indirectness of population	No indirectness
Interventions	(n=70) Intervention 1: Oral feeding - Early oral feeding. Recommended oral feeding once they felt hungry regardless of laboratory parameters. The diet was gradually progressed from clear liquid to a low-fat solid diet. Duration Unclear. Concurrent medication/care: All patients received conservative treatment according to their individual conditions, including limited PN if they were in malnutrition and EN was contraindicated or not feasible, prophylactic antibiotics if they were at risk for infection, glucose control (insulin or acarbose oral) if they were at risk for hyperglycaemia, treatment to maintain the homeostasis, appropriate fluid resuscitation therapy, and Traditional Chinese Medicine (TCM) formulation. PN was given after adequate fluid resuscitation and when the patient had achieved full hemodynamic stabilisation (usually 48–72 h after admission). Adequate protein delivery (1.2–2.0 g/kg

	<p>daily) and calories (15–30 kcal/kg daily) were given to patients according to their individual condition. The volume of PN was gradually reduced after oral ‘refeeding’ (usually 12–24 h after the first oral intake). Indirectness: No indirectness</p> <p>(n=76) Intervention 2: Oral feeding.</p> <p>Conventional oral ‘refeeding’ (recommenced oral feeding once their abdominal pain resolved and biochemical markers had normalised.)</p> <p>Duration Unclear. Concurrent medication/care: All patients received conservative treatment according to their individual conditions, including limited PN if they were in malnutrition and EN was contraindicated or not feasible, prophylactic antibiotics if they were at risk for infection, glucose control (insulin or acarbose oral) if they were at risk for hyperglycaemia, treatment to maintain the homeostasis, appropriate fluid resuscitation therapy, and Traditional Chinese Medicine (TCM) formulation. PN was given after adequate fluid resuscitation and when the patient had achieved full hemodynamic stabilisation (usually 48–72 h after admission). Adequate protein delivery (1.2–2.0 g/kg daily) and calories (15–30 kcal/kg daily) were given to patients according to their individual condition. The volume of PN was gradually reduced after oral feeding (usually 12–24 h after the first oral intake). Indirectness: No indirectness</p>
Funding	Academic or government funding

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: EARLY ORAL FEEDING versus CONVENTIONAL ORAL FEEDING

Protocol outcome 1: Length of critical care or hospital stay at <1 year

- Actual outcome for Adults >16 years: Length of hospital stay at Unclear; Group 1: mean 13.7 (SD 5.4); n=67, Group 2: mean 15.7 (SD 6.2); n=71

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 3, Reason: Refusal to follow prescribed feeding schedule; Group 2 Number missing: 5, Reason: Refusal to follow prescribed feeding schedule

Protocol outcome 2: Requiring total parenteral nutrition at <1 year

- Actual outcome for Adults >16 years: Parenteral nutrition at Unclear; Group 1: 65/67, Group 2: 69/71

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 3, Reason: Refusal to follow prescribed feeding schedule; Group 2 Number missing: 5, Reason: Refusal to follow prescribed feeding schedule

Protocol outcome 3: Adverse events (for example, tube displacements, aspirational pneumonia, ischaemic gut and central line infections) at <1 year

- Actual outcome for Adults >16 years: Abdominal pain relapse at Unclear; Group 1: 7/67, Group 2: 10/71

Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 3, Reason: Refusal to follow prescribed feeding schedule; Group 2 Number missing: 5, Reason: Refusal to follow prescribed feeding schedule	
Protocol outcomes not reported by the study	Quality of life at <1 year; Weight loss/BMI at <1 year; Achieving nutrition (meeting nutritional requirements; at least 20-25 kcal/kg) at <1 year; Infections at <1 year; Serious adverse events at <1 year; Mortality at <1 year

978-1-4731-3083-8

H.8.2 Observational studies

Study	Individual patient data meta-analysis of single-arm from RCTs trial: Bakker 2014⁷⁰
Study type	Systematic Review
Number of studies (number of participants)	8 (n=165 (95 with predicted severe AP))
Countries and setting	Conducted in Canada, Greece, Hungary, New Zealand, Spain, United Kingdom, USA; Setting: Systematic review: mixed
Line of therapy	1st line
Duration of study	Intervention + follow up: systematic review - mixed
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Adults >16 years
Subgroup analysis within study	Sys review – pre-specified in protocol: Predicted severe pancreatitis (defined as APACHE-II score ≥8, Imrie score ≥3, Ranson score ≥3, or CRP >150 mg/L)
Inclusion criteria	Randomised trials with early EN in one arm of the study in adults with acute pancreatitis. The following inclusion criteria were used: consecutive patients with acute pancreatitis, use of a validated classification system or generally accepted parameter to predict severity on admission, and initiation of EN according to a pre-specified protocol.
Exclusion criteria	Not stated

245

Recruitment/selection of patients	Consecutive within each trial
Age, gender and ethnicity	Age - Median (IQR): Early EN: 53 (42-66); delayed EN: 55 (45-70) years. Gender (M:F): 64/36%. Ethnicity: Not stated
Further population details	1. Patients in critical care: Systematic review: mixed
Extra comments	.
Indirectness of population	No indirectness
Interventions	(n=47) Intervention 1: Enteral feeding - Early gastric feeding. Enteral feeding within 24 hours of admission. Duration Systematic review: mixed. Concurrent medication/care: Systematic review: mixed. Indirectness: No indirectness (n=48) Intervention 2: Enteral feeding - Late enteral feeding. Enteral feeding 24 hours or more after admission. Duration Systematic review: mixed. Concurrent medication/care: Systematic review: mixed. Indirectness: No indirectness
Funding	Academic or government funding
Protocol outcomes not reported by the study	Quality of life at <1 year; Length of critical care or hospital stay at <1 year; Achieving nutrition (meeting nutritional requirements; at least 20-25 kcal/kg) at <1 year; Requiring total parenteral nutrition at <1 year; Adverse events (e.g. tube displacements, aspirational pneumonia, ischemic gut and central line infections) at <1 year; Weight loss/BMI at <1 year

Study	Propensity matched cohort trial: Jin 2017⁵³⁷
Study type	Non-randomised comparative study
Number of studies (number of participants)	1 (n=104)

Countries and setting	Conducted in China; Setting: Single hospital
Line of therapy	Unclear
Duration of study	Intervention + follow up: unclear
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Revised Atlanta classification
Stratum	Adults >16 years
Subgroup analysis within study	Not applicable
Inclusion criteria	Moderately severe or severe acute pancreatitis
Exclusion criteria	GI bleeding or GI obstruction; allergic to components of the EN fluid; malignant tumours; multiple onsets; unable to describe subjective symptoms; pregnancy
Recruitment/selection of patients	Prospective, consecutive sample
Age, gender and ethnicity	Age - Mean (SD): Early: 43.9 (15.9); late: 45.2 (13.5). Gender (M:F): 68/32%. Ethnicity: Not stated
Further population details	1. Patients in critical care: Mixed (54.3% in the early group and 48.1% in the late group were in CCU).
Extra comments	42% severe; 58% moderately severe. 100% had abdominal pain
Indirectness of population	No indirectness
Interventions	(n=35) Intervention 1: Enteral feeding - Early gastric feeding. Early (within 3 days of hospital admission) enteral feeding with a nasojejunal feeding tube placed under X ray guidance, with peptide formulation. Enteral nutrition was given continuously using an infusion pump at 20 ml/h in the first 24 h, 40 ml/h from 24 to 48 h, 60-80 ml/h between 48 and 72 h to reach 25 kcal/kg/d based on ideal weight at 72 h. PN was initiated if full nutrition could not be achieved using the enteral route after 3 attempts. Duration Unclear. Concurrent medication/care: Rehydration, correction of electrolyte disorders and organ function support

	(n=52) Intervention 2: Enteral feeding - Late enteral feeding. Late (starting after 3 days from hospital admission) enteral feeding with a nasojejunal feeding tube placed under X ray guidance, with peptide formulation. Enteral nutrition was given continuously using an infusion pump at 20 ml/h in the first 24 h, 40 ml/h from 24 to 48 h, 60-80 ml/h between 48 and 72 h to reach 25 kcal/kg/d based on ideal weight at 72 h. PN was initiated if full nutrition could not be achieved using the enteral route after 3 attempts. Duration Unclear. Concurrent medication/care: Rehydration, correction of electrolyte disorders and organ function support. Indirectness: No indirectness
Funding	Funding not stated
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: EARLY ENTERAL FEEDING versus LATE ENTERAL FEEDING</p> <p>Protocol outcome 1: Mortality at <1 year - Actual outcome for Adults >16 years: Mortality at unclear; Group 1: 0/35, Group 2: 1/52 Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Key confounders: matched for age, sex, aetiology, disease severity, abdominal pain, VAS of abdominal pain, abdominal distension, AGI grade and serum albumin level at admission; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 2: Length of critical care or hospital stay at <1 year - Actual outcome for Adults >16 years: Length of hospital stay at unclear; Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Key confounders: matched for age, sex, aetiology, disease severity, abdominal pain, VAS of abdominal pain, abdominal distension, AGI grade and serum albumin level at admission; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 3: Infections at <1 year - Actual outcome for Adults >16 years: Pancreatic infections at unclear; Group 1: 1/35, Group 2: 6/52 Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Key confounders: matched for age, sex, aetiology, disease severity, abdominal pain, VAS of abdominal pain, abdominal distension, AGI grade and serum albumin level at admission; Group 1 Number missing: ; Group 2 Number missing: - Actual outcome for Adults >16 years: Extra-pancreatic infections (systemic or localised) at unclear; Group 1: 2/35, Group 2: 15/52 Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Key confounders: matched for age, sex, aetiology, disease severity, abdominal pain, VAS of abdominal pain, abdominal distension, AGI grade and serum albumin level at admission; Group 1 Number missing: ; Group 2 Number missing: - Actual outcome for Adults >16 years: Multi-site infections at unclear; Group 1: 0/35, Group 2: 6/52</p>	

<p>Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Key confounders: matched for age, sex, aetiology, disease severity, abdominal pain, VAS of abdominal pain, abdominal distension, AGI grade and serum albumin level at admission; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 4: Adverse events (e.g. tube displacements, aspirational pneumonia, ischemic gut and central line infections) at <1 year - Actual outcome for Adults >16 years: Abnormal glucose metabolism at unclear; Group 1: 22/35, Group 2: 31/52 Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low; Indirectness of outcome: No indirectness ; Key confounders: matched for age, sex, aetiology, disease severity, abdominal pain, VAS of abdominal pain, abdominal distension, AGI grade and serum albumin level at admission; Group 1 Number missing: ; Group 2 Number missing: - Actual outcome for Adults >16 years: Surgical or percutaneous intervention at unclear; Group 1: 2/35, Group 2: 11/52; Comments: Early:1 percutaneous and 1 surgical; late: 8 percutaneous and 3 surgical Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Key confounders: matched for age, sex, aetiology, disease severity, abdominal pain, VAS of abdominal pain, abdominal distension, AGI grade and serum albumin level at admission; Group 1 Number missing: ; Group 2 Number missing: - Actual outcome for Adults >16 years: Non-infective pancreatic complications at unclear; Group 1: 31/35, Group 2: 50/52 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Key confounders: matched for age, sex, aetiology, disease severity, abdominal pain, VAS of abdominal pain, abdominal distension, AGI grade and serum albumin level at admission; Group 1 Number missing: ; Group 2 Number missing:</p>	
Protocol outcomes not reported by the study	Quality of life at <1 year; Achieving nutrition (meeting nutritional requirements; at least 20-25 kcal/kg) at <1 year; Requiring total parenteral nutrition at <1 year; Serious adverse events at <1 year; Weight loss/BMI at <1 year

Study	Wereszczynska-siemiakowska 2013¹¹⁴²
Study type	Non-randomised comparative study
Number of studies (number of participants)	1 (n=197)
Countries and setting	Conducted in Poland; Setting: Hospital inpatients
Line of therapy	1st line

Duration of study	Intervention + follow up: unclear
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Two of the following characteristics: upper abdominal pain, serum amylase or lipase activities at least 3 times higher than normal, and findings of abdominal contrast-enhanced computed tomography (CT), magnetic resonance imaging, or ultrasonography suggesting AP.
Stratum	Adults >16 years
Subgroup analysis within study	Not applicable
Inclusion criteria	Severe AP within the first 48 hours of admission to hospital and treatment with total enteral feeding
Exclusion criteria	Younger than 18 years of age; admission after 72 hours of the onset of symptoms; acute exacerbation of chronic pancreatitis; AP confirmed during laparotomy for acute abdomen; treatment with total parenteral feeding alone; early deaths of patients with severe AP who did not receive total enteral feeding.
Recruitment/selection of patients	Consecutive
Age, gender and ethnicity	Age - Median (IQR): Early: 49 (39-56); delayed: 50 (41-62.5). Gender (M:F): Early: 74/26%; delayed: 61/39%. Ethnicity:
Further population details	1. Patients in critical care: Not stated / Unclear
Extra comments	The diagnosis of severe AP was established by the presence of one or more of the following within the first 48 hours: SIRS; Acute Physiology and Chronic Health Evaluation (APACHE) II score, 8 or greater; Bedside Index of Severity in AP (BISAP), 3 or greater; Panc 3 score; Ranson score, 3 or greater; Balthazar score C-E; or organ failure assessed using Sequential Organ Failure Assessment (SOFA) score
Indirectness of population	No indirectness
Interventions	(n=97) Intervention 1: Enteral feeding - Early gastric feeding. Enteral nutrition started within the first 48 hours after admission to hospital. Duration Unclear. Concurrent medication/care: Patients were managed by standard medical treatment in AP: intravenous fluid and electrolytes, analgesia, prophylactic antibiotics, and other supportive therapies

	<p>for organ failure, as indicated. Emergency endoscopic retrograde cholangiopancreatography was performed within 24 to 72 hours on patients with suspected choledocholithiasis.. Indirectness: No indirectness</p> <p>(n=100) Intervention 2: Enteral feeding - Late enteral feeding. Enteral nutrition started more than 48 hours after admission to hospital. Duration Unclear. Concurrent medication/care: Patients were managed by standard medical treatment in AP: intravenous fluid and electrolytes, analgesia, prophylactic antibiotics, and other supportive therapies for organ failure, as indicated. Emergency endoscopic retrograde cholangiopancreatography was performed within 24 to 72 hours on patients with suspected choledocholithiasis.. Indirectness: No indirectness</p>
<p>Funding</p>	<p>Funding not stated</p>
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: EARLY ENTERAL FEEDING versus DELAYED ENTERAL FEEDING</p> <p>Protocol outcome 1: Mortality at <1 year - Actual outcome for Adults >16 years: Mortality at Unclear; Group 1: 0/97, Group 2: 9/100 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 2: Length of critical care or hospital stay at <1 year - Actual outcome for Adults >16 years: Length of hospital stay at Unclear; ; Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 3: Infections at <1 year - Actual outcome for Adults >16 years: Infected necrosis or infected fluid collection at Unclear; OR; 4.094 (95%CI 1.169 to 14.343, Comments: Adjusted for APACHE II score at day 3, persistence of SIRS after 48 hours); Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing: - Actual outcome for Adults >16 years: Localised infections (pneumonia or UTI) at Unclear; Group 1: 26/97, Group 2: 39/100 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing: - Actual outcome for Adults >16 years: Pancreatic infections at Unclear; Group 1: 4/97, Group 2: 18/100 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;</p>	

<p>Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing: - Actual outcome for Adults >16 years: Systemic infections (sepsis) at Unclear; Group 1: 2/97, Group 2: 4/100 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 4: Adverse events (e.g. tube displacements, aspirational pneumonia, ischemic gut and central line infections) at <1 year - Actual outcome for Adults >16 years: Requiring surgery at Unclear; Group 1: 7/97, Group 2: 11/100 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing: - Actual outcome for Adults >16 years: Pancreatic complications (necrosis, pseudocyst, ascites, haemorrhage, fistula) at Unclear; Group 1: 63/97, Group 2: 86/100 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 5: Serious adverse events at <1 year - Actual outcome for Adults >16 years: Multi-organ failure at Unclear; Group 1: 9/97, Group 2: 16/100 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p>	
Protocol outcomes not reported by the study	Quality of life at <1 year; Achieving nutrition (meeting nutritional requirements; at least 20-25 kcal/kg) at <1 year; Requiring total parenteral nutrition at <1 year; Weight loss/BMI at <1 year

H.9 Early versus late nutritional intervention in people with chronic pancreatitis

None.

H.10 Specialist versus non-specialist nutritional assessment in people with chronic pancreatitis

None.

H.11 Prophylactic antimicrobial agents to prevent infection in people with acute pancreatitis

Study	Bassi 1998 ¹⁰⁰
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=60)
Countries and setting	Conducted in Greece, Italy; Setting: University of Verona; Pancreatic Disease Center, Cardarelli Hospital, Naples; Agia Holga Hospital; Mestre Hospital
Line of therapy	Not applicable
Duration of study	Intervention time: 2 weeks
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Evidence of pancreatic necrosis was detected by CT and intravenous contrast medium and confirmed by CRP values above 100 mg/L and extending to at least 50% volume of the gland.
Stratum	Adults (>16 years)
Subgroup analysis within study	Not applicable
Inclusion criteria	No history of pancreatic disease; definite diagnosis of severe pancreatitis of any etiology with onset of pain symptoms occurring not more than 5 days before admission; definite evidence of pancreatic necrosis as detected by CT and intravenous contrast medium and confirmed by CRP values above 100 mg/L and extending to at least 50% volume of the gland; and no antibiotic intake during the hours immediately before admission.
Exclusion criteria	Not reported
Recruitment/selection of patients	Patients admitted to the participating centers with acute necrotising pancreatitis were screened
Age, gender and ethnicity	Age - Range: 34-70. Gender (M:F): 34/26. Ethnicity: Not reported
Further population details	1. Severity of pancreatitis (as defined by study): Severe pancreatitis (Ranson score 4.4 (3-6), 4.7 (3-6); Apache II score 12 (10-21), 11 (9-22); CRP mg dl 301 (155-485), 314 (145-510), pancreatic necrosis >50%).
Extra comments	n or mean (range) in the imipenem and pefloxacin groups, respectively: Ranson score 4.4 (3-6), 4.7 (3-6); Apache II score 12 (10-21), 11 (9-22); CRP mg dl 301 (155-485), 314 (145-510), biliary etiology 18, 19; biliary + alcoholic 4, 4; alcoholic 4, 5; post ERCP 2, 0; idiopathic 2, 2; days from abdominal pain to admission 2.1 (1.5-5), 1.9 (0.5-5). Severe necrotic component >50% pancreatic volume
Indirectness of population	No indirectness
Interventions	(n=30) Intervention 1: Prophylactic antimicrobial therapy - Quinolone. 400 mg Pefloxacin IV, 2 times daily. Duration 2 weeks. Concurrent medication/care: Patients with pancreatitis of biliary etiology underwent endoscopic sphincterotomy

	<p>within 72 hours of admission Further details: 1. Drug class: Quinolones 2. Drug dose: Not stated / Unclear 3. Drug route: Intravenous 4. Duration of therapy: Not stated / Unclear</p> <p>(n=30) Intervention 2: Prophylactic antimicrobial therapy - Carbapenem. 500 mg Imipenem IV, given 3 times daily. Duration 2 weeks . Concurrent medication/care: Patients with pancreatitis of biliary etiology underwent endoscopic sphincterotomy within 72 hours of admission Further details: 1. Drug class: Quinolones 2. Drug dose: Not stated / Unclear 3. Drug route: Intravenous 4. Duration of therapy: Not stated / Unclear</p>
Funding	Academic or government funding (Supported by Italian Ministry of the University grant)
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: PEFLOXACIN versus IMIPENEM</p> <p>Protocol outcome 1: Length of stay (in intensive therapy unit or hospital) at <1 year - Actual outcome for Adults (>16 years): Length of hospital stay at 2 weeks; Risk of bias: High; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 2: Mortality at <1 year - Actual outcome for Adults (>16 years): Mortality (postoperative) at 2 weeks; Group 1: 5/30, Group 2: 3/30; Risk of bias: High; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 3: Infected necrosis at <1 year - Actual outcome for Adults (>16 years): Infected necrosis at 2 weeks; Group 1: 10/30, Group 2: 3/30; Risk of bias: High; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 4: Extra-pancreatic infection at <1 year - Actual outcome for Adults (>16 years): Extra-pancreatic infection at 2 weeks; Group 1: 13/30, Group 2: 6/30; Risk of bias: High; Indirectness of outcome: No indirectness</p>	
Protocol outcomes not reported by the study	Quality of life at <1 year; Colonisation by resistant organisms at >6 months; Serious adverse events at <6 months; Serious adverse events at >6 months; Colonisation by resistant organisms at <6 months

Study	Delcenserie 1996²⁷⁸
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=23)

Countries and setting	Conducted in France; Setting: Departments of Gastroenterology and Internal Medicine, CHU Nord, Amiens Cedex, France
Line of therapy	Not applicable
Duration of study	Intervention time: 10 days
Method of assessment of guideline condition	Unclear method of assessment/diagnosis
Stratum	Adults (>16 years)
Subgroup analysis within study	Not applicable
Inclusion criteria	No previous pancreatic disease; admission within 48 hours of onset; no previous antibiotic treatment; and acute alcoholic pancreatitis, with two or more fluid collections demonstrated by CT within 48 hours.
Exclusion criteria	<18 years; antibiotic allergy; and the need to carry out endoscopic retrograde cholangiopancreatography (ERCP)
Recruitment/selection of patients	Patients admitted into hospital with severe alcoholic acute pancreatitis were recruited
Age, gender and ethnicity	Age - Range: 21-74. Gender (M:F): 21/2. Ethnicity: Not reported
Further population details	1. Severity of pancreatitis (as defined by study): Severe pancreatitis
Extra comments	The Ranson early objective signs ranged from 0 to 7, with a mean value of 2.3 ± 2 .
Indirectness of population	No indirectness
Interventions	<p>(n=11) Intervention 1: Prophylactic antimicrobial therapy – Combination of antimicrobials. Subjects received intravenous ceftazidime, 2 g every 8 hours; intravenous amikacin, 7.5 mg/kg every 12 hours; and intravenous metronidazole, 0.5 g every 8 hours for 10 days. Duration 10 days . Concurrent medication/care: All patients also received medical treatment. Further details: 1. Drug class: Systematic review: mixed 2. Drug dose: Not stated / Unclear 3. Drug route: Intravenous 4. Duration of therapy: Not stated / Unclear</p> <p>(n=12) Intervention 2: No prophylactic antimicrobial therapy. Subjects received medical treatment only. Duration 10 days. Concurrent medication/care: None reported Further details: 1. Drug class: Not applicable 2. Drug dose: Not applicable 3. Drug route: Not applicable 4. Duration of therapy: Not applicable</p>
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: CEFTAZIDIME, AMIKACIN, METRONIDAZOLE versus NO PROPHYLACTIC ANTIMICROBIAL THERAPY

<p>Protocol outcome 1: Length of stay (in intensive therapy unit or hospital) at <1 year - Actual outcome for Adults (>16 years): Length of hospitalisation at 10 days; Group 1: mean 22 days (SD 10.7); n=11, Group 2: mean 27.8 days (SD 24.6); n=12; Risk of bias: Low; Indirectness of outcome: No indirectness</p>	
<p>Protocol outcome 2: Mortality at <1 year - Actual outcome for Adults (>16 years): Mortality at 10 days; Group 1: 1/11, Group 2: 3/12; Risk of bias: Low; Indirectness of outcome: No indirectness</p>	
<p>Protocol outcome 3: Infected necrosis at <1 year - Actual outcome for Adults (>16 years): Superinfection of necrotic pancreatic tissue at 10 days; Group 1: 0/11, Group 2: 3/12; Risk of bias: Low; Indirectness of outcome: No indirectness</p>	
<p>Protocol outcome 4: Extra-pancreatic infection at <1 year - Actual outcome for Adults (>16 years): Patients with infection at 10 days; Group 1: 0/11, Group 2: 7/12; Risk of bias: Low; Indirectness of outcome: No indirectness</p>	
<p>Protocol outcome 5: Serious adverse events at <6 months - Actual outcome for Adults (>16 years): Multiorgan failure at 10 days; Group 1: 1/11, Group 2: 1/12; Risk of bias: Low; Indirectness of outcome: No indirectness</p>	
Protocol outcomes not reported by the study	Quality of life at <1 year; Colonisation by resistant organisms at >6 months; Serious adverse events at >6 months; Colonisation by resistant organisms at <6 months

Study	Dellinger 2007²⁸⁰
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=100)
Countries and setting	Conducted in Austria, Belgium, Canada, Estonia, Germany, Latvia, Lithuania, Portugal, Spain, United Kingdom, USA; Setting: 32 sites within North America and Europe
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 42 days (at least 35 days follow up)
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Adults (>16 years)
Subgroup analysis within study	Not applicable:

Inclusion criteria	Male or female patients ≥18 years of age with a confirmed diagnosis of necrotising pancreatitis within 120 hours of onset of symptoms. Patients with ≥30% necrosis of the pancreas confirmed by contrast-enhanced CT were eligible for inclusion. Alternatively, patients who were unsuitable for CT scan in the judgment of the investigator, and who had non-contrast scans with extensive or multiple peripancreatic fluid collections and pancreatic edema (Balthazar grade E), and had either CRP >120 mg/L or a multiple organ dysfunction (MOD) score >2 were also eligible. In addition randomisation and receipt of first dose of study treatment was required within 120 hours of the onset of symptoms for inclusion in the study.
Exclusion criteria	Patients diagnosed with concurrent pancreatic or peripancreatic infection were excluded from the study, as were patients who had received an investigational drug <30 days prior to enrollment, antimicrobial therapy for >48 hours prior to randomisation, or who had allergy to beta-lactam antimicrobial agents. In addition, patients who received or were likely to require probenecid or who had progressing underlying disease, neutropenia, or cirrhosis (Child-Pugh class C), and pregnant or lactating females were also excluded.
Age, gender and ethnicity	Age - Other: 18-64 years, n=68; 65-74 years, n=18; >75 years, n=14. Gender (M:F): 70/30. Ethnicity: white 98, black 2
Further population details	1. Severity of pancreatitis (as defined by study): Severe pancreatitis
Extra comments	Baseline characteristics (n) for intervention and control group, respectively: biliary etiology 22, 12; alcohol etiology 18, 26; other etiology 10, 12; <30% necrosis at CECT 15, 10; ≥30% necrosis at CECT 26, 31; not recorded 9,9. . Baseline characteristics, mean (range) for intervention and control group, respectively: days between symptom onset and 1st dose 3(1-6), 3(1-8); ranson score 4.5(1-8), 3.8(0-8); modified Glasgow score 4.2(1-8), 3.4(0-7); APACHE II 12.7(2-30), 11.5(0-39); CTSI 7.1(6-10), 7.7(6-10); MOD 3.7(0-13), 2.8(0-12); CRP 274(120-456), 262(50-661).
Indirectness of population	No indirectness
Interventions	(n=50) Intervention 1: Prophylactic antimicrobial therapy - Carbapenem. Meropenem 1 g powder reconstituted in fluid administered by intravenous infusion over 15 to 30 minutes every 8 hours. . Duration 7-21 days (14 days recommended). Concurrent medication/care: The use of non-protocol antibiotics during this time was discouraged but could not be prohibited in these seriously ill patients. Most patients received nutritional support and the incidence of support was not different between the meropenem and placebo arms. Further details: 1. Drug class: Carbapenems 2. Drug dose: (1g every 8 hours). 3. Drug route: Intravenous 4. Duration of therapy: Comments: 31 patients in this group received drug for a duration <14 days: 11 stopped as they were diagnosed an infection and started non-study antibiotic or received surgery; 5 recovered; 2 died; 1 refused further drug. 25 patients received additional antibiotics other than study drug for clinical indications. (n=50) Intervention 2: Placebo. dose-and administration-matched placebo. Duration 7-21 days (14 days recommended).

	<p>Concurrent medication/care: The use of non-protocol antibiotics during this time was discouraged but could not be prohibited in these seriously ill patients. Most patients received nutritional support and the incidence of support was not different between the meropenem and placebo arms.</p> <p>Further details: 1. Drug class: 2. Drug dose: 3. Drug route: 4. Duration of therapy: Comments: 32 patients in this group received drug for a duration <14 days: 10 stopped as they were diagnosed an infection and started non-study antibiotic or received surgery; 2 recovered; 4 died. 27 patients received additional antibiotics other than study drug for clinical indications.</p>
Funding	Equipment / drugs provided by industry (Supported by a grant from AstraZeneca Pharmaceuticals)
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: MEROPENEM versus PLACEBO</p> <p>Protocol outcome 1: Mortality at <1 year - Actual outcome for Adults (>16 years): Mortality at within 42 days of randomisation; Group 1: 10/50, Group 2: 9/50; Risk of bias: High; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 2: Infected necrosis at <1 year - Actual outcome for Adults (>16 years): Pancreatic infection at within 42 days of randomisation; Group 1: 9/40, Group 2: 6/40; Risk of bias: High; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 3: Extra-pancreatic infection at <1 year - Actual outcome for Adults (>16 years): Nonpancreatic nosocomial infections at within 42 days of randomisation; Group 1: 16/50, Group 2: 24/50; Risk of bias: Low; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 4: Colonisation by resistant organisms at <6 months - Actual outcome for Adults (>16 years): Pancreatic infection by meropenem-resistant bacteria at within 42 days of randomisation; Group 1: 5/40, Group 2: 2/40; Risk of bias: High; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 5: Serious adverse events at <6 months - Actual outcome for Adults (>16 years): Serious adverse events at within 42 days of randomisation; Group 1: 6/50, Group 2: 9/50; Risk of bias: High; Indirectness of outcome: No indirectness</p>	
Protocol outcomes not reported by the study	Quality of life at <1 year; Colonisation by resistant organisms at >6 months; Serious adverse events at >6 months; Length of stay (in intensive therapy unit or hospital) at <1 year

Pancreatitis

Clinical evidence tables

Study	Garcia-Barrasa 2009 ³⁸⁴
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=41)
Countries and setting	Conducted in Spain; Setting: Surgical Gastrointestinal Service of Bellvitge Hospital
Line of therapy	Not applicable
Duration of study	Intervention time: 10 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Diagnosed according to the Atlanta criteria
Stratum	Adults (>16 years)
Subgroup analysis within study	Not applicable
Inclusion criteria	All patients without previous antibiotic treatment and with detectable pancreatic necrosis in a CECT scan performed within 48-72 hours of admission.
Exclusion criteria	Patients with a quinolone allergy or clinical evidence of sepsis on admission.
Recruitment/selection of patients	Patients admitted to hospital with acute pancreatitis and pancreatic necrosis were recruited.
Age, gender and ethnicity	Age - Range: 31-84. Gender (M:F): 29/12. Ethnicity: Not reported
Further population details	1. Severity of pancreatitis (as defined by study): Severe pancreatitis (Severe pancreatitis according to the Atlanta classification).
Extra comments	Percentage in intervention and control group, respectively: biliary 72.7, 57.9; alcohol 9.1, 26.3; others 18.2, 15.8. Number of patients in the intervention and control group, respectively: necrosis <30% 11, 9; necrosis 30-50% 3, 6; necrosis >50% 8,4. Mean in intervention and control group, respectively: APACHE score 10, 14; CRP mg/L in first 48 h 313(25-431), 326(106-453).
Indirectness of population	No indirectness
Interventions	(n=22) Intervention 1: Prophylactic antimicrobial therapy - Quinolone. 300 mg ciprofloxacin q. 12 hours for 10 days. Duration 10 days. Concurrent medication/care: All patients were treated medically on admission (aggressive fluid resuscitation along with electrolyte imbalance, complete avoidance of oral intake, pain control and total parenteral nutrition Further details: 1. Drug class: Quinolones 2. Drug dose: Low dose (BNF dose: 400 mg). 3. Drug route: Not stated / Unclear 4. Duration of therapy: Not stated / Unclear Comments: In 7 patients, medication had to be discontinued and open antibiotic treatment had to be started after a mean of 7 days (range 3-9)

	<p>(n=19) Intervention 2: Placebo. Control patients were given placebo.. Duration 10 days. Concurrent medication/care: All patients were treated medically on admission (aggressive fluid resuscitation along with electrolyte imbalance, complete avoidance of oral intake, pain control and total parenteral nutrition Further details: 1. Drug class: Not applicable 2. Drug dose: Not applicable 3. Drug route: Not applicable 4. Duration of therapy: Not applicable Comments: In 8 patients placebo had to be discontinued and open antibiotic treatment had to be started instead after a mean of 6 days (range 4-8 days)</p>
Funding	Academic or government funding (Supported by the Bellvitge Hospital)
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: CIPROFLOXACIN versus PLACEBO</p> <p>Protocol outcome 1: Length of stay (in intensive therapy unit or hospital) at <1 year - Actual outcome for Adults (>16 years): Length of hospital stay at 10 days; Risk of bias: Very high; Indirectness of outcome: No indirectness - Actual outcome for Adults (>16 years): Length of CCU stay at 10 days; Risk of bias: Very high; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 2: Mortality at <1 year - Actual outcome for Adults (>16 years): Mortality at 10 days; Group 1: 4/22, Group 2: 2/19; Risk of bias: Very high; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 3: Infected necrosis at <1 year - Actual outcome for Adults (>16 years): Infected necrosis at 10 days; Group 1: 8/22, Group 2: 8/19; Risk of bias: Very high; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 4: Extra-pancreatic infection at <1 year - Actual outcome for Adults (>16 years): Number of people with one or more extra-pancreatic infections at 10 days; Group 1: 6/22, Group 2: 8/22; Risk of bias: Very high; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 5: Serious adverse events at <6 months - Actual outcome for Adults (>16 years): Organ failure at 10 days; Group 1: 13/22, Group 2: 10/19; Risk of bias: Very high; Indirectness of outcome: No indirectness</p>	
Protocol outcomes not reported by the study	Quality of life at <1 year; Colonisation by resistant organisms at >6 months; Serious adverse events at >6 months; Colonisation by resistant organisms at <6 months

Study	He 2003 ⁴⁵⁰
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=70)
Countries and setting	Conducted in China; Setting: Not reported
Line of therapy	Not applicable
Duration of study	Not clear:
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Diagnosed with the diagnosis criteria proposed by the Pancreas Surgery Group of the Chinese Medical Association in 1997
Stratum	Adults (>16 years)
Subgroup analysis within study	Not applicable
Inclusion criteria	Subjects with a clinical diagnosis and one of the following predisposing factors of deep fungal infections, such as gerontism, history of diabetes, dysfunction of one or more organs, non-iatrogenic fasting hyperglycemia (≥ 9 mmol/L), central venous catheter, TPN, retaining urethral catheterisation, operation, gastrointestinal fistula, CCU, breathing machine supported ≥ 5 days, administration of broad spectrum antibiotics ≥ 5 days or super broad spectrum antibiotics ≥ 3 days
Exclusion criteria	Not reported
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - -: . Gender (M:F): 37/33. Ethnicity: Not reported
Further population details	1. Severity of pancreatitis (as defined by study): Severe pancreatitis
Extra comments	Etiological factors - Fluconazole group: Biliary - 11, Alcholemlia - 6, Others - 5; Control group: Biliary - 11, Alcholemlia - 7, Injury - 1, Others - 4 APACHIII scores - Fluconazole group: 13.2 ± 2.5 , Control group: 11.6 ± 4.7
Indirectness of population	No indirectness
Interventions	(n=22) Intervention 1: Prophylactic antimicrobial therapy - Imidazole antifungal. Subjects were given venous instillation of 100 mg fluconazole once a day plus routine treatment. Duration Until relief of predisposing factors. Concurrent medication/care: All patients received routine treatment Further details: 1. Drug class: Imidazole antifungals 2. Drug dose: Not stated / Unclear 3. Drug route: Intravenous 4. Duration of therapy: Not stated / Unclear

	(n=23) Intervention 2: No prophylactic antimicrobial therapy. Subjects received routine treatment only. Duration For the duration of the study. Concurrent medication/care: Not reported Further details: 1. Drug class: Not applicable 2. Drug dose: Not applicable 3. Drug route: Not applicable 4. Duration of therapy: Not applicable
Funding	Funding not stated
RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: FLUCONAZOLE versus NO PROPHYLACTIC ANTIMICROBIAL THERAPY	
Protocol outcome 1: Extra-pancreatic infection at <1 year - Actual outcome for Adults (>16 years): Fungal infections at Duration of study; Group 1: 2/22, Group 2: 7/23; Risk of bias: High; Indirectness of outcome: No indirectness	
Protocol outcomes not reported by the study	Quality of life at <1 year; Mortality at <1 year; Infected necrosis at <1 year; Colonisation by resistant organisms at <6 months; Colonisation by resistant organisms at >6 months; Serious adverse events at <6 months; Serious adverse events at >6 months; Length of stay (in intensive therapy unit or hospital) at <1 year

Study (subsidiary papers)	Isenmann 2004 ⁵⁰⁰ (Forsmark 2005 ³⁶³)
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=114)
Countries and setting	Conducted in Germany; Setting: Universities of Ulm, Essen, Nuremberg, Magdeburg and Heidenheim, Germany
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 21 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Acute pancreatitis was defined as abdominal pain in combination with a 3-fold elevation of serum amylase and/or lipase. A serum CRP >150 mg/dl and/or presence of pancreatic necrosis on contrast enhanced CT scanning (CECT) were chosen to define severity.
Stratum	Adults (>16 years)
Subgroup analysis within study	Not applicable:
Inclusion criteria	Patients with a predicted severe attack of acute pancreatitis. Acute pancreatitis was defined as abdominal pain in combination with a 3-fold elevation of serum amylase and/or lipase. A serum CRP >150 mg/dl and/or presence of pancreatic necrosis on contrast enhanced CT scanning (CECT) were chosen to define severity. Study inclusion had to be performed within 72h after the onset of upper abdominal pain.
Exclusion criteria	Not stated
Recruitment/selection of patients	Patients with predicted severe attack of acute pancreatitis presenting at participating hospitals
Age, gender and ethnicity	Age - Median (range): Ciprofloxacin/metronidazole group: 47.9(25.1-72.5), control group: 45.6(21.9-78.4). Gender (M:F): 87/27. Ethnicity: Not reported
Further population details	1. Severity of pancreatitis (as defined by study): Severe pancreatitis (serum CRP at inclusion mg/L intervention group 175(1-790), control group 176(0-492); presence of pancreatic necrosis on CECT).
Extra comments	Baseline characteristics, N or median(range), for intervention and control group, respectively: alcohol etiology 32, 34; biliary etiology 13, 9; other etiology 13, 13; Ranson 48h points 2.5(0-6), 2(0-7); serum CRP at inclusion mg/L 175(1-790), 176(0-492); study inclusion after onset of symptoms, hrs 52(4-84), 41(11-89). End of study medication at day 14 or 21 with no additional antibiotics: rectal temperature <37 degrees for >72 hrs and at least two of the following: a) peripheral white blood cell count within normal limits, b) decrease of serum CPR <50% of recent maximum, c) decrease of serum lipase <50% of recent maximum, d) CECT without progression of necrotic areas, e) oral food intake tolerated. End of study medication and open antibiotic treatment if a) newly developed sepsis or SIRS, b) newly developed multi organ failure (2 or more organ systems), c) extrapancreatic infection (pneumonia, urinary tract infection, intra-abdominal infection. sepsis without known focus) or pancreatic infection proven by fine needle aspiration/positive

	intraoperative smears, d) increase of serum CRP and clinically suspected extrapancreatic/pancreatic infection
Indirectness of population	No indirectness
Interventions	<p>(n=58) Intervention 1: Prophylactic antimicrobial therapy - Combination of antimicrobials. Ciprofloxacin 2x400 mg/day intravenously in combination with metronidazole 2x500 mg/day. Duration 14-21 days. Concurrent medication/care: Not stated</p> <p>Further details: 1. Drug class: Not applicable (Combination of florowuinolone and nitroimidazole derivative). 2. Drug dose: Not applicable (ciprofloxacin 2x400 mg/day, metronidazole 2x500mg/day). 3. Drug route: Intravenous 4. Duration of therapy: (21 days).</p> <p>Comments: Study medication was given for 3-23 days (median 14 days) after the onset of symptoms. 16 people discontinued study medication and switched to open antibiotic treatment</p> <p>(n=56) Intervention 2: Placebo. Placebo. Duration 14-21 days. Concurrent medication/care: Not stated</p> <p>Further details: 1. Drug class: Not applicable 2. Drug dose: Not applicable 3. Drug route: Not applicable 4. Duration of therapy: Not applicable</p> <p>Comments: Study medication was given for 2-19 days (median 12 days) after onset of symptoms in the placebo group. 26 people discontinued placebo and switched over to antibiotic open treatment</p>
Funding	Equipment / drugs provided by industry (Supported by study medication provided from Bayer Vital and Ratiopharm as well as financial grant from Bayer Vital)

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: COMBINATION (CIPROFLOXACIN PLUS METRONIDAZOLE) versus PLACEBO

Protocol outcome 1: Length of stay (in intensive therapy unit or hospital) at <1 year

- Actual outcome for Adults (>16 years): CCU stay (days) at 21 days; Risk of bias: High; Indirectness of outcome: No indirectness
- Actual outcome for Adults (>16 years): Hospitalisation (days) at 21 days; Risk of bias: High; Indirectness of outcome: No indirectness

Protocol outcome 2: Mortality at <1 year

- Actual outcome for Adults (>16 years): Mortality at 21 days; Group 1: 3/58, Group 2: 4/56; Risk of bias: High; Indirectness of outcome: No indirectness

Protocol outcome 3: Infected necrosis at <1 year

- Actual outcome for Adults (>16 years): Infected pancreatic necrosis at 21 days; Group 1: 7/58, Group 2: 5/56; Risk of bias: High; Indirectness of outcome: No indirectness

Protocol outcome 4: Extra-pancreatic infection at <1 year

<p>- Actual outcome for Adults (>16 years): Extra-pancreatic infections at 21 days; Group 1: 13/58, Group 2: 13/56; Risk of bias: High; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 5: Serious adverse events at <6 months</p> <p>- Actual outcome for Adults (>16 years): Serious adverse events (pulmonary insufficiency) at 21 days; Group 1: 26/58, Group 2: 25/55; Risk of bias: High; Indirectness of outcome: No indirectness</p> <p>- Actual outcome for Adults (>16 years): Serious adverse events (renal insufficiency) at 21 days; Group 1: 7/58, Group 2: 6/55; Risk of bias: High; Indirectness of outcome: No indirectness</p> <p>- Actual outcome for Adults (>16 years): Serious adverse events (shock) at 21 days; Group 1: 5/58, Group 2: 7/55; Risk of bias: High; Indirectness of outcome: No indirectness</p> <p>- Actual outcome for Adults (>16 years): Serious adverse events (SIRS) at 21 days; Group 1: 31/58, Group 2: 24/55; Risk of bias: High; Indirectness of outcome: No indirectness</p>	
<p>Protocol outcomes not reported by the study</p>	<p>Quality of life at <1 year; Colonisation by resistant organisms at >6 months; Serious adverse events at >6 months; Colonisation by resistant organisms at <6 months</p>

Study (subsidiary papers)	Luiten 1995 ⁶⁸⁶ (Luiten 1997 ⁶⁸⁷)
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=109)
Countries and setting	Conducted in Netherlands; Setting: 16 participating hospitals in the Netherlands
Line of therapy	Not applicable
Duration of study	Intervention + follow up: Selective decontamination was done until the risk of acquiring a new infection was absent and follow up was continued till discharge or death
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Clinical examination and elevated plasma levels of amylase (>1000 international units/L), or at diagnostic laparotomy
Stratum	Adults (>16 years)
Subgroup analysis within study	Not applicable
Inclusion criteria	Define
Exclusion criteria	Define
Recruitment/selection of patients	Patients admitted to participating hospitals with objective clinical signs of severe acute pancreatitis were recruited.
Age, gender and ethnicity	Age - Range: 20-91. Gender (M:F): Define. Ethnicity: Not reported
Further population details	1. Severity of pancreatitis (as defined by study): Severe pancreatitis
Extra comments	Etiology - SD group: Alcohol - 19, Gallstones - 17, Blunt abdominal trauma - 1, Postoperative - 2, ERCP-induced - 1, Unknown - 10; Control group - Alcohol - 12, Gallstones - 19, Hyperparathyroidism - 2, Postoperative - 2, ERCP-induced - 3, Unknown - 14
Indirectness of population	No indirectness
Interventions	(n=50) Intervention 1: Prophylactic antimicrobial therapy - Combination of antimicrobials. The selective decontamination regimen consisted of colistin sulfate (200 mg), amphotericin (500 mg) and norfloxacin (Noroxin, Merck & Co., West Point, PA; 50 mg) every 6 hours. A sticky paste containing 2% of the three selective decontamination drugs was smeared along the upper and lower gums every 6 hours and at the tracheostomy, if present. The aforementioned daily dose was also given in a rectal enema every day. A short-term systemic prophylaxis of cefotaxime sodium (Claforan, Hoechst-Roussel Pharm., Inc., Somerville NJ; 500 mg) was given every 8 hours until gram-negative bacteria were eliminated from the oral cavity and rectum. . Duration 7.4 days. Concurrent medication/care: A nasogastric tube was always inserted. Intravenous crystalloid solutions were given according to clinical requirements. Oxvæn therapv. based on arterial blood gas analysis. was administered by face mask and was replaced by assisted

	<p>ventilation if the patient developed respiratory insufficiency. Further details: 1. Drug class: Systematic review: mixed 2. Drug dose: Not stated / Unclear 3. Drug route: Systematic review: mixed (Oral, topical and rectal). 4. Duration of therapy: Not stated / Unclear</p> <p>(n=52) Intervention 2: No prophylactic antimicrobial therapy. A nasogastric tube was always inserted. Intravenous crystalloid solutions were given according to clinical requirements. Oxygen therapy, based on arterial blood gas analysis, was administered by face mask and was replaced by assisted ventilation if the patient developed respiratory insufficiency.. Duration Until the presence of infection was indicated. Concurrent medication/care: None reported Further details: 1. Drug class: Not applicable 2. Drug dose: Not applicable 3. Drug route: Not applicable 4. Duration of therapy: Not applicable</p>
Funding	Equipment / drugs provided by industry (Supported by a grant from Merck Shard & Dohme B.V., the Netherlands and a grant from Roussel B.V., the Netherlands)
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: SELECTIVE DECONTAMINATION (COLISTIN SULFATE, AMPHOTERICIN, NORFLOXACIN) versus NO PROPHYLACTIC ANTIMICROBIAL THERAPY</p> <p>Protocol outcome 1: Length of stay (in intensive therapy unit or hospital) at <1 year - Actual outcome for Adults (>16 years): Length of hospital stay at Duration of study; Risk of bias: Low; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 2: Mortality at <1 year - Actual outcome for Adults (>16 years): Mortality at Duration of study; Group 1: 11/50, Group 2: 18/52; Risk of bias: Low; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 3: Infected necrosis at <1 year - Actual outcome for Adults (>16 years): Infected necrosis at Duration of study; Group 1: 9/50, Group 2: 20/52; Risk of bias: Low; Indirectness of outcome: No indirectness</p>	
Protocol outcomes not reported by the study	Quality of life at <1 year; Colonisation by resistant organisms at <6 months; Colonisation by resistant organisms at >6 months; Serious adverse events at <6 months; Serious adverse events at >6 months; Extra-pancreatic infection at <1 year

Study	Manes 2003 ⁷⁰⁷
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=176)
Countries and setting	Conducted in Italy; Setting: Carderelli Hospital, Napoli, Italy
Line of therapy	Not applicable
Duration of study	Intervention time: 14 days
Method of assessment of guideline condition	Unclear method of assessment/diagnosis
Stratum	Adults (>16 years)
Subgroup analysis within study	Not applicable
Inclusion criteria	subjects older than 18 years, a diagnosis of AP with definite evidence of pancreatic necrosis as assessed by means of contrast-enhanced CT scan, admission within 72 hours of onset of symptoms, no intake of antibiotics in the 3 days before admission, and C-reactive protein concentration >120 mg/L within 48 hours of admission.
Exclusion criteria	Referred patients, immunocompromised patients, and patients with underlying chronic pancreatitis were excluded from the study.
Recruitment/selection of patients	Patients admitted to hospital with necrotising acute pancreatitis were recruited.
Age, gender and ethnicity	Age - Range: 19-91. Gender (M:F): 106/70. Ethnicity: Not reported
Further population details	1. Severity of pancreatitis (as defined by study): Severe pancreatitis (Glasgow score (mean, SD) for meropenem and imipenem groups, respectively: 6.0 (3.1), 5.0 (3.3)).
Extra comments	Number of patients in the meropenem and imipenem group, respectively: biliary etiology 57, 56; alcohol etiology 11, 9; other etiology 20, 23; necrosis <30% 51, 54; necrosis 30-50% 25, 21; necrosis >50% 12, 13. Mean (SD) for meropenem and imipenem groups, respectively: CRP mg/dl 219.3 (31.1), 235.2 (34.4); Glasgow score 6.0 (3.1), 5.0 (3.3); CE-CT score 7.0 (2.4), 7.0 (3.1)
Indirectness of population	No indirectness
Interventions	(n=88) Intervention 1: Prophylactic antimicrobial therapy - Carbapenem. 500 mg meropenem intravenously every 8 hours. Duration 14 days. Concurrent medication/care: All patients received the usual supportive medical treatment; endoscopic retrograde cholangiopancreatography with endoscopic sphincterotomy was performed in 96 patients with biliary forms. Further details: 1. Drug class: Carbapenems 2. Drug dose: Not stated / Unclear 3. Drug route: Intravenous 4. Duration of therapy: Not stated / Unclear

	(n=88) Intervention 2: Prophylactic antimicrobial therapy - Carbapenem. 500 mg imipenem intravenously every 6 hours. Duration 14 days. Concurrent medication/care: All patients received the usual supportive medical treatment; endoscopic retrograde cholangiopancreatography with endoscopic sphincterotomy was performed in 96 patients with biliary forms. Further details: 1. Drug class: 2. Drug dose: 3. Drug route: 4. Duration of therapy:
Funding	Funding not stated
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: MEROPENEM versus IMIPENEM</p> <p>Protocol outcome 1: Length of stay (in intensive therapy unit or hospital) at <1 year - Actual outcome for Adults (>16 years): Length of hospital stay at 14 days; Mean imipenem group 24, meropenem group 23.3; Risk of bias: High; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 2: Mortality at <1 year - Actual outcome for Adults (>16 years): Mortality at 14 days; Group 1: 12/88, Group 2: 10/88; Risk of bias: High; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 3: Infected necrosis at <1 year - Actual outcome for Adults (>16 years): Infected necrosis at 14 days; Group 1: 10/88, Group 2: 12/88; Risk of bias: High; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 4: Extra-pancreatic infection at <1 year - Actual outcome for Adults (>16 years): Extra-pancreatic infection at 14 days; Group 1: 19/88, Group 2: 21/88; Risk of bias: High; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 5: Serious adverse events at <6 months - Actual outcome for Adults (>16 years): Multiorgan failure at 14 days; Group 1: 6/88, Group 2: 8/88; Risk of bias: High; Indirectness of outcome: No indirectness</p>	
Protocol outcomes not reported by the study	Quality of life at <1 year; Colonisation by resistant organisms at >6 months; Serious adverse events at >6 months; Colonisation by resistant organisms at <6 months

Study	Nordback 2001 ⁸⁰⁶
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=58)
Countries and setting	Conducted in Finland; Setting: Single centre, Tampere University Hospital
Line of therapy	Unclear
Duration of study	Not clear:
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Adults (>16 years)
Subgroup analysis within study	Not applicable
Inclusion criteria	Diagnosis of acute pancreatitis based on clinical criteria, an increase in serum amylase activity by at least three times the upper normal range, and CT verification of pancreatitis. The diagnosis of necrotizing pancreatitis was based on a serum C-reactive protein concentration >150 mg/L during the first 48 hours after admission and identification of necrotic areas in the pancreas with dynamic CT by the radiologist on duty.
Exclusion criteria	Those who had been started on antibiotics at the referring clinic, those admitted directly to intensive care unit because of early multi-organ failure, and those with frequent early need of antibiotic for other reasons, those who refused to participate in the study and those suspected of having a reaction to any of the study drugs
Recruitment/selection of patients	September 1995 to May 1999
Age, gender and ethnicity	Age - Mean (SD): intervention group 47(8); control group 46(7). Gender (M:F): 51/7. Ethnicity: not stated
Further population details	1. Severity of pancreatitis (as defined by study): Severe pancreatitis
Extra comments	Baseline characteristics, n or mean(SD) for intervention and control group, respectively: alcohol etiology 20, 25; biliary etiology 1, 2; other etiology 4, 6; CRP 211(44), 214(41); pancreatic necrosis on CT ,30% 8, 13; 30-50% 7, 10; >50% 10, 10. .
Indirectness of population	No indirectness
Interventions	(n=25) Intervention 1: Prophylactic antimicrobial therapy - Carbapenem. Imipenem 1.0 g plus cilastatin, IV three times a day. Duration unclear. Concurrent medication/care: non-operative conservative treatment was always attempted first. The three patients with gallstone pancreatitis underwent early ERCP. Patients with infected necrosis received surgery Further details: 1. Drug class: Carbapenems 2. Drug dose: 3. Drug route: Intravenous 4. Duration of therapy: Not stated / Unclear Comments: overall 11 patients received other antibiotics besides those originally used for this study

	<p>(n=33) Intervention 2: No prophylactic antimicrobial therapy. No antimicrobial therapy. Duration unclear. Concurrent medication/care: non-operative conservative treatment was always attempted first. The three patients with gallstone pancreatitis underwent early ERCP. Patients with infected necrosis first received imipenem at a dosage similar to that used in the early imipenem group for 5 days and if indication to surgery persisted or patient deteriorated surgery was performed.</p> <p>Further details: 1. Drug class: 2. Drug dose: 3. Drug route: 4. Duration of therapy: Comments: overall 11 patients received other antibiotics besides those originally used for this study</p>
Funding	Funding not stated
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: IMIPENEM PLUS CILASTATIN versus NO PROPHYLACTIC ANTIMICROBIAL THERAPY</p> <p>Protocol outcome 1: Length of stay (in intensive therapy unit or hospital) at <1 year - Actual outcome for Adults (>16 years): length of hospital stay at unclear; Group 1: mean 20 (SD 13); n=23, Group 2: mean 17 (SD 10); n=28; Risk of bias: Very high; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 2: Mortality at <1 year - Actual outcome for Adults (>16 years): Mortality at unclear; Group 1: 2/25, Group 2: 5/33; Risk of bias: Very high; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 3: Serious adverse events at <6 months - Actual outcome for Adults (>16 years): major organ complications at unclear; Group 1: 5/25, Group 2: 11/33; Risk of bias: Very high; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 4: infected pancreatic necrosis at <6 months - Actual outcome for Adults (>16 years): infected pancreatic necrosis at unclear; Group 1: 1/25, Group 2: 6/33; Risk of bias: Very high; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 5: extra-pancreatic infection at <6 months - Actual outcome for Adults (>16 years): extra-pancreatic infection at unclear; Group 1: 4/25, Group 2: 1/33; Risk of bias: Very high; Indirectness of outcome: No indirectness</p>	
Protocol outcomes not reported by the study	<p>Quality of life at <1 year; Extra-pancreatic infection at <1 year (available from published review that sought information from the author); Colonisation by resistant organisms at <6 months; Colonisation by resistant organisms at >6 months; Serious adverse events at >6 months; Infected necrosis at <1 year (available from published review that sought information from the author)</p>

Study	Pederzoli 1993 ⁸⁴⁷
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=74)
Countries and setting	Conducted in Italy; Setting: Six centers in Italy
Line of therapy	Not applicable
Duration of study	Intervention time: 14 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Necrotising AP was diagnosed on the basis of standard clinical criteria, ultrasonographic and computed tomographic scans.
Stratum	Adults (>16 years)
Subgroup analysis within study	Not applicable
Inclusion criteria	No previous pancreatic disease, admission within 48 hours of onset, no clinical evidence of sepsis, no previous antibiotic treatment, availability of contrast enhanced CT scan within 72 hours of onset and presence of detectable pancreatic necrosis.
Exclusion criteria	Not reported
Recruitment/selection of patients	Patients admitted to hospital with necrotising AP were included
Age, gender and ethnicity	Age - Range: 20-84 years. Gender (M:F): 44/30. Ethnicity: Not reported
Further population details	1. Severity of pancreatitis (as defined by study): Not stated / Unclear (Mild, moderate and severe necrosis included).
Extra comments	n or mean in intervention and control group, respectively: biliary etiology 21, 16; alcohol etiology 13, 11; other etiology 7, 6; Ranson 3.7, 3.6; mild necrosis 15, 20; moderate necrosis 12, 11; severe necrosis 14, 2.
Indirectness of population	No indirectness
Interventions	(n=41) Intervention 1: Prophylactic antimicrobial therapy - Carbapenem. 500 mg Imipenem given intravenously every eight hours for 14 days.. Duration 14 days. Concurrent medication/care: All patients received the same medical treatment Further details: 1. Drug class: Carbapenems 2. Drug dose: Not stated / Unclear (BNF dose). 3. Drug route: Intravenous 4. Duration of therapy: Not stated / Unclear (n=33) Intervention 2: No prophylactic antimicrobial therapy. Patients in this group only received medical treatment. Duration 14 days. Concurrent medication/care: All patients received the same medical treatment. Further details: 1. Drug class: Not applicable 2. Drug dose: Not applicable 3. Drug route: Not applicable 4. Duration of

	therapy: Not applicable
Funding	Funding not stated
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: IMIPENEM versus NO PROPHYLACTIC ANTIMICROBIAL THERAPY</p> <p>Protocol outcome 1: Mortality at <1 year - Actual outcome for Adults (>16 years): Mortality at 14 days; Group 1: 3/41, Group 2: 4/33; Risk of bias: Low; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 2: Infected necrosis at <1 year - Actual outcome for Adults (>16 years): Pancreatic sepsis at 14 days; Group 1: 5/41, Group 2: 10/33; Risk of bias: Low; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 3: Extra-pancreatic infection at <1 year - Actual outcome for Adults (>16 years): Non-Pancreatic sepsis at 14 days; Group 1: 6/41, Group 2: 16/33; Risk of bias: Low; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 4: Serious adverse events at <6 months - Actual outcome for Adults (>16 years): Multiorgan failure at 14 days; Group 1: 12/41, Group 2: 13/33; Risk of bias: Low; Indirectness of outcome: No indirectness</p>	
Protocol outcomes not reported by the study	Quality of life at <1 year; Colonisation by resistant organisms at <6 months; Colonisation by resistant organisms at >6 months; Serious adverse events at >6 months; Length of stay (in intensive therapy unit or hospital) at <1 year

Study	Røkke 2007 ⁹¹⁹
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=73)
Countries and setting	Conducted in Norway; Setting: Seven Norwegian hospitals
Line of therapy	Not applicable
Duration of study	Intervention time: 5-7 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Diagnosis of acute pancreatitis was based on clinical examination, serum amylase levels above three times the normal upper limit or CT characteristics typical for acute pancreatitis.
Stratum	Adults (>16 years)
Subgroup analysis within study	Not applicable
Inclusion criteria	Criteria for inclusion included a duration of symptoms of less than 72h. Diagnosis of acute pancreatitis was based on clinical examination, serum amylase levels above three times the normal upper limit or CT characteristics typical for acute pancreatitis. The diagnosis of severe pancreatitis was based on a) CRP levels above 120 mg/l within the first 24 h or above 200 mg/l within 48h or b) pancreatitis necrosis as defined by dynamic CT.
Exclusion criteria	Age below 18 years, ongoing antibiotic treatment, previous episodes of acute pancreatitis, post-ERCP pancreatitis, concomitant bacterial infection such as cholangitis or cholecystitis, allergy to imipenem and pregnancy
Recruitment/selection of patients	Patients admitted to hospital with severe pancreatitis were eligible for inclusion
Age, gender and ethnicity	Age - Range: 19-84. Gender (M:F): 49/24. Ethnicity: Not reported
Further population details	1. Severity of pancreatitis (as defined by study): Severe pancreatitis (Imipenem and control group, respectively: APACHE II 7 (0-18), 6 (1-15); CRP 228 (122-448), 240 (49-457), CT pancreatic necrosis <30% 19, 18; CT necrosis 30-50% 3, 1; CT necrosis >50% 4, 9).
Extra comments	Imipenem and control group, n or mean (range), respectively: alcoholic cause 8, 10; biliary 20, 17; others 8, 10; APACHE II 7 (0-18), 6 (1-15); CRP 228 (122-448), 240 (49-457), CT pancreatic necrosis <30% 19, 18; CT necrosis 30-50% 3, 1; CT necrosis >50% 4, 9.
Indirectness of population	No indirectness
Interventions	(n=36) Intervention 1: Prophylactic antimicrobial therapy - Carbapenem. Early therapy with imipenem, 500 mg three times daily for 5-7 days. Duration 5-7 days. Concurrent medication/care: Not reported Further details: 1. Drug class: Carbapenems 2. Drug dose: Not stated / Unclear (BNF dose). 3. Drug route: Not stated / Unclear 4. Duration of therapy: Not stated / Unclear

	<p>Comments: Patients in both groups were given antibiotics on demand when infection was diagnosed</p> <p>(n=37) Intervention 2: No prophylactic antimicrobial therapy. Patients in the control group did not receive any treatment.. Duration 5-7 days. Concurrent medication/care: Not reported</p> <p>Further details: 1. Drug class: Not applicable 2. Drug dose: Not applicable 3. Drug route: Not applicable 4. Duration of therapy: Not applicable</p> <p>Comments: Patients in both groups were given antibiotics on demand when infection was diagnosed</p>
Funding	Study funded by industry (Supported by MSD)
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: IMIPENEM versus NO THERAPY</p> <p>Protocol outcome 1: Length of stay (in intensive therapy unit or hospital) at <1 year - Actual outcome for Adults (>16 years): Hospitalisation at 4 weeks; Mean Imipenem: 18; control: 22; Risk of bias: High; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 2: Mortality at <1 year - Actual outcome for Adults (>16 years): Mortality at 4 weeks; Group 1: 3/36, Group 2: 4/37; Risk of bias: High; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 3: Extra-pancreatic infection at <1 year - Actual outcome for Adults (>16 years): Peri-pancreatic infection at 4 weeks; Group 1: 3/36, Group 2: 7/37; Risk of bias: High; Indirectness of outcome: No indirectness - Actual outcome for Adults (>16 years): Extra-pancreatic infection at 4 weeks; Group 1: 3/36, Group 2: 12/37; Risk of bias: High; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 4: Serious adverse events at <6 months - Actual outcome for Adults (>16 years): Organ failure at 4 weeks; Group 1: 6/36, Group 2: 9/37; Risk of bias: Low; Indirectness of outcome: No indirectness</p>	
Protocol outcomes not reported by the study	Quality of life at <1 year; Colonisation by resistant organisms at <6 months; Colonisation by resistant organisms at >6 months; Serious adverse events at >6 months; Infected necrosis at <1 year

Study	Sainio 1995 ⁹⁴⁰
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=60)
Countries and setting	Conducted in Finland; Setting: Second department of surgery, Helsinki University central hospital.
Line of therapy	Not applicable
Duration of study	Intervention time: 14 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Dynamic CECT within 24 hours of admission, the pancreas was scanned at a preselected level for 60 seconds in a Siemens Somatom, Somatom DR2, or DRH
Stratum	Adults (>16 years)
Subgroup analysis within study	Not applicable
Inclusion criteria	CRP concentration above 120 mg/L within 48 hours of admission and low contrast enhancement of the pancreas (below 30 Hounsfield units [HU] on CECT. If CECT could not be done because of impaired renal function or allergy, early extrapancreatic scores were recorded and patients with scores of 4 or more points were included in the study.
Exclusion criteria	Treatment elsewhere for more than 2 days before admission to the hospital, continuing antimicrobial treatment, a previous severe episode of pancreatitis, and aetiology other than alcohol and no history of alcohol intake before admission.
Recruitment/selection of patients	60 consecutive patients admitted to hospital (July 1989 - November 1993)
Age, gender and ethnicity	Age - Mean (SD): 43 (11.3), 38.7 (8.4). Gender (M:F): 53/7. Ethnicity: Not reported
Further population details	1. Severity of pancreatitis (as defined by study): Not stated / Unclear
Extra comments	Alcohol-induced necrotising pancreatitis. Baseline characteristics for intervention and control group, respectively: mean (range) maximum C-reactive protein in first 48 hrs, mg/dl 308 (141-548), 343 (140-496); mean hospital (SD) stay 33.2 (22.1), 43.8 (43.1).
Indirectness of population	No indirectness
Interventions	(n=30) Intervention 1: Prophylactic antimicrobial therapy - Cephalosporin. Three doses of 1.5 g cefuroxime per day intravenously was started on admission and continued until clinical recovery and fall to normal of CRP concentrations. In cases of full recovery but moderately raised CRP concentrations, antibiotic treatment was continued with cefuroxime by mouth (two doses of 250 mg per day). Duration Up to 14 days. Concurrent medication/care: Adequate fluid replacement by central venous catheter, with monitoring of central venous pressure, and assistance of respiratory or renal function when needed.

	<p>Further details: 1. Drug class: Cephalosporins 2. Drug dose: Not stated / Unclear (BNF dose). 3. Drug route: Intravenous 4. Duration of therapy: Not stated / Unclear</p> <p>(n=30) Intervention 2: No prophylactic antimicrobial therapy. No antibiotic treatment was given before infection had been clinically, microbiologically, or radiologically verified, or until there was a secondary rise in CRP of more than 20% after the acute phase.. Duration Up to 14 days. Concurrent medication/care: Adequate fluid replacement by central venous catheter, with monitoring of central venous pressure, and assistance of respiratory or renal function when needed.</p> <p>Further details: 1. Drug class: Not applicable 2. Drug dose: Not applicable 3. Drug route: Not applicable 4. Duration of therapy: Not applicable</p>
Funding	Funding not stated
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: CEFUROXIME versus NO PROPHYLACTIC ANTIMICROBIAL THERAPY</p> <p>Protocol outcome 1: Length of stay (in intensive therapy unit or hospital) at <1 year - Actual outcome for Adults (>16 years): Length of hospital stay at 14 days; MD 10.6 (p value 0.24); Risk of bias: High; Indirectness of outcome: No indirectness - Actual outcome for Adults (>16 years): Length of CCU stay at 14 days; MD 10.9 (p value 0.06); Risk of bias: High; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 2: Mortality at <1 year - Actual outcome for Adults (>16 years): Mortality at 14 days; Group 1: 1/30, Group 2: 7/30; Risk of bias: High; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 3: Infected necrosis at <1 year - Actual outcome for Adults (>16 years): Abscess or infected necrosis at 14 days; Group 1: 9/30, Group 2: 12/30; Risk of bias: High; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 4: Extra-pancreatic infection at <1 year - Actual outcome for Adults (>16 years): Peripancreatic infection at 14 days; Group 1: 21/30, Group 2: 18/30; Risk of bias: High; Indirectness of outcome: No indirectness - Actual outcome for Adults (>16 years): Blood culture positive sepsis at 14 days; Group 1: 4/30, Group 2: 8/30; Risk of bias: High; Indirectness of outcome: No indirectness - Actual outcome for Adults (>16 years): Urinary tract infection at 14 days; Group 1: 6/30, Group 2: 17/30; Risk of bias: High; Indirectness of outcome: No indirectness - Actual outcome for Adults (>16 years): Pneumonia/ARDS at 14 days; Group 1: 11/30, Group 2: 17/30; Risk of bias: High; Indirectness of outcome: No indirectness</p>	
Protocol outcomes not reported by the study	Quality of life at <1 year; Colonisation by resistant organisms at >6 months; Serious adverse events at <6 months; Serious adverse events at >6 months; Colonisation by resistant organisms at <6 months

Study	Xue 2009 ¹¹⁶⁷
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=59)
Countries and setting	Conducted in China; Setting: West China Hospital of Sichuan University
Line of therapy	Not applicable
Duration of study	Intervention + follow up: 7-14 days and 1 month follow-up
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: The diagnostic criteria for severe acute pancreatitis formulated at the 2002 Bangkok World Congress of Gastroenterology were adopted. Necrosis was confirmed by contrast-enhanced computerised tomography (CECT).
Stratum	Adults (>16 years)
Subgroup analysis within study	Not applicable
Inclusion criteria	Hospitalised male and female patients (≥18 years of age) with a confirmed diagnosis of SAP. Patients with 30% or more necrosis of the pancreas (as proven by contrast enhanced CT) were eligible for inclusion.
Exclusion criteria	concurrent sepsis or (peri)pancreatic infection caused by a second disease; direct transfer to the intensive care unit due to multiple organ failure; recurrent or endoscopic retrograde cholangiopancreatography (ERCP), or traumatic or operative pancreatitis; pregnancy, malignancy or immunodeficiency; a history of allergy to imipenem-clastin; a history of antibiotic administration within 48 hours prior to enrollment; and possible death within 48 hours after enrollment.
Recruitment/selection of patients	Patients admitted to hospital with a confirmed diagnosis of SAP in January-December 2007
Age, gender and ethnicity	Age - Mean (SD): Study group: 48.4 (15.1) Control group: 47.5 (12.3). Gender (M:F): 28/28. Ethnicity: Not reported
Further population details	1. Severity of pancreatitis (as defined by study): Severe pancreatitis (N or mean(SD) for intervention and control group, respectively: Ranson score 4.8(1.5), 5.3(1.7), 24h APACHE II Score 12.7(2.1), 11.9(3.7), pancreatic necrosis in CECT 30-50% 17, 18; pancreatic necrosis in CECT >50% 12, 9.).
Extra comments	N or mean (SD) for intervention and control group, respectively: biliary etiology 15, 14; alcoholic etiology 4, 2; hyperlipidemic 2, 2; idiopathic 8, 9; Ranson score 4.8(1.5), 5.3(1.7), 24h APACHE II Score 12.7(2.1), 11.9(3.7), pancreatic necrosis in CECT 30-50% 17, 18; pancreatic necrosis in CECT >50% 12, 9. . Patient who had been enrolled in the trial were withdrawn if they died, received surgery because of a lack of response to intensive care treatment within 72h of admission, or had serious adverse effect after administration of imipenem-cilastatin
Indirectness of population	No indirectness
Interventions	(n=30) Intervention 1: Prophylactic antimicrobial therapy - Carbapenem. 500mg imipenem-cilastatin every 8 hours by

	<p>30 mins IV drip within 72 h of onset of symptoms. All 500mg doses were diluted in 100 mL normal saline solution.. Duration 7-14 days. Concurrent medication/care: The use of non-study antibiotics in the study group or any antibiotics in the control group was not encouraged until progressive pancreatitis was manifested by clinical deterioration, and/or infection was microbiologically verified or strongly suspected, or after an initial severe inflammatory response syndrome, a secondary rise in serum C-reactive protein (CRP) was measured. During the hospital stay, all patients received daily intensive care (monitoring of temperature, oxygen saturation, central venous pressure vis central venous catheter, liquid intake and output, and were given supportive care and nutritive administration. Further details: 1. Drug class: Carbapenems 2. Drug dose: Not stated / Unclear (BNF dose). 3. Drug route: Intravenous 4. Duration of therapy: Not stated / Unclear</p> <p>Comments: In patients who were switched to open antibiotic treatment, the choice of antibiotic was at the investigator's discretion and the recommendation of the study protocol was to use imipenem, possibly in combination to vancomycin. If the presence of bacteria was confirmed, appropriate antibiotic therapy was guided by the results of drug sensitivity testing.</p> <p>(n=29) Intervention 2: No prophylactic antimicrobial therapy. The control group did not receive any antibiotics. Duration 7-14 days. Concurrent medication/care: The use of non-study antibiotics in the study group or any antibiotics in the control group was not encouraged until progressive pancreatitis was manifested by clinical deterioration, and/or infection was microbiologically verified or strongly suspected, or after an initial severe inflammatory response syndrome, a secondary rise in serum C-reactive protein (CRP) was measured. During the hospital stay, all patients received daily intensive care (monitoring of temperature, oxygen saturation, central venous pressure vis central venous catheter, liquid intake and output, and were given supportive care and nutritive administration. Further details: 1. Drug class: Not applicable 2. Drug dose: Not applicable 3. Drug route: Not applicable 4. Duration of therapy: Not applicable</p> <p>Comments: In patients who were switched to open antibiotic treatment, the choice of antibiotic was at the investigator's discretion and the recommendation of the study protocol was to use imipenem, possibly in combination to vancomycin. If the presence of bacteria was confirmed, appropriate antibiotic therapy was guided by the results of drug sensitivity testing.</p>
Funding	Academic or government funding (Supported by Sichuan Province Science and Technology Tackling Key Project)
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: IMIPENEM-CILASTATIN versus NO PROPHYLACTIC ANTIMICROBIAL THERAPY</p> <p>Protocol outcome 1: Length of stay (in intensive therapy unit or hospital) at <1 year - Actual outcome for Adults (>16 years): Hospital stay at 6 weeks; Other: Median (range) for intervention and control groups, respectively: 28.3 (23-71), 30.7(25-60); Risk of bias: Low; Indirectness of outcome: No indirectness</p>	

Protocol outcome 2: Mortality at <1 year

- Actual outcome for Adults (>16 years): Mortality at 6 weeks; Group 1: 3/29, Group 2: 4/27; Risk of bias: Low; Indirectness of outcome: No indirectness

Protocol outcome 3: Infected necrosis at <1 year

- Actual outcome for Adults (>16 years): Infected necrosis at 6 weeks; Group 1: 8/29, Group 2: 10/27; Risk of bias: Low; Indirectness of outcome: No indirectness

Protocol outcome 4: Extra-pancreatic infection at <1 year

- Actual outcome for Adults (>16 years): Extra-pancreatic infection (n of events - Lung, intestine, blood and urinary tract) at 6 weeks; Group 1: 18/29, Group 2: 15/27; Risk of bias: Low; Indirectness of outcome: No indirectness

Protocol outcome 5: Serious adverse events at <6 months

- Actual outcome for Adults (>16 years): Organ complication (n of events - Acute respiratory distress syndrome, Acute renal failure, Hepatic insufficiency, Shock, Pancreatic pseudocyst) at 6 weeks; Group 1: 28/29, Group 2: 23/27; Risk of bias: Low; Indirectness of outcome: No indirectness

Protocol outcomes not reported by the study

Quality of life at <1 year; Colonisation by resistant organisms at >6 months; Serious adverse events at >6 months; Colonisation by resistant organisms at <6 months

H.12 Methods of management of infected necrosis in people with acute pancreatitis

Study (subsidiary papers)	Van Santvoort 2010¹¹⁰² (Besselink 2006¹²⁴)
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=88)
Countries and setting	Conducted in Netherlands; Setting: 7 University medical centers and 12 large teaching hospitals of the Dutch Pancreatitis Study Group.
Line of therapy	Unclear
Duration of study	Intervention time: 3 years
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Diagnosed by contrast enhanced CT. Infected necrosis was defined as a positive culture of pancreatic or peripancreatic necrotic tissue obtained by means of fine-needle aspiration or from the first drainage procedure or operation.
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients with a confirmed or suspected infected pancreatic or peripancreatic necrosis due for surgical intervention.
Exclusion criteria	A flare-up of chronic pancreatitis, previous exploratory laparotomy during the current episode of pancreatitis, previous drainage or surgery for confirmed or suspected infected necrosis, pancreatitis caused by abdominal surgery, and an acute intraabdominal event (for example, perforation of a visceral organ, bleeding, or the abdominal compartment syndrome)
Recruitment/selection of patients	Patients were admitted to participating hospitals
Age, gender and ethnicity	Age - Mean (SD): MI group: 57.6 (2.1) PON group: 57.4 (2). Gender (M:F): 44:38. Ethnicity: Not reported

Further population details	1. Severity of infection: Not stated / Unclear 2. Severity of pancreatitis: Severe pancreatitis
Extra comments	MI group Etiology: Gallstones - 60%, Alcohol - 7%, Other - 33%; BMI (median): 28; CT severity index (median): 8 PON group Etiology: Gallstones - 64%, Alcohol - 11%, Other - 24%; BMI (median): 27; CT severity index (median): 8
Indirectness of population	No indirectness
Interventions	<p>(n=43) Intervention 1: Minimally invasive surgery - Percutaneous. The first step in the step-up approach was percutaneous or endoscopic transgastric drainage. The preferred route was through the left retroperitoneum. If there was no clinical improvement after 72 hours and if the position of the drain was inadequate or other fluid collections could be drained, a second drainage procedure was performed. If this was not possible, or if there was no clinical improvement after an additional 72 hours, the second step, video -assisted retroperitoneal debridement with postoperative lavage was performed.. Duration During admission. Concurrent medication/care: Postoperative management included the following: Continuous postoperative lavage with normal saline or peritoneal dialysis fluid was started. On the third postoperative day, the lavage amounted to at least 10 L per 24 hours. CECT was performed 1 week after every drain placement and surgical intervention. Catheters were removed if collapse of the cavity was shown through CECT.</p> <p>Further details: 1. Procalcitonin-led antibiotic treatment: Not stated / Unclear 2. Type of minimally invasive surgery : Systematic review: mixed</p> <p>(n=45) Intervention 2: Open surgery. Laparotomy through a bilateral subcostal incision. After blunt removal of all necrotic tissue, 2 large-bore drains for post-operative lavage were inserted, and the abdomen was closed.. Duration During admission. Concurrent medication/care: Postoperative management included the following: Continuous postoperative lavage with normal saline or peritoneal dialysis fluid was started. On the third postoperative day, the lavage amounted to at least 10 L per 24 hours. CECT was performed 1 week after every drain placement and surgical intervention. Catheters were removed if collapse of the cavity was shown through CECT.</p> <p>Further details: 1. Procalcitonin-led antibiotic treatment: Not stated / Unclear 2. Type of minimally invasive surgery : Not applicable</p>
Funding	Academic or government funding (Supported by a grant from the Dutch Organisation for Health Research and Development)

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: PERCUTANEOUS OR ENDOSCOPIC DRAINAGE versus OPEN SURGERY

Protocol outcome 1: Length of stay (in intensive therapy unit or hospital) at <1 year

- Actual outcome: Days in CCU at During admission; Other: Median; Risk of bias: High; Indirectness of outcome: No indirectness
- Actual outcome: Days in hospital at During admission; Other: Median; Risk of bias: High; Indirectness of outcome: No indirectness

Protocol outcome 2: Mortality at <1 year

- Actual outcome: Mortality at During admission; Group 1: 8/43, Group 2: 7/45; Risk of bias: Low; Indirectness of outcome: No indirectness

Protocol outcome 3: Number of procedures (repeated procedures) at <1 year

- Actual outcome: Total number of operations at During admission; Other: Median; Risk of bias: Low; Indirectness of outcome: No indirectness
- Actual outcome: Total number of drainage procedures at During admission; Other: Median; Risk of bias: Low; Indirectness of outcome: No indirectness

Protocol outcome 4: Complications (for example, bleeding, fistulae) at <1 year

- Actual outcome: New onset multiple organ failure at During admission; Group 1: 5/43, Group 2: 19/45; Risk of bias: Low; Indirectness of outcome: No indirectness
- Actual outcome: Multiple organ failure at During admission; Group 1: 5/43, Group 2: 18/45; Risk of bias: Low; Indirectness of outcome: No indirectness
- Actual outcome: Multiple systemic complications at During admission; Group 1: 0/43, Group 2: 1/45; Risk of bias: Low; Indirectness of outcome: No indirectness
- Actual outcome: Intraabdominal bleeding requiring intervention at During admission; Group 1: 7/43, Group 2: 10/45; Risk of bias: Low; Indirectness of outcome: No indirectness
- Actual outcome: Enterocutaneous fistula or perforation of a visceral organ requiring intervention at During admission; Group 1: 6/43, Group 2: 10/45; Risk of bias: Low; Indirectness of outcome: No indirectness

Protocol outcome 5: Pancreatic function (for example, development of diabetes) at <1 year

- Actual outcome: New onset diabetes at During admission; Group 1: 7/43, Group 2: 17/45; Risk of bias: Low; Indirectness of outcome: No indirectness
- Actual outcome: Use of pancreatic enzymes at During admission; Group 1: 3/43, Group 2: 15/45; Risk of bias: Low; Indirectness of outcome: No indirectness

Protocol outcomes not reported by the study

Quality of life at <1 year; Recurrence of infection at <1 year

Study	Besselink 2006 ¹²³
Study type	Non-randomised comparative study
Number of studies (number of participants)	1 (n=106)
Countries and setting	Conducted in Netherlands
Line of therapy	1st line
Duration of study	Intervention and follow-up: 3 years (2000-2003)
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: The diagnosis of necrotising pancreatitis was accepted when confirmed by contrast-enhanced CT or during surgery
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	All consecutive patients undergoing surgical treatment for infected necrotising pancreatitis between 1 October 2000 and 1 October 2003. Indications for intervention were persistent sepsis despite maximal conservative therapy or clinical deterioration after initial clinical improvement (suspected infection), documented infection of peri-pancreatic necrosis by FNA, air collections in (peri)pancreatic necrosis on contrast-enhanced CT images, suspected bowel perforation or active bleeding.
Exclusion criteria	Patients younger than 18 years, those with acute flare-up of chronic pancreatitis and patients undergoing elective surgery for pancreatic pseudocysts were excluded.
Recruitment/selection of patients	Computer database search for acute pancreatitis operation codes
Age, gender and ethnicity	Age - Median (range): 59 (20-81). Gender (M:F): 76/30. Ethnicity: not stated
Further population details	1. Severity of infection: Not stated / Unclear 2. Severity of pancreatitis: Not stated / Unclear

Extra comments	Etiology: biliary n=34, ERCP n=13, alcoholic n=11, idiopathic n=29, other n=19.
Indirectness of population	No indirectness
Interventions	<p>(n=23) Intervention 1: Open surgery. Open abdomen strategy (OAS): the abdomen was left open following the first laparotomy for debridement; planned relaparotomy or relaparotomy on demand were both possible after the first laparotomy. . Duration unclear. Concurrent medication/care: not stated Further details: 1. Procalcitonin-led antibiotic treatment: Not applicable 2. Type of minimally invasive surgery : Not applicable</p> <p>(n=53) Intervention 2: Open surgery. Continuous postoperative lavage (CPL): rinsing of the necrosectomy areas after debridement for INP, followed by closure of the abdomen and continuous postoperative local or locoregional lavage with liberal amounts of fluids . Duration unclear. Concurrent medication/care: not stated Further details: 1. Procalcitonin-led antibiotic treatment: Not applicable 2. Type of minimally invasive surgery : Not applicable</p> <p>(n=18) Intervention 3: Minimally invasive surgery - Percutaneous. Minimally invasive procedures (MIP): open or videoscopically assisted retroperitoneal debridement, followed by closure of the abdomen and continuous local or locoregional lavage with liberal amounts of fluids. The preferred route was straight into the retroperitoneum through a small left-sided lumbar incision. If this was not possible, an anterior transabdominal laparoscopic approach was used. . Duration unclear. Concurrent medication/care: not stated Further details: 1. Procalcitonin-led antibiotic treatment: Not applicable 2. Type of minimally invasive surgery : Not applicable</p> <p>(n=12) Intervention 4: Open surgery. Laparotomy with primary abdominal closure (PAC): laparotomy and blunt debridement of necrotic tissue, followed by abdominal closure with no postoperative lavage system in place. . Duration unclear. Concurrent medication/care: not stated Further details: 1. Procalcitonin-led antibiotic treatment: Not applicable 2. Type of minimally invasive surgery : Not applicable</p>
Funding	Academic or government funding (Senter, an agency of the Dutch Ministry of Economic Affairs)

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: OPEN SURGERY (OPEN ABDOMEN STRATEGY) versus MINIMALLY INVASIVE SURGERY (RETROPERITONEAL DEBRIDEMENT)

Protocol outcome 1: Length of stay (in intensive therapy unit or hospital) at <1 year

- Actual outcome: Postop. CCU stay in survivors at unclear; Mean (Median (range) for OAS and MIP, respectively: 16 (0-68); 2 (0-83)); Risk of bias: Very high; Indirectness of outcome: No indirectness
- Actual outcome: Postop. hospital stay in survivors at unclear; Risk of bias: Very high; Indirectness of outcome: No indirectness

Protocol outcome 2: Mortality at <1 year

- Actual outcome: In-hospital deaths at unclear; Group 1: 16/23, Group 2: 2/18; Risk of bias: Very high; Indirectness of outcome: No indirectness

Protocol outcome 3: Number of procedures (repeated procedures) at <1 year

- Actual outcome: Reintervention at unclear; Group 1: 23/23, Group 2: 12/18; Risk of bias: Very high; Indirectness of outcome: No indirectness

Protocol outcome 4: Complications (for example, bleeding, fistulae) at <1 year

- Actual outcome: Bowel perforation at unclear; Group 1: 7/23, Group 2: 3/18; Risk of bias: Very high; Indirectness of outcome: No indirectness
- Actual outcome: Bleeding (transfusion) at unclear; Group 1: 11/23, Group 2: 3/18; Risk of bias: Very high; Indirectness of outcome: No indirectness

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: OPEN SURGERY (CONTINUOUS POSTOPERATIVE LAVAGE) versus MINIMALLY INVASIVE SURGERY (RETROPERITONEAL DEBRIDEMENT)

Protocol outcome 1: Length of stay (in intensive therapy unit or hospital) at <1 year

- Actual outcome: Postop. CCU stay in survivors at unclear; Risk of bias: Very high; Indirectness of outcome: No indirectness
- Actual outcome: Postop. hospital stay in survivors at unclear; Risk of bias: Very high; Indirectness of outcome: No indirectness

Protocol outcome 2: Mortality at <1 year

- Actual outcome: In-hospital deaths at unclear; Group 1: 13/53, Group 2: 2/18; Risk of bias: Very high; Indirectness of outcome: No indirectness

Protocol outcome 3: Number of procedures (repeated procedures) at <1 year

- Actual outcome: Reintervention at unclear; Group 1: 39/53, Group 2: 12/18; Risk of bias: Very high; Indirectness of outcome: No indirectness

Protocol outcome 4: Complications (for example, bleeding, fistulae) at <1 year

- Actual outcome: Bowel perforation at unclear; Group 1: 11/53, Group 2: 3/18; Risk of bias: Very high; Indirectness of outcome: No indirectness
- Actual outcome: Bleeding (transfusion) at unclear; Group 1: 17/53, Group 2: 3/18; Risk of bias: Very high; Indirectness of outcome: No indirectness

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: OPEN SURGERY (LAPAROTOMY WITH PRIMARY ABDOMINAL CLOSURE) versus MINIMALLY

INVASIVE SURGERY (RETROPERITONEAL DEBRIDEMENT)

Protocol outcome 1: Length of stay (in intensive therapy unit or hospital) at <1 year

- Actual outcome: Postop. CCU stay in survivors at unclear; Risk of bias: Very high; Indirectness of outcome: No indirectness
- Actual outcome: Postop. hospital stay in survivors at unclear; Risk of bias: Very high; Indirectness of outcome: No indirectness

Protocol outcome 2: Mortality at <1 year

- Actual outcome: In-hospital deaths at unclear; Group 1: 5/12, Group 2: 2/18; Risk of bias: Very high; Indirectness of outcome: No indirectness

Protocol outcome 3: Number of procedures (repeated procedures) at <1 year

- Actual outcome: Reintervention at unclear; Group 1: 2/12, Group 2: 12/18; Risk of bias: Very high; Indirectness of outcome: No indirectness

Protocol outcome 4: Complications (for example, bleeding, fistulae) at <1 year

- Actual outcome: Bowel perforation at unclear; Group 1: 0/0, Group 2: 3/18; Risk of bias: Very high; Indirectness of outcome: No indirectness
- Actual outcome: Bleeding (transfusion) at unclear; Group 1: 2/12, Group 2: 3/18; Risk of bias: Very high; Indirectness of outcome: No indirectness

Protocol outcomes not reported by the study

Quality of life at <1 year; Pancreatic function (for example, development of diabetes) at <1 year; Recurrence of infection at <1 year

Study	Garg 2010 ³⁹¹
Study type	Non-randomised comparative study
Number of studies (number of participants)	1 (n=80)
Countries and setting	Conducted in India; Setting: tertiary care academic centre
Line of therapy	1st line
Duration of study	Other: 1997-2006
Method of assessment of guideline condition	--: Diagnosis of AP was made in the presence of suggestive clinical deatures, increased serum amilase levels (>3 times the upper limit of normal), and evidence of AP on imaging studies. Diagnosis of IPN was made when pancreatic necrotic tissue obtained by FNA showed presence of bacteria on Gram stain or when it grew an organism on culture. In pts with suspected IPN, presence of extraintestinal gas in the pancreatic bed on a CT scan was taken as another evidence of infected necrosis.
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	All consecutive patients with AP admitted to the hospital were included in the study. Patients with IPN formed the study group.
Exclusion criteria	Define
Recruitment/selection of patients	consecutive patients
Age, gender and ethnicity	Age – not stated: . Gender (M:F): 52/28. Ethnicity: not reported
Further population details	1. Severity of infection: Not stated / Unclear 2. Severity of pancreatitis: Not stated / Unclear

Extra comments	Etiology: gallstone n=48, alcohol n=10, others n=22..
Indirectness of population	--
Interventions	<p>(n=30) Intervention 1: Open surgery. Surgical necrosectomy, lavage and drainage. Initial surgical treatment included debridement (necrosectomy) and if required (for example, intraoperative bleeding necessitating packing or inadequate necrosectomy), planned re-explorations after 48 hours. When intraoperative assessment was considered satisfactory regarding hemostasis/necrosectomy, the abdomen was closed, multiple drains were placed, and perioperative lavage was carried out. . Duration 1997-2002. Concurrent medication/care: not stated Further details: 1. Procalcitonin-led antibiotic treatment: 2. Type of minimally invasive surgery :</p> <p>(n=50) Intervention 2: Combination of intervention techniques - Step-up approach. Primary conservative medical treatment: aggressive medical management that included combination antibiotics, organ support, intensive nutritional support and percutaneous drainage if required (for IPN that had become organised and walled off, under US or CT guidance). If clinical improvement was noted, the patient was continued on conservative treatment and antibiotics were given for 4 weeks. If no improvement, the patient was subjected to surgery. . Duration 2003-2006. Concurrent medication/care: not stated Further details: 1. Procalcitonin-led antibiotic treatment: 2. Type of minimally invasive surgery :</p>
Funding	Funding not stated (No conflict of interest declared)
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: OPEN SURGERY (NECROSECTOMY) versus STEP-UP APPROACH</p> <p>Protocol outcome 1: Length of stay (in intensive therapy unit or hospital) at <1 year - Actual outcome: Hospital stay.; Risk of bias: Very high; Indirectness of outcome: No indirectness</p>	
Protocol outcomes not reported by the study	Quality of life at <1 year; Recurrence of infection at <1 year; Number of procedures (repeated procedures) at <1 year; Complications (for example, bleeding, fistulae) at <1 year; Pancreatic function (for example, development of diabetes) at <1 year; Mortality at <1 year

Study	Gluck 2012 ⁴⁰⁶
Study type	Non-randomised comparative study
Number of studies (number of participants)	1 (n=102)
Countries and setting	Conducted in USA; Setting: The Digestive Disease Institute, Virginia Mason Medical Center
Line of therapy	Unclear
Duration of study	Intervention time: 5 years
Method of assessment of guideline condition	Unclear method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Define
Exclusion criteria	Define
Recruitment/selection of patients	All patients had been admitted to the hospital.
Age, gender and ethnicity	Age - Mean (SD): SPD: 53.5 DMD: 55.9. Gender (M:F): Define. Ethnicity: Not reported
Further population details	1. Severity of infection: Not stated / Unclear 2. Severity of pancreatitis: Not stated / Unclear
Indirectness of population	No indirectness
Interventions	(n=50) Intervention 1: Minimally invasive surgery - Endoscopic. CT-guided percutaneous drains were placed as in SPD cohort, but only 10 mL of fluid was aspirated. The patient was then rapidly transferred to a fluoroscopically equipped endoscopy suite at which time the WOPN was accessed either transestrically or transduodenally. Endoscopic

	<p>ultrasound was used if there was an inconclusive luminal bulge.. Duration During admission. Concurrent medication/care: All patients received culture directed antibiotics, and all patients were managed by critical care specialists or hospitalists. Further details: 1. Procalcitonin-led antibiotic treatment: Not stated / Unclear 2. Type of minimally invasive surgery : Percutaneous</p> <p>(n=52) Intervention 2: Percutaneous drainage (radiological). Symptomatic SAP patients has percutaneous drainage catheters placed into areas of WOPN.. Duration During admission. Concurrent medication/care: All patients received culture directed antibiotics, and all patients were managed by critical care specialists or hospitalists. Further details: 1. Procalcitonin-led antibiotic treatment: Not stated / Unclear 2. Type of minimally invasive surgery : Not applicable</p>
Funding	Funding not stated
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENDOSCOPY versus PERCUTANEOUS DRAINAGE (RADIOLOGICAL)</p> <p>Protocol outcome 1: Length of stay (in intensive therapy unit or hospital) at <1 year - Actual outcome: Length of stay in hospital at During admission; Group 1: mean 24 days (SD 23); n=49, Group 2: mean 54 days (SD 41); n=45; Risk of bias: Very high; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 2: Mortality at <1 year - Actual outcome: Mortality at During admission; Group 1: 2/49, Group 2: 3/45; Risk of bias: Very high; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 3: Complications (for example, bleeding, fistulae) at <1 year - Actual outcome: Pseudoaneurysm bleeding at During admission; Group 1: 0/49, Group 2: 5/45; Risk of bias: Very high; Indirectness of outcome: No indirectness</p>	
Protocol outcomes not reported by the study	Quality of life at <1 year; Number of procedures (repeated procedures) at <1 year; Pancreatic function (for example, development of diabetes) at <1 year; Recurrence of infection at <1 year
Study	He 2017⁴⁴⁹

Study type	Non-randomised comparative study
Number of studies (number of participants)	1 (n=26)
Countries and setting	Conducted in China; Setting: Hospital
Line of therapy	Adjunctive to current care
Duration of study	Intervention and follow-up: 1 year
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Acute pancreatitis was its severity are defined by the revision of the Atlanta classification
Stratum	Overall
Subgroup analysis within study	Not applicable:
Inclusion criteria	Patients aged 18-70 years admitted or transferred to hospital with suspected infected pancreatic necrosis, and an indication for intervention. IPN was defined as extraluminal gas in the pancreatic and/or peripancreatic tissues on CECT, or when percutaneous, image-guided, fine-needle aspiration is positive for bacteria and/or fungi on a Gram stain and culture
Exclusion criteria	Serious heart, lung, liver, or brain disease, coagulation dysfunction and patients who could not tolerate endoscopic treatment or CT-guided percutaneous catheter drainage. Pregnant or lactating women and patients who did not sign the consent were excluded from the study.
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Median (IQR): ETN group 48 (27-55); PCD group 48 (43-59). Gender (M:F): 12:12. Ethnicity: Not reported
Further population details	1. Severity of infection: Not stated / Unclear 2. Severity of pancreatitis: Not stated / Unclear
Indirectness of population	No indirectness

<p>Interventions</p>	<p>(n=13) Intervention 1: Minimally invasive surgery - Endoscopic. The initial session of endoscopic transluminal drainage consists of an endoscopic ultrasound-guided puncture and placing 2 double-pigtail stents and a nasocystic catheter in the necrotic collection. EUS was used to visualise the extent of the necrosis and obvious blood vessels. The necrotic cavity was punctured under EUS guidance using a 19 gauge needle. The content of the necrotic collection was aspirated to confirm the correct position. Then zebra guidewire was inserted through the 19 gauge needle to the necrotic cavity. The outer sheath of a 10F cystogastrostomy was advanced into the stomach wall followed by balloon dilation of the tract up to 1cm. Two double-pigtail plastic stents and a 6F nasocystic catheter were placed in the collection. The cavity was irrigated with 1L of normal saline per 24 hours by nasocystic catheter. Clinical improvement as CECT were observed 3-5 days later after ETD. Patients with clinical improvement would continue to be observed to see if symptoms reappear again or whether the necrotic cavity did not decrease after 2 weeks, in which case they would also receive ETN. The second session of ETN consisted of removing the necrotic tissue from the necrotic cavity under endoscopic observation. The ETN was repeated in those with no clinical improvement in the subsequent 3-5 days. Duration During admission. Concurrent medication/care: All patients received enteral nutrition, mainly through the nasojejunal tube, and an oral diet was restored if oral feeding was tolerated. If the required caloric intake would not be reached, the patient would receive additional parenteral nutrition. All patients received intravenous antibiotics which were adjusted according to the culture results or stopped if there was clinical improvement Further details: 1. Procalcitonin-led antibiotic treatment: 2. Type of minimally invasive surgery :</p> <p>(n=13) Intervention 2: Minimally invasive surgery - Percutaneous. The initial session of PCD consists of CT or ultrasound-guided percutaneous placement of 12-16F catheters in the pancreatic or peripancreatic collection using the Seldinger technique. The preferred route includes the retroperitoneum and/or transperitoneal. If possible, each necrotic area is given at least 2 catheters to achieve sufficient convection and drainage. Drains are kept open by flushing with 0.9% saline solution every 8 hours. The clinical improvement and CECT were also observed 3-5 days after PCD. If a patient does not have clinical improvement, or changes in pancreatic necrosis after 3-5 days, 1 or more catheters were changed to double-catheterisation cannulas; then double-catheterisation cannulas were continuously flushed with saline and continuous negative pressure drainage. In the case of clinical improvement, irrigation is continued. If patients failed to improve for another 5 days, they were converted to open surgery. Duration During admission. Concurrent medication/care: All patients received enteral nutrition, mainly through the nasojejunal tube, and an oral diet was restored if oral feeding was tolerated. If the required caloric intake would not be reached, the patient would receive additional parenteral nutrition. All patients received intravenous antibiotics which were adjusted according to the culture results or stopped if there was clinical improvement Further details: 1. Procalcitonin-led antibiotic treatment: 2. Type of minimally invasive surgery :</p>
<p>Funding</p>	<p>Academic or government funding (Supported by the National clinical key specialty construction project. Jiangxi)</p>

Provincial Science and Technology Project and Science and Technology project of Health and Family Planning Commission of Jiangxi Province)

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENDOSCOPIC versus PERCUTANEOUS

Protocol outcome 1: Length of stay (in intensive therapy unit or hospital) at <1 year

- Actual outcome: Length of stay in hospital at During admission; Group 1: mean 40 Days (SD 25); n=11, Group 2: mean 66 Days (SD 37); n=13

Risk of bias: All domain - Very high, Selection - Very high, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: Difference in number of patients with alcohol abuse (36.4% versus 15.4%), number of patients with organ failure (18.2% versus 46.2%); Group 1 Number missing: 2, Reason: 1 transferred to surgery due to ACS and septic shock, 1 withdrew to receive self expanding metal stent drainage; Group 2 Number missing: 0

- Actual outcome: Length of stay in CCU at During admission; Group 1: mean 17 Days (SD 13); n=11, Group 2: mean 25 Days (SD 18); n=13

Risk of bias: All domain - Very high, Selection - Very high, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: Difference in number of patients with alcohol abuse (36.4% versus 15.4%), number of patients with organ failure (18.2% versus 46.2%); Group 1 Number missing: 2, Reason: 1 transferred to surgery due to ACS and septic shock, 1 withdrew to receive self expanding metal stent drainage; Group 2 Number missing: 0

Protocol outcome 2: Mortality at <1 year

- Actual outcome: Mortality at 1 year; Group 1: 3/11, Group 2: 3/13

Risk of bias: All domain - Very high, Selection - Very high, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: Difference in number of patients with alcohol abuse (36.4% versus 15.4%), number of patients with organ failure (18.2% versus 46.2%); Group 1 Number missing: 2, Reason: 1 transferred to surgery due to ACS and septic shock, 1 withdrew to receive self expanding metal stent drainage; Group 2 Number missing: 0

Protocol outcome 3: Complications (eg bleeding, fistulae) at <1 year

- Actual outcome: Upper gastrointestinal bleeding at 1 year; Group 1: 1/11, Group 2: 0/13

Risk of bias: All domain - Very high, Selection - Very high, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: Difference in number of patients with alcohol abuse (36.4% versus 15.4%), number of patients with organ failure (18.2% versus 46.2%); Group 1 Number missing: 2, Reason: 1 transferred to surgery due to ACS and septic shock, 1 withdrew to receive self expanding metal stent drainage; Group 2 Number missing: 0

- Actual outcome: Intraabdominal bleeding requiring intervention at 1 year; Group 1: 1/11, Group 2: 2/13

Risk of bias: All domain - Very high, Selection - Very high, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: Difference in number of patients with alcohol abuse (36.4% versus 15.4%), number of patients with organ failure (18.2% versus 46.2%); Group 1 Number missing: 2, Reason: 1 transferred to surgery due to ACS and septic shock, 1 withdrew to receive self expanding metal stent drainage; Group 2 Number missing: 0

- Actual outcome: Enterocutaneous fistula or perforation at 1 year; Group 1: 1/11, Group 2: 5/13
 Risk of bias: All domain - Very high, Selection - Very high, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: Difference in number of patients with alcohol abuse (36.4% versus 15.4%), number of patients with organ failure (18.2% versus 46.2%); Group 1 Number missing: 2, Reason: 1 transferred to surgery due to ACS and septic shock, 1 withdrew to receive self expanding metal stent drainage; Group 2 Number missing: 0

- Actual outcome: Pancreatic fistula at 1 year; Group 1: 0/11, Group 2: 1/13
 Risk of bias: All domain - Very high, Selection - Very high, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: Difference in number of patients with alcohol abuse (36.4% versus 15.4%), number of patients with organ failure (18.2% versus 46.2%); Group 1 Number missing: 2, Reason: 1 transferred to surgery due to ACS and septic shock, 1 withdrew to receive self expanding metal stent drainage; Group 2 Number missing: 0

- Actual outcome: New onset organ failure at 1 year; Group 1: 2/11, Group 2: 2/13
 Risk of bias: All domain - Very high, Selection - Very high, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: Difference in number of patients with alcohol abuse (36.4% versus 15.4%), number of patients with organ failure (18.2% versus 46.2%); Group 1 Number missing: 2, Reason: 1 transferred to surgery due to ACS and septic shock, 1 withdrew to receive self expanding metal stent drainage; Group 2 Number missing: 0

- Actual outcome: Multiple organ failure at 1 year; Group 1: 1/11, Group 2: 0/13
 Risk of bias: All domain - Very high, Selection - Very high, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: Difference in number of patients with alcohol abuse (36.4% versus 15.4%), number of patients with organ failure (18.2% versus 46.2%); Group 1 Number missing: 2, Reason: 1 transferred to surgery due to ACS and septic shock, 1 withdrew to receive self expanding metal stent drainage; Group 2 Number missing: 0

Protocol outcomes not reported by the study	Quality of life at <1 year; Number of procedures (repeated procedures) at <1 year; Pancreatic function (eg development of diabetes) at <1 year; Recurrence of infection at <1 year
---	--

Study	Kumar 2014 ⁶²²
Study type	Non-randomised comparative study
Number of studies (number of participants)	1 (n=24)
Countries and setting	Conducted in USA; Setting: The center for Pancreatic Disease, Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Boston, MA.
Line of therapy	Unclear
Duration of study	Not clear: 1 year
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: All patients had CT of the abdomen and pelvis within 5 days before the procedure.
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Fever, leukocytosis, positive fluid aspirate Gram stain, and/or positive blood cultures.
Exclusion criteria	Patients with other prior intervention for WOPN were excluded.
Recruitment/selection of patients	Patients were admitted to hospital.
Age, gender and ethnicity	Age - Mean (SD): DEN: 58.9 (3.9) SUA: 53.3 (3). Gender (M:F): 17:7. Ethnicity:
Further population details	1. Severity of infection: Not stated / Unclear 2. Severity of pancreatitis: Not stated / Unclear
Extra comments	DEN - Etiology: Alcohol - 3, Gallstone - 7, Unknown - 2; APACHE-II: 10.1 (1.1); TPN use: 3; CT severity index: 8.3 (0.8) SUA - Etiology: Alcohol - 3, Gallstone - 5, Hypertriglyceridemia: 1, Post-ERCP: 1, Unknown - 2; APACHE-II: 9.4 (1.2); TPN use: 2; CT severity index: 7.8 (0.8)

Indirectness of population	No indirectness
Interventions	<p>(n=12) Intervention 1: Minimally invasive surgery - Endoscopic. All procedures were performed by a single endoscopist using a standardised technique. Linear endoscopic ultrasound was employed to localise the site of WOPN entry and avoid vascular injury. Walled off pancreatic necrosis contents were aspirated and sent for Gram stain and culture. . Duration During admission. Concurrent medication/care: Not reported Further details: 1. Procalcitonin-led antibiotic treatment: 2. Type of minimally invasive surgery :</p> <p>(n=12) Intervention 2: Combination of intervention techniques - Step-up approach. With the use of cross-sectional imaging to avoid injury to vasculature and organs, a percutaneous needle was placed into the necrotic collection. Fluid was aspirated and sent for Gram stain and culture. The collection was followed with repeat cross-sectional imaging. If the collection size was no longer decreasing with irrigation, the drains were repositioned or additional drains were placed at the discretion of the radiologist. Those patients with lack of response to drainage or with clinical signs or symptoms of infection or abdominal pain were taken to surgery at the discretion of the surgical team. Surgical technique was at the discretion of the attending surgeon and included both open and minimally invasive approaches.. Duration During admission. Concurrent medication/care: Not reported Further details: 1. Procalcitonin-led antibiotic treatment: Not stated / Unclear 2. Type of minimally invasive surgery : Not stated / Unclear</p>
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: DIRECT ENDOSCOPIC NECROSECTOMY versus STEP-UP APPROACH

Protocol outcome 1: Length of stay (in intensive therapy unit or hospital) at <1 year

- Actual outcome: Floor length of stay at During admission; Group 1: mean 5.3 days (SD 1.4); n=12, Group 2: mean 23.6 days (SD 6.5); n=12; Risk of bias: Very high;

Indirectness of outcome: No indirectness

Protocol outcome 2: Number of procedures (repeated procedures) at <1 year

- Actual outcome: Number of procedures at During admission; Group 1: mean 1.5 (SD 0.3); n=12, Group 2: mean 2.8 (SD 0.2); n=12; Risk of bias: Very high; Indirectness

of outcome: No indirectness

Protocol outcome 3: Complications (for example, bleeding, fistulae) at <1 year

- Actual outcome: Complications at During admission: Group 1: 1/12. Group 2: 8/12: Risk of bias: Very high: Indirectness of outcome: No indirectness

Protocol outcome 4: Pancreatic function (for example, development of diabetes) at <1 year

- Actual outcome: New exocrine insufficiency at During admission; Group 1: 3/12, Group 2: 5/12; Risk of bias: Very high; Indirectness of outcome: No indirectness
- Actual outcome: New endocrine insufficiency at During admission; Group 1: 0/12, Group 2: 7/12; Risk of bias: Very high; Indirectness of outcome: No indirectness

Protocol outcome 4: Morality at <1 year

- Actual outcome: Mortality at During admission; Group 1: 0/12, Group 2: 0/12; Risk of bias: Very high; Indirectness of outcome: No indirectness

Protocol outcomes not reported by the study

Quality of life at <1 year; Recurrence of infection at <1 year; Mortality at <1 year

Study	Pupelis 2015 ⁸⁸⁴
Study type	Non-randomised comparative study
Number of studies (number of participants)	1 (n=70)
Countries and setting	Conducted in Latvia; Setting: Riga East Clinical University
Line of therapy	Unclear
Duration of study	Intervention time: 10 years
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: New or first episodes of acute pancreatitis were confirmed by CECT after the acute phase (first week) from the onset of disease.
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients who were treated at Riga East hospital with acute necrotising pancreatitis and were operated on due to the infected necrosis were prospectively included.
Exclusion criteria	Not reported
Recruitment/selection of patients	Patients were admitted to hospital
Age, gender and ethnicity	Age - Median (IQR): FOCUSED OPEN NECROSECTOMY: 52 (46-64) CONVENTIONAL:: 47 (41-62). Gender (M:F): 54:16. Ethnicity: Not reported
Further population details	1. Severity of infection: Not stated / Unclear 2. Severity of pancreatitis: Not stated / Unclear
Indirectness of population	No indirectness

Interventions	<p>(n=31) Intervention 1: Minimally invasive surgery - Percutaneous. Ultrasound-guided percutaneous acute necrotic collections (ANC) drainage was performed under local anaesthesia. Ultrasound-guided surgery included a provision of intraoperative ultrasound and ultrasound-guided minimally invasive interventions. The main intraoperative ultrasound steps were as follows: stereotypical diagnostics ensuring the recognition of anatomical structures and its relation to ANC and necrotic tissue; intraoperative navigation - precise definition of the surgical access; intraoperative monitoring - ultrasonography in real time during the surgical manipulation in reaching deep collections through the avascular zone; controlled drain provision; precise definition of necroses and assistance in focused necrosectomy.. Duration During admission. Concurrent medication/care: All patients received conservative treatment during the early phase of the disease. Further details: 1. Procalcitonin-led antibiotic treatment: Not stated / Unclear 2. Type of minimally invasive surgery : Percutaneous</p> <p>(n=39) Intervention 2: Open surgery. Conventional open necrosectomy was performed using the longitudinal midline or bilateral subcostal trans-peritoneal approach, adhering to the semi-opened or closed drainage principles. The laparotomy was executed providing examination of the abdominal cavity, peripancreatic and paracolic spaces and providing proper necrosectomy using blunt finger dissection combined with a suction and drainage. Once the necrosectomy was finished, 2 large bore drains for postoperative lavage were inserted, and the abdomen was closed in cases when completeness of necrosectomy was achieved. . Duration During admission. Concurrent medication/care: All patients received conservative treatment during the early phase of the disease. Further details: 1. Procalcitonin-led antibiotic treatment: 2. Type of minimally invasive surgery :</p>
Funding	Funding not stated
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ULTRASOUND-GUIDED FOCUSED OPEN NECROSECTOMY versus OPEN SURGERY</p> <p>Protocol outcome 1: Length of stay (in intensive therapy unit or hospital) at <1 year - Actual outcome: Length of stay in hospital at During admission; Other: Median; Risk of bias: Very high; Indirectness of outcome: No indirectness - Actual outcome: Length of stay in CCU at During admission; Other: Median; Risk of bias: Very high; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 2: Mortality at <1 year - Actual outcome: Mortality at During admission; Group 1: 2/31, Group 2: 5/39; Risk of bias: Very high; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 3: Number of procedures (repeated procedures) at <1 year</p>	

<p>- Actual outcome: Repeat necrosectomy at During admission; Group 1: 8/31, Group 2: 18/39; Risk of bias: Very high; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 4: Complications (for example, bleeding, fistulae) at <1 year</p> <p>- Actual outcome: Pancreatic fistulae at During admission; Group 1: 4/31, Group 2: 5/39; Risk of bias: Very high; Indirectness of outcome: No indirectness</p> <p>- Actual outcome: Intestinal fistulae at During admission; Group 1: 4/31, Group 2: 3/39; Risk of bias: Very high; Indirectness of outcome: No indirectness</p>	
<p>Protocol outcomes not reported by the study</p>	<p>Quality of life at <1 year; Pancreatic function (for example, development of diabetes) at <1 year; Recurrence of infection at <1 year</p>

Study	Rasch 2016 ⁹⁰¹
Study type	Non-randomised comparative study
Number of studies (number of participants)	1 (n=220)
Countries and setting	Conducted in Germany; Setting: 7 tertiary referral centers and 3 secondary hospitals in Germany
Line of therapy	Unclear
Duration of study	Intervention time: 6 years
Method of assessment of guideline condition	Unclear method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients with necrotising pancreatitis requiring treatment (percutaneous and/or transgastric/transduodenal drainage, surgical/percutaneous and/or endoscopic necrosectomy) in the late phase of pancreatitis (>10 days after onset of symptoms) were included in the study.
Exclusion criteria	Not reported
Recruitment/selection of patients	Patients were admitted to hospital.
Age, gender and ethnicity	Age - Range: 18-88. Gender (M:F): 2.6:1. Ethnicity: Not reported
Further population details	1. Severity of infection: Not stated / Unclear 2. Severity of pancreatitis: Not stated / Unclear
Extra comments	All patients: Etiology - Biliary: 41.4%, Alcoholic: 29.1%, Iatrogen: 13.6%, Drug induced: 2.7%, Hypertriglyceridemia: 1.8%

Indirectness of population	No indirectness
Interventions	<p>(n=30) Intervention 1: Open surgery. Primary open surgical necrosectomy was performed in 30/220. 36/190 patients in the step-up group needed open surgical intervention later in the course of disease.. Duration During admission. Concurrent medication/care: Not reported Further details: 1. Procalcitonin-led antibiotic treatment: Not stated / Unclear 2. Type of minimally invasive surgery : Not stated / Unclear</p> <p>(n=190) Intervention 2: Minimally invasive surgery - Percutaneous. 190/220 patients were treated according to a step-up approach.. Duration During admission. Concurrent medication/care: Not reported Further details: 1. Procalcitonin-led antibiotic treatment: Not stated / Unclear 2. Type of minimally invasive surgery : Percutaneous Comments: 197/220 recieved percutaneous drainage, transgastric drainage or both. Without further intervention 50.8% of these patients recovered and 49.2% underwent minimally invasive necrosectomy.</p>
Funding	No funding

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: STEP-UP APPROACH versus OPEN SURGERY

Protocol outcome 1: Length of stay (in intensive therapy unit or hospital) at <1 year

- Actual outcome: Length of stay in hospital at During admission ; Other: Median; Risk of bias: Very high; Indirectness of outcome: No indirectness

Protocol outcome 2: Mortality at <1 year

- Actual outcome: Mortality at During admission or within 4 weeks of discharge; Group 1: 20/190, Group 2: 10/30; Risk of bias: Very high; Indirectness of outcome: No indirectness

Protocol outcome 3: Complications (for example, bleeding, fistulae) at <1 year

- Actual outcome: Severe complication (sepsis, persistent MODS or erosion bleeding) at During admission; Group 1: 85/190, Group 2: 25/30; Risk of bias: Very high; Indirectness of outcome: No indirectness

Protocol outcome 4: Pancreatic function (for example, development of diabetes) at <1 year

- Actual outcome: Emergence of type 4c diabetes at During admission ; Group 1: 9/190, Group 2: 10/30; Risk of bias: Very high; Indirectness of outcome: No indirectness

Protocol outcomes not reported by the study

Quality of life at <1 year; Number of procedures (repeated procedures) at <1 year; Recurrence of infection at <1 year

Study	Szeliga 2014 ¹⁰⁵¹
Study type	Non-randomised comparative study
Number of studies (number of participants)	1 (n=34)
Countries and setting	Conducted in Poland; Setting: Department of general, gastroenterological and oncological surgery, Collegium Medicum, Nicolaus Copernicus University, Torun
Line of therapy	Unclear
Duration of study	Other: data collection 2007-2010
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients with diagnosis of severe acute pancreatitis on the basis of Atlanta criteria. All patients had a post-inflammatory, infected focus or foci within the pancreas and/or pancreatic region. The diagnosis of necrosis infection was not based only on typical clinical symptoms but also on CT results and in 27 cases on microbiological examination.
Exclusion criteria	not stated
Recruitment/selection of patients	All patients with severe acute pancreatitis treated at Nicolaus Copernicus University, Torun
Age, gender and ethnicity	Age - Mean (range): 52(28-78). Gender (M:F): 21/13. Ethnicity: not stated
Further population details	1. Severity of infection: Not stated / Unclear 2. Severity of pancreatitis: Severe pancreatitis
Extra comments	Aetiology: n=14 biliary; n=18 alcohol, n=2 other.

Indirectness of population	No indirectness
Interventions	<p>(n=7) Intervention 1: Combination of intervention techniques - Combined approach upfront. Type 1: laparotomy + necrosectomy + passive drainage (scheduled repeated laparotomies) + targeted antibiotic therapy. Duration unclear. Concurrent medication/care: not stated Further details: 1. Procalcitonin-led antibiotic treatment: 2. Type of minimally invasive surgery :</p> <p>(n=5) Intervention 2: Combination of intervention techniques - Combined approach upfront. Type 2: laparotomy + necrosectomy + active drainage + targeted antibiotic therapy. Duration unclear. Concurrent medication/care: not stated Further details: 1. Procalcitonin-led antibiotic treatment: 2. Type of minimally invasive surgery :</p> <p>(n=12) Intervention 3: Combination of intervention techniques - Step-up approach. Type 3: video-assisted retroperitoneal debridement. For patients in whom an attempt of percutaneous drainage to collect fluid or foci of pancreatic necrosis had been made, but no satisfactory clinical outcomes were observed after such a procedure. Approx. 5-cm incision in the left lumbar area was made at the site of a drain to be introduced, or after determination during an ultrasound examination so that it would not interfere with significant anatomical structures (for example, large vessels) and would be at the lowest distance in relation to the targetspace indicated for drainage. After integuments were dissected, the peripancreatic space was reached bluntly, most frequently with a dinger and under ultrasound supervision, so to achieve free flow of infected, necrotic tissues. then a laparoscopic camera was introduced and under video supervision necrotic tissues were flushed out using a suction-flushing device. No attempt was undertaken to remove fragments of necrotic pancreas that were not demarcated; they were left for subsequently placed active flushing gravitational drainage covering the bed after necrosectomy. . Duration unclear. Concurrent medication/care: After the procedure the patient was supervised at the CCU, having basic signal signs monitored, with compensated nutrition and water-electrolyte balance. Further details: 1. Procalcitonin-led antibiotic treatment: 2. Type of minimally invasive surgery :</p> <p>(n=10) Intervention 4: Percutaneous drainage (radiological). Type 4: Percutaneous drainage (12 to 20 F drains) of necrotic and suppurative cisterns from the pancreatic area. Duration unclear. Concurrent medication/care: not stated Further details: 1. Procalcitonin-led antibiotic treatment: 2. Type of minimally invasive surgery :</p>
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: COMBINED APPROACH UPFRONT (LAPAROTOMY+NECROSECTOMY+PASSIVE DRAINAGE) versus STEP-UP APPROACH (PERCUTANEOUS DRAINAGE+VARD)

Protocol outcome 1: Length of stay (in intensive therapy unit or hospital) at <1 year

- Actual outcome: Duration of hospitalisation (days) at perioperative; Risk of bias: Very high; Indirectness of outcome: No indirectness

Protocol outcome 2: Mortality at <1 year

- Actual outcome: Deaths at perioperative; Group 1: 5/7, Group 2: 2/12; Risk of bias: Very high; Indirectness of outcome: No indirectness

Protocol outcome 3: Complications (for example, bleeding, fistulae) at <1 year

- Actual outcome: N of patients with complications (wound infection, haemorrhage at surgical site, pancreatic fistula, intestinal fistula) at perioperative; Group 1: 7/7, Group 2: 6/12; Risk of bias: Very high; Indirectness of outcome: No indirectness

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: COMBINED APPROACH UPFRONT (LAPAROTOMY+NECROSECTOMY+PASSIVE DRAINAGE) versus PERCUTANEOUS DRAINAGE (RADIOLOGICAL)

Protocol outcome 1: Length of stay (in intensive therapy unit or hospital) at <1 year

- Actual outcome: Duration of hospitalisation (days) at perioperative; Risk of bias: Very high; Indirectness of outcome: No indirectness

Protocol outcome 2: Mortality at <1 year

- Actual outcome: Deaths at perioperative; Group 1: 5/7, Group 2: 1/10; Risk of bias: Very high; Indirectness of outcome: No indirectness

Protocol outcome 3: Complications (for example, bleeding, fistulae) at <1 year

- Actual outcome: N of patients with complications (wound infection, haemorrhage at surgical site, pancreatic fistula, intestinal fistula) at perioperative; Group 1: 7/7, Group 2: 2/10; Risk of bias: Very high; Indirectness of outcome: No indirectness

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: COMBINED APPROACH UPFRONT (LAPAROTOMY+NECROSECTOMY+ACTIVE DRAINAGE) versus COMBINED APPROACH UPFRONT (LAPAROTOMY+NECROSECTOMY+PASSIVE DRAINAGE)

Protocol outcome 1: Length of stay (in intensive therapy unit or hospital) at <1 year

- Actual outcome: Duration of hospitalisation (days) at perioperative; Risk of bias: Very high; Indirectness of outcome: No indirectness

Protocol outcome 2: Mortality at <1 year

- Actual outcome: Deaths at perioperative; Group 1: 1/5, Group 2: 5/7; Risk of bias: Very high; Indirectness of outcome: No indirectness

Protocol outcome 3: Complications (for example, bleeding, fistulae) at <1 year

- Actual outcome: N of patients with complications (wound infection, haemorrhage at surgical site, pancreatic fistula, intestinal fistula) at perioperative; Group 1: 5/5, Group 2: 7/7; Risk of bias: Very high; Indirectness of outcome: No indirectness

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: COMBINED APPROACH UPFRONT (LAPAROTOMY+NECROSECTOMY+ACTIVE DRAINAGE) versus STEP-UP APPROACH (PERCUTANEOUS DRAINAGE+VARD)

Protocol outcome 1: Length of stay (in intensive therapy unit or hospital) at <1 year

- Actual outcome: Duration of hospitalisation (days) at perioperative; Risk of bias: Very high; Indirectness of outcome: No indirectness

Protocol outcome 2: Mortality at <1 year

- Actual outcome: Deaths at perioperative; Group 1: 1/5, Group 2: 2/12; Risk of bias: Very high; Indirectness of outcome: No indirectness

Protocol outcome 3: Complications (for example, bleeding, fistulae) at <1 year

- Actual outcome: N of patients with complications (wound infection, haemorrhage at surgical site, pancreatic fistula, intestinal fistula) at perioperative; Group 1: 5/5, Group 2: 6/12; Risk of bias: Very high; Indirectness of outcome: No indirectness

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: COMBINED APPROACH UPFRONT (LAPAROTOMY+NECROSECTOMY+ACTIVE DRAINAGE) versus PERCUTANEOUS DRAINAGE (RADIOLOGICAL)

Protocol outcome 1: Length of stay (in intensive therapy unit or hospital) at <1 year

- Actual outcome: Duration of hospitalisation (days) at perioperative; Risk of bias: Very high; Indirectness of outcome: No indirectness

Protocol outcome 2: Mortality at <1 year

- Actual outcome: Deaths at perioperative; Group 1: 1/5, Group 2: 1/10; Risk of bias: Very high; Indirectness of outcome: No indirectness

Protocol outcome 3: Complications (for example, bleeding, fistulae) at <1 year

- Actual outcome: N of patients with complications (wound infection, haemorrhage at surgical site, pancreatic fistula, intestinal fistula) at perioperative; Group 1: 5/5, Group 2: 2/10; Risk of bias: Very high; Indirectness of outcome: No indirectness

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: STEP-UP APPROACH (PERCUTANEOUS DRAINAGE+VARD) versus PERCUTANEOUS DRAINAGE (RADIOLOGICAL)

Protocol outcome 1: Length of stay (in intensive therapy unit or hospital) at <1 year

- Actual outcome: Duration of hospitalisation (days) at perioperative; Risk of bias: Very high; Indirectness of outcome: No indirectness

Protocol outcome 2: Mortality at <1 year

<p>- Actual outcome: Deaths at perioperative; Group 1: 2/12, Group 2: 1/10; Risk of bias: Very high; Indirectness of outcome: No indirectness</p>	
<p>Protocol outcome 3: Complications (for example, bleeding, fistulae) at <1 year</p> <p>- Actual outcome: N of patients with complications (wound infection, haemorrhage at surgical site, pancreatic fistula, intestinal fistula) at perioperative; Group 1: 6/12, Group 2: 2/10; Risk of bias: Very high; Indirectness of outcome: No indirectness</p>	
<p>Protocol outcomes not reported by the study</p>	<p>Quality of life at <1 year; Number of procedures (repeated procedures) at <1 year; Pancreatic function (for example, development of diabetes) at <1 year; Recurrence of infection at <1 year</p>

Study	Van brunschot 2017¹⁰⁹⁶
Study type	Systematic Review
Number of studies (number of participants)	15 (n=1485 (in infected necrosis subgroup))

Countries and setting	Conducted in Brazil, Canada, Germany, Hungary, India, Netherlands, United Kingdom, USA; Setting: Not stated
Line of therapy	Unclear
Duration of study	Not clear:
Method of assessment of guideline condition	Method of assessment /diagnosis not stated
Stratum	Overall
Subgroup analysis within study	Sys review – pre-specified in protocol: Infected pancreatic necrosis
Inclusion criteria	<p>1. Observational cohort studies (both retrospective and prospective) or randomised trials reporting on the outcome of patients undergoing surgical necrosectomy or endoscopic necrosectomy for infected or sterile pancreatic and/or peripancreatic necrosis.</p> <p>2. Cohorts with a sample size of ≥ 30 patients.</p>
Exclusion criteria	<p>1. Cohorts which included patients with chronic pancreatitis.</p> <p>2. No data available for 1 or more of these variables: sex, age, method of necrosectomy, median time from hospital admission to necrosectomy, sterile or infected necrosis, and mortality.</p>
Recruitment/selection of patients	Not stated
Age, gender and ethnicity	Age - Mean (SD): Minimally invasive: 45 (11); open (MI matched): 46 (14); endoscopic: 41 (14); open (endoscopic matched): 42 (10). Gender (M:F): 70/30% in minimally invasive cohort; 60/40% in endoscopic cohort. Ethnicity: Not stated

Further population details	1. Severity of infection: Systematic review: mixed 2. Severity of pancreatitis: Systematic review: mixed
Indirectness of population	No indirectness
Interventions	<p>(n=127) Intervention 1: Minimally invasive surgery - Endoscopic. Endoscopic pancreatic necrosectomy is performed following endoscopic ultrasound-guided transgastric or transduodenal drainage of the pancreatic necrotic cavity. Usually, the drainage canal is created using electrocautery and balloon dilation. For endoscopic necrosectomy, further balloon dilation is needed in order to allow entrance of necrosectomy instruments (for example, snares, baskets, grasping forceps). Postprocedural lavage and re-necrosectomy was performed at the treating physician's discretion.</p> <p>. Duration Unclear. Concurrent medication/care: Unclear. Indirectness: No indirectness Further details: 1. Procalcitonin-led antibiotic treatment: Not applicable 2. Type of minimally invasive surgery : Endoscopic</p> <p>(n=335) Intervention 2: Minimally invasive surgery - Percutaneous. Minimally invasive surgical pancreatic necrosectomy is usually preceded radiologic catheter drainage, the drain being preferably placed in the left retroperitoneum. A small incision close to the drain entrance allows the surgeon to follow the drain tract into the necrotic cavity. Subsequent pancreatic necrosectomy can be performed under direct vision or videoscopic guidance using basic surgical instruments. Post-operative lavage and re-necrosectomy was performed at the treating surgeon's discretion.</p> <p>. Duration Unclear. Concurrent medication/care: Unclear. Indirectness: No indirectness Further details: 1. Procalcitonin-led antibiotic treatment: Not applicable 2. Type of minimally invasive surgery : Percutaneous</p> <p>(n=127) Intervention 3: Open surgery. Pancreatic necrosectomy performed through a bilateral subcostal incision with blunt and/or surgical removal of necrotic tissue. Post-operative lavage and re-necrosectomy was performed at the treating surgeon's discretion.</p> <p>«. Duration Unclear. Concurrent medication/care: Unclear. Indirectness: No indirectness</p>

	<p>Further details: 1. Procalcitonin-led antibiotic treatment: Not applicable 2. Type of minimally invasive surgery : Not applicable</p> <p>(n=335) Intervention 4: Open surgery. Pancreatic necrosectomy performed through a bilateral subcostal incision with blunt and/or surgical removal of necrotic tissue. Post-operative lavage and re-necrosectomy was performed at the treating surgeon's discretion.</p> <p>. Duration Unclear. Concurrent medication/care: Unclear. Indirectness: No indirectness</p> <p>Further details: 1. Procalcitonin-led antibiotic treatment: Not applicable 2. Type of minimally invasive surgery : Not applicable</p>
Funding	Study funded by industry
Protocol outcomes not reported by the study	Quality of life at <1 year; Recurrence of infection at <1 year; Number of procedures (repeated procedures) at <1 year; Complications (eg bleeding, fistulae) at <1 year; Pancreatic function (eg development of diabetes) at <1 year; Length of stay (in intensive therapy unit or hospital) at <1 year

Study	Van Brunshot 2017¹⁰⁹⁷
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=98)
Countries and setting	Conducted in Netherlands; Setting: 7 university medical centers and 12 teaching hospitals of the Dutch Pancreatitis Study Group
Line of therapy	1st line
Duration of study	Intervention and follow-up: 6 months' follow-up

Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Acute pancreatitis defined as having at least 2 of: upper abdominal pain; serum lipase or amylase levels >3-times the ULN; characteristic finding of acute pancreatitis on cross-sectional abdominal imaging
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Adults with a high suspicion or evidence of infected necrosis with an indication for invasive intervention and for whom both the endoscopic and surgical step-up approach were deemed feasible.
Exclusion criteria	Previous invasive interventions for necrotising pancreatitis, an acute flare of chronic pancreatitis, recurrent acute pancreatitis and an indication for emergency laparotomy
Age, gender and ethnicity	Age - Mean (SD): Endoscopic: 63 (14); surgical: 60 (11) years. Gender (M:F): 64/36%. Ethnicity: Not stated
Further population details	1. Severity of infection: Not stated / Unclear (Approximately 50% had <30% pancreatic necrosis). 2. Severity of pancreatitis: Severe pancreatitis (Average APACHEII score 9-10).
Extra comments	71% had complete encapsulation of the necrotic collection; 28% had single organ failure and 16% had multiple organ failure at baseline. Infected necrosis was defined as a positive culture obtained by FNA or the presence of gas within necrotic collections on contrast-enhanced CT. Infected necrosis was suspected in necrotising pancreatitis patients with clinical signs of persistent sepsis or progressive clinical deterioration despite maximal CCU support without other causes for infection.
Indirectness of population	No indirectness
Interventions	(n=51) Intervention 1: Combination of intervention techniques - Step-up approach. Endoscopic ultrasound-guided transluminal (transgastric or transduodenal) drainage with placement of 2 double pigtail stents and 1 nasocystic catheter. If drainage alone did not lead to considerable clinical improvement endoscopic transluminal necrosectomy was performed.. Duration N/A. Concurrent medication/care: Additional

	<p>endoscopic/percutaneous drainage and endoscopic or surgical necrosectomies were allowed. Indirectness: No indirectness Further details: 1. Procalcitonin-led antibiotic treatment: Not applicable 2. Type of minimally invasive surgery : Endoscopic</p> <p>(n=47) Intervention 2: Combination of intervention techniques - Step-up approach. Radiological CT-guided or ultrasound-guided percutaneous catheter drainage, preferably through the left retroperitoneum with the catheter as guidance for video-assisted retroperitoneal debridement (VARD) if needed. If drainage was not successful a VARD procedure was performed.. Duration N/A. Concurrent medication/care: Additional endoscopic/percutaneous drainage and endoscopic or surgical necrosectomies were allowed. Indirectness: No indirectness Further details: 1. Procalcitonin-led antibiotic treatment: Not applicable 2. Type of minimally invasive surgery : Percutaneous</p>
Funding	Academic or government funding
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENDOSCOPIC STEP-UP APPROACH versus SURGICAL STEP-UP APPROACH</p> <p>Protocol outcome 1: Length of stay (in intensive therapy unit or hospital) at <1 year - Actual outcome: Days in hospital at 6 months ; Group 1: mean 53 (SD 47); n=51, Group 2: mean 69 (SD 38); n=47; Comments: Median (IQR): 35 (19-85); 65 (40-90) Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 3, Reason: 1 spontaneous improvement; 2 treated in surgery group; Group 2 Number missing: 1, Reason: 1 spontaneous improvement</p> <p>Protocol outcome 2: Mortality at <1 year - Actual outcome: Mortality at 6 months; Group 1: 9/51, Group 2: 6/47; Comments: Most common causes of death were multiorgan failure or progressive sepsis Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 3, Reason: 1 spontaneous improvement; 2 treated in surgery group; Group 2</p>	

Number missing: 1, Reason: 1 spontaneous improvement

Protocol outcome 3: Number of procedures (repeated procedures) at <1 year

- Actual outcome: Median number of drainage procedures at 6 months ; ;

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 3, Reason: 1 spontaneous improvement; 2 treated in surgery group; Group 2 Number missing: 1, Reason: 1 spontaneous improvement

Protocol outcome 4: Complications (eg bleeding, fistulae) at <1 year

- Actual outcome: Bleeding requiring intervention at 6 months; Group 1: 11/51, Group 2: 10/47

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 3, Reason: 1 spontaneous improvement; 2 treated in surgery group; Group 2 Number missing: 1, Reason: 1 spontaneous improvement

- Actual outcome: Perforation of visceral organ or enterocutaneous fistula requiring intervention at 6 months; Group 1: 4/51, Group 2: 8/47

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 3, Reason: 1 spontaneous improvement; 2 treated in surgery group; Group 2 Number missing: 1, Reason: 1 spontaneous improvement

- Actual outcome: Pancreatic fistula at 6 months (excluding those who had died); Group 1: 2/42, Group 2: 13/41

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 3, Reason: 1 spontaneous improvement; 2 treated in surgery group; Group 2 Number missing: 1, Reason: 1 spontaneous improvement

- Actual outcome: New onset single organ failure at 6 months; Group 1: 7/51, Group 2: 13/47

Risk of bias: All domain - ; Indirectness of outcome: No indirectness

- Actual outcome: New onset multiple organ failure at 6 months; Group 1: 2/51, Group 2: 6/47

Risk of bias: All domain - ; Indirectness of outcome: No indirectness

Protocol outcome 5: Pancreatic function (eg development of diabetes) at <1 year

- Actual outcome: Exocrine insufficiency (fecal elastase <200 mg/g) at 6 months (excluding those who had died); Group 1: 22/42, Group 2: 19/41;

Comments: Also reports N using enzymes and N with steatorrhea

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 3, Reason: 1 spontaneous improvement; 2 treated in surgery group; Group 2 Number missing: 1, Reason: 1 spontaneous improvement

<p>- Actual outcome: Endocrine insufficiency at 6 months (excluding those who had died); Group 1: 10/42, Group 2: 9/41 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 3, Reason: 1 spontaneous improvement; 2 treated in surgery group; Group 2 Number missing: 1, Reason: 1 spontaneous improvement</p>	
Protocol outcomes not reported by the study	Quality of life at <1 year; Recurrence of infection at <1 year

Study	Van Santvoort 2007¹¹⁰³
Study type	Non-randomised comparative study
Number of studies (number of participants)	1 (n=30)
Countries and setting	Conducted in Netherlands; Setting: Department of surgery, University Medical Center Utrecht
Line of therapy	Unclear
Duration of study	Intervention time: 10 years
Method of assessment of guideline condition	Unclear method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients admitted to the hospital who underwent primary pancreatic necrosectomy were eligible for inclusion.
Exclusion criteria	Not reported
Recruitment/selection of patients	Participants had been admitted to hospital

Age, gender and ethnicity	Age - Median (range): Retroperitoneal: 52 (34-66) Laparotomy: 53 (39-75). Gender (M:F): 22:8. Ethnicity: Not reported
Further population details	1. Severity of infection: Not stated / Unclear 2. Severity of pancreatitis: Not stated / Unclear
Extra comments	Retro group: Etiology - Biliary: 8, Alcohol: 3, Post-ERCP: 1, Other/Unknown: 3; CT severity index - 4-6: 4, 8-10: 11; APACHE II score 24h preoperatively: 9 (5-18) Lap group: Etiology - Biliary: 5, Alcohol: 2, Post-ERCP: 2, Other/Unknown: 6; CT severity index - 4-6: 5, 8-10: 10; APACHE II score 24h preoperatively: 9 (5-20)
Indirectness of population	No indirectness
Interventions	(n=15) Intervention 1: Open surgery. After a bilateral subcostal or median incision, the lesser sac is entered through the gastrocolic omentum. Blunt debridement of all necrotic tissue is performed. Two double-lumen catheters are inserted through separate incisions and positioned in the retroperitoneal space. Six patients received pre-operative PCD.. Duration During admission. Concurrent medication/care: Not reported Further details: 1. Procalcitonin-led antibiotic treatment: Not stated / Unclear 2. Type of minimally invasive surgery : Not stated / Unclear (n=15) Intervention 2: Minimally invasive surgery - Percutaneous. As the first step, a 12F to 14F percutaneous drain is placed in the collection through the left retroperitoneum. If drainage does not lead to clinical improvement (combined normalisation of body temperature and decreased WBC count and CRP level) within the next days, the patient is operated on.. Duration During admission. Concurrent medication/care: Not reported Further details: 1. Procalcitonin-led antibiotic treatment: Not stated / Unclear 2. Type of minimally invasive surgery : Not stated / Unclear
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: PERCUTANEOUS DRAINAGE versus OPEN SURGERY

Protocol outcome 1: Length of stay (in intensive therapy unit or hospital) at <1 year

- Actual outcome: Postoperative hospital stay at During admission; Other: Median (range); Risk of bias: Very high; Indirectness of outcome: No indirectness

<p>Protocol outcome 2: Mortality at <1 year - Actual outcome: Mortality at During admission; Group 1: 1/15, Group 2: 6/15; Risk of bias: Very high; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 3: Number of procedures (repeated procedures) at <1 year - Actual outcome: Further necrosectomy at During admission; Group 1: 11/15, Group 2: 13/15; Risk of bias: Very high; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 4: Complications (for example, bleeding, fistulae) at <1 year - Actual outcome: Bowel perforation at During admission; Group 1: 1/15, Group 2: 2/15; Risk of bias: Very high; Indirectness of outcome: No indirectness - Actual outcome: Bleeding at During admission; Group 1: 4/15, Group 2: 1/15; Risk of bias: Very high; Indirectness of outcome: No indirectness - Actual outcome: GI fistulas at During admission; Group 1: 1/15, Group 2: 3/15; Risk of bias: Very high; Indirectness of outcome: No indirectness - Actual outcome: Pancreatic fistulas at During admission; Group 1: 2/15, Group 2: 0/15; Risk of bias: Very high; Indirectness of outcome: No indirectness</p>	
Protocol outcomes not reported by the study	Quality of life at <1 year; Pancreatic function (for example, development of diabetes) at <1 year; Recurrence of infection at <1 year

H.13 Timing of management of infected necrosis in people with acute pancreatitis

Study	Guo 2014 ⁴²²
Study type	Non-randomised comparative study
Number of studies (number of participants)	1 (n=223)
Countries and setting	Conducted in China; Setting: West China Hospital, Sichuan University
Line of therapy	Unclear
Duration of study	Intervention + follow up: Unclear
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Diagnosis was confirmed by CECT
Stratum	Adults >16 years
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients diagnosed with acute pancreatitis with pancreatic necrosis or peripancreatic necrosis were included.
Exclusion criteria	Not reported

Recruitment/selection of patients	Patients were admitted to hospital
Age, gender and ethnicity	Age - Median (range): 47 (22-74). Gender (M:F): 136:87. Ethnicity: Not reported
Further population details	1. Severity of infection: Not stated / Unclear 2. Severity of pancreatitis: Not stated / Unclear
Extra comments	Early group: Aetiology: Biliary - 67/136, Alcohol - 13/136, Others - 56/136; BMI (Median (Range)) - 27(30-33); APACHE II score (Median (Range)) - 10 (2-32) Late group: Aetiology: Biliary - 41/87, Alcohol - 11/87, Others - 35/87; BMI (Median (Range)) - 31 (22-34); APACHE II score (Median (Range)) - 6 (2-30)
Indirectness of population	No indirectness
Interventions	(n=87) Intervention 1: Late intervention (as defined by studies) - Late combination of interventions. Intervention was postponed until approximately 4 weeks after the onset of disease, whenever possible. Open pancreatic necrosectomy, retroperitoneal pancreatic necrosectomy, or primary percutaneous catheter drainage with pigtail plastic stents were the possible types of intervention.. Duration Unclear. Concurrent medication/care: Cultures were taken during all primary procedures to confirm the diagnosis of infected necrosis. Further details: 1. Procalcitonin-led antibiotic treatment: Not stated / Unclear 2. Type of minimally intervention: Systematic review: mixed (n=136) Intervention 2: Early intervention (as defined by studies) - Early combination of interventions. Intervention was postponed until approximately 4 weeks after the onset of disease, whenever possible. However, when severe clinical deterioration persisted, a prompt intervention was performed. Open pancreatic necrosectomy, retroperitoneal pancreatic necrosectomy, or primary percutaneous catheter drainage with pigtail plastic stents were the possible types of intervention.. Duration Unclear. Concurrent medication/care: Cultures were taken during all primary procedures to confirm the diagnosis of infected necrosis. Further details: 1. Procalcitonin-led antibiotic treatment: 2. Type of minimally intervention:
Funding	No funding

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: LATE COMBINATION OF INTERVENTIONS versus EARLY COMBINATION OF INTERVENTIONS

Protocol outcome 1: Mortality at <1 year

- Actual outcome for Adults >16 years: OF: Mortality at Unclear; Group 1: 3/21, Group 2: 23/61

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

- Actual outcome for Adults >16 years: NOF: Mortality at Unclear; Group 1: 6/66, Group 2: 5/75

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 2: Number of procedures (repeated procedures) at <1 year

- Actual outcome for Adults >16 years: OF: Re-intervention at Unclear; Group 1: 2/21, Group 2: 17/61

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

- Actual outcome for Adults >16 years: NOF: Re-intervention at Unclear; Group 1: 3/66, Group 2: 7/75

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 3: Complications (for example, bleeding, fistulae) at <1 year

- Actual outcome for Adults >16 years: OF: Intra-abdominal bleeding at Unclear; Group 1: 5/21, Group 2: 24/61

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

- Actual outcome for Adults >16 years: OF: Enterocutaneous fistula at Unclear; Group 1: 3/21, Group 2: 6/61

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

- Actual outcome for Adults >16 years: OF: New-onset organ failure at Unclear; Group 1: 6/21, Group 2: 16/61

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

- Actual outcome for Adults >16 years: NOF: Intra-abdominal bleeding at Unclear; Group 1: 3/66, Group 2: 3/75

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

- Actual outcome for Adults >16 years: NOF: Enterocutaneous fistula at Unclear; Group 1: 9/66, Group 2: 6/75

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

- Actual outcome for Adults >16 years: NOF: New-onset organ failure at Unclear; Group 1: 1/66, Group 2: 4/75

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcomes not reported by the study	Quality of life at <1 year; Recurrence of infection at <1 year; Pancreatic function (for example, development of diabetes) at <1 year; Length of stay (in intensive therapy unit or hospital) at <1 year
---	--

H.14 Management of pain in people with chronic pancreatitis

Study (subsidiary papers)	Ahmed 2014 ¹⁴ (Banks 1997 ⁸⁵ ; Bhardwaj 2009 ¹²⁷ ; Durgaprasad 2005 ³²³ ; Jarosz 2010 ⁵²⁴ ; Kirk 2006 ⁶⁰¹ ; Siriwardena 2012 ¹⁰⁰¹ ; Uden 1990 ^{1084, 1086})
Study type	Systematic Review
Number of studies (number of participants)	8 (n=503)
Countries and setting	Conducted in multiple countries; Setting: Systematic review: mixed
Line of therapy	Unclear
Duration of study	Systematic review: mixed
Method of assessment of guideline condition	Systematic review: method of assessment mixed
Stratum	Adults >16 years
Subgroup analysis within study	Not applicable
Inclusion criteria	Randomised trials evaluating antioxidant for treatment of pain in chronic pancreatitis, all adult patients with established chronic pancreatitis according to the criteria of at least one international guideline. Patients must have had some degree of pain, described as constant or recurrent pain attacks
Exclusion criteria	Quasi-randomised trials
Recruitment/selection of patients	Systematic review: mixed
Age, gender and ethnicity	Age - Range: 21–91 years. Gender (M:F) 231:81 (not reported for 91 participants). Ethnicity: Not reported
Further population details	
Indirectness of population	Serious indirectness: Includes some acute pancreatitis patients
Interventions	Systematic review: see study characteristics
Funding	No funding

RESULTS

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ANTIOXIDANT versus CONTROL

Banks 1997

Protocol outcome 1: quality of life

- Actual outcome: activities of daily living at 10 weeks; MD; 3.3 (95%CI 10.3 to -3.7) ADL 0-120 Top=High is good outcome;

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness

Protocol outcome 2: pain

- Actual outcome: pain VAS at 10 weeks: MD; -2.8 (95%CI 2.2 to -7.7) VAS 0-100 Top=High is poor outcome;

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness

Protocol outcome 2: adverse events

- Actual outcome: adverse events: Group 1:1/13, Group 2: 1/13

Risk of bias: All domain – Very high, Selection - High, Blinding - Low, Incomplete outcome data - high, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness

Bhardwaj 2009**Protocol outcome 1: pain**

- Actual outcome: reduction in painful days per month: Group 1: mean 7.37 (SD 6.75); n=66, Group 2: mean 3.21 (SD 3.99); n=53

- Actual outcome: reduction in pain medication – oral analgesic tablets/month: Group 1: mean 10.51 (SD 11.77); n=71, Group 2: mean 4.36 (SD 5.78); n=56

- Actual outcome: reduction in pain medication – parenteral analgesic injections/month: Group 1: mean 2.59 (SD 3.88); n=71, Group 2: mean 1.89 (SD 3.01); n=56

- Actual outcome: pain free participants: Group 1: 23/71, Group 2: 7/56

Risk of bias: All domain - high, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low,

Indirectness of outcome: No indirectness ; Group 1 Number missing: 15; Group 2 Number missing: 5

Protocol outcome 2: adverse events

- Actual outcome: adverse events: Group 1: 12/71, Group 2: 3/56

Risk of bias: All domain - high, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low,

Indirectness of outcome: No indirectness ; Group 1 Number missing: 15; Group 2 Number missing: 5

Protocol outcome: mortality

- Actual outcome: mortality: Group 1: 0/71, Group 2: 0/56

Risk of bias: All domain - high, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low,

Indirectness of outcome: No indirectness ; Group 1 Number missing: 15; Group 2 Number missing: 5

Durgaprasad 2005**Protocol outcome 1: pain**

- Actual outcome: pain VAS: Group 1: mean 5.81 (SD 2.09); n=8, Group 2: mean 6.57 (SD 1.38); n=7, VAS 0-10 Top=High is poor outcome

Risk of bias: All domain – Very high, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Number missing overall 5/20

Protocol outcome 2: adverse events

- Actual outcome: adverse events: Group 1: 0/8, Group 2: 0/7

Ri Risk of bias: All domain – Very high, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Number missing overall 5/20

Jarosz 2010

Protocol outcome 1: pain

- Actual outcome: number of pain free participants: Group 1: 22/32, Group 2: 11/35

Risk of bias: All domain – Very high, Selection - High, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Number missing overall 24/91

Kirk 2006

Protocol outcome 1: adverse events

- Actual outcome: adverse events: Group 1: 1/19, Group 2: 1/19

Risk of bias: All domain – Very high, Selection - high, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - High;

Indirectness of outcome: No indirectness ; Number missing overall 17/36

Siriwardena 2012

Protocol outcome 1: pain

- Actual outcome: daily NRS average: Group 1: mean 2.93 (SD 1.96); n=33, Group 2: mean 3.05 (SD 1.96); n=37: NRS 0-10 Top=High is poor outcome

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: unclear; Group 2 Number missing: unclear

Protocol outcome 2: Quality of life

- Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0

- Actual outcome: EORTC-QLQ-PAN28 overall: MD; -4.1 (95%CI -8.5 to 0.2) EORTC QLQ-PAN28 30-126 Top=High is good outcome;

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: unclear; Group 2 Number missing: unclear

- Actual outcome: EORTC-QLQ-PAN28 pancreatic pain: MD; -0.08 (95%CI -1.05 to 0.90) EORTC QLQ-C30 30-126 Top=High is good outcome;

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: unclear; Group 2 Number missing: unclear

- Actual outcome: EQ-5D: MD; 0.04 (95%CI -0.10 to 0.19) EQ-5D 0-1 Top=High is good outcome

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: unclear; Group 2 Number missing: unclear

- Actual outcome: EQ-5D VAS: MD; 2.3 (95%CI -6.5 to 11.1) EQ-5D VAS 0-100 Top=High is good outcome

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: unclear; Group 2 Number missing: unclear

Protocol outcome 3: Adverse events

- Actual outcome: adverse events: Group 1: 8/33, Group 2: 1/37

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: unclear; Group 2 Number missing: unclear	
Uden 1990	
Protocol outcome 1: adverse events	
- Actual outcome: adverse events: Group 1: 0/20, Group 2: 0/20	
Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - High;	
Indirectness of outcome: No indirectness ; Group 1 Number missing:4; Group 2 Number missing: 1	
Protocol outcome 2: pain	
- Actual outcome: pain/distress at 10 weeks: Median difference 0.26 (95%CI -0.06 to 0.84) 0-10 Top=High is poor outcome	
Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;	
Indirectness of outcome: No indirectness ; Group 1 Number missing: 4); Group 2 Number missing: 1	
Protocol outcomes not reported by the study	Serious adverse events at 1 year or under; Return to usual activities ; Pancreatic function (endocrine and exocrine)

Study	Malesci 1995 ⁷⁰⁴
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=24)
Countries and setting	Conducted in Denmark; Setting: Not reported
Line of therapy	Unclear
Duration of study	Intervention time: 8 months
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: presence of ductal changes at endoscopic retrograde cholangiopancreatography; pancreatic calcifications; abnormalities at ultrasonography scan; pancreatic insufficiency at the secretin-cerulein test.
Stratum	Adults over 16
Subgroup analysis within study	Not applicable
Inclusion criteria	all patients had complained of typical recurrent pancreatic pain and had had at least one episode of long-lasting pain (>12h) with concomitant elevation of serum pancreatic enzyme levels
Exclusion criteria	exclusion criteria included pancreatic pseudocysts, ductal changes typical of "advanced pancreatitis", steatorrhea with passage of more than 20 g fat/day, previous pancreatic surgery, concomitant peptic ulcer, or cholelithiasis.
Recruitment/selection of patients	Not reported

Study	Malesci 1995⁷⁰⁴
Age, gender and ethnicity	Age - Range: 21-70. Gender (M:F): 19:3. Ethnicity: Not reported
Further population details	1. Severity of pain: Not stated / Unclear 2. Types of nerve blocks: Not applicable
Indirectness of population	No indirectness
Interventions	<p>(n=24) Intervention 1: Enzyme replacement therapy. Participants were given pancreatic extract (Pancrex-Duo, Samil-Sandoz, Italy) as capsules of enteric-coated microspheres, each capsule containing 34,376 USP units of protease, 13,000 USP units of lipase, and 43,570 USP units of amylase. The dose given was four times daily (at meals and bedtime).. Duration 4 months. Concurrent medication/care: Strict alcohol abstinence was strongly recommended to all the recruited patients at least one year before the entered the study. Patients were allowed to consume analgesics: the drug and manner of administration were the patients' choice in accordance with pre-study habits. Further details: 1. Types of surgery: Not applicable</p> <p>(n=24) Intervention 2: Enzyme replacement therapy. Participants were given placebo four times daily (at meals and bedtime). Duration 4 months. Concurrent medication/care: Strict alcohol abstinence was strongly recommended to all the recruited patients at least one year before the entered the study. Patients were allowed to consume analgesics: the drug and manner of administration were the patients' choice in accordance with pre-study habits. Further details: 1. Types of surgery: Not applicable</p>
Funding	Funding not stated
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: PANCREX-DUO versus PLACEBO</p> <p>Protocol outcome 1: Pain (duration of pain, reduction in pain, medication reduction) - Actual outcome for Adults over 16: Pain (People experiencing long-lasting (>12h) pain attacks) at 4 months; Group 1: 14/22, Group 2: 11/22 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - High; Indirectness of outcome: No indirectness ; Group 1 Number missing: 2; Group 2 Number missing: 2 - Actual outcome for Adults over 16: Pain (Use of analgesics) at 4 months; Group 1: 10/22, Group 2: 5/22 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - High; Indirectness of outcome: No indirectness ; Group 1 Number missing: 2; Group 2 Number missing: 2</p>	
Protocol outcomes not reported by the study	Quality of life ; Mortality ; Pain (duration of pain, reduction in pain, medication reduction) ; Serious adverse events at 1 year or under; Adverse events at 1 year or under; Return to usual activities ; Return to usual activities ; Pancreatic function (endocrine and exocrine)

Study	Mossner 1992 ⁷⁶³
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=47)
Countries and setting	Conducted in Germany; Setting: Not reported
Line of therapy	Unclear
Duration of study	Intervention time: 4 weeks
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: CP documented by typical duct abnormalities at ERCP or calcifications on plain X-ray films or typical signs in CT or sonography (calcifications, duct abnormalities, organ enlargement)
Stratum	Adults over 16
Subgroup analysis within study	Not applicable
Inclusion criteria	Acute or chronic abdominal pain most likely due to chronic pancreatitis, activity of the disease not so severe as to need treatment by parenteral nutrition or intensive care, CP documented by typical duct abnormalities at ERCP or calcifications on plain X-ray films or typical signs in CT or sonography (calcifications, duct abnormalities, organ enlargement), quantitative fecal fat below 30g/day, age range between 20 and 60, history of CP of more than 50 months
Exclusion criteria	History of gastric resections or vagotomy, history of pancreatic resections included Whipple operation, pancreas divisum, complications of CP such as pseudocysts, kidney abnormalities in sonography, bilirubin above 1.5 mg/dl, cholesterol above 500 mg/dl, triglycerides above 1000 mg/dl
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - -: Not reported. Gender (M:F): 41:6. Ethnicity: Not reported
Further population details	1. Severity of pain: Not stated / Unclear 2. Types of nerve blocks: Not applicable
Indirectness of population	No indirectness
Interventions	(n=47) Intervention 1: Enzyme replacement therapy. Patients received either placebo or pancreatic extracts in double-blind randomised manner for 14 days. This was followed by crossover treatment for another 14 days with either verum or placebo. A new preparation of acid-protected commercially available porcine pancreatic enzymes was applied together with meals in a higher dosage that commonly used for treatment of pancreatic insufficiency (5x2 capsules a day; Panzytrat 20,000, Nordmark Arzneimittel, Uetersen, FRG; capsules with microtablets, containing per capsule according to the information provided by the manufacturer, triacylglycerol lipase 20,000 Pharmacopoea europaea units, (Ph Eur U), amylase 20,000 Ph Eur U, proteases 1000 Ph Eur U). This dosage ensured the application of 10,000 Ph Eur U of proteases/day.. Duration 14 days. Concurrent medication/care: Not reported

Study	Mossner 1992⁷⁶³
	<p>Further details: 1. Types of surgery: Not applicable</p> <p>(n=47) Intervention 2: Enzyme replacement therapy. Patients received either placebo or pancreatic extracts in double-blind randomised manner for 14 days. This was followed by crossover treatment for another 14 days with either verum or placebo. . Duration 14 days. Concurrent medication/care: Not reported</p> <p>Further details: 1. Types of surgery: Not applicable</p>
Funding	Study funded by industry (The study was supported by a grant from Nordmark Arzneimittel, Uetersen, FRG.)
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: PANZYTRAT versus PLACEBO</p> <p>Protocol outcome 1: Pain (duration of pain, reduction in pain, medication reduction)</p> <p>- Actual outcome for Adults over 16: Pain (Pain score) at 2 weeks; Group 1: mean 1.08 (SD 0.87); n=47,</p> <p>Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - High;</p> <p>Indirectness of outcome: No indirectness ; Group 1 Number missing: 4; Group 2 Number missing: 4</p>	
Protocol outcomes not reported by the study	Quality of life ; Mortality ; Pain (duration of pain, reduction in pain, medication reduction) ; Serious adverse events at 1 year or under; Adverse events at 1 year or under; Return to usual activities ; Return to usual activities ; Pancreatic function (endocrine and exocrine)

H.15 Management of pancreatic duct obstruction in people with chronic pancreatitis

Study (subsidiary papers)	Cahen 2007¹⁸² (Cahen 2011¹⁸¹)
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=39)
Countries and setting	Conducted in Netherlands; Setting: The Hepato-Pancreatico-Biliary outpatient clinic of the study hospital

Line of therapy	Unclear
Duration of study	Intervention plus follow up: 2 years
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Based on clinical symptoms and morphological changes detected by imaging studies; pancreatic insufficiency or both.
Stratum	Adults over 16
Subgroup analysis within study	Not applicable
Inclusion criteria	Diagnosis of chronic pancreatitis, based on clinical symptoms and morphological changes detected by imaging studies; pancreatic insufficiency or both, obstruction of the pancreatic duct due to stenosis, intraductal stones, or both located left of the spine, with dilation of the duct by at least 5 mm proximal to the obstruction, as determined by magnetic resonance cholangiopancreatography, abdominal computed tomography, or both, severe recurrent pancreatic pain insufficiently relieved by non-narcotic analgesics or requiring opiates.
Exclusion criteria	Age <18 or >80, enlargement of the pancreatic head >4 cm, contraindications to surgery (American Society of Anesthesiologists class IV, severe portal hypertension), contraindications to endoscopic treatment (gastrectomy with Billroth II reconstruction, other pancreatitis-related complications requiring surgery), previous pancreatic surgery, suspected pancreatic cancer, life expectancy <2 years, pregnancy.
Recruitment/selection of patients	Patients were invited to participate after attending the clinic
Age, gender and ethnicity	Age - Mean (SD): Endo: 52 (9) Surgery: 46 (12). Gender (M:F): 26:13. Ethnicity: Not reported
Further population details	1. Presence of an inflammatory mass: Not stated / Unclear
Extra comments	Endoscopy: Aetiology - Alcohol: 9, Idiopathic: 7, Hereditary: 1, Pancreas divisum: 2; Continuous pain: 12, Intermittent pain: 7; Izbicki pain score (Mean (SD)): 73 (12); Duration of symptoms: 16 (14); SF-36 Physical health component: 31 (8), Mental health component: 33 (8) Surgery: Aetiology - Alcohol: 12, Idiopathic: 5, Hereditary: 1, Pancreas divisum: 0, Other: 2; Continuous pain: 12, Intermittent pain: 9; Izbicki pain score (Mean (SD)): 69 (18); Duration of symptoms: 21 (19); SF-36 Physical health component: 35 (8), Mental health component: 37 (12)

Indirectness of population	No indirectness
Interventions	<p>(n=19) Intervention 1: Combination of techniques - eg ESWL plus pancreatic endotherapy. Endoscopic treatment was performed by experienced endoscopists who had each performed more than 1000 ERCPs. The procedure was performed with the patient under conscious sedation or, if endoscopy was preceded by shock-wave lithotripsy, with the patient under general anaesthesia with propofol. If one or more intraductal stones more than 7 mm in diameter were identified by imaging studies, the patient was referred for lithotripsy. After lithotripsy, stone fragments were removed during a consecutive endoscopic transampullary drainage procedure with a balloon or Dormia basket and the use of the "rotation-perfusion" technique. If stone removal was incomplete, a 6-French nasopancreatic catheter was left in place, and lavage with saline (1L per 24h) was performed until the next treatment. If obstruction of the main duct could not be completely resolved, one or two endoprotheses were placed during the last endoscopic procedure. If an endoprosthesis had been inserted, an elective endoscopic pancreatogram was scheduled for every 3 months. When complete runoff of contrast material was observed after removal of the stent and an extraction balloon could be passed through the pancreatic duct, endoscopic treatment was terminated. Persistent strictures were treated by repeated dilation and sequential insertion of multiple stents. (16 people underwent lithotripsy). Duration 2 years. Concurrent medication/care: In patients with persistent or recurrent pain, imagine studies were repeated and evaluated by a multidisciplinary team of gastroenterologists, surgeons and radiologists. If a recurrent pancreatic duct obstruction was seen in a patient who had completed endoscopic treatment, stent therapy was resumed. Further details: 1. Types of endotherapy: Not stated / Unclear 2. Types of surgery: Not applicable</p> <p>(n=20) Intervention 2: Surgery - Resection and/or surgical drainage procedure. Surgery was performed 4 weeks after randomisation by experienced hepatobiliary surgeons. A pancreaticojejunostomy was performed by the method of Partington and Rochelle. The pancreatic duct was incised over the full length up to 2 cm from the ampulla. When retrieval of concretions from the head area required further opening of the duct toward the ampulla, a limited wedge resection of pancreatic tissue was performed. The patency of the anastomosis was evaluated by means of magnetic resonance cholangiopancreatography 3 months after the procedure and again if symptoms recurred. . Duration 2 years. Concurrent medication/care: In patients with persistent or recurrent pain, imagine studies were repeated and evaluated by a multidisciplinary team of gastroenterologists, surgeons and radiologists. If a recurrent pancreatic duct obstruction was seen in a patient who had completed endoscopic treatment, stent therapy was resumed. Further details: 1. Types of endotherapy: Not applicable 2. Types of surgery: Surgical drainage</p>
Funding	Study funded by industry (Supported by an unrestricted grant from AstraZeneca, the Netherlands)

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ESWL PLUS PANCREATIC ENDOTHERAPY versus SURGICAL DRAINAGE

Protocol outcome 1: Quality of life

- Actual outcome for Adults over 16: QoL (SF-36; Physical health component) at 2 years; Group 1: mean 38 (SD 9); n=19, Group 2: mean 47 (SD 7); n=20; SF-36 0-100
Top=High is good outcome

Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 1

- Actual outcome for Adults over 16: QoL (SF-36; Mental health component) at 2 years; Group 1: mean 40 (SD 9); n=19, Group 2: mean 45 (SD 9); n=20; SF-36 0-100
Top=High is good outcome

Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 1

- Actual outcome for Adults over 16: QoL (SF-36; Physical health component) at 7 years; Group 1: mean 43 (SD 11); n=16, Group 2: mean 48 (SD 9); n=15; SF-36 0-100
Top=High is good outcome

Risk of bias: All domain - Very high, Selection - Low, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: 3; Group 2 Number missing: 5

- Actual outcome for Adults over 16: QoL (SF-36; Mental health component) at 7 years; Group 1: mean 46 (SD 9); n=16, Group 2: mean 48 (SD 10); n=15; SF-36 0-100
Top=High is good outcome

Risk of bias: All domain - Very high, Selection - Low, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: 3; Group 2 Number missing: 5

Protocol outcome 2: Mortality

- Actual outcome for Adults over 16: Mortality at 2 years; Group 1: 1/19, Group 2: 0/20

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 1

Protocol outcome 3: Pain (duration of pain, reduction in pain, medication reduction)

- Actual outcome for Adults over 16: Pain (Izbicki pain score) at 2 years; Group 1: mean 51 (SD 23); n=19, Group 2: mean 25 (SD 15); n=20

Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 1

- Actual outcome for Adults over 16: Pain (Pain relief) at 2 years; Group 1: 6/19, Group 2: 15/20

Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 1

- Actual outcome for Adults over 16: Pain (Izbicki pain score) at 7 years; Group 1: mean 39 (SD 28); n=16, Group 2: mean 22 (SD 31); n=15; Izbicki pain score 0-100
Top=High is poor outcome

Risk of bias: All domain - Very high, Selection - Low, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: 3; Group 2 Number missing: 5

- Actual outcome for Adults over 16: Pain (Pain relief) at 7 years; Group 1: 6/16, Group 2: 12/15
Risk of bias: All domain - Very high, Selection - Low, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: 3; Group 2 Number missing: 5

Protocol outcome 4: Length of stay (in critical care or hospital) at 1 year or under

- Actual outcome for Adults over 16: Hospital stay at 2 years; Mean; , Comments: Endoscopy (Median (range)): 8 (0-128)

Surgery (Median (range)): 11 (5-59) ;

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 1

Protocol outcome 5: Repeated procedures

- Actual outcome for Adults over 16: Number of procedures at 2 years; Mean; , Comments: Endoscopy (Median (range)): 8 (1-21)

Surgery (Median (range)): 3 (1-9);

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 1

Protocol outcome 6: Pancreatic function (endocrine and exocrine)

- Actual outcome for Adults over 16: Pancreatic function (Exocrine insufficiency persisted) at 2 years; Group 1: 11/19, Group 2: 13/20

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 1

- Actual outcome for Adults over 16: Pancreatic function (Exocrine insufficiency developed) at 2 years; Group 1: 6/19, Group 2: 1/20

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 1

- Actual outcome for Adults over 16: Pancreatic function (Endocrine insufficiency developed) at 2 years; Group 1: 3/19, Group 2: 1/20

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 1

- Actual outcome for Adults over 16: Pancreatic function (Endocrine insufficiency persisted) at 2 years; Group 1: 3/19, Group 2: 4/20

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 1

- Actual outcome for Adults over 16: Pancreatic function (Exocrine insufficiency persisted) at 7 years; Group 1: 10/16, Group 2: 11/15

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 3; Group 2 Number missing: 5

- Actual outcome for Adults over 16: Pancreatic function (Exocrine insufficiency developed) at 7 years; Group 1: 6/16, Group 2: 2/15

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: 3; Group 2 Number missing: 5

- Actual outcome for Adults over 16: Pancreatic function (Endocrine insufficiency developed) at 7 years; Group 1: 7/16, Group 2: 3/15

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: 3; Group 2 Number missing: 5
 - Actual outcome for Adults over 16: Pancreatic function (Endocrine insufficiency persisted) at 7 years; Group 1: 4/16, Group 2: 4/15
 Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: 3; Group 2 Number missing: 5

Protocol outcomes not reported by the study	Complications at 1 year or under; Pain (duration of pain, reduction in pain, medication reduction)
---	--

Study	Dite 2003²⁹⁹
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=72)
Countries and setting	Conducted in Czech Republic; Setting: Not reported
Line of therapy	Unclear
Duration of study	Intervention plus follow up: 5 years
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Established by imaging methods such as ultrasound, ERCP, computed tomography, and endosonography
Stratum	Adults over 16
Subgroup analysis within study	Not applicable
Inclusion criteria	Age 18-70, a diagnosis of chronic pancreatitis established by imaging methods such as ultrasound, ERCP, computed tomography, and endosonography, an obstructive form of chronic pancreatitis, with a pain score of more than 3 on Melzack's score, failure of conservative management during the previous 3 years, duration of clinical disease over 5 years, indication for interventional treatment (with both surgery and endoscopy being possible therapeutic alternatives in order for the patient to be included), established in consensus by a consulting gastroenterologist and surgeon.

Exclusion criteria	Aged under 18 or over 70 years, pregnancy, previous interventional therapy for chronic pancreatitis, such as celiac plexus blockade, pancreatic endotherapy, or pancreatic surgery for chronic pancreatitis, suspected pancreatic malignancy, refusal to consent to the study therapies and/or noncompliance with follow-up examinations.
Recruitment/selection of patients	Patients were invited to participate.
Age, gender and ethnicity	Age - Range: 26-53. Gender (M:F): Not reported. Ethnicity: Not reported
Further population details	1. Presence of an inflammatory mass: Not stated / Unclear
Indirectness of population	No indirectness
Interventions	<p>(n=36) Intervention 1: Pancreatic endotherapy - Endoscopic techniques – pancreatic stent (plastic or metal), pancreatic sphincterotomy, drainage. Endotherapy was carried out by two experienced therapeutic endoscopists (who had each performed over 200 therapeutic ERCPs prior to the start of the study). Endotherapy consisted of pancreatic sphincterotomy, dilation or bougienage of strictures, stenting in case of strictures that could not be resolved by sphincterotomy alone, and/or stone extraction, after mechanical lithotripsy when appropriate; extracorporeal shock-wave lithotripsy (ESWL) was not included in the treatment protocol. Stenting was planned for 12-24 months, with stent exchanges being performed every 2-4 months. After the initial treatment period, consisting of either stone extraction and/or long-term stenting over several months, further endoscopic treatment was not carried out.. Duration 5 years. Concurrent medication/care: Not reported Further details: 1. Types of endotherapy: Not stated / Unclear 2. Types of surgery: Not applicable</p> <p>(n=36) Intervention 2: Surgery - Resection and/or surgical drainage procedure. Surgery was carried out by one experienced abdominal surgeon (who had performed 90 pancreatic operations before the start of the study). The surgical therapy was tailored to the individuals situation and included resection procedures for localised disease and drainage procedures for diffuse disease with ductaldilation. In patients in whom chronic pancreatitis was limited predominantly to the pancreatic head, either duodenum-preserving pancreatic head resection or - if the duodenum and/or bile duct were also involved and stenosed - pancreatoduodenectomy (Whipple's resection) were performed. Chronic pancreatitis predominantly affecting the pancreatic tail was treated surgically by left pancreatic resection. Partington-Rochelle pancreatojejunal anastomosis (a drainage procedure) was used in patients with absence of focal pancreatic enlargement, grossly dilated pancreatic duct, and chronic pancreatic pseudocysts if present.. Duration 5 years. Concurrent medication/care: Not reported Further details: 1. Types of endotherapy: Not applicable 2. Types of surgery: Systematic review: mixed</p>

Funding	Funding not stated
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENDOTHERAPY versus RESECTION AND/OR SURGICAL DRAINAGE PROCEDURE</p> <p>Protocol outcome 1: Pain (duration of pain, reduction in pain, medication reduction) - Actual outcome for Adults over 16: Pain (Complete absence of abdominal pain) at 5 years; Group 1: 5/36, Group 2: 12/36 Risk of bias: All domain - Very high, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing: - Actual outcome for Adults over 16: Pain (Partial relief of abdominal pain) at 5 years; Group 1: 17/36, Group 2: 19/36 Risk of bias: All domain - Very high, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 2: Pancreatic function (endocrine and exocrine) - Actual outcome for Adults over 16: Pancreatic function (New onset diabetes) at 5 years; Group 1: 12/36, Group 2: 14/36 Risk of bias: All domain - Very high, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p>	
Protocol outcomes not reported by the study	Quality of life ; Mortality ; Complications at 1 year or under; Pain (duration of pain, reduction in pain, medication reduction) ; Length of stay (in critical care or hospital) at 1 year or under; Repeated procedures

Study	Dumonceau 2007³¹⁹
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=55)
Countries and setting	Conducted in Switzerland; Setting: Not reported
Line of therapy	Unclear

Duration of study	Intervention plus follow up: 2 years
Method of assessment of guideline condition	Unclear method of assessment/diagnosis
Stratum	Adults over 16
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients were considered eligible if they had painful chronic pancreatitis with at least one calcification >4 mm in the pancreatic head or body with upstream dilation of the MPD and no previous intervention on the pancreas.
Exclusion criteria	The presence of a pancreatic fluid collection >2 cm, serum alkaline phosphatases greater than twice the normal value or cholangitis, age <18 years or pregnancy or lactation, and unwillingness to participate.
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (SD): ESWL alone: 51.8 (12.3) ESWL with endoscopy: 49 (10.1). Gender (M:F): 43:12. Ethnicity: Not reported
Further population details	1. Presence of an inflammatory mass: Not stated / Unclear
Extra comments	ESWL group: Alcoholism: 19, N of pain episodes in the last year: 2.5, Intensity of pain: 7.2, Pain present at inclusion: 11, Continuous pain: 10, diabetes: 6 ESWL plus endotherapy group: Alcoholism: 20, N of pain episodes in the last year: 3, Intensity of pain: 7.3, Pain present at inclusion: 20, Continuous pain: 8, diabetes: 4
Indirectness of population	No indirectness
Interventions	(n=26) Intervention 1: Pancreatic ESWL - Extracorporeal Shock wave lithotripsy – with or without ERCP. One or more sessions of ESWL were performed in all patients using the Lithostar Plus until the obstructive stones were broken into fragments <2 mm, as measured by x-ray.. Duration 2 years. Concurrent medication/care: Follow-up consisted clinical examination 1 month after treatment (supplemented with secretin-enhanced magnetic resonance cholangio-pancreatography in centre 1), and every 6 months thereafter. Further details: 1. Types of endotherapy: Different types of endotherapy 2. Types of surgery: Not applicable

	<p>(n=29) Intervention 2: Pancreatic ESWL - Extracorporeal Shock wave lithotripsy – with or without ERCP. One or more sessions of ESWL were performed in all patients using the Lithostar Plus until the obstructive stones were broken into fragments <2 mm, as measured by x-ray. In addition to this, the patients in the ESWL combined with endoscopy group underwent an endoscopic retrograde pancreatography immediately after the last ESWL session with attempted extraction of stone fragments and insertion of 10-French plastic pancreatic stents if pancreatic strictures were identified.. Duration 2 years. Concurrent medication/care: Follow-up consisted clinical examination 1 month after treatment (supplemented with secretin-enhanced magnetic resonance cholangio-pancreatography in centre 1), and every 6 months thereafter. Further details: 1. Types of endotherapy: Different types of endotherapy 2. Types of surgery: Not applicable</p>
Funding	Funding not stated
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: EXTRACORPOREAL SHOCK WAVE LITHOTRIPSY versus EXTRACORPOREAL SHOCK WAVE LITHOTRIPSY WITH ERP</p> <p>Protocol outcome 1: Pain (duration of pain, reduction in pain, medication reduction) - Actual outcome for Adults over 16: Pain (Pain relapse at 2 years) at 2 years; Group 1: 10/24, Group 2: 13/24 Risk of bias: All domain - Very high, Selection - Low, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 2; Group 2 Number missing: 5 - Actual outcome for Adults over 16: Pain (Pain intensity) at 2 years; Group 1: mean 5.7 (SD 2.1); n=24, Group 2: mean 5.7 (SD 1.3); n=24; VAS pain score 1-10 Top=High is poor outcome Risk of bias: All domain - Very high, Selection - Low, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 2; Group 2 Number missing: 5</p> <p>Protocol outcome 2: Length of stay (in critical care or hospital) at 1 year or under - Actual outcome for Adults over 16: Length of hospital stay at 2 years; Group 1: mean 3.1 days (SD 5.3); n=24, Group 2: mean 8.6 days (SD 16.5); n=24 Risk of bias: All domain - Very high, Selection - Low, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 2; Group 2 Number missing: 5</p>	
Protocol outcomes not reported by the study	Quality of life ; Mortality ; Complications at 1 year or under; Pain (duration of pain, reduction in pain, medication reduction) ; Repeated procedures ; Pancreatic function (endocrine and exocrine)

H.16 Management of small-duct disease in people with chronic pancreatitis

Study	Basinski 2005 ⁹³
Study type	Non-randomised comparative study
Number of studies (number of participants)	1 (n=48)
Countries and setting	Conducted in Poland; Setting: Not reported
Line of therapy	Unclear
Duration of study	Not clear:
Method of assessment of guideline condition	Unclear method of assessment/diagnosis
Stratum	Adults over 16
Subgroup analysis within study	Not applicable
Inclusion criteria	Chronic pancreatitis diagnosed by CT scan and endoscopic retrograde cholangiopancreatography, persistent pain for at least 3 months, scoring at least 66.7% on the pain visual analog scale.
Exclusion criteria	Patients with pancreatic inflammatory tumors or pseudocysts were excluded from the study.
Recruitment/selection of patients	Not reported
Age, gender and ethnicity	Age - Mean (SD): NCPB: 49.9 (7.8) VSPL: 47.3 (%). Gender (M:F): NCPB: 3.01, VSPL: 3.51. Ethnicity: Not reported
Further population details	

Indirectness of population	No indirectness
Interventions	<p>(n=18) Intervention 1: Surgery - Partial or total resection and drainage operation. Because unilateral (preferably left-sided) splanchnicectomy was reported to be adequate in control of the intractable pancreatic pain, all patients were given a left-sided intervention. General anaesthesia was administered with single bronchus intubation in every case. The patient was placed in the right lateral decubitus position with the left arm elevated at a 90° angle, and fixed with support-arms and bandages, and the table was then tilted 30 degrees anteriorly in the longitudinal axis. After desufflation of the lung, two trocars were inserted into the thorax. After identification of the splanchnic nerve, situated above the aorta on the left or above the azygos vein on the right, the parietal pleura was incised and the nerve together with its minor connecting branches, was prepared to a distance of 5-8 cm and then excised. After insufflation of the lung, the trocars were removed, a single chest tube was placed, and the wounds were closed according to surgical standards. Duration During admission. Concurrent medication/care: Not reported. Indirectness: No indirectness Further details: 1. Types of endotherapy: Not applicable 2. Types of surgery: Not stated / Unclear</p> <p>(n=30) Intervention 2: Endoscopic treatment. Patients were fixed in the prone position with a slight bending forward. The lower margin of the 12th rib was marked on both sides of the body. After the superficial anaesthesia with 1% lignocaine, the 20-G needle pierced into the point located 5-7 cm laterally from the midline on both sides just under the lower margin of the 12th rib, at the angle of 30-45 towards the trunk of L1 and TH12 vertebrae or the space between L1 and TH12 vertebrae. The canal of the needle was then additionally anaesthetised with further 6-10 ml of 1% lignocaine. The needle was pierced into until the resistance of bone was met.. Duration During admission. Concurrent medication/care: Not reported. Indirectness: No indirectness Further details: 1. Types of endotherapy: Not stated / Unclear 2. Types of surgery: Not stated / Unclear</p>
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: VSPL versus NCPB

Protocol outcome 1: Pain (duration of pain, reduction in pain, medication reduction)

- Actual outcome for Adults over 16: Pain (Use of opioids) at Unclear; Group 1: 11/18, Group 2: 17/30

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcomes not reported by the study	Quality of life ; Mortality ; Complications at 1 year or under; Pain (duration of pain, reduction in pain, medication reduction) ; Length of stay (in critical care or hospital) at 1 year or under; Repeated procedures ; Pancreatic function (endocrine and exocrine)
---	---

H.17 Management of pseudocysts

Study	Akshintala 2014 ²⁰
Study type	Non-randomised comparative study
Number of studies (number of participants)	1 (n=81)
Countries and setting	Conducted in USA; Setting: academic centre
Line of therapy	1st line
Duration of study	Intervention + follow up: 19 year
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Adults over 16
Subgroup analysis within study	Not applicable
Inclusion criteria	Adult patients with symptomatic pseudocysts within <1 cm of the gastric or duodenal wall who underwent ED (endoscopic drainage) or PD (percutaneous drainage). Only those pseudocysts within 1cm of the gastric or duodenal wall were included in this study because these would allow for either percutaneous drainage or endoscopic drainage.
Exclusion criteria	Patients were excluded if they had acute fluid collections or walled-off pancreatic necrosis (WOPN) as determined by a history of acute necrotising pancreatitis, with a CT scan of the abdomen demonstrating necrosis of >30% of the pancreas, with an associated post-necrotic peripancreatic fluid collection. Pseudocysts that could be drained by only one approach were excluded. Patients with cystic neoplasms as diagnosed by fine-needle aspiration cytology or subsequent surgical resection histopathology were also excluded.
Recruitment/selection of patients	Patients who underwent endoscopic or percutaneous drainage for symptomatic pseudocysts between January 1993 and December 2011 were identified from an institutional claims database.
Age, gender and ethnicity	Age - Mean (SD): ED- 47.1 (14.9); PD- 52.7 (12.68). Gender (M:F): Male: ED- 28 (68.3%); 26 (65%) . Ethnicity:
Further population details	1. Presence of pain: 2. Type of pancreatitis:

Extra comments	. A total of 32 patients (78%) in the endoscopic drainage group and 38 patients (95%) in the percutaneous drainage group underwent their index procedures as inpatients. However, all patients undergoing endoscopic drainage or percutaneous drainage as outpatients were subsequently admitted after their index procedures. Pseudocysts, n(%): single: ED 31 (75.6%); 22 (55%);multiple- 10 (24.4%); 18 (45%)
Indirectness of population	--
Interventions	<p>(n=41) Intervention 1: Endoscopic drainage. Endoscopic drainage was performed by using monitored sedation after appropriate antibiotic prophylaxis. The conventional transmural approach by using a duodenoscope or therapeutic upper GI endoscope was performed only if a visible gastric or duodenal bulge from a pseudocyst was appreciated by the endoscopist. The transmural drainage approach of using EUS guidance, was performed by using linear array echo endoscopes.. Duration during admission. Concurrent medication/care: not stated . Indirectness: No indirectness Further details: 1. Type of stent: 2. Type of surgery: Comments: 909 days follow-up</p> <p>(n=40) Intervention 2: Percutaneous drainage . Percutaneous drainage was performed under CT guidance and/or US and fluoroscopic guidance. The pseudocyst was identified, and a suitable route for catheter drainage was chosen. Using a real-time imaging guidance,a site for needle insertion was chosen that would avoid the spleen, interposed bowel, and blood vessels. The site was marked on the skin. The skin and subcutaneous tissue were anaesthetised with a subcutaneous injection of 1% lidocaine solution. The pseudocyst was first punctured under CT/US guidance with an 18guage single-wall needle and a small aliquot of fluid was obtained for Gram stain, culture, and fluid amylase levels.. Duration during admission. Concurrent medication/care: not stated . Indirectness: No indirectness Further details: 1. Type of stent: 2. Type of surgery: Comments: 671 days follow-up</p>
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENDOSCOPIC DRAINAGE versus PERCUTANEOUS DRAINAGE

Protocol outcome 1: Mortality at 1 year or under

- Actual outcome: Mortality at end of follow-up ; Group 1: 0/41, Group 2: 0/40

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 2: Complications

- Actual outcome: Procedural adverse events at end of follow-up ; Group 1: 6/41, Group 2: 6/40

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 3: Length of stay (in critical care or hospital) at 1 year or under

- Actual outcome: length of stay in hospital at end of follow-up ; Group 1: mean 6.5 (SD 6.7); n=41, Group 2: mean 14.8 (SD 14.4); n=40

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 4: Repeated procedures

- Actual outcome: Re-intervention at end of follow-up ; Group 1: 4/41, Group 2: 17/40

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcomes not reported by the study

Quality of life ; Resolution of presenting symptoms (e.g. Pain, nutritional status, gastric outlet obstruction) ; Resolution or recurrence of pseudocysts ; Length of stay (in critical care or hospital) at 1 year or under

Study	Andersson 2006 ⁴⁰
Study type	Non-randomised comparative study
Number of studies (number of participants)	1 (n=44)
Countries and setting	Conducted in Sweden; Setting: Hospital
Line of therapy	1st line
Duration of study	Intervention + follow up: 10 years
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Adults over 16
Subgroup analysis within study	Not applicable:
Inclusion criteria	Patients >15 years of age with pancreatic pseudocysts.
Exclusion criteria	Patients primarily treated at another hospital were excluded.
Recruitment/selection of patients	All patients >15 years of age admitted to the department of surgery, University Hospital of Lund, Sweden, between January 1994 and December 2003 were identified from the hospital records, aided by a computer search.

Age, gender and ethnicity	Age - Mean (SD): 55 (14). Gender (M:F): Male- 29 (66%). Ethnicity:
Further population details	1. Presence of pain: Not stated / Unclear 2. Type of pancreatitis: Acute pancreatitis (77% acute; 23% chronic).
Extra comments	34 patients had acute pancreatitis and 10 chronic pancreatitis. Ultrasonography was performed in 93% and CT examination in 91% of patients.
Indirectness of population	No indirectness
Interventions	<p>(n=20) Intervention 1: Percutaneous drainage . Percutaneous puncture and drainage procedures were performed under US or CT guidance.. Duration during admission. Concurrent medication/care: not stated Further details: 1. Type of stent: 2. Type of surgery:</p> <p>(n=21) Intervention 2: Standard treatment. conservative treatment. Duration during admission. Concurrent medication/care: not stated . Indirectness: No indirectness Further details: 1. Type of stent: 2. Type of surgery:</p> <p>(n=3) Intervention 3: Open Surgery - Drainage or resection. surgery (e.g. internal drainage with cystogastrostomy or external drainage). No further details. . Duration during admission . Concurrent medication/care: not stated . Indirectness: No indirectness Further details: 1. Type of stent: 2. Type of surgery:</p>
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: PERCUTANEOUS DRAINAGE versus STANDARD TREATMENT

Protocol outcome 1: Complications

- Actual outcome: complications at 10 years; Group 1: 4/20, Group 2: 0/21

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 2: Resolution or recurrence of pseudocysts

- Actual outcome: recurrences at 10 years; Group 1: 14/20, Group 2: 11/21

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: PERCUTANEOUS DRAINAGE versus DRAINAGE OR RESECTION

Protocol outcome 1: Resolution or recurrence of pseudocysts

- Actual outcome: recurrences at 10 years; Group 1: 15/20, Group 2: 1/3

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: DRAINAGE OR RESECTION versus STANDARD TREATMENT

Protocol outcome 1: Complications

- Actual outcome: Length of hospital stay at 10 years; Mean; Interventional treatment: 14 (2-60) days; conservative treatment: 10 (0-141) days;

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 2: Resolution or recurrence of pseudocysts

- Actual outcome: recurrences at 10 years; Group 1: 1/3, Group 2: 11/21

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcomes not reported by the study

Quality of life ; Mortality at 1 year or under; Resolution of presenting symptoms (e.g. Pain, nutritional status, gastric outlet obstruction) ; Length of stay (in critical care or hospital) at 1 year or under; Length of stay (in critical care or hospital) at 1 year or under; Repeated procedures

Study	Bhasin 2011 ¹²⁹
Study type	Non-randomised comparative study
Number of studies (number of participants)	1 (n=11)
Countries and setting	Conducted in India; Setting: Not reported.
Line of therapy	1st line
Duration of study	Intervention time: 8 weeks
Method of assessment of guideline condition	Unclear method of assessment/diagnosis
Stratum	Adults over 16:
Subgroup analysis within study	Not applicable:

Inclusion criteria	Patients with symptomatic large (>6cm) pseudocysts of pancreas located at tail region of pancreas.
Exclusion criteria	Patients with pancreatic mass, pregnancy, age less than 18 years, presence of chronic cardiac, renal or pulmonary failure, or patients not giving informed consent were excluded.
Recruitment/selection of patients	Not reported.
Age, gender and ethnicity	Age - Mean (SD): 41+/- 9 years. Gender (M:F): 9/2. Ethnicity: Not reported
Further population details	1. Presence of pain: Not stated / Unclear 2. Type of pancreatitis: Not stated / Unclear
Extra comments	. Patients were told the pros and cons of both methods and the stent or NPD was placed as per the patients' choice.
Indirectness of population	No indirectness
Interventions	<p>(n=5) Intervention 1: Endoscopic drainage. Endoscopic transpapillary nasopancreatic drainage. All patients were symptomatic, had pseudocysts of the pancreas at tail end of pancreas and all had documented persistence of pseudocysts for 6 weeks or more. Initially, an attempt was made for contrast-free pancreatic duct cannulation and if that was not possible, minimal contrast was injected. Once cannulated, minimal contrast was injected to confirm pancreatic duct (PD) disruption, defined by free extravasation of contrast outside the pancreatic ductal system as seen on fluoroscopy. PD disruption was defined as complete when the main duct upstream to the disruption was not opacified and as partial when the main duct was visualised upstream from the site of disruption. After confirming the ductal disruption, a 5-Fr NPD was placed across the papilla in to the PD by advancing it over a 0.025 or 0.035 in. hydrophilic guide wire. An attempt was made to place the NPD across the area of the disruption and if that was not possible, it was placed as close as possible to the disruption. . Duration 6 weeks. Concurrent medication/care: Intravenous ciproflaxin was administered for antibiotic prophylaxis.</p> <p>Further details: 1. Type of stent: 2. Type of surgery:</p> <p>(n=6) Intervention 2: Pancreatic endoscopic stent. Endoscopic retrograde cholangiopancreatography (ERCP), using a standard technique using a TJF 145 or TJF 160 side-viewing duodenoscope under conscious sedation by intravenous midazolam and hyoscine butylbromide to inhibit duodenal contractions. Initially, an attempt was made for contrast-free pancreatic duct cannulation and if that was not possible, minimal contrast was injected. Once cannulated, minimal contrast was injected to confirm pancreatic duct (PD) disruption, defined by free extravasation of contrast outside the pancreatic ductal system as seen on fluoroscopy. PD disruption was defined as complete when the main duct upstream to the disruption was not opacified and as partial when the main duct was visualised upstream from the site of disruption. After confirming the ductal disruption, a 5-Fr stent was placed across the papilla in to the PD by advancing it over a 0.025 or 0.035 in. hydrophilic guide wire. . Duration After the procedure all cases were admitted and kept under observation for 48 to 72 hours. Concurrent medication/care: Intravenous ciproflaxin was administered for antibiotic prophylaxis Indirectness: No indirectness</p>

	Further details: 1. Type of stent: 2. Type of surgery:
Funding	Funding not stated
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENDOSCOPIC TRANSPAILLARY NASOPANCREATIC DRAINAGE versus PANCREATIC ENDOSCOPIC STENT</p> <p>Protocol outcome 1: Complications - Actual outcome: Significant complications at 3-10 days (after insertion of stent); Group 1: 0/4, Group 2: 4/6 Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness, Comments: It should be noted that the patients who developed complications in the ERP arm are also included in the resolution of pseudocysts; Baseline details: No significant difference in the size of the pseudocysts between the two groups. ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 2: Resolution or recurrence of pseudocysts - Actual outcome: Resolution of pseudocysts at 4-8 weeks; Group 1: 4/4, Group 2: 2/6; Comments: One patient in the NPD group is not included as deep cannulation could not be achieved. Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Baseline details: No significant difference in the size of the pseudocysts between the two groups. ; Group 1 Number missing: ; Group 2 Number missing: - Actual outcome: Recurrence of pseudocysts at 16.4+/-11.4 months; Group 1: 0/4, Group 2: 0/2 Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness, Comments: The ERP group required additional percutaneous drainage and antibiotics for successful outcomes therefore only one patient is included for this arm. ; Baseline details: No significant difference in the size of the pseudocysts between the two groups. ; Group 1 Number missing: ; Group 2 Number missing:</p>	
Protocol outcomes not reported by the study	Quality of life ; Mortality at 1 year or under; Resolution of presenting symptoms (e.g. Pain, nutritional status, gastric outlet obstruction) ; Length of stay (in critical care or hospital) at 1 year or under; Length of stay (in critical care or hospital) at 1 year or under; Repeated procedures
Study	Davila-cervantes 2004²⁶⁹
Study type	Non-randomised comparative study
Number of studies (number of participants)	1 (n=16)

Countries and setting	Conducted in Mexico; Setting: Hospital
Line of therapy	1st line
Duration of study	Other: Retrospective collection of data from between March 1996 and November 2003. Median follow up 22 months (range 1-72 months)
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: All cases originated in a well-documented episode of acute pancreatitis. Diagnosis of pancreatic pseudocysts was confirmed by ultrasonography and CT scan.
Stratum	Overall:
Subgroup analysis within study	Not applicable:
Inclusion criteria	Patients presented with mature pseudocysts developed after a documented episode of acute pancreatitis.
Exclusion criteria	NR
Recruitment/selection of patients	10 patients undergoing laproscopic surgical management at one institution from March 1996 to November 2003, compared to 6 patients who underwent conventional open drainage at the same institution during the same time period.
Age, gender and ethnicity	Age - Mean (range): Laparoscopic 42 (17-68) years; open surgery 36 (18-54) years. Gender (M:F): 11/5. Ethnicity: NR
Further population details	1. Presence of pain: Not stated / Unclear (Indication for drainage was abdominal pain in 7/16 people). 2. Type of pancreatitis: Acute pancreatitis
Extra comments	None of the patients had evidence of chronic alcoholic pancreatitis. Etiology of pancreatitis was alcoholic in 8 people, biliary in 5, toxic in 2 and associated with systemic lupus erythematosus in 1. Indications for drainage were abdominal pain in 7 people, abdominal mass unresponsive to conservative management in 7 people and food intolerance in 2 people.. 3 patients in the laproscopic group and all patients in the open surgery group had previous abdominal operations (appendectomy, cesarean section, cholecystectomy, pancreatic necrosectomy)
Indirectness of population	No indirectness
Interventions	(n=10) Intervention 1: Laparoscopic drainage - Laparoscopic drainage. Type of drainage chosen according to the size and location of the pseudocyst (4 people had Roux-en-Y cystojejunostomy, 4 had extraluminal cystogastrostomy and 2 had intraluminal cystogastrostomy). Closed drains used in all cases.. Duration N/A. Concurrent medication/care: All procedures performed under general anaesthesia. In 6 patients, intraoperative ultrasound was used at the beginning of the procedure to confirm the position of the pseudocyst and after drainage to rule out non-communicated persistent collections. Diet initiated 48 hours after surgery.. Indirectness: No indirectness Further details: 1. Type of stent: Not applicable 2. Type of surgery: Not applicable

	(n=6) Intervention 2: Open Surgery - Drainage or resection. Conventional open drainage (3 people had cystojejunostomy and 3 had cystogastrostomy). Duration N/A. Concurrent medication/care: NR. Indirectness: No indirectness Further details: 1. Type of stent: Not applicable 2. Type of surgery: Not applicable
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: LAPAROSCOPIC DRAINAGE versus DRAINAGE OR RESECTION

Protocol outcome 1: Mortality at 1 year or under

- Actual outcome for Adults over 16: All-cause mortality at median 22 months (range 1-72); Group 1: 1/10, Group 2: 0/6
 Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 2: Complications

- Actual outcome for Adults over 16: Upper gastrointestinal bleeding at NR; Group 1: 1/10, Group 2: 0/6
 Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:
 - Actual outcome for Adults over 16: Post-operative abscess at NR; Group 1: 1/10, Group 2: 0/6
 Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:
 - Actual outcome for Adults over 16: Small bowel obstruction secondary to an internal hernia (requiring reoperation) at NR; Group 1: 0/10, Group 2: 1/6
 Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:
 - Actual outcome for Adults over 16: Pneumonia at NR; Group 1: 0/10, Group 2: 1/6
 Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:
 - Actual outcome for Adults over 16: Overall complications at NR; Group 1: 2/10, Group 2: 2/6
 Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 3: Resolution of presenting symptoms (e.g. Pain, nutritional status, gastric outlet obstruction)

- Actual outcome for Adults over 16: Asymptomatic with no evidence of recurrent disease by CT scan at median 22 months; Group 1: 10/10, Group 2: 6/6
 Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

<p>Protocol outcome 4: Resolution or recurrence of pseudocysts - Actual outcome for Adults over 16: Presented with residual pseudocyst at NR; Group 1: 1/10, Group 2: 1/6 Risk of bias: All domain - ; Indirectness of outcome: No indirectness</p>	
<p>Protocol outcome 5: Length of stay (in CCU or hospital) at 1 year or under - Actual outcome for Adults over 16: Length of hospital stay (reported as median, range) at NR; Median (range): laproscopic: 7 (4-15); open surgery: 14 (8-21) days; Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p>	
Protocol outcomes not reported by the study	Quality of life ; Length of stay (in CCU or hospital) at 1 year or under; Repeated procedures

Study	Heider 1999 ⁴⁵¹
Study type	Non-randomised comparative study
Number of studies (number of participants)	1 (n=173)
Countries and setting	Conducted in USA; Setting: Hospital
Line of therapy	Not applicable
Duration of study	Other: Retrospective collection of data from between December 1984 and May 1995
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Well-documented pancreatic pseudocyst
Stratum	Adults over 16:
Subgroup analysis within study	Not applicable
Inclusion criteria	Well-documented pancreatic pseudocyst (definition of pancreatic pseudocyst by the Atlantic International Symposium applied retrospectively to CT and US reports for a uniform definition)
Exclusion criteria	Transfer from other hospitals with insufficient information, incomplete data, or a misdiagnosis of pancreatic pseudocyst.
Recruitment/selection of patients	Computerised index search of the University of North Carolina Hospitals medical records from December 1984 to May 1995 using the key word pseudocyst
Age, gender and ethnicity	Age - Mean (SD): 45 ± 1 years. Gender (M:F): 112/61. Ethnicity: NR
Further population details	1. Presence of pain: Not stated / Unclear (71% presented with abdominal pain). 2. Type of pancreatitis: Not stated / Unclear (27% had documented chronic pancreatitis).

Extra comments	27% had documented chronic pancreatitis. Etiology was alcohol in 61%, gallstones in 10%, and miscellaneous causes in 29%.
Indirectness of population	No indirectness
Interventions	<p>(n=66) Intervention 1: Percutaneous drainage . Defined as non-operative, US- or CT- guided percutaneous placement of a catheter for pseudocyst drainage. Duration N/A. Concurrent medication/care: NR. Indirectness: No indirectness Further details: 1. Type of stent: Not applicable 2. Type of surgery: Not applicable</p> <p>(n=66) Intervention 2: Open Surgery - Drainage or resection. Surgical treatment included internal or external drainage, longitudinal pancreaticojejunostomy, or distal pancreatectomy. Duration N/A. Concurrent medication/care: NR. Indirectness: No indirectness Further details: 1. Type of stent: Not applicable 2. Type of surgery: Not applicable</p> <p>(n=41) Intervention 3: Standard treatment. Observation (defined by lack of intervention other than fluid management and pain control). Duration N/A. Concurrent medication/care: NR. Indirectness: No indirectness Further details: 1. Type of stent: Not applicable 2. Type of surgery: Not applicable</p>
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: PERCUTANEOUS DRAINAGE versus DRAINAGE OR RESECTION

Protocol outcome 1: Mortality at 1 year or under

- Actual outcome for Adults over 16: Mortality at NR; Group 1: 6/66, Group 2: 0/66

Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 2: Complications

- Actual outcome for Adults over 16: Bleeding at NR; Group 1: 6/66, Group 2: 3/66

Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

- Actual outcome for Adults over 16: Infection at NR; Group 1: 30/66, Group 2: 10/66

Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

- Actual outcome for Adults over 16: Fistula at NR; Group 1: 5/66, Group 2: 4/66

Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:
- Actual outcome for Adults over 16: Number of people without late sequelae (after hospital discharge; defined as recurrent cyst, recurrent pancreatitis, fistula, infection) at After hospital discharge; Group 1: 33/66, Group 2: 45/66
Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 3: Resolution or recurrence of pseudocysts

- Actual outcome for Adults over 16: Failure (defined as radiographic persistence of a symptomatic pseudocyst in the observed group and a persistent symptomatic pseudocyst requiring a further procedure in the intervention groups) at NR; Group 1: 38/66, Group 2: 8/66
Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 4: Length of stay (in CCU or hospital) at 1 year or under

- Actual outcome for Adults over 16: Length of hospital stay at NR; Group 1: mean 45 days (SD 5); n=66, Group 2: mean 18 days (SD 2); n=66
Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: PERCUTANEOUS DRAINAGE versus STANDARD TREATMENT

Protocol outcome 1: Mortality at 1 year or under

- Actual outcome for Adults over 16: Mortality at NR; Group 1: 6/66, Group 2: 0/41
Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 2: Complications

- Actual outcome for Adults over 16: Bleeding at NR; Group 1: 6/66, Group 2: 1/41
Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:
- Actual outcome for Adults over 16: Infection at NR; Group 1: 30/66, Group 2: 3/41
Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:
- Actual outcome for Adults over 16: Fistula at NR; Group 1: 5/66, Group 2: 1/41
Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:
- Actual outcome for Adults over 16: Number of people without late sequelae (after hospital discharge; defined as recurrent cyst, recurrent pancreatitis, fistula, infection) at After hospital discharge; Group 1: 33/66, Group 2: 28/41

Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 3: Resolution or recurrence of pseudocysts

- Actual outcome for Adults over 16: Failure (defined as radiographic persistence of a symptomatic pseudocyst in the observed group and a persistent symptomatic pseudocyst requiring a further procedure in the intervention groups) at NR; Group 1: 38/66, Group 2: 3/41

Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: DRAINAGE OR RESECTION versus STANDARD TREATMENT

Protocol outcome 1: Mortality at 1 year or under

- Actual outcome for Adults over 16: Mortality at NR; Group 1: 0/66, Group 2: 0/41

Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 2: Complications

- Actual outcome for Adults over 16: Bleeding at NR; Group 1: 3/66, Group 2: 1/41

Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

- Actual outcome for Adults over 16: Infection at NR; Group 1: 10/66, Group 2: 3/41

Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

- Actual outcome for Adults over 16: Fistula at NR; Group 1: 4/66, Group 2: 1/41

Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

- Actual outcome for Adults over 16: Number of people without late sequelae (after hospital discharge; defined as recurrent cyst, recurrent pancreatitis, fistula, infection) at After hospital discharge; Group 1: 45/66, Group 2: 28/41

Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 3: Resolution or recurrence of pseudocysts

- Actual outcome for Adults over 16: Failure (defined as radiographic persistence of a symptomatic pseudocyst in the observed group and a persistent symptomatic pseudocyst requiring a further procedure in the intervention groups) at NR; Group 1: 8/66, Group 2: 3/41

Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcomes not reported by the study	Quality of life ; Resolution of presenting symptoms (e.g. Pain, nutritional status, gastric outlet obstruction) ; Length of stay (in CCU or hospital) at 1 year or under; Repeated procedures
---	---

Study	Johnson 2009 ⁵⁴⁷
Study type	Non-randomised comparative study
Number of studies (number of participants)	1 (n=54)
Countries and setting	Conducted in USA; Setting: Department of General surgery and Gastroenterology, Cleveland Clinic
Line of therapy	Unclear
Duration of study	Not clear:
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: CP was diagnosed in the setting of recurrent episodes of documented pancreatitis supplemented by evidence of exocrine and/or endocrine insufficiency when appropriate.
Stratum	Adults over 16
Subgroup analysis within study	Not applicable
Inclusion criteria	Participants included were those who had undergone an intervention for a diagnosed pancreatic pseudocyst.
Exclusion criteria	Not reported
Recruitment/selection of patients	Participants had been treated at the Cleveland Clinic
Age, gender and ethnicity	Age - Mean (SD): Surgery: 49, Endoscopy: 52. Gender (M:F): Not reported. Ethnicity: Not reported
Further population details	1. Presence of pain: Not stated / Unclear 2. Type of pancreatitis: Systematic review: mixed
Extra comments	Surgery: Pseudocyst diameter: 9.1 cm; Aetiology: Alcohol - 8, Biliary - 8, Postoperative - 1, Idiopathic - 11, Other - 2; Multiple pseudocysts - 12 Surgery: Pseudocyst diameter: 9.5 cm; Aetiology: Alcohol - 8, Biliary - 8, Postoperative - 5, Idiopathic - 5, Other - 1; Multiple pseudocysts - 5
Indirectness of population	No indirectness
Interventions	(n=30) Intervention 1: Open Surgery - Drainage or resection. Surgical treatment consisted of pseudocyst drainage and also additional pancreatobiliary procedures in certain cases as deemed necessary by the surgeon at the time of operation. Cholecystectomy was performed when there was a question of gallstones either contributing to. or

	<p>potentially complicating pancreatitis. Longitudinal pancreaticojejunostomy was performed when feasible in the presence of chronic pancreatitis. Splenectomy and gastric drainage procedures were selectively performed by the operating surgeon in the presence of splenic vein thrombosis and gastric outlet obstruction, respectively. . Duration During admission. Concurrent medication/care: Not reported. Indirectness: No indirectness Further details: 1. Type of stent: Not applicable 2. Type of surgery: Different types of surgery</p> <p>(n=24) Intervention 2: Endoscopic drainage. Endoscopic drainage was performed using monitored sedation and consisted of transmural drainage through the gastric wall with or without transpapillary drainage. Transmural drainage was performed if a visible bulge was appreciated by the endoscopist. Using Seldinger technique, the tract was balloon-dilated and stented with either 1 or 2 double pigtail stents at the discretion of the endoscopist. A pancreatic duct sphincterotomy was performed and pancreatic duct stent was placed unless technical reasons prevented access to the pancreatic duct. . Duration During admission. Concurrent medication/care: Not reported. Indirectness: No indirectness Further details: 1. Type of stent: Not applicable 2. Type of surgery: Not applicable</p>
Funding	No funding

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENDOSCOPIC DRAINAGE/PANCREATIC ENDOSCOPIC STENT versus SURGERY

Protocol outcome 1: Mortality at 1 year or under

- Actual outcome for Adults over 16: Mortality at Unclear; Group 1: 0/24, Group 2: 0/30

Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 2: Complications

- Actual outcome for Adults over 16: Complications at Unclear; Group 1: 5/24, Group 2: 6/30; Comments: Endoscopic: 2 technical failures, 2 episodes of post-procedure heamorrhage and 1 stent malfunction leading to pseudocyst infection; surgery group: 3 incisional hernias, 1 post-op deep vein thrombosis, 1 heamorrhage into a pseudocyst from a splenic artery pseudoaneurysm and 1 pancreatic fistula.

Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 3: Resolution or recurrence of pseudocysts

- Actual outcome for Adults over 16: Resolution of pseudocysts at Unclear; Group 1: 21/24, Group 2: 28/30

Risk of bias: All domain - Very high, Selection - Very high, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcomes not reported by the study	Quality of life ; Resolution of presenting symptoms (e.g. Pain, nutritional status, gastric outlet obstruction) ; Length of stay (in CCU or hospital) at 1 year or under; Length of stay (in CCU or hospital) at 1 year or under; Repeated procedures
---	---

Study	Melman 2009⁷³⁴
Study type	Non-randomised comparative study
Number of studies (number of participants)	1 (n=83)

Countries and setting	Conducted in USA; Setting: Barnes-Jewish Hospital, Washington University Medical Center
Line of therapy	Unclear
Duration of study	Intervention + follow up: 16 months
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: The diagnosis of a pancreatic pseudocyst was established by abdominal computed tomography scan, magnetic resonance cholangiopancreatogram, endoscopic ultrasound, or abdominal ultrasound.
Stratum	Adults over 16
Subgroup analysis within study	Not applicable
Inclusion criteria	Data was collected on patients who underwent transgastric pancreatic pseudocyst drainage.
Exclusion criteria	Not reported
Recruitment/selection of patients	Data was collected retrospectively
Age, gender and ethnicity	Age - Mean (SD): Endo: 51.8 (1.9), Lap: 46.5 (3.6), Open: 52 (3.8). Gender (M:F): Unclear. Ethnicity: Not reported
Further population details	1. Presence of pain: Not stated / Unclear 2. Type of pancreatitis: Not stated / Unclear
Extra comments	Gallstone pancreatitis: Endo: 51.7%, Lap: 50%, Open: 59.1%; Pseudocyst size (cm): Endo: 9.1±0.4, Lap: 10.4±0.5, Open: 9.5±0.8
Indirectness of population	No indirectness
Interventions	<p>(n=45) Intervention 1: Endoscopic drainage. Endoscopic cases were managed in a dedicated endoscopy suite with the patient under procedural sedation by an anesthetist. Endoscopic ultrasound was used selectively. All cases were managed using a transmural approach. Endoscopic retrograde cholangiopancreatography was performed before endoscopic pancreatic cystgastrostomy. The pancreatic cystgastrostomy was created by puncturing the cyst through the posterior gastric wall, introducing a guidewire through the needle into the pancreatic cyst, and dilating the tract with a balloon. Double pigtail catheters were exchanged over the wire.. Duration During admission . Concurrent medication/care: Not reported. Indirectness: No indirectness Further details: 1. Type of stent: Not applicable 2. Type of surgery: Not applicable</p> <p>(n=22) Intervention 2: Open Surgery - Drainage or resection. Open cyst gastrostomy usually was achieved through a midline or bilateral subcostal incision. After an exploration through the lesser sac, an anterior gastrotomy was performed at the position overlying the area in which the cyst was adherent to the posterior wall of the stomach. An 8- to 10-cm posterior gastrotomy was extended through the cyst wall, and the pancreatic pseudocyst was aspirated and debrided of its contents. A biopsy of the cyst wall was performed. The cystgastrostomy was performed with a running</p>

	<p>suture between the gastric and cyst walls to complete the anastomosis. The anterior gastrotomy then was closed.. Duration During admission. Concurrent medication/care: Not reported. Indirectness: No indirectness Further details: 1. Type of stent: Not applicable 2. Type of surgery: Different types of surgery</p> <p>(n=16) Intervention 3: Laparoscopic drainage - Laparoscopic drainage. The laparoscopic transgastric technique was similar to the open surgery technique, except that the pancreatic cystgastrostomy was accomplished using a linear endoscopic stapler to create the cystenteric anastomosis. . Duration During admission. Concurrent medication/care: Not reported. Indirectness: No indirectness Further details: 1. Type of stent: Not applicable 2. Type of surgery: Not applicable</p>
Funding	Funding not stated
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENDOSCOPIC DRAINAGE versus OPEN SURGERY</p> <p>Protocol outcome 1: Complications - Actual outcome for Adults over 16: Complications (Grade 2 or greater complications) at 16 months; Group 1: 7/45, Group 2: 5/22 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 2: Resolution of presenting symptoms (e.g. Pain, nutritional status, gastric outlet obstruction) - Actual outcome for Adults over 16: Resolution (Primary success rate) at 16 months; Group 1: 16/45, Group 2: 18/22 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing: - Actual outcome for Adults over 16: Resolution (Overall success rate) at 16 months; Group 1: 38/45, Group 2: 20/22 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENDOSCOPIC DRAINAGE versus LAPAROSCOPIC DRAINAGE</p> <p>Protocol outcome 1: Complications - Actual outcome for Adults over 16: Complications (Grade 2 or greater complications) at 16 months; Group 1: 7/45, Group 2: 4/16 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 2: Resolution of presenting symptoms (e.g. Pain, nutritional status, gastric outlet obstruction)</p>	

- Actual outcome for Adults over 16: Resolution (Primary success rate) at 16 months; Group 1: 16/45, Group 2: 14/16
 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:
 - Actual outcome for Adults over 16: Resolution (Overall success rate) at 16 months; Group 1: 38/45, Group 2: 15/16
 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: LAPAROSCOPIC DRAINAGE versus OPEN SURGERY

Protocol outcome 1: Complications

- Actual outcome for Adults over 16: Complications (Grade 2 or greater complications) at 16 months; Group 1: 4/16, Group 2: 5/22
 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 2: Resolution of presenting symptoms (e.g. Pain, nutritional status, gastric outlet obstruction)

- Actual outcome for Adults over 16: Resolution (Primary success rate) at 16 months; Group 1: 14/16, Group 2: 18/22
 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:
 - Actual outcome for Adults over 16: Resolution (Overall success rate) at 16 months; Group 1: 15/16, Group 2: 20/22
 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
 Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcomes not reported by the study	Quality of life ; Mortality at 1 year or under; Resolution or recurrence of pseudocysts ; Length of stay (in CCU or hospital) at 1 year or under; Length of stay (in CCU or hospital) at 1 year or under; Repeated procedures
---	---

Study	Morton 2005 ⁷⁶¹
Study type	Non-randomised comparative study
Number of studies (number of participants)	1 (n=14,914)
Countries and setting	
Line of therapy	1st line
Duration of study	Intervention + follow up: 4 years

Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Adults over 16
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients >17 years of age. Cases were identified by International Classification of Diseases, Ninth Revision (ICD-9) diagnosis code for pancreatic pseudocysts (PP), 577.2, and by procedure code 52.01 for percutaneous drainage (PD) and codes 52.4 and 52.96 for surgical drainage (SD) of pseudocysts. No specific ICD-9 code exists for endoscopic drainage.
Exclusion criteria	To ensure homogeneity of the two comparison cohorts, cases with ICD-9 diagnoses codes for gastrointestinal malignancies were excluded. Cases that had procedure codes for both SD and PD were excluded because primary treatment could not be established temporarily.
Recruitment/selection of patients	The period studies was from January 1, 1997 through December 31, 2001.
Age, gender and ethnicity	Age - Mean (SD): PD- 53 (16); SD- 51 (15). Gender (M:F): Male- PD- 58%; SD-59%. Ethnicity:
Further population details	1. Presence of pain: Not stated / Unclear 2. Type of pancreatitis: mixed
Extra comments	Surgically treated patients had significantly less frequent diagnoses of acute pancreatitis, both acute and chronic pancreatitis, diabetes, and cirrhosis but had significantly more frequent diagnoses of chronic pancreatitis, biliary tract disorders, and other pancreatic disorders.
Indirectness of population	No indirectness
Interventions	(n=8121) Intervention 1: Percutaneous drainage . no details . Duration during admission. Concurrent medication/care: not stated . Indirectness: No indirectness Further details: 1. Type of stent: 2. Type of surgery: (n=6409) Intervention 2: Open Surgery - Drainage or resection. no details . Duration during admission. Concurrent medication/care: not stated . Indirectness: No indirectness Further details: 1. Type of stent: 2. Type of surgery:
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: PERCUTANEOUS DRAINAGE versus SURGICAL DRAINAGE

Protocol outcome 1: Mortality at 1 year or under

- Actual outcome: Mortality at end of follow-up ; Group 1: 479/8121, Group 2: 179/6409

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low,

<p>Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 2: Complications - Actual outcome: complications (Intra-abdominal abcess and bleeding requiring transfusion) at end of follow-up ; Group 1: 1335/8121, Group 2: 864/6409 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 3: Length of stay (in CCU or hospital) at 1 year or under - Actual outcome: Length of stay in hospital at end of follow-up ; Group 1: mean 21 (SD 22); n=8121, Group 2: mean 15 (SD 15); n=6409 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Low, Other 2 - Low, Other 3 - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p>	
Protocol outcomes not reported by the study	Quality of life ; Resolution of presenting symptoms (e.g. Pain, nutritional status, gastric outlet obstruction) ; Resolution or recurrence of pseudocysts ; Length of stay (in CCU or hospital) at 1 year or under; Repeated procedures

Study	Rasch 2017 ⁹⁰⁰
Study type	Non-randomised comparative study
Number of studies (number of participants)	1 (n=129)
Countries and setting	Conducted in Germany; Setting: Tertiary referral centre
Line of therapy	Unclear
Duration of study	Intervention + follow up: Median follow-up 4.7 months
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: International Classification of Diseases (ICD)-10 code K85 and K86
Stratum	Adults over 16
Subgroup analysis within study	Not applicable

Inclusion criteria	Patients with pancreatic pseudocysts larger than 10 mm who presented more than one time
Exclusion criteria	Patients with cysts suspicious of dysplasia or walled of necrosis
Recruitment/selection of patients	Consecutive
Age, gender and ethnicity	Age - Mean (SD): 52 (14.9). Gender (M:F): 1:2. Ethnicity: Not stated
Further population details	1. Presence of pain: People presenting with pain (Majority (63.6%) presented with abdominal pain). 2. Type of pancreatitis: Chronic pancreatitis (Majority (65.1%) chronic; 14.7% acute; 16.3% idiopathic; 3.9% iatrogenic or trauma).
Extra comments	17.8% had pancreatic duct obstruction and 13.2% had bile duct obstruction.
Indirectness of population	No indirectness
Interventions	<p>(n=44) Intervention 1: Standard treatment. Unclear. Duration Unclear. Concurrent medication/care: Not stated. Indirectness: No indirectness Further details: 1. Type of stent: Not applicable 2. Type of surgery: Not applicable</p> <p>(n=41) Intervention 2: Endoscopic drainage - EUS-guided. All endoscopic drainage procedures were performed under endosonographic guidance by a linear scanner. Duration Unclear. Concurrent medication/care: Not stated. Indirectness: No indirectness Further details: 1. Type of stent: Not applicable 2. Type of surgery: Not applicable</p> <p>(n=8) Intervention 3: Percutaneous drainage . Pig tail catheters were placed by Seldinger's technique under sonographic or computertomographic guidance. Duration Unclear. Concurrent medication/care: Not stated. Indirectness: No indirectness Further details: 1. Type of stent: Not applicable 2. Type of surgery: Not applicable</p> <p>(n=21) Intervention 4: Open Surgery - Drainage or resection. A gastro- or duodenocystostomy was carried out with a cystostome, fluid specimen were obtained by aspiration and 1–3 double pig tails were placed via a guide wire. All surgical drainage procedures were cystojejunostomies with a Roux-en-Y reconstruction.. Duration Unclear. Concurrent medication/care: Not stated. Indirectness: No indirectness Further details: 1. Type of stent: Not applicable 2. Type of surgery: Different types of surgery (Drainage or resection).</p>

Funding	No funding
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: EUS-GUIDED versus STANDARD TREATMENT</p>	
<p>Protocol outcome 1: Complications - Actual outcome for Adults over 16: Complications at Unclear; Group 1: 9/41, Group 2: 0/44 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p>	
<p>Protocol outcome 2: Resolution of presenting symptoms (e.g. Pain, nutritional status, gastric outlet obstruction) - Actual outcome for Adults over 16: Improvement of symptoms at Unclear; Group 1: 32/41, Group 2: 24/44 Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p>	
<p>Protocol outcome 3: Repeated procedures - Actual outcome for Adults over 16: Re-intervention at Unclear; Group 1: 9/41, Group 2: 0/44 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p>	
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: EUS-GUIDED versus PERCUTANEOUS DRAINAGE</p>	
<p>Protocol outcome 1: Complications - Actual outcome for Adults over 16: Complications at Unclear; Group 1: 9/41, Group 2: 1/8 Risk of bias: All domain - ; Indirectness of outcome: No indirectness</p>	
<p>Protocol outcome 2: Resolution of presenting symptoms (e.g. Pain, nutritional status, gastric outlet obstruction) - Actual outcome for Adults over 16: Improvement of symptoms at Unclear; Group 1: 32/41, Group 2: 7/8 Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p>	
<p>Protocol outcome 3: Repeated procedures - Actual outcome for Adults over 16: Re-intervention at Unclear; Group 1: 9/41, Group 2: 4/8</p>	

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: EUS-GUIDED versus DRAINAGE OR RESECTION

Protocol outcome 1: Complications

- Actual outcome for Adults over 16: Complications at Unclear; Group 1: 9/41, Group 2: 6/21; Comments: Most commonly stent occlusion or haemorrhage in endoscopic and infection in surgical

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 2: Resolution of presenting symptoms (e.g. Pain, nutritional status, gastric outlet obstruction)

- Actual outcome for Adults over 16: Improvement of symptoms at Unclear; Group 1: 32/41, Group 2: 17/21

Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 3: Repeated procedures

- Actual outcome for Adults over 16: Re-intervention at Unclear; Group 1: 9/41, Group 2: 0/21

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: PERCUTANEOUS DRAINAGE versus STANDARD TREATMENT

Protocol outcome 1: Complications

- Actual outcome for Adults over 16: Complications at Unclear; Group 1: 1/8, Group 2: 0/44; Comments: 1 haemorrhage

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 2: Resolution of presenting symptoms (e.g. Pain, nutritional status, gastric outlet obstruction)

- Actual outcome for Adults over 16: Improvement of symptoms at Unclear; Group 1: 7/8, Group 2: 25/44

Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low;
Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 3: Repeated procedures

- Actual outcome for Adults over 16: Re-intervention at Unclear; Group 1: 4/8, Group 2: 0/44

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: PERCUTANEOUS DRAINAGE versus DRAINAGE OR RESECTION

Protocol outcome 1: Complications

- Actual outcome for Adults over 16: Complications at Unclear; Group 1: 1/8, Group 2: 6/21

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 2: Resolution of presenting symptoms (e.g. Pain, nutritional status, gastric outlet obstruction)

- Actual outcome for Adults over 16: Improvement of symptoms at Unclear; Group 1: 7/8, Group 2: 17/21

Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 3: Repeated procedures

- Actual outcome for Adults over 16: Re-intervention at Unclear; Group 1: 4/8, Group 2: 0/21

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: DRAINAGE OR RESECTION versus STANDARD TREATMENT

Protocol outcome 1: Mortality at 1 year or under

- Actual outcome for Adults over 16: Mortality at Unclear; ;

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 2: Complications

- Actual outcome for Adults over 16: Complications at Unclear; Group 1: 6/21, Group 2: 0/44; Comments: 6 infections with resection

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 3: Resolution of presenting symptoms (e.g. Pain, nutritional status, gastric outlet obstruction)

- Actual outcome for Adults over 16: Improvement of symptoms at Unclear; Group 1: 17/21, Group 2: 25/44

Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - High, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

<p>Protocol outcome 4: Repeated procedures - Actual outcome for Adults over 16: Re-intervention at Unclear; Group 1: 0/21, Group 2: 0/44 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing: - Actual outcome for Adults over 16: Length of hospital stay (days) at Unclear; ; Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p>	
Protocol outcomes not reported by the study	Quality of life ; Resolution or recurrence of pseudocysts ; Length of stay (in CCU or hospital) at 1 year or under; Length of stay (in CCU or hospital) at 1 year or under

Study	Saul 2016 ⁹⁵⁴
Study type	Non-randomised comparative study
Number of studies (number of participants)	1 (n=61)
Countries and setting	Conducted in Mexico; Setting: Hospital
Line of therapy	1st line
Duration of study	Other: Retrospective analysis of data obtained between the years 2000 to 2012.
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Pancreatic pseudocyst defined as a fluid collection in the pancreatic or peripancreatic area that had a well-defined wall and contained no solid debris or recognisable parachymal necrosis.
Stratum	Overall:
Subgroup analysis within study	Not applicable
Inclusion criteria	People with pancreatic pseudocysts treated with endoscopic or surgical treatment
Exclusion criteria	People treated outside the hospital
Recruitment/selection of patients	Retrospective analysis of paper and electronic records of people with pancreatic pseudocysts treated with endoscopic or surgical treatment from 2000 to 2012.
Age, gender and ethnicity	Age - Mean (SD): 41.5 (13.8) years. Gender (M:F): 39/22 . Ethnicity:

Further population details	1. Presence of pain: Not stated / Unclear 2. Type of pancreatitis: Not stated / Unclear
Extra comments	Cause of pancreatitis was gallstones in 25, alcoholic in 9, hypertriglyceridemia in 3, idiopathic in 9 and unspecified in 18.
Indirectness of population	No indirectness
Interventions	<p>(n=21) Intervention 1: Endoscopic drainage. Intubated and received 1g I.V. of ceftazidime 30 minutes before the procedure. A convex linear-array echoendoscope was used, and once the pseudocysts was identified, it was accessed using a 19-gauge needle, and a 0.035-inch guidewire was inserted through the needle into the pseudocysts with fluoroscopic guidance. After removal of the needles, a needle knife was inserted over the guidewire to create a bigger fistula. The gastric wall was dilated up to 15mm using a wire-guided balloon and two double pigtail plastic stents (7F and 4cm) were deployed for drainage. Transgastric in 16/21 and transduodenal in 5/21.. Duration Procedure length not reported but 8 weeks after the drainage an ERP or MRCP was performed.. Concurrent medication/care: Not reported.. Indirectness: Serious indirectness; Indirectness comment: Number in each group not by patient but by case (n=61 but number of procedures was 64) Further details: 1. Type of stent: Different types of stent (pigtail plastic stents). 2. Type of surgery: Not applicable</p> <p>(n=43) Intervention 2: Combination of techniques. Open and laparoscopic approaches: open drainage, cystogastrostomy, cystojejunostomy, distal pancreatectomy, PPC resection and pancreato-jejunostomy. In those patients with an open drainage due to inflammation, a second surgery (distal pancreatectomy or PPC resection) was performed months later. They were considered as different procedures and they were analysed separately. . Duration Not reported. . Concurrent medication/care: Not reported.. Indirectness: Serious indirectness; Indirectness comment: Number in each group not by patient but by case (n=61 but number of procedures was 64) Further details: 1. Type of stent: Not applicable 2. Type of surgery: Different types of surgery (Open and laproscopic approaches. Open drainage 13, cystogastrostomy 10, cystojejunostomy 8, distal pancreatectomy 6, PPC resection 5 and pancreato-jejunostomy 1).</p>
Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENDOSCOPIC DRAINAGE versus COMBINATION OF TECHNIQUES

Protocol outcome 1: Mortality at 1 year or under

- Actual outcome for Adults over 16: Mortality at Median (IQR) follow-up: endoscopic 270 (30-1915); combination 580 (0-4320) days; Group 1: 0/21, Group 2: 1/43;

Comments: 1 death due to sepsis

Risk of bias: All domain - Very high, Selection - Very high, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

<p>Protocol outcome 2: Complications - Actual outcome for Adults over 16: Overall complications (included bleeding, infection, stent migration) at Median (IQR) follow-up: endoscopic 270 (30-1915); combination 580 (0-4320) days; Group 1: 5/21, Group 2: 11/43 Risk of bias: All domain - Very high, Selection - Very high, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p>	
<p>Protocol outcome 3: Resolution or recurrence of pseudocysts - Actual outcome for Adults over 16: Clinical success (complete resolution or decrease in the size of pseudocysts to 2cm or smaller on CT with associated resolution of symptoms). at 8 weeks; Group 1: 19/21, Group 2: 39/43 Risk of bias: All domain - Very high, Selection - Very high, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing: - Actual outcome for Adults over 16: Recurrence (pancreatic pseudocyst found on CT in association with symptoms after initial resolution) at Median (IQR) follow-up: endoscopic 270 (30-1915); combination 580 (0-4320) days; Group 1: 2/21, Group 2: 2/43 Risk of bias: All domain - Very high, Selection - Very high, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p>	
<p>Protocol outcome 4: Length of stay (in CCU or hospital) at 1 year or under - Actual outcome for Adults over 16: Hospital length of stay (median, range) at Median (IQR) follow-up: endoscopic 270 (30-1915); combination 580 (0-4320) days; Median (range): Endoscopic 0 (0-10); Combination 7 (2-42) days); Risk of bias: All domain - Very high, Selection - Very high, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing: - Actual outcome for Adults over 16: CCU stay at Median (IQR) follow-up: endoscopic 270 (30-1915); combination 580 (0-4320) days; Group 1: mean 0.19 days (SD 0.13); n=21, Group 2: mean 1.4 days (SD 0.72); n=43 Risk of bias: All domain - Very high, Selection - Very high, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p>	
<p>Protocol outcomes not reported by the study</p>	<p>Quality of life ; Resolution of presenting symptoms (e.g. Pain, nutritional status, gastric outlet obstruction) ; Length of stay (in CCU or hospital) at 1 year or under; Repeated procedures</p>

Study	Talar-wojnarowska 2010 ¹⁰⁵⁵
Study type	Non-randomised comparative study
Number of studies (number of participants)	1 (n=21)
Countries and setting	Conducted in Poland; Setting: Department of Digestive Tract Diseases of Lodz Medical University
Line of therapy	Unclear
Duration of study	Intervention + follow up: 5 years
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: The diagnosis of chronic pancreatitis was based on the presence of pancreatic calcifications on CT scan, ultrasound or endoscopic ultrasound or historic confirmation after previous chronic pancreatitis surgical treatment.
Stratum	Adults over 16
Subgroup analysis within study	Not applicable
Inclusion criteria	All people admitted with chronic pancreatitis and pancreatic pseudocysts
Exclusion criteria	Patients with an episode of acute pancreatitis in the preceding 6 weeks.
Recruitment/selection of patients	Participants were treated at the center
Age, gender and ethnicity	Age -47.2 (7.3) years. Gender (M:F): 23:14. Ethnicity: not stated
Further population details	1. Presence of pain: Not stated / Unclear 2. Type of pancreatitis: Chronic pancreatitis
Indirectness of population	No indirectness
Interventions	(n=10) Intervention 1: Endoscopic drainage. No details given. Duration During admission. Concurrent medication/care: Not reported. Indirectness: No indirectness Further details: 1. Type of stent: Not applicable 2. Type of surgery: Not applicable (n=4) Intervention 2: Percutaneous drainage . No details given. Duration During admission. Concurrent medication/care: Not reported. Indirectness: No indirectness Further details: 1. Type of stent: Not applicable 2. Type of surgery: Not applicable (n=7) Intervention 3: Open Surgery - Drainage or resection. No details given. Duration During admission. Concurrent medication/care: Not reported. Indirectness: No indirectness Further details: 1. Type of stent: Not applicable 2. Type of surgery: Different types of surgery

Funding	Academic or government funding (Study supported by Lodz Medical University grant 502-11-718)
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ENDOSCOPIC DRAINAGE versus DRAINAGE OR RESECTION</p> <p>Protocol outcome 1: Complications - Actual outcome for Adults over 16: Complications at Unclear; Group 1: 1/10, Group 2: 2/7 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 2: Resolution or recurrence of pseudocysts - Actual outcome for Adults over 16: Recurrence of pseudocysts at 26 months; Group 1: 4/10, Group 2: 1/7 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 3: Length of stay (in CCU or hospital) at 1 year or under - Actual outcome for Adults over 16: Length of stay in hospital at Unclear; Group 1: mean 7.2 days (SD 3.2); n=10, Group 2: mean 15.4 days (SD 5.7); n=7 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: PERCUTANEOUS DRAINAGE versus ENDOSCOPIC DRAINAGE</p> <p>Protocol outcome 1: Complications - Actual outcome for Adults over 16: Complications at Unclear; Group 1: 2/4, Group 2: 1/10 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 2: Resolution or recurrence of pseudocysts - Actual outcome for Adults over 16: Recurrence of pseudocysts at 26 months; Group 1: 3/4, Group 2: 4/10 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 3: Length of stay (in CCU or hospital) at 1 year or under - Actual outcome for Adults over 16: Length of stay in hospital at Unclear; Group 1: mean 13.2 days (SD 4.2); n=4, Group 2: mean 7.2 days (SD 3.2); n=10 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;</p>	

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:	
RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: PERCUTANEOUS DRAINAGE versus DRAINAGE OR RESECTION	
Protocol outcome 1: Complications	
- Actual outcome for Adults over 16: Complications at Unclear; Group 1: 2/4, Group 2: 2/7	
Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;	
Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:	
Protocol outcome 2: Resolution or recurrence of pseudocysts	
- Actual outcome for Adults over 16: Recurrence of pseudocysts at 26 months; Group 1: 3/4, Group 2: 1/7	
Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;	
Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:	
Protocol outcome 3: Length of stay (in CCU or hospital) at 1 year or under	
- Actual outcome for Adults over 16: Length of stay in hospital at Unclear; Group 1: mean 13.2 days (SD 4.2); n=4, Group 2: mean 15.4 days (SD 3.2); n=7	
Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;	
Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:	
Protocol outcomes not reported by the study	Quality of life ; Mortality at 1 year or under; Resolution of presenting symptoms (e.g. Pain, nutritional status, gastric outlet obstruction) ; Length of stay (in CCU or hospital) at 1 year or under; Repeated procedures

Study	Varadarajulu 2008¹¹⁰⁷
Study type	Non-randomised comparative study
Number of studies (number of participants)	1 (n=30)
Countries and setting	Conducted in USA; Setting: University of Alabama Hospital
Line of therapy	1st line

Duration of study	Intervention + follow up: 4 weeks
Method of assessment of guideline condition	Method of assessment /diagnosis not stated
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients over 18 years of age who had undergone surgical cyst-gastrostomy and EUS-guided cyst-gastrostomy at the tertiary referral centre were included.
Exclusion criteria	Not reported
Recruitment/selection of patients	Participants had been treated at the hospital
Age, gender and ethnicity	Age - Mean (SD): Surgery: 42.3 EUS: 43.1. Gender (M:F): 21:9. Ethnicity: 73% white
Further population details	1. Presence of pain: Not stated / Unclear 2. Type of pancreatitis: Not stated / Unclear
Extra comments	Surgery - Mean pseudocyst size: 6179 mm ² ; Location - Head: 20%, Body: 10%, Tail: 40 %, Multiple: 30%; Aetiology - Idiopathic: 60%, Gallstones: 20%, Alcohol: 20% EUS - Mean pseudocyst size: 7588 mm ² ; Location - Head: 10%, Body: 15%, Tail: 50 %, Multiple: 25%; Aetiology - Idiopathic: 60%, Gallstones: 20%, Alcohol: 20%
Indirectness of population	No indirectness
Interventions	(n=10) Intervention 1: Open Surgery - Drainage or resection. Patients were placed in the supine position and intravenous cefaxolin was administered before incision. A limited upper midline incision was made, approximately 10 cm in length at the middle third of the distance from the umbilicus to the xiphoid process, to allow access to the abdomen. Cautery was used to create an approximate 5-cm longitudinal gastrostomy near the greater curvature of the fundus. Cautery was used to incise an approximate 2 cm opening in the posterior gastric wall. The pseudocysts were aspirated and irrigated. . Duration During admission. Concurrent medication/care: Patients were discharged from hospital when a soft diet was tolerated and pain control was adequate. . Indirectness: No indirectness Further details: 1. Type of stent: Not applicable 2. Type of surgery: Not stated / Unclear (n=20) Intervention 2: Combination of techniques. After administration of one dose of IV ciprofloxacin (400 mg), an EUS-guided cyst-gastrostomy was performed at the endoscopy suite, with the patient under conscious sedation with a combination of midazolam, meperidine, and ketamine administered by the endoscopist. A sample of the cysts aspirate was sent for assessment of carcinoembryonic antigen, amylase and lipase levels in all patients. An ERCP was routinely attempted in all patients, unless the extrinsic compression caused by the pseudocyst precluded duodenoscope passage to the second portion of the duodenum. . Duration During admission. Concurrent medication/care: Not reported. Indirectness: No indirectness

	Further details: 1. Type of stent: Not applicable 2. Type of surgery: Not applicable
Funding	Funding not stated
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ERCP AND ENDOSCOPIC DRAINAGE CYST-GASTROSTOMY versus SURGICAL CYST-GASTROSTOMY</p> <p>Protocol outcome 1: Complications - Actual outcome for Adults over 16: Complications at During admission; Group 1: 0/20, Group 2: 0/10 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness, Comments: ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 2: Resolution or recurrence of pseudocysts - Actual outcome for Adults over 16: Resolution of pseudocysts (Treatment success) at 4-6 weeks; Group 1: 19/20, Group 2: 10/10 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness, Comments: ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 3: Length of stay (in CCU or hospital) at 1 year or under - Actual outcome for Adults over 16: Length of post-procedure hospital stay at During admission; Mean; , Comments: Surgery: Median (range): 6.5 (4-20) EUS: 2.6 (1-11); Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness, Comments: ; Group 1 Number missing: ; Group 2 Number missing:</p> <p>Protocol outcome 4: Repeated procedures - Actual outcome for Adults over 16: Repeated procedures (Reintervention) at During admission; Group 1: 0/20, Group 2: 1/10 Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness, Comments: ; Group 1 Number missing: ; Group 2 Number missing:</p>	
Protocol outcomes not reported by the study	Quality of life ; Mortality at 1 year or under; Resolution of presenting symptoms (e.g. Pain, nutritional status, gastric outlet obstruction) ; Length of stay (in CCU or hospital) at 1 year or under
Study	Varadarajulu 2013¹¹⁰⁶
Study type	RCT (Patient randomised; Parallel)

Number of studies (number of participants)	1 (n=40)
Countries and setting	Conducted in USA; Setting: Hospital
Line of therapy	1st line
Duration of study	Follow up (post intervention): 24 months
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: All patients were evaluated with CT.
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Diagnosis of pancreatic pseudocyst based on CT criteria; pseudocyst measuring ≥ 6 cm in size and located adjacent to the stomach; documented history of acute or chronic pancreatitis; persistent pancreatic pain requiring narcotics or analgesics; symptomatic gastric outlet or bile duct obstruction induced by the pseudocyst.
Exclusion criteria	Age <18 or >80 years; contraindications to surgery: ASA class IV, severe portal hypertension; contraindication to endoscopic drainage: gastrectomy with Billroth II reconstruction, gastric bypass surgery, prior surgery for pancreas-related complications; pregnancy; associated pancreatic necrosis on CT; pseudocyst not adjacent to the stomach; multiloculated pseudocyst or multiple pseudocysts
Recruitment/selection of patients	Consecutive patients with pancreatic pseudocysts from the pancreaticobiliary clinic or inpatient ward service
Age, gender and ethnicity	Age - Mean (SD): Endoscopy: 48 (14); Surgery 51 (17). Gender (M:F): 28/12. Ethnicity: NR
Further population details	1. Presence of pain: People presenting with pain (All had persistent pancreatic pain requiring narcotics or analgesics). 2. Type of pancreatitis: Not stated / Unclear
Extra comments	Cause of pancreatitis: alcohol 15, gallstones 16, idiopathic 5, hypertriglyceridemia 1, post-surgery 1 and post-trauma 2.
Indirectness of population	No indirectness
Interventions	(n=20) Intervention 1: Pancreatic endoscopic stent. Endoscopic cystogastrostomy. Performed with EUS guidance and fluoroscopy by 2 endosonographers while the patient was under conscious sedation after administration of IV ciprofloxacin. Two plastic stents deployed to facilitate the drainage of pseudocyst contents into the stomach. Transmural stents removed at 2 months evaluation if the pseudocyst had resolved on CT scan. If the pseudocyst was persistent, additional drainage performed by placement of more stents. If the patient failed one additional intervention by endoscopy they were converted to surgery. Transpapillary pancreatic duct stents were also placed in patients in whom a duct leak was evident at endoscopic retrograde cholangiopancreatogram (ERCP). At follow up an ERCP was repeated to assess for resolution of duct leak and in patients with an unsuccessful first ERCP, an MRCP was performed and a pancreatic duct stent placed in patients in whom leak was evident. If a disconnected duct was noted, the transgastric stents were left in place to decrease likelihood of pseudocyst recurrence.. Duration 24 months. Concurrent

	<p>medication/care: Oral ciprofloxacin 500 mg twice daily for 3 days.. Indirectness: No indirectness Further details: 1. Type of stent: Different types of stent (plastic transmural stent). 2. Type of surgery: Not applicable</p> <p>(n=20) Intervention 2: Open Surgery - Drainage or resection. Surgical cystogastrostomy. Performed by one pancreatic surgeon. After administration of intravenous cefazolin, an incision was made at the middle-third of the distance from the umbilicus to xiphoid process, to allow access to the abdomen. The anterior stomach was exposed and a 2-cm gastrostomy was created with cautery. This small opening allowed adequate access to the posterior stomach and the cyst was palpated. After localizing the pseudocyst where it was adhered to the posterior wall of the stomach, it was aspirated and entered with cautery. Once entry was obtained, an endovascular stapler was used to create at least a 6-cm cystogastrostomy. A nasogastric tube then was left in the stomach and passed into the pseudocyst cavity to allow for intermittent irrigation until postoperative day 1. The anterior gastrostomy was closed and the patient was transferred to the surgical floor after postoperative monitoring. The nasogastric tube was removed on postoperative day 1 and clear liquids were started on day 2. . Duration 24 months. Concurrent medication/care: NR. Indirectness: No indirectness Further details: 1. Type of stent: Not applicable 2. Type of surgery: Not applicable</p>
--	---

Funding	Funding not stated
---------	--------------------

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: PANCREATIC ENDOSCOPIC STENT versus DRAINAGE OR RESECTION

Protocol outcome 1: Quality of life

- Actual outcome for Adults over 16: SF36 physical component score at 24 months; MD; 4.48 (95%CI 0.73 to 8.23, Comments: 4.48 lower in the surgery group than the endoscopic group);

Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

- Actual outcome for Adults over 16: SF36 mental component score at 24 months; MD; 4.41 (95%CI 0.55 to 8.26, Comments: 4.41 lower in the surgery group);

Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 2: Complications

- Actual outcome for Adults over 16: Complications (including wound infection and haematemesis) at 24 months; Group 1: 0/20, Group 2: 2/20

Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low;

Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:

Protocol outcome 3: Resolution or recurrence of pseudocysts

- Actual outcome for Adults over 16: Treatment success (resolution of symptoms at 4 weeks for surgery group; resolution or a decrease in the size of the fluid collection to

<p>2 cm or smaller on CT with resolution of symptoms at 8 weeks) at 8 and 4 weeks in endoscopic and surgery groups, respectively; Group 1: 19/20, Group 2: 20/20 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing: - Actual outcome for Adults over 16: Recurrence (new onset abdominal pain in the presence of a pancreatic fluid collection on CT after resolution of the initial presentation) at 24 months; Group 1: 0/20, Group 2: 1/20 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p>	
<p>Protocol outcome 4: Length of stay (in CCU or hospital) at 1 year or under - Actual outcome for Adults over 16: Length of hospital stay at 24 months; (95%CI -5 to -3); Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p>	
<p>Protocol outcome 5: Repeated procedures - Actual outcome for Adults over 16: Reintervention at 24 months; Group 1: 1/20, Group 2: 1/20 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: ; Group 2 Number missing:</p>	
Protocol outcomes not reported by the study	Mortality at 1 year or under; Resolution of presenting symptoms (e.g. Pain, nutritional status, gastric outlet obstruction) ; Length of stay (in CCU or hospital) at 1 year or under

H.18 Management of pancreatic ascites and pleural effusion secondary to pancreatitis

None.

H.19 Management of biliary obstruction in people with chronic pancreatitis

Study	Haapamäki 2017 ⁴³⁰
Study type	RCT (Patient randomised; Parallel)

Number of studies (number of participants)	1 (n=60)
Countries and setting	Conducted in Finland; Setting: Helsinki University Hospital, Turku University Hospital, Oulu University Hospital
Line of therapy	Unclear
Duration of study	Intervention + follow up: 2 years
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Indication for initial ERCP was suspected biliary obstruction caused by chronic pancreatitis as judged by elevated bilirubin and/or AFOS values.
Stratum	Adults
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients who were suspected to have biliary obstruction caused by chronic pancreatitis were included.
Exclusion criteria	Patients with malignancies, known liver cirrhosis, acute or chronic hepatitis or abnormal hepatic imaging studies, and patients with their first attack of acute pancreatitis.
Recruitment/selection of patients	Patients who were admitted to hospital for endoscopic retrograde cholangiopancreatography.
Age, gender and ethnicity	Age - Median (range): 53 (33-78). Gender (M:F): 54:6. Ethnicity: Not reported
Further population details	
Extra comments	Plastic group: Etiology - Alcohol: 29/60, Biliary: 0/60, Autoimmune: 0/60, Idiopathic: 1/60 Metal group: Etiology - Alcohol: 26/60, Biliary: 1/60, Autoimmune: 1/60, Idiopathic: 2/60
Indirectness of population	No indirectness
Interventions	(n=30) Intervention 1: Metal stent - Fully covered metal stent. Dilation was performed with an 8-mm balloon

	<p>in both groups. The original plastic stent was replaced with a single covered self-expandable metallic stent (cSEMS). At three months, the position and function of the stent were checked by ERCP. In case of stent migration, the stent was replaced with a new cSEMS. At six months after randomisation, all stents were removed.. Duration 6 months. Concurrent medication/care: All patients were prepared and sedated for ERCP according to the standard medical practice at the hospital. At the initial ERCP, an endoscopic sphincterotomy was performed and one 10-Fr plastic stent was inserted for the treatment of cholestasis. CBD dilation was performed only if deemed necessary. Any existing CBD stones above the stricture were removed. Pancreatic stents were inserted if indicated Further details: 1. Type of stent: Fully covered metal stent 2. Type of stent insertion: Endoscopic insertion 3. Type of surgery: Not applicable</p> <p>(n=30) Intervention 2: Plastic stent - Multiple plastic stents. Dilation was performed with an 8-mm balloon in both groups. The original plastic stent was replaced with three plastic stents. At three months, balloon dilation was performed and the number of plastic stents was increased to a maximum of six 10-Fr stents when possible. At six months after randomisation, all stents were removed.. Duration 6 months. Concurrent medication/care: All patients were prepared and sedated for ERCP according to the standard medical practice at the hospital. At the initial ERCP, an endoscopic sphincterotomy was performed and one 10-Fr plastic stent was inserted for the treatment of cholestasis. CBD dilation was performed only if deemed necessary. any existing CBD stones above the stricture were removed. Pancreatic stents were inserted if indicated Further details: 1. Type of stent: Multiple plastic stent 2. Type of stent insertion: Endoscopic insertion 3. Type of surgery: Not applicable</p>
Funding	Funding not stated
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: FULLY COVERED METAL STENT versus MULTIPLE PLASTIC STENTS</p> <p>Protocol outcome 1: Mortality at <1 year - Actual outcome for Adults: Mortality at 2 years; Group 1: 3/30, Group 2: 1/30; Risk of bias: High; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 2: Complications (eg bleeding, fistulae) at not defined</p>	

<p>- Actual outcome for Adults: Adverse events at 2 years; Group 1: 8/28, Group 2: 7/30; Risk of bias: High; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 3: Recurrence of biliary obstruction, including failed stent (removal and additional stents) at not defined</p> <p>- Actual outcome for Adults: Stricture resolution (as defined by normal liver function tests) - Bilirubin level (4-20µmol/L) at 2 years; Other: Median (Range); Risk of bias: Very high; Indirectness of outcome: No indirectness</p> <p>- Actual outcome for Adults: Recurrent strictures at 2 years; Group 1: 2/22, Group 2: 3/25; Risk of bias: High; Indirectness of outcome: No indirectness</p> <p>- Actual outcome for Adults: Stricture resolution (as defined by normal liver function tests) - Alkaline phosphatase level (35-105 U/L) at 2 years; Other: Median (Range); Risk of bias: Very high; Indirectness of outcome: No indirectness</p>	
Protocol outcomes not reported by the study	Quality of life at not defined; Biliary infections at not defined; Number of procedures (repeated procedures) at not defined; Length of stay (in intensive therapy unit or hospital) at not defined

Study	Regimbeau 2012 ⁹⁰⁶
Study type	Non-randomised comparative study
Number of studies (number of participants)	1 (n=39)
Countries and setting	Conducted in France; Setting: Amiens University Hospital, France
Line of therapy	Unclear
Duration of study	Intervention + follow up:
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: The diagnosis of CP was based on one or more of the following three criteria: 1) at least moderate duct anomalies according to the Cambridge classification, 2) the presence of pancreatic calcification, or 3) fibrosis in histologic specimens. Stricture was defined as a narrowing of the common bile duct (CBD) with prestenosis dilation or delayed runoff of contrast on imaging using MRI, CT, or ERCP.
Stratum	Adults

Subgroup analysis within study	Not applicable
Inclusion criteria	All consecutive patients with CP that were managed in the hospital between 2004 and 2009 were included.
Exclusion criteria	Patients with pancreatic malignancy, cirrhosis, primary sclerosing cholangitis, recent acute pancreatitis (i.e., in the previous three weeks), postsurgical stricture or secondary stenosis caused by gallstones, or pseudocysts were excluded from the study.
Recruitment/selection of patients	Patients were admitted to the hospital.
Age, gender and ethnicity	Age - Median (range): Endoscopy group: 52 (49-55) Surgery: 52 (38-66). Gender (M:F): 35:4. Ethnicity: Not reported
Further population details	
Extra comments	Endoscopy group: Median (range) BMI: 19.9 (18-21), Median time since onset of CP: 6.5 years, Preoperative jaundice: 18/33, Preoperative diabetes: 25/33, preoperative exocrine pancreatic insufficiency: 13/33 Surgery group: Median (range) BMI: 19.9 (16-22), Median time since onset of CP: 5.8 years, Preoperative jaundice: 3/6, Preoperative diabetes: 5/6, preoperative exocrine pancreatic insufficiency: 3/6
Indirectness of population	No indirectness
Interventions	(n=16) Intervention 1: Plastic stent - Single plastic stent. A flexible guidewire was passed through the stricture followed by a guiding catheter. Although the biliary stent's diameter and length were matched to the characteristics of the observed stenosis, the decision to perform sphincterotomy of the CBD stricture and the choice of stent were left to the endoscopist. In the event of an associated, symptomatic pancreatic duct stricture, a plastic pancreatic stent was inserted concomitantly. Oral ciprofloxacin therapy (500 mg twice daily) was started before ERCP and continued 3 days thereafter. The minimum defined time for stent therapy was 12 months (with multiple plastic or metallic stents). Patients with plastic stents had a routine stent exchange in 3 months, whereas patients with metallic stents had a routine stent exchange in 6 months to improve the calibration of the CBD and to decrease the number procedures. At the end of the period defined for ET therapy, the stents were removed. . Duration During admission. Concurrent medication/care: Before biliary drainage all the patients underwent a comprehensive imagine workup (including pancreatic MRI or contrast-enhanced, triple phase CT scan) and a nutritional status evaluation, then received appropriate therapy for diabetes or exocrine pancreatic insufficiency. Further details: 1. Type of stent: plastic. 2. Type of stent insertion: Endoscopic insertion 3. Type of surgery: Not

	<p>applicable</p> <p>(n=23) Intervention 2: Open surgery - Choledocho-jejunostomy. Surgical treatment consisted of choledochoduodenostomy or choledochojejunostomy. For patients with a symptomatic inflammatory cephalic mass (diameter >4cm), surgical biliary drainage consisted of a duodenum-preserving pancreatic head resection (the Frey procedure) with concomitant decompression of the CBD within the head of the pancreas to avoid a biliary bypass. 17 people who were originally in the endoscopy group went on to have surgery.. Duration During admission. Concurrent medication/care: Before biliary drainage all the patients underwent a comprehensive imagine workup (including pancreatic MRI or contrast-enhanced, triple phase CT scan) and a nutritional status evaluation, then received appropriate therapy for diabetes or exocrine pancreatic insufficiency. Further details: 1. Type of stent: Not applicable 2. Type of stent insertion: Not applicable 3. Type of surgery: Choledocho-jejunostomy</p>
Funding	Funding not stated
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: PLASTIC OR METAL STENTS versus CHOLEDOCHO-JEJUNOSTOMY OR CHOLECHODUODENOSTOMY</p> <p>Protocol outcome 1: Length of stay (in intensive therapy unit or hospital) at not defined - Actual outcome for Adults: Length of stay in hospital at Unclear; Other: Median; Risk of bias: Very high; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 2: Mortality at <1 year - Actual outcome for Adults: Mortality at Unclear; Group 1: 0/16, Group 2: 0/23; Risk of bias: Very high; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 3: Complications (eg bleeding, fistulae) at not defined - Actual outcome for Adults: Event free survival at Unclear; Risk of bias: Very high; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 4: Recurrence of biliary obstruction, including failed stent (removal and additional stents) at not defined - Actual outcome for Adults: Successful treatment at Unclear; Group 1: 10/16, Group 2: 20/23; Risk of bias: Very high; Indirectness of outcome: No indirectness</p>	
Protocol outcomes not reported by the study	Quality of life at not defined; Biliary infections at not defined

978-1-4731-3083-8 **H.20 Management of type 3c diabetes secondary to pancreatitis**

None.

H.21 Receiving specialist input in people with acute pancreatitis

None.

H.22 Follow-up of pancreatic exocrine function in people with chronic pancreatitis

None.

H.23 Follow-up to identify diabetes in people with chronic pancreatitis

None.

H.24 Follow-up to identify pancreatic cancer in people with chronic pancreatitis

None.

Appendix I: Health economic evidence tables

I.1 Patient information

None.

I.2 Lifestyle interventions: stopping or reducing alcohol consumption

None.

I.3 Aetiology of acute pancreatitis

None.

I.4 Aetiology of chronic pancreatitis

None.

I.5 Diagnosing chronic pancreatitis

None.

I.6 Type of intravenous fluid for resuscitation in people with acute pancreatitis

None.

I.7 Speed of intravenous fluid for resuscitation in people with acute pancreatitis

None

I.8 Route of feeding in people with severe acute pancreatitis

Study	Louie 2005 ⁶⁷⁹			
Study details	Population & interventions	Costs	Health outcomes	Cost effectiveness
<p>Economic analysis: CCA</p> <p>Study design: RCT</p> <p>Approach to analysis: Within trial analysis</p> <p>Perspective: Canadian hospital or regional health authority</p> <p>Time horizon: length of treatment</p> <p>Discounting: N/A</p>	<p>Population: 18 years and over, with acute pancreatitis, a Ranson's score of 3 or greater and inability to tolerate oral fluids after a maximum time from admission of 96 hours, able to accept enteral nutrition (n=28).</p> <p>Patient characteristics: Mean age: 61.3 years Male: 54%</p> <p>Intervention 1: Parenteral nutrition: long-term vascular catheters were placed percutaneously and infused with 10% dextrose solution and Intralipid and then increased over 2 days to achieve 100% of the target energy rate (n=18).</p> <p>Intervention 2: Enteral nutrition: nasojejunal (NJ) feeding tubes were placed and infused with a semielemental product with low fat content, 25 ml/hour and increased by 10 ml/hour every 6 hours until target rate was</p>	<p>Total costs (mean per patient): Intervention 1: £1,338 Intervention 2: £705 Incremental (2-1): -£633 (95% CI: NR; p=NR)</p> <p>Currency & cost year: Currency and cost year unclear, assumed to be 2004 Canadian dollars, presented as 2004 UK pounds^(a)</p> <p>Cost components incorporated: Cost of nutrition, production of parenteral nutrition, placement of NJ and catheters, radiology costs, operative costs and general and intensive care costs (applied to length of hospital stay for each non-operative complication).</p>	<p>12 outcome measures reported. Key results:</p> <p><u>Morbidity secondary to pancreatitis</u> <i>Infected fluid collections per patient</i> Intervention 1: 0.22 Intervention 2: 0.1 Incremental (2-1): -0.12</p> <p><u>Morbidity secondary to nutritional practices</u> <i>Infected central lines per patient</i> Intervention 1: 0.11 Intervention 2: 0 Incremental (2-1): -0.11</p> <p><i>Dislodged or removed NJ tubes per patient</i> Intervention 1: 0 Intervention 2: 0.9 Incremental (2-1): 0.9</p> <p>Of all 12 outcomes, 8 favoured enteral nutrition, 2 favoured parenteral nutrition and 2 were</p>	<p><u>Morbidity secondary to pancreatitis: infected fluid collections</u> Dominant (parenteral nutrition is cheaper and leads to fewer infections)</p> <p><u>Morbidity secondary to nutritional practices: infected central line:</u> Dominant (parenteral nutrition is cheaper and leads to fewer infections)</p> <p><i>Dislodged or removed NJ tubes</i> 0.9 more dislodged or removed tubes per person but £633 cheaper per person with enteral compared with parenteral nutrition</p> <p>Analysis of uncertainty: 2 alternative scenarios were investigated to consider the possible costs of enteral nutrition. If only 1 NJ tube was used due to improved tube placement, the average cost of parenteral nutrition would remain £1,338 compared with a reduced £557 for enteral nutrition (95% CI £84 to £1,478). If, in addition, 1 patient unsuitable for enteral nutrition due to alcohol withdrawal was reallocated to parenteral nutrition, the cost of enteral nutrition would fall to £491 (95% CI £118 to £1,577), significantly different from the cost of parenteral nutrition.</p>

	achieved (n=10).		virtually equal. See clinical evidence table for Louie 2005 for full details.	No sensitivity analysis was conducted on any other key parameters.
Data sources				
Health outcomes: Within trial analysis: single RCT of 28 patients in Canadian hospitals. Quality-of-life weights: NA. Cost sources: Within trial analysis: Canadian hospitals.				
Comments				
Source of funding: NR. Limitations: Canadian health service perspective; outcomes were not valued using QALYs. Data taken from a single study of 28 patients; currency and cost year not stated, costs taken from the Canadian health system; sensitivity analysis not undertaken.				
Overall applicability: ^(b) Partially applicable Overall quality: ^(c) Potentially serious limitations				

Abbreviations: CCA: cost–consequences analysis; 95% CI: 95% confidence interval; NR: not reported;

(a) Converted using 2004 purchasing power parities⁸²⁴

(b) Directly applicable / Partially applicable / Not applicable

(c) Minor limitations / Potentially serious limitations / Very serious limitations

I.9 Early versus late nutritional intervention in people with chronic pancreatitis

None.

I.10 Specialist versus non-specialist nutritional assessment in people with chronic pancreatitis

None.

I.11 Prophylactic antimicrobial agents to prevent infection in people with acute pancreatitis

None.

I.12 Methods of management of infected necrosis in people with acute pancreatitis

Study	Van Santvoort 2010 ¹⁵⁰
--------------	-----------------------------------

Study details	Population & interventions	Costs	Health outcomes	Cost effectiveness
<p>Economic analysis: CCA (health outcomes: death, major complications, length of stay)</p> <p>Study design: Randomised control trial</p> <p>Approach to analysis: Patients were randomly assigned to either primary open necrosectomy or the minimally invasive step-up approach. Follow-up visits took place 3 and 6 months after discharge</p> <p>Perspective: Dutch NHS</p> <p>Follow-up 6 months</p> <p>Discounting: n/a</p>	<p>Population: Adults with acute pancreatitis and signs of pancreatic necrosis, peri-pancreatic necrosis or both, as detected by CT (n=88)</p> <p>Patient characteristics: Mean age: 57.5 years Male: 73%</p> <p>Intervention 1: Open surgery (necrosectomy); laparotomy through a bilateral subcostal incision. After blunt removal of all necrotic tissue, 2 large-bore drains for post-operative lavage were inserted, and the abdomen was closed (n=43).</p> <p>Intervention 2: Minimally invasive step-up approach; the first step was percutaneous (95%) or endoscopic (5%) transgastric drainage. If there was no clinical improvement a second drainage was performed. The third step was video-assisted retroperitoneal debridement with postoperative lavage (n=43).</p>	<p>Total costs (mean per patient): Intervention 1: £56,955 Intervention 2: £51,978 Incremental (2–1): –£4,977 (95% CI: NR; p=NR)</p> <p>Currency & cost year: 2008 Euros (presented here as 2008 UK pounds^(b))</p> <p>Cost components incorporated: Hospital stay, critical care stay, necrosectomies, drainage-radiologic-endoscopic procedures, microbiology, medication, visits to GP, visits to outpatient clinics, physiotherapy, re-admissions to hospital</p>	<p>Over 20 outcome measures were reported. See clinical evidence table for Van Santvoort 2010 for full details. Key results:</p> <p>Death Intervention 1: 16% Intervention 2: 19% Incremental (2–1): +3.0% (95% CI: NR; p=0.70)</p> <p>Length of stay <u>Days in CCU</u> Intervention 1: 11 Intervention 2: 9 Incremental (2–1): –2 days (95% CI: NR; p=0.26)</p> <p><u>Days in hospital</u> Intervention 1: 60 Intervention 2: 50 Incremental (2–1): –10 days (95% CI: NR; p=0.53)</p> <p>Major complications^(c) Intervention 1: 0.87 Intervention 2: 0.42 Incremental (2–1): –0.45 (95% CI: NR; p=NR)</p>	<p>ICERs: Death: £163,229 per death averted with open surgery</p> <p>Lengths of stay: Minimally invasive step-up approach dominates open surgery</p> <p>Major complications: Minimally invasive step-up approach dominates open surgery</p> <p>Analysis of uncertainty: No sensitivity analysis was conducted</p>

Data sources
Health outcomes: Within trial. Cost sources: Resource use (number of procedures) was captured through the trial records. Unit costs relevant to the Dutch healthcare system were applied to the combined resource use.
Comments
Source of funding: Study was supported by a grant from the Dutch organisation for health research and development. Limitations: Dutch cohort of patients, the study did not collect quality of life data. The study had a short, 6-month time horizon; unit costs are representative of the Dutch healthcare system.
Overall applicability: partially applicable ^(d) Overall quality: potentially serious limitations ^(e)

Abbreviations: CCA: cost–consequences analysis; CCU: critical care unit; CT: computed tomography; 95% CI: 95% confidence interval; ICER: incremental cost-effectiveness ratio; NR: not reported

- (a) For studies where the time horizon is longer than the treatment duration, an assumption needs to be made about the continuation of the study effect. For example, does a difference in utility between groups during treatment continue beyond the end of treatment and if so for how long.
- (b) Converted using purchasing power parities⁸²⁴
- (c) Composite of ‘multiple-organ failure’, ‘multiple systemic complications’, ‘intraabdominal bleeding requiring intervention’ and ‘enterocutaneous fistula or perforation of a visceral organ requiring intervention’; number of complications per person
- (d) Directly applicable / Partially applicable / Not applicable
- (e) Minor limitations / Potentially serious limitations / Very serious limitations

Study	Van Brunschot 2017 ¹⁴⁶			
Study details	Population & interventions	Costs	Health outcomes	Cost effectiveness
<p>Economic analysis: CUA (health outcome: QALYs)</p> <p>Study design: within-trial analysis (RCT)</p> <p>Approach to analysis: outcomes and resource use from same trial</p> <p>Perspective: Dutch public health system</p>	<p>Population: Adults with acute pancreatitis and a high suspicion or evidence of infected necrosis with an indication for invasive intervention and for whom both the endoscopic and surgical step-up approach were deemed feasible (n=98).</p> <p>Patient characteristics: Mean age: 62 Male: 64%</p> <p>Intervention 1:</p>	<p>Total costs: Intervention 1: £63,391 Intervention 2: £51,674 Incremental (2–1): –£11,717 (95% CI: –£30,725 to £9,305; p=NR)^{(a) (b)}</p> <p>Currency & cost year: 2014 Euros (presented here as 2014 UK pounds^(c))</p> <p>Cost components incorporated:^(c)</p>	<p>QALYs gained:^(d) Intervention 1: 0.2656 Intervention 2: 0.2495 Incremental (2–1): –0.0161 (95% CI: –0.0743 to 0.0464; p=NR)</p>	<p>ICER: £728,000 per QALY gained (for percutaneous step-up compared with endoscopic step-up).</p> <p>Probability endoscopic step-up is cost effective compared to percutaneous step-up (at a threshold of £42,934): 89%^(e)</p> <p>Analysis of uncertainty: 1000 bootstrapped samples</p>

<p>Follow-up 6 months</p> <p>Discounting: n/a</p>	<p>Minimally invasive percutaneous step-up approach: Radiological CT-guided or ultrasound-guided percutaneous catheter drainage, preferably through the left retroperitoneum with the catheter as guidance for video-assisted retroperitoneal debridement (VARD) if needed. If drainage was not successful a VARD procedure was performed. (n=47)</p> <p>Intervention 2: Minimally invasive endoscopic step-up approach: Endoscopic ultrasound-guided transluminal (transgastric or transduodenal) drainage with placement of 2 double-pigtail stents and 1 nasocystic catheter. If drainage alone did not lead to considerable clinical improvement endoscopic transluminal necrosectomy was performed. (n=51)</p>	<p>Hospital stay, critical care stay, general ward stay, laboratory, microbiology, conventional radiology, endoscopy, study intervention, other interventions, surgical procedures, outpatient clinic contact, non-hospital medical costs.</p>	<p>were used to calculate the results above. No deterministic sensitivity analyses were conducted.</p>
---	--	--	--

Data sources

Health outcomes: Within trial. **Quality of life:** quality of life measured within trial at 3 months and 6 months after start using EQ-5D-3L; utility weights taken from UK population. **Cost sources:** Unit costing based on the 2015 Dutch manual for costing in healthcare research, except for the experimental interventions, which were calculated by the researchers' expert judgement.

Comments

Source of funding: Olympus, Netherlands Organisation for Health Research and Development, Dutch Digestive Disease Foundation, Fonds NutsOhra.

Limitations: The majority (77%) of patients were excluded from the study, so may have limited applicability. The interventions differ in some respects from current UK practice. The study had a short, 6-month time horizon. Quality of life was compared only for surviving patients over the first 6 months; mortality and life expectancy were not included in QALY calculations. Costs are based on the Dutch healthcare system.

Overall applicability: partially applicable^(f) **Overall quality:** potentially serious limitations^(g)

Abbreviations: CUA: cost–utility analysis; 95% CI: 95% confidence interval; ICER: incremental cost-effectiveness ratio; NR: not reported; QALYs: quality-adjusted life years; RCT: randomised controlled trial

(a) Difference in cost between the primary interventions was +£802, the cost difference is largely driven by a difference of £9,247 for hospital stay (general ward admissions)

(b) Patients' travel expenses also reported; these have been excluded from the total costs for each arm reported here. 95% CI for incremental cost difference between arms reported above is for the incremental difference between the total costs including travel expenses (CI around –£11,717) – however travel expenses only differed by £9 between the 2 arms

- (c) Converted using purchasing power parities⁸²⁴
- (d) QALYs were reported based on utility valuations from both Dutch and UK EQ-5D valuation sets; only UK results are reported here
- (e) The probability cost effective was calculated in the paper from the total costs, including travel costs. The result would have been similar without travel costs.
- (f) Directly applicable / Partially applicable / Not applicable
- (g) Minor limitations / Potentially serious limitations / Very serious limitations

I.13 Timing of management of infected necrosis in people with acute pancreatitis

None.

I.14 Management of pain in people with chronic pancreatitis

None.

I.15 Management of pancreatic duct obstruction in people with chronic pancreatitis

Study	Dumonceau 2007 ³¹⁹			
Study details	Population & interventions	Costs	Health outcomes	Cost effectiveness
<p>Economic analysis: CCA (health outcomes: pain relapse, length of hospital stay, intensity of pain)</p> <p>Study design: Randomised control trial</p> <p>Approach to analysis: Patients were randomly assigned to either ESWL alone or ESWL in combination with endoscopy.</p> <p>Perspective: Belgian public healthcare</p>	<p>Population: Patients with uncomplicated painful chronic pancreatitis and calcifications obstructing the main pancreatic duct (n=55).</p> <p>Patient characteristics: Age: 50.3 years Male: 78%</p>	<p>Total costs (mean per patient): Intervention 1: £9,221 Intervention 2: £3,289 Incremental (2-1): -£5,932 (95% CI: NR; p=0.001)</p> <p>Currency & cost year: 2003 Euros (presented here as 2003 UK pounds^(a))</p>	<p>11 outcome measures reported. Key results:</p> <p><u>Pain relapse at 2 years (% patients):</u> Intervention 1: 45% Intervention 2: 38% Incremental (2-1): -7%</p> <p><u>Intensity of relapsing pain (10 point visual analogue scale):</u> Intervention 1: 5.7 Intervention 2: 5.7</p>	<p><u>Pain relapse:</u> ESWL dominates ESWL in combination with endotherapy</p> <p><u>Intensity of pain:</u> ESWL is less costly and equally effective compared to ESWL in combination with endotherapy</p> <p><u>Complications:</u> ESWL dominates ESWL in combination with endotherapy</p> <p><u>Length of hospital stay:</u> ESWL dominates ESWL in combination with endotherapy</p>

insurance system		Cost components incorporated: Initial hospital stay, interventions (ESWL, endoscopy), and procedure-related complications. Follow-up hospital stays and procedures.	Incremental (2–1): 0 <u>Complications (% patients):</u> Intervention 1: 3% Intervention 2: 0% Incremental (2–1): –3% <u>Length of hospital stay (per patient):</u> Intervention 1: 8.6 days Intervention 2: 3.1 days Incremental (2–1): –5.5 days Of all 13 outcomes, 6 favoured ESWL alone, 4 favoured ESWL with endotherapy and 3 were equal. See clinical evidence table for Dumoncaeu 2007 for full details.	Analysis of uncertainty: No sensitivity analysis was conducted.
Follow-up: mean 21.5 months	Intervention 1: ESWL in combination with endotherapy (n=29). Intervention 2: ESWL (n=26).			
Discounting: n/a				

Data sources

Health outcomes: Within trial analysis. **Cost sources:** Resource use was captured from the trial. Unit costs were based on rates for Belgian public healthcare insurance and applied to resource use.

Comments

Source of funding: NR. **Limitations:** Belgian public healthcare insurance perspective. The study did not collect quality of life data. Costs were not discounted. Short follow-up time that may not capture all costs and benefits. Sensitivity analysis not undertaken. **Other:** None.

Overall applicability: partially applicable^(b) **Overall quality:** potentially serious limitations^(c)

Abbreviations: CCA: cost–consequences analysis; 95% CI: 95% confidence interval; ESWL: extracorporeal shock wave lithotripsy; NR: not reported;

(a) Converted using 2003 purchasing power parities⁸²⁴

(b) Directly applicable / Partially applicable / Not applicable

(c) Minor limitations / Potentially serious limitations / Very serious limitations

I.16 Management of small-duct disease in people with chronic pancreatitis

None.

I.17 Management of pseudocysts

None.

I.18 Management of pancreatic ascites and pleural effusion secondary to pancreatitis

None.

I.19 Management of biliary obstruction in people with chronic pancreatitis

None.

I.20 Management of type 3c diabetes secondary to pancreatitis

None.

I.21 Receiving specialist input in people with acute pancreatitis

None.

I.22 Follow-up of pancreatic exocrine function in people with chronic pancreatitis

None.

I.23 Follow-up to identify diabetes in people with chronic pancreatitis

None.

I.24 Follow-up to identify pancreatic cancer in people with chronic pancreatitis

None.

Appendix J: GRADE tables

J.1 Patient information

None.

J.2 Lifestyle interventions: stopping or reducing alcohol consumption

J.2.1 Clinical evidence profile: Structured programme to support people with acute pancreatitis in stopping or reducing alcohol consumption versus usual care

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Structured programme to stop alcohol	Usual care	Relative (95% CI)	Absolute		
N of episodes of recurrent AP at 36 months (follow-up 36 months)												
1	randomised trials	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	7/39 (17.9%)	31.1%	RR 0.58 (0.26 to 1.28)	131 fewer per 1000 (from 230 fewer to 87 more)	⊕○○○ VERY LOW	CRITICAL
Admissions to hospital (n of patients admitted for abdominal complaints fulfilling criteria of recurrent AP) at 2 years (follow-up 2 years)												
1	randomised trials	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	3/39 (7.7%)	20%	RR 0.38 (0.11 to 1.32)	124 fewer per 1000 (from 178 fewer to 64 more)	⊕○○○ VERY LOW	IMPORTANT

¹ Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

² Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs

J.3 Aetiology of acute pancreatitis

None

J.4 Aetiology of chronic pancreatitis

None

J.5 Diagnosing chronic pancreatitis

None

J.6 Type of intravenous fluid for resuscitation in people with acute pancreatitis

J.6.1 Clinical evidence profile: Balanced crystalloid (Ringer-lactate) vs normal saline (RCT)

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Balanced crystalloid (Ringer-lactate)	Normal saline (RCT)	Relative (95% CI)	Absolute		
Mortality												
2	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	very serious ²	none	0/38 (0%)	1.19%	Peto OR 0.15 (0.00 to 7.54)	48 fewer per 1000 (from 173 fewer to 78 more) ³	⊕⊕○○ LOW	CRITICAL
Serious adverse events (transfer to critical care)												
2	randomised trials	very serious ¹	no serious inconsistency	no serious indirectness	very serious	none	1/19 (5.3%)	14.3%	RR 0.37 (0.06 to 2.20)	90 fewer per 1000 (from 134 fewer to 172 more)	⊕○○○ VERY LOW	IMPORTANT

Local complications (infection)												
1	randomised trials	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	0/19 (0%)	1/21 (4.8%)	Peto OR 0.15 (0 to 7.54)	40 fewer per 1000 (from 48 fewer to 226 more)	⊕○○○ VERY LOW	IMPORTANT
Local complications (necrosis)												
1	randomised trials	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	0/19 (0%)	2/21 (9.5%)	Peto OR 0.14 (0.01 to 2.36)	81 fewer per 1000 (from 94 fewer to 104 more)	⊕○○○ VERY LOW	IMPORTANT
Local complications (peri-pancreatic necrosis)												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	very serious ²	none	4/10 (40%)	10/14 (71.4%)	RR 0.56 (0.24 to 1.28)	314 fewer per 1000 (from 543 fewer to 200 more)	⊕⊕○○ LOW	IMPORTANT
Systemic complications (renal failure)												
1	randomised trials	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	1/19 (5.3%)	2/21 (9.5%)	RR 0.55 (0.05 to 5.62)	43 fewer per 1000 (from 90 fewer to 440 more)	⊕○○○ VERY LOW	IMPORTANT
Systemic complications (respiratory organ failure)												
1	randomised trials	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	0/19 (0%)	1/21 (4.8%)	Peto OR 0.15 (0 to 7.54)	40 fewer per 1000 (from 48 fewer to 226 more)	⊕○○○ VERY LOW	IMPORTANT
Systemic complications (shock)												
1	randomised trials	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	0/19 (0%)	1/21 (4.8%)	Peto OR 0.15 (0 to 7.54)	40 fewer per 1000 (from 48 fewer to 226 more)	⊕○○○ VERY LOW	IMPORTANT
Systemic complications (persistent organ failure)												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	very serious ²	none	0/19 (0%)	1/21 (4.8%)	Peto OR 0.15 (0 to 7.54)	48 fewer per 1000 (from 173 fewer to 78 more) ³	⊕⊕○○ LOW	IMPORTANT

¹ Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

² Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs

J.6.2 Clinical evidence profile: Balanced crystalloid (Ringer-lactate) vs normal saline (non-randomised comparative studies)

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Balanced crystalloid (Ringer-lactate)	Normal saline (obs)	Relative (95% CI)	Absolute		
Mortality												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	4/68 (5.9%)	21/130 (16.2%)	RR 0.36 (0.13 to 1.02)	104 fewer per 1000 (from 141 fewer to 3 more)	⊕000 VERY LOW	CRITICAL
Length of stay (in critical care) (Better indicated by lower values)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	68	130	-	MD 2 higher (0.19 to 3.81 higher)	⊕000 VERY LOW	CRITICAL

¹ Downgraded by 2 increments if the majority of the evidence was from studies with observational/non-randomised study design. Further downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

² Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs

J.7 Speed of intravenous fluid for resuscitation in people with acute pancreatitis

J.7.1 Clinical evidence profile: Aggressive intravenous fluid resuscitation therapy versus conservative intravenous fluid resuscitation therapy in adults with acute pancreatitis (RCTs)

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Aggressive fluid therapy	Conservative fluid therapy	Relative (95% CI)	Absolute		
Mortality												
3	randomised trials	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	14/110 (12.7%)	11.8%	RR 0.90 (0.49 to 1.67)	12 fewer per 1000 (from 60 fewer to 79 more)	⊕○○○ VERY LOW	CRITICAL
Length of time in CCU (days) (Better indicated by lower values)												
1	randomised trials	very serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	64	68	-	MD 2 lower (4.23 lower to 0.23 higher)	⊕○○○ VERY LOW	CRITICAL
Local complications (infection)												
1	randomised trials	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	2/19 (10.5%)	0%	POR 8.68 (0.52 to 144.35)	105 more per 1000 (from 52 fewer to 263 more) ³	⊕○○○ VERY LOW	IMPORTANT
Local complications (necrosis)												
1	randomised trials	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	1/19 (5.3%)	0%	Peto OR 8.21 (0.16 to 415.76)	52 more per 1000 (from 78 fewer to 183 more) ³	⊕○○○ VERY LOW	IMPORTANT
Systemic complications (Multiple organ dysfunction syndrome)												
1	randomised trials	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	18/64 (28.1%)	20/68 (29.4%)	RR 0.96 (0.56 to 1.64)	12 fewer per 1000 (from 129 fewer to 188 more)	⊕○○○ VERY LOW	IMPORTANT

Systemic complications (Sepsis)												
1	randomised trials	very serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	36/36 (100%)	13/40 (32.5%)	RR 3 (1.93 to 4.64)	650 more per 1000 (from 302 more to 1000 more)	⊕⊕⊕⊕ LOW	IMPORTANT
Systemic complications (Abdominal compartment syndrome)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	14/64 (21.9%)	18/68 (26.5%)	RR 0.83 (0.45 to 1.52)	45 fewer per 1000 (from 146 fewer to 138 more)	⊕⊕⊕⊕ VERY LOW	IMPORTANT
Systemic complications (renal failure)												
1	randomised trials	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	2/19 (10.5%)	1/21 (4.8%)	RR 2.21 (0.22 to 22.47)	58 more per 1000 (from 37 fewer to 1000 more)	⊕⊕⊕⊕ VERY LOW	IMPORTANT
Systemic complications (respiratory failure)												
1	randomised trials	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	1/19 (5.3%)	0%	Peto OR 8.21 (0.16 to 415.76)	52 more per 1000 (from 78 fewer to 183 more) ³	⊕⊕⊕⊕ VERY LOW	IMPORTANT
Systemic complications (shock)												
1	randomised trials	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	1/19 (5.3%)	0%	Peto OR 8.21 (0.16 to 415.76)	52 more per 1000 (from 78 fewer to 183 more) ³	⊕⊕⊕⊕ VERY LOW	IMPORTANT
Serious adverse events (Days using ventilation) (Better indicated by lower values)												
1	randomised trials	very serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	64	68	-	MD 3 lower (4.61 to 1.39 lower)	⊕⊕⊕⊕ VERY LOW	IMPORTANT
Serious adverse events (transfer to CCU)												
1	randomised trials	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	4/19 (21.1%)	0%	Peto OR 9.78 (1.27 to 75.43)	210 more per 1000 (from 17 more to 403 more) ³	⊕⊕⊕⊕ VERY LOW	IMPORTANT
Systemic complications (development of SIRS)												

1	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	4/27 (14.8%)	9/33 (27.3%)	RR 0.54 (1.19 to 1.57)	125 fewer per 1000 (from 221 fewer to 155 more)	⊕○○○ VERY LOW	IMPORTANT
Systemic complications (persistent SIRS)												
1	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	2/27 (7.4%)	7/33 (21.2%)	RR 0.35 (0.08 to 1.54)	138 fewer per 1000 (from 195 fewer to 115 more)	⊕○○○ VERY LOW	IMPORTANT
Serious adverse events (development of severe acute pancreatitis)												
1	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	0/27 (0%)	1/33 (3%)	Peto OR 0.16 (0 to 8.34)	25 fewer per 1000 (from 30 fewer to 222 more) ³	⊕○○○ VERY LOW	IMPORTANT

¹ Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

² Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs

³ Peto Odds Ratio

J.7.2 Clinical evidence profile: Aggressive intravenous fluid resuscitation therapy versus conservative intravenous fluid resuscitation therapy in adults with acute pancreatitis (non-randomised comparative studies)

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Aggressive fluid therapy	Conservative fluid therapy	Relative (95% CI)	Absolute		
Mortality												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	0/17 (0%)	5/28 (17.9%)	RR 0.17 (0.03 to 1.14)	148 fewer per 1000 (from 173 fewer to 25 more)	⊕○○○ VERY LOW	CRITICAL
Mortality												

1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	4/113 (3.5%)	16/173 (9.2%)	Peto OR 0.38 (0.13 to 1.12)	57 fewer per 1000 (from 80 fewer to 11 more)	⊕000 VERY LOW	CRITICAL
Mortality - 500-1000ml versus <500ml												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	427	269	OR 0.46 (0.15 to 1.41)	-	⊕000 VERY LOW	CRITICAL
Mortality - >1000ml versus <500ml												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	314	269	OR 0.64 (0.2 to 2.05)	-	⊕000 VERY LOW	CRITICAL
Length of hospital stay (Better indicated by lower values)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	17	28	-	MD 3 higher (37.7 lower to 43.7 higher)	⊕000 VERY LOW	CRITICAL
Local complications (Acute collection) 3100-4100 ml versus >4100ml												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	123	61	OR 1.90 (1.00 to 3.61)	-	⊕000 VERY LOW	IMPORTANT
Local complications (Acute collection) <3100 ml versus 3100-4100 ml												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	63	123	OR 0.60 (0.30 to 1.20)	-	⊕000 VERY LOW	IMPORTANT
Local complications (Pancreatic necrosis)												
1	observational	very	no serious	no serious	very serious ²	none	8/17	11/28	RR 1.20	79 more	⊕000	IMPORTANT

	studies	serious ¹	inconsistency	indirectness			(47.1%)	(39.3%)	(0.61 to 2.37)	per 1000 (from 153 fewer to 538 more)	VERY LOW	
Local complications (Pancreatic necrosis)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	26/173 (15%)	8/113 (7.1%)	RR 2.12 (1.00 to 4.52)	79 more per 1000 (from 0 more to 249 more)	⊕○○○ VERY LOW	IMPORTANT
Local complications (Pancreatic necrosis) 3100-4100 ml versus >4100ml												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	123	61	OR 1.80 (0.60 to 5.40)	-	⊕○○○ VERY LOW	IMPORTANT
Local complications (Pancreatic necrosis) <3100 ml versus 3100-4100 ml												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	63	123	OR 1.50 (0.60 to 3.75)	-	⊕○○○ VERY LOW	IMPORTANT
Local complications (Pseudocysts)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	11/17 (64.7%)	20/28 (71.4%)	RR 0.91 (0.59 to 1.38)	64 fewer per 1000 (from 293 fewer to 271 more)	⊕○○○ VERY LOW	IMPORTANT
Local complications (acute peripancreatic fluid collections and/or pancreatic necrosis and/or peripancreatic necrosis) - 500-1000 ml versus <500 ml												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	427	269	OR 0.67 (0.43 to 1.04)	-	⊕○○○ VERY LOW	IMPORTANT

Local complications (acute peripancreatic fluid collections and/or pancreatic necrosis and/or peripancreatic necrosis) - >1000 ml versus <500 ml												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	314	269	OR 1.15 (0.71 to 1.86)	-	⊕○○○ VERY LOW	IMPORTANT
Systemic complications (Cardiovascular failure)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	4/113 (3.5%)	4.1%	RR 0.87 (0.26 to 2.92)	5 fewer per 1000 (from 30 fewer to 79 more)	⊕○○○ VERY LOW	IMPORTANT
Systemic complications (Pulmonary failure)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	4/113 (3.5%)	5.2%	RR 0.68 (0.21 to 2.16)	17 fewer per 1000 (from 41 fewer to 60 more)	⊕○○○ VERY LOW	IMPORTANT
Systemic complications (Multisystem organ failure)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	5/113 (4.4%)	10.4%	RR 0.43 (0.16 to 1.11)	59 fewer per 1000 (from 87 fewer to 11 more)	⊕○○○ VERY LOW	IMPORTANT
Systemic complications (Respiratory complications)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	21/32 (65.6%)	97.3%	RR 0.67 (0.52 to 0.87)	321 fewer per 1000 (from 126 fewer to 467 fewer)	⊕○○○ VERY LOW	IMPORTANT
Systemic complications (Fluid overload)												

1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	0/32 (0%)	0%	No events	-	⊕000 VERY LOW	IMPORTANT
Systemic complications (Persistent organ failure)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	6/17 (35.3%)	12/28 (42.9%)	RR 0.82 (0.38 to 1.78)	77 fewer per 1000 (from 266 fewer to 334 more)	⊕000 VERY LOW	IMPORTANT
Systemic complications (Persistent organ failure) 3100-4100 ml versus <3100ml												
1	observational studies	very serious ²	no serious inconsistency	no serious indirectness	very serious ²	none	123	63	OR 2.10 (0.30 to 14.70)	-	⊕000 VERY LOW	IMPORTANT
Systemic complications (persistent organ failure) - >4100 ml versus 3100-4100 ml												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	61	123	OR 7.70 (1.50 to 39.53)	-	⊕000 VERY LOW	IMPORTANT
Systemic complications (persistent organ failure) - 500-1000 ml versus <500 ml												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	427	269	OR 0.56 (0.28 to 1.12)	-	⊕000 VERY LOW	IMPORTANT
Systemic complications (persistent organ failure) - >1000ml versus <500ml												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	314	269	OR 0.50 (0.22 to 1.14)	-	⊕000 VERY LOW	IMPORTANT
Systemic complications (Renal failure)												

1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	5/113 (4.4%)	5.2%	RR 0.85 (0.29 to 2.47)	8 fewer per 1000 (from 37 fewer to 76 more)	⊕○○○ VERY LOW	IMPORTANT
Systemic complications (SIRS)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	15/17 (88.2%)	20/28 (71.4%)	RR 1.24 (0.92 to 1.65)	171 more per 1000 (from 57 fewer to 464 more)	⊕○○○ VERY LOW	IMPORTANT
Serious adverse events (pulmonary oedema)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	0/32 (0%)	0/67 (0%)	Not estimable	No events	⊕○○○ VERY LOW	IMPORTANT

¹ Downgraded by 2 increments if the majority of the evidence was from studies with observational/non-randomised study design. Further downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

² Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs

J.7.3 Clinical evidence profile: Aggressive intravenous fluid resuscitation therapy versus conservative intravenous fluid resuscitation therapy in children with acute pancreatitis (non-randomised comparative studies)

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Aggressive fluid therapy	Conservative fluid therapy	Relative (95% CI)	Absolute		
Serious adverse events (CCU transfer rate)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	5/126 (4%)	14/75 (18.7%)	RR 0.21 (0.08 to	147 fewer per 1000 (from 80 fewer to	⊕○○○ VERY	IMPORTANT

									0.57)	172 fewer)	LOW	
Serious adverse events (Readmission rate)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	5/126 (4%)	5/75 (6.7%)	RR 0.6 (0.18 to 1.99)	27 fewer per 1000 (from 55 fewer to 66 more)	⊕○○○ VERY LOW	IMPORTANT
Serious adverse events (SAP rate)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	9/126 (7.1%)	16%	RR 0.45 (0.2 to 1.01)	88 fewer per 1000 (from 128 fewer to 2 more)	⊕○○○ VERY LOW	IMPORTANT

¹ Downgraded by 2 increments if the majority of the evidence was from studies with observational/non-randomised study design. Further downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

² Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs

J.8 Route of feeding in people with severe acute pancreatitis

J.8.1 Clinical evidence profile: Enteral versus parenteral nutrition

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Enteral	Parenteral	Relative (95% CI)	Absolute		
Mortality (follow-up during hospitalisation)												
8	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	18/186 (9.7%)	17.4%	RR 0.36 (0.22 to 0.59)	111 fewer per 1000 (from 71 fewer to 136 fewer)	⊕⊕⊕○ MODERATE	CRITICAL
Length of hospital stay - Overall (follow-up hospitalisation; Better indicated by lower values)												
3	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	55	58	-	MD 2.46 lower (8.45 lower to 3.53 higher)	⊕⊕○○ LOW	CRITICAL

Length of hospital stay - Severe (Ranson's criteria >3) (follow-up hospitalisation; Better indicated by lower values)												
1	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	13	13	-	MD 7.3 lower (9.24 to 5.36 lower)	⊕⊕⊕⊕ MODERATE	CRITICAL
Achieving nutrition - kcal/kg/day (day 5) (follow-up hospitalisation; Better indicated by lower values)												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	very serious ²	none	11	11	-	MD 0.71 higher (0.76 lower to 2.18 higher)	⊕⊕⊕⊕ LOW	CRITICAL
Achieving nutrition - Days to goal (follow-up hospitalisation; Better indicated by lower values)												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	serious ²	none	10	18	-	MD 1.4 higher (0.56 lower to 3.36 higher)	⊕⊕⊕⊕ MODERATE	CRITICAL
Infections - Pancreatic (for example, infected necrosis, abscess) (follow-up hospitalisation)												
5	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	22/127 (17.3%)	22.2%	RR 0.36 (0.24 to 0.54)	142 fewer per 1000 (from 102 fewer to 169 fewer)	⊕⊕⊕⊕ MODERATE	IMPORTANT
Infections - Extra-pancreatic (for example, UTI, pneumonia) (follow-up hospitalisation)												
4	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	9/72 (12.5%)	14.4%	RR 0.73 (0.34 to 1.57)	39 fewer per 1000 (from 95 fewer to 82 more)	⊕⊕⊕⊕ VERY LOW	IMPORTANT
Infections - Systemic (for example, central line infection, blood culture) (follow-up hospitalisation)												
6	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	2/108 (1.9%)	19.9%	RR 0.15 (0.06 to 0.41)	169 fewer per 1000 (from 117 fewer to 187 fewer)	⊕⊕⊕⊕ MODERATE	IMPORTANT
Infections – type not specified (follow-up hospitalisation)												
1	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	16/25 (64%)	15/25 (60%)	RR 1.07 (0.69 to 1.65)	42 more per 1000 (from 186 fewer to 390 more)	⊕⊕⊕⊕ VERY LOW	IMPORTANT
Serious adverse events (follow-up hospitalisation)												
6	randomised trials	no serious risk of bias	very serious ³	no serious indirectness	serious ²	none	42/143 (29.4%)	69.4%	RR 0.51 (0.29 to 0.92)	340 fewer per 1000 (from 56 fewer to 493 fewer)	⊕⊕⊕⊕ VERY LOW	IMPORTANT

Adverse events - Operative intervention (follow-up during hospitalisation)												
8	randomised trials	serious ¹	serious ³	no serious indirectness	no serious imprecision	none	43/186 (23.1%)	41.1%	RR 0.5 (0.27 to 0.92)	205 fewer per 1000 (from 33 fewer to 300 fewer)	⊕⊕⊕⊕ LOW	IMPORTANT
Adverse events - Non-infective pancreatic complications (for example,, necrosis, pseudocyst, fistulae) (follow-up hospitalisation)												
6	randomised trials	serious ¹	serious ³	no serious indirectness	very serious ²	none	60/143 (42%)	21.4%	RR 1.09 (0.53 to 2.24)	19 more per 1000 (from 101 fewer to 265 more)	⊕⊕⊕⊕ VERY LOW	IMPORTANT
Adverse events - Feeding complications (for example,, tube displacement, hyperglycaemia, diabetes) (follow-up hospitalisation)												
5	randomised trials	serious ¹	very serious ³	no serious indirectness	very serious ²	none	24/97 (24.7%)	14.7%	RR 1.03 (0.27 to 3.85)	4 more per 1000 (from 107 fewer to 419 more)	⊕⊕⊕⊕ VERY LOW	IMPORTANT

¹ Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

² Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

³ Downgraded by 1 or 2 increments because of heterogeneity, I²>50%, p<0.04, unexplained by subgroup analysis.

J.8.2 Clinical evidence profile: Enteral (gastric) versus parenteral nutrition

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Enteral (gastric)	Parenteral nutrition	Relative (95% CI)	Absolute		
Mortality (follow-up 3 months)												
1	randomised trials	serious ¹	no serious inconsistency	serious ²	very serious ³	none	1/23 (4.3%)	0/25 (0%)	Peto OR 8.06 (0.16 to 407.6)	40 more per 1000 (from 70 fewer to 150 more)	⊕⊕⊕⊕ VERY LOW	CRITICAL
Achieving nutrition (25 kcal/kg/day) (follow-up 10 days)												
1	randomised trials	serious ¹	no serious inconsistency	serious ²	very serious ³	none	16/24 (66.7%)	17/26 (65.4%)	RR 1.02 (0.68 to 1.52)	13 more per 1000 (from 209 fewer to 340 more)	⊕⊕⊕⊕ VERY LOW	CRITICAL
Infections - Pancreatic (e.g. infected necrosis, abscess) (follow-up 3 months)												

1	randomised trials	serious ¹	no serious inconsistency	serious ²	very serious ³	none	1/23 (4.3%)	0/25 (0%)	Peto OR 8.06 (0.16 to 407.6)	40 more per 1000 (from 70 fewer to 150 more)	⊕○○○ VERY LOW	IMPORTANT
Infections - Systemic (e.g. central line infection, blood culture) (follow-up 3 months)												
1	randomised trials	serious ¹	no serious inconsistency	serious ²	very serious ³	none	2/23 (8.7%)	0/25 (0%)	Peto OR 8.43 (0.51 to 139.29)	90 more per 1000 (from 50 fewer to 220 more)	⊕○○○ VERY LOW	IMPORTANT
Serious adverse events - Multiple or single organ failure (follow-up 3 months)												
1	randomised trials	serious ¹	no serious inconsistency	serious ²	very serious ³	none	2/23 (8.7%)	2/25 (8%)	RR 1.09 (0.17 to 7.1)	7 more per 1000 (from 66 fewer to 488 more)	⊕○○○ VERY LOW	IMPORTANT
Adverse events - General (e.g., pleural effusion) (follow-up 3 months)												
1	randomised trials	serious ¹	no serious inconsistency	serious ²	serious ³	none	12/23 (52.2%)	7/25 (28%)	RR 1.86 (0.89 to 3.91)	241 more per 1000 (from 31 fewer to 815 more)	⊕○○○ VERY LOW	IMPORTANT
Adverse events - Non-infective pancreatic complications (e.g., necrosis, pseudocyst, fistulae) (follow-up 3 months)												
1	randomised trials	serious ¹	no serious inconsistency	serious ²	serious ³	none	9/23 (39.1%)	4/25 (16%)	RR 2.45 (0.87 to 6.87)	232 more per 1000 (from 21 fewer to 939 more)	⊕○○○ VERY LOW	IMPORTANT
Adverse events - Surgical intervention (follow-up 3 months)												
1	randomised trials	serious ¹	no serious inconsistency	serious ²	very serious ³	none	1/24 (4.2%)	1/26 (3.8%)	RR 1.08 (0.07 to 16.38)	3 more per 1000 (from 36 fewer to 592 more)	⊕○○○ VERY LOW	IMPORTANT

¹ Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

² Downgraded by 1 increment because the majority of evidence was from an indirect population

³ Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

J.8.3 Clinical evidence profile: Enteral (gastric) versus enteral (jejunal or duodenal) parenteral nutrition

Quality assessment	No of patients	Effect	Quality	Importance
--------------------	----------------	--------	---------	------------

No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Gastric	Duodenal/jejunal	Relative (95% CI)	Absolute		
Mortality (follow-up unclear)												
3	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	very serious ¹	none	14/82 (17.1%)	28.6%	RR 0.69 (0.37 to 1.29)	89 fewer per 1000 (from 180 fewer to 83 more)	⊕⊕⊕⊕ LOW	CRITICAL
Length of hospital stay (days) (follow-up unclear; Better indicated by lower values)												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	serious ¹	none	16	14	-	MD 5.87 lower (20.98 lower to 9.24 higher)	⊕⊕⊕⊕ MODERATE	CRITICAL
Achieving nutrition - Tolerating administration of at least 75% of target within 48 h (follow-up 48 h)												
1	randomised trials	serious ²	no serious inconsistency	no serious indirectness	very serious ¹	none	19/27 (70.4%)	17/22 (77.3%)	RR 0.91 (0.65 to 1.27)	70 fewer per 1000 (from 270 fewer to 209 more)	⊕⊕⊕⊕ VERY LOW	CRITICAL
Achieving nutrition - Tolerating administration of at least 75% of target within 60 h (follow-up 60 h)												
1	randomised trials	serious ²	no serious inconsistency	no serious indirectness	very serious ¹	none	21/27 (77.8%)	17/22 (77.3%)	RR 1.01 (0.74 to 1.36)	8 more per 1000 (from 201 fewer to 278 more)	⊕⊕⊕⊕ VERY LOW	CRITICAL
Achieving nutrition - Achieving goal nutrient requirement within 3 days (follow-up 3 days)												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	no serious imprecision	none	39/39 (100%)	39/39 (100%)	RR 1 (0.95 to 1.05)	0 fewer per 1000 (from 50 fewer to 50 more)	⊕⊕⊕⊕ HIGH	CRITICAL
Requiring TPN (follow-up unclear)												
1	randomised trials	serious ²	no serious inconsistency	no serious indirectness	very serious ¹	none	0/27 (0%)	1/22 (4.5%)	Peto OR 0.11 (0 to 5.55)	40 fewer per 1000 (from 45 fewer to 164 more)	⊕⊕⊕⊕ VERY LOW	CRITICAL
Infections - Pancreatic (e.g. infected necrosis, abscess) (follow-up unclear)												

2	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	very serious ¹	none	5/55 (9.1%)	17.1%	RR 0.59 (0.21 to 1.67)	70 fewer per 1000 (from 135 fewer to 115 more)	⊕⊕⊕⊕ LOW	IMPORTANT
Infections - Extrapaneatic (follow-up unclear)												
2	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	serious ¹	none	4/55 (7.3%)	16.4%	RR 0.36 (0.12 to 1.05)	105 fewer per 1000 (from 144 fewer to 8 more)	⊕⊕⊕⊕ MODERATE	IMPORTANT
Infections - Systemic (e.g. central line infection, blood culture) (follow-up unclear)												
2	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	very serious ¹	none	11/55 (20%)	18.7%	RR 0.97 (0.46 to 2.05)	6 fewer per 1000 (from 101 fewer to 196 more)	⊕⊕⊕⊕ LOW	IMPORTANT
Serious complications requiring tube removal (follow-up unclear)												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	no serious imprecision	none	0/16 (0%)	0/14 (0%)	-	-	⊕⊕⊕⊕ HIGH	CRITICAL
Adverse events - Tube displacement (follow-up unclear)												
2	randomised trials	serious ²	no serious inconsistency	no serious indirectness	very serious ¹	none	2/43 (4.7%)	5.8%	RR 0.84 (0.13 to 5.68)	9 fewer per 1000 (from 50 fewer to 271 more)	⊕⊕⊕⊕ VERY LOW	IMPORTANT
Adverse events - Surgical intervention (follow-up unclear)												
2	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	very serious ¹	none	5/55 (9.1%)	9.7%	RR 1.19 (0.34 to 4.17)	18 more per 1000 (from 64 fewer to 307 more)	⊕⊕⊕⊕ LOW	IMPORTANT

¹ Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

² Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

J.8.4 Clinical evidence profile: Early versus conventional (delayed) oral 're-feeding'

Quality assessment	No of patients	Effect	Quality	Importance
--------------------	----------------	--------	---------	------------

No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Early	Conventional oral re-feeding	Relative (95% CI)	Absolute		
Length of hospital stay (follow-up unclear; Better indicated by lower values)												
1	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	67	71	-	MD 2 lower (3.94 to 0.06 lower)	⊕⊕⊕⊕ LOW	CRITICAL
Requiring parenteral nutrition (follow-up unclear)												
1	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	65/67 (97%)	69/71 (97.2%)	RR 1 (0.94 to 1.06)	0 fewer per 1000 (from 58 fewer to 58 more)	⊕⊕⊕⊕ MODERATE	CRITICAL
Adverse events (abdominal pain relapse) (follow-up unclear)												
1	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	7/67 (10.4%)	10/71 (14.1%)	RR 0.74 (0.3 to 1.84)	37 fewer per 1000 (from 99 fewer to 118 more)	⊕⊕⊕⊕ VERY LOW	IMPORTANT

¹ Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

² Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

J.8.5 Clinical evidence profile: Early versus on-demand enteral nutrition

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Early	On-demand enteral nutrition	Relative (95% CI)	Absolute		
Mortality (follow-up 6 months)												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	very serious ¹	none	11/101 (10.9%)	7/104 (6.7%)	RR 1.62 (0.65 to 4.01)	42 more per 1000 (from 24 fewer to 203 more)	⊕⊕⊕⊕ LOW	CRITICAL
Requiring parenteral nutrition (follow-up 6 months)												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	very serious ¹	none	5/101 (5%)	10/103 (9.7%)	RR 0.51 (0.18 to 1.44)	48 fewer per 1000 (from 80 fewer to 43 more)	⊕⊕⊕⊕ LOW	CRITICAL

Infection - Pancreatic (e.g. infected necrosis, abscess) (follow-up 6 months)												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	very serious ¹	none	9/101 (8.9%)	15/104 (14.4%)	RR 0.62 (0.28 to 1.35)	55 fewer per 1000 (from 104 fewer to 50 more)	⊕⊕○○ LOW	IMPORTANT
Infection - Extra-pancreatic (e.g. UTI, pneumonia) (follow-up 6 months)												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	very serious ¹	none	12/101 (11.9%)	13/104 (12.5%)	RR 0.95 (0.46 to 1.98)	6 fewer per 1000 (from 67 fewer to 123 more)	⊕⊕○○ LOW	IMPORTANT
Infection - Systemic (e.g. central line infection, blood culture) (follow-up 6 months)												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	very serious ¹	none	17/101 (16.8%)	18/104 (17.3%)	RR 0.97 (0.53 to 1.78)	5 fewer per 1000 (from 81 fewer to 135 more)	⊕⊕○○ LOW	IMPORTANT
Serious adverse events - Necrosis (follow-up 6 months)												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	no serious imprecision	none	64/104 (61.5%)	65/104 (62.5%)	RR 0.98 (0.8 to 1.22)	12 fewer per 1000 (from 125 fewer to 138 more)	⊕⊕⊕⊕ HIGH	IMPORTANT
Serious adverse events - Multiple or single organ failure (follow-up 6 months)												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	very serious ¹	none	33/67 (49.3%)	37/73 (50.7%)	RR 0.97 (0.7 to 1.35)	15 fewer per 1000 (from 152 fewer to 177 more)	⊕⊕○○ LOW	IMPORTANT
Adverse events - Tube displacement (follow-up 6 months)												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	very serious ¹	none	38/99 (38.4%)	14/32 (43.8%)	RR 0.88 (0.55 to 1.4)	53 fewer per 1000 (from 197 fewer to 175 more)	⊕⊕○○ LOW	IMPORTANT

¹ Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

J.8.6 Clinical evidence profile: Early versus late enteral nutrition (observational data)

Quality assessment	No of patients	Effect	Quality	Importance

No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Early	Delayed enteral nutrition (observational)	Relative (95% CI)	Absolute		
Mortality - adjusted (follow-up unclear)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	3/47 (6.4%)	7/48 (14.6%)	OR 0.46 (0.11 to 1.92)	73 fewer per 1000 (from 127 fewer to 101 more)	⊕○○○ VERY LOW	CRITICAL
Mortality (follow-up unclear)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	0/35 (0%)	1/52 (1.9%)	Peto OR 0.19 (0 to 10.22)	16 fewer per 1000 (from 19 fewer to 148 more)	⊕○○○ VERY LOW	CRITICAL
Mortality (follow-up unclear)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	0/97 (0%)	9/100 (9%)	Peto OR 0.13 (0.03 to 0.49)	77 fewer per 1000 (from 44 fewer to 87 fewer)	⊕○○○ VERY LOW	CRITICAL
Additional parenteral nutrition (follow-up unclear)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	5/97 (5.2%)	13/100 (13%)	RR 0.4 (0.15 to 1.07)	78 fewer per 1000 (from 110 fewer to 9 more)	⊕○○○ VERY LOW	IMPORTANT
Pancreatic infections - adjusted data - Infected pancreatic necrosis (follow-up unclear)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	7/47 (14.9%)	9/48 (18.8%)	OR 0.66 (0.22 to 1.95)	55 fewer per 1000 (from 139 fewer to 123 more)	⊕○○○ VERY LOW	IMPORTANT
Pancreatic infections - adjusted data - Infected pancreatic necrosis or infected fluid collection (Copy) (follow-up unclear)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	4/97 (4.1%)	18/100 (18%)	OR 0.24 (0.07 to 0.86)	Not estimable ³	⊕○○○ VERY LOW	IMPORTANT
Infections - Pancreatic infections (follow-up unclear)												
1	observational	very	no serious	no serious	very serious ²	none	1/35	6/52	RR 0.25	87 fewer per 1000	⊕○○○	IMPORTANT

	studies	serious ¹	inconsistency	indirectness			(2.9%)	(11.5%)	(0.03 to 1.97)	(from 112 fewer to 112 more)	VERY LOW	
Infections - Extra-pancreatic infections												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	26/97 (26.8%)	39/100 (39%)	RR 0.69 (0.46 to 1.04)	121 fewer per 1000 (from 211 fewer to 16 more)	⊕○○○ VERY LOW	IMPORTANT
Infections - Systemic infections (follow-up unclear)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	2/97 (2.1%)	4/100 (4%)	RR 0.52 (0.1 to 2.75)	19 fewer per 1000 (from 36 fewer to 70 more)	⊕○○○ VERY LOW	IMPORTANT
Infections - Extra-pancreatic or systemic infections (follow-up unclear)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	2/35 (5.7%)	15/52 (28.8%)	RR 0.2 (0.05 to 0.81)	231 fewer per 1000 (from 55 fewer to 274 fewer)	⊕○○○ VERY LOW	IMPORTANT
Serious adverse events - Organ failure (follow-up unclear)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	15/47 (31.9%)	24/48 (50%)	OR 0.51 (0.22 to 1.18)	162 fewer per 1000 (from 320 fewer to 41 more)	⊕○○○ VERY LOW	IMPORTANT
Serious adverse events -Multi-organ failure (follow-up unclear)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	9/97 (9.3%)	16/100 (16%)	RR 0.58 (0.27 to 1.25)	67 fewer per 1000 (from 117 fewer to 40 more)	⊕○○○ VERY LOW	IMPORTANT
Adverse events - Pancreatic complications (necrosis, pseudocyst, ascites, haemorrhage, fistula) (follow-up unclear)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	31/35 (88.6%)	50/52 (96.2%)	RR 0.92 (0.81 to 1.05)	77 fewer per 1000 (from 183 fewer to 48 more)	⊕○○○ VERY LOW	IMPORTANT
Adverse events - Pancreatic complications (necrosis, pseudocyst, ascites, haemorrhage, fistula) (follow-up unclear)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	63/97 (64.9%)	86/100 (86%)	RR 0.76 (0.64 to 0.89)	206 fewer per 1000 (from 95 fewer to 310 fewer)	⊕○○○ VERY LOW	IMPORTANT

Adverse events - Operative intervention (follow-up unclear)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	2/35 (5.7%)	11/52 (21.2%)	RR 0.27 (0.06 to 1.15)	154 fewer per 1000 (from 199 fewer to 32 more)	⊕○○○ VERY LOW	IMPORTANT
Adverse events - Operative intervention (follow-up unclear)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	7/97 (7.2%)	11/100 (11%)	RR 0.66 (0.27 to 1.62)	37 fewer per 1000 (from 80 fewer to 68 more)	⊕○○○ VERY LOW	IMPORTANT
Adverse events - Feeding complications (abnormal glucose metabolism)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	22/35 (62.9%)	31/52 (59.6%)	RR 1.05 (0.75 to 1.48)	30 more per 1000 (from 149 fewer to 286 more)	⊕○○○ VERY LOW	IMPORTANT

¹ Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

² Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

³ Absolute risk difference could not be calculated because adjusted control group event rates were not reported.

J.9 Early versus late nutritional intervention in people with chronic pancreatitis

None

J.10 Specialist versus non-specialist nutritional assessment in people with chronic pancreatitis

None

J.11 Prophylactic antimicrobial agents to prevent infection in people with acute pancreatitis

J.11.1 Clinical evidence profile: Antibiotic prophylaxis versus no therapy

Quality assessment	No of patients	Effect	Quality	Importance

No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Antibiotic therapy	No therapy	Relative (95% CI)	Absolute		
Mortality (follow-up 1-6 weeks)												
6	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	no serious imprecision	none	13/172 (7.6%)	15%	RR 0.48 (0.26 to 0.91)	78 fewer per 1000 (from 13 fewer to 111 fewer)	⊕⊕⊕⊕ HIGH	CRITICAL
Mortality (Selective decontamination)												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	serious ³	none	11/50 (22%)	18/52 (34.6%)	RR 0.64 (0.33 to 1.21)	125 fewer per 1000 (from 232 fewer to 73 more)	⊕⊕⊕○ MODERATE	CRITICAL
Length of hospital stay (follow-up 10 days; Better indicated by lower values)												
2	randomised trials	very serious ¹	no serious inconsistency	no serious indirectness	serious ³	none	34	40	-	MD 1.67 higher (4.3 lower to 7.64 higher)	⊕○○○ VERY LOW	CRITICAL
Infected necrosis (follow-up 1-6 weeks)												
5	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	serious ³	none	23/136 (16.9%)	30.3%	RR 0.54 (0.35 to 0.84)	139 fewer per 1000 (from 48 fewer to 197 fewer)	⊕⊕⊕○ MODERATE	CRITICAL
Infected necrosis (Selective decontamination)												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	serious ³	none	9/50 (18%)	20/52 (38.5%)	RR 0.47 (0.24 to 0.93)	204 fewer per 1000 (from 27 fewer to 292 fewer)	⊕⊕⊕○ MODERATE	CRITICAL
Infected necrosis (Peri-pancreatic infection) (follow-up 5-14 days)												
2	randomised trials	serious ¹	serious ²	no serious indirectness	very serious ³	none	24/66 (36.4%)	39.5	RR 0.97 (0.66 to 1.41)	12 fewer per 1000 (from 134 fewer to 162 more)	⊕○○○ VERY LOW	IMPORTANT
Extra-pancreatic infection (follow-up 1-6 weeks)												
6	randomised trials	no serious risk of bias	very serious ²	no serious indirectness	very serious ³	none	33/175 (18.9%)	40.5%	RR 0.47 (0.17 to 1.26)	215 fewer per 1000 (from 336 fewer to 105 more)	⊕○○○ VERY LOW	IMPORTANT

Extra-pancreatic infection (Blood culture positive sepsis) (follow-up 14 days)												
1	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	very serious ³	none	4/30 (13.3%)	8/30 (26.7%)	RR 0.5 (0.17 to 1.48)	133 fewer per 1000 (from 221 fewer to 128 more)	⊕○○○ VERY LOW	IMPORTANT
Extra-pancreatic infection (Pneumonia/ARDS) (follow-up 14 days)												
1	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	serious ³	none	11/30 (36.7%)	17/30 (56.7%)	RR 0.65 (0.37 to 1.14)	198 fewer per 1000 (from 357 fewer to 79 more)	⊕⊕○○ LOW	IMPORTANT
Extra-pancreatic infection (Urinary tract infection) (follow-up 14 days)												
1	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	serious ³	none	6/30 (20%)	17/30 (56.7%)	RR 0.35 (0.16 to 0.77)	368 fewer per 1000 (from 130 fewer to 476 fewer)	⊕⊕○○ LOW	IMPORTANT
Serious adverse events (Multiorgan failure) (follow-up 1-6 weeks)												
4	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	serious ³	none	47/117 (40.2%)	39.4%	RR 0.93 (0.73 to 1.2)	28 fewer per 1000 (from 106 fewer to 79 more)	⊕⊕⊕○ MODERATE	IMPORTANT
Serious adverse events (major organ complications) <6 months												
1	randomised trials	very serious ¹	no serious inconsistency	no serious indirectness	very serious ³	none	5/25 (20%)	11/33 (33.3%)	RR 0.6 (0.24 to 1.51)	133 fewer per 1000 (from 253 fewer to 170 more)	⊕○○○ VERY LOW	IMPORTANT

¹ Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

² Downgraded by 1 or 2 increments because of heterogeneity unexplained by subgroup analysis

³ Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

J.11.2 Clinical evidence profile: Antibiotic prophylaxis versus placebo

Quality assessment	No of patients	Effect	Quality	Importance

No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Antibiotic therapy	Placebo	Relative (95% CI)	Absolute		
Mortality (follow-up 10-42 days)												
3	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	17/130 (13.1%)	10.5%	RR 1.09 (0.58 to 2.08)	9 more per 1000 (from 44 fewer to 113 more)	⊕○○○ VERY LOW	CRITICAL
Infected necrosis (follow-up 10-42 days)												
3	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	24/120 (20%)	15%	RR 1.18 (0.7 to 2)	27 more per 1000 (from 45 fewer to 150 more)	⊕○○○ VERY LOW	CRITICAL
Extra-pancreatic infection (follow-up 10-42 days)												
3	randomised trials	no serious risk of bias ¹	no serious inconsistency	no serious indirectness	serious ²	none	35/130 (26.9%)	36.4%	RR 0.77 (0.53 to 1.11)	84 fewer per 40 (from 171 fewer to 40 more)	⊕⊕⊕○ MODERATE	IMPORTANT
Serious adverse events <6 months (follow-up 42 days)												
1	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	6/50 (12%)	9/50 (18%)	RR 0.67 (0.26 to 1.73)	59 fewer per 1000 (from 133 fewer to 131 more)	⊕○○○ VERY LOW	IMPORTANT
Serious adverse events (Pulmonary insufficiency) (follow-up 21 days)												
1	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	26/58 (44.8%)	25/55 (45.5%)	RR 0.99 (0.66 to 1.48)	5 fewer per 1000 (from 155 fewer to 218 more)	⊕○○○ VERY LOW	IMPORTANT
Serious adverse events (Renal insufficiency) (follow-up 21 days)												
1	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	7/58 (12.1%)	6/55 (10.9%)	RR 1.11 (0.4 to 3.09)	12 more per 1000 (from 65 fewer to 228 more)	⊕○○○ VERY LOW	IMPORTANT
Serious adverse events (Shock) (follow-up 21 days)												
1	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	5/58 (8.6%)	7/55 (12.7%)	RR 0.68 (0.23 to 2.01)	41 fewer per 1000 (from 98 fewer to 129 more)	⊕○○○ VERY LOW	IMPORTANT
Serious adverse events (SIRS) (follow-up 21 days)												
1	randomised	serious ¹	no serious	no serious	serious ²	none	31/58	24/55	RR 1.22	96 more per 1000 (from	⊕⊕○○	IMPORTANT

	trials		inconsistency	indirectness			(53.4%)	(43.6%)	(0.83 to 1.8)	74 fewer to 349 more)	LOW	
Serious adverse event (multiorgan failure)												
1	randomised trials	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	13/22 (59.1%)	10/19 (52.6%)	RR 1.12 (0.65 to 1.95)	63 more per 1000 (from 184 fewer to 500 more)	⊕○○○ VERY LOW	IMPORTANT
Colonisation by resistant organism <6 months (follow-up 42 days)												
1	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	5/40 (12.5%)	2/40 (5%)	RR 2.5 (0.51 to 12.14)	75 more per 1000 (from 25 fewer to 557 more)	⊕○○○ VERY LOW	IMPORTANT

¹ Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

² Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

J.11.3 Clinical evidence profile: Prophylactic antimicrobial therapy versus other prophylactic antimicrobial therapy (Same class; Carbapenems)

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Meropenem	Imipenem	Relative (95% CI)	Absolute		
Mortality (follow-up 14 days)												
1	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	12/88 (13.6%)	10/88 (11.4%)	RR 1.2 (0.55 to 2.63)	23 more per 1000 (from 51 fewer to 185 more)	⊕○○○ VERY LOW	CRITICAL
Infected necrosis (follow-up 14 days)												
1	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	10/88 (11.4%)	12/88 (13.6%)	RR 0.83 (0.38 to 1.83)	23 fewer per 1000 (from 85 fewer to 113 more)	⊕○○○ VERY LOW	CRITICAL
Extra-pancreatic infection (follow-up 14 days)												
1	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	19/88 (21.6%)	21/88 (23.9%)	RR 0.9 (0.52 to 1.56)	24 fewer per 1000 (from 115 fewer to 134 more)	⊕○○○ VERY	IMPORTANT

											LOW	
Serious adverse event (Multiorgan failure) (follow-up 14 days)												
1	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	6/88 (6.8%)	8/88 (9.1%)	RR 0.75 (0.27 to 2.07)	23 fewer per 1000 (from 66 fewer to 97 more)	⊕○○○ VERY LOW	IMPORTANT

¹ Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

² Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

J.11.4 Prophylactic antimicrobial therapy versus other prophylactic antimicrobial therapy (Different class; Quinolones versus carbapenems)

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Pefloxacin	Imipenem	Relative (95% CI)	Absolute		
Mortality (follow-up 2 weeks)												
1	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	5/30 (16.7%)	3/30 (10%)	RR 1.67 (0.44 to 6.36)	67 more per 1000 (from 56 fewer to 536 more)	⊕○○○ VERY LOW	CRITICAL
Infected necrosis (follow-up 2 weeks)												
1	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	10/30 (33.3%)	3/30 (10%)	RR 3.33 (1.02 to 10.92)	233 more per 1000 (from 2 more to 992 more)	⊕⊕○○ LOW	CRITICAL
Extra-pancreatic infection (follow-up 2 weeks)												
1	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	13/30 (43.3%)	6/30 (20%)	RR 2.17 (0.95 to 4.94)	234 more per 1000 (from 10 fewer to 788 more)	⊕⊕○○ LOW	IMPORTANT

¹ Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

² Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

J.12 Methods of management of infected necrosis in people with acute pancreatitis

J.12.1 Clinical evidence profile: Minimally invasive surgery versus open surgery

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Minimally invasive surgery	Open surgery	Relative (95% CI)	Absolute		
Mortality (follow-up during admission)												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	very serious ¹	none	8/43 (18.6%)	7/45 (15.6%)	RR 1.2 (0.47 to 3.01)	31 more per 1000 (from 82 fewer to 313 more)	⊕⊕⊕⊕ LOW	CRITICAL
Enterocutaneous fistula or perforation of a visceral organ requiring intervention (follow-up during admission)												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	very serious ¹	none	6/43 (14%)	10/45 (22.2%)	RR 0.63 (0.25 to 1.58)	82 fewer per 1000 (from 167 fewer to 129 more)	⊕⊕⊕⊕ LOW	IMPORTANT
Intraabdominal bleeding (follow-up during admission)												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	very serious ¹	none	7/43 (16.3%)	10/45 (22.2%)	RR 0.73 (0.31 to 1.75)	60 fewer per 1000 (from 153 fewer to 167 more)	⊕⊕⊕⊕ LOW	IMPORTANT
Multiple organ failure (follow-up during admission)												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	no serious imprecision	none	5/43 (11.6%)	18/45 (40%)	RR 0.29 (0.12 to 0.71)	284 fewer per 1000 (from 116 fewer to 352 fewer)	⊕⊕⊕⊕ HIGH	IMPORTANT
Multiple systemic complications (follow-up during admission)												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	serious ¹	none	0/43 (0%)	1/45 (2.2%)	RR 0.35 (0.01 to 8.33)	14 fewer per 1000 (from 22 fewer to 163 more)	⊕⊕⊕⊕ MODERATE	IMPORTANT

New onset multiple organ failure (follow-up during admission)												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	no serious imprecision	none	5/43 (11.6%)	19/45 (42.2%)	RR 0.28 (0.11 to 0.67)	304 fewer per 1000 (from 139 fewer to 376 fewer)	⊕⊕⊕⊕ HIGH	IMPORTANT
New onset diabetes (follow-up during admission)												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	serious ¹	none	7/43 (16.3%)	17/45 (37.8%)	RR 0.43 (0.2 to 0.93)	215 fewer per 1000 (from 26 fewer to 302 fewer)	⊕⊕⊕○ MODERATE	IMPORTANT
Use of pancreatic enzymes (follow-up during admission)												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	no serious imprecision	none	3/43 (7%)	15/45 (33.3%)	RR 0.21 (0.07 to 0.67)	263 fewer per 1000 (from 110 fewer to 310 fewer)	⊕⊕⊕⊕ HIGH	IMPORTANT

¹ Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

² Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

J.12.2 Clinical evidence profile: Minimally invasive surgery (endoscopic) versus open surgery

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Endoscopic	Open	Relative (95% CI)	Absolute		
Mortality (follow-up during admission)												
1	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	No serious imprecision	none	11/127 (8.7%)	34/127 (26.8%)	RR 0.32 (0.18 to 0.58)	182 fewer per 1000 (from 182 fewer to 220 fewer) ²	⊕○○○ VERY LOW	CRITICAL

¹ Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

² Absolute risk not adjusted for paired data

J.12.3 Clinical evidence profile: Minimally invasive surgery (endoscopic) versus minimally invasive surgery (percutaneous)

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Endoscopic	Percutaneous	Relative (95% CI)	Absolute		
Mortality (follow-up during admission)												
1	randomised trials	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	3/11 (27.3%)	3/13 (23.1%)	RR 1.18 (0.3 to 4.72)	42 more per 1000 (from 162 fewer to 858 more)	⊕000 VERY LOW	CRITICAL
Length of stay (hospital) (Better indicated by lower values) (follow-up during admission)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	11	13	-	MD 26 lower (50.96 to 1.04 lower)	⊕000 VERY LOW	CRITICAL
Length of stay (CCU) (Better indicated by lower values) (follow-up during admission)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	11	13	-	MD 8 lower (20.44 lower to 4.44 higher)	⊕000 VERY LOW	CRITICAL
Complications (new-onset organ failure) (follow-up during admission)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	2/11 (18.2%)	2/13 (15.4%)	RR 1.18 (0.2 to 7.06)	28 more per 1000 (from 123 fewer to 932 more)	⊕000 VERY LOW	CRITICAL
Complications (multiple organ failure) (follow-up during admission)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	1/11 (9.1%)	0/13 (0%)	Peto OR 8.86 (0.17 to 452.79)	91 more per 1000 (from 120 fewer to 302 more) ³	⊕000 VERY LOW	CRITICAL
Complications (upper gastrointestinal bleeding) (follow-up during admission)												

1	observational studies	very serious ²	no serious inconsistency	no serious indirectness	very serious ²	none	1/11 (9.1%)	0/13 (0%)	Peto OR 8.86 (0.17 to 452.79)	91 more per 1000 (from 120 fewer to 302 more) ³	⊕○○○ VERY LOW	CRITICAL
Complications (intra-abdominal bleeding requiring intervention) (follow-up during admission)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	1/11 (9.1%)	2/13 (15.4%)	RR 0.59 (0.06 to 5.68)	63 fewer per 1000 (from 145 fewer to 720 more)	⊕○○○ VERY LOW	CRITICAL
Complications (enterocutaneous fistula or perforation) (follow-up during admission)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	1/11 (9.1%)	5/13 (38.5%)	RR 0.24 (0.03 to 1.73)	292 fewer per 1000 (from 373 fewer to 281 more)	⊕○○○ VERY LOW	CRITICAL
Complications (Pancreatic fistula) (follow-up during admission)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	0/11 (0%)	1/13 (7.7%)	OR 0.16 (0 to 8.06)	64 fewer per 1000 (from 77 fewer to 325 more)	⊕○○○ VERY LOW	CRITICAL

¹ Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

² Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

³ Risk difference calculated in Review Manager

J.12.4 Clinical evidence profile: Endoscopic step-up compared to minimally-invasive surgical step-up approach

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Endoscopic step-up	Surgical step-up	Relative (95% CI)	Absolute		
Mortality (follow-up 6 months)												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	very serious ¹	none	9/51 (17.6%)	12.8%	RR 1.38 (0.53 to 3.59)	49 more per 1000 (from 60 fewer to 332 more)	⊕⊕○○ LOW	CRITICAL
Length of hospital stay (follow-up 6 months; Better indicated by lower values)												

1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	serious ¹	none	51	47	-	MD 16 lower (32.86 lower to 0.86 higher)	⊕⊕⊕⊕ MODERATE	CRITICAL
Complications - Bleeding requiring reintervention (follow-up 6 months)												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	very serious ¹	none	11/51 (21.6%)	21.3%	RR 1.01 (0.47 to 2.17)	2 more per 1000 (from 113 fewer to 249 more)	⊕⊕⊕⊕ LOW	IMPORTANT
Complications - New onset multiple organ failure (follow-up 6 months)												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	very serious ¹	none	2/51 (3.9%)	12.8%	RR 0.31 (0.07 to 1.45)	88 fewer per 1000 (from 119 fewer to 58 more)	⊕⊕⊕⊕ LOW	IMPORTANT
Complications - New onset single organ failure (follow-up 6 months)												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	serious ¹	none	7/51 (13.7%)	27.7%	RR 0.5 (0.22 to 1.14)	139 fewer per 1000 (from 216 fewer to 39 more)	⊕⊕⊕⊕ MODERATE	IMPORTANT
Complications - Pancreatic fistula (follow-up 6 months)												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	no serious imprecision	none	2/42 (4.8%)	31.7%	RR 0.15 (0.04 to 0.62)	269 fewer per 1000 (from 120 fewer to 304 fewer)	⊕⊕⊕⊕ HIGH	IMPORTANT
Complications - Perforation of visceral organ or enterocutaneous fistula requiring intervention (follow-up 6 months)												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	very serious ¹	none	4/51 (7.8%)	17%	RR 0.46 (0.15 to 1.43)	92 fewer per 1000 (from 145 fewer to 73 more)	⊕⊕⊕⊕ LOW	IMPORTANT
Pancreatic function - Endocrine insufficiency (follow-up 6 months)												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	very serious ¹	none	10/42 (23.8%)	22%	RR 1.08 (0.49 to 2.39)	18 more per 1000 (from 112 fewer to 306 more)	⊕⊕⊕⊕ LOW	IMPORTANT
Pancreatic function - Exocrine insufficiency (follow-up 6 months)												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	very serious ¹	none	22/42 (52.4%)	46.3%	RR 1.13 (0.73 to 1.75)	60 more per 1000 (from 125 fewer to 347 more)	⊕⊕⊕⊕ LOW	IMPORTANT

¹ Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

J.12.5 Clinical evidence profile: Dual modality drainage versus percutaneous drainage

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Dual modality drainage	Percutaneous drainage	Relative (95% CI)	Absolute		
Mortality (follow-up during admission)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	2/49 (4.1%)	3/45 (6.7%)	RR 0.61 (0.11 to 3.5)	26 fewer per 1000 (from 59 fewer to 167 more)	⊕○○○ VERY LOW	CRITICAL
Length of stay in hospital (Better indicated by lower values) (follow-up during admission)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	49	45	-	MD 30 lower (43.6 to 16.4 lower)	⊕○○○ VERY LOW	CRITICAL
Pseudoaneurysm (follow-up during admission)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	0/49 (0%)	5/45 (11.1%)	Peto OR 0.11 (0.02 to 0.68)	98 fewer per 1000 (from 33 fewer to 109 fewer)	⊕○○○ VERY LOW	IMPORTANT

¹ Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

² Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

J.12.6 Clinical evidence profile: Minimally invasive surgery versus open surgery

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Minimally invasive surgery	Open surgery	Relative (95% CI)	Absolute		

Mortality (follow-up unclear)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	2/18 (11.1%)	34/88 (38.6%)	RR 0.29 (0.08 to 1.09)	274 fewer per 1000 (from 355 fewer to 35 more)	⊕○○○ VERY LOW	CRITICAL
Mortality (follow-up during admission)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	64/334 (19.2%)	80/335 (23.9%)	RR 0.75 (0.57 to 0.98)	60 fewer per 1000 (from 5 fewer to 103 fewer) ³	⊕○○○ VERY LOW	CRITICAL
Complications (Bleeding) (follow-up unclear)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	3/18 (16.7%)	30/88 (34.1%)	RR 0.49 (0.17 to 1.43)	174 fewer per 1000 (from 283 fewer to 147 more)	⊕○○○ VERY LOW	IMPORTANT
Complications (Bowel perforation) (follow-up unclear)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	3/18 (16.7%)	18/88 (20.5%)	RR 0.81 (0.27 to 2.48)	39 fewer per 1000 (from 149 fewer to 303 more)	⊕○○○ VERY LOW	IMPORTANT
Number of procedures (Reintervention) (follow-up unclear)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	12/18 (66.7%)	64/88 (72.7%)	RR 0.92 (0.65 to 1.3)	58 fewer per 1000 (from 255 fewer to 218 more)	⊕○○○ VERY LOW	IMPORTANT

¹ Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

² Absolute risk not adjusted for paired data

³ Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

J.12.7 Clinical evidence profile: Step-up approach versus open surgery

Quality assessment							No of patients		Effect		Quality	Importance
No of	Design	Risk of	Inconsistency	Indirectness	Imprecision	Other	Step-up	Open	Relative	Absolute		

studies		bias				considerations	approach	surgery	(95% CI)			
Mortality (follow-up during admission)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	20/190 (10.5%)	10/30 (33.3%)	RR 0.32 (0.16 to 0.61)	227 fewer per 1000 (from 130 fewer to 280 fewer)	⊕○○○ VERY LOW	CRITICAL
Severe complication (Sepsis, persistent MODS or erosion bleeding) (follow-up during admission)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	85/190 (44.7%)	25/30 (83.3%)	RR 0.54 (0.43 to 0.67)	383 fewer per 1000 (from 275 fewer to 475 fewer)	⊕○○○ VERY LOW	IMPORTANT
Emergence of type 3c diabetes (follow-up during admission)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	9/190 (4.7%)	10/30 (33.3%)	RR 0.14 (0.06 to 0.32)	287 fewer per 1000 (from 227 fewer to 313 fewer)	⊕○○○ VERY LOW	IMPORTANT

¹ Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

J.12.8 Clinical evidence profile: Focused open necrosectomy versus conventional open necrosectomy

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Focused open necrosectomy	Conventional open necrosectomy	Relative (95% CI)	Absolute		
Mortality (follow-up during admission)												
1	randomised trials	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	2/31 (6.5%)	5/39 (12.8%)	RR 0.5 (0.1 to 2.42)	64 fewer per 1000 (from 115 fewer to 182 more)	⊕○○○ VERY LOW	CRITICAL
Intestinal fistulae (follow-up during admission)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	4/31 (12.9%)	3/39 (7.7%)	RR 1.68 (0.41 to)	52 more per 1000 (from 45 fewer to)	⊕○○○ VERY	IMPORTANT

												6.94)	457 more)	LOW	
Pancreatic fistulae (follow-up during admission)															
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	4/31 (12.9%)	5/39 (12.8%)	RR 1.01 (0.29 to 3.43)	1 more per 1000 (from 91 fewer to 312 more)	⊕○○○ VERY LOW	IMPORTANT			
Repeat necrosectomy (follow-up during admission)															
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	8/31 (25.8%)	18/39 (46.2%)	RR 0.56 (0.28 to 1.11)	203 fewer per 1000 (from 332 fewer to 51 more)	⊕○○○ VERY LOW	IMPORTANT			

¹ Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

² Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

J.12.9 Clinical evidence profile: Percutaneous drainage versus laparotomy plus necrosectomy plus active drainage

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	PCD	Lap + Nec + Active drainage	Relative (95% CI)	Absolute		
Mortality (follow-up perioperative)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	1/10 (10%)	1/5 (20%)	RR 0.5 (0.04 to 6.44)	100 fewer per 1000 (from 192 fewer to 1000 more)	⊕○○○ VERY LOW	CRITICAL
Complications (Wound infection, haemorrhage at surgical site, pancreatic fistula, intestinal fistula) (follow-up perioperative)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	2/10 (20%)	5/5 (100%)	RR 0.25 (0.08 to 0.76)	750 fewer per 1000 (from 240 fewer to 920 fewer)	⊕○○○ VERY LOW	IMPORTANT

¹ Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

² Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

J.12.10 Clinical evidence profile: Percutaneous drainage versus laparotomy plus necrosectomy plus passive drainage

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	PCD	Lap + Nec + Passive drainage	Relative (95% CI)	Absolute		
Mortality (follow-up perioperative)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	1/10 (10%)	5/7 (71.4%)	RR 0.14 (0.02 to 0.95)	614 fewer per 1000 (from 36 fewer to 700 fewer)	⊕○○○ VERY LOW	CRITICAL
Complications (Wound infection, haemorrhage at surgical site, pancreatic fistula, intestinal fistula) (follow-up perioperative)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	2/10 (20%)	7/7 (100%)	RR 0.24 (0.08 to 0.73)	760 fewer per 1000 (from 270 fewer to 920 fewer)	⊕○○○ VERY LOW	IMPORTANT

¹ Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

² Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

J.12.11 Clinical evidence profile: Percutaneous drainage plus VARD versus laparotomy plus necrosectomy plus active drainage

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	PCD + VARD	Lap + Nec + AD	Relative (95% CI)	Absolute		
Mortality (follow-up perioperative)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	very serious ³	none	2/12 (16.7%)	1/5 (20%)	RR 0.83 (0.1 to 7.24)	34 fewer per 1000 (from 180 fewer to 1000 more)	⊕○○○ VERY LOW	CRITICAL
Complications (Wound infection, haemorrhage at surgical site, pancreatic fistula, intestinal fistula) (follow-up perioperative)												

1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	6/12 (50%)	5/5 (100%)	RR 0.55 (0.3 to 0.99)	450 fewer per 1000 (from 10 fewer to 700 fewer)	⊕○○○ VERY LOW	IMPORTANT
---	-----------------------	---------------------------	--------------------------	-------------------------	----------------------	------	------------	------------	-----------------------	---	------------------	-----------

¹ Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

² Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

J.12.12 Clinical evidence profile: Percutaneous drainage plus VARD versus laparotomy plus necrosectomy plus passive drainage

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	PCD + VARD	Lap + Nec + PD	Relative (95% CI)	Absolute		
Mortality (follow-up perioperative)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	2/12 (16.7%)	5/7 (71.4%)	RR 0.23 (0.06 to 0.9)	550 fewer per 1000 (from 71 fewer to 671 fewer)	⊕○○○ VERY LOW	CRITICAL
Complications (Wound infection, haemorrhage at surgical site, pancreatic fistula, intestinal fistula) (follow-up perioperative)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	6/12 (50%)	7/7 (100%)	RR 0.53 (0.3 to 0.95)	470 fewer per 1000 (from 50 fewer to 700 fewer)	⊕○○○ VERY LOW	IMPORTANT

¹ Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

² Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

J.12.13 Clinical evidence profile: Percutaneous drainage plus VARD versus percutaneous drainage

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	PCD + VARD	PCD	Relative (95% CI)	Absolute		
Mortality (follow-up perioperative)												

1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	2/12 (16.7%)	1/10 (10%)	RR 1.67 (0.18 to 15.8)	67 more per 1000 (from 82 fewer to 1000 more)	⊕○○○ VERY LOW	CRITICAL
Complications (Wound infection, haemorrhage at surgical site, pancreatic fistula, intestinal fistula) (follow-up perioperative)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	6/12 (50%)	2/10 (20%)	RR 2.5 (0.64 to 9.77)	300 more per 1000 (from 72 fewer to 1000 more)	⊕○○○ VERY LOW	IMPORTANT

¹ Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

² Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

J.12.14 Clinical evidence profile: Percutaneous drainage versus laparotomy

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Percutaneous drainage	Laparotomy	Relative (95% CI)	Absolute		
Mortality (follow-up during admission)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	1/15 (6.7%)	6/15 (40%)	RR 0.17 (0.02 to 1.22)	332 fewer per 1000 (from 392 fewer to 88 more)	⊕○○○ VERY LOW	CRITICAL
Bleeding (follow-up during admission)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	4/15 (26.7%)	1/15 (6.7%)	RR 4 (0.5 to 31.74)	200 more per 1000 (from 33 fewer to 1000 more)	⊕○○○ VERY LOW	IMPORTANT
Bowel perforation (follow-up during admission)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	1/15 (6.7%)	2/15 (13.3%)	RR 0.5 (0.05 to 4.94)	67 fewer per 1000 (from 127 fewer to 525 more)	⊕○○○ VERY LOW	IMPORTANT
GI fistulas (follow-up during admission)												

1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	1/15 (6.7%)	3/15 (20%)	RR 0.33 (0.04 to 2.85)	134 fewer per 1000 (from 192 fewer to 370 more)	⊕○○○ VERY LOW	IMPORTANT
Pancreatic fistulas (follow-up during admission)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	2/15 (13.3%)	0/15 (0%)	Peto OR 7.94 (0.47 to 133.26)	-	⊕○○○ VERY LOW	IMPORTANT
Further necrosectomy (follow-up during admission)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	11/15 (73.3%)	13/15 (86.7%)	RR 0.85 (0.59 to 1.22)	130 fewer per 1000 (from 355 fewer to 191 more)	⊕○○○ VERY LOW	IMPORTANT

¹ Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

² Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

J.12.15 Minimally invasive surgery (direct endoscopic necrosectomy) versus step-up approach

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Minimally invasive surgery	Step-up approach	Relative (95% CI)	Absolute		
Mortality (follow-up during admission)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	0/12 (0%)	0/12 (0%)	Not estimable	No events	⊕○○○ VERY LOW	CRITICAL
Floor length of stay (Better indicated by lower values) (follow-up during admission)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	12	12	-	MD 18.3 lower (22.07 to 14.53)	⊕○○○ VERY	IMPORTANT

										lower)	LOW	
Complications (follow-up during admission)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	1/12 (8.3%)	8/12 (66.7%)	RR 0.13 (0.02 to 0.85)	580 fewer per 1000 (from 100 fewer to 653 fewer)	⊕○○○ VERY LOW	IMPORTANT
Number of procedures (Better indicated by lower values) (follow-up during admission)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	12	12	-	MD 1.3 lower (1.5 to 1.1 lower)	⊕○○○ VERY LOW	IMPORTANT
Pancreatic function (new exocrine insufficiency) (follow-up during admission)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	3/12 (25%)	5/12 (41.7%)	RR 0.6 (0.18 to 1.97)	167 fewer per 1000 (from 342 fewer to 404 more)	⊕○○○ VERY LOW	IMPORTANT
Pancreatic function (new endocrine insufficiency) (follow-up during admission)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	0/12 (0%)	7/12 (58.3%)	Peto OR 0.07 (0.01 to 0.37)	494 fewer per 1000 (from 242 fewer to 570 fewer)	⊕○○○ VERY LOW	IMPORTANT

¹ Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

² Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

J.13 Timing of management of infected necrosis in people with acute pancreatitis

J.13.1 Clinical evidence profile: late intervention versus early intervention

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Late intervention	Early intervention	Relative (95% CI)	Absolute		

OF: Mortality												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	3/21 (14.3%)	23/61 (37.7%)	RR 0.38 (0.13 to 1.13)	234 fewer per 1000 (from 328 fewer to 49 more)	⊕○○○ VERY LOW	CRITICAL
OF: Number of procedures (Re-intervention)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	2/21 (9.5%)	17/61 (27.9%)	RR 0.34 (0.09 to 1.36)	184 fewer per 1000 (from 254 fewer to 100 more)	⊕○○○ VERY LOW	IMPORTANT
OF: Complications (Intra-abdominal bleeding)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	5/21 (23.8%)	24/61 (39.3%)	RR 0.61 (0.26 to 1.38)	153 fewer per 1000 (from 291 fewer to 150 more)	⊕○○○ VERY LOW	IMPORTANT
OF: Complications (Enterocutaneous fistula)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	3/21 (14.3%)	6/61 (9.8%)	RR 1.45 (0.40 to 5.30)	44 more per 1000 (from 59 fewer to 423 more)	⊕○○○ VERY LOW	IMPORTANT
OF: Complications (New-onset organ failure)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	6/21 (28.6%)	16/61 (26.2%)	RR 1.09 (0.49 to 2.42)	24 more per 1000 (from 134 fewer to 372 more)	⊕○○○ VERY LOW	IMPORTANT
NOF: Mortality												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	6/66 (9.1%)	5/75 (6.7%)	RR 1.36 (0.44 to 4.26)	24 more per 1000 (from 37 fewer to 217 more)	⊕○○○ VERY LOW	CRITICAL
NOF: Number of procedures (Re-intervention)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	3/66 (4.5%)	7/75 (9.3%)	RR 0.49 (0.13 to 1.81)	48 fewer per 1000 (from 81 fewer to 76 more)	⊕○○○ VERY LOW	IMPORTANT
NOF: Complications (Intra-abdominal bleeding)												

1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	3/66 (4.5%)	3/75 (4%)	RR 1.14 (0.24 to 5.44)	6 more per 1000 (from 30 fewer to 178 more)	⊕○○○ VERY LOW	IMPORTANT
NOF: Complications (Enterocutaneous fistula)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	9/66 (13.6%)	6/75 (8%)	RR 1.7 (0.64 to 4.54)	56 more per 1000 (from 29 fewer to 283 more)	⊕○○○ VERY LOW	IMPORTANT
NOF: Complications (New-onset organ failure)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	1/66 (1.5%)	4/75 (5.3%)	RR 0.28 (0.03 to 2.48)	38 fewer per 1000 (from 52 fewer to 79 more)	⊕○○○ VERY LOW	IMPORTANT

¹ Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

² Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

J.14 Management of pain in people with chronic pancreatitis

J.14.1 Clinical evidence profile: Antioxidants versus placebo

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Antioxidant	Placebo	Relative (95% CI)	Absolute		
Quality of life (activities of daily living) - crossover trial (follow-up 10 weeks; range of scores: 0-120; Better indicated by higher values)												
1	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	13	13	-	MD 3.3 lower (10.3 lower to 3.7 higher)	⊕⊕○○ LOW	CRITICAL
Quality of life (EQ-5D) (follow-up 6 months; range of scores: 0-1; Better indicated by higher values)												
1	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	33	37	-	MD 0.04 higher (0.1 lower to 0.18 higher)	⊕○○○ VERY LOW	CRITICAL

Quality of life (EQ-5D VAS) (follow-up 6 months; range of scores: 0-100; Better indicated by higher values)												
1	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	33	37	-	MD 2.3 higher (6.5 lower to 11.1 higher)	⊕⊕⊕○ MODERATE	CRITICAL
Mortality (follow-up 6 months)												
1	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	0/76 (0%)	0/71 (0%)	-	0 fewer per 1000 (from 26 fewer to 26 more)	⊕⊕⊕○ MODERATE	CRITICAL
Pain (visual analogue scale score) (follow-up 6 weeks - 6 months; range of scores: 0-10; Better indicated by lower values)												
3	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	54	57	-	MD 0.27 lower (0.69 lower to 0.15 higher)	⊕⊕⊕○ MODERATE	CRITICAL
Pain (descriptive scale) (follow-up 10 weeks; range of scores: 0-5; Better indicated by lower values)												
1	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	13	13	-	MD 0.09 lower (0.29 lower to 0.11 higher)	⊕⊕○○ LOW	CRITICAL
Pain (numerical rating scale) (follow-up 10 weeks; range of scores: 0-10; Better indicated by lower values)												
1	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	13	13	-	MD 0.25 lower (0.72 lower to 0.22 higher)	⊕⊕○○ LOW	CRITICAL
Pain (reduction in pain medication) - Oral analgesic tablets per month (follow-up 6 months; Better indicated by higher values)												
1	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	71	56	-	MD 6.15 higher (3.02 to 9.28 higher)	⊕⊕⊕○ MODERATE	CRITICAL
Pain (reduction in pain medication) - parallel trials - Parenteral analgesic injections per month (follow-up 6 months; Better indicated by higher values)												
1	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	71	56	-	MD 0.7 higher (0.5 lower to 1.9 higher)	⊕⊕○○ LOW	CRITICAL
Pain (reduction in number of painful days per month) - parallel trials (follow-up 6 months; Better indicated by higher values)												
1	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	66	53	-	MD 4.16 higher (2.21 to 6.11 higher)	⊕⊕⊕○ MODERATE	CRITICAL
Pain-free participants (follow-up 1 day - 6 months)												

3	randomised trials	serious ¹	serious ³	no serious indirectness	serious ²	none	64/136 (47.1%)	31.4%	RR 1.73 (0.95 to 3.15)	229 more per 1000 (from 16 fewer to 675 more)	⊕○○○ VERY LOW	CRITICAL
Adverse effects (follow-up 10 weeks - 6 months)												
3	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	21/117 (17.9%)	5.4%	RR 3.44 (1.30 to 9.09)	132 more per 1000 (from 16 more to 437 more)	⊕⊕⊕○ MODERATE	CRITICAL
Adverse effects (follow-up 6 - 20 weeks)												
3	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	3/47 (6.4%)	0/46 (0%)	Peto OR 8.28 (0.81 to 84.88)	64 more per 1000 (from 15 fewer to 143 more)	⊕○○○ VERY LOW	CRITICAL

¹ Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

² Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs

³ Downgraded by 1 or 2 increments because heterogeneity, I²=71%, p= >0.1, unexplained by subgroup analysis

J.14.2 Clinical evidence profile: Enzyme replacement therapy versus placebo

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Enzyme replacement therapy	Placebo	Relative (95% CI)	Absolute		
Pain (People experiencing long-lasting (>12 hour) pain attacks) (follow-up 4 months)												
1	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	14/22 (63.6%)	11/22 (50%)	RR 1.27 (0.75 to 2.15)	135 more per 1000 (from 125 fewer to 575 more)	⊕⊕○○ LOW	CRITICAL
Pain (Use of analgesics) (follow-up 4 months)												
1	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	10/22 (45.5%)	5/22 (22.7%)	RR 2 (0.82 to 4.9)	227 more per 1000 (from 41 fewer to 886 more)	⊕⊕○○ LOW	CRITICAL

Pain (Pain score) (follow-up 2 weeks; Better indicated by lower values)												
1	randomised trials	very serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	47	47	-	MD 0.18 lower (25.63 lower to 25.27 higher)	⊕⊕⊕⊕ LOW	CRITICAL

¹ Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

² Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

J.15 Management of pancreatic duct obstruction in people with chronic pancreatitis

J.15.1 Clinical evidence profile: ESWL and endotherapy versus surgery

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	ESWL plus endotherapy	Surgery	Relative (95% CI)	Absolute		
QoL (SF-36; Mental health component at 2 years) (follow-up 2 years; Better indicated by lower values)												
1	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	19	20	-	MD 5 lower (10.65 lower to 0.65 higher)	⊕⊕⊕⊕ LOW	CRITICAL
QoL (SF-36; Mental health component at 7 years) (follow-up 7 years; Better indicated by lower values)												
1	randomised trials	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	15	15	-	MD 2 lower (8.81 lower to 4.81 higher)	⊕⊕⊕⊕ VERY LOW	CRITICAL
QoL (SF-36; Physical health component at 2 years) (follow-up 2 years; Better indicated by lower values)												
1	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	19	20	-	MD 9 lower (14.08 to 3.92 lower)	⊕⊕⊕⊕ LOW	CRITICAL
QoL (SF-36; Physical health component at 7 years) (follow-up 7 years; Better indicated by lower values)												
1	randomised trials	very serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	16	15	-	MD 5 lower (12.06 lower to 2.06 higher)	⊕⊕⊕⊕ VERY LOW	CRITICAL
Mortality (follow-up 2 years)												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	very serious ²	none	1/19 (5.3%)	0/20 (0%)	Peto OR 7.79 (0.15 to 393.02)	-	⊕⊕⊕⊕ LOW	CRITICAL
Pain (Pain relief at 2 years) (follow-up 2 years)												

1	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	6/19 (31.6%)	15/20 (75%)	RR 0.42 (0.21 to 0.86)	435 fewer per 1000 (from 105 fewer to 593 fewer)	⊕⊕○○ LOW	CRITICAL
Pain (Pain relief at 7 years) (follow-up 7 years)												
1	randomised trials	very serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	6/16 (37.5%)	12/15 (80%)	RR 0.47 (0.24 to 0.93)	424 fewer per 1000 (from 56 fewer to 608 fewer)	⊕○○○ VERY LOW	CRITICAL
Pain (Izbicki pain score at 2 years) (follow-up 2 years; Better indicated by lower values)												
1	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	19	20	-	MD 26 higher (13.75 to 38.25 higher)	⊕○○○ VERY LOW	CRITICAL
Pain (Izbicki pain score at 7 years) (follow-up 7 years; Better indicated by lower values)												
1	randomised trials	very serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	16	15	-	MD 17 higher (3.84 lower to 37.84 higher)	⊕○○○ VERY LOW	CRITICAL
Pancreatic function (Endocrine insufficiency developed at 2 years) (follow-up 2 years)												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	very serious ²	none	3/19 (15.8%)	1/20 (5%)	RR 3.16 (0.36 to 27.78)	108 more per 1000 (from 32 fewer to 1000 more)	⊕⊕○○ LOW	IMPORTANT
Pancreatic function (Endocrine insufficiency developed at 7 years) (follow-up 7 years)												
1	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	7/16 (43.8%)	3/15 (20%)	RR 2.19 (0.69 to 6.94)	238 more per 1000 (from 62 fewer to 1000 more)	⊕○○○ VERY LOW	IMPORTANT
Pancreatic function (Endocrine insufficiency persisted at 2 years) (follow-up 2 years)												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	very serious ²	none	3/19 (15.8%)	4/20 (20%)	RR 0.79 (0.2 to 3.07)	42 fewer per 1000 (from 160 fewer to 414 more)	⊕⊕○○ LOW	IMPORTANT
Pancreatic function (Endocrine insufficiency persisted at 7 years) (follow-up 7 years)												
1	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	4/16 (25%)	4/15 (26.7%)	RR 0.94 (0.28 to 3.09)	16 fewer per 1000 (from 192 fewer to 557 more)	⊕○○○ VERY LOW	IMPORTANT

Pancreatic function (Exocrine insufficiency developed at 2 years) (follow-up 2 years)												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	serious ²	none	6/19 (31.6%)	1/20 (5%)	RR 6.32 (0.84 to 47.69)	266 more per 1000 (from 8 fewer to 1000 more)	⊕⊕⊕⊕ MODERATE	IMPORTANT
Pancreatic function (Exocrine insufficiency developed at 7 years) (follow-up 7 years)												
1	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	6/16 (37.5%)	2/15 (13.3%)	RR 2.81 (0.67 to 11.83)	241 more per 1000 (from 44 fewer to 1000 more)	⊕⊕⊕⊕ VERY LOW	IMPORTANT
Pancreatic function (Exocrine insufficiency persisted at 2 years) (follow-up 2 years)												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	very serious ²	none	11/19 (57.9%)	13/20 (65%)	RR 0.89 (0.54 to 1.47)	72 fewer per 1000 (from 299 fewer to 306 more)	⊕⊕⊕⊕ LOW	IMPORTANT
Pancreatic function (Exocrine insufficiency persisted at 7 years) (follow-up 7 years)												
1	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	10/16 (62.5%)	11/15 (73.3%)	RR 0.85 (0.52 to 1.39)	110 fewer per 1000 (from 352 fewer to 286 more)	⊕⊕⊕⊕ VERY LOW	IMPORTANT

¹ Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias.

²Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

J.15.2 Clinical evidence profile: Endotherapy versus surgery

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Endotherapy	Surgery	Relative (95% CI)	Absolute		
Pain (Complete absence of abdominal pain) (follow-up 5 years)												

1	randomised trials	very serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	5/36 (13.9%)	12/36 (33.3%)	RR 0.42 (0.16 to 1.06)	193 fewer per 1000 (from 280 fewer to 20 more)	⊕○○○ VERY LOW	CRITICAL
Pain (Partial relief of abdominal pain) (follow-up 5 years)												
1	randomised trials	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	17/36 (47.2%)	19/36 (52.8%)	RR 0.89 (0.56 to 1.42)	58 fewer per 1000 (from 232 fewer to 222 more)	⊕○○○ VERY LOW	CRITICAL
Pancreatic function (New onset diabetes) (follow-up 5 years)												
1	randomised trials	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	12/36 (33.3%)	14/36 (38.9%)	RR 0.86 (0.46 to 1.59)	54 fewer per 1000 (from 210 fewer to 229 more)	⊕○○○ VERY LOW	IMPORTANT

¹ Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias.

² Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

J.15.3 Clinical evidence profile: ESWL versus ESWL and endotherapy

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	ESWL	ESWL plus endotherapy	Relative (95% CI)	Absolute		
Pain (Pain relapse at 2 years) (follow-up 2 years)												
1	randomised trials	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	10/24 (41.7%)	13/24 (54.2%)	RR 0.77 (0.42 to 1.4)	125 fewer per 1000 (from 314 fewer to 217 more)	⊕○○○ VERY LOW	CRITICAL
Pain (Pain intensity; VAS score) (follow-up mean 2 years; Better indicated by lower values)												
1	randomised trials	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	24	24	-	MD 0 higher (0.99 lower to 0.99 higher)	⊕○○○ VERY	CRITICAL

												LOW	
Length of hospital stay (Better indicated by lower values) (follow-up 2 years)													
1	randomised trials	very serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	24	24	-	MD 5.5 lower (12.43 lower to 1.43 higher)	⊕○○○ VERY LOW	IMPORTANT	
Procedure related complications (follow-up 1 month)													
1	randomised trials	very serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	0/24 (0%)	1/24 (4.2%)	Peto OR 0.14 (0 to 6.82)	36 fewer per 1000 (from 42 fewer to 187 more)	⊕○○○ VERY LOW	IMPORTANT	

¹ Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias.

² Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

J.16 Management of small-duct disease in people with chronic pancreatitis

J.16.1 Clinical evidence profile: VSPL versus NCPB

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	VSPL	NCPB	Relative (95% CI)	Absolute		
Pain (Use of opioids) (follow-up unclear)												
1	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	11/18 (61.1%)	17/30 (56.7%)	RR 1.08 (0.67 to 1.75)	45 more per 1000 (from 187 fewer to 425 more)	⊕○○○ VERY LOW	CRITICAL

¹ Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias.

² Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

J.17 Management of pseudocysts

J.17.1 Clinical evidence profile: Endoscopic drainage versus open surgical drainage or resection

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Endoscopic drainage	Surgical drainage or resection	Relative (95% CI)	Absolute		
Mortality (follow-up Median 4.7 months)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	0/41 (0%)	0/21 (0%)	-	- I	⊕000 VERY LOW	CRITICAL
Complications - Grade 2 or greater (follow-up 16 months)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	7/45 (15.6%)	5/22 (22.7%)	RR 0.68 (0.24 to 1.91)	73 fewer per 1000 (from 173 fewer to 207 more)	⊕000 VERY LOW	CRITICAL
Complications (follow-up unclear)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	1/10 (10%)	2/7 (28.6%)	RR 0.35 (0.04 to 3.15)	186 fewer per 1000 (from 274 fewer to 614 more)	⊕000 VERY LOW	CRITICAL
Complications (follow-up Median 4.7 months)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	9/41 (22%)	6/21 (28.6%)	RR 0.77 (0.32 to 1.87)	66 fewer per 1000 (from 194 fewer to 249 more)	⊕000 VERY LOW	CRITICAL
Resolution of presenting symptoms - Overall success rate (follow-up 16 months)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	38/45 (84.4%)	20/22 (90.9%)	RR 0.93 (0.77 to 1.11)	64 fewer per 1000 (from 209 fewer to 100 more)	⊕000 VERY LOW	CRITICAL

Resolution of presenting symptoms - Primary success rate (follow-up 16 months)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	16/45 (35.6%)	18/22 (81.8%)	RR 0.43 (0.28 to 0.67)	466 fewer per 1000 (from 270 fewer to 589 fewer)	⊕○○○ VERY LOW	CRITICAL
Recurrence of pseudocysts (follow-up 26 months)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	4/10 (40%)	1/7 (14.3%)	RR 2.8 (0.39 to 20.02)	257 more per 1000 (from 87 fewer to 1000 more)	⊕○○○ VERY LOW	CRITICAL
Length of hospital stay (days) (follow-up unclear; Better indicated by lower values)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	10	7	-	MD 8.2 lower (12.87 to 3.53 lower)	⊕○○○ VERY LOW	IMPORTANT
Repeated procedure (reintervention) (follow-up Median 4.7 months)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	9/41 (22%)	0/21 (0%)	Peto OR 5.7 (1.3 to 25.06)	220 more per 1000 (from 80 more to 360 more)	⊕○○○ VERY LOW	IMPORTANT

¹ Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

² Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

J.17.2 Clinical evidence profile: Combined endoscopic drainage and pancreatic endoscopic stent versus open surgical drainage

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Combined endoscopic drainage and pancreatic endoscopic stent	Surgical drainage	Relative (95% CI)	Absolute		
Mortality (follow-up unclear)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	0/24 (0%)	0/30	-	-	⊕○○○ VERY	CRITICAL

								0%			LOW	
Complications (follow-up unclear)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	5/24 (20.8%)	6/30 (20%)	RR 1.04 (0.36 to 3)	8 more per 1000 (from 128 fewer to 400 more)	⊕○○○ VERY LOW	CRITICAL
Complications (timing of exposure During admission)												
1	observational studies ³	serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	0 cases 0 controls		-	-	⊕○○○ VERY LOW	CRITICAL
								0%				
Complications - Overall complications (including wound infection, and haematemesis) (follow-up 24 months)												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	very serious ²	none	0/20 (0%)	2/20 (10%)	RR 0.2 (0.01 to 3.92)	80 fewer per 1000 (from 99 fewer to 292 more)	⊕⊕○○ LOW	CRITICAL
Resolution of pseudocysts (follow-up unclear)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	21/24 (87.5%)	28/30 (93.3%)	RR 0.94 (0.78 to 1.12)	56 fewer per 1000 (from 205 fewer to 112 more)	⊕○○○ VERY LOW	CRITICAL
Resolution of pseudocysts (timing of exposure 4-6 weeks)												
1	observational studies ³	serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	19 cases 10 controls		RR 0.97 (0.82 to 1.16)	30 fewer per 1000 (from 180 fewer to 160 more)	⊕○○○ VERY LOW	CRITICAL
								100%				
Resolution of presenting symptoms - Treatment success (resolution of symptoms at 4 weeks for surgery group; resolution or a decrease in the size of the fluid collection to 2 cm or smaller on CT with resolution of symptoms at 8 weeks) (follow-up 4-8 weeks)												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	no serious imprecision	none	19/20 (95%)	20/20 (100%)	RR 0.95 (0.83 to 1.09)	50 fewer per 1000 (from 170 fewer to 90 more)	⊕⊕⊕⊕ HIGH	CRITICAL

Recurrence (new onset abdominal pain in the presence of a pancreatic fluid collection on CT after resolution of the initial presentation) (follow-up 24 months)												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	very serious ²	none	0/20 (0%)	1/20 (5%)	RR 0.33 (0.01 to 7.72)	34 fewer per 1000 (from 49 fewer to 336 more)	⊕⊕⊕⊕ LOW	CRITICAL
Repeated procedures (reintervention) - Observational (timing of exposure during admission)												
1	observational studies ³	serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	0 cases 1 controls		RR 0.17 (0.01 to 3.94)	83 fewer per 1000 (from 99 fewer to 294 more)	⊕⊕⊕⊕ VERY LOW	IMPORTANT
								10%				
Repeated procedures (reintervention) - RCT (follow-up 24 months)												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	very serious ²	none	1/20 (5%)	1/20 (5%)	RR 1 (0.07 to 14.9)	0 fewer per 1000 (from 47 fewer to 695 more)	⊕⊕⊕⊕ LOW	IMPORTANT

¹ Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

² Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

³ case-control

J.17.3 Clinical evidence profile: Endoscopic drainage versus combination of open and laparoscopic surgical techniques

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Endoscopic drainage	Combination of open and laparoscopic surgical techniques	Relative (95% CI)	Absolute		
Mortality (follow-up ≤12 months)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	0/21 (0%)	1/43 (2.3%)	RR 0.67 (0.03 to 15.7)	8 fewer per 1000 (from 23 fewer to 342 more)	⊕⊕⊕⊕ VERY LOW	CRITICAL
Overall complications (including bleeding, infection, stent migration) (follow-up Median (IQR) follow-up: endoscopic 270 (30-1915); combination 580 (0-4320) days)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	5/21 (23.8%)	11/43 (25.6%)	RR 0.93 (0.37 to)	18 fewer per 1000 (from 161)	⊕⊕⊕⊕ VERY	CRITICAL

									2.33)	fewer to 340 more)	LOW	
Clinical success (complete resolution or decrease in the size of pseudocysts to 2cm or smaller on CT with associated resolution of symptoms). (follow-up 8 weeks)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	19/21 (90.5%)	39/43 (90.7%)	RR 1 (0.84 to 1.18)	0 fewer per 1000 (from 145 fewer to 163 more)	⊕○○○ VERY LOW	CRITICAL
Recurrence (pancreatic pseudocyst found on CT in association with symptoms after initial resolution) (follow-up Median (IQR) follow-up: endoscopic 270 (30-1915); combination 580 (0-4320) days)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	2/21 (9.5%)	2/43 (4.7%)	RR 2.05 (0.31 to 13.54)	49 more per 1000 (from 32 fewer to 583 more)	⊕○○○ VERY LOW	CRITICAL
Length of CCU stay (days) (follow-up Median (IQR) follow-up: endoscopic 270 (30-1915); combination 580 (0-4320) days; Better indicated by lower values)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	21	43	-	MD 1.21 lower (1.43 to 0.99 lower)	⊕○○○ VERY LOW	IMPORTANT

¹ Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

² Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

J.17.4 Clinical evidence profile: Endoscopic drainage versus laparoscopic drainage

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Endoscopic	Laparoscopic drainage	Relative (95% CI)	Absolute		
Complications (Grade 2 or greater) (follow-up 16 months)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	7/45 (15.6%)	4/16 (25%)	RR 0.62 (0.21 to 1.85)	95 fewer per 1000 (from 198 fewer to 213 more)	⊕○○○ VERY LOW	CRITICAL
Resolution of presenting symptoms or pseudocysts - Overall success rate (follow-up 16 months)												
1	observational	serious ¹	no serious	no serious	serious ²	none	38/45	15/16	RR 0.9 (0.75	94 fewer per 1000	⊕○○○	CRITICAL

	studies		inconsistency	indirectness			(84.4%)	(93.8%)	to 1.08)	(from 234 fewer to 75 more)	VERY LOW	
Resolution of presenting symptoms or pseudocysts - Primary success rate (follow-up 16 months)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	16/45 (35.6%)	14/16 (87.5%)	RR 0.41 (0.26 to 0.63)	516 fewer per 1000 (from 324 fewer to 648 fewer)	⊕○○○ VERY LOW	CRITICAL

¹ Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

² Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

J.17.5 Clinical evidence profile: Endoscopic drainage versus pancreatic endoscopic stent

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Endoscopic drainage	Pancreatic endoscopic stent	Relative (95% CI)	Absolute		
Significant complications (follow-up 3-10 days after stent insertion)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	0/4 (0%)	4/6 (66.7%)	RR 0.16 (0.01 to 2.28)	560 fewer per 1000 (from 660 fewer to 853 more)	⊕○○○ VERY LOW	CRITICAL
Resolution of pseudocysts (follow-up 4-8 weeks)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	4/4 (100%)	2/6 (33.3%)	RR 2.52 (0.89 to 7.1)	507 more per 1000 (from 37 fewer to 1000 more)	⊕○○○ VERY LOW	CRITICAL
Recurrence of pseudocysts (follow-up 16.4+/- 11.4 months)												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	0/4 (0%)	0/2 (0%)	-	-	⊕○○○ VERY LOW	CRITICAL

¹ Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

² Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

J.17.6 Clinical evidence profile: Endoscopic drainage versus standard treatment

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Endoscopic drainage	Standard treatment (observation)	Relative (95% CI)	Absolute		
Mortality (follow-up Median 4.7 months)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	0/41 (0%)	0/44 (0%)	-	-	⊕000 VERY LOW	CRITICAL
Complications (follow-up Median 4.7 months)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	9/41 (22%)	0/44 (0%)	Peto OR 9.89 (2.5 to 39.09)	220 more per 1000 (from 90 more to 350 more)	⊕000 VERY LOW	CRITICAL
Repeated procedure (reintervention) (follow-up Median 4.7 months)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	9/41 (22%)	0/44 (0%)	Peto OR 9.89 (2.5 to 39.09)	220 more per 1000 (from 90 more to 350 more)	⊕000 VERY LOW	IMPORTANT

¹ Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

J.17.7 Clinical evidence profile: Percutaneous versus surgical drainage or resection

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Percutaneous	Surgical drainage or resection	Relative (95% CI)	Absolute		
Mortality (follow-up unclear)												

1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	6/66 (9.1%)	0/66 (0%)	RR 8 (1.56 to 40.9)	90 more per 1000 (from 20 more to 160 more)	⊕○○○ VERY LOW	CRITICAL
Mortality (follow-up 4 years)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	479/8121 (5.9%)	179/6409 (2.8%)	RR 2.11 (1.78 to 2.5)	31 more per 1000 (from 22 more to 42 more)	⊕○○○ VERY LOW	CRITICAL
Mortality (follow-up Median 4.7 months)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	0/8 (0%)	0/21 (0%)	-	-	⊕○○○ VERY LOW	CRITICAL
Complications - Overall complications (follow-up unclear)												
1	observational studies	serious ¹	serious ³	no serious indirectness	very serious ²	none	2/4 (50%)	2/7 (28.6%)	RR 1.75 (0.38 to 8.06)	214 more per 1000 (from 177 fewer to 1000 more)	⊕○○○ VERY LOW	CRITICAL
Complications - Intra-abdominal abscess and bleeding requiring transfusion (follow-up 4 years)												
1	observational studies	serious ¹	serious ³	no serious indirectness	serious ²	none	1335/8121 (16.4%)	864/6409 (13.5%)	RR 1.22 (1.13 to 1.32)	30 more per 1000 (from 18 more to 43 more)	⊕○○○ VERY LOW	CRITICAL
Complications - Post-operative bleeding, infection or fistula (follow-up 10 years)												
1	observational studies	serious ¹	serious ³	no serious indirectness	serious ²	none	4/20 (20%)	2/3 (66.7%)	RR 0.3 (0.09 to 0.98)	467 fewer per 1000 (from 13 fewer to 607 fewer)	⊕○○○ VERY LOW	CRITICAL
Complications (follow-up Median 4.7 months)												
1	observational studies	serious ¹	serious ³	no serious indirectness	very serious ²	none	1/8 (12.5%)	6/21 (28.6%)	RR 0.44 (0.06 to 3.09)	160 fewer per 1000 (from 269 fewer to 597 more)	⊕○○○ VERY LOW	CRITICAL
Complications - Post-operative bleeding, infection or fistula (follow-up unclear)												
1	observational studies	serious ¹	serious ³	no serious indirectness	no serious imprecision	none	41/66	17/66	RR 2.41 (1.54 to 3.94)	363 more per 1000	⊕○○○ VERY LOW	CRITICAL

	studies			indirectness	imprecision ²		(62.1%)	(25.8%)	to 3.79)	(from 139 more to 719 more)	VERY LOW	
Resolution of pseudocyst or symptoms (follow-up unclear)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	33/66 (50%)	45/66 (68.2%)	RR 0.73 (0.55 to 0.98)	184 fewer per 1000 (from 14 fewer to 307 fewer)	⊕○○○ VERY LOW	CRITICAL
Recurrence of pseudocyst - Failure: radiographic persistence of a symptomatic pseudocyst in the observed group and a persistent symptomatic pseudocyst requiring a further procedure in the intervention groups (follow-up unclear)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	38/66 (57.6%)	8/66 (12.1%)	RR 4.75 (2.4 to 9.39)	455 more per 1000 (from 170 more to 1000 more)	⊕○○○ VERY LOW	CRITICAL
Recurrences (follow-up 10 years)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	15/20 (75%)	1/3 (33.3%)	RR 2.25 (0.45 to 11.37)	417 more per 1000 (from 183 fewer to 1000 more)	⊕○○○ VERY LOW	CRITICAL
Recurrence of pseudocyst - Recurrence of pseudocysts (follow-up 26 months)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	3/4 (75%)	1/7 (14.3%)	RR 5.25 (0.78 to 35.13)	607 more per 1000 (from 31 fewer to 1000 more)	⊕○○○ VERY LOW	CRITICAL
Length of hospital stay (follow-up unclear; Better indicated by lower values)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	66	66	-	MD 27 higher (25.7 to 28.3 higher)	⊕○○○ VERY LOW	IMPORTANT
Length of hospital stay (follow-up 4 years; Better indicated by lower values)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	8121	6409	-	MD 6 higher (5.4 to 6.6 higher)	⊕○○○ VERY LOW	IMPORTANT
Length of hospital stay (follow-up unclear; Better indicated by lower values)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	4	7	-	MD 2.2 lower (6.95 lower to 2.55 higher)	⊕○○○ VERY	IMPORTANT

												LOW	
Repeated procedure (reintervention) (follow-up Median 4.7 months)													
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	4/8 (50%)	0/21 (0%)	Peto OR 57.97 (5.69 to 590.19)	500 more per 1000 (from 170 more to 830 more)	⊕○○○ VERY LOW	IMPORTANT	

¹ Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
² Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.
³ Downgraded by 1 or 2 increments because the point estimate varies widely across studies, unexplained by subgroup analysis.

J.17.8 Clinical evidence profile: Percutaneous drainage versus endoscopic drainage

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Percutaneous drainage	Endoscopic drainage	Relative (95% CI)	Absolute		
Mortality (follow-up unclear)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	0/40 (0%)	0/41 (0%)	-	-	⊕○○○ VERY LOW	CRITICAL
Mortality (follow-up Median 4.7 months)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	0/8 (0%)	0/41 (0%)	-	-	⊕○○○ VERY LOW	CRITICAL
Complications (follow-up unclear)												
1	observational studies	serious ¹	serious ²	no serious indirectness	very serious ³	none	2/4 (50%)	1/10 (10%)	RR 5 (0.61 to 40.91)	400 more per 1000 (from 39 fewer to 1000 more)	⊕○○○ VERY LOW	CRITICAL
Complications (follow-up Median 4.7 months)												

1	observational studies	serious ¹	serious ²	no serious indirectness	very serious ³	none	1/8 (12.5%)	9/41 (22%)	RR 0.57 (0.08 to 3.89)	94 fewer per 1000 (from 202 fewer to 634 more)	⊕○○○ VERY LOW	CRITICAL
Procedural adverse events (follow-up unclear)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	very serious ³	none	6/40 (15%)	6/41 (14.6%)	RR 1.02 (0.36 to 2.91)	3 more per 1000 (from 94 fewer to 280 more)	⊕○○○ VERY LOW	CRITICAL
Recurrence of pseudocysts (follow-up 16 months)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	very serious ³	none	3/4 (75%)	4/10 (40%)	RR 1.88 (0.73 to 4.83)	352 more per 1000 (from 108 fewer to 1000 more)	⊕○○○ VERY LOW	CRITICAL
Length of hospital stay (follow-up unclear; Better indicated by lower values)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	40	41	-	MD 8.3 higher (3.39 to 13.21 higher)	⊕○○○ VERY LOW	IMPORTANT
Length of hospital stay (follow-up unclear; Better indicated by lower values)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	serious ³	none	4	10	-	MD 6 higher (1.43 to 10.57 higher)	⊕○○○ VERY LOW	IMPORTANT
Repeated procedures (re-intervention) (follow-up unclear)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	17/40 (42.5%)	9.8%	RR 4.36 (1.61 to 11.82)	329 more per 1000 (from 60 more to 1000 more)	⊕○○○ VERY LOW	IMPORTANT
Repeated procedures (re-intervention) (follow-up Median 4.7 months)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	serious ³	none	4/8 (50%)	9/41 (22%)	RR 2.28 (0.92 to 5.61)	281 more per 1000 (from 18 fewer to 1000 more)	⊕○○○ VERY LOW	IMPORTANT

¹ Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

² Downgraded by 1 or 2 increments because the point estimate varies widely across studies, unexplained by subgroup analysis.

³ Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

J.17.9 Clinical evidence profile: Percutaneous drainage versus standard treatment (observation)

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Percutaneous drainage	Standard treatment (observation)	Relative (95% CI)	Absolute		
Mortality (follow-up unclear)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	6/66 (9.1%)	0/41 (0%)	Peto OR 5.48 (1.02 to 25.59)	90 more per 1000 (from 10 fewer to 170 more)	⊕○○○ VERY LOW	CRITICAL
Mortality (follow-up Median 4.7 months)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	0/8 (0%)	0/44 (0%)	-	-	⊕○○○ VERY LOW	CRITICAL
Complications - Post-operative bleeding, infection or fistula (follow-up 10 years)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	4/20 (20%)	0/21 (0%)	Peto OR 9.17 (1.19 to 70.44)	200 more per 1000 (from 10 more to 390 more)	⊕○○○ VERY LOW	CRITICAL
Complications - Post-operative bleeding, infection or fistula (follow-up unclear)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision ²	none	41/66 (62.1%)	5/41 (12.2%)	RR 5.09 (2.91 to 11.83)	499 more per 1000 (from 233 more to 1000 more)	⊕○○○ VERY LOW	CRITICAL
Complications (follow-up Median 4.7 months)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	1/8 (12.5%)	0/44 (0%)	Peto OR 665.14 (2.91 to 152094.1)	130 more per 1000 (from 120 fewer to 370 more)	⊕○○○ VERY LOW	CRITICAL
Resolution of pseudocyst or symptoms (follow-up after discharge)												

1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	serious ¹	none	33/66 (50%)	28/41 (68.3%)	RR 0.73 (0.53 to 1.01)	184 fewer per 1000 (from 321 fewer to 7 more)	⊕000 VERY LOW	CRITICAL
Failure (defined as radiographic persistence of a symptomatic pseudocyst in the observed group and a persistent symptomatic pseudocyst requiring a further procedure in the intervention groups) (follow-up unclear)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	38/66 (57.6%)	3/41 (7.3%)	RR 7.87 (2.6 to 23.85)	503 more per 1000 (from 117 more to 1000 more)	⊕000 VERY LOW	CRITICAL
Recurrence (follow-up 10 years)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	14/20 (70%)	11/21 (52.4%)	RR 1.34 (0.81 to 2.2)	178 more per 1000 (from 100 fewer to 629 more)	⊕000 VERY LOW	CRITICAL
Repeated procedure (re-intervention) (follow-up Median 4.7 months)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	4/8 (50%)	0/44 (0%)	Peto OR 998.5 (60.74 to 16415.31)	500 more per 1000 (from 170 more to 830 more)	⊕000 VERY LOW	IMPORTANT

¹ Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

² Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

J.17.10 Laparoscopic drainage versus open surgical drainage or resection

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Laparoscopic drainage	Surgical drainage or resection	Relative (95% CI)	Absolute		
Mortality (all-cause) (follow-up unclear)												
1	observational	serious ¹	no serious	no serious	very serious ²	none	1/10	0/6	Peto OR 4.95	100 more per 1000	⊕000	CRITICAL

	studies		inconsistency	indirectness			(10%)	(0%)	(0.09 to 283.86)	(from 180 fewer to 380 more)	VERY LOW	
Complications - Overall (follow-up Median 22 months)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	2/10 (20%)	2/6 (33.3%)	RR 0.6 (0.11 to 3.21)	133 fewer per 1000 (from 297 fewer to 737 more)	⊕○○○ VERY LOW	CRITICAL
Complications - Grade 2 or greater (follow-up 16 months)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	4/16 (25%)	5/22 (22.7%)	RR 1.1 (0.35 to 3.46)	23 more per 1000 (from 148 fewer to 559 more)	⊕○○○ VERY LOW	CRITICAL
Resolution of presenting symptoms - Asymptomatic with no evidence of recurrent disease by CT scan (follow-up Median 22 months)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	10/10 (100%)	6/6 (100%)	RR 1 (0.78 to 1.27)	0 fewer per 1000 (from 220 fewer to 270 more)	⊕○○○ VERY LOW	CRITICAL
Resolution of presenting symptoms - Overall success rate (follow-up 16 months)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	15/16 (93.8%)	20/22 (90.9%)	RR 1.03 (0.86 to 1.24)	27 more per 1000 (from 127 fewer to 218 more)	⊕○○○ VERY LOW	CRITICAL
Resolution of presenting symptoms - Primary success rate (follow-up 16 months)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	14/16 (87.5%)	18/22 (81.8%)	RR 1.07 (0.82 to 1.4)	57 more per 1000 (from 147 fewer to 327 more)	⊕○○○ VERY LOW	CRITICAL
Residual pseudocyst (follow-up unclear)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	1/10 (10%)	1/6 (16.7%)	RR 0.6 (0.05 to 7.92)	67 fewer per 1000 (from 158 fewer to 1000 more)	⊕○○○ VERY LOW	CRITICAL

¹ Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

² Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

J.17.11 Open surgical drainage/resection versus standard treatment (observation)

978-1-4731-3083-8

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Surgical drainage/resection	Standard treatment (observation)	Relative (95% CI)	Absolute		
Mortality (follow-up unclear)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	0/66 (0%)	0/41 (0%)	-	-	⊕000 VERY LOW	CRITICAL
Mortality (follow-up Median 4.7 months)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	0/21 (0%)	0/44 (0%)	-	-	⊕000 VERY LOW	CRITICAL
Complications - Post-operative bleeding, infection or fistula (follow-up 10 years)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	2/3 (66.7%)	0/21 (0%)	Peto OR 4288.26 (59.08 to 311264.3)	670 more per 1000 (from 190 more to 1000 more)	⊕000 VERY LOW	CRITICAL
Complications - Post-operative bleeding, infection or fistula (follow-up unclear)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	17/66 (25.8%)	5/41 (12.2%)	RR 2.11 (0.84 to 5.29)	135 more per 1000 (from 20 fewer to 523 more)	⊕000 VERY LOW	CRITICAL
Complications (follow-up Median 4.7 months)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	6/21 (28.6%)	0/44 (0%)	Peto OR 28.72 (4.83 to 170.64)	290 more per 1000 (from 90 more to 480 more)	⊕000 VERY LOW	CRITICAL
Resolution of pseudocyst and symptoms (after hospital discharge; defined as recurrent cyst, recurrent pancreatitis, fistula, infection) (follow-up unclear)												

1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	45/66 (68.2%)	28/41 (68.3%)	RR 1 (0.77 to 1.3)	0 fewer per 1000 (from 157 fewer to 205 more)	⊕○○○ VERY LOW	CRITICAL
Failure (radiographic persistence of a symptomatic pseudocyst) (follow-up unclear)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	8/66 (12.1%)	3/41 (7.3%)	RR 1.66 (0.47 to 5.89)	48 more per 1000 (from 39 fewer to 358 more)	⊕○○○ VERY LOW	CRITICAL
Recurrence (follow-up 10 years)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	1/3 (33.3%)	11/21 (52.4%)	RR 0.64 (0.12 to 3.32)	189 fewer per 1000 (from 461 fewer to 1000 more)	⊕○○○ VERY LOW	CRITICAL
Repeated procedure (reintervention) (follow-up Median 4.7 months)												
1	observational studies	serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	0/21 (0%)	0/44 (0%)	Not estimable	-	⊕○○○ VERY LOW	IMPORTANT

¹ Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

² Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

J.18 Management of pancreatic ascites and pleural effusion secondary to pancreatitis

None

J.19 Management of biliary obstruction in people with chronic pancreatitis

J.19.1 Clinical evidence profile: Metal stents versus plastic stents

Quality assessment	No of patients	Effect	Quality	Importance
--------------------	----------------	--------	---------	------------

No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Covered metal stents	Multiple plastic stents	Relative (95% CI)	Absolute		
Mortality (follow-up mean 2 years)												
1	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	3/28 (10.7%)	4/30 (13.3%)	RR 0.8 (0.2 to 3.28)	27 fewer per 1000 (from 107 fewer to 304 more)	⊕○○○ VERY LOW	CRITICAL
Recurrent strictures (follow-up mean 2 years)												
1	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	2/28 (7.1%)	3/30 (10%)	RR 0.71 (0.13 to 3.96)	29 fewer per 1000 (from 87 fewer to 296 more)	⊕○○○ VERY LOW	CRITICAL
Adverse events (follow-up mean 2 years)												
1	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	8/28 (28.6%)	7/30 (23.3%)	RR 1.22 (0.51 to 2.93)	51 more per 1000 (from 114 fewer to 450 more)	⊕○○○ VERY LOW	IMPORTANT

¹ Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias.

² Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

J.19.2 Clinical evidence profile: Stenting versus surgery

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Stenting	Surgery	Relative (95% CI)	Absolute		
Mortality												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	0/16 (0%)	0/23 (0%)	Not estimable	No events	⊕○○○ VERY LOW	CRITICAL

Successful treatment												
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	10/16 (62.5%)	20/23 (87%)	RR 0.72 (0.48 to 1.08)	243 fewer per 1000 (from 452 fewer to 70 more)	⊕○○○ VERY LOW	CRITICAL

¹ Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias.

² Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

J.20 Management of type 3c diabetes secondary to pancreatitis

None.

J.21 Receiving specialist input in people with acute pancreatitis

None.

J.22 Follow-up of pancreatic exocrine function in people with chronic pancreatitis

None.

J.23 Follow-up to identify diabetes in people with chronic pancreatitis

None.

J.24 Follow-up to identify pancreatic cancer in people with chronic pancreatitis

None.

Appendix K: Forest plots

K.1 Patient information

None

K.2 Lifestyle interventions: stopping or reducing alcohol consumption

K.2.1 Structured programme to support people with acute pancreatitis in stopping or reducing alcohol consumption versus usual care

Figure 26: Recurrent episodes of pancreatitis (number of recurrent episodes of acute pancreatitis) at 36 months





Figure 27: Admissions to hospital (n of patients admitted for abdominal complaints fulfilling criteria of recurrent acute pancreatitis) at 2 years



K.3 Aetiology of acute pancreatitis

None


K.4 Aetiology of chronic pancreatitis

None

K.5 Diagnosing chronic pancreatitis

K.5.1 Coupled sensitivity and specificity forest plots

Figure 28: Sensitivity and specificity of index test Secretin Pancreatic Function test (SPFT) for chronic pancreatitis in people with suspected chronic pancreatitis whose diagnosis has not been confirmed by any of CT scan, ultrasound scan or upper GI endoscopy



K.6 Type of intravenous fluid for resuscitation in people with acute pancreatitis

K.6.1 Balanced crystalloid (Ringer-lactate) vs normal saline (RCT)

Figure 29: Mortality <1 year




Figure 30: Serious adverse events (transfer to ICU) < 1 year




Figure 31: Local complications (infection) <6 months



Figure 32: Local complications (necrosis) <6 months



Figure 33: Local complications (peri-pancreatic necrosis) <6 months




Figure 34: Systemic complications (renal failure) <6 months




Figure 35: Systemic complications (respiratory organ failure) <6 months



Figure 36: Systemic complications (shock) <6 months



Figure 37: Systemic complications (persistent organ failure) <6 months



K.6.2 Balanced crystalloid (Ringer-lactate) vs normal saline (non-randomised comparative studies)

Figure 38: Mortality <1 year





Figure 39: Length of stay (in CCU) <1 year



K.7 Speed of intravenous fluid for resuscitation in people with acute pancreatitis

K.7.1 Aggressive fluid resuscitation versus conservative fluid resuscitation (Randomised controlled trials)

K.7.1.1 Adults (>16 years)

Figure 40: Mortality at <1 year




Figure 41: Length of stay (CCU) <1 year




Figure 42: Local complications (infection) <6 months




Figure 43: Local complications (necrosis) <6 months




Figure 44: Systemic complications (multiple organ dysfunction syndrome) during admission




Figure 45: Systemic complications (sepsis) during admission




Figure 46: Systemic complications (abdominal compartment syndrome) during admission




Figure 47: Systemic complications (Development of SIRS) during admission




Figure 48: Systemic complications (persistent SIRS) during admission




Figure 49: Systemic complications (renal failure) during admission




Figure 50: Systemic complications (respiratory failure) during admission




Figure 51: Systemic complications (shock) during admission




Figure 52: Serious adverse events (days using ventilation) during admission




Figure 53: Serious adverse events (transfer to CCU) during admission





Figure 54: Serious adverse events (development of severe acute pancreatitis) during admission



K.7.2 Aggressive fluid resuscitation versus conservative fluid resuscitation (Non-randomised comparative studies)

K.7.2.1 Adults and young people (>16 years)

Figure 55: Mortality at <1 year




Figure 56: Mortality at <1 year

Figure 57: Length of stay (in hospital) <1 year






Figure 58: Local complications (acute collection) at <6 months



Note: Group B: 3100-4100ml; Group C: >4100ml

Figure 59: Local complications (acute collection) at < 1 year



Note: Group A: <3100ml; Group B: 3100-4100ml

Figure 60: Local complications (pancreatic necrosis) at <6 months






Figure 61: Local complications (pancreatic necrosis) at < 6 months



Note: Group B: 3100-4100ml; Group C: >4100ml

Figure 62: Local complications (pancreatic necrosis) at < 6 months



Note: Group A: <3100ml; Group B: 3100-4100ml

Figure 63: Local complications (Development of a pseudocyst) at <6 months



Figure 64: Local complications (acute peripancreatic fluid collections and/or pancreatic necrosis and/or peripancreatic necrosis) during admission




Figure 65: Systemic complications (cardiovascular failure) during admission




Figure 66: Systemic complications (pulmonary failure) during admission




Figure 67: Systemic complications (multi-system organ failure) during admission





Figure 68: Systemic complications (respiratory complications) during admission




Note: Respiratory complications included pleural effusions, atelectases and pneumonia.

Figure 69: Systemic complications (persistent organ failure) during admission




Figure 70: Systemic complications (persistent organ failure) during admission



Note: Group A: <3100ml; Group B: 3100-4100ml

Figure 71: Systemic complications (persistent organ failure) during admission




Note: De-Madaria 2011 Group B: 3100-4100ml; Group C: >4100ml

Figure 72: Systemic complications (renal failure) during admission



Figure 73: Systemic complications (SIRS) during admission



K.7.2.2 Children (<16 years)

Figure 74: Serious adverse events (CCU transfer rate) during admission




Figure 75: Serious adverse events (readmission rate) during admission




Figure 76: Serious adverse events (severe acute pancreatitis rate) during admission



K.8 Route of feeding in people with severe acute pancreatitis

K.8.1 Enteral (jejunal or duodenal) versus parenteral nutrition for acute pancreatitis

Figure 77: Mortality at ≤1 year




Figure 78: Length of hospital stay (days) at ≤1 year




Figure 79: Achieving nutrition (kcal/kg/day) at ≤1 year




Figure 80: Achieving nutrition (days to goal) at ≤1 year





Figure 81: Infections at ≤1 year



Test for subgroup differences: Chi² = 20.24, df = 3 (P = 0.0002), I² = 85.2%

Figure 82: Serious adverse events at ≤1 year





Figure 83: Adverse events at ≤1 year



K.8.2 Enteral (gastric) versus parenteral nutrition for acute pancreatitis

Figure 84: Mortality at ≤1 year



Figure 85: Achieving nutrition (25 kcal/kg/day) at ≤1 year




Figure 86: Infections at ≤1 year




Figure 87: Serious adverse events at ≤1 year





Figure 88: Adverse events at ≤1 year



K.8.3 Enteral (gastric) versus enteral (jejunal or duodenal nutrition for acute pancreatitis)

Figure 89: Mortality at ≤1 year



Figure 90: Length of hospital stay (days) at ≤1 year




Figure 91: Achieving nutrition at ≤1 year




Figure 92: Requiring total parenteral nutrition at ≤1 year






Figure 93: Infections at ≤1 year



Test for subgroup differences: Chi² = 2.32, df = 2 (P = 0.31), I² = 13.8%

Figure 94: Adverse events at ≤1 year



K.8.4 Early versus conventional (delayed) oral 're-feeding' for acute pancreatitis

Figure 95: Length of hospital stay (days) at ≤1 year




Figure 96: Requiring parenteral nutrition at ≤1 year




Figure 97: Abdominal pain relapse at ≤1 year



K.8.5 Early versus on-demand enteral nutrition for acute pancreatitis

Figure 98: Mortality at ≤1 year




Figure 99: Requiring parenteral nutrition at ≤1 year




Figure 100: Infection at ≤1 year




Figure 101: Serious adverse events at ≤1 year





Figure 102: Adverse events at ≤1 year



K.8.6 Early versus late enteral nutrition for acute pancreatitis

Figure 103: Mortality at ≤1 year




Figure 104: Mortality at ≤1 year




Figure 105: Additional parenteral nutrition at ≤ 1 year




Figure 106: Pancreatic infections at ≤ 1 year




Figure 107: Infections at ≤ 1 year




Figure 108: Serious adverse events – organ failure at ≤ 1 year




Figure 109: Serious adverse events – multi-organ failure at ≤ 1 year





Figure 110: Adverse events at ≤1 year



K.9 Early versus late nutritional intervention in people with chronic pancreatitis

None.

K.10 Specialist versus non-specialist nutritional assessment in people with chronic pancreatitis

None.

K.11 Prophylactic antimicrobial agents to prevent infection in people with acute pancreatitis

K.11.1 Prophylactic antimicrobial therapy versus no prophylactic antimicrobial therapy

Figure 111: Mortality <1 year




Figure 112: Mortality (Selective decontamination) <1 year




Figure 113: Length of hospital stay <1 year




Figure 114: Infected necrosis <1 year



Figure 115: Infected necrosis (Selective decontamination) <1 year




Figure 116: Infected necrosis (Peri-pancreatic infection) <1 year




Figure 117: Extra-pancreatic infection <1 year




Figure 118: Extra-pancreatic infection (Blood culture positive sepsis) <1 year




Figure 119: Extra-pancreatic infection (Pneumonia/ARDS) <1 year




Figure 120: Extra-pancreatic infection (Urinary tract infection) <1 year




Figure 121: Serious adverse events (multi-organ failure) <6 months





Figure 122: Serious adverse events (major organ complication) <6 months



K.11.2 Prophylactic antimicrobial therapy versus placebo

Figure 123: Mortality <1 year



Figure 124: Infected necrosis <1 year



Figure 125: Extra-pancreatic infection <1 year



Figure 126: Serious adverse events <6 months



Figure 127: Serious adverse events (Pulmonary insufficiency) <6 months




Figure 128: Serious adverse events (Renal insufficiency) <6 months




Figure 129: Serious adverse events (Shock) <6 months




Figure 130: Serious adverse events (SIRS) <6 months




Figure 131: Serious adverse events (multi-organ failure) <6 months





Figure 132: Colonisation by resistant organisms <6 months



K.11.3 Prophylactic antimicrobial therapy versus other prophylactic antimicrobial therapy (same class)

K.11.3.1 Carbapenems

Figure 133: Mortality <1 year




Figure 134: Infected necrosis <1 year




Figure 135: Extra-pancreatic infection <1 year





Figure 136: Serious adverse events (multi-organ failure) <6 months



K.11.4 Prophylactic antimicrobial therapy versus other prophylactic antimicrobial therapy (different class)

K.11.4.1 Quinolones versus carbapenems

Figure 137: Mortality <1 year




Figure 138: Infected necrosis <1 year





Figure 139: Extra-pancreatic infection <1 year



K.12 Methods of management of infected necrosis in people with acute pancreatitis

K.12.1 Minimally invasive surgery versus open surgery (randomised controlled trial)

Figure 140: Mortality at ≤1 year




Figure 141: Complications (enterocutaneous fistula or perforation of a visceral organ requiring intervention) at ≤1 year




Figure 142: Complications (intra-abdominal bleeding) at ≤1 year



Figure 143: Complications (multiple organ failure) at ≤1 year




Figure 144: Complications (multiple systemic complications) at ≤1 year




Figure 145: Complications (new-onset multiple organ failure) at ≤1 year




Figure 146: Pancreatic functions (new-onset diabetes) at ≤1 year






Figure 147: Pancreatic functions (use of pancreatic enzymes) at ≤1 year



K.12.2 Minimally invasive surgery (endoscopic) versus open surgery

Figure 148: Mortality at ≤1 year



K.12.3 Endoscopic step-up versus percutaneous drainage with step-up to open surgery

Figure 149: Mortality at ≤1 year




Figure 150: Length of stay (hospital) at ≤ 1 year




Figure 151: Length of stay (ICU) at ≤ 1 year




Figure 152: Complications (new-onset organ failure) at ≤ 1 year




Figure 153: Complications (multiple organ failure) at ≤ 1 year




Figure 154: Complications (upper gastrointestinal bleeding) at ≤ 1 year




Figure 155: Complications (intra-abdominal bleeding requiring intervention) at ≤ 1 year




Figure 156: Complications (enterocutaneous fistula or perforation) at ≤1 year





Figure 157: Complications (pancreatic fistula) at ≤1 year



K.12.4 Endoscopic step-up compared to minimally-invasive surgical step-up approach

Figure 158: Mortality at ≤1 year




Figure 159: Length of hospital stay at ≤1 year




Figure 160: Complications at ≤1 year





Figure 161: Pancreatic function at ≤1 year



K.12.5 Minimally invasive procedure (endoscopic – dual modality drainage) versus percutaneous drainage

Figure 162: Mortality at ≤1 year




Figure 163: Length of stay in hospital at ≤1 year





Figure 164: Complications (pseudoaneurysm) at ≤1 year



K.12.6 Minimally invasive surgery (open or videoscopically assisted retroperitoneal debridement) versus open surgery (open abdomen strategy; continuous postoperative lavage; laparotomy with primary abdomen closure)

Figure 165: Mortality at ≤1 year




Figure 166: Mortality at ≤1 year




Figure 167: Complications (bleeding) at ≤1 year




Figure 168: Complications (bowel perforation) at ≤1 year





Figure 169: Number of procedures (re-intervention) at ≤1 year



K.12.7 Combination of interventions (step-up approach) versus open surgery

Figure 170: Mortality at ≤1 year




Figure 171: Severe complication (sepsis, persistent MODS or erosion bleeding) at ≤1 year





Figure 172: Pancreatic function (emergence of type 3c diabetes) at ≤1 year



K.12.8 Minimally invasive surgery (focused open necrosectomy) versus open surgery (conventional open necrosectomy)

Figure 173: Mortality at ≤1 year




Figure 174: Complications (intestinal fistulae) at ≤1 year




Figure 175: Complications (pancreatic fistulae) at ≤1 year





Figure 176: Number of procedures (repeat necrosectomy) at ≤1 year



K.12.9 Percutaneous drainage versus combination of interventions (laparotomy, necrosectomy and active drainage)

Figure 177: Mortality at ≤1 year





Figure 178: Complications (Wound infection, haemorrhage at surgical site, pancreatic fistula, intestinal fistula) at ≤1 year



K.12.10 Percutaneous drainage versus combination of interventions (laparotomy, necrosectomy and passive drainage)

Figure 179: Mortality at ≤1 year





Figure 180: Complications (wound infection, haemorrhage at surgical site, pancreatic fistula, intestinal fistula) at ≤1 year



K.12.11 Combination of interventions (percutaneous drainage and VARD) versus combination of interventions (laparotomy, necrosectomy and active drainage)

Figure 181: Mortality at ≤1 year





Figure 182: Complications (wound infection, haemorrhage at surgical site, pancreatic fistula, intestinal fistula) at ≤1 year



K.12.12 Combination of interventions (percutaneous drainage and VARD) versus combination of interventions (laparotomy, necrosectomy and passive drainage)

Figure 183: Mortality at ≤1 year





Figure 184: Complications (wound infection, haemorrhage at surgical site, pancreatic fistula, intestinal fistula) at ≤1 year



K.12.13 Combination of interventions (percutaneous drainage and VARD) versus percutaneous drainage

Figure 185: Mortality at ≤1 year





Figure 186: Complications (wound infection, haemorrhage at surgical site, pancreatic fistula, intestinal fistula) at ≤1 year



K.12.14 Percutaneous drainage versus open surgery (laparotomy)

Figure 187: Mortality at ≤1 year




Figure 188: Complications (bleeding) at ≤1 year




Figure 189: Complications (bowel perforation) at ≤1 year




Figure 190: Complications (GI fistulas) at ≤1 year




Figure 191: Complications (pancreatic fistulas) at ≤1 year





Figure 192: Number of procedures (further necrosectomy) at ≤1 year



K.12.15 Minimally invasive surgery versus step-up approach

Figure 193: Floor length of stay at ≤1 year




Figure 194: Complications at ≤1 year




Figure 195: Number of procedures at ≤1 year




Figure 196: Pancreatic function (new exocrine insufficiency) at ≤1 year





Figure 197: Pancreatic function (new endocrine insufficiency) at ≤1 year



K.13 Timing of management of infected necrosis in people with acute pancreatitis

K.13.1 Minimally invasive surgery versus step-up approach

Figure 198: Mortality at ≤ 1 year




Figure 199: Number of procedures (Re-intervention) at ≤ 1 year




Figure 200: Complications (Intra-abdominal bleeding) at ≤ 1 year




Figure 201: Complications (Enterocutaneous fistula) at ≤ 1 year





Figure 202: Complications (New-onset organ failure) at ≤ 1 year



K.13.2 Late intervention versus early intervention in people with no organ failure

Figure 203: Mortality at ≤1 year




Figure 204: Number of procedures (Re-intervention) at ≤1 year




Figure 205: Complications (Intra-abdominal bleeding) at ≤1 year




Figure 206: Complications (Enterocutaneous fistula) at ≤1 year





Figure 207: Complications (New-onset organ failure) at ≤1 year



K.14 Management of pain in people with chronic pancreatitis

K.14.1 Antioxidants versus placebo

Figure 208: Quality of life (Activities of Daily Living) at 10 weeks




Figure 209: Quality of life (EQ5D) at 6 months




Figure 210: Quality of life (EQ-VAS) at 6 months






Figure 211: Pain (VAS) at ≤6 months




Note: Banks 1997 is a crossover trial, the variance has been adjusted to account for paired data

Figure 212: Pain (descriptive scale) at 10 weeks



Note: Banks 1997 is a crossover trial

Figure 213: Pain (numerical rating scale) at 10 weeks



Note: Banks 1997 is a crossover trial

Figure 214: Pain (reduction in pain medication) at 6 months




Figure 215: Pain (reduction in number of painful days) at 6 months




Figure 216: Pain (pain free participants) at 6 months






Figure 217: Adverse events at ≤6 months



Note: Banks 1997 is a crossover trial, the variance has been adjusted to account for paired data

Figure 218: Adverse events at ≤ 20 weeks



Uden 1990 and Kirk 2006 are crossover trials, adjustment was not possible due to there being zero events in one or both arms

K.14.2 Enzyme replacement therapy versus placebo

Figure 219: Pain (People experiencing long-lasting (>12 hour) pain attacks) at 4 months




Figure 220: Pain (Use of analgesics) at 4 months





Figure 221: Pain (Pain score) at 2 weeks



K.15 Management of pancreatic duct obstruction in people with chronic pancreatitis

K.15.1 ESWL and endotherapy versus surgery

Figure 222: Quality of life (SF-36, Mental health component) at 2 years




Figure 223: Quality of life (SF-36, Mental health component) at 7 years




Figure 224: Quality of life (SF-36, Physical health component) at 2 years




Figure 225: Quality of life (SF-36, Physical health component) at 7 years




Figure 226: Mortality at 2 years




Figure 227: Pain (Pain relief) at 2 years




Figure 228: Pain (Pain relief) at 7 years



Figure 229: Pain (Izbicki pain score at 2 years)




Figure 230: Pain (Izbicki pain score at 7 years)




Figure 231: Pancreatic function (Endocrine insufficiency developed at 2 years)




Figure 232: Pancreatic function (Endocrine insufficiency developed at 7 years)




Figure 233: Pancreatic function (Endocrine insufficiency persisted at 2 years)



Figure 234: Pancreatic function (Endocrine insufficiency persisted at 7 years)




Figure 235: Pancreatic function (Exocrine insufficiency developed at 2 years)




Figure 236: Pancreatic function (Exocrine insufficiency developed at 7 years)




Figure 237: Pancreatic function (Exocrine insufficiency persisted at 2 years)





Figure 238: Pancreatic function (Exocrine insufficiency persisted at 7 years)



K.15.2 Endotherapy versus surgery

Figure 239: Pain (Complete absence of pain) at 5 years




Figure 240: Pain (Partial relief of pain) at 5 years





Figure 241: Pancreatic function (New onset diabetes)



K.15.3 ESWL versus ESWL and endotherapy

Figure 242: Pain (Pain relapse) at 2 years




Figure 243: Pain (Pain intensity; VAS score) at 2 years




Figure 244: Length of hospital stay at 2 years






Figure 245: Procedure related complications at 1 month



K.16 Management of small-duct disease in people with chronic pancreatitis

K.16.1 VSPL versus NCPB

Figure 246: Pain (Use of opioids); timepoint unclear



K.17 Management of pseudocysts

K.17.1 Endoscopic drainage versus open surgical drainage or resection

Figure 247: Complications at ≤12 months and >12 months




Figure 248: Resolution of presenting symptoms or pseudocysts at >12 months




Figure 249: Recurrence of pseudocysts at >12 months




Figure 250: Length of hospital stay at ≤12 months





Figure 251: Repeated procedure (re-intervention) at ≤12 months



K.17.2 Combined endoscopic drainage and pancreatic duct stent versus open surgical drainage

Figure 252: Complications at unclear follow-up




Figure 253: Resolution of pseudocysts at unclear follow-up




Figure 254: Resolution of presenting symptoms (treatment success) at unclear follow-up




Figure 255: Recurrence (new onset abdominal pain in the presence of a pancreatic fluid collection on CT after resolution of the initial presentation) at >12 months




Figure 256: Repeated procedures (re-intervention) at ≤12 months or >12 months



K.17.3 Endoscopic drainage versus combination of open and laparoscopic surgery

Figure 257: Mortality at ≤12 months




Figure 258: Overall complications (including bleeding, infection, stent migration) at >12 months




Figure 259: Clinical success (complete resolution or decrease in the size of pseudocysts to 2cm or smaller on CT with associated resolution of symptoms) at ≤12 months




Figure 260: Recurrence (pancreatic pseudocyst found on CT in association with symptoms after initial resolution) at >12 months





Figure 261: Length of CCU stay (days) at >12 months



K.17.4 Endoscopic drainage versus laparoscopic drainage

Figure 262: Complications (grade 2 or greater) at >12 months





Figure 263: Resolution of presenting symptoms at >12 months



K.17.5 Endoscopic drainage versus endoscopic pancreatic stent

Figure 264: Significant complications at ≤12 months





Figure 265: Resolution of pseudocysts at ≤12 months



K.17.6 Endoscopic drainage versus standard treatment (observation)

Figure 266: Complications at ≤12 months





Figure 267: Repeated procedure (re-intervention) at ≤12 months



K.17.7 Percutaneous drainage versus open surgical drainage or resection

Figure 268: Mortality at ≤12 months





Figure 269: Complications at ≤12 months and >12 months




Figure 270: Resolution of pseudocyst or symptoms at unclear follow-up




Figure 271: Recurrence of pseudocyst at >12 months




Figure 272: Length of hospital stay ≤12 months




Figure 273: Repeated procedure (re-intervention) at ≤12 months



K.17.8 Percutaneous drainage versus endoscopic drainage

Figure 274: Complications at ≤12 months




Figure 275: Procedural adverse events at unclear follow-up




Figure 276: Recurrence of pseudocysts at >12 months




Figure 277: Length of hospital stay (days) at ≤12 months




Figure 278: Repeated procedures (re-intervention) at ≤12 months



K.17.9 Percutaneous drainage versus standard treatment (observation)

Figure 279: Mortality at ≤12 months




Figure 280: Complications - Post-operative bleeding, infection or fistula at >12 months




Figure 281: Complications at ≤12 months




Figure 282: Resolution of pseudocysts or symptoms at unclear follow-up




Figure 283: Failure (defined as radiographic persistence of a symptomatic pseudocyst in the observed group and a persistent symptomatic pseudocyst requiring a further procedure in the intervention groups) at unclear follow-up




Figure 284: Recurrence at >12 months





Figure 285: Repeated procedures (re-intervention) at ≤12 months



K.17.10 Laparoscopic drainage versus open surgical drainage or resection

Figure 286: Mortality at ≤12 months



Figure 287: Complications at >12 months




Figure 288: Resolution of presenting symptoms at >12 months





Figure 289: Residual pseudocyst at unclear follow-up



K.17.11 Open surgical drainage or resection versus standard treatment (observation)

Figure 290: Complications – Post-operative bleeding, infection or fistula at >12 months




Figure 291: Complications – Post-operative bleeding, infection or fistula at unclear follow-up




Figure 292: Complications at ≤12 months




Figure 293: Resolution of pseudocyst and symptoms (after hospital discharge; defined as recurrent cyst, recurrent pancreatitis, fistula, infection) at unclear follow-up




Figure 294: Failure (radiographic persistence of a symptomatic pseudocyst) at unclear follow-up

up





Figure 295: Recurrence at >12 months



K.18 Management of pancreatic ascites and pleural effusion secondary to pancreatitis

None.

K.19 Management of biliary obstruction in people with chronic pancreatitis

K.19.1 Metal stents versus plastic stents

Figure 296: Mortality at 2 years




Figure 297: Recurrence of biliary obstruction (Recurrent strictures) at 2 years






Figure 298: Complications (Adverse events) at 2 years



K.19.2 Stenting versus surgery

Figure 299: Recurrence of biliary obstruction (Successful treatment) at 1 year



K.20 Management of type 3c diabetes secondary to pancreatitis

None.

K.21 Receiving specialist input in people with acute pancreatitis

None.

K.22 Follow-up of pancreatic exocrine function in people with chronic pancreatitis

None.

K.23 Follow-up to identify diabetes in people with chronic pancreatitis

None.

K.24 Follow-up to identify pancreatic cancer in people with chronic pancreatitis

None.

Appendix L: Excluded clinical studies

L.1 Patient information

Reference	Reason for exclusion
Duggan 2011 ³¹⁶	Abstract only
Haritha 2015 ⁴⁴¹	Incorrect study design (questionnaire on patients' knowledge of smoking)
Nordeen 2012 ⁸⁰⁷	Abstract only
Wlochaj 2015 ¹¹⁵⁴	Incorrect study design (survey on patients' knowledge of nutrition)

L.2 Lifestyle interventions: stopping or reducing alcohol consumption

Study	Exclusion reason
Ammann 1994 ³⁷	Incorrect interventions
Apte 1998 ⁴⁷	Inappropriate study design (narrative review)
Conway 2005 ²⁴²	Inappropriate study design (narrative summary review)
Estruch 1993 ³⁴⁷	Not review population
Haber 2001 ⁴³¹	Inappropriate study design (proceedings of a workshop)
Hanck 2004 ⁴³⁸	Inappropriate study design (narrative review)
Jaakkola 1994 ⁵¹⁵	Inappropriate study design (no control group)
Kume 2015 ⁶²⁵	Not review population. Inappropriate study design (case-control)
Lang 2012 ⁶³⁴	Inappropriate study design (before and after study with no control group)
Maejima 1996 ⁶⁹³	Inappropriate study design (non-comparative)
Mayerle 2007 ⁷²⁴	Inappropriate study design (narrative review)
Nikkola 2013 ⁷⁹⁹	Inappropriate study design
Nordback 2005 ⁸⁰⁴	Inappropriate study design (non-comparative). Inappropriate comparison. Incorrect interventions
Pezzilli 2015 ⁸⁶¹	Inappropriate study design (narrative review)
Piette 1998 ⁸⁶⁸	Inappropriate study design (case-control)
Samokhvalov 2015 ⁹⁴⁴	Systematic review is not relevant to review question or unclear PICO

Study	Exclusion reason
Sand 2007 ⁹⁴⁷	Inappropriate study design (narrative review)
Sarles 1990 ⁹⁵²	Inappropriate study design (narrative review)
Schenker 1998 ⁹⁵⁷	Inappropriate study design (narrative review)
Schneider 2005 ⁹⁶³	Inappropriate study design (narrative review)
Strum 1995 ¹⁰³³	Inappropriate study design (case series)

L.3 Aetiology of acute pancreatitis

Study	Exclusion reason
Ansari 1996 ⁴²	Incorrect interventions
Chak 1999 ²⁰³	Incorrect study design
Chen 2017 ²¹⁵	Incorrect study design
Choudhary 2016 ²²⁴	Incorrect study design
Cimen 2015 ²²⁷	Incorrect study design
Di Leo 2017 ²⁹³	Incorrect study design. Incorrect population
Easler 2016 ³²⁶	Incorrect study design
Gaitch 2016 ³⁸¹	Incorrect population
Gasiorowska 2011 ³⁹³	Not review population
Giefer 2017 ³⁹⁸	Incorrect study design
Jalaly 2017 ⁵²²	Incorrect study design
Ma 2017 ⁶⁹⁰	Incorrect study design
Mariani 2009 ⁷¹²	Incorrect study design
Nitsche 1995 ⁸⁰¹	Incorrect interventions
Park 2016 ⁸⁴²	Incorrect study design
Poddar 2017 ⁸⁷¹	Incorrect population
Raizner 2013 ⁸⁹¹	Not review population
Reid 2017 ⁹⁰⁷	Incorrect study design

Repiso Ortega 2011 ⁹⁰⁸	Incorrect study design
Safari 2016 ⁹³¹	Narrative review
Shimizu 2001 ⁹⁹²	Incorrect study design
Sisman 2015 ¹⁰⁰²	Not review population
Smith 2015 ¹⁰⁰⁶	Narrative review
Stabuc 2008 ¹⁰²²	Incorrect study design
Sugiyama 1998 ¹⁰³⁹	Incorrect study design
Wilcox 2016 ¹¹⁴³	Inappropriate comparison
Zhan 2011 ¹¹⁸²	Incorrect study design

L.4 Aetiology of chronic pancreatitis

Study	Exclusion reason
Al-Haddad 2008 ²¹	Incorrect study design
Ammann 2007 ³⁸	Incorrect study design
Aoun 2008 ⁴³	Incorrect study design
Aoun 2010 ⁴⁴	Incorrect study design
Aparisi 2005 ⁴⁵	Incorrect study design
Applebaum-Shapiro 2001 ⁴⁶	Incorrect study design
Aspinwall 2013 ⁵⁵	Not guideline condition
Avanthi 2015 ⁵⁸	Incorrect study design
Ballard 2015 ⁷⁷	Incorrect study design
Bang 2008 ⁸¹	Inappropriate comparison
Buechter 2017 ¹⁶⁷	Incorrect population
Buijs 2015 ¹⁷⁰	Incorrect study design
Buijs 2016 ¹⁶⁹	Incorrect population
Camara 2015 ¹⁸⁸	Incorrect study design

Campa 2013 ¹⁸⁹	Incorrect study design
Cohn 2002 ²³⁷	Incorrect study design
Cohn 2003 ²³⁶	Incorrect study design
Conwell 2017 ²⁴³	Incorrect study design
Derikx 2010 ²⁸³	Incorrect study design
Detlefsen 2015 ²⁸⁴	Incorrect interventions
Ellis 2001 ³⁴¹	Incorrect study design
Ellis 2004 ³⁴⁰	Incorrect study design
Hara 2015 ⁴³⁹	Incorrect study design
Hart 2013 ⁴⁴⁴	Inappropriate comparison
Ito 2014 ⁵⁰⁵	Incorrect study design
Jiaming 2001 ⁵³¹	Unavailable
Joergensen 2010 ⁵³⁸	Inappropriate comparison
Joergensen 2010 ⁵³⁹	Incorrect study design
Lerch 2010 ⁶⁴⁸	Incorrect study design
Li 2011 ⁶⁵⁵	Incorrect study design
Liu 2017 ⁶⁶⁸	Incorrect study design
Lowenfels 1997 ⁶⁸¹	Incorrect study design
Lucidi 2011 ⁶⁸⁴	Incorrect study design
Maes 1999 ⁶⁹⁴	Not review population
Masson 2013 ⁷¹⁶	Incorrect study design
Mayerle 2013 ⁷²³	Systematic review is not relevant to review question or unclear PICO
Midha 2010 ⁷³⁸	Incorrect study design
Palermo 2016 ⁸²⁹	Incorrect study design
Pandya 1997 ⁸³²	Incorrect study design
Pezzilli 2009 ⁸⁶⁰	Incorrect study design

Poddar 2017 ⁸⁷²	Incorrect study design
Poddar 2017 ⁸⁷¹	Incorrect study design
Rolston 2001 ⁹²⁰	Incorrect study design
Romagnuolo 2008 ⁹²¹	Incorrect study design
Romagnuolo 2016{Romagnuolo, 2016 #1643}	Incorrect study design
Sherman 2004 ⁹⁹¹	Not review population
Spanier 2008 ¹⁰¹⁵	Incorrect study design
Strate 2003 ¹⁰³¹	Incorrect study design
Tazelaar 2003 ¹⁰⁶⁶	Incorrect study design
Testoni 2014 ¹⁰⁷⁰	Incorrect study design
Vue 2016 ¹¹²²	Incorrect population
Wang 2009 ¹¹³¹	Inappropriate comparison
Wang 2013 ¹¹³²	Incorrect interventions
Wilcox 2016 ¹¹⁴³	Incorrect study design

L.5 Diagnosing chronic pancreatitis

Reference	Reason for exclusion
Akisik 2009 ¹⁹	Inappropriate study design (two-gate study)
Alkaade 2008 ²⁸	Inappropriate reference test
Amann 1996 ³⁵	Inappropriate population
Ashkar 2014 ⁵³	SR not relevant to pico
Balci 2006 ⁷⁵	Inappropriate population
Balci 2008 ⁷⁶	Inappropriate population
Bang 2008 ⁸¹	Inappropriate population
Benini 1992 ¹²⁰	Inappropriate population
Benini 2013 ¹¹⁹	Inappropriate population

Reference	Reason for exclusion
Bhutani 2009 ¹³¹	Inappropriate index test
Bian 2013 ¹³²	Inappropriate study design and population
Boedeker 1999 ¹⁴⁴	Inappropriate study design
Brugge 1990 ¹⁶³	Inappropriate population
Buscail 1995 ¹⁷²	Inappropriate population
Cappellex 2000 ¹⁹²	Inappropriate population
Casellas 2004 ¹⁹⁸	Inappropriate target condition
Catalano 1998 ²⁰²	Inappropriate population
Catalano 2007 ²⁰¹	Inappropriate study design
Chen 2007 ²¹⁶	Inappropriate population
Chowdhury 2005 ²²⁵	Inappropriate reference standard
Chowdhury 2016 ²²⁶	Inappropriate population
Coenegrachts 2004 ²³³	Inappropriate study design; inappropriate population
Conwell 2002 ²⁴⁵	Inappropriate study design
Conwell 2007 ²⁴⁶	Inappropriate population
Conwell 2007 ²⁴⁷	Inappropriate study design
Conwell 2014 ²⁴⁴	Inappropriate study design
Czako 2007 ²⁵⁹	Inappropriate study design
Dancygier 1991 ²⁶⁶	Inappropriate study design
De Backer 2002 ²⁷³	Inappropriate study design
Detlefsen 2015 ²⁸⁴	Inappropriate population
Diakowska 2005 ²⁹⁴	Inappropriate study design
Dietrich 2009 ²⁹⁵	Inappropriate population
Dominguez-Munoz 1993 ³⁰⁶	Inappropriate population
Dominguez-Munoz 1995 ³⁰⁴	Inappropriate population
Dominguez-Munoz 1998 ³⁰⁵	Inappropriate population
Dominguez-Munoz 2012 ³⁰³	Inappropriate population
Draganov 2004 ³⁰⁹	Inappropriate gold standard
Draganov 2005 ³¹¹	Inappropriate reference standard

Reference	Reason for exclusion
Duggan 2016 ³¹⁷	Inappropriate study design
Dominguez-Munoz 2012 ³⁰³	Inappropriate population
Fritscher-Ravens 2002 ³⁷¹	Inappropriate population
Furuya 1996 ³⁷⁸	Inappropriate population
Gardner 2010 ³⁸⁸	Inappropriate study design
Girish 2009 ⁴⁰¹	Inappropriate population
Glasbrenner 1996 ⁴⁰³	Inappropriate population
Glaser 1994 ⁴⁰⁴	Inappropriate study design
Gleeson 2007 ⁴⁰⁵	Inappropriate study design
Gonzalez-Sanchez 2017 ⁴⁰⁹	Incorrect population
Gredal 2003 ⁴¹⁴	Inappropriate population
Gullo 1990 ⁴¹⁸	Inappropriate study design
Gullo 1996 ⁴¹⁷	Inappropriate population
Gullo 1999 ⁴¹⁹	Inappropriate study design
Hardt 2002 ⁴⁴⁰	Inappropriate population
Hernandez 2010 ⁴⁵³	Inappropriate study design
Hocke 2012 ⁴⁶⁰	Inappropriate population
Hoki 2009 ⁴⁶²	Inappropriate population
Hollerbach 2001 ⁴⁶⁴	Inappropriate population
Iglesias-Garcia 2013 ⁴⁸⁹	Inappropriate population
Iglesias-Garcia 2015 ⁴⁹⁰	Inappropriate study design
Ishii 2007 ⁵⁰¹	Inappropriate study design
Issa 2017 ⁵⁰²	Systematic review: references checked
Jensen 2008 ⁵²⁸	Inappropriate study design
Jung 2015 ⁵⁵²	Inappropriate population
Kahl 2002 ⁵⁵⁸	Inappropriate population
Kamisawa 2007 ⁵⁶⁹	Inappropriate population
Kamisawa 2008 ⁵⁷¹	Inappropriate population
Kamisawa 2014 ⁵⁷⁰	Inappropriate study design

Reference	Reason for exclusion
Kanno 2015 ⁵⁷⁵	Inappropriate study design
Kanno 2016 ⁵⁷⁴	Inappropriate population
Kataoka 1997 ⁵⁸³	Inappropriate population
Kataoka 1999 ⁵⁸¹	Inappropriate reference test
Keim 2003 ⁵⁸⁹	Inappropriate reference test
Keller 2011 ⁵⁹⁰	Inappropriate study design
Ketwaroo 2015 ⁵⁹²	Inappropriate study design
Kitagawa 1997 ⁶⁰³	Inappropriate population
Kothari 2017 ⁶¹⁵	Incorrect reference standard
Kothari 2017 ⁶¹⁴	Incorrect reference standard
Kuwahara 2017 ⁶²⁹	Incorrect reference standard
Kuwahara 2017 ⁶³⁰	Incorrect reference standard
Lankisch 1993 ⁶³⁵	Inappropriate study design
Lankisch 1998 ⁶³⁶	Inappropriate population
Lara 2017 ⁶³⁷	Incorrect reference standard
Lei 2000 ⁶⁴⁶	Inappropriate study design
Liu 2016 ⁶⁷⁰	SR not relevant to PICO
Llamoza-Torres 2016 ⁶⁷¹	Inappropriate index test
Lock 1997 ⁶⁷²	Inappropriate reference test
Loser 1997 ⁶⁷⁶	Inappropriate study design
Loser 1998 ⁶⁷⁷	Inappropriate study design; population
Maeshiro 2007 ⁶⁹⁵	Inappropriate study design
Mahajan 2016 ⁶⁹⁸	Inappropriate study design
Miyakawa 2007 ⁷⁴⁶	Inappropriate population
Mizuno 2009 ⁷⁴⁷	Inappropriate population
Morishima 2016 ⁷⁵⁹	Inappropriate population
Pelley 2012 ⁸⁴⁸	Inappropriate study design
Pezzilli 2000 ⁸⁶³	Inappropriate comparison
Poddar 2017 ⁸⁷²	Inappropriate population

Reference	Reason for exclusion
Poddar 2017 ⁸⁷¹	Inappropriate population
Pungpapong 2007 ⁸⁸²	Inappropriate population
Pungpapong 2007 ⁸⁸¹	Inappropriate population
Saftoiu 2011 ⁹³³	Inappropriate population
Sahai 1998 ⁹³⁶	Inappropriate population
Sai 2008 ⁹³⁸	Inappropriate design; Inappropriate population
Sainani 2015 ⁹³⁹	Inappropriate study design
Sato 2017 ⁹⁵³	Incorrect reference standard
Schlaudraff 2008 ⁹⁶⁰	Inappropriate population
Seicean 2010 ⁹⁷⁵	Inappropriate study design
Sheridan 2002 ⁹⁹⁰	Inappropriate study design
Songur 2000 ¹⁰¹¹	Inappropriate population; Inappropriate reference test
Stevens 2009 ¹⁰²⁷	Inappropriate population
Stevens 2010 ¹⁰²⁶	Inappropriate reference test
Sugiyama 2007 ¹⁰⁴⁰	Inappropriate population
Sugumar 2011 ¹⁰⁴¹	Inappropriate design
Trikudanathan 2015 ¹⁰⁸⁰	Inappropriate population
Trikudanathan 2016 ¹⁰⁷⁹	Inappropriate population
Uskudar 2009 ¹⁰⁸⁹	Inappropriate study design, Inappropriate population
Wejnarska 2016 ¹¹⁴⁰	Inappropriate population
Yanagisawa 2017 ¹¹⁷⁰	Inappropriate population
Yanling 2001 ¹¹⁷⁵	Inappropriate study design
Zhang 2003 ¹¹⁸⁵	Inappropriate study design

L.6 Type of intravenous fluid for resuscitation in people with acute pancreatitis

Study	Exclusion reason
Abu-El-Haija 2017 ⁷	Systematic review is not relevant to review question or unclear PICO

Aggarwal 2014 ¹³	Inappropriate study design (narrative review)
Bolado 2016 ¹⁴⁶	Not in English
Bortolotti 2014 ¹⁴⁸	Inappropriate study design
Brown 2002 ¹⁶⁰	Inappropriate comparison
Buxbaum 2014 ¹⁷⁷	Not guideline condition
Caraceni 2013 ¹⁹⁴	Incorrect study design
Choi 2016 ²²²	Not review population
De-Madaria 2011 ²⁷²	Inappropriate comparison
De-Madaria 2014 ²⁷⁰	Incorrect study design
Dimagno 2014 ²⁹⁷	Not review population
Dimagno 2015 ²⁹⁶	Incorrect study design
Eckerwall 2006 ³³¹	Incorrect interventions
Gardner 2008 ³⁹⁰	Inappropriate study design
Haydock 2013 ⁴⁴⁷	Inappropriate study design
Haydock 2013 ⁴⁴⁸	Systematic review is not relevant to review question or unclear PICO
Kuwabara 2011 ⁶²⁸	Inappropriate study design
Lipinski 2015{Lipinski, 2015 #290}	Inappropriate intervention
Mao 2009 ⁷¹⁰	Inappropriate comparison
Maurer 2015 ⁷²¹	Inappropriate study design
Mok 2016 ⁷⁵²	Not review population
Mole 2011 ⁷⁵³	No relevant outcomes
Mosztbacher 2017 ⁷⁶⁴	Inappropriate study design
Nakamura 2014 ⁷⁸¹	Not guideline condition
Niederau 2006 ⁷⁹⁵	Inappropriate study design
Platell 2001 ⁸⁷⁰	Systematic review is not relevant to review question or unclear PICO
Pupelis 2008 ⁸⁸⁶	Incorrect interventions

Sagi 2014 ⁹³⁴	Inappropriate comparison
Schepers 2013 ⁹⁵⁹	Inappropriate study design
Sharma 2016 ⁹⁸³	Incorrect interventions
Shaygan-Nejad 2015 ⁹⁸⁵	Incorrect interventions. Not review population
Shen 2014 ⁹⁸⁷	Systematic review is not relevant to review question or unclear PICO
Sun 2015 ¹⁰⁴⁶	Incorrect interventions
Szabo 2015 ¹⁰⁴⁹	Inappropriate comparison
Szczygiel 1991 ¹⁰⁵⁰	Incorrect interventions
Talukdar 2011 ¹⁰⁵⁹	Inappropriate study design
Tenner 2013 ¹⁰⁶⁹	Inappropriate study design
Trikudanathan 2012 ¹⁰⁷⁸	Systematic review is not relevant to review question or unclear PICO
Wall 2011 ¹¹²⁶	Incorrect interventions
Wang 2013 ¹¹³⁰	Incorrect interventions
Warndorf 2011 ¹¹³⁴	Incorrect interventions
Weinberg 2014 ¹¹³⁸	Not guideline condition
Weitz 2014 ¹¹³⁹	Inappropriate study design
Wu 2011 ¹¹⁵⁹	Inappropriate study design
Wyncoll 1999 ¹¹⁶³	Inappropriate study design
Zhao 2013 ¹¹⁸⁸	Incorrect interventions

L.7 Speed of intravenous fluid for resuscitation in people with acute pancreatitis

Study	Exclusion reason
Aboelsoud 2016 ⁴	Incorrect interventions
Aggarwal 2014 ¹³	Inappropriate study design (narrative review)
Bortolotti 2014 ¹⁴⁸	Inappropriate study design

Brown 2002 ¹⁶⁰	Incorrect interventions
Buxbaum 2014 ¹⁷⁷	Not review population
Caraceni 2013 ¹⁹⁴	Inappropriate study design
Choi 2016 ²²²	Not guideline condition
De-Madaria 2014 ²⁷⁰	Inappropriate study design
Dimagno 2014 ²⁹⁷	Not review population
Dimagno 2015 ²⁹⁶	Inappropriate study design
Du 2011 ³¹³	Inappropriate comparison
Gardner 2008 ³⁹⁰	Inappropriate study design (narrative review)
Haydock 2013 ⁴⁴⁷	Inappropriate study design (survey)
Haydock 2013 ⁴⁴⁸	Systematic review is not relevant to review question or unclear PICO
Kuwabara 2011 ⁶²⁸	Inappropriate study design
Lipinski 2015 ⁶⁶⁴	Incorrect interventions
Mao 2009 ⁷¹⁰	Inappropriate intervention
Maurer 2015 ⁷²¹	Inappropriate study design
Mok 2016 ⁷⁵²	Not guideline condition
Mole 2011 ⁷⁵³	No relevant outcomes
Nakamura 2014{Nakamura, 2014 #266}	Not guideline condition
Niederau 2006 ⁷⁹⁵	Inappropriate study design
Platell 2001 ⁸⁷⁰	Systematic review is not relevant to review question or unclear PICO
Pupelis 2008 ⁸⁸⁶	Incorrect interventions
Sagi 2014 ⁹³⁴	Inappropriate comparison
Schepers 2013 ⁹⁵⁹	Inappropriate study design
Sharma 2016 ⁹⁸³	Incorrect interventions
Shaygan-Nejad 2015 ⁹⁸⁵	Incorrect interventions. Not review population
Shen 2014 ⁹⁸⁷	Systematic review is not relevant to review question or unclear PICO

Sun 2015 ¹⁰⁴⁶	Incorrect interventions
Szczygiel 1991 ¹⁰⁵⁰	Incorrect interventions
Talukdar 2014 ¹⁰⁵⁶	Inappropriate study design
Tenner 2013 ⁶⁶⁴	Inappropriate study design
Trikudanathan 2012 ¹⁰⁷⁸	Systematic review is not relevant to review question or unclear PICO
Warndorf 2011 ⁹³⁹	Incorrect interventions
Weinberg 2014 ¹¹³⁸	Not guideline condition
Weitz 2014 ¹¹³⁹	Inappropriate study design
Wu 2011 ⁹⁸³	Inappropriate study design
Wyncoll 1999 ¹¹⁶³	Inappropriate study design
Zhao 2013 ¹¹⁸⁸	Incorrect interventions

L.8 Route of feeding in people with severe acute pancreatitis

Study	Exclusion reason
Abou-Assi 2002 ⁶	Abstract only
Abu-El-Haija 2016 ⁸	Inappropriate comparison
Al Samaraee 2010 ²³	Systematic review: references checked
Alsolaiman 2003 ³²	Incorrect study design: comment article
Buxbaum 2017 ¹⁷⁸	Not Severe acute pancreatitis. Incorrect interventions
Cao 2008 ¹⁹¹	Systematic review: references checked
Chang 2013 ²⁰⁸	Systematic review: references checked
Cui 2013 ²⁵⁸	Not in the English language
Davies 2011 ²⁶⁷	Incorrect study design: survey
Eatock 2000 ³²⁸	Incorrect study design: non-comparative
Eckerwall 2007 ³³³	Not Severe acute pancreatitis. Not Moderately severe acute pancreatitis. Incorrect interventions
Erstad 2000 ³⁴⁵	Narrative review: references checked
Gianotti 2009 ³⁹⁶	Guideline report: references checked

Study	Exclusion reason
Horibe 2016 ⁴⁶⁹	Systematic review: references checked
Jafari 2015 ⁵¹⁷	Systematic review: references checked
Jeejeebhoy 2007 ⁵²⁶	Narrative review: references checked
Jiang 2007 ⁵³²	Systematic review: references checked
Kahl 2014 ⁵⁵⁹	Not Severe acute pancreatitis. Not Moderately severe acute pancreatitis. Incorrect interventions
Kale-Pradhan 1999 ⁵⁶⁴	Narrative review: references checked
Kalfarentzos 1991 ⁵⁶⁶	Incorrect study design: narrative review
Karamitsios 1997 ⁵⁷⁸	Narrative review: references checked
Kaushik 2004 ⁵⁸⁴	Incorrect study design: narrative review
Krishnan 2017 ⁶¹⁸	Narrative review: references checked
Kuwabara 2011 ⁶²⁷	Incorrect study type
Larino-Noia 2014 ⁶³⁸	Majority had mild acute pancreatitis
Li 2013 ⁶⁵⁶	Systematic review: references checked
Li 2013 ⁶⁵⁴	Majority had mild acute pancreatitis
Li 2014 ⁶⁵⁹	Systematic review: references checked
Ma 2016 ⁶⁸⁹	Incorrect interventions
Makola 2007 ⁷⁰²	Systematic review: references checked
Marik 2004 ⁷¹³	Systematic review: references checked
Marta 2016 ⁷¹⁴	Systematic review: references checked
McClave 1997 ⁷²⁹	Majority had mild acute pancreatitis
McClave 1998 ⁷³⁰	Systematic review: references checked
McClave 2006 ⁷²⁸	Systematic review: references checked
Mirtallo 2012 ⁷⁴²	Guideline report: references checked
Nakad 1998 ⁷⁷⁹	Incorrect study design: non-comparative
Navaneethan 2010 ⁷⁸⁹	Narrative review: references checked
Olah 2002 ⁸¹⁶	Majority had mild acute pancreatitis
Olah 2010 ⁸¹⁷	Systematic review: references checked
Olah 2014 ⁸¹⁸	Narrative review: references checked
Pandey 2004 ⁸³¹	Incorrect outcomes

Study	Exclusion reason
Pendharkar 2016 ⁸⁴⁹	Incorrect interventions
Petrov 2007 ⁸⁵⁹	Systematic review: references checked
Petrov 2008 ⁸⁵⁵	Systematic review: references checked
Petrov 2008 ⁸⁵⁷	Systematic review: references checked
Petrov 2009 ⁸⁵⁶	Systematic review: references checked
Petrov 2010 ⁸⁵⁸	Systematic review: references checked
Petrov 2013 ⁸⁵⁴	Incorrect interventions
Piciucchi 2010 ⁸⁶⁷	Incorrect study design: observational (sufficient randomised data for this comparison)
Pisters 1992 ⁸⁶⁹	Incorrect study design: narrative review
Powell 2000 ⁸⁷⁷	Incorrect interventions
Pupelis 2000 ⁸⁸³	Incorrect interventions
Pupelis 2006 ⁸⁸⁵	Incorrect study design: non-comparative
Quan 2011 ⁸⁸⁸	Systematic review: references checked
Shen 2017 ⁹⁸⁶	Incorrect outcomes
Singh 2012 ⁹⁹⁶	Incorrect study design: observational (sufficient randomised data for this comparison)
Siow 2008 ¹⁰⁰⁰	Systematic review: references checked
Spanier 2008 ¹⁰¹⁴	Not review population
Stimac 2016 ¹⁰²⁸	Incorrect interventions
Sun 2004 ¹⁰⁴³	Inappropriate comparison
Sun 2013 ¹⁰⁴⁴	Inappropriate comparison
Sun 2013 ¹⁰⁴⁵	Inappropriate comparison
Szabo 2015 ¹⁰⁴⁹	Incorrect population and comparisons
Tao 2016 ¹⁰⁶³	Incorrect study design: observational (sufficient randomised data for this comparison)
Targarona Modena 2006 ¹⁰⁶⁵	Incorrect study design: observational (sufficient randomised data for this comparison)
Teich 2010 ¹⁰⁶⁸	Not Severe acute pancreatitis. Not Moderately severe acute pancreatitis. Incorrect interventions
Thomson 2006 ¹⁰⁷¹	Review: references checked

Study	Exclusion reason
Vaughn 2017 ¹¹¹⁰	Systematic review: references checked
Windsor 1998 ¹¹⁴⁹	Majority had mild acute pancreatitis
Wu 2015 ¹¹⁶²	Inappropriate comparison
Yi 2012 ¹¹⁷⁷	Systematic review: references checked
Zhang 2011 ¹¹⁸⁶	Not in the English language
Zhang 2014 ¹¹⁸⁴	Inappropriate comparison
Zhao 2003 ¹¹⁸⁷	Inappropriate comparison
Zhu 2016 ¹¹⁹⁶	Systematic review: references checked
Zou 2014 ¹¹⁹⁷	Not review population

L.9 Early versus late nutritional intervention in people with chronic pancreatitis

Reference	Reason for exclusion
Kataoka 2014 ⁵⁸²	Incorrect intervention
Makola 2006 ⁷⁰¹	Incorrect intervention
Mizushima 2004 ⁷⁴⁸	Incorrect intervention
Skipworth 2011 ¹⁰⁰³	Incorrect intervention
Stanga 2005 ¹⁰²³	Incorrect intervention

L.10 Specialist versus non-specialist nutritional assessment in people with chronic pancreatitis

Reference	Reason for exclusion
Avanesov 2017 ⁵⁷	Incorrect study design
Issa 2017 ⁵⁰³	Incorrect study design
Kaushik 2004 ⁵⁸⁴	Incorrect study design; incorrect population
Kumar 2013 ⁶²⁴	Incorrect study design; incorrect population
McClave 1998 ⁷³⁰	Incorrect study design
Mirtallo 2012 ⁷⁴²	Incorrect study design

L.11 Prophylactic antimicrobial agents to prevent infection in people with acute pancreatitis

Study	Exclusion reason
Abu-El-Haija 2017 ⁷	Incorrect study design
Arlt 2014 ⁵⁰	Incorrect study design
Bai 2008 ⁶⁶	Systematic review: References checked. Systematic review: methods are not adequate/unclear
Baltatzis 2016 ⁷⁹	Incorrect study design
Baltatzis 2016 ⁷⁸	Incorrect study design
Bartholomew 1996 ⁹²	Incorrect study design
Bassi 1992 ⁹⁵	Incorrect study design
Bassi 1992 ¹⁰¹	Incorrect study design
Bassi 1996 ⁹⁷	Incorrect study design
Bassi 2004 ⁹⁶	Incorrect study design
Beger 2009 ¹¹²	Inappropriate study design (narrative review)
Besselink 2008 ¹²⁵	Incorrect study design
Calandra 2004 ¹⁸⁷	Not guideline condition. Not review population
Dambrauskas 2007 ²⁶⁵	Systematic review: references checked. Systematic review: methods are not adequate/unclear
da Silveira 2002 ²⁶⁴	Incorrect study design
De Campos 2006 ²⁷⁴	Incorrect study design
De Waele 2003 ²⁷⁷	Incorrect study design
De Waele 2014 ²⁷⁶	Incorrect study design
Eggimann 2006 ³³⁴	Incorrect study design
Galeiras 2016 ³⁸²	Incorrect study design
Hart 2008 ⁴⁴³	Systematic review: References checked. Systematic review: methods are not adequate/unclear
Ho 1997 ⁴⁵⁹	Incorrect study design

Howard 2002 ⁴⁷⁵	Incorrect study design
Hubaczová 2000 ⁴⁸⁰	Order cancelled (abstract)
Ignatavicius 2012 ⁴⁹¹	Incorrect study design
Jafri 2009 ⁵¹⁸	Systematic review: references checked. Systematic review: methods are not adequate/unclear
Jiang 2012 ⁵³³	Systematic review: References checked. Systematic review: methods are not adequate/unclear
Johnson 1996 ⁵⁴⁶	Incorrect study design
Lim 2015 ⁶⁶²	Systematic review: References checked. Systematic review: methods are not adequate/unclear
Luiten 1999 ⁶⁸⁵	Incorrect study design
Mandal 2017 ⁷⁰⁶	Incorrect study design
Manes 2006 ⁷⁰⁸	Inappropriate comparison
Maraví-Poma 2003 ⁷¹¹	Incorrect interventions. Inappropriate comparison
Marusic 2008 ⁷¹⁵	Incorrect study design
Mazaki 2006 ⁷²⁷	Systematic review: References checked
Mcclelland 1992 ⁷³¹	Incorrect study design
Moggia 2017 ⁷⁵⁰	Incorrect intervention
Mourad 2017 ⁷⁶⁶	Incorrect study design
Moyshenyat 2006 ⁷⁶⁷	Systematic review: References checked. Systematic review: methods are not adequate/unclear
Nicholson 2011 ⁷⁹⁴	Incorrect study design
Oldach 1995 ⁸²¹	Incorrect study design
Papakostas 2000 ⁸³⁴	Systematic review: References checked. Systematic review: methods are not adequate/unclear
Piascik 2004 ⁸⁶⁶	Incorrect study design
Piascik 2010 ⁸⁶⁵	Incorrect interventions
Powell 1998 ⁸⁷⁶	Incorrect study design
Powell 1999 ⁸⁷⁵	Incorrect study design

Rada 2015 ⁸⁹⁰	Systematic review: references checked. Systematic review: methods are not adequate/unclear
Rao 2012 ⁸⁹⁷	Unavailable
Schwarz 1997 ⁹⁶⁹	Not in English
Segarra-Newnham 1998 ⁹⁷³	Systematic review: references checked. Systematic review: methods are not adequate/unclear
Segarra-Newnham 2009 ⁹⁷⁴	Systematic review: references checked. Systematic review: methods are not adequate/unclear
Sharma 2001 ⁹⁸⁴	Incorrect study design
Slavin 2001 ¹⁰⁰⁵	Incorrect study design
Spicak 2002 ¹⁰¹⁸	Not in English
Spicak 2003 ¹⁰¹⁷	Not in English
Spicak 2004 ¹⁰¹⁶	Abstract only
Swidnicka-Siergiejko 2007 ¹⁰⁴⁷	Incorrect study design
Talukdar 2014 ¹⁰⁵⁶	Incorrect study design
Ukai 2015 ¹⁰⁸⁷	Systematic review: References checked. Systematic review: methods are not adequate/unclear
Villatoro 2003 ¹¹¹⁴	Systematic review: not latest version
Villatoro 2010 ¹¹¹⁵	Systematic review: methods are not adequate/unclear. Systematic review: references checked
Vries 2007 ¹¹²¹	Systematic review: References checked. Systematic review: methods are not adequate/unclear
Wang 2012 ¹¹³³	Unavailable
Wittau 2008 ¹¹⁵¹	Systematic review is not relevant to review question or unclear PICO
Wittau 2011 ¹¹⁵²	Systematic review: References checked. Systematic review: methods are not adequate/unclear
Xiong 2006 ¹¹⁶⁴	Systematic review: References checked. Systematic review: methods are not adequate/unclear
Xu 2008 ¹¹⁶⁵	Systematic review: References checked
Yang 2009 ¹¹⁷⁴	Unavailable

Yao 2010 ¹¹⁷⁶	Systematic review: References checked. Systematic review: methods are not adequate/unclear
Zainutdinov 2016 ¹¹⁷⁹	Incorrect comparison
Zhang 2010 ¹¹⁸³	Systematic review is not relevant to review question or unclear PICO
Zhou 2005 ¹¹⁹⁴	Incorrect study design

L.12 Methods of management of infected necrosis in people with acute pancreatitis

Study	Exclusion reason
Abdelhafez 2013 ³	Inappropriate comparison
Ai 2010 ¹⁷	Not review population
Ala-Kokko 2001 ²⁴	Narrative article
Albers 2016 ²⁵	Not in English
Alfasser 2012 ³¹	Not review population
Alvarez-Sanchez 2014 ³³	Systematic review is not relevant to review question or unclear PICO
Alvi 2011 ³⁴	Not review population
Ang 2013 ⁴¹	Inappropriate comparison
Ashley 2001 ⁵⁴	Not review population
Aultman 1997 ⁵⁶	Not review population
Babu 2009 ⁶⁴	Systematic review is not relevant to review question or unclear PICO
Babu 2010 ⁶³	Inappropriate comparison
Bakker 2009 ⁷²	Narrative review
Bakker 2012 ⁶⁸	Incorrect interventions
Bala 2009 ⁷⁴	Inappropriate comparison
Bang 2014 ⁸⁰	Not review population
Baril 2000 ⁸⁶	Incorrect study design

Baron 2002 ⁸⁸	Incorrect study design
Barreda 2015 ⁸⁹	Not review population
Baudin 2012 ¹⁰²	Inappropriate study design
Bausch 2012 ¹⁰³	Not review population
Beck 2012 ¹⁰⁵	Incorrect study design
Beenen 2011 ¹⁰⁸	No relevant outcomes
Beger 1986 ¹¹⁰	Incorrect interventions
Beger 1988 ¹¹¹	Not review population
Beger 1989 ¹⁰⁹	Narrative article
Beger 1995 ¹¹³	Narrative review
Bello 2012 ¹¹⁷	Systematic review is not relevant to review question or unclear PICO
Berzin 2008 ¹²²	Inappropriate comparison
Besselink 2007 ¹²⁶	Incorrect interventions
Boland 2010 ¹⁴⁷	Inappropriate comparison
Bosscha 2001 ¹⁵⁰	Not review population
Bradley 1991 ¹⁵⁵	No relevant outcomes
Bradley 2008 ¹⁵⁶	Systematic review is not relevant to review question or unclear PICO
Branum 1998 ¹⁵⁸	Inappropriate study design
Bruennler 2008 ¹⁶²	Inappropriate comparison. Incorrect interventions
Bucher 2008 ¹⁶⁴	Inappropriate comparison
Buchler 2000 ¹⁶⁵	Incorrect study design
Busse 2015 ¹⁷⁵	Inappropriate comparison
Carter 2000 ¹⁹⁵	Inappropriate comparison
Castellanos 2005 ²⁰⁰	Inappropriate comparison
Castellanos 2013 ¹⁹⁹	Inappropriate comparison

Chang 2006 ²⁰⁷	Inappropriate comparison
Chang 2014 ²⁰⁶	Systematic review is not relevant to review question or unclear PICO
Charnley 2006 ²¹⁰	Incorrect study design
Chaudhary 1997 ²¹¹	Inappropriate comparison
Cheung 2005 ²¹⁹	Inappropriate comparison
Cheung 2010 ²²⁰	Not review population
Cirocchi 2013 ²²⁸	Systematic review is not relevant to review question or unclear PICO
Coelho 2008 ²³²	Inappropriate comparison
Connor 2003 ²³⁹	Not review population
Connor 2005 ²⁴⁰	Not review population
Connor 2006 ²⁴¹	Narrative review
Cresswell 2015 ²⁵⁶	Inappropriate comparison
Dhingra 2015 ²⁹¹	Incorrect interventions
Doctor 2011 ³⁰⁰	Incorrect interventions
Doglietto 1994 ³⁰¹	Not review population
Dominioni 1997 ³⁰⁷	Paper not available
Dong 2008 ³⁰⁸	Incorrect study design
Easler 2012 ³²⁷	Narrative review
Easler 2014 ³²⁵	Not review population
Echenique 1998 ³³⁰	Inappropriate comparison
Eggink 1984 ³³⁵	Inappropriate comparison
Endlicher 2003 ³⁴²	Inappropriate comparison
Escourrou 2008 ³⁴⁶	Inappropriate comparison
Farkas 2006 ³⁵²	Inappropriate comparison
Foitzik 1995 ³⁶¹	Not review population

Fotoohi 1999 ³⁶⁴	Not review population
Fotoohi 2007 ³⁶⁵	Narrative review
Freeny 1998 ³⁶⁶	Inappropriate comparison
Fugger 1995 ³⁷²	Inappropriate comparison
Gambiez 1998 ³⁸³	Not review population
Gardner 2009 ³⁸⁶	Incorrect interventions
Gardner 2011 ³⁸⁷	Inappropriate comparison
Gentile 1998 ³⁹⁴	Inappropriate comparison
Gomatos 2016 ⁴⁰⁸	Not review population
Gou 2013 ⁴¹²	Paper not available
Guo 2001 ⁴²¹	Not in English
Guo 2013 ⁴²³	Incorrect interventions
Guo 2014 ⁴²²	Incorrect interventions
Gurusamy 2016 ⁴²⁸	Review protocol
Haghshenasskashani 2011 ⁴³²	Systematic review is not relevant to review question or unclear PICO
Harris 2004 ⁴⁴²	Inappropriate comparison
Hocke 2008 ⁴⁶¹	Not in English
Holleman 2016 ⁴⁶³	Not review population
Hookey 2006 ⁴⁶⁷	Incorrect study design
Horvath 2001 ⁴⁷¹	Inappropriate comparison
Horvath 2010 ⁴⁷⁰	Incorrect study design
Howard 1989 ⁴⁷³	Narrative article
Huang 1993 ⁴⁷⁹	Not review population
Huggett 2015 ⁴⁸¹	Inappropriate comparison
Hughes 2007 ⁴⁸²	Narrative review
Hungness 2002 ⁴⁸⁵	Incorrect interventions

Jagielski 2015 ⁵²⁰	Incorrect study design
Jiang 2016 ⁵³⁵	Not guideline condition
Kalfarentzos 1999 ⁵⁶⁷	Inappropriate comparison
Karjula 2015 ⁵⁸⁰	Inappropriate comparison
Ke 2016 ⁵⁸⁶	Systematic review is not relevant to review question or unclear PICO
Khreiss 2015 ⁵⁹³	Not review population
Kulkarni 2014 ⁶²⁰	Not review population
Lee 2006 ⁶⁴⁵	Inappropriate study design
Lee 2007 ⁶⁴³	Inappropriate comparison
Li 2016 ⁶⁵⁷	Incorrect interventions
Lopes 2007 ⁶⁷⁴	Inappropriate comparison
Loveday 2008 ⁶⁸⁰	Systematic review is not relevant to review question or unclear PICO
Madenci 2014 ⁶⁹¹	Inappropriate comparison
Mathew 2014 ⁷¹⁷	Inappropriate comparison
Mier 1997 ⁷³⁹	Inappropriate comparison
Mikami 2005 ⁷⁴⁰	Narrative review
Mortele 2009 ⁷⁶⁰	Not review population
Mouli 2013 ⁷⁶⁵	Systematic review is not relevant to review question or unclear PICO
Mukai 2014 ⁷⁷¹	Not review population
Mukai 2015 ⁷⁶⁹	Not review population
Mukai 2015 ⁷⁷⁰	Not review population
Munene 2011 ⁷⁷³	Not review population
Navalho 2006 ⁷⁸⁸	Inappropriate comparison
Nieuwenhuijs 2003 ⁷⁹⁸	Systematic review: methods are not adequate/unclear
Papachristou 2007 ⁸³³	Inappropriate comparison

Parekh 2006 ⁸³⁵	Inappropriate comparison
Pascual 2013 ⁸⁴³	Paper not available
Raraty 2010 ⁸⁹⁹	Not review population
Rau 1997 ⁹⁰³	Narrative review
Rische 2013 ⁹¹³	Inappropriate comparison
Rocha 2009 ⁹¹⁶	Not review population
Rosenberg 2015 ⁹²³	Narrative review
Schrover 2008 ⁹⁶⁷	Inappropriate comparison
Seewald 2005 ⁹⁷²	Incorrect study design
Seifert 2009 ⁹⁷⁶	Incorrect study design
Shenvi 2016 ⁹⁸⁹	Incorrect interventions
Solanki 2013 ¹⁰¹⁰	Outcomes not fully reported
Tong 2012 ¹⁰⁷⁴	No relevant outcomes
Vallance 2014 ¹⁰⁹⁰	No relevant outcomes
Van Baal 2011 ¹⁰⁹¹	Systematic review is not relevant to review question or unclear PICO
Van Brunschot 2012 ¹⁰⁹⁴	Narrative review
Van Brunschot 2013 ¹⁰⁹⁸	Review protocol
Van Brunschot 2014 ¹⁰⁹⁵	Systematic review is not relevant to review question or unclear PICO
Van Grinsven 2016 ¹¹⁰⁰	Incorrect interventions
Van Santvoort 2011 ¹¹⁰¹	Not review population
Voermans 2007 ¹¹¹⁹	Incorrect study design
Wronski 2013 ¹¹⁵⁷	Inappropriate comparison
Zerem 2011 ¹¹⁸¹	Incorrect study design

L.13 Timing of management of infected necrosis in people with acute pancreatitis

Study	Exclusion reason
Abdelhafez 2013 ³	Inappropriate comparison
Ai 2010 ¹⁷	Not review population
Ala-Kokko 2001 ²⁴	Narrative article
Albers 2016 ²⁵	Not in English
Alsfasser 2012 ³¹	Not review population
Alvarez-Sanchez 2014 ³³	Systematic review is not relevant to review question or unclear PICO
Alvi 2011 ³⁴	Not review population
Ang 2013 ⁴¹	Inappropriate comparison
Arlt 2014 ⁵⁰	Inappropriate comparison. Incorrect interventions
Ashley 2001 ⁵⁴	Not review population
Aultman 1997 ⁵⁶	Not review population
Babu 2009 ⁶⁴	Systematic review is not relevant to review question or unclear PICO
Babu 2010 ⁶³	Inappropriate comparison
Bakker 2009 ⁷²	Narrative review
Bakker 2012 ⁶⁸	Inappropriate comparison
Bala 2009 ⁷⁴	Inappropriate comparison
Bang 2014 ⁸⁰	Not review population
Baril 2000 ⁸⁶	Incorrect study design
Baron 2002 ⁸⁸	Incorrect study design
Barreda 2015 ⁸⁹	Not review population
Baudin 2012 ¹⁰²	Inappropriate study design
Beattie 2002 ¹⁰⁴	Incorrect study design
Beck 2012 ¹⁰⁵	Incorrect study design
Becker 2009 ¹⁰⁶	Incorrect study design

Beenen 2011 ¹⁰⁸	Inappropriate comparison
Beger 1986 ¹¹⁰	Incorrect interventions
Beger 1988 ¹¹¹	Not review population
Beger 1989 ¹⁰⁹	Narrative review
Beger 1995 ¹¹³	Narrative review
Bello 2012 ¹¹⁷	Systematic review is not relevant to review question or unclear PICO
Berzin 2008 ¹²²	Inappropriate comparison
Besselink 2006 ¹²⁴	Inappropriate comparison. Not review population. Incorrect interventions
Besselink 2006 ¹²³	Inappropriate comparison
Besselink 2007 ¹²⁶	Systematic review is not relevant to review question or unclear PICO
Boland 2010 ¹⁴⁷	Inappropriate comparison
Bosscha 2001 ¹⁵⁰	Not review population
Bradley 1991 ¹⁵⁵	Inappropriate comparison
Bradley 2008 ¹⁵⁶	Systematic review is not relevant to review question or unclear PICO
Branum 1998 ¹⁵⁸	Inappropriate study design
Brunschot 2014 ¹⁰⁹⁵	Systematic review is not relevant to review question or unclear PICO
Bucher 2008 ¹⁶⁴	Inappropriate comparison
Buchler 2000 ¹⁶⁵	Incorrect study design
Busse 2015 ¹⁷⁵	Inappropriate comparison
Castellanos 2005 ²⁰⁰	Inappropriate comparison
Castellanos 2013 ¹⁹⁹	Inappropriate comparison
Chang 2006 ²⁰⁷	Inappropriate comparison
Chang 2014 ²⁰⁶	Systematic review is not relevant to review question or unclear PICO
Chaudhary 1997 ²¹¹	Inappropriate comparison
Cheung 2005 ²¹⁹	Inappropriate comparison
Cheung 2010 ²²⁰	Not review population

Cirocchi 2013 ²²⁸	Systematic review is not relevant to review question or unclear PICO
Connor 2003 ²³⁹	Not review population
Connor 2005 ²⁴⁰	Not review population
Connor 2005 ²³⁸	Incorrect study design
Connor 2006 ²⁴¹	Narrative review
Cresswell 2015 ²⁵⁶	Inappropriate comparison
Dhingra 2015 ²⁹¹	Incorrect interventions
Doctor 2011 ³⁰⁰	Incorrect study design
Doglietto 1994 ³⁰¹	Not review population
Dominioni 1997 ³⁰⁷	Paper not available
Dong 2008 ³⁰⁸	Incorrect study design
Easler 2012 ³²⁷	Narrative review
Easler 2014 ³²⁵	Not review population
Echenique 1998 ³³⁰	Inappropriate comparison
Eggink 1984 ³³⁵	Inappropriate comparison
Endlicher 2003 ³⁴²	Inappropriate comparison
Farkas 1998 ³⁵³	Incorrect interventions
Farkas 2006 ³⁵²	Inappropriate comparison
Fernandez-del Castillo 1998 ³⁵⁸	Not review population
Foitzik 1995 ³⁶¹	Not review population
Fotoohi 2007 ³⁶⁵	Narrative review
Fugger 1995 ³⁷²	Inappropriate comparison
Gambiez 1998 ³⁸³	Not review population
Gardner 2009 ³⁸⁶	Incorrect interventions
Gardner 2011 ³⁸⁷	Inappropriate comparison
Garg 2010 ³⁹¹	Inappropriate comparison

Gentile 1998 ³⁹⁴	Inappropriate comparison
Gluck 2012 ⁴⁰⁶	Inappropriate comparison
Gomatos 2016 ⁴⁰⁸	Not review population
Gotzinger 2003 ⁴¹¹	Not review population
Gou 2013 ⁴¹²	Paper not available
Guo 2001 ⁴²¹	Not in English
Guo 2013 ⁴²³	Incorrect interventions
Gurusamy 2016 ⁴²⁸	Review protocol
Haghshenasskashani 2011 ⁴³²	Systematic review is not relevant to review question or unclear PICO
Harris 2004 ⁴⁴²	Inappropriate comparison
Hocke 2008 ⁴⁶¹	Not in English
Hollemans 2016 ⁴⁶³	Not review population
Horvath 2001 ⁴⁷¹	Incorrect study design
Howard 1989 ⁴⁷³	Narrative review
Huang 1993 ⁴⁷⁹	Not review population
Huggett 2015 ⁴⁸¹	Not review population
Hughes 2007 ⁴⁸²	Narrative review
Hungness 2002 ⁴⁸⁵	Not review population
Jagielski 2015 ⁵²⁰	Incorrect study design
Jiang 2016 ⁵³⁵	Not review population
Kalfarentzos 1999 ⁵⁶⁷	Inappropriate comparison
Karjula 2015 ⁵⁸⁰	Inappropriate comparison
Ke 2016 ⁵⁸⁶	Systematic review is not relevant to review question or unclear PICO
Khreiss 2015 ⁵⁹³	Not review population
Kulkarni 2014 ⁶²⁰	Not review population
Kumar 2014 ⁶²²	Inappropriate comparison

Lee 2006 ⁶⁴⁵	Inappropriate study design
Lee 2007 ⁶⁴³	Inappropriate comparison
Li 2016 ⁶⁵⁷	Inappropriate comparison
Loveday 2008 ⁶⁸⁰	Systematic review is not relevant to review question or unclear PICO
Madenci 2014 ⁶⁹¹	Inappropriate comparison
Mathew 2014 ⁷¹⁷	Inappropriate comparison
Mier 1997 ⁷³⁹	Not review population
Mikami 2005 ⁷⁴⁰	Narrative review
Moggia 2017 ⁷⁵⁰	Not review population
Mortele 2009 ⁷⁶⁰	Not review population
Mouli 2013 ⁷⁶⁵	Systematic review is not relevant to review question or unclear PICO
Mukai 2014 ⁷⁷¹	Not review population
Mukai 2015 ⁷⁶⁹	Not review population
Mukai 2015 ⁷⁷⁰	Not review population
Munene 2011 ⁷⁷³	Not review population
Nieuwenhuijs 2003 ⁷⁹⁸	Systematic review: methods are not adequate/unclear
Pascual 2013 ⁸⁴³	Paper not available
Pupelis 2015 ⁸⁸⁴	Inappropriate comparison
Raraty 2010 ⁸⁹⁹	Not review population
Rasch 2016 ⁹⁰¹	Inappropriate comparison
Rau 1997 ⁹⁰³	Narrative review
Rau 2005 ⁹⁰²	Incorrect interventions
Rosenberg 2015 ⁹²³	Narrative review
Ross 2014 ⁹²⁴	Incorrect study design
Shenvi 2016 ⁹⁸⁹	Incorrect interventions
Szeliga 2014 ¹⁰⁵¹	Inappropriate comparison

Vallance 2014 ¹⁰⁹⁰	Inappropriate comparison
Van Baal 2011 ¹⁰⁹¹	Systematic review is not relevant to review question or unclear PICO
Van Brunschot 2012 ¹⁰⁹⁴	Narrative review
Van Brunschot 2013 ¹⁰⁹⁸	Review protocol
Van Grinsven 2016 ¹¹⁰⁰	Narrative review
Van Grinsven 2017 ¹⁰⁹⁹	Inappropriate comparison
Wronski 2013 ¹¹⁵⁷	Inappropriate comparison
Zerem 2011 ¹¹⁸¹	Incorrect study design

L.14 Management of pain in people with chronic pancreatitis

Study	Exclusion reason
Adamek 1999 ¹⁰	Incorrect study design
Ahmed Ali 2012 ¹⁵	Inappropriate comparison
Ahmed Ali 2015 ¹⁶	Not review population
Aimoto 2013 ¹⁸	Inappropriate comparison
Aljebreen 2014 ²⁷	Inappropriate comparison
Amornyotin 2015 ³⁹	Incorrect interventions
Arendt 1999 ⁴⁹	Unavailable
Armbrecht 1986 ⁵¹	No relevant outcomes
Bachmann 2014 ⁶⁵	Inappropriate comparison
Banks 1991 ⁸³	Incorrect study design
Basinski 2005 ⁹³	Not review population
Bassi 1999 ⁹⁸	Incorrect study design
Beckingham 1997 ¹⁰⁷	Systematic review is not relevant to review question or unclear PICO
Behrns 2008 ¹¹⁵	Incorrect study design
Bejanin 1993 ¹¹⁶	Unavailable
Bergman 2012 ¹²¹	Not review population
Bhardwaj 2013 ¹²⁸	Incorrect study design

Bilton 1994 ¹³³	Not review population
Binmoeller 1995 ¹³⁴	Incorrect study design
Bliss 2015 ¹³⁹	Not review population
Bloechle 1995 ¹⁴²	Unavailable
Bloechle 1996 ¹⁴⁰	Incorrect study design
Bloechle 2001 ¹⁴¹	Unavailable
Bouwense 2012 ¹⁵³	No relevant outcomes
Brand 2000 ¹⁵⁷	Incorrect study design
Brown 1997 ¹⁶¹	Systematic review is not relevant to review question or unclear PICO
Buchler 1996 ¹⁶⁶	Incorrect study design. Not in English
Buhler 1999 ¹⁶⁸	Not review population
Burton 2011 ¹⁷¹	Incorrect study design
Buscher 2002 ¹⁷³	Incorrect study design
Buscher 2007 ¹⁷⁴	Incorrect study design
Butorova 2007 ¹⁷⁶	Unavailable
Byrne 2009 ¹⁷⁹	Not review population
Cahen 2007 ¹⁸³	Unavailable
Cahen 2007 ¹⁸²	Not review population
Cai 2013 ¹⁸⁶	Incorrect interventions
Capurso 2012 ¹⁹³	Incorrect study design
Cartmell 2004 ¹⁹⁶	No extractable outcomes
Chan 2001 ²⁰⁴	Not review population
Chauhan 2010 ²¹²	Incorrect study design
Chauhan 2012 ²¹³	Incorrect study design
Chen 2015 ²¹⁴	Unavailable
Chiang 2007 ²²¹	Inappropriate comparison
Classen 1990 ²³⁰	Incorrect study design
Cremer 1989 ²⁵⁵	Incorrect study design
Davies 1996 ²⁶⁸	Incorrect study design
De las Heras Castano 2000 ²⁷⁵	Incorrect study design

D'Egidio 1991 ²⁶⁰	Incorrect study design
Delhaye 2004 ²⁷⁹	Incorrect study design
Deprez ²⁸²	Abstract only
D'Haese 2014 ²⁶²	Incorrect study design
Dhingra 2013 ²⁹⁰	No extractable outcomes
Dhir 2015 ²⁹²	Incorrect study design
Dite 2003 ²⁹⁹	Not review population
Duffas 2005 ³¹⁵	Inappropriate comparison
Dumonceau 2007 ³¹⁹	Not review population
Duvnjak 1998 ³²⁴	Inappropriate comparison
Eisenach 2003 ³³⁸	Incorrect interventions
Fan 1993 ³⁵⁰	Not review population
Fitzsimmons 1999 ³⁵⁹	Incorrect study design
Fitzsimmons 2005 ³⁶⁰	Incorrect study design
Folsch 1997 ³⁶²	Not review population
Fujisawa 2014 ³⁷⁴	Inappropriate comparison
Fuller 1981 ³⁷⁵	Incorrect interventions
Funnell 1994 ³⁷⁶	Incorrect study design
Gabbrielli 2005 ³⁸⁰	Incorrect study design
Garzya 1985 ³⁹²	Not in English
Giovannini 2016 ⁴⁰⁰	Incorrect study design
Gooshe 2015 ⁴¹⁰	Systematic review is not relevant to review question or unclear PICO
Gooshe 2015 ⁴¹⁰	Incorrect interventions
Gress 2001 ⁴¹⁵	Incorrect study design
Guda 2005 ⁴¹⁶	Systematic review is not relevant to review question or unclear PICO
Gupta 2007 ⁴²⁴	Incorrect study design
Gurusamy 2016 ⁴²⁹	Inappropriate comparison. Systematic review is not relevant to review question or unclear PICO
Halder 2015 ⁴³³	Inappropriate comparison
Halgreen 1986 ⁴³⁴	Study prior to search cut-off date

Heider 1999 ⁴⁵¹	Incorrect study design
Hernandez 2011 ⁴⁵⁴	Systematic review is not relevant to review question or unclear PICO
Herrerías 1989 ⁴⁵⁵	Unavailable
Heyries 2010 ⁴⁵⁶	Conference abstract
Hirota 2010 ⁴⁵⁷	Systematic review is not relevant to review question or unclear PICO
Hoogerwerf 2005 ⁴⁶⁶	Incorrect study design
Horibe 2015 ⁴⁶⁸	Not review population. Systematic review is not relevant to review question or unclear PICO
Howell 1993 ⁴⁷⁶	Incorrect study design
Hu 2016 ⁴⁷⁸	Unavailable
Inui 2005 ⁴⁹⁴	Incorrect study design
Irani 2012 ⁴⁹⁷	Not review population
Isaksson 1983 ⁴⁹⁸	Study prior to study cut-off date
Itoi 2009 ⁵⁰⁷	Inappropriate comparison
Izbicki 1994 ⁵¹³	Inappropriate comparison
Izbicki 1995 ⁵¹⁴	Not in English
Izbicki 1996 ⁵¹¹	Incorrect study design
Izbicki 1997 ⁵¹²	Unavailable
Izbicki 1998 ⁵¹⁰	Incorrect study design
Izbicki 1998 ⁵⁰⁹	Inappropriate comparison
Jacobson 2005 ⁵¹⁶	Incorrect study design
Jagielski 2017 ⁵¹⁹	Incorrect study design
Jazrawi 2011 ⁵²⁵	Incorrect study design
Jeppe 2011 ⁵³⁰	Conference abstract
Jeppe 2013 ⁵²⁹	Incorrect study design
Jiang 2014 ⁵³⁴	Not in English
Jimenez 2000 ⁵³⁶	Inappropriate comparison
Johanns 1996 ⁵⁴⁰	Incorrect study design
John 2014 ⁵⁴¹	Conference abstract
John 2014 ⁵⁴²	Conference abstract

John 2016 ⁵⁴³	Conference abstract
Joliat 2017 ⁵⁴⁸	Inappropriate comparison
Jouannaud 2006 ⁵⁵¹	Not review population
Junming 2015 ⁵⁵³	Conference abstract
Kandiah 2014 ⁵⁷²	Conference abstract
Kapural 2010 ⁵⁷⁶	Conference abstract
Kapural 2011 ⁵⁷⁷	Incorrect interventions
Karasawa 2002 ⁵⁷⁹	Incorrect study design
King 2010 ⁶⁰⁰	Systematic review is not relevant to review question or unclear PICO. Not review population
Kirk 2006 ⁶⁰¹	Incorrect interventions
	Incorrect study design
Klapdor 2012 ⁶⁰⁴	Not review population
Klempa 1995 ⁶⁰⁵	Unavailable
Knill-Jones 1973 ⁶⁰⁶	Not in English
Knop 2010 ⁶⁰⁷	Incorrect study design
Kocher 2008 ⁶⁰⁸	Systematic review is not relevant to review question or unclear PICO
Kocher 2011 ⁶⁰⁹	Systematic review is not relevant to review question or unclear PICO
Koninger 2004 ⁶¹²	Unavailable
Kozarek 1985 ⁶¹⁷	Incorrect study design
Kwek 2014 ⁶³¹	Incorrect study design
Lang 1991 ⁶³³	Not review population
Larvin 1991 ⁶⁴⁰	Incorrect study design
Leksowski 2007 ⁶⁴⁷	Incorrect study design
Lerch 2009 ⁶⁴⁹	Incorrect study design
Levy 1989 ⁶⁵⁰	Unavailable
Li 2006 ⁶⁵³	Unavailable
Li 2015 ⁶⁵⁸	Incorrect interventions
Li 2016 ⁶⁵¹	Inappropriate comparison
Liu 1997 ⁶⁶⁷	Incorrect study design

Lorenz 1988 ⁶⁷⁵	Unavailable
Lu 2013 ⁶⁸²	Inappropriate comparison
Madsen 1985 ⁶⁹²	Study prior to search cut-off date
Magyar 1997 ⁶⁹⁶	No relevant outcomes
Makin 2012 ⁷⁰⁰	Incorrect study design
Malhotra 2007 ⁷⁰⁵	Review protocol
Mayyas 2010 ⁷²⁶	Not review population. Systematic review is not relevant to review question or unclear PICO
McCloy 1998 ⁷³²	Incorrect study design
McMahon 1991 ⁷³³	Incorrect study design
Melman 2009 ⁷³⁴	Not review population
Mergener 2005 ⁷³⁷	Incorrect study design
Milek 2014 ⁷⁴¹	Inappropriate comparison
Mobius 2007 ⁷⁴⁹	Inappropriate comparison
Mohseni Salehi Monfared 2009 ⁷⁵¹	Incorrect study design
Monkemuller 2004 ⁷⁵⁴	Incorrect study design
Moole 2016 ⁷⁵⁵	Systematic review is not relevant to review question or unclear PICO
Morgan 2003 ⁷⁵⁷	Incorrect study design
Mossner 1993 ⁷⁶²	Incorrect study design
Muhl 2009 ⁷⁶⁸	Incorrect study design
Muller 2008 ⁷⁷²	Inappropriate comparison
Nakahara 2013 ⁷⁸⁰	Incorrect study design
Nakamura 2012 ⁷⁸²	Not review population
Nandi 2002 ⁷⁸⁴	Abstract only
Ni 2015 ⁷⁹³	Incorrect study design
Niemann 2000 ⁷⁹⁷	Inappropriate comparison
Noda 1994 ⁸⁰²	Incorrect interventions
Nussinson 1991 ⁸⁰⁸	Incorrect study design
Ohwada 1997 ⁸¹³	Not review population
O'Keefe 2001 ⁸¹¹	Not review population

Olazabal 1978 ⁸²⁰	Not review population
Oracz 2010 ⁸²³	Not in English
Paisley 2014 ⁸²⁷	Incorrect study design
Paris 1993 ⁸³⁷	Not review population
Park 2009 ⁸⁴⁰	Not in English
Puli 2009 ⁸⁸⁰	Not review population. Systematic review is not relevant to review question or unclear PICO
Puylaert 2011 ⁸⁸⁷	Incorrect study design
Ramesh 2013 ⁸⁹²	Incorrect study design
Riediger 2007 ⁹¹²	Inappropriate comparison
Rubenstein 2002 ⁹²⁵	Incorrect study design
Rupasinghe 2017 ⁹²⁶	Incorrect study design
Rustagi 2015 ⁹²⁸	Incorrect study design
Rustagi 2015 ⁹²⁸	Systematic review is not relevant to review question or unclear PICO. Incorrect interventions
Safdi 2006 ⁹³²	Not review population
Sahai 2010 ⁹³⁵	Incorrect study design
Sahel 1987 ⁹³⁷	Incorrect study design
Salim 1991 ⁹⁴²	Incorrect population
Samuelson 2016 ⁹⁴⁵	Unavailable
Santosh 2009 ⁹⁴⁹	Inappropriate comparison
Sarfeh 1988 ⁹⁵⁰	Inappropriate comparison
Sawai 2006 ⁹⁵⁵	Not review population
Schofield 1994 ⁹⁶⁵	Abstract only
Shah 2010 ⁹⁸⁰	Incorrect study design
Shah 2013 ⁹⁷⁹	Incorrect interventions
Shao 2012 ⁹⁸¹	Unavailable
Shen 2014 ⁹⁸⁸	Inappropriate comparison
Shrikhande 2006 ⁹⁹³	Incorrect study design
Siriwardena 2012 ¹⁰⁰¹	Incorrect interventions
Slaff 1984 ¹⁰⁰⁴	Results not fully reported

Staahl 2007 ¹⁰²¹	No extractable outcomes
Stefaniak 2008 ¹⁰²⁴	Incorrect interventions
Stevens 2012 ¹⁰²⁵	Inappropriate comparison
Strate 2005 ¹⁰³²	Unavailable
Strate 2006 ¹⁰³⁰	Unavailable
Strate 2008 ¹⁰²⁹	Inappropriate comparison
Sukharamwala 2015 ¹⁰⁴²	Systematic review is not relevant to review question or unclear PICO. Inappropriate comparison
Talukdar 2015 ¹⁰⁵⁸	Systematic review is not relevant to review question or unclear PICO
Talukdar 2016 ¹⁰⁵⁷	Incorrect intervention
Tandan 2010 ¹⁰⁶²	Not review population
Thorat 2012 ¹⁰⁷²	Not review population
Trespi 1997 ¹⁰⁷⁶	Unavailable
Uden 1989 ¹⁰⁸⁵	Abstract only
Usatoff 2000 ¹⁰⁸⁸	Incorrect study design
Vantini 1990 ¹¹⁰⁵	Incorrect interventions
Varadarajulu 2011 ¹¹⁰⁸	Not review population
Verhaegh 2013 ¹¹¹³	Incorrect study design
Vitkomb 2010 ¹¹¹⁸	Unavailable
Wilder-Smith 1999 ¹¹⁴⁴	Inappropriate comparison
Will 2006 ¹¹⁴⁷	Incorrect study design
Will 2011 ¹¹⁴⁶	Not review population
Winstead 2009 ¹¹⁵⁰	Systematic review is not relevant to review question or unclear PICO
Witzigmann 2003 ¹¹⁵³	Inappropriate comparison
Wolf 1995 ¹¹⁵⁵	Incorrect study design
Yaghoobi 2016 ¹¹⁶⁸	Systematic review is not relevant to review question or unclear PICO
Yang 2014 ¹¹⁷²	Not in English
Zambudio 2014 ¹¹⁸⁰	Incorrect study design
Zhou 2015 ¹¹⁹¹	Systematic review is not relevant to review question or unclear

	PICO. Incorrect interventions
Zhu 2017 ¹¹⁹⁵	Unavailable

L.15 Management of pancreatic duct obstruction in people with chronic pancreatitis

Study	Exclusion reason
Adamek 1999 ¹⁰	Incorrect study design
Ahmed Ali 2012 ¹⁵	Inappropriate comparison
Ahmed Ali 2014 ¹⁴	Incorrect interventions
Ahmed Ali 2015 ¹⁶	Not review population
Aimoto 2013 ¹⁸	Inappropriate comparison
Aljebreen 2014 ²⁷	Inappropriate comparison
Amornytin 2015 ³⁹	Incorrect interventions
Arendt 1999 ⁴⁹	Unavailable
Armbrecht 1986 ⁵¹	No relevant outcomes
Bachmann 2014 ⁶⁵	Inappropriate comparison
Banks 1991 ⁸³	Incorrect study design
Basinski 2005 ⁹³	Not review population
Bassi 1999 ⁹⁸	Incorrect study design
Beckingham 1997 ¹⁰⁷	Systematic review is not relevant to review question or unclear PICO
Bergman 2012 ¹²¹	Not review population
Binmoeller 1995 ¹³⁴	Incorrect study design
Bloechle 1996 ¹⁴⁰	Not in English
Bouwense 2012 ¹⁵³	No relevant outcomes
Brand 2000 ¹⁵⁷	Incorrect study design
Brown 1997 ¹⁶¹	Systematic review is not relevant to review question or unclear PICO
Buchler 1996 ¹⁶⁶	Not in English

Buhler 1999 ¹⁶⁸	Not review population
Buscher 2002 ¹⁷³	Incorrect study design
Buscher 2007 ¹⁷⁴	Incorrect study design
Byrne 2009 ¹⁷⁹	Not review population
Cai 2013 ¹⁸⁶	Incorrect interventions
Cartmell 2004 ¹⁹⁶	No relevant outcomes
Chauhan 2010 ²¹²	Incorrect study design
Chauhan 2012 ²¹³	Incorrect study design
Chiang 2007 ²²¹	Inappropriate comparison
Classen 1990 ²³⁰	Incorrect study design
Cremer 1989 ²⁵⁵	Incorrect study design
Davies 1996 ²⁶⁸	Incorrect study design
D'Egidio 1991 ²⁶⁰	Incorrect study design
Delhaye 2004 ²⁷⁹	Incorrect study design
D'Haese 2014 ²⁶²	Incorrect study design
Dhir 2015 ²⁹²	Incorrect study design
Duffas 2005 ³¹⁵	Inappropriate comparison
Eisenach 2003 ³³⁸	Incorrect interventions
Fan 1993 ³⁵⁰	Not review population
Folsch 1997 ³⁶²	Not review population
Fujisawa 2014 ³⁷⁴	Inappropriate comparison
Fuller 1981 ³⁷⁵	Incorrect interventions
Funnell 1994 ³⁷⁶	Incorrect study design
Gabbrielli 2005 ³⁸⁰	Incorrect study design
Garzya 1985 ³⁹²	Not in English
Giovannini 2016 ⁴⁰⁰	Incorrect study design

Gooshe 2015 ⁴¹⁰	Incorrect interventions
Gress 2001 ⁴¹⁵	Incorrect study design
Guda 2005 ⁴¹⁶	Systematic review is not relevant to review question or unclear PICO
Gupta 2007 ⁴²⁴	Incorrect study design
Gurusamy 2016 ⁴²⁹	Inappropriate comparison
Halder 2015 ⁴³³	Inappropriate comparison
Halgreen 1986 ⁴³⁴	Not review population
Heider 1999 ⁴⁵¹	Incorrect study design
Heyries 2010 ⁴⁵⁶	Conference abstract
Hirota 2010 ⁴⁵⁷	Systematic review is not relevant to review question or unclear PICO
Hoogerwerf 2005 ⁴⁶⁶	Incorrect study design
Horibe 2015 ⁴⁶⁸	Not review population
Howell 1993 ⁴⁷⁶	Incorrect study design
Inui 2005 ⁴⁹⁴	Incorrect study design
Irani 2012 ⁴⁹⁷	Not review population
Isaksson 1983 ⁴⁹⁸	Not review population
Itoi 2009 ⁵⁰⁷	Inappropriate comparison
Izbicki 1994 ⁵¹³	Inappropriate comparison
Izbicki 1995 ⁵¹⁴	Not in English
Izbicki 1996 ⁵¹¹	Incorrect study design
Izbicki 1998 ⁵¹⁰	Incorrect study design
Izbicki 1998 ⁵⁰⁹	Inappropriate comparison
Jacobson 2005 ⁵¹⁶	Incorrect study design
Jagielski 2017 ⁵¹⁹	Incorrect study design
Jazrawi 2011 ⁵²⁵	Incorrect study design
Jeppe 2011 ⁵³⁰	Conference abstract

Jeppe 2013 ⁵²⁹	Incorrect study design
Jiang 2014 ⁵³⁴	Not in English
Jimenez 2000 ⁵³⁶	Inappropriate comparison
Johanns 1996 ⁵⁴⁰	Incorrect study design
John 2014 ⁵⁴¹	Conference abstract
John 2014 ⁵⁴²	Conference abstract
John 2016 ⁵⁴³	Conference abstract
Joliat 2017 ⁵⁴⁸	Inappropriate comparison
Jouannaud 2006 ⁵⁵¹	Not review population
Junming 2015 ⁵⁵³	Conference abstract
Kaido 2006 ⁵⁶³	Inappropriate comparison
Kandiah 2014 ⁵⁷²	Conference abstract
Kapuraj 2010 ⁵⁷⁶	Conference abstract
Kapuraj 2011 ⁵⁷⁷	Incorrect interventions
Karasawa 2002 ⁵⁷⁹	Incorrect study design
King 2010 ⁶⁰⁰	Not review population
Kirk 2006 ⁶⁰¹	Incorrect interventions
Knill-Jones 1973 ⁶⁰⁶	Not in English
Knop 2010 ⁶⁰⁷	Incorrect study design
Kocher 2008 ⁶⁰⁸	Systematic review is not relevant to review question or unclear PICO
Kocher 2011 ⁶⁰⁹	Systematic review is not relevant to review question or unclear PICO
Kozarek 1985 ⁶¹⁷	Incorrect study design
Kwek 2014 ⁶³¹	Incorrect study design
Lang 1991 ⁶³³	Not review population
Larvin 1991 ⁶⁴⁰	Incorrect study design
Leksowski 2007 ⁶⁴⁷	Incorrect study design

Lerch 2009 ⁶⁴⁹	Incorrect study design
Li 2015 ⁶⁵⁸	Incorrect interventions
Li 2016 ⁶⁵¹	Inappropriate comparison
Liu 1997 ⁶⁶⁷	Incorrect study design
Lu 2013 ⁶⁸²	Inappropriate comparison
Madsen 1985 ⁶⁹²	Not review population
Magyar 1997 ⁶⁹⁶	No relevant outcomes
Makin 2012 ⁷⁰⁰	Incorrect study design
Malesci 1995 ⁷⁰⁴	Not review population
Malhotra 2007 ⁷⁰⁵	Review protocol
Mayyas 2010 ⁷²⁶	Not review population
McMahon 1991 ⁷³³	Incorrect study design
Melman 2009 ⁷³⁴	Not review population
Mergener 2005 ⁷³⁷	Incorrect study design
Milek 2014 ⁷⁴¹	Inappropriate comparison
Monkemuller 2004 ⁷⁵⁴	Incorrect study design
Moole 2016 ⁷⁵⁵	Systematic review is not relevant to review question or unclear PICO
Morgan 2003 ⁷⁵⁷	Incorrect study design
Mossner 1992 ⁷⁶³	Not review population
Muhl 2009 ⁷⁶⁸	Incorrect study design
Nakahara 2013 ⁷⁸⁰	Incorrect study design
Nakamura 2012 ⁷⁸²	Not review population
Ni 2015 ⁷⁹³	Incorrect study design
Niemann 2000 ⁷⁹⁷	Inappropriate comparison
Noda 1994 ⁸⁰²	Incorrect interventions
Nussinson 1991 ⁸⁰⁸	Incorrect study design

Ohwada 1997 ⁸¹³	Not review population
O'Keefe 2001 ⁸¹¹	Not review population
Olazabal 1978 ⁸²⁰	Not review population
Oracz 2010 ⁸²³	Not in English
Paris 1993 ⁸³⁷	Not review population
Puli 2009 ⁸⁸⁰	Not review population
Puylaert 2011 ⁸⁸⁷	Incorrect study design
Ramesh 2013 ⁸⁹²	Incorrect study design
Riediger 2007 ⁹¹²	Inappropriate comparison
Rubenstein 2002 ⁹²⁵	Inappropriate comparison
Rustagi 2015 ⁹²⁸	Incorrect interventions
Safdi 2006 ⁹³²	Not review population
Sahai 2010 ⁹³⁵	Incorrect study design
Sahel 1987 ⁹³⁷	Incorrect study design
Santosh 2009 ⁹⁴⁹	Inappropriate comparison
Sarfeh 1988 ⁹⁵⁰	Inappropriate comparison
Sawai 2006 ⁹⁵⁵	Not review population
Seza 2011 ⁹⁷⁸	Not review population
Shah 2013 ⁹⁷⁹	Incorrect interventions
Shen 2014 ⁹⁸⁸	Inappropriate comparison
Shrikhande 2006 ⁹⁹³	Incorrect study design
Siriwardena 2012 ¹⁰⁰¹	Incorrect interventions
Staahl 2007 ¹⁰²¹	No relevant outcomes
Stefaniak 2008 ¹⁰²⁴	Incorrect interventions
Stevens 2012 ¹⁰²⁵	Inappropriate comparison
Sukharamwala 2015 ¹⁰⁴²	Inappropriate comparison

Talukdar 2016 ¹⁰⁵⁷	Not review population
Thorat 2012 ¹⁰⁷²	Not review population
Usatoff 2000 ¹⁰⁸⁸	Incorrect study design
Vantini 1990 ¹¹⁰⁵	Incorrect interventions
Varadarajulu 2011 ¹¹⁰⁸	Not review population
Verhaegh 2013 ¹¹¹³	Incorrect study design
Wilder-Smith 1999 ¹¹⁴⁴	Inappropriate comparison
Will 2006 ¹¹⁴⁷	Incorrect study design
Will 2011 ¹¹⁴⁶	Not review population
Winstead 2009 ¹¹⁵⁰	Systematic review is not relevant to review question or unclear PICO
Witzigmann 2003 ¹¹⁵³	Inappropriate comparison
Wolf 1995 ¹¹⁵⁵	Incorrect study design
Yaghoobi 2016 ¹¹⁶⁸	Systematic review is not relevant to review question or unclear PICO
Yang 2014 ¹¹⁷²	Not in English
Zambudio 2014 ¹¹⁸⁰	Incorrect study design
Zhou 2015 ¹¹⁹¹	Incorrect interventions

L.16 Management of small-duct disease in people with chronic pancreatitis

Study	Exclusion reason
Akshintala 2014 ²⁰	Not review population
Andersson 2006 ⁴⁰	Not review population
Ardengh 2014 ⁴⁸	Not review population
Azeem 2012 ⁶⁰	Not review population
Barthet 1993 ⁹¹	Not review population
Bhasin 2011 ¹²⁹	Not review population

Boerma 2002 ¹⁴⁵	Not review population
Boutros 2010 ¹⁵¹	Not review population
Bouwense 2011 ¹⁵²	Not review population
Chen 2017 ²¹⁷	Not review population
Clarke 2012 ²²⁹	Not review population
Davila-Cervantes 2004 ²⁶⁹	Not review population
D'Egidio 1992 ²⁶¹	Not review population
Epelboym 2014 ³⁴⁴	Not review population
Farkas 2004 ³⁵¹	Not review population
Farnbacher 2002 ³⁵⁵	Not review population
Giovannini 2012 ³⁹⁹	Not review population
Howard 2002 ⁴⁷⁴	Not review population
Huizinga 1992 ⁴⁸³	Not review population
Iqbal 2009 ⁴⁹⁵	Not review population
John 2015 ⁵⁴⁵	Not review population
John 2017 ⁵⁴⁴	Not review population
Jordan 2001 ⁵⁴⁹	Not review population
Keck 2010 ⁵⁸⁸	Not review population
Kondo 2014 ⁶¹¹	Not review population
Lu 2014 ⁶⁸³	Not review population
Naoum 2003 ⁷⁸⁵	Not review population
Rosch 2002 ⁹²²	Not review population
Saul 2016 ⁹⁵⁴	Not review population
Sharma 2002 ⁹⁸²	Not review population
Teh 2006 ¹⁰⁶⁷	Not review population
Trevino 2010 ¹⁰⁷⁷	Not review population

Varadarajulu 2007 ¹¹⁰⁹	Not review population
Varadarajulu 2008 ¹¹⁰⁷	Not review population
Vitas 1992 ¹¹¹⁷	Not review population
Will 2007 ¹¹⁴⁵	Not review population
Yang 2016 ¹¹⁷¹	Not review population

L.17 Management of pseudocysts

Study	Exclusion reason
Adams 1992 ¹¹	Incorrect interventions
Aljarabah 2007 ²⁶	Systematic review: study designs inappropriate
Ardengh 2014 ⁴⁸	Not review population: cysts not pseudocysts
Azeem 2012 ⁶⁰	Not review population
Barthet 1993 ⁹¹	Not review population
Binmoeller 1995 ¹³⁵	Incorrect study design
Boerma 2002 ¹⁴⁵	Not review population
Boutros 2010 ¹⁵¹	Inappropriate comparison
Bouwense 2011 ¹⁵²	Not review population
Chen 2017 ²¹⁷	Not review population
Clarke 2012 ²²⁹	Incorrect study design
D'Egidio 1992 ²⁶¹	Inappropriate comparison
Epelboym 2014 ³⁴⁴	Not review population
Farkas 2004 ³⁵¹	Not review population
Farnbacher 2002 ³⁵⁵	Not review population
Giovannini 2012 ³⁹⁹	Systematic review: methods are not adequate/unclear
Howard 2002 ⁴⁷⁴	Not review population
Huizinga 1992 ⁴⁸³	Inappropriate comparison
Iqbal 2009 ⁴⁹⁵	Not review population
John 2015 ⁵⁴⁵	Not review population
John 2017 ⁵⁴⁴	Not review population

Study	Exclusion reason
Jordan 2001 ⁵⁴⁹	Not review population
Kahaleh 2006 ⁵⁵⁷	Inappropriate comparison
Keck 2010 ⁵⁸⁸	Not review population
Kondo 2014 ⁶¹¹	Not pseudocysts. Not review population
Lu 2014 ⁶⁸³	Not review population
Naoum 2003 ⁷⁸⁵	Confounding by indication: severity of pseudocysts dictated which treatment was received
Rosch 2002 ⁹²²	Inappropriate comparison. Not review population
Russell 2013 ⁹²⁷	Incorrect interventions
Seven 2012 ⁹⁷⁷	Not review population
Sharma 2002 ⁹⁸²	Inappropriate comparison
Smits 1995 ¹⁰⁰⁷	Inappropriate comparison
Teh 2006 ¹⁰⁶⁷	Inappropriate comparison
Trevino 2010 ¹⁰⁷⁷	Not review population: Peripancreatic fluid collections not just pseudocysts
Varadarajulu 2007 ¹¹⁰⁹	Not review population: Peripancreatic fluid collections not just pseudocysts
Vitas 1992 ¹¹¹⁷	All procedures performed prior to 1990
Will 2007 ¹¹⁴⁵	Not review population
Williams 1992 ¹¹⁴⁸	Incorrect interventions
Yang 2016 ¹¹⁷¹	Inappropriate comparison.

L.18 Management of pancreatic ascites and pleural effusion secondary to pancreatitis

Study	Exclusion reason
Abadia 2010 ¹	Conference abstract
Adler 1990 ¹²	Incorrect study design
Allen 2014 ²⁹	Incorrect population
Alonso Ordas 2017 ³⁰	Abstract only

Azoulay 2003 ⁵¹	Incorrect study design
Bakker 2011 ⁶⁹	Incorrect study design
Banimahd 2009 ⁸²	Incorrect study design
Bassi 2000 ⁹⁴	Incorrect study design
Bassi 2000 ⁹⁹	Incorrect study design
Bhasin 2006 ¹³⁰	Incorrect study design
Bintcliffe 2016 ¹³⁶	Incorrect study design
Bracher 1999 ¹⁵⁴	Incorrect study design
Cabay 1998 ¹⁸⁰	Incorrect study design
Cheng 2017 ²¹⁸	Incorrect population
Closset 2000 ²³¹	Incorrect study design
Cohen 2001 ²³⁴	Incorrect study design
Cohen 2007 ²³⁵	Incorrect study design
Cope 2001 ²⁴⁸	Incorrect study design
Coronel 2017 ²⁴⁹	Incorrect study design
Costamagna 2001 ²⁵²	Incorrect study design
Da Cunha 1995 ²⁶³	Incorrect study design
Dhar 1996 ²⁸⁹	Incorrect study design
Falconi 2002 ³⁴⁸	Incorrect study design
Feig 1992 ³⁵⁶	Not review population
Felix 2014 ³⁵⁷	Incorrect population
Fotoohi 1999 ³⁶⁴	Incorrect study design
Friess 1994 ³⁷⁰	Incorrect study design
Friess 1996 ³⁶⁹	Incorrect study design
Futagawa ³⁷⁹	Incorrect population
Gjorup 1992 ⁴⁰²	Incorrect population

Gumaste 1992 ⁴²⁰	Incorrect study design
Halttunen 2005 ⁴³⁶	Incorrect study design
Halttunen 2007 ⁴³⁵	Incorrect study design
Hassenpflug 2012 ⁴⁴⁵	Incorrect study design
Heo 2017 ⁴⁵²	Incorrect study design
Holst 1998 ⁴⁶⁵	Not in English
Houlihan 2013 ⁴⁷²	Incorrect study design
Igami 2009 ⁴⁸⁷	Incorrect study design
Ihse 1994 ⁴⁹²	Incorrect study design
Irani 2012 ⁴⁹⁷	Incorrect study design
Jain 2009 ⁵²¹	Incorrect study design
Jenkins 1995 ⁵²⁷	Incorrect study design
Jiang 2016 ⁵³⁵	Incorrect study design
Jorge 1991 ⁵⁵⁰	Incorrect study design
Kaman 2001 ⁵⁶⁸	Incorrect study design
Kanneganti 2009 ⁵⁷³	Incorrect study design
Karjula 2015 ⁵⁸⁰	Incorrect study design
Kawakatsu 2016 ⁵⁸⁵	Incorrect study design
King 2010 ⁶⁰⁰	Incorrect study design
Koizumi 2005 ⁶¹⁰	Incorrect study design
Kozarek 1991 ⁶¹⁶	Incorrect study design
Kurumboor 2009 ⁶²⁶	Incorrect study design
Larsen 2014 ⁶³⁹	Incorrect study design
Le Moine 2004 ⁶⁴¹	Incorrect study design
Lee 2014 ⁶⁴⁴	Incorrect study design
Liang 2007 ⁶⁶⁰	Incorrect study design

Lipsett 1992 ⁶⁶⁵	Incorrect study design
Lipsett 1998 ⁶⁶⁶	Incorrect study design
Liu 2015 ⁶⁶⁹	Inappropriate comparison
Mattison 1997 ⁷²⁰	Incorrect study design
Mithofer 1997 ⁷⁴⁴	Incorrect study design
Mittal 2007 ⁷⁴⁵	Incorrect study design
Moorthy 2007 ⁷⁵⁶	Incorrect study design
Morgan 2007 ⁷⁵⁸	Incorrect study design
Munoz-Bongrand 2004 ⁷⁷⁵	Inappropriate comparison
Nabi 2017 ⁷⁷⁷	Incorrect study design
Nair 2007 ⁷⁷⁸	Incorrect study design
Nakamura 2014 ⁷⁸¹	Incorrect population
Niedergethmann 2010 ⁷⁹⁶	Incorrect intervention
Nikou 2004 ⁸⁰⁰	Incorrect intervention
Nordback 1996 ⁸⁰⁵	Incorrect study design
Nwariaku 1995 ⁸⁰⁹	Not review population
Okabayashi 2004 ⁸¹⁴	Incorrect study design
Okamoto 2008 ⁸¹⁵	Incorrect intervention
Olakowski 2009 ⁸¹⁹	Not in English
Ondrejka 2000 ⁸²²	Not in English
O'Toole 2007 ⁸¹²	Incorrect study design
Pai 2009 ⁸²⁶	Incorrect study design
Palani Velu 2014 ⁸²⁸	Incorrect comparator
Pandey 2014 ⁸³⁰	Incorrect study design
Parekh 1992 ⁸³⁶	Incorrect study design
Park 2011 ⁸³⁹	Incorrect study design

Patil 2016 ⁸⁴⁴	Abstract only
Pearson 2012 ⁸⁴⁶	Incorrect study design
Pericleous 2016 ⁸⁵⁰	Incorrect study design
Phillips 2000 ⁸⁶⁴	Incorrect study design
Prabhudesai 1993 ⁸⁷⁸	Incorrect study design
Pratt 2008 ⁸⁷⁹	Incorrect intervention
Ramesh 2013 ⁸⁹³	Incorrect study design
Ramos-de la Medina 2006 ⁸⁹⁴	Incorrect population
Rana 2010 ⁸⁹⁵	Incorrect study design
Rana 2017 ⁸⁹⁶	Incorrect study design
Raptis 1994 ⁸⁹⁸	Not review condition
Reszetow 2006 ⁹⁰⁹	Incorrect study design
Ridgeway 1996 ⁹¹⁰	Incorrect study design
Ridolfi 2014 ⁹¹¹	Incorrect study design
Roberts 2012 ⁹¹⁴	Incorrect study design
Rockey 1990 ⁹¹⁷	Incorrect study design
Sanchez 2016 ⁹⁴⁶	Not in English
Santos 2017 ⁹⁴⁸	Incorrect study design
Schmidt 2009 ⁹⁶²	Incorrect comparator
Schweigert 2013 ⁹⁷¹	Incorrect study design
Schweigert 2013 ⁹⁷⁰	Incorrect study design
Sikora 2005 ⁹⁹⁴	Incorrect study design
Simmons 1997 ⁹⁹⁵	Incorrect study design
Singh 2013 ⁹⁹⁸	Incorrect study design
Smoczynski 2007 ¹⁰⁰⁹	Incorrect study design
Sorrentino 2017 ¹⁰¹³	Incorrect population

Srikanth 2002 ¹⁰¹⁹	Incorrect population
Suc 2004 ¹⁰³⁵	Incorrect population
Sugimoto 2015 ¹⁰³⁷	Incorrect study design
Tahir 2011 ¹⁰⁵²	Incorrect study design
Tajima 2006 ¹⁰⁵³	Incorrect study design
Tanaka 2013 ¹⁰⁶¹	Incorrect study design
Tsiotos 1995 ¹⁰⁸²	Incorrect population
Tsiotos 1999 ¹⁰⁸¹	Incorrect study design
Uchikov 2000 ¹⁰⁸³	Incorrect study design
Vansonnenberg 1997 ¹¹⁰⁴	Incorrect study design
Velamati 2006 ¹¹¹¹	Incorrect study design
Voss 2003 ¹¹²⁰	Incorrect study design
Wakefield 1996 ¹¹²⁴	Incorrect study design
Wang 2017 ¹¹²⁹	Incorrect population
Weniger 2016 ¹¹⁴¹	Incorrect study design
Wolfsen 1992 ¹¹⁵⁶	Incorrect study design
Wronski 2011 ¹¹⁵⁸	Incorrect study design
Xu 2014 ¹¹⁶⁶	Incorrect study design
Yokoi 2016 ¹¹⁷⁸	Incorrect study design
Zhou 2016 ¹¹⁹²	Incorrect study design

L.19 Management of biliary obstruction in people with chronic pancreatitis

Study	Exclusion reason
Abdallah 2007 ²	Incorrect study design
Acosta 2006 ⁹	Incorrect comparison

Arslanlar 2007 ⁵²	Systematic review is not relevant to review question or unclear PICO
Ayub 2010 ⁵⁹	Unavailable
Azzopardi 2012 ⁶²	Incorrect study design
Bakhru 2011 ⁶⁷	Unavailable
Baron 2009 ⁸⁷	Incorrect study design
Baron 2010{Baron, 2010 #847}	Incorrect study design
Barthet 1994 ⁹⁰	Incorrect study design
Behm 2009 ¹¹⁴	Incorrect study design
Blero 2015 ¹³⁸	Incorrect study design
Boskoski 2016 ¹⁴⁹	Unavailable
Brijbassie 2016 ¹⁵⁹	Unavailable
Cahen 2005 ¹⁸⁵	Incorrect study design
Cahen 2008 ¹⁸⁴	Incorrect study design
Cantu 2005 ¹⁹⁰	Incorrect study design
Chang 2016 ²⁰⁵	Incorrect study design
Chaput 2016 ²⁰⁹	Incorrect study design
Choo 2012 ²²³	Incorrect study design
Costamagna 2007 ²⁵¹	Incorrect study design
Costamagna 2013 ²⁵⁰	Incorrect study design
Coté 2016 ²⁵³	Not review population
Cremer 1992 ²⁵⁴	Incorrect study design
Devieri 1990 ²⁸⁷	Incorrect study design
Devieri 1992 ²⁸⁵	Unavailable
Devieri 1994 ²⁸⁶	Incorrect study design
Devieri 2014 ²⁸⁸	Incorrect study design
Devieri 2015 ²⁹²	Incorrect study design

Ding 2012 ²⁹⁸	Incorrect comparison
Draganov 2002 ³¹⁰	Incorrect study design
Dubravcsik 2012 ³¹⁴	Incorrect comparison
Dumonceau 1999 ³²⁰	Incorrect study design
Dumonceau 1999 ³²¹	Incorrect study design
Dumonceau 2010 ³¹⁸	Incorrect study design
Dumonceau 2011 ³²²	Systematic review is not relevant to review question or unclear PICO
Eickhoff 2001 ³³⁶	Incorrect study design
Eickhoff 2003 ³³⁷	Not in English
Eisendrath 1999 ¹⁷⁰	Incorrect study design
Enya 2004 ³⁴³	Incorrect study design
Familiari 2013 ³⁴⁹	Systematic review is not relevant to review question or unclear PICO
Farnbacher 2000 ³⁵⁴	Incorrect study design
French 2003 ³⁶⁷	Incorrect study design
Frey 1990 ³⁶⁸	Systematic review is not relevant to review question or unclear PICO
Fujino 2009 ³⁷³	Inappropriate comparison
Garcia-Cano 2010 ³⁸⁵	Not in English
Giacino 2012 ³⁹⁵	Incorrect study design
Gibbons 1998 ³⁹⁷	Systematic review is not relevant to review question or unclear PICO
Goenka 1997 ⁴⁰⁷	Incorrect study design
Gouma 2007 ⁴¹³	Incorrect study design
Gupta 2006 ⁴²⁶	Incorrect study design
Gupta 2007 ⁴²⁴	Incorrect study design
Gupta 2011 ⁴²⁷	Incorrect study design
Hammel 2001 ⁴³⁷	Incorrect study design
Hausegger 1996 ⁴⁴⁶	Incorrect study design

Hu 2014 ⁴⁷⁷	Incorrect study design
Huizinga 1992 ⁴⁸⁴	Incorrect study design
Igarashi 2004 ⁴⁸⁸	Incorrect study design
Ikeda 2010 ⁴⁹³	Incorrect interventions
Irani 2014 ⁴⁹⁶	Incorrect study design
Isayama 2009 ⁴⁹⁹	Incorrect study design
Ito 2012 ⁵⁰⁴	Not review population
Itoi 2012 ⁵⁰⁸	Incorrect study design
Jang 2010 ⁵²³	Incorrect study design
Kaffes 2013 ⁵⁵⁵	Incorrect study design
Kaffes 2015 ⁵⁵⁴	Incorrect study design
Kahaleh 2008 ²⁰⁹	Incorrect study design
Kahaleh 2013 ⁵⁵⁶	Incorrect study design
Kahl 2002 ⁵⁶²	Incorrect study design
Kahl 2003 ⁵⁶⁰	Incorrect study design
Kahl 2004 ⁵⁶¹	Incorrect study design
Kianicka 2013 ⁵⁹⁴	Incorrect study design
Kiehne 2000 ⁵⁹⁵	Incorrect study design
Kikuyama 2009 ⁵⁹⁷	Incorrect interventions
Kikuyama 2009 ⁵⁹⁶	Incorrect study design
Kim 1998 ⁵⁹⁹	Inappropriate comparison
Kim 2015 ⁵⁹⁸	Incorrect study design
Kulkarni 2015 ⁶¹⁹	Incorrect study design
Kumar 2004 ⁶²³	Incorrect study design
Kwon 2016 ⁶³²	Incorrect study design
Lee 2011 ⁶⁴²	Unavailable

Li 2014 ⁶⁵²	Incorrect study design
Lillemoe 1992 ⁶⁶¹	Incorrect study design
Lin 2010 ⁶⁶³	Incorrect interventions
Long 1990 ⁶⁷³	Incorrect study design
Lytras 2011 ⁶⁸⁸	Not review population
Mahajan 2009 ⁶⁹⁷	Incorrect study design
Mangiavillano 2014 ⁷⁰⁹	Incorrect study design
Matlock 2005 ⁷¹⁸	Incorrect study design
Matsubayashi 2016 ⁷¹⁹	Not review population
Mauri 2013 ⁷²²	Incorrect study design
Menon 2001 ⁷³⁵	Incorrect study design
Merdrignac 2016 ⁷³⁶	Incorrect study design
Mitchell 2003 ⁷⁴³	Incorrect study design
Muniraj 2013 ⁷⁷⁴	Systematic review is not relevant to review question or unclear PICO
Myburgh 1993 ⁷⁷⁶	Inappropriate comparison
Nakanuma 2010 ⁷⁸³	Incorrect study design
Nealon 1996 ⁷⁹⁰	Incorrect study design
O'Brien 1998 ⁸¹⁰	Incorrect study design
Oria 2007 ⁸²⁵	Incorrect comparison
Park 2003 ⁸⁷³	Incorrect study design
Park 2008 ⁸⁴¹	Incorrect study design
Park 2016 ⁸⁴²	Incorrect study design
Pausawasadi 2012 ⁸⁴⁵	Incorrect study design
Pearson 2012 ⁸⁴⁶	Not review population
Perri 2011 ⁸⁵²	Unavailable
Perri 2012 ⁸⁵¹	Incorrect study design

Poincloux 2015 ⁸⁷³	Incorrect interventions
Poley 2012 ⁸⁷⁴	Incorrect interventions
Ray 2015 ⁹⁰⁴	Incorrect study design
Rebibo 2013 ⁹⁰⁵	Incorrect study design
Rocca 2006 ⁹¹⁵	Incorrect study design
Ryu 2013 ⁹³⁰	Incorrect study design
Sakai 2009 ⁹⁴¹	Incorrect study design
Saluja 2014 ⁹⁴³	Incorrect study design
Sarkaria 2014 ⁹⁵¹	Incorrect study design
Saxena 2015 ⁹⁵⁶	Incorrect study design
Schepers 2017 ⁹⁵⁸	Review protocol
Schlosser 2001 ⁹⁶¹	Incorrect study design
Schnelldorfer 2003 ⁹⁶⁴	Incorrect study design
Schutz 1995 ⁹⁶⁸	Incorrect study design
Smits 1996 ¹⁰⁰⁸	Incorrect study design
Suc 1998 ¹⁰³⁴	Incorrect population
Targarona 1996 ¹⁰⁶⁴	Incorrect population. Incorrect intervention
Van Berkel 2004 ¹⁰⁹²	Incorrect study design
Van Boeckel 2009 ¹⁰⁹³	Incorrect study design
Velanovich 2009 ¹¹¹²	Systematic review is not relevant to review question or unclear PICO
Vitale 2000 ¹¹¹⁶	Incorrect study design
Wagh 2013 ¹¹²³	Incorrect study design
Waldthaler 2013 ¹¹²⁵	Inappropriate comparison
Walter 2015 ¹¹²⁷	Incorrect study design
Walter 2015 ¹¹²⁸	Incorrect population
Wasan 2005 ¹¹³⁵	Not review population

Weber 2014 ¹¹³⁶	Incorrect study design
Weigt 2016 ¹¹³⁷	Incorrect interventions
Yamaguchi 2006 ¹¹⁶⁹	Incorrect study design
Yang 2012 ¹¹⁷³	Incorrect intervention
Zheng 2015 ¹¹⁹⁰	Incorrect interventions
Zhou 2002 ¹¹⁹³	Incorrect comparison

L.20 Management of type 3c diabetes secondary to pancreatitis

None.

L.21 Receiving specialist input in people with acute pancreatitis

Study	Exclusion reason
Avanesov 2017 ⁵⁷	Incorrect study design
Banks 2006 ⁸⁴	Incorrect study design
Issa 2017 ⁵⁰³	Incorrect study design
Loser 1993 ⁶⁷⁸	Incorrect study design
Mayumi 2002 ⁷²⁵	Incorrect study design
Park 2009 ⁸³⁸	No relevant outcomes
Pezzilli 2006 ⁸⁶²	Incorrect study design
Soran 2001 ¹⁰¹²	Incorrect interventions
Sriskandarajah 2016 ¹⁰²⁰	Incorrect interventions
Toh 2000 ¹⁰⁷³	Incorrect interventions
Toouli 2002 ¹⁰⁷⁵	Incorrect study design
Working Group IAP/APA APG 2013 ⁴⁸⁶	Incorrect study design
Wyncoll 1999 ¹¹⁶³	Incorrect study design

L.22 Follow-up of pancreatic exocrine function in people with chronic pancreatitis

Study	Exclusion reason
Adamek 1999 ¹⁰	Inappropriate study design
Ammann 1996 ³⁶	Incorrect interventions
Belyaev 2013 ¹¹⁸	Inappropriate comparison
Dranka-Bojarowska 2015 ³¹²	Incorrect interventions
Ekbom 1994 ³³⁹	Incorrect interventions
Endlicher 2003 ³⁴²	Inappropriate study design
Furuya 1997 ³⁷⁷	Incorrect interventions
Maire 2011 ⁶⁹⁹	Inappropriate comparison
Sudo 2014 ¹⁰³⁶	Incorrect interventions
Sugito 2012 ¹⁰³⁸	Inappropriate study design
Symersky 2006 ¹⁰⁴⁸	Incorrect interventions
Takuma 2011 ¹⁰⁵⁴	Not review question
Tanaka 2014 ¹⁰⁶⁰	Incorrect interventions

L.23 Follow-up to identify diabetes in people with chronic pancreatitis

Study	Exclusion reason
Bittner 1994 ¹³⁷	Inappropriate comparison. Incorrect interventions
Hiroyoshi 1999 ⁴⁵⁸	Incorrect interventions.
Ito 2007 ⁵⁰⁶	Non-comparative study; not follow-up tests
Malecka-Panas 2002 ⁷⁰³	Not review population: healthy controls
Quartuccio 2017 ⁸⁸⁹	Incorrect interventions.
Roeyen 2016 ⁹¹⁸	Inappropriate comparison. Incorrect interventions. Non-comparative study
Ruxer 2012 ⁹²⁹	Not English language

Schrader 2010 ⁹⁶⁶	Inappropriate comparison. Incorrect interventions
------------------------------	---

L.24 Follow-up to identify pancreatic cancer in people with chronic pancreatitis

Study	Exclusion reason
Keane 2014 ⁵⁸⁷	Not relevant to review question
Kirkegard 2017 ⁶⁰²	Incorrect comparison
Konzen 1993 ⁶¹³	Not relevant to review question

Appendix M: Excluded health economic studies

M.1 Patient information

None.

M.2 Lifestyle interventions: stopping or reducing alcohol consumption

None.

M.3 Aetiology of acute pancreatitis

None.

M.4 Aetiology of chronic pancreatitis

None.

M.5 Diagnosing chronic pancreatitis

None.

M.6 Type of intravenous fluid for resuscitation in people with acute pancreatitis

None.

M.7 Speed of intravenous fluid for resuscitation in people with acute pancreatitis

None.

M.8 Route of feeding in people with severe acute pancreatitis

None.

M.9 Early versus late nutritional intervention in people with chronic pancreatitis

None.

M.10 Specialist versus non-specialist nutritional assessment in people with chronic pancreatitis

None.

- M.11 Prophylactic antimicrobial agents to prevent infection in people with acute pancreatitis**
None.
- M.12 Methods of management of infected necrosis in people with acute pancreatitis**
None.
- M.13 Timing of management of infected necrosis in people with acute pancreatitis**
None.
- M.14 Management of pain in people with chronic pancreatitis**
None.
- M.15 Management of pancreatic duct obstruction in people with chronic pancreatitis**
None.
- M.16 Management of small-duct disease in people with chronic pancreatitis**
None.
- M.17 Management of pseudocysts**
None.
- M.18 Management of pancreatic ascites and pleural effusion secondary to pancreatitis**
None.
- M.19 Management of biliary obstruction in people with chronic pancreatitis**
None.
- M.20 Management of type 3c diabetes secondary to pancreatitis**
None.

M.21 Receiving specialist input in people with acute pancreatitis

None.

M.22 Follow-up of pancreatic exocrine function in people with chronic pancreatitis

None.

M.23 Follow-up to identify diabetes in people with chronic pancreatitis

None.

M.24 Follow-up to identify pancreatic cancer in people with chronic pancreatitis

None.

Appendix N: Unit costs

N.1 Patient information

None.

N.2 Lifestyle interventions: stopping or reducing alcohol consumption

None.

N.3 Aetiology of acute pancreatitis

None.

N.4 Aetiology of chronic pancreatitis

None.

N.5 Diagnosing chronic pancreatitis

None.

N.6 Type of intravenous fluid for resuscitation in people with acute pancreatitis

Table 2: Unit costs of fluids for resuscitation

Fluid regimen	Volume	Unit cost
0.9% Sodium Chloride (saline)	1 litre bag	£2.50
Ringer's lactate solution	1 litre bag	£0.70

Source: NICE CG174 *Intravenous fluid therapy in adults in hospital*⁷⁸⁶

N.7 Speed of intravenous fluid for resuscitation in people with acute pancreatitis

None.

N.8 Route of feeding in people with severe acute pancreatitis

None.

N.9 Early versus late nutritional intervention in people with chronic pancreatitis

None.

N.10 Specialist versus non-specialist nutritional assessment in people with chronic pancreatitis

None.

N.11 Prophylactic antimicrobial agents to prevent infection in people with acute pancreatitis

Table 3: UK costs of antimicrobials

Drug	Dose	Unit cost	Cost per week
Quinolones			
Ciprofloxacin	250 mg, 2 times a day	£0.75 per 10 tablets	£1.04
Carbapenem			
Imipenem IV (with cilastatin)	500 mg, 3 times a day	£75.45 per 10 vials	£158.45
	1 g, 3 times a day		£316.89
Meropenem IV	500 mg, 3 times a day	£76.90 per 10 vials	£161.49
	1 g, 3 times a day	£153.50 per 10 vials	£322.35
Cephalosporin			
Ceftazidime IV	2 g, 3 times a day	£27.70 per 10 vials	£58.17
Cefuroxime IV	1.5 g, per day	£4.70 per vial	£32.90
Aminoglycoside			
	500 mg, twice a day	£60 per 5 vials	£168.00
Imidazole			
Metronidazole IV	500 mg, 3 times a day	£62 per 20 bags	£65.10
Fluconazole IV	100 mg, once a day	£12.60 per 5 bottles	£88.20

Sources: NHS Drug Tariff, September 2016;⁷⁹¹, BNF, November 2016¹⁴³

N.12 Methods of management of infected necrosis in people with acute pancreatitis

None.

N.13 Timing of management of infected necrosis in people with acute pancreatitis

None.

N.14 Management of pain in people with chronic pancreatitis

None.

N.15 Management of pancreatic duct obstruction in people with chronic pancreatitis

Table 4: UK costs of interventions for treating pancreatic duct disease

HRG code	Procedure	Mean cost per procedure
Surgery		
GA04, GA05, GA06	Elective Major to Complex open Hepatobiliary or Pancreatic Procedures	£7,547
Endotherapy		
GB05, GB06, GB09	Elective Major to Complex Therapeutic Endoscopic Retrograde Cholangiopancreatography	£1,840
Extracorporeal shock wave lithotripsy (ESWL)		
LB36Z	Extracorporeal Lithotripsy (all organs, not pancreas-specific), Day cases (all cases)	£470 (£405)

Source: NHS Reference costs 2015/16²⁸¹

N.16 Management of small-duct disease in people with chronic pancreatitis

None.

N.17 Management of pseudocysts

Table 5: UK costs of interventions for treating pseudocysts

HRG code	Procedure	Number of cases ^(a)	Mean cost per procedure
Pancreatic endoscopic stent by ERCP		29,987	£1,996
GB06E	Intermediate Therapeutic Endoscopic Retrograde Cholangiopancreatography with CC Score 6+	3,084	£4,121
GB06F	Intermediate Therapeutic Endoscopic Retrograde Cholangiopancreatography with CC Score 4–5	3,162	£2,708
GB06G	Intermediate Therapeutic Endoscopic Retrograde Cholangiopancreatography with CC Score 2–3	7,160	£2,048
GB06H	Intermediate Therapeutic Endoscopic Retrograde Cholangiopancreatography with CC Score 0–1	16,581	£1,442
EUS guided pseudocyst drainage^(b)		5,898	£4,903
GB09D	Complex Therapeutic Endoscopic Retrograde Cholangiopancreatography with CC Score 5+	794	£5,530
GB09E	Complex Therapeutic Endoscopic Retrograde Cholangiopancreatography with CC Score 2–4	1,187	£2,961
GB09F	Complex Therapeutic Endoscopic Retrograde Cholangiopancreatography with CC Score 0–1	1,295	£1,811
GA05C	Very Major Open, Hepatobiliary or Pancreatic Procedures, with CC Score 3+	725	£9,337
GA05D	Very Major Open, Hepatobiliary or Pancreatic Procedures, with CC Score 0–2	1,897	£6,273
Percutaneous drainage of pseudocyst^(c)		1,300	£5,431

HRG code	Procedure	Number of cases ^(a)	Mean cost per procedure
GA06C	Major Open, Hepatobiliary or Pancreatic Procedures, with CC Score 2+	579	£7,301
GA06D	Major Open, Hepatobiliary or Pancreatic Procedures, with CC Score 0–1	721	£3,930
Laparoscopic pseudocyst drainage^(d)		3,922	£6,560
GA06C	Major Open, Hepatobiliary or Pancreatic Procedures, with CC Score 2+	579	£7,301
GA06D	Major Open, Hepatobiliary or Pancreatic Procedures, with CC Score 0–1	721	£3,930
GA05C	Very Major Open, Hepatobiliary or Pancreatic Procedures, with CC Score 3+	725	£9,337
GA05D	Very Major Open, Hepatobiliary or Pancreatic Procedures, with CC Score 0–2	1,897	£6,273
Pseudocyst drainage by open surgery^(e)		3,922	£6,560

Source: NHS Reference costs 2015/16²⁸¹

- (a) 'Number of cases' refers to annual number of cases classified to these codes, this will include other procedures coded in the same category, not only the procedure of interest in this review
- (b) GB09 if coded to J611 + Y76 – cystogastrostomy of pancreas or GA05 if coded to K614 + Y76 – drainage of cyst of pancreas
- (c) GA06 if coded to J611 + Y752 – cystogastrostomy of pancreas
- (d) Same 4 codes used as for laparoscopic pseudocyst drainage; GA06 if coded to J611 + Y53 – cystogastrostomy of pancreas or GA05 coded to K614 + Y53 – drainage of cyst of pancreas
- (e) Same 4 codes used as for laparoscopic pseudocyst drainage; GA06 if coded to J611 – cystogastrostomy of pancreas or GA05 coded to K614 – drainage of cyst of pancreas

N.18 Management of pancreatic ascites and pleural effusion secondary to pancreatitis

None.

N.19 Management of biliary obstruction in people with chronic pancreatitis

Table 6: UK costs of interventions for treating biliary obstruction

Procedure	Unit cost
Therapeutic Endoscopic Retrograde Cholangiopancreatography ^(a)	£2,177
Very Major Open Hepatobiliary or Pancreatic Procedures ^(b)	£7,120

Source: NHS reference costs 2015/16²⁸¹

- (a) Weighted cost of intermediate, major and complex intervention based on activity (GB05F, GB05G, GB05H, GB06E, GB06F, GB06G, GB06H, GB09D, GB09E, GB09F)
- (b) Weighted cost of very major open procedures based on activity (GA05C, GA05D)

Table 7: UK costs of stents

Stent	Unit cost
Endoscopic Retrograde Cholangiopancreatography 7fr 11cm biliary plastic stent 9cm between flaps	£21
Endoscopic Retrograde Cholangiopancreatography dual platform (short or long wire) biliary metal stent	£688
Endoscopic Retrograde Cholangiopancreatography dual platform (short or long wire)	£150

Stent	Unit cost
biliary dilatation fusion titan balloon	

Source: NHS Supply Chain Catalogue 2015⁷⁹²

N.20 Management of type 3c diabetes secondary to pancreatitis

None.

N.21 Receiving specialist input in people with acute pancreatitis

None.

N.22 Follow-up of pancreatic exocrine function in people with chronic pancreatitis

None.

N.23 Follow-up to identify diabetes in people with chronic pancreatitis

None.

N.24 Follow-up to identify pancreatic cancer in people with chronic pancreatitis

None.

Appendix O: Research Recommendations

O.1 Priority research recommendations

- O.1.1 Research recommendation: In people with suspected (or under investigation for) chronic pancreatitis, whose diagnosis has not been confirmed by the use of ‘first-line’ tests (for example, CT scan, ultrasound scan, upper GI endoscopy or combinations of these), what is the accuracy of magnetic resonance cholangiopancreatography (MRCP) with or without secretin and endoscopic ultrasound to identify whether chronic pancreatitis is present?**

Why this is important:

People with chronic pancreatitis usually present with chronic abdominal pain. However, there are many other causes of chronic abdominal pain (for example, peptic ulcer disease, gallstone disease, gastric cancer, pancreatic cancer and abdominal aortic aneurysm). First-line tests to exclude these other causes include abdominal ultrasound, upper GI endoscopy and abdominal CT scan. Where the diagnosis has still not been confirmed following these first-line tests, it is important to have a clinical algorithm of specialist tests to be able to identify people with chronic pancreatitis. Appropriate management options can then be offered. A diagnostic cohort study is needed to determine the accuracy of MRCP with or without secretin and endoscopic ultrasound in diagnosing chronic pancreatitis.

Criteria for selecting priority research recommendations

PICO question	<p>Population: people with suspected (or under investigation for) chronic pancreatitis, whose diagnosis has not been confirmed by the use of ‘first-line’ tests</p> <p>Target condition: Chronic pancreatitis in people presenting with chronic abdominal pain, and normal or uncertain CT or ultrasound scan or upper GI endoscopy</p> <p>Index tests:</p> <ul style="list-style-type: none"> • Combination of MRCP plus or minus secretin with EUS (cut-off: Rosemont criteria: presence of chronic pancreatitis if >5) (including elastography) • MRCP with or without secretin • EUS (cut-off: Rosemont criteria: presence of chronic pancreatitis if >5) (including elastography) <p>Reference standard: Biopsy, clinical follow-up or subsequent CT scan</p> <p>Outcome measures: Diagnostic accuracy of the test or combination of tests</p>
Importance to patients or the population	<p>Delayed diagnosis of chronic pancreatitis is very common and has been repeatedly highlighted as a concern by patient support groups. Identification of chronic pancreatitis in its early stages before complications occur will potentially slow down the progression of the disease and reduce complications.</p>
Relevance to NICE guidance	<p>When the guideline is updated this will enable more definitive diagnosis of chronic pancreatitis.</p>
Relevance to the NHS	<p>Accurate diagnosis will lead to better and earlier treatment for people with chronic pancreatitis. This will result in reduced resource use by preventing complications, which leads to lower downstream costs.</p>
National priorities	<p>None.</p>
Current evidence base	<p>The systematic review in the NICE guideline identified only 1 study, with the evidence rated as very low quality. This was not sufficient to inform a</p>

	recommendation.
Equality	None.
Study design	Diagnostic accuracy study using a prospective cohort design.
Feasibility	The proposed research can be carried out in a realistic timescale and at an acceptable cost. There are no ethical or technical issues.
Other comments	None.
Importance	<ul style="list-style-type: none"> • High: the research is essential to inform future updates of key recommendations in the guideline.

O.1.2 Research recommendation: What is the most clinically effective and cost-effective speed of administration of intravenous fluid for resuscitation in people with acute pancreatitis?

Why this is important:

There is clinical uncertainty about the optimal rate of fluid for resuscitation in severe acute pancreatitis. Severe acute pancreatitis causes the depletion of body fluids and reduction of the intravascular volume severe enough to cause hypotension, acute renal failure and pancreatic hypoperfusion aggravating the damage to the pancreas. In addition, there is conflicting evidence about the effect of aggressive or conservative fluid management on outcomes in other conditions with a pathophysiology.

Current guidelines recommend using goal-directed therapy for fluid management, but do not recommend using a particular type of fluid. A randomised controlled trial is needed to determine whether aggressive rates of intravenous fluid administration for the initial period of fluid resuscitation are more clinically or cost-effective than conservative rates in people with acute pancreatitis.

Criteria for selecting priority research recommendations

PICO question	<p>Population: People with acute pancreatitis enrolled shortly after admission to the emergency department</p> <p>Intervention(s), for example:</p> <ul style="list-style-type: none"> • conservative IV fluid management using a balanced solution for resuscitation (for example, Hartmann's solution). • Moderate IV fluid management using a balanced solution for resuscitation (for example, Hartmann's solution). • Aggressive IV fluid management using a balanced solution for resuscitation (for example, Hartmann's solution). <p>Comparison: to each other</p> <p>Outcome(s): mortality (at 90 days and 12 months), hospital mortality, CCU admissions, rates of severe pancreatitis, multiple organ failure, necrotising pancreatitis and rates of surgical and non-surgical intervention in adult patients with acute pancreatitis (all grades of severity), length of hospital stay, quality of life.</p> <p>Follow-up: 90 days</p>
Importance to patients or the population	Identifying the most appropriate speed of early fluid administration may reduce the proportion of patients with acute pancreatitis who go on to develop severe disease, which would reduce mortality and improve quality of life.
Relevance to NICE guidance	The answer to this question will allow NICE to make a strong recommendation about the optimal speed of IV fluid resuscitation in acute pancreatitis.
Relevance to the NHS	Acute pancreatitis is a common condition with an annual incidence of 150–420 cases per million. About a-third of patients will develop severe acute pancreatitis, which has a significant risk of mortality and morbidity, and requires

	prolonged and resource-intensive hospital care. It is feasible that the appropriate use of early fluid administration may reduce the proportion of patients with acute pancreatitis who go on to develop severe disease. This would have a significant impact on the resource consumption of people with acute pancreatitis.
National priorities	None.
Current evidence base	The NICE committee was unable to find enough evidence to make a strong recommendation. The body of evidence was limited to 3 randomised trials and 6 non-randomised studies, all with small sample sizes. The evidence was low to very low quality and there was no consistent evidence of benefit of either aggressive or conservative fluid resuscitation strategies.
Equality	None. All patients presenting with acute pancreatitis will be included.
Study design	A randomised-controlled trial should be undertaken to determine whether aggressive or conservative rates of intravenous fluid administration for the initial period of fluid resuscitation are more clinically or cost-effective at reducing 90-day mortality, hospital mortality, CCU admissions, rates of severe pancreatitis, multiple organ failure, and necrotizing pancreatitis in adult patients with acute pancreatitis (all grades of severity). The study population should include adult patients (aged more than 16 years old) with all grades of severity of acute pancreatitis enrolled shortly after admission to the Emergency Department. Acute pancreatitis should be defined as at least two of: (1) Characteristic abdominal pain (2) Serum amylase or lipase more than three times the upper limit of normal (3) Cross-sectional imaging showing changes consistent with acute pancreatitis. The study should also consider the impact of different fluid rates of administration on quality of life.
Feasibility	Patients will need to be recruited from the Accident and Emergency department following emergency admissions and recruitment will need to take place 24-hours a day, which is a technical issue for research. All patients presenting with acute pancreatitis will be included in the study. However, it would be beneficial to stratify mild, moderate and severe acute pancreatitis although this may be difficult to achieve as the disease severity is not known at presentation and fluid administration should be started promptly.
Other comments	It would be important to attempt to begin fluid administration within 3–6 hours of admission as there is evidence to suggest that patients admitted to hospital with acute pancreatitis are under-hydrated. The definitions of conservative, moderate and aggressive should be set a priori by the investigators.
Importance	<ul style="list-style-type: none"> High: the research is essential to inform future updates of key recommendations in the guideline.

O.1.3 Research recommendation: Is the long-term use of opioids more clinically effective and cost effective than non-opioid analgesia (including non-pharmacological analgesia) in people with chronic pain due to chronic pancreatitis?

Why this is important:

Chronic pancreatitis is a complex condition needing biopsychosocial management. The pain is varied in nature, intensity, duration and severity, along with acute exacerbations. It is also multifactorial, making it difficult to have a standard regimen that can work for everyone. Some people also develop psychosocial factors such as reduction in quality of life, relationship issues, addiction to painkillers and financial difficulties.

Chronic pancreatitis is usually managed pharmacologically with a combination of opioids and other interventions. However, the use of opioids in managing chronic pancreatitis is known to cause serious side-effects – including tolerance, addiction, tiredness and constipation. These side-effects are frequently worse than the disease itself. Therefore, the whole rationale for the use of opioids in chronic pancreatitis is questionable. A cohort study is needed to determine how effective long-term opioid use is in this population compared with non-opiate pain management strategies, including analgesia and psychological therapies.

Criteria for selecting priority research recommendations

PICO question	Population: People with painful chronic pancreatitis Intervention(s): non-opiate pain management strategies, including analgesia and psychological therapies Comparison: Opioids Outcomes: Quality of life, pain, tolerance, addiction, tiredness, constipation, breakthrough pain, flare ups, hospital admissions, amount of rescue analgesia being used. Follow-up: at least 12 months
Importance to patients or the population	Clear evidence on the benefits and harms of opioids in chronic pancreatitis should enable more appropriate use of this intervention, which could prevent overuse of opioids and the related harms of, for example, opioid tolerance and addiction. Therefore, quality of life could be improved by targeting opioid use to those who are likely to benefit through successful pain management.
Relevance to NICE guidance	Clarification of the role of opioids in managing pain in chronic pancreatitis would allow the NICE guideline on pancreatitis to make firm recommendations regarding their use in clinical practice. Pain management is one of the most important aspects of care for people with chronic pancreatitis as it is often the most troublesome symptom.
Relevance to the NHS	Opioids are commonly used in both acute and chronic pancreatitis. The side effects of opioids are extensive including addiction, tolerance, and constipation. This also reduces quality of life for patients. With little evidence to support their use, they might even cause harm at high doses such as reduced systemic hormone levels, reduced immunity and death. Clinicians widely use the WHO analgesic ladder to guide escalation of pharmacological therapy, which is also included in the SIGN 2013 chronic pain guidance. Whilst the guidance does accept that the analgesic ladder was not devised for use in chronic pain, it advocates its use for non-specialists in chronic pain management. Therefore, new evidence specific to chronic pain may be more cost effective if some therapies are proven to have a positive effect.
National priorities	None
Current evidence base	The evidence review in this guideline did not identify any studies for either short- or long-term use of opioids in chronic pancreatitis. Although it is known that opioids are good analgesics for acute pain and for pain at the end of life there is little evidence of their use for long-term pain. The recent opioid awareness campaign clearly highlights the long-term harm in using opioids at high doses over long periods.
Equality	Not applicable
Study design	Appropriately designed and powered cohort studies.
Feasibility	Most pancreatitis patients will require analgesia and opioids are commonly used for their acute episodes. Enrolling an opioid-naïve patient in chronic pancreatitis might be difficult. This can lead to challenges in the design, but could be addressed by the active treatment arm showing reduction in opioid use with better quality of life.
Other comments	None

Importance	<ul style="list-style-type: none"> High: the research is essential to inform future updates of key recommendations in the guideline.
-------------------	---

O.1.4 Research recommendation: What is the most clinically effective and cost-effective intervention for managing small-duct disease (in the absence of pancreatic duct obstruction, inflammatory mass or pseudocyst) in people with chronic pancreatitis presenting with pain?

Why this is important:

Chronic pancreatitis with small duct disease is more difficult to treat than without the disease because there is no anatomically correctable pancreatic abnormality – for example, pancreatic duct obstruction, inflammatory mass or pseudocysts. A randomised controlled trial study is needed to determine what the most effective intervention is for treating small duct disease. The following interventions should be compared with each other and with no treatment: surgery (partial resection, total resection with or without islet transplant, or drainage), endoscopic treatment, or standard care (for example, pharmacological treatment only, enzyme replacement therapy, nerve blocks).

Criteria for selecting priority research recommendations

PICO question	<p>Population: People with chronic pancreatitis presenting with pain, without pancreatic duct obstruction, inflammatory mass or pseudocyst</p> <p>Intervention(s): Surgery (partial resection, total resection with or without islet transplant, or drainage), endoscopic treatment, or standard care (for example, pharmacological treatment only, enzyme replacement therapy, nerve blocks).</p> <p>Comparison: Compared with each other and with no treatment</p> <p>Outcome(s): Quality of life, mortality, complications, pain, length of hospital stay</p> <p>Follow-up: 12–24 months</p>
Importance to patients or the population	Chronic pancreatitis is a difficult disease to treat and patients become extremely frustrated because of the variation in treatments that are available or not available in different centres. Patients with small duct disease are particularly affected by this lack of consistency.
Relevance to NICE guidance	The answer to this question will allow NICE to make a strong recommendation about the management of small-duct disease when the guideline is updated.
Relevance to the NHS	Reduction in pain and complications will improve quality of life and overall patient care and reduce hospital length of stay and, therefore, should be cost effective.
National priorities	None.
Current evidence base	Only a single small, non-randomised study was identified by the systematic review within this NICE guideline. Therefore, more robust evidence is required to inform evidence-based practice.
Equality	None.
Study design	Appropriately designed and powered multicentre randomised controlled trials or cohort studies.
Feasibility	The proposed research can be carried out in a realistic timescale and at an acceptable cost. There are no ethical or technical issues.
Other comments	None.
Importance	<ul style="list-style-type: none"> High: the research is essential to inform future updates of key recommendations in the guideline.

O.1.5 Research recommendation: What is the most clinically effective and cost-effective insulin regimen to minimise hypo- and hyper-glycaemia for type 3c diabetes secondary to pancreatitis?

Why this is important:

Type 3c diabetes is associated with metabolic instability and risk of decompensation leading to severe hypoglycaemia and ketoacidosis, in addition to poor quality of life. However, there is no evidence available in this population to inform practice. Therefore, research specifically on type 3c diabetes is essential to inform future updates of key recommendations in this guideline. National adoption of evidence-based insulin management in type 3c diabetes has the potential to cost-effectively improve health and well-being, reducing the incidence of acute and long-term complications of poorly controlled glucose levels in chronic pancreatitis. A randomised controlled trial is needed to determine the most effective insulin therapy regimen in this population, comparing twice daily insulin injections, an insulin analogue multiple daily dose basal bolus regimen, and insulin pump therapy.

Criteria for selecting priority research recommendations

PICO question	Population: Adults with insulin-treated type 3c diabetes. Intervention(s): <ul style="list-style-type: none"> • Twice daily insulin injections • insulin analogue multiple daily dose basal bolus regimen, • insulin pump (CSII) therapy Comparison: To each other Outcome(s): Glucose variability and time in range, HbA1c, severe hypoglycaemia, episodes of ketoacidosis, mortality, nutritional status and quality of life, admissions. Follow-up: at least 6 months
Importance to patients or the population	Recommendations for insulin management specifically in type 3c diabetes could improve the ability to control glucose levels, reducing the incidence of acute and long-term complications.
Relevance to NICE guidance	The answer to this question will allow NICE to make an evidence-based recommendation in an important type of diabetes not adequately addressed by existing guidelines, which is essential to inform future updates of key recommendations in the guidance.
Relevance to the NHS	National adoption of evidence-based insulin management in type 3c diabetes has the potential to cost-effectively improve health and well-being, reducing incidence of acute and long-term complications of poorly controlled glucose levels in chronic pancreatitis.
National priorities	None
Current evidence base	The guideline found no relevant studies and could only recommended following type 1 diabetes guidelines.
Equality	People with type 3c diabetes have been potentially disadvantaged in terms of equity of access to interventions provided to those with insulin-requiring type 1 diabetes, including structured education, multiple daily dose insulin regimens and insulin pump therapy.
Study design	Appropriately designed and powered randomised controlled trials comparing glycaemic control attained with twice daily insulin injections with an insulin analogue multiple daily dose basal bolus regimen and with insulin pump (CSII) therapy. Studies should last at least 6 months and should assess glucose variability and time within range (3–10 mmol/litre) in addition to HbA1c and hypoglycaemia.

	Hypoglycaemia awareness in addition to severe events requiring assistance in treatment and episodes of diabetic ketoacidosis should be compared. Nutritional status should be assessed. Patient reported outcomes should include validated treatment satisfaction, hypoglycaemia fear and quality of life measures (including improved independence). Data collected should enable health economic analysis. The study should also stratify participants by residual insulin (C-peptide) status to determine whether this influences requirement for and impact of a more complex insulin regimen.
Feasibility	Through appropriate multidisciplinary involvement in trial design and completion, together with carefully structured patient education and support, this research should not raise additional feasibility, ethical, safety or technical issues.
Other comments	This research will necessitate a multidisciplinary approach, facilitating enhanced evidence-based diabetes management for type 3c diabetes.
Importance	<ul style="list-style-type: none"> • High: the research is essential to inform future updates of key recommendations in the guideline.

O.2 Other research recommendations

O.2.1 Research recommendation: What is the most clinically effective and cost-effective type of intravenous fluid for resuscitation in people with acute pancreatitis?

Why is this important?

There is clinical uncertainty about the optimal resuscitation fluid for people with severe acute pancreatitis. Severe acute pancreatitis causes the depletion of body fluids and reduction of the intravascular fluid volume, severe enough to cause hypotension, acute kidney injury and pancreatic hypoperfusion, aggravating the damage to the pancreas. There are only a few small studies looking at the fluid type given to patients with acute severe pancreatitis. Existing clinical guidelines give conflicting advice on which fluid type to use for initial resuscitation: the British Society of Gastroenterology Guidelines makes no specific recommendation on fluid type, whereas the American College of Gastroenterology Guidelines recommend using Ringer's Lactate solution for initial resuscitation. The NICE committee undertook a systematic review of the evidence in this area, and was unable to find enough evidence to make a strong recommendation. Acute pancreatitis is a common condition with an incidence of 150-420 cases per million population. About one-third of patients will develop severe acute pancreatitis, which has a significant risk of mortality and morbidity, and requires prolonged and resource-intensive hospital care. Identifying the most clinically effective type of fluid to use during the resuscitation of people with acute pancreatitis may reduce the proportion of patients with acute pancreatitis who go on to develop severe disease. Identifying whether the type of fluid used for resuscitation could reduce this disease burden would have a significant impact on mortality, quality of life and resource use of people with acute pancreatitis.

Criteria for selecting research recommendations

PICO Question	<p>Population: Adult (aged > 16years) patients with new onset acute pancreatitis presenting to the Emergency Department. Defined as at least 2 of: (1) Characteristic abdominal pain (2) Serum amylase or lipase more than three times the upper limit of normal (3) Cross-sectional imaging changes consistent with acute pancreatitis.</p> <p>Intervention: Balanced salt solution (Hartmann's solution or Plasmalyte) for intravenous fluid resuscitation over the first 24hours of admission.</p>
----------------------	--

	<p>Comparators: “Normal” (0.9%) sodium chloride for intravenous fluid resuscitation over the first 24 hours of admission.</p> <p>Outcomes: Hospital and 90-day mortality, rates of critical care unit admission, rates of severe acute pancreatitis, multiple organ failure, necrotizing pancreatitis and rates of surgical and non-surgical intervention, length of hospital stay.</p>
Importance to patients or the population	<p>Acute pancreatitis is a common condition with an incidence of 150-420 cases per million population. About one-third of patients will develop severe acute pancreatitis, which has a significant risk of mortality and morbidity, and requires prolonged and resource-intensive hospital care. Identifying the most clinically effective type of fluid to use during the resuscitation of people with acute pancreatitis may reduce the proportion of patients with acute pancreatitis who go on to develop severe disease. Identifying whether the type of fluid used for resuscitation could reduce this disease burden would have a significant impact on mortality, quality of life and resource use of people with acute pancreatitis.</p>
Relevance to NICE guidance	<p>The answer to this question will allow NICE to make an evidence-based recommendation in an area with current variation in practice.</p>
Relevance to the NHS	<p>The impact on the NHS may be small.</p>
National priorities	<p>Not relevant</p>
Current evidence base	<p>There are only two small randomised controlled trials looking at this area, and one small non-randomised retrospective study. All these studies demonstrated a trend to clinical benefit using Ringer’s lactate compared to 0.9% normal saline; however the numbers of patients involved was small.</p>
Equality	<p>N/A</p>
Study design	<p>Randomised-controlled trial</p>
Feasibility	<p>Feasibility with this research is an important issue to consider. To identify a true effect, patients should be enrolled into the study as soon as possible after presenting to the Emergency Department, ideally within 3 hours. This represents a significant logistical barrier to recruitment. This time period for enrolment also means that it would not be possible to stratify patients into subgroups of “severe”, “moderate” or “mild” acute pancreatitis at the time of enrolment. Therefore, patients with all grades of acute pancreatitis should be enrolled and subsequently analysed according to severity grading.</p>
Other comments	<p>N/A</p>
Importance	<p>Medium: the research is relevant to the recommendations in the guidance, but the research recommendations are not essential to future updates.</p>

O.2.2 Research recommendation: What is the most clinically effective and cost-effective intervention for managing pancreatic duct obstruction, with or without an inflammatory mass, in children with chronic pancreatitis presenting with pain?

Why is this important?

The surgical treatment of obstructive chronic pancreatitis is the preferred option in adults. However, in children the success of endoscopy versus surgery has not been investigated. Endoscopy has the potential to reduce complications, although multiple procedures may be necessary. Surgery is more invasive but is only likely to require one procedure. Therefore, a trial is needed to determine the most suitable approach in this group.

Criteria for selecting research recommendations

PICO Question	<p>Population: Children (≤ 16 years) with chronic pancreatitis and pancreatic duct obstruction, with or without an inflammatory mass, presenting with chronic pain</p> <p>Intervention: Pancreatic endotherapy (endoscopic techniques – pancreatic stent (plastic or metal), pancreatic sphincterotomy, drainage); surgery (resection or surgical drainage procedure)</p> <p>Comparators: Standard treatment or no treatment; to each other</p> <p>Outcomes: Quality of life, mortality, complications, pain – acute or chronic (duration of pain, reduction in pain, medication reduction); length of stay (in CCU or hospital); repeated procedures; pancreatic function (endocrine and exocrine); growth; education.</p>
Importance to patients or the population	Appropriate management of pancreatic duct obstruction should improve quality of life, minimise need for analgesia medication and subsequent problems with addiction, reduce the need for repeated procedures, and potentially delay the onset of diabetes and exocrine insufficiency.
Relevance to NICE guidance	The answer to this question will allow NICE to make an evidence-based recommendation to ensure optimal management of this complication of pancreatitis in children.
Relevance to the NHS	Due to the small number of people affected this will have a negligible impact on NHS finances.
National priorities	N/A
Current evidence base	No studies in children were identified that could be included in the guideline. The committee were aware that only case studies are available for this group.
Equality	N/A
Study design	Prospective cohort study
Feasibility	Realistic as a cohort study, but not as a randomised trial because the numbers for recruitment are too small (approximately 20 per year in the UK).
Other comments	N/A
Importance	High: the research is essential to inform future updates of key recommendations in the guidance.

O.2.3 Research recommendation: What is the clinical effectiveness and cost effectiveness of metal stents compared to surgery for treating biliary obstruction in adults with chronic pancreatitis?

Why is this important?

Approximately 20% of patients with chronic pancreatitis develop some degree of biliary obstruction (some reports have lower and some higher estimates). The treatment of choice for patients with chronic pancreatitis who develop biliary obstruction is not known. Metal endoscopic stenting can relieve biliary obstruction for 6 to 12 months and, if the stent is fully covered, it can be removed and if necessary replaced, potentially more than once. Alternatively, surgery may be undertaken, either by biliary-enteric anastomosis or by resecting diseased pancreas in some way, with steps to ensure biliary drainage. Such surgery is major, becoming complex major with pancreatic resection, although the result is likely to be more sustained. Furthermore pancreatic resection can remove or reduce pain from chronic pancreatitis. Therefore, a randomised-controlled trial should be undertaken to determine whether the use of fully covered metal stents is more clinically- and cost-effective than

surgery in the management of chronic pancreatitis with biliary obstruction. The study should also consider the impact of treatments on quality of life and an important proviso is that if pancreas cancer cannot be excluded and the pancreatic lesion is resectable, appropriately radical surgery is appropriate.

Criteria for selecting research recommendations

PICO Question	<p>Population: patients with chronic pancreatitis and evidence of biliary obstruction (abnormal liver function tests and imaging evidence of biliary stricture with no features of malignancy)</p> <p>Intervention: sequential covered metal biliary stenting over 24 months with ancillary non-surgical management</p> <p>Comparators: surgery, the nature of which to be determined by disease profile, e.g. if pain then some form of pancreatic head resection with relief of biliary obstruction; if painless and no other indication for surgery then hepaticojejunostomy</p> <p>Outcome: episodes of recurrent biliary obstruction after treatment; pain and its management; complications of treatment including mortality; hospital stay; need for further intervention.</p>
Importance to patients or the population	If clinically effective endoscopic treatment would be more easily tolerated by patients and should be less likely to result in mortality. If however treatment failure is significantly more common after endoscopic treatment, including recurrent biliary obstruction and/or continued pain, more comprehensive treatment with surgery will be preferred.
Relevance to NICE guidance	Interventions for chronic pancreatitis are currently provided ad hoc, depending on whether the patient is (i) referred to a tertiary centre (ii) assessed by a particular specialist or is reviewed by a multi-disciplinary team (iii) provided with a comprehensive range of treatment options. Trials in chronic pancreatitis will ensure greater priority is placed on the management of patients with this condition and will bring clarity to the preferred treatment options.
Relevance to the NHS	No specific impact except hopefully a modest saving on bed occupancy and/or more effective service delivery.
National priorities	No
Current evidence base	The current evidence base is insufficient to determine the treatment of choice for biliary obstruction in chronic pancreatitis and there are no ongoing trials that will address this. Previous studies have concentrated on surgery vs plastic stents (which were inferior to metal stents).
Equality	N/A
Study design	A randomized trial of sequential covered metal stenting of the bile duct for 24 months vs surgery, recruiting for 24 months with at least one year of follow-up. The primary outcome measure would be liver function tests after the first intervention (stenting or surgery) for the length of follow up, measured serially. Secondary outcome measures would include pain and its management, nutritional status, the number and nature of further interventions, complications including mortality and quality of life. It would be highly desirable to keep an accurate record of all patients with chronic pancreatitis who might be considered for such a trial but who are not randomised, since following their management will also greatly assist defining optimal management pathways.
Feasibility	This research can feasibly be completed in a well-designed multicentre UK study. The study would have to be conducted in tertiary referral centres practising the full range of treatments for chronic pancreatitis.
Other comments	N/A

Importance	High: the research is essential to inform future updates of key recommendations in the guidance.
-------------------	--

O.2.4 Research recommendation: What is the clinical effectiveness and cost effectiveness of performing genetic marker and autoantibody tests for identifying the aetiology of chronic pancreatitis in people with no known family history of pancreatitis, no significant alcohol history, and normal serum calcium and lipid levels?

Why this is important:

In patients with chronic pancreatitis but no known aetiology, autoimmune pancreatitis and hereditary pancreatitis are possible causes. The yield of positive tests and their impact on successful management in these groups of patients is unknown. Therefore, this study has the potential to identify appropriate tests for this group of patients and to avoid unnecessary testing.

Criteria for selecting research recommendations

PICO Question	Population: People with a diagnosis of chronic pancreatitis and no known family history of pancreatitis, no significant alcohol history, and normal serum calcium and lipids Intervention: <ul style="list-style-type: none"> • For the identification of autoimmune chronic pancreatitis: autoantibodies (for example IgG4, ANA) • For the identification of hereditary chronic pancreatitis (including CFTR): genetic markers (PRSS1, SPINK1, CFTR) Comparators: No test Outcome: Quality of life; mortality; number of repeated tests or any pancreatitis-related admissions; early detection of cancer (for hereditary pancreatitis); early detection of extra-pancreatic involvement (for IgG4 related pancreatitis); confirmation of aetiology or identification of a cause
Importance to patients or the population	Providing people with a cause of their pancreatitis can reassure a patient and may improve the subsequent management of their condition.
Relevance to NICE guidance	When the guideline is updated this will enable evidence-based recommendations about the appropriate level of testing to identify the cause of chronic pancreatitis.
Relevance to the NHS	The outcome of this study should prevent unnecessary tests being undertaken.
National priorities	No
Current evidence base	No studies were identified.
Equality	No
Study design	Cohort or randomised-controlled trial
Feasibility	A randomised-controlled trial may not be feasible because these tests are well established in clinical practice.
Other comments	It will be important to consider the wider implications of genetic testing (for example, the impact of the genetic results on the ability to obtain life insurance and a mortgage if diagnosed with hereditary pancreatitis). Genetic counselling must be offered and consideration could be given to aligning the test with pancreatic cancer screening.

Importance	Medium: the research is relevant to the recommendations in the guidance, but the research recommendations are not essential to future updates.
-------------------	--

O.2.5 Research recommendation: What is the clinical effectiveness and cost effectiveness of assessing the aetiology of acute pancreatitis to prevent recurrent attacks in people in whom the aetiology is unconfirmed by first-line test results within normal ranges?

Why is this important?

The most common causes for pancreatitis in the western world are gallstones and alcohol. In the context of unremarkable social history and negative first line testing for gallstones, the diagnosis of rarer causes such as hereditary, metabolic, autoimmune, malignant and anatomical may result in reduced attacks and recurrent admissions. Whether this is clinically and cost effective to perform is unknown and no ongoing trials have been identified. Therefore, a randomised-controlled trial or cohort study should be performed to determine whether second line testing with genetic testing, autoimmune serology and endoscopic ultrasound is clinically and cost-effective at reducing recurrent admission with pancreatitis in patients with normal range first line tests.

Criteria for selecting research recommendations

PICO Question	<p>Population: People with a diagnosis of acute pancreatitis and aetiology unconfirmed by first-line tests within normal range (that is, patient enquiry for alcohol and genetic causes, ultrasound for gallstones and blood tests for metabolic causes).</p> <p>Intervention: Testing for aetiology of acute pancreatitis with any of the following tests:</p> <ul style="list-style-type: none"> • History: drug history, specific questioning for Sphincter of Oddi dysfunction • Blood tests: autoantibodies, antibodies, serological tests, tests for hypercalcaemia and hyperlipidaemia • DNA test • Endoscopic ultrasound (EUS) of gall bladder and bile duct, EUS with duodenoscopy • MRCP, secretin-MRCP • Combinations of tests <p>Comparators: No test</p> <p>Outcome: Quality of life, pancreatitis-related mortality, number of repeated tests, any pancreatitis-related admissions (including recurrent attacks), confirmation of aetiology or identification of a cause, adverse events following investigations</p>
Importance to patients or the population	Finding the cause for the acute pancreatitis has the potential to prevent further attacks, alleviate suffering and improve quality of life.
Relevance to NICE guidance	When the guideline is updated this will enable evidence-based recommendations about the appropriate level of testing to identify the cause of acute pancreatitis.
Relevance to the NHS	It is important to identify the cause of recurrent pancreatitis because if the cause can be abolished this will reduce suffering and potentially mortality. It also has the potential to reduce unnecessary tests.
National priorities	No
Current evidence base	No studies were identified to address this clinical question.

<p>PICO Question</p>	<p>Population: People with a diagnosis of acute pancreatitis and aetiology unconfirmed by first-line tests within normal range (that is, patient enquiry for alcohol and genetic causes, ultrasound for gallstones and blood tests for metabolic causes).</p> <p>Intervention: Testing for aetiology of acute pancreatitis with any of the following tests:</p> <ul style="list-style-type: none"> • History: drug history, specific questioning for Sphincter of Oddi dysfunction • Blood tests: autoantibodies, antibodies, serological tests, tests for hypercalcaemia and hyperlipidaemia • DNA test • Endoscopic ultrasound (EUS) of gall bladder and bile duct, EUS with duodenoscopy • MRCP, secretin-MRCP • Combinations of tests <p>Comparators: No test</p> <p>Outcome: Quality of life, pancreatitis-related mortality, number of repeated tests, any pancreatitis-related admissions (including recurrent attacks), confirmation of aetiology or identification of a cause, adverse events following investigations</p>
<p>Equality</p>	<p>No</p>
<p>Study design</p>	<p>Randomised-controlled trial or cohort</p>
<p>Feasibility</p>	<p>A randomised-controlled trial may be unlikely because most people will routinely be tested on one of these tests.</p>
<p>Other comments</p>	<p>It will be important to consider the wider implications of genetic testing (for example, the impact of the genetic results on the ability to obtain life insurance and a mortgage if diagnosed with hereditary pancreatitis). Genetic counselling must be offered and consideration could be given to aligning the test with pancreatic cancer screening.</p>
<p>Importance</p>	<p>Medium: the research is relevant to the recommendations in the guidance, but the research recommendations are not essential to future updates.</p>

Appendix P: NICE technical team

Name	Role
Fiona Glen	Guideline Lead
Phil Alderson	Clinical Advisor
Peter O'Neill	Technical Lead
Jamie Elvidge	Health Economist
Ben Doak	Guideline Commissioning Manager
Jill Peacock	Guideline Coordinator
Annette Mead	Editor

Appendix Q: References

1. Abadia MA, Dot-Bach J, Peracaula MM, Bertroli JA, Curell AB, Salord JC et al. EUS-guided cholangiography when endoscopic retrograde cholangiography failed: 6-year single center experience. *Gastrointestinal Endoscopy*. 2010; 71(5):AB284
2. Abdallah AA, Krige JEJ, Bornman PC. Biliary tract obstruction in chronic pancreatitis. *HPB*. 2007; 9(6):421-428
3. Abdelhafez M, Elnegouly M, Hasab Allah MS, Elshazli M, Mikhail HM, Yosry A. Transluminal retroperitoneal endoscopic necrosectomy with the use of hydrogen peroxide and without external irrigation: A novel approach for the treatment of walled-off pancreatic necrosis. *Surgical Endoscopy*. 2013; 27(10):3911-20
4. Aboelsoud MM, Siddique O, Morales A, Seol Y, Al-Qadi MO. Fluid choice matters in critically-ill patients with acute pancreatitis: Lactated ringer's vs. Isotonic saline. *Rhode Island Medicine*. 2016; 99(10):39-42
5. Abou-Assi S, Craig K, O'Keefe SJ. Hypocaloric jejunal feeding is better than total parenteral nutrition in acute pancreatitis: results of a randomized comparative study. *American Journal of Gastroenterology*. 2002; 97(9):2255-2262
6. Abou-Assi SG, Craig K, Mihas A, O'Keefe S. The nutritional management of acute pancreatitis: A prospective randomized study of jejunal versus intravenous feeding. *Journal of Parenteral & Enteral Nutrition*. 2002; 26(4):S27
7. Abu-El-Haija M, Kumar S, Quiros JA, Balakrishnan K, Barth B, Bitton S et al. The management of acute pancreatitis in the pediatric population: a clinical report from the NASPGHAN pancreas committee. *Journal of Pediatric Gastroenterology and Nutrition*. 2017; 23:23
8. Abu-El-Haija M, Wilhelm R, Heinzman C, Siqueira BN, Zou Y, Fei L et al. Early enteral nutrition in children with acute pancreatitis. *Journal of Pediatric Gastroenterology and Nutrition*. 2016; 62(3):453-6
9. Acosta JM, Katkhouda N, Debian KA, Groshen SG, Tsao-Wei DD, Berne TV. Early ductal decompression versus conservative management for gallstone pancreatitis with ampullary obstruction: a prospective randomized clinical trial. *Annals of Surgery*. 2006; 243(1):33-40
10. Adamek HE, Jakobs R, Buttman A, Adamek MU, Schneider AR, Riemann JF. Long term follow up of patients with chronic pancreatitis and pancreatic stones treated with extracorporeal shock wave lithotripsy. *Gut*. 1999; 45(3):402-5
11. Adams DB, Anderson MC. Changing concepts in the surgical management of pancreatic pseudocysts. *American Surgeon*. 1992; 58(3):173-80
12. Adler J, Barkin JS. Management of pseudocysts, inflammatory masses, and pancreatic ascites. *Gastroenterology Clinics of North America*. 1990; 19(4):863-71
13. Aggarwal A, Manrai M, Kochhar R. Fluid resuscitation in acute pancreatitis. *World Journal of Gastroenterology*. 2014; 20(48):18092-103
14. Ahmed Ali U, Jens S, Busch OR, Keus F, van Goor H, Gooszen HG et al. Antioxidants for pain in chronic pancreatitis. *Cochrane Database of Systematic Reviews* 2014, Issue 8. Art. No.: CD008945. DOI: 10.1002/14651858.CD008945.pub2.

15. Ahmed Ali U, Nieuwenhuijs VB, van Eijck CH, Gooszen HG, van Dam RM, Busch OR et al. Clinical outcome in relation to timing of surgery in chronic pancreatitis: a nomogram to predict pain relief. *Archives of Surgery*. 2012; 147(10):925-32
16. Ahmed Ali U, Pahlplatz JM, Nealon WH, van Goor H, Gooszen HG, Boermeester MA. Endoscopic or surgical intervention for painful obstructive chronic pancreatitis. *Cochrane Database of Systematic Reviews* 2015, Issue 3. Art. No.: CD007884. DOI: 10.1002/14651858.CD007884.pub3.
17. Ai X, Qian X, Pan W, Xu J, Hu W, Terai T et al. Ultrasound-guided percutaneous drainage may decrease the mortality of severe acute pancreatitis. *Journal of Gastroenterology*. 2010; 45(1):77-85
18. Aimoto T, Uchida E, Matsushita A, Kawano Y, Mizutani S, Kobayashi T. Long-term outcomes after frey's procedure for chronic pancreatitis with an inflammatory mass of the pancreatic head, with special reference to locoregional complications. *Journal of Nippon Medical School*. 2013; 80(2):148-54
19. Akisik MF, Sandrasegaran K, Jennings SG, Aisen AM, Lin C, Sherman S et al. Diagnosis of chronic pancreatitis by using apparent diffusion coefficient measurements at 3.0-T MR following secretin stimulation. *Radiology*. 2009; 252(2):418-425
20. Akshintala VS, Saxena P, Zaheer A, Rana U, Hutfless SM, Lennon AM et al. A comparative evaluation of outcomes of endoscopic versus percutaneous drainage for symptomatic pancreatic pseudocysts. *Gastrointestinal Endoscopy*. 2014; 79(6):921-928
21. Al-Haddad M, Wallace MB. Diagnostic approach to patients with acute idiopathic and recurrent pancreatitis, what should be done? *World Journal of Gastroenterology*. 2008; 14(7):1007-1010
22. Al-Omran M, AlBalawi ZH, Tashkandi MF, Al-Ansary LA. Enteral versus parenteral nutrition for acute pancreatitis. *Cochrane Database of Systematic Reviews* 2010, Issue 1. Art. No.: CD002837. DOI: 10.1002/14651858.CD002837.pub2.
23. Al Samaraee A, McCallum IJ, Coyne PE, Seymour K. Nutritional strategies in severe acute pancreatitis: A systematic review of the evidence. *Surgeon Journal of the Royal Colleges of Surgeons of Edinburgh & Ireland*. 2010; 8(2):105-10
24. Ala-Kokko TI, Tieranta N, Laurila J, Syrjala H. Determinants of ICU mortality in necrotizing pancreatitis: the influence of *Staphylococcus epidermidis*. *Acta Anaesthesiologica Scandinavica*. 2001; 45(7):853-7
25. Albers D, Toermer T, Charton JP, Neuhaus H, Schumacher B. Endoscopic therapy for infected pancreatic necrosis using fully covered self-expandable metal stents: Combination of transluminal necrosectomy, transluminal and percutaneous drainage. *Zeitschrift für Gastroenterologie*. 2016; 54(1):26-30
26. Aljarabah M, Ammori BJ. Laparoscopic and endoscopic approaches for drainage of pancreatic pseudocysts: A systematic review of published series. *Surgical Endoscopy*. 2007; 21(11):1936-44
27. Aljebreen AM, Alharbi OR, Azzam N, Almadi MA. Efficacy of spyglass-guided electrohydraulic lithotripsy in difficult bile duct stones. *Saudi Journal of Gastroenterology*. 2014; 20(6):366-70
28. Alkaade S, Cem Balci N, Momtahn AJ, Burton F. Normal pancreatic exocrine function does not exclude MRI/MRCP chronic pancreatitis findings. *Journal of Clinical Gastroenterology*. 2008; 42(8):950-955

29. Allen PJ, Gonen M, Brennan MF, Bucknor AA, Robinson LM, Pappas MM et al. Pasireotide for postoperative pancreatic fistula. *New England Journal of Medicine*. 2014; 370(21):2014-2022
30. Alonso Ordas N, Gomez Herrero H, Ortega Molina L. Pancreatic-thoracic fistula. An unusual complication of pancreatitis. *Archivos de Bronconeumologia*. 2017; 53(6):344
31. Alsfasser G, Schwandner F, Pertschy A, Hauenstein K, Foitzik T, Klar E. Treatment of necrotizing pancreatitis: Redefining the role of surgery. *World Journal of Surgery*. 2012; 36(5):1142-1147
32. Alsolaiman MM, Green JA, Barkin JS. Should enteral feeding be the standard of care for acute pancreatitis? *American Journal of Gastroenterology*. 2003; 98(11):2565-7
33. Alvarez-Sanchez MV, Jenssen C, Faiss S, Napoleon B. Interventional endoscopic ultrasonography: An overview of safety and complications. *Surgical Endoscopy and Other Interventional Techniques*. 2014; 28(3):712-734
34. Alvi AR, Sheikh GM, Kazim SF. Delayed surgical therapy reduces mortality in patients with acute necrotizing pancreatitis. *Journal of the Pakistan Medical Association*. 2011; 61(10):973-977
35. Amann ST, Bishop M, Curington C, Toskes PP. Fecal pancreatic elastase 1 is inaccurate in the diagnosis of chronic pancreatitis. *Pancreas*. 1996; 13(3):226-230
36. Ammann RW, Heitz PU, Kloppel G. Course of alcoholic chronic pancreatitis: A prospective clinicomorphological long-term study. *Gastroenterology*. 1996; 111(1):224-231
37. Ammann RW, Muellhaupt B, Meyenberger C, Heitz PU. Alcoholic nonprogressive chronic pancreatitis: prospective long-term study of a large cohort with alcoholic acute pancreatitis (1976-1992). *Pancreas*. 1994; 9(3):365-73
38. Ammann RW, Muellhaupt B. Do the diagnostic criteria differ between alcoholic and nonalcoholic chronic pancreatitis? *Journal of Gastroenterology*. 2007; 42(Suppl 17):118-126
39. Amornytin S, Saivaew K, Vichitkala K. Pain score within twenty-four hours post-endoscopic ultrasonography: A comparison between with or without fine needle aspiration procedure. *Journal of Gastroenterology and Hepatology Research*. 2015; 4(7):1694-1697
40. Andersson B, Nilsson E, Willner J, Andersson R. Treatment and outcome in pancreatic pseudocysts. *Scandinavian Journal of Gastroenterology*. 2006; 41(6):751-6
41. Ang TL, Kwek AB, Tan SS, Ibrahim S, Fock KM, Teo EK. Direct endoscopic necrosectomy: A minimally invasive endoscopic technique for the treatment of infected walled-off pancreatic necrosis and infected pseudocysts with solid debris. *Singapore Medical Journal*. 2013; 54(4):206-11
42. Ansari E, Talenti DA, Scopelliti JA, Saadat JM, Zehr BD. Serum lipase and amylase ratio in acute alcoholic and nonalcoholic pancreatitis by using Dupont ACA discrete clinical analyzer. *Digestive Diseases and Sciences*. 1996; 41(9):1823-1827
43. Aoun E, Chang CCH, Greer JB, Papachristou GI, Barmada MM, Whitcomb DC. Pathways to injury in chronic pancreatitis: Decoding the role of the high-risk SPINK1 N34S haplotype using meta-analysis. *PloS One*. 2008; 3(4):e2003
44. Aoun E, Muddana V, Papachristou GI, Whitcomb DC. SPINK1 N34S is strongly associated with recurrent acute pancreatitis but is not a risk factor for the first or sentinel acute pancreatitis event. *American Journal of Gastroenterology*. 2010; 105(2):446-451

45. Aparisi L, Farre A, Gomez-Cambronero L, Martinez J, De Las Heras G, Corts J et al. Antibodies to carbonic anhydrase and IgG4 levels in idiopathic chronic pancreatitis: Relevance for diagnosis of autoimmune pancreatitis. *Gut*. 2005; 54(5):703-709
46. Applebaum-Shapiro SE, Peters JA, O'Connell JA, Aston CE, Whitcomb DC. Motivations and concerns of patients with access to genetic testing for hereditary pancreatitis. *American Journal of Gastroenterology*. 2001; 96(5):1610-1617
47. Apte MV, Haber PS, Norton ID, Wilson JS. Alcohol and the pancreas. *Addiction Biology*. 1998; 3(2):137-50
48. Ardengh JC, Lopes CV, De Lima-Filho ER, Kemp R, Santos JSD. Impact of endoscopic ultrasound-guided fine-needle aspiration on incidental pancreatic cysts. A prospective study. *Scandinavian Journal of Gastroenterology*. 2014; 49(1):114-120
49. Arendt T, Fischer T, Becker B, Folsch UR. Treatment of meteoristic complaints in chronic pancreatitis: Microbial enzyme therapy and simethicone vs pancreatic enzyme monotherapy. A prospective, randomized, multicenter study in gastroenterologic/internal practices. *Verdauungskrankheiten*. 1999; 17(1):10-5
50. Arlt A, Erhart W, Schafmayer C, Held HC, Hampe J. Antibiosis of necrotizing pancreatitis. *Viszeralmedizin*. 2014; 30(5):318-24
51. Armbrecht U, Svanvik J, Stockbrügger R. Enzyme substitution in chronic pancreatitis: Effects on clinical and functional parameters and on the hydrogen (H₂) breath test. *Scandinavian Journal of Gastroenterology Supplement*. 1986; 126:55-9
52. Arslanlar S, Jain R. Benign biliary strictures related to chronic pancreatitis: Balloons, stents, or surgery. *Current Treatment Options in Gastroenterology*. 2007; 10(5):369-375
53. Ashkar M, Gardner TB. Role of endoscopic ultrasound in pancreatic diseases: A systematic review. *Minerva Gastroenterologica e Dietologica*. 2014; 60(4):227-45
54. Ashley SW, Perez A, Pierce EA, Brooks DC, Moore FD, Jr., Whang EE et al. Necrotizing pancreatitis: contemporary analysis of 99 consecutive cases. *Annals of Surgery*. 2001; 234(4):572-9; discussion 579-80
55. Aspinwall LG, Taber JM, Leaf SL, Kohlmann W, Leachman SA. Genetic testing for hereditary melanoma and pancreatic cancer: A longitudinal study of psychological outcome. *Psycho-Oncology*. 2013; 22(2):276-289
56. Aultman DF, Bilton BD, Zibari GB, McMillan RW, McDonald JC. Nonoperative therapy for acute necrotizing pancreatitis. *American Surgeon*. 1997; 63(12):1114-1118
57. Avanesov M, Loser A, Keller S, Weinrich JM, Laqmani A, Adam G et al. Diagnosing acute pancreatitis-Clinical and radiological characterisation of patients without threefold increase of serum lipase. *European Journal of Radiology*. 2017; 95:278-285
58. Avanthi SU, Ravi Kanth VV, Agarwal J, Lakhtakia S, Gangineni K, Rao GV et al. Association of claudin2 and PRSS1-PRSS2 polymorphisms with idiopathic recurrent acute and chronic pancreatitis: A case-control study from India. *Journal of Gastroenterology and Hepatology*. 2015; 30(12):1796-1801
59. Ayub K, Slavin J, Imada R. Endoscopic retrograde cholangiopancreatography in gallstone-associated acute pancreatitis. *Cochrane Database of Systematic Reviews* 2010, Issue 1. Art. No.: CD003630. DOI: 10.1002/14651858.CD003630.pub3.

60. Azeem N, Baron TH, Topazian MD, Zhong N, Fleming CJ, Kendrick ML. Outcomes of endoscopic and percutaneous drainage of pancreatic fluid collections arising after pancreatic tail resection. *Journal of the American College of Surgeons*. 2012; 215(2):177-185
61. Azoulay E. Pleural effusions in the intensive care unit. *Current Opinion in Pulmonary Medicine*. 2003; 9(4):291-297
62. Azzopardi N. Endoscopic retrograde cholangiopancreatography stents: Indications, risks and novel uses. *Gastroenterology Insights*. 2012; 4(1):43-51
63. Babu BI, Sheen AJ, Lee SH, O'Shea S, Eddleston JM, Siriwardena AK. Open pancreatic necrosectomy in the multidisciplinary management of postinflammatory necrosis. *Annals of Surgery*. 2010; 251(5):783-6
64. Babu BI, Siriwardena AK. Current status of minimally invasive necrosectomy for post-inflammatory pancreatic necrosis. *HPB*. 2009; 11(2):96-102
65. Bachmann K, Tomkoetter L, Erbes J, Hofmann B, Reeh M, Perez D et al. Beger and Frey procedures for treatment of chronic pancreatitis: Comparison of outcomes at 16-year follow-up. *Journal of the American College of Surgeons*. 2014; 219(2):208-16
66. Bai Y, Gao J, Zou DW, Li ZS. Prophylactic antibiotics cannot reduce infected pancreatic necrosis and mortality in acute necrotizing pancreatitis: evidence from a meta-analysis of randomized controlled trials. *American Journal of Gastroenterology*. 2008; 103(1):104-10
67. Bakhru MR, Kahaleh M. Expandable metal stents for benign biliary disease. *Gastrointestinal Endoscopy Clinics of North America*. 2011; 21(3):447-462
68. Bakker OJ, Santvoort HC, Brunschot S, Geskus RB, Besselink MG, Bollen TL et al. Endoscopic transgastric vs surgical necrosectomy for infected necrotizing pancreatitis: A randomized trial. *JAMA*. 2012; 307(10):1053-61
69. Bakker OJ, van Baal MC, van Santvoort HC, Besselink MG, Poley JW, Heisterkamp J et al. Endoscopic transpapillary stenting or conservative treatment for pancreatic fistulas in necrotizing pancreatitis: multicenter series and literature review. *Annals of Surgery*. 2011; 253(5):961-7
70. Bakker OJ, van Brunschot S, Farre A, Johnson CD, Kalfarentzos F, Louie BE et al. Timing of enteral nutrition in acute pancreatitis: Meta-analysis of individuals using a single-arm of randomised trials. *Pancreatology*. 2014; 14(5):340-6
71. Bakker OJ, van Brunschot S, van Santvoort HC, Besselink MG, Bollen TL, Boermeester MA et al. Early versus on-demand nasoenteric tube feeding in acute pancreatitis. *New England Journal of Medicine*. 2014; 371(21):1983-93
72. Bakker OJ, van Santvoort HC, Besselink MG, van der Harst E, Hofker HS, Gooszen HG et al. Prevention, detection, and management of infected necrosis in severe acute pancreatitis. *Current Gastroenterology Reports*. 2009; 11(2):104-10
73. Bakker OJ, van Santvoort HC, van Brunschot S, Ahmed Ali U, Besselink MG, Boermeester MA et al. Pancreatitis, very early compared with normal start of enteral feeding (PYTHON trial): Design and rationale of a randomised controlled multicenter trial. *Trials*. 2011; 12:73
74. Bala M, Almogy G, Klimov A, Rivkind AI, Verstandig A. Percutaneous "stepped" drainage technique for infected pancreatic necrosis. *Surgical Laparoscopy, Endoscopy and Percutaneous Techniques*. 2009; 19(4):e113-e118

75. Balci NC, Alkaade S, Akduman IE, Bilgin M, Murdock CP, Burton FR. Serial contrast-enhanced MRI of the pancreas. Correlation with secretin-stimulated endoscopic pancreatic function test. *Academic Radiology*. 2006; 13(11):1367-1372
76. Balci NC, Alkaade S, Magas L, Momtahan AJ, Burton FR. Suspected chronic pancreatitis with normal MRCP: findings on MRI in correlation with secretin MRCP. *Journal of Magnetic Resonance Imaging*. 2008; 27(1):125-31
77. Ballard DD, Flueckiger JR, Fogel EL, McHenry L, Lehman GA, Watkins JL et al. Evaluating adults with idiopathic pancreatitis for genetic predisposition: Higher prevalence of abnormal results with use of complete gene sequencing. *Pancreas*. 2015; 44(1):116-121
78. Baltatzis M, Jegatheeswaran S, O'Reilly DA, Siriwardena AK. Antibiotic use in acute pancreatitis: Global overview of compliance with international guidelines. *Pancreatology*. 2016; 16(2):189-93
79. Baltatzis M, Mason JM, Chandrabalan V, Stathakis P, McIntyre B, Jegatheeswaran S et al. Antibiotic use in acute pancreatitis: An audit of current practice in a tertiary centre. *Pancreatology*. 2016; 16(6):946-951
80. Bang JY, Holt BA, Hawes RH, Hasan MK, Arnoletti JP, Christein JD et al. Outcomes after implementing a tailored endoscopic step-up approach to walled-off necrosis in acute pancreatitis. *British Journal of Surgery*. 2014; 101(13):1729-1738
81. Bang SJ, Kim MH, Kim DH, Lee TY, Kwon S, Oh HC et al. Is pancreatic core biopsy sufficient to diagnose autoimmune chronic pancreatitis? *Pancreas*. 2008; 36(1):84-9
82. Banimahd F, Spinello IM. Large-volume paracentesis: A fast, convenient, and safe technique. *Journal of Emergency Medicine*. 2009; 37(4):409-10
83. Banks PA. Management of pancreatic pain. *Pancreas*. 1991; 6(Suppl 1):S52-9
84. Banks PA, Freeman ML, Fass R, Baroni DS, Mutlu EA, Bernstein DE et al. Practice guidelines in acute pancreatitis. *American Journal of Gastroenterology*. 2006; 101(10):2379-2400
85. Banks PA, Hughes M, Ferrante M, Noordhoek EC, Ramagopal V, Slivka A. Does allopurinol reduce pain of chronic pancreatitis? *International Journal of Pancreatology*. 1997; 22(3):171-6
86. Baril NB, Ralls PW, Wren SM, Selby RR, Radin R, Parekh D et al. Does an infected peripancreatic fluid collection or abscess mandate operation? *Annals of Surgery*. 2000; 231(3):361-7
87. Baron TH. Biliary self-expandable metal stents. *ASGE Clinical Update*. 2009; 17(2):1-4
88. Baron TH, Harewood GC, Morgan DE, Yates MR. Outcome differences after endoscopic drainage of pancreatic necrosis, acute pancreatic pseudocysts, and chronic pancreatic pseudocysts. *Gastrointestinal Endoscopy*. 2002; 56(1):7-17
89. Barreda L, Targarona J, Pando E, Reynel M, Portugal J, Barreda C. Medical versus surgical management for emphysematous pancreatic necrosis: Is gas within pancreatic necrosis an absolute indication for surgery? *Pancreas*. 2015; 44(5):808-811
90. Barthet M, Bernard JP, Duval JL, Affriat C, Sahel J. Biliary stenting in benign biliary stenosis complicating chronic calcifying pancreatitis. *Endoscopy*. 1994; 26(7):569-572

91. Barthet M, Bugallo M, Moreira LS, Bastid C, Sastre B, Sahel J. Management of cysts and pseudocysts complicating chronic pancreatitis. A retrospective study of 143 patients. *Gastroenterologie Clinique et Biologique*. 1993; 17(4):270-6
92. Bartholomew M, Barkin J. Early antibiotic treatment in acute necrotizing pancreatitis. *Gastrointestinal Endoscopy*. 1996; 44(6):763-4
93. Basinski A, Stefaniak T, Vingerhoets A, Makarewicz W, Kaska L, Stanek A et al. Effect of NCPB and VSPL on pain and quality of life in chronic pancreatitis patients. *World Journal of Gastroenterology*. 2005; 11(32):5010-4
94. Bassi C, Butturini G, Salvia R, Contro C, Valerio A, Falconi M et al. A single-institution experience with fistulojejunostomy for external pancreatic fistulas. *American Journal of Surgery*. 2000; 179(3):203-6
95. Bassi C, DiCarlo V, Zerbi A, Galloro V, Uomo G, Fontana G et al. Role of imipenem (I) in preventing infected necrosis (IN) during acute pancreatitis (NP) Results of the Italian Multicenter Study. *Digestion*. 1992; 52(2):68
96. Bassi C, Falconi M, Beger HG, Isenmann R. Discussion on prophylactic antibiotic treatment in patients with predicted severe pancreatitis: A placebo-controlled, double-blind trial [3] (multiple letters). *Gastroenterology*. 2004; 127(3):1015-7
97. Bassi C, Falconi M, Caldiron E, Salvia R, Minelli EB, Pederzoli P. Use of antibiotics in necrotizing pancreatitis. *Problems in General Surgery*. 1996; 13(4):80-85
98. Bassi C, Falconi M, Caldiron E, Salvia R, Sartori N, Butturini G et al. Assessment and treatment of severe pancreatitis. Protease inhibitor. *Digestion*. 1999; 60 (Suppl 1):5-8
99. Bassi C, Falconi M, Salvia R, Caldiron E, Butturini G, Pederzoli P. Role of octreotide in the treatment of external pancreatic pure fistulas: A single-institution prospective experience. *Langenbecks Archives of Surgery*. 2000; 385(1):10-3
100. Bassi C, Falconi M, Talamini G, Uomo G, Papaccio G, Dervenis C et al. Controlled clinical trial of pefloxacin versus imipenem in severe acute pancreatitis. *Gastroenterology*. 1998; 115(6):1513-7
101. Bassi C, Vesentini S, Campedelli A, Nifosi F, Girelli R, Falconi M et al. Imipenem Prophylaxis In Necrotizing Pancreatitis: Results Of A Multicenter Study. *International Journal of Pancreatology*. 1992; 12(1):77
102. Baudin G, Chassang M, Gelsi E, Novellas S, Bernardin G, Hebuterne X et al. CT-guided percutaneous catheter drainage of acute infectious necrotizing pancreatitis: Assessment of effectiveness and safety. *American Journal of Roentgenology*. 2012; 199(1):192-199
103. Bausch D, Wellner U, Kahl S, Kuesters S, Richter-Schrag HJ, Utzolino S et al. Minimally invasive operations for acute necrotizing pancreatitis: Comparison of minimally invasive retroperitoneal necrosectomy with endoscopic transgastric necrosectomy. *Surgery*. 2012; 152(3 Suppl 1):S128-34
104. Beattie GC, Mason J, Swan D, Madhavan KK, Siriwardena AK. Outcome of necrosectomy in acute pancreatitis: The case for continued vigilance. *Scandinavian Journal of Gastroenterology*. 2002; 37(12):1449-53
105. Beck WC, Bhutani MS, Raju GS, Nealon WH. Surgical management of late sequelae in survivors of an episode of acute necrotizing pancreatitis. *Journal of the American College of Surgeons*. 2012; 214(4):682-8; discussion 688-90

106. Becker V, Huber W, Meining A, Prinz C, Umgelter A, Ludwig L et al. Infected necrosis in severe pancreatitis--combined nonsurgical multi-drainage with directed transabdominal high-volume lavage in critically ill patients. *Pancreatology*. 2009; 9(3):280-6
107. Beckingham JJ, Krige JE, Bornman PC, Terblanche J. Endoscopic management of pancreatic pseudocysts. *British Journal of Surgery*. 1997; 84(12):1638-45
108. Beenen E, Brown L, Connor S. A comparison of the hospital costs of open vs. minimally invasive surgical management of necrotizing pancreatitis. *HPB*. 2011; 13(3):178-184
109. Beger HG. Surgical management of necrotizing pancreatitis. *Surgical Clinics of North America*. 1989; 69(3):529-49
110. Beger HG, Bittner R, Block S, Buchler M. Bacterial contamination of pancreatic necrosis. A prospective clinical study. *Gastroenterology*. 1986; 91(2):433-8
111. Beger HG, Buchler M, Bittner R, Block S, Nevalainen T, Roscher R. Necrosectomy and postoperative local lavage in necrotizing pancreatitis. *British Journal of Surgery*. 1988; 75(3):207-12
112. Beger HG, Gansauge F, Poch B, Schwarz M. The use of antibiotics for acute pancreatitis: Is there a role? *Current Infectious Disease Reports*. 2009; 11(2):101-7
113. Beger HG, Rau B. Necrosectomy and postoperative local lavage in necrotizing pancreatitis. *Annali Italiani di Chirurgia*. 1995; 66(2):209-215
114. Behm B, Brock A, Clarke BW, Ellen K, Northup PG, Dumonceau JM et al. Partially covered self-expandable metallic stents for benign biliary strictures due to chronic pancreatitis. *Endoscopy*. 2009; 41(6):547-551
115. Behrns KE. Local resection of the pancreatic head for pancreatic pseudocysts. *Journal of Gastrointestinal Surgery*. 2008; 12(12):2227-30
116. Bejanin H, Liguory C, Ink O, Fritsch J, Choury AD, Lefebvre JF et al. Endoscopic drainage of pseudocysts of the pancreas. Study of 26 cases. *Gastroenterologie Clinique et Biologique*. 1993; 17(11):804-10
117. Bello B, Matthews JB. Minimally invasive treatment of pancreatic necrosis. *World Journal of Gastroenterology*. 2012; 18(46):6829-35
118. Belyaev O, Herzog T, Chromik AM, Meurer K, Uhl W. Early and late postoperative changes in the quality of life after pancreatic surgery. *Langenbecks Archives of Surgery*. 2013; 398(4):547-55
119. Benini L, Amodio A, Campagnola P, Agugiaro F, Cristofori C, Micciolo R et al. Fecal elastase-1 is useful in the detection of steatorrhea in patients with pancreatic diseases but not after pancreatic resection. *Pancreatology*. 2013; 13(1):38-42
120. Benini L, Caliarì S, Bonfante F, Bardelli E, Castellani G, Sembenini C et al. Fecal fat concentration in the screening of steatorrhea. *Digestion*. 1992; 53(1-2):94-100
121. Bergman JJ, Berkel AM, Bruno MJ, Fockens P, Rauws EA, Tijssen JG et al. A randomized trial of endoscopic balloon dilation and endoscopic sphincterotomy for removal of bile duct stones in patients with a prior Billroth II gastrectomy. *Gastrointestinal Endoscopy*. 2012; 53(1):19-26
122. Berzin TM, Banks PA, Maurer R, Morteale KJ. CT-guided percutaneous catheter drainage in necrotizing pancreatitis: Outcomes among patients discharged with drains in place. *Journal of Vascular and Interventional Radiology*. 2008; 19(7):1002-6

123. Besselink MG, de Bruijn MT, Rutten JP, Boermeester MA, Hofker HS, Gooszen HG et al. Surgical intervention in patients with necrotizing pancreatitis. *British Journal of Surgery*. 2006; 93(5):593-9
124. Besselink MG, Santvoort HC, Nieuwenhuijs VB, Boermeester MA, Bollen TL, Buskens E et al. Minimally invasive 'step-up approach' versus maximal necrosectomy in patients with acute necrotising pancreatitis (PANTER trial): design and rationale of a randomised controlled multicenter trial [ISRCTN13975868]. *BMC Surgery*. 2006; 6:6
125. Besselink MGH, van Santvoort HC, Bollen TL, Boermeester MA, Dejong CHC, Gooszen HG. Management of patients with severe acute pancreatitis in the new millennium: Prophylaxis, nutrition, imaging and intervention. *Netherlands Journal of Critical Care*. 2008; 12(1):14-19
126. Besselink MGH, Verwer TJ, Schoenmaeckers EJP, Buskens E, Ridwan BU, Visser MR et al. Timing of surgical intervention in necrotizing pancreatitis. *Archives of Surgery*. 2007; 142(12):1194-1201
127. Bhardwaj P, Garg PK, Maulik SK, Saraya A, Tandon RK, Acharya SK. A randomized controlled trial of antioxidant supplementation for pain relief in patients with chronic pancreatitis. *Gastroenterology*. 2009; 136(1):149-159.e2
128. Bhardwaj P, Yadav RK. Chronic pancreatitis: Role of oxidative stress and antioxidants. *Free Radical Research*. 2013; 47(11):941-9
129. Bhasin DK, Rana SS, Nanda M, Chandail VS, Gupta R, Kang M et al. Comparative evaluation of transpapillary drainage with nasopancreatic drain and stent in patients with large pseudocysts located near tail of pancreas. *Journal of Gastrointestinal Surgery*. 2011; 15(5):772-6
130. Bhasin DK, Rana SS, Siyad I, Poddar U, Thapa BR, Sinha SK et al. Endoscopic transpapillary nasopancreatic drainage alone to treat pancreatic ascites and pleural effusion. *Journal of Gastroenterology and Hepatology*. 2006; 21(6):1059-64
131. Bhutani MS, Arantes VN, Verma D, Moezzi J, Suryaprasad S, Kapadia AS et al. Histopathologic correlation of endoscopic ultrasound findings of chronic pancreatitis in human autopsies. *Pancreas*. 2009; 38(7):820-824
132. Bian Y, Wang L, Chen C, Lu JP, Fan JB, Chen SY et al. Quantification of pancreatic exocrine function of chronic pancreatitis with secretin-enhanced MRCP. *World Journal of Gastroenterology*. 2013; 19(41):7177-7182
133. Bilton D, Schofield D, Mei G, Kay PM, Bottiglieri T, Braganza JM. Placebo-controlled trials of antioxidant therapy including S-adenosylmethionine in patients with recurrent nongallstone pancreatitis. *Drug Investigation*. 1994; 8(1):10-20
134. Binmoeller KF, Jue P, Seifert H, Nam WC, Izbicki J, Soehendra N. Endoscopic pancreatic stent drainage in chronic pancreatitis and a dominant stricture: Long-term results. *Endoscopy*. 1995; 27(9):638-44
135. Binmoeller KF, Seifert H, Walter A, Soehendra N. Transpapillary and transmural drainage of pancreatic pseudocysts. *Gastrointestinal Endoscopy*. 1995; 42(3):219-24
136. Bintcliffe OJ, Lee GYC, Rahman NM, Maskell NA. The management of benign non-infective pleural effusions. *European Respiratory Review*. 2016; 25(141):303-316

137. Bittner R, Butters M, Buchler M, Nagele S, Roscher R, Beger HG. Glucose homeostasis and endocrine pancreatic function in patients with chronic pancreatitis before and after surgical therapy. *Pancreas*. 1994; 9(1):47-53
138. Blero D, Huberty V, Deviere J. Novel biliary self-expanding metal stents: Indications and applications. *Expert Review of Gastroenterology and Hepatology*. 2015; 9(3):359-367
139. Bliss LA, Yang CJ, Eskander MF, de Geus SW, Callery MP, Kent TS et al. Surgical management of chronic pancreatitis: Current utilization in the united states. *HPB*. 2015; 17(9):804-10
140. Bloechle C, Izbicki JR, Tesch C, Gawad K, Binmoeller KF, Broelsch CE. The influence of drainage versus resection on segmental portal hypertension in chronic pancreatitis. *Langenbecks Archiv für Chirurgie*. 1996; Suppl II Kongressbericht:1279-80
141. Bloechle C, Strate T, Schneider C, Gonzalez C, Kuechler T, Schrenck T. Organ preserving surgery for chronic pancreatitis - long-term results of a randomized controlled study comparing resection (SR) vs. extended drainage (ED). *Chirurgisches Forum*. 2001; 30:559-61
142. Bloechle C, Tesch C, Kuehn R, Gawad K, Bienmoeller KF, Izbicki JR. Effect of drainage versus resection on non-occlusive segmental portal hypertension in chronic pancreatitis: A prospective randomized study. *Pancreas*. 1995; 11(4):422
143. BMJ Group and the Royal Pharmaceutical Society of Great Britain. British National Formulary Available from: <https://www.evidence.nhs.uk/formulary/bnf/current> Last accessed: 04 April 2017.
144. Boedeker C, Goetze O, Pfaffenbach B, Luypaerts A, Geypens B, Adamek RJ. 13C mixed-triglyceride breath test: Isotope selective non-dispersive infrared spectrometry in comparison with isotope ratio mass spectrometry in volunteers and patients with chronic pancreatitis. *Scandinavian Journal of Gastroenterology*. 1999; 34(11):1153-1156
145. Boerma D, van Gulik TM, Rauws EA, Obertop H, Gouma DJ. Outcome of pancreaticojejunostomy after previous endoscopic stenting in patients with chronic pancreatitis. *European Journal of Surgery*. 2002; 168(4):223-8
146. Bolado F, de-Madaria E. Novel findings in the management of acute pancreatitis. *Gastroenterología y Hepatología*. 2016; 39 Suppl 1:102-108
147. Boland B, Colquhoun S, Menon V, Kim A, Lo S, Nissen NN. Current surgical management of infected pancreatic necrosis. *American Surgeon*. 2010; 76(10):1096-1099
148. Bortolotti P, Saulnier F, Colling D, Redheuil A, Preau S. New tools for optimizing fluid resuscitation in acute pancreatitis. *World Journal of Gastroenterology*. 2014; 20(43):16113-22
149. Boskoski I, Costamagna G. Benign biliary strictures: Endoscopic management. *Techniques in Gastrointestinal Endoscopy*. 2016; 18(2):62-66
150. Bosscha K, Reijnders K, Jacobs MH, Post MW, Algra A, van der Werken C. Quality of life after severe bacterial peritonitis and infected necrotizing pancreatitis treated with open management of the abdomen and planned re-operations. *Critical Care Medicine*. 2001; 29(8):1539-43
151. Boutros C, Somasundar P, Espat NJ. Open cystogastrostomy, retroperitoneal drainage, and G-J enteral tube for complex pancreatitis-associated pseudocyst: 19 patients with no recurrence. *Journal of Gastrointestinal Surgery*. 2010; 14(8):1298-303

152. Bouwense SA, Buscher HC, van Goor H, Wilder-Smith OH. Has central sensitization become independent of nociceptive input in chronic pancreatitis patients who fail thoracoscopic splanchnicectomy? *Regional Anesthesia and Pain Medicine*. 2011; 36(6):531-6
153. Bouwense SA, Olesen SS, Drewes AM, Poley JW, Goor H, Wilder-Smith OH. Effects of pregabalin on central sensitization in patients with chronic pancreatitis in a randomized, controlled trial. *PLoS One*. 2012; 7(8):e42096
154. Bracher GA, Manocha AP, DeBanto JR, Gates LK, Jr., Slivka A, Whitcomb DC et al. Endoscopic pancreatic duct stenting to treat pancreatic ascites. *Gastrointestinal Endoscopy*. 1999; 49(6):710-5
155. Bradley IEL, Allen K. A prospective longitudinal study of observation versus surgical intervention in the management of necrotizing pancreatitis. *American Journal of Surgery*. 1991; 161(1):19-25
156. Bradley IEL, Howard TJ, Van Sonnenberg E, Fotoohi M. Intervention in necrotizing pancreatitis: An evidence-based review of surgical and percutaneous alternatives. *Journal of Gastrointestinal Surgery*. 2008; 12(4):634-639
157. Brand B, Kahl M, Sidhu S, Nam VC, Sriram PV, Jaeckle S et al. Prospective evaluation of morphology, function, and quality of life after extracorporeal shockwave lithotripsy and endoscopic treatment of chronic calcific pancreatitis. *American Journal of Gastroenterology*. 2000; 95(12):3428-38
158. Branum G, Galloway J, Hirchowicz W, Fendley M, Hunter J. Pancreatic necrosis: results of necrosectomy, packing, and ultimate closure over drains. *Annals of Surgery*. 1998; 227(6):870-7
159. Brijbassie A, Yeaton P. Approach to the patient with a biliary stricture. *Techniques in Gastrointestinal Endoscopy*. 2016; 18(2):44-51
160. Brown A, Baillargeon JD, Hughes MD, Banks PA. Can fluid resuscitation prevent pancreatic necrosis in severe acute pancreatitis? *Pancreatology*. 2002; 2(2):104-7
161. Brown A, Hughes M, Tenner S, Banks PA. Does pancreatic enzyme supplementation reduce pain in patients with chronic pancreatitis: a meta-analysis. *American Journal of Gastroenterology*. 1997; 92(11):2032-2035
162. Bruennler T, Langgartner J, Lang S, Wrede CE, Klebl F, Zierhut S et al. Outcome of patients with acute, necrotizing pancreatitis requiring drainage-does drainage size matter? *World Journal of Gastroenterology*. 2008; 14(5):725-730
163. Brugge WR, Alpern ZA, Burke CA. Basal chymotrypsin secretion and the bentiromide test in chronic pancreatitis. *International Journal of Pancreatology*. 1990; 7(4):369-378
164. Bucher P, Pugin F, Morel P. Minimally invasive necrosectomy for infected necrotizing pancreatitis. *Pancreas*. 2008; 36(2):113-119
165. Buchler MW, Gloor B, Muller CA, Friess H, Seiler CA, Uhl W. Acute necrotizing pancreatitis: Treatment strategy according to the status of infection. *Annals of Surgery*. 2000; 232(5):619-622
166. Buchler MW, Lubke D, Muller MW, Friess H. Comparison between pylorus-preserving whipple operation and duodenum-preserving pancreatic head resection. *Acta Chirurgica Austriaca*. 1996; 28(4):200-204

167. Buechter M, Manka P, Heinemann FM, Lindemann M, Juntermanns B, Canbay A et al. Outcome and genetic factors in IgG4-associated autoimmune pancreatitis and cholangitis: a single center experience. *Gastroenterology research & practice*. 2017; 2017:6126707
168. Buhler L, Schmidlin F, de Perrot M, Borst F, Mentha G, Morel P. Long-term results after surgical management of chronic pancreatitis. *Hepato-Gastroenterology*. 1999; 46(27):1986-9
169. Buijs J, Cahen DL, van Heerde MJ, Hansen BE, van Buuren HR, Peppelenbosch MP et al. Testing for anti-PBP antibody is not useful in diagnosing autoimmune pancreatitis. *American Journal of Gastroenterology*. 2016; 111(11):1650-1654
170. Buijs J, Cahen DL, Van Heerde MJ, Rauws EA, De Buy Wenniger LJM, Hansen BE et al. The long-term impact of autoimmune pancreatitis on pancreatic function, quality of life, and life expectancy. *Pancreas*. 2015; 44(7):1065-1071
171. Burton F, Alkaade S, Collins D, Muddana V, Slivka A, Brand RE et al. Use and perceived effectiveness of non-analgesic medical therapies for chronic pancreatitis in the United States. *Alimentary Pharmacology and Therapeutics*. 2011; 33(1):149-59
172. Buscail L, Escourrou J, Moreau J, Delvaux M, Louvel D, Lapeyre F et al. Endoscopic ultrasonography in chronic pancreatitis: A comparative prospective study with conventional ultrasonography, computed tomography, and ERCP. *Pancreas*. 1995; 10(3):251-7
173. Buscher HC, Jansen JB, van Dongen R, Bleichrodt RP, van Goor H. Long-term results of bilateral thoracoscopic splanchnicectomy in patients with chronic pancreatitis. *British Journal of Surgery*. 2002; 89(2):158-62
174. Buscher HCJL, van Goor H, Wilder-Smith OHG. Effect of thoracoscopic splanchnic denervation on pain processing in chronic pancreatitis patients. *European Journal of Pain*. 2007; 11(4):437-443
175. Busse MJ, Ainsworth AP. Ten years of experience with transgastric necrosectomy for walled-off necrosis in acute pancreatitis. *Danish Medical Journal*. 2015; 62(9):A5131
176. Butorova LI, Vasil'ev AP, Kozlov IM, Kuz'michev SB, Popova TN, Eletskaia AO et al. [Chronic pancreatitis: comparative assessment of effectiveness of dose-dependent therapy and prophylaxis of recurrence by polyenzyme drugs]. *Experimental & Clinical Gastroenterology*. 2007; (6):96-102
177. Buxbaum J, Yan A, Yeh K, Lane C, Nguyen N, Laine L. Aggressive hydration with lactated Ringer's solution reduces pancreatitis after endoscopic retrograde cholangiopancreatography. *Clinical Gastroenterology and Hepatology*. 2014; 12(2):303-7.e1
178. Buxbaum JL, Quezada M, Da B, Jani N, Lane C, Mwendela D et al. Early aggressive hydration hastens clinical improvement in mild acute pancreatitis. *American Journal of Gastroenterology*. 2017; 112(5):797-803
179. Byrne MF, McLoughlin MT, Mitchell RM, Gerke H, Pappas TN, Branch MS et al. The fate of patients who undergo "preoperative" ERCP to clear known or suspected bile duct stones. *Surgical Endoscopy*. 2009; 23(1):74-9
180. Cabay JE, Boverie JH, Dondelinger RF. Percutaneous catheter drainage of external fistulas of the pancreatic ducts. *European Radiology*. 1998; 8(3):445-8
181. Cahen DL, Gouma DJ, Laramée P, Nio Y, Rauws EA, Boermeester MA et al. Long-term outcomes of endoscopic vs surgical drainage of the pancreatic duct in patients with chronic pancreatitis. *Gastroenterology*. 2011; 141(5):1690-5

182. Cahen DL, Gouma DJ, Nio Y, Rauws EA, Boermeester MA, Busch OR et al. Endoscopic versus surgical drainage of the pancreatic duct in chronic pancreatitis. *New England Journal of Medicine*. 2007; 356(7):676-84
183. Cahen DL, Gouma DJ, Nio Y, Rauws EAJ, Boermeester MA, Busch OR et al. Surgical drainage of the pancreatic duct in patients with chronic pancreatitis is more effective than endoscopic drainage: Randomized trial. *Nederlands Tijdschrift voor Geneeskunde*. 2007; 151(47):2624-30
184. Cahen DL, Rauws EA, Gouma DJ, Fockens P, Bruno MJ. Removable fully covered self-expandable metal stents in the treatment of common bile duct strictures due to chronic pancreatitis: A case series. *Endoscopy*. 2008; 40(8):697-700
185. Cahen DL, Van Berkel AMM, Oskam D, Rauws EAJ, Weverling GJ, Huibregtse K et al. Long-term results of endoscopic drainage of common bile duct strictures in chronic pancreatitis. *European Journal of Gastroenterology and Hepatology*. 2005; 17(1):103-108
186. Cai GH, Huang J, Zhao Y, Chen J, Wu HH, Dong YL et al. Antioxidant therapy for pain relief in patients with chronic pancreatitis: Systematic review and meta-analysis. *Pain Physician*. 2013; 16(6):521-32
187. Calandra T, Marchetti O. Clinical trials of antifungal prophylaxis among patients undergoing surgery. *Clinical Infectious Diseases*. 2004; 39 (Suppl 4):S185-92
188. Camara SN, Ramdany S, Zhao G, Gou SM, Xiong JX, Yang ZY et al. Etiology, pathology, management and prognosis of chronic pancreatitis in Chinese population: A retrospective study. *Journal of Huazhong University of Science and Technology Medical Sciences*. 2015; 35(3):384-9
189. Campa D, Rizzato C, Capurso G, Giese N, Funel N, Greenhalf W et al. Genetic susceptibility to pancreatic cancer and its functional characterisation: The PANcreatic Disease ReseArch (PANDoRA) consortium. *Digestive and Liver Disease*. 2013; 45(2):95-9
190. Cantu P, Hookey LC, Morales A, Le Moine O, Deviere J. The treatment of patients with symptomatic common bile duct stenosis secondary to chronic pancreatitis using partially covered metal stents: A pilot study. *Endoscopy*. 2005; 37(8):735-739
191. Cao Y, Xu Y, Lu T, Gao F, Mo Z. Meta-analysis of enteral nutrition versus total parenteral nutrition in patients with severe acute pancreatitis. *Annals of Nutrition and Metabolism*. 2008; 53(3-4):268-75
192. Cappellet O, Delhaye M, Deviere J, Le Moine O, Metens T, Nicaise N et al. Chronic pancreatitis: Evaluation of pancreatic exocrine function with MR pancreatography after secretin stimulation. *Radiology*. 2000; 215(2):358-364
193. Capurso G, Cocomello L, Benedetto U, Camma C, Delle Fave G. Meta-analysis: The placebo rate of abdominal pain remission in clinical trials of chronic pancreatitis. *Pancreas*. 2012; 41(7):1125-1131
194. Caraceni P, Domenicali M, Tovoli A, Napoli L, Ricci CS, Tufoni M et al. Clinical indications for the albumin use: Still a controversial issue. *European Journal of Internal Medicine*. 2013; 24(8):721-8
195. Carter CR, McKay CJ, Imrie CW. Percutaneous necrosectomy and sinus tract endoscopy in the management of infected pancreatic necrosis: An initial experience. *Annals of Surgery*. 2000; 232(2):175-180

196. Cartmell MT, O'Reilly DA, Porter C, Kingsnorth AN. A double-blind placebo-controlled trial of a leukotriene receptor antagonist in chronic pancreatitis in humans. *Journal of Hepato-Biliary-Pancreatic Surgery*. 2004; 11(4):255-9
197. Casas M, Mora J, Fort E, Aracil C, Busquets D, Galter S et al. Total enteral nutrition vs. total parenteral nutrition in patients with severe acute pancreatitis. *Revista Española de Enfermedades Digestivas*. 2007; 99(5):264-269
198. Casellas F, Guarner L, Antolin M, Malagelada JR. Hydrogen breath test with low-dose rice flour for assessment of exocrine pancreatic insufficiency. *Pancreas*. 2004; 29(4):306-310
199. Castellanos G, Pinero A, Doig LA, Serrano A, Fuster M, Bixquert V. Management of infected pancreatic necrosis using retroperitoneal necrosectomy with flexible endoscope: 10 years of experience. *Surgical Endoscopy and Other Interventional Techniques*. 2013; 27(2):443-453
200. Castellanos G, Pinero A, Serrano A, Llamas C, Fuster M, Fernandez JA et al. Translumbar retroperitoneal endoscopy: an alternative in the follow-up and management of drained infected pancreatic necrosis. *Archives of Surgery*. 2005; 140(10):952-5
201. Catalano MF. Diagnosing early-stage chronic pancreatitis: Is endoscopic ultrasound a reliable modality? *Journal of Gastroenterology*. 2007; 42(Suppl 17):78-84
202. Catalano MF, Lahoti S, Geenen JE, Hogan WJ. Prospective evaluation of endoscopic ultrasonography, endoscopic retrograde pancreatography, and secretin test in the diagnosis of chronic pancreatitis. *Gastrointestinal Endoscopy*. 1998; 48(1):11-17
203. Chak A, Hawes RH, Cooper GS, Hoffman B, Catalano MF, Wong RCK et al. Prospective assessment of the utility of EUS in the evaluation of gallstone pancreatitis. *Gastrointestinal Endoscopy*. 1999; 49(5):599-604
204. Chan C, Vilatoba M, Bartolucci A, Vickers S. Improved reduction in pain in chronic pancreatitis with combined intraoperative celiac axis plexus block and lateral pancreaticojejunostomy. *Current Surgery*. 2001; 58(2):220-222
205. Chang A, Aswakul P, Prachayakul V. Chronic pancreatic pain successfully treated by endoscopic ultrasound-guided pancreaticogastrostomy using fully covered self-expandable metallic stent. *World Journal of Clinical Cases*. 2016; 4(4):112-7
206. Chang YC. Is necrosectomy obsolete for infected necrotizing pancreatitis? Is a paradigm shift needed? *World Journal of Gastroenterology*. 2014; 20(45):16925-16934
207. Chang YC, Tsai HM, Lin XZ, Chang CH, Chuang JP. No debridement is necessary for symptomatic or infected acute necrotizing pancreatitis: Delayed, mini-retroperitoneal drainage for acute necrotizing pancreatitis without debridement and irrigation. *Digestive Diseases and Sciences*. 2006; 51(8):1388-95
208. Chang YS, Fu HQ, Xiao YM, Liu JC. Nasogastric or nasojejunal feeding in predicted severe acute pancreatitis: A meta-analysis. *Critical Care*. 2013; 17(3):R118
209. Chaput U, Vienne A, Audureau E, Bauret P, Bichard P, Coumaros D et al. Temporary placement of fully covered self-expandable metal stents for the treatment of benign biliary strictures. *United European Gastroenterology Journal*. 2016; 4(3):403-412
210. Charnley RM, Lochan R, Gray H, O'Sullivan CB, Scott J, Oppong KE. Endoscopic necrosectomy as primary therapy in the management of infected pancreatic necrosis. *Endoscopy*. 2006; 38(9):925-8

211. Chaudhary A, Dhar P, Sachdev A, Agarwal AK. Surgical management of pancreatic necrosis presenting with locoregional complications. *British Journal of Surgery*. 1997; 84(7):965-968
212. Chauhan S, Forsmark CE. Pain management in chronic pancreatitis: A treatment algorithm. *Best Practice & Research: Clinical Gastroenterology*. 2010; 24(3):323-35
213. Chauhan SS, Pannu DS, Forsmark CE. Antioxidants as adjunctive therapy for pain in chronic pancreatitis. *Practical Gastroenterology*. 2012; 36(3):42-49
214. Chen Q, Yin HX. Clinical effects of anisodamine combined with Xuebijing in treatment of severe pancreatitis. *World Chinese Journal of Digestology*. 2015; 23(21):3464-8
215. Chen WJ, Sun XF, Zhang RX, Xu MJ, Dou TH, Zhang XB et al. Hypertriglyceridemic acute pancreatitis in emergency department: typical clinical features and genetic variants. *Journal of Digestive Diseases*. 2017; 18(6):359-368
216. Chen Y, Zheng B, Robbins DH, Lewin DN, Mikhitarian K, Graham A et al. Accurate discrimination of pancreatic ductal adenocarcinoma and chronic pancreatitis using multimarker expression data and samples obtained by minimally invasive fine needle aspiration. *International Journal of Cancer*. 2007; 120(7):1511-1517
217. Chen YI, Levy MJ, Moreels TG, Hajijeve G, Will U, Artifon EL et al. An international multicenter study comparing EUS-guided pancreatic duct drainage with enteroscopy-assisted endoscopic retrograde pancreatography after Whipple surgery. *Gastrointestinal Endoscopy*. 2017; 85(1):170-177
218. Cheng Y, Briarava M, Lai M, Wang X, Tu B, Cheng N et al. Pancreaticojejunostomy versus pancreaticogastrostomy reconstruction for the prevention of postoperative pancreatic fistula following pancreaticoduodenectomy. *Cochrane Database of Systematic Reviews 2017, Issue 9*. Art. No.: CD012257. DOI: 10.1002/14651858.CD012257.pub2.
219. Cheung MT, Ho CN, Siu KW, Kwok PC. Percutaneous drainage and necrosectomy in the management of pancreatic necrosis. *ANZ Journal of Surgery*. 2005; 75(4):204-7
220. Cheung MT, Li WH, Kwok PC, Hong JK. Surgical management of pancreatic necrosis: Towards lesser and later. *Journal of Hepato-biliary-pancreatic Sciences*. 2010; 17(3):338-44
221. Chiang KC, Yeh CN, Hsu JT, Chen HM, Chen HY, Hwang TL et al. Pancreaticoduodenectomy versus Frey's procedure for chronic pancreatitis: preliminary data on outcome and pancreatic function. *Surgery Today*. 2007; 37(11):961-6
222. Choi JH, Kim HJ, Lee BU, Kim TH, Song IH. Vigorous periprocedural hydration with lactated Ringer's solution reduces the risk of pancreatitis after retrograde cholangiopancreatography in hospitalized patients. *Clinical Gastroenterology and Hepatology*. 2016; 15(1):86-92
223. Choo L, Conway J, Mishra G. The role of endoscopic ultrasound in biliary obstruction. *Current Gastroenterology Reports*. 2012; 14(6):520-527
224. Choudhary NS, Bansal RK, Shah V, Nasa M, Puri R, Thandassery R et al. Prospective evaluation of yield of endoscopic ultrasonography in the etiological diagnosis of idiopathic acute pancreatitis. *Journal of Digestive Endoscopy*. 2016; 7(4):133-136
225. Chowdhury R, Bhutani MS, Mishra G, Toskes PP, Forsmark CE. Comparative analysis of direct pancreatic function testing versus morphological assessment by endoscopic ultrasonography for the evaluation of chronic unexplained abdominal pain of presumed pancreatic origin. *Pancreas*. 2005; 31(1):63-68

226. Chowdhury SD, Kurien RT, Ramachandran A, Joseph AJ, Simon EG, Dutta AK et al. Pancreatic exocrine insufficiency: Comparing fecal elastase 1 with 72-h stool for fecal fat estimation. *Indian Journal of Gastroenterology*. 2016; 35(6):441-444
227. Cimen O, Agaoglu N, Peker K, Kerim Aslan M, Soyturk M, Eken H et al. MRCP in the prognosis of acute pancreatitis. *Medical Science Technology*. 2015; 56:156-160
228. Cirocchi R, Trastulli S, Desiderio J, Boselli C, Parisi A, Noya G et al. Minimally invasive necrosectomy versus conventional surgery in the treatment of infected pancreatic necrosis: A systematic review and a meta-analysis of comparative studies. *Surgical Laparoscopy, Endoscopy and Percutaneous Techniques*. 2013; 23(1):8-20
229. Clarke B, Slivka A, Tomizawa Y, Sanders M, Papachristou GI, Whitcomb DC et al. Endoscopic therapy is effective for patients with chronic pancreatitis. *Clinical Gastroenterology and Hepatology*. 2012; 10(7):795-802
230. Classen M, Cremer M, Faustini S, Meiser G, zum Buschenfelde M, Neuhaus H et al. Electromagnetic shock-wave lithotripsy of gallbladder calculi. Multicentered preliminary report on experience with 276 patients. *Hepato-Gastroenterology*. 1990; 37(4):425-7
231. Closset J, Gelin M. The management of pancreatic ascites and pancreaticopleural effusion. *Acta Gastroenterologica Belgica*. 2000; 63(3):269
232. Coelho D, Ardengh JC, Eulalio JM, Manso JE, Monkemuller K, Coelho JF. Management of infected and sterile pancreatic necrosis by programmed endoscopic necrosectomy. *Digestive Diseases*. 2008; 26(4):364-9
233. Coenegrachts K, Van Steenberghe W, De Keyser F, Vanbeckevoort D, Bielen D, Chen F et al. Dynamic contrast-enhanced MRI of the pancreas: Initial results in healthy volunteers and patients with chronic pancreatitis. *Journal of Magnetic Resonance Imaging*. 2004; 20(6):990-997
234. Cohen M, Sahn SA. Resolution of pleural effusions. *Chest*. 2001; 119(5):1547-1562
235. Cohen SA, Siegel JH. Endotherapy for pancreatic fistulae: Inside out or outside in? *American Journal of Gastroenterology*. 2007; 102(3):525-526
236. Cohn JA. Motion-genetic testing is useful in the diagnosis of nonhereditary pancreatic conditions: Arguments against the motion. *Canadian Journal of Gastroenterology*. 2003; 17(1):53-55
237. Cohn JA, Noone PG, Jowell PS. Idiopathic pancreatitis related to CFTR: Complex inheritance and identification of a modifier gene. *Journal of Investigative Medicine*. 2002; 50(Suppl 5):247S-255S
238. Connor S, Alexakis N, Raraty MG, Ghaneh P, Evans J, Hughes M et al. Early and late complications after pancreatic necrosectomy. *Surgery*. 2005; 137(5):499-505
239. Connor S, Ghaneh P, Raraty M, Sutton R, Rosso E, Garvey CJ et al. Minimally invasive retroperitoneal pancreatic necrosectomy. *Digestive Surgery*. 2003; 20(4):270-7
240. Connor S, Raraty MG, Howes N, Evans J, Ghaneh P, Sutton R et al. Surgery in the treatment of acute pancreatitis--minimal access pancreatic necrosectomy. *Scandinavian Journal of Surgery*. 2005; 94(2):135-42
241. Connor S, Raraty MG, Neoptolemos JP, Layer P, Runzi M, Steinberg WM et al. Does infected pancreatic necrosis require immediate or emergency debridement? *Pancreas*. 2006; 33(2):128-34

242. Conway DI. Alcohol consumption and the risk for disease. Is there a dose-risk relationship between alcohol and disease? *Evidence-Based Dentistry*. 2005; 6(3):76-7
243. Conwell DL, Banks PA, Sandhu BS, Sherman S, Al-Kaade S, Gardner TB et al. Validation of Demographics, Etiology, and Risk Factors for Chronic Pancreatitis in the USA: A Report of the North American Pancreas Study (NAPS) Group. *Digestive Diseases and Sciences*. 2017; 62(8):2133-2140
244. Conwell DL, Lee LS, Yadav D, Longnecker DS, Miller FH, Morteale KJ et al. American Pancreatic Association practice guidelines in chronic pancreatitis evidence-based report on diagnostic guidelines. *Pancreas*. 2014; 43(8):1143-1162
245. Conwell DL, Zuccaro G, Morrow JB, Van Lente F, Obuchowski N, Vargo JJ et al. Cholecystokinin-stimulated peak lipase concentration in duodenal drainage fluid: A new pancreatic function test. *American Journal of Gastroenterology*. 2002; 97(6):1392-1397
246. Conwell DL, Zuccaro G, Purich E, Fein S, Vargo JJ, Dumot JA et al. Comparison of endoscopic ultrasound chronic pancreatitis criteria to the endoscopic secretin-stimulated pancreatic function test. *Digestive Diseases and Sciences*. 2007; 52(5):1206-1210
247. Conwell DL, Zuccaro Jr G, Vargo JJ, Dumot JA, VanLente F, Khandwala F et al. Comparison of the secretin stimulated endoscopic pancreatic function test to retrograde pancreatogram. *Digestive Diseases and Sciences*. 2007; 52(4):1076-1081
248. Cope C, Tuite C, Burke DR, Long WB. Percutaneous management of chronic pancreatic duct strictures and external fistulas with long-term results. *Journal of Vascular and Interventional Radiology*. 2001; 12(1):104-10
249. Coronel E, DaVee T, Lee JH. Advances in endotherapy in chronic pancreatitis. *Gastrointestinal Intervention*. 2017; 6(1):25-31
250. Costamagna G, Boskoski I. Current treatment of benign biliary strictures. *Annals of Gastroenterology*. 2013; 26(1):37-40
251. Costamagna G, Familiari P, Tringali A, Mutignani M. Multidisciplinary approach to benign biliary strictures. *Current Treatment Options in Gastroenterology*. 2007; 10(2):90-101
252. Costamagna G, Mutignani M, Ingrosso M, Vamvakousis V, Alevras P, Manta R et al. Endoscopic treatment of postsurgical external pancreatic fistulas. *Endoscopy*. 2001; 33(4):317-22
253. Coté GA, Slivka A, Tarnasky P, Mullady DK, Elmunzer BJ, Elta G et al. Effect of covered metallic stents compared with plastic stents on benign biliary stricture resolution: A randomized clinical trial. *JAMA*. 2016; 315(12):1250-7
254. Cremer M, Deviere J, Delhaye M, Balze M, Vandermeeren A. Stenting in severe chronic pancreatitis: Results of medium-term follow-up in seventy-six patients. *Bildgebung/Imaging*. 1992; 59(Suppl. 1):20-24
255. Cremer M, Deviere J, Engelholm L. Endoscopic management of cysts and pseudocysts in chronic pancreatitis: Long-term follow-up after 7 years of experience. *Gastrointestinal Endoscopy*. 1989; 35(1):1-9
256. Cresswell AB, Nageswaran H, Belgaumkar A, Kumar R, Menezes N, Riga A et al. The two-port laparoscopic retroperitoneal approach for minimal access pancreatic necrosectomy. *Annals of the Royal College of Surgeons of England*. 2015; 97(5):354-358

257. Cronin P, Begley C. Living with chronic pancreatitis: a qualitative study. *Chronic Illness*. 2013; 9(3):233-47
258. Cui LH, Wang XH, Peng LH, Yu L, Yang YS. The effects of early enteral nutrition with addition of probiotics on the prognosis of patients suffering from severe acute pancreatitis. *Chinese Critical Care Medicine*. 2013; 25(4):224-8
259. Czako L. Diagnosis of early-stage chronic pancreatitis by secretin-enhanced magnetic resonance cholangiopancreatography. *Journal of Gastroenterology*. 2007; 42(Suppl 17):113-117
260. D'Egidio A, Schein M. Pancreatic pseudocysts: a proposed classification and its management implications. *British Journal of Surgery*. 1991; 78(8):981-4
261. D'Egidio A, Schein M. Percutaneous drainage of pancreatic pseudocysts: A prospective study. *World Journal of Surgery*. 1992; 16(1):141-5; discussion 145-6
262. D'Haese JG, Ceyhan GO, Demir IE, Layer P, Uhl W, Lohr M et al. Pancreatic enzyme replacement therapy in patients with exocrine pancreatic insufficiency due to chronic pancreatitis: A 1-year disease management study on symptom control and quality of life. *Pancreas*. 2014; 43(6):834-841
263. da Cunha JE, Machado M, Bacchella T, Penteado S, Mott CB, Jukemura J et al. Surgical treatment of pancreatic ascites and pancreatic pleural effusions. *Hepato-Gastroenterology*. 1995; 42(5):748-51
264. da Silveira EB, Barkin JS. Antibiotic prophylaxis in acute necrotizing pancreatitis. *American Journal of Gastroenterology*. 2002; 97(6):1557-9
265. Dambrauskas Z, Gulbinas A, Pundzius J, Barauskas G. Meta-analysis of prophylactic parenteral antibiotic use in acute necrotizing pancreatitis. *Medicina (Kaunas, Lithuania)*. 2007; 43(4):291-300
266. Dancygier H. Endoscopic ultrasonography of the upper gastrointestinal tract. *Bailliere's Clinical Gastroenterology*. 1991; 5(1):19-36
267. Davies AR, Morrison SS, Ridley EJ, Bailey M, Banks MD, Cooper DJ et al. Nutritional therapy in patients with acute pancreatitis requiring critical care unit management: A prospective observational study in Australia and New Zealand. *Critical Care Medicine*. 2011; 39(3):462-8
268. Davies MM, Oshodi TO, Havard TJ, Lewis MH. Long-term results of longitudinal pancreaticojejunostomy for chronic pancreatic pain. *HPB Surgery*. 1996; 10(2):83-6
269. Davila-Cervantes A, Gomez F, Chan C, Bezaury P, Robles-Diaz G, Uscanga LF et al. Laparoscopic drainage of pancreatic pseudocysts. *Surgical Endoscopy and Other Interventional Techniques*. 2004; 18(10):1420-1426
270. de-Madaria E, Banks PA, Moya-Hoyo N, Wu BU, Rey-Riveiro M, Acevedo-Piedra NG et al. Early factors associated with fluid sequestration and outcomes of patients with acute pancreatitis. *Clinical Gastroenterology and Hepatology*. 2014; 12(6):997-1002
271. de-Madaria E, Herrera-Marante I, González-Camacho V, Bonjoch L, Quesada-Vázquez N, Almenta-Saavedra I et al. Fluid resuscitation with lactated Ringer's solution vs normal saline in acute pancreatitis: A triple-blind, randomized, controlled trial. *United European Gastroenterology Journal*. 2017;

272. de-Madaria E, Soler-Sala G, Sanchez-Paya J, Lopez-Font I, Martinez J, Gomez-Escolar L et al. Influence of fluid therapy on the prognosis of acute pancreatitis: A prospective cohort study. *American Journal of Gastroenterology*. 2011; 106(10):1843-1850
273. De Backer AI, Mortele KJ, Ros PR, Vanbeckevoort D, Vanschoubroek I, De Keulenaer B. Chronic pancreatitis: Diagnostic role of computed tomography and magnetic resonance imaging. *Journal Belge de Radiologie*. 2002; 85(6):304-310
274. De Campos T, Assef JC, Rasslan S. Questions about the use of antibiotics in acute pancreatitis. *World Journal of Emergency Surgery*. 2006; 1:20
275. De las Heras Castano G, Garcia de la Paz A, Fernandez MD, Fernandez Forcelledo JL. Use of antioxidants to treat pain in chronic pancreatitis. *Revista Española de Enfermedades Digestivas*. 2000; 92(6):375-85
276. De Waele JJ, Rello J, Anzueto A, Moreno R, Lipman J, Sakr Y et al. Infections and use of antibiotics in patients admitted for severe acute pancreatitis: Data from the epic II study. *Surgical Infections*. 2014; 15(4):394-398
277. De Waele JJ, Vogelaers D, Blot S, Colardyn F. Fungal infections in patients with severe acute pancreatitis and the use of prophylactic therapy. *Clinical Infectious Diseases*. 2003; 37(2):208-13
278. Delcenserie R, Yzet T, Ducroix JP. Prophylactic antibiotics in treatment of severe acute alcoholic pancreatitis. *Pancreas*. 1996; 13(2):198-201
279. Delhaye M, Arvanitakis M, Verset G, Cremer M, Deviere J. Long-term clinical outcome after endoscopic pancreatic ductal drainage for patients with painful chronic pancreatitis. *Clinical Gastroenterology and Hepatology*. 2004; 2(12):1096-106
280. Dellinger EP, Tellado JM, Soto NE, Ashley SW, Barie PS, Dugernier T et al. Early antibiotic treatment for severe acute necrotizing pancreatitis: a randomized, double-blind, placebo-controlled study. *Annals of Surgery*. 2007; 245(5):674-83
281. Department of Health. NHS reference costs 2015-16. 2016. Available from: <https://www.gov.uk/government/publications/nhs-reference-costs-2015-to-2016> Last accessed: 27/09/2017.
282. Deprez PH, Delazzer S, Galanti L, Lebrun J, Geubel A, Horsmans Y. Clinical and nutritional effects of anti-oxidant supplementation: A prospective randomized study in patients with chronic pancreatitis. *Gastroenterology*. 2003; 124(4):A90
283. Derikx MHM, Drenth JPH. Genetic factors in chronic pancreatitis; Implications for diagnosis, management and prognosis. *Best Practice & Research: Clinical Gastroenterology*. 2010; 24(3):251-270
284. Detlefsen S, Mortensen MB, Pless TK, Criebe AS, De Muckadell OBS. Laparoscopic and percutaneous core needle biopsy plays a central role for the diagnosis of autoimmune pancreatitis in a single-center study from Denmark. *Pancreas*. 2015; 44(6):845-858
285. Deviere J, Baize M, Vandermeeren A, Buset M, Delhaye M, Cremer M. Endoscopic stenting for biliary strictures. *Acta Gastroenterologica Belgica*. 1992; 55(3):295-305
286. Deviere J, Cremer M, Baize M, Love J, Sugai B, Vandermeeren A. Management of common bile duct stricture caused by chronic pancreatitis with metal mesh self expandable stents. *Gut*. 1994; 35(1):122-126

287. Deviere J, Devaere S, Baize M, Cremer M. Endoscopic biliary drainage in chronic pancreatitis. *Gastrointestinal Endoscopy*. 1990; 36(2):96
288. Deviere J, Reddy DN, Puspok A, Ponchon T, Bruno MJ, Bourke MJ et al. Successful management of benign biliary strictures with fully covered self-expanding metal stents. *Gastroenterology*. 2014; 147(2):385-395
289. Dhar P, Tomey S, Jain P, Azfar M, Sachdev A, Chaudhary A. Internal pancreatic fistulae with serous effusions in chronic pancreatitis. *Australian and New Zealand Journal of Surgery*. 1996; 66(9):608-11
290. Dhingra R, Singh N, Sachdev V, Upadhyay AD, Saraya A. Effect of antioxidant supplementation on surrogate markers of fibrosis in chronic pancreatitis: A randomized, placebo-controlled trial. *Pancreas*. 2013; 42(4):589-95
291. Dhingra R, Srivastava S, Behra S, Vadiraj PK, Venuthurimilli A, Shalimar et al. Single or multiport percutaneous endoscopic necrosectomy performed with the patient under conscious sedation is a safe and effective treatment for infected pancreatic necrosis (with video). *Gastrointestinal Endoscopy*. 2015; 81(2):351-359
292. Dhir V, Teoh AYB, Bapat M, Bhandari S, Joshi N, Maydeo A. EUS-guided pseudocyst drainage: Prospective evaluation of early removal of fully covered self-expandable metal stents with pancreatic ductal stenting in selected patients. *Gastrointestinal Endoscopy*. 2015; 82(4):650-657
293. Di Leo M, Bianco M, Zuppardo RA, Guslandi M, Calabrese F, Mannucci A et al. Meta-analysis of the impact of SPINK1 p.N34S gene variation in Caucasian patients with chronic pancreatitis. An update. *Digestive and Liver Disease*. 2017; 49(8):847-853
294. Diakowska D, Knast W, Diakowski W, Grabowski K, Strutynska-Karpinska M, Markocka-Maczka K et al. Fecal elastase 1 determination for the diagnosis of chronic pancreatitis (results before and after surgical treatment). *Gastroenterologia Polska*. 2005; 12(5):403-407
295. Dietrich CF, Hirche TO, Ott M, Ignee A. Real-time tissue elastography in the diagnosis of autoimmune pancreatitis. *Endoscopy*. 2009; 41(8):718-720
296. DiMagno MJ. Clinical update on fluid therapy and nutritional support in acute pancreatitis. *Pancreatology*. 2015; 15(6):583-8
297. DiMagno MJ, Wamsteker EJ, Maratt J, Rivera MA, Spaete JP, Ballard DD et al. Do larger periprocedural fluid volumes reduce the severity of post-endoscopic retrograde cholangiopancreatography pancreatitis? *Pancreas*. 2014; 43(4):642-7
298. Ding G, Qin M, Cai W, Zou F, Zhao H. The safety and utility of pancreatic duct stents in the emergency ERCP of acute biliary pancreatitis but difficult sphincterotomy. *Hepato-Gastroenterology*. 2012; 59(120):2374-6
299. Dite P, Ruzicka M, Zboril V, Novotny I. A prospective, randomized trial comparing endoscopic and surgical therapy for chronic pancreatitis. *Endoscopy*. 2003; 35(7):553-8
300. Doctor N, Philip S, Gandhi V, Hussain M, Barreto SG. Analysis of the delayed approach to the management of infected pancreatic necrosis. *World Journal of Gastroenterology*. 2011; 17(3):366-71
301. Doglietto GB, Gui D, Pacelli F, Brisinda G, Bellantone R, Crucitti P et al. Open vs closed treatment of secondary pancreatic infections: A review of 42 cases. *Archives of Surgery*. 1994; 129(7):689-693

302. Doley RP, Yadav TD, Wig JD, Kochhar R, Singh G, Bharathy KG et al. Enteral nutrition in severe acute pancreatitis. *Journal of the Pancreas*. 2009; 10(2):157-62
303. Dominguez-Munoz JE, Alvarez-Castro A, Larino-Noia J, Nieto L, Iglesias-Garcia J. Endoscopic ultrasonography of the pancreas as an indirect method to predict pancreatic exocrine insufficiency in patients with chronic pancreatitis. *Pancreas*. 2012; 41(5):724-728
304. Dominguez-Munoz JE, Hieronymus C, Sauerbruch T, Malfertheiner P. Fecal elastase test: Evaluation of a new noninvasive pancreatic function test. *American Journal of Gastroenterology*. 1995; 90(10):1834-1837
305. Dominguez-Munoz JE, Malfertheiner P. Optimized serum pancreolauryl test for differentiating patients with and without chronic pancreatitis. *Clinical Chemistry*. 1998; 44(4):869-875
306. Dominguez-Munoz JE, Pieramico O, Buchler M, Malfertheiner P. Clinical utility of the serum pancreolauryl test in diagnosis and staging of chronic pancreatitis. *American Journal of Gastroenterology*. 1993; 88(8):1237-1241
307. Dominioni L, Chiappa A, Bianchi V, Interdonato PF, Festi L, Carcano G et al. Infected pancreatic necrosis complicated by multiple organ failure. *Hepato-Gastroenterology*. 1997; 44(16):968-74
308. Dong X, Gao SL, Xie QP, Xu L, Xu YL, Wu YL. In situ high-volume modified continuous closed and/or open lavage for infected necrotizing pancreatitis. *Pancreas*. 2008; 36(1):44-9
309. Draganov P, George S, Toskes PP, Forsmark CE. Is a 15-minute collection of duodenal secretions after secretin stimulation sufficient to diagnose chronic pancreatitis? *Pancreas*. 2004; 28(1):89-92
310. Draganov P, Hoffman B, Marsh W, Cotton P, Cunningham J. Long-term outcome in patients with benign biliary strictures treated endoscopically with multiple stents. *Gastrointestinal Endoscopy*. 2002; 55(6):680-686
311. Draganov P, Patel A, Fazel A, Toskes P, Forsmark C. Prospective evaluation of the accuracy of the intraductal secretin stimulation test in the diagnosis of chronic pancreatitis. *Clinical Gastroenterology and Hepatology*. 2005; 3(7):695-699
312. Dranka-Bojarowska D, Lekstan A, Olakowski M, Jablonska B, Lewinski A, Musialski P et al. The assessment of serum concentration of adiponectin, leptin and serum carbohydrate antigen-19.9 in patients with pancreatic cancer and chronic pancreatitis. *Journal of Physiology and Pharmacology*. 2015; 66(5):653-63
313. Du XJ, Hu WM, Xia Q, Huang ZW, Chen GY, Jin XD et al. Hydroxyethyl starch resuscitation reduces the risk of intra-abdominal hypertension in severe acute pancreatitis. *Pancreas*. 2011; 40(8):1220-5
314. Dubravcsik Z, Hritz I, Fejes R, Balogh G, Viranyi Z, Hausinger P et al. Early ERCP and biliary sphincterotomy with or without small-caliber pancreatic stent insertion in patients with acute biliary pancreatitis: better overall outcome with adequate pancreatic drainage. *Scandinavian Journal of Gastroenterology*. 2012; 47(6):729-36
315. Duffas JP, Suc B, Msika S, Fourtanier G, Muscari F, Hay JM et al. A controlled randomized multicenter trial of pancreatogastrostomy or pancreatojejunostomy after pancreatoduodenectomy. *American Journal of Surgery*. 2005; 189(6):720-729

316. Duggan S, Smyth N, Sulliva MO, Feehan S, Ridgway PF, Conlon KC. How do you feed? results from a transatlantic survey of nutrition practice in acute pancreatitis. *Pancreatology*. 2011; 11(3):319
317. Duggan SN, Ni Chonchubhair HM, Lawal O, O'Connor DB, Conlon KC. Chronic pancreatitis: A diagnostic dilemma. *World Journal of Gastroenterology*. 2016; 22(7):2304-2313
318. Dumonceau JM. Biliary endoscopic retrograde cholangiopancreatography. *Endoscopy*. 2010; 42(1):58-61
319. Dumonceau JM, Costamagna G, Tringali A, Vahedi K, Delhaye M, Hittelet A et al. Treatment for painful calcified chronic pancreatitis: Extracorporeal shock wave lithotripsy versus endoscopic treatment: A randomised controlled trial. *Gut*. 2007; 56(4):545-52
320. Dumonceau JM, Deviere J. The ultraflex diamond stent for malignant biliary obstruction. *Gastrointestinal Endoscopy Clinics of North America*. 1999; 9(3):513-520
321. Dumonceau JM, Nicaise N, Deviere J. The ultraflex diamond stent for benign biliary obstruction. *Gastrointestinal Endoscopy Clinics of North America*. 1999; 9(3):541-545
322. Dumonceau JM, Tringali A, Blero D, Deviere J, Laugiers R, Heresbach D et al. Biliary stenting: Indications, choice of stents and results: European Society of Gastrointestinal Endoscopy (ESGE) clinical guideline. *Endoscopy*. 2011; 44(3):277-298
323. Durgaprasad S, Pai CG, Vasanthkumar, Alvres JF, Namitha S. A pilot study of the antioxidant effect of curcumin in tropical pancreatitis. *Indian Journal of Medical Research*. 2005; 122(4):315-8
324. Duvnjak M, Dodig M, Smircic-Duvnjak L, Simicevic VN. Enzyme substitution therapy of exocrine pancreatic insufficiency in chronic pancreatitis - A comparison of three different regimens. *Pharmaca*. 1998; 36(1-2):49-58
325. Easler J, Muddana V, Furlan A, Dasyam A, Vippera K, Slivka A et al. Portosplenoenteric venous thrombosis in patients with acute pancreatitis is associated with pancreatic necrosis and usually has a benign course. *Clinical Gastroenterology and Hepatology*. 2014; 12(5):854-862
326. Easler JJ, de-Madaria E, Nawaz H, Moya-Hoyo N, Koutroumpakis E, Rey-Riveiro M et al. Patients with sentinel acute pancreatitis of alcoholic etiology are at risk for organ failure and pancreatic necrosis: A dual-center experience. *Pancreas*. 2016; 45(7):997-1002
327. Easler JJ, Zureikat A, Papachristou GI. An update on minimally invasive therapies for pancreatic necrosis. *Expert Review of Gastroenterology and Hepatology*. 2012; 6(6):745-753
328. Eatock FC, Brombacher GD, Steven A, Imrie CW, McKay CJ, Carter R. Nasogastric feeding in severe acute pancreatitis may be practical and safe. *International Journal of Pancreatology*. 2000; 28(1):23-9
329. Eatock FC, Chong P, Menezes N, Murray L, McKay CJ, Carter CR et al. A randomized study of early nasogastric versus nasojejunal feeding in severe acute pancreatitis. *American Journal of Gastroenterology*. 2005; 100(2):432-9
330. Echenique AM, Sleeman D, Yrizarry J, Scagnelli T, Guerra JJ, Jr., Casillas VJ et al. Percutaneous catheter-directed debridement of infected pancreatic necrosis: Results in 20 patients. *Journal of Vascular and Interventional Radiology*. 1998; 9(4):565-71

331. Eckerwall G, Olin H, Andersson B, Andersson R. Fluid resuscitation and nutritional support during severe acute pancreatitis in the past: What have we learned and how can we do better? *Clinical Nutrition*. 2006; 25(3):497-504
332. Eckerwall GE, Axelsson JB, Andersson RG. Early nasogastric feeding in predicted severe acute pancreatitis: A clinical, randomized study. *Annals of Surgery*. 2006; 244(6):959-65; discussion 965-7
333. Eckerwall GE, Tingstedt BB, Bergenzaun PE, Andersson RG. Immediate oral feeding in patients with mild acute pancreatitis is safe and may accelerate recovery--a randomized clinical study. *Clinical Nutrition*. 2007; 26(6):758-63
334. Eggimann P, Jamdar S, Siriwardena AK. Pro/con debate: Antifungal prophylaxis is important to prevent fungal infection in patients with acute necrotizing pancreatitis receiving broad-spectrum antibiotics. *Critical Care (London, England)*. 2006; 10(5):229
335. Eggink WF, Eeftinck Schattenkerk M, Obertop H, Van der Ven WJ, Bruining HA. The role of early surgery in the treatment of acute hemorrhagic necrotizing pancreatitis (AHNP). *Netherlands Journal of Surgery*. 1984; 36(1):6-9
336. Eickhoff A, Jakobs R, Leonhardt A, Eickhoff JC, Riemann JF. Endoscopic stenting for common bile duct stenoses in chronic pancreatitis: Results and impact on long-term outcome. *European Journal of Gastroenterology and Hepatology*. 2001; 13(10):1161-1167
337. Eickhoff A, Jakobs R, Leonhardt A, Eickhoff JC, Riemann JF. Self-expandable metal mesh stents for common bile duct stenosis in chronic pancreatitis: Retrospective evaluation of long-term follow-up and clinical outcome of a pilot study. *Zeitschrift für Gastroenterologie*. 2003; 41(7):649-654
338. Eisenach JC, Carpenter R, Curry R. Analgesia from a peripherally active kappa-opioid receptor agonist in patients with chronic pancreatitis. *Pain*. 2003; 101(1-2):89-95
339. Ekblom A, McLaughlin JK, Karlsson BM, Nyren O, Gridley G, Adami HO et al. Pancreatitis and pancreatic cancer: A population-based study. *Journal of the National Cancer Institute*. 1994; 86(8):625-627
340. Ellis I. Genetic counseling for hereditary pancreatitis - The role of molecular genetics testing for the cationic trypsinogen gene, cystic fibrosis and serine protease inhibitor Kazal type 1. *Gastroenterology Clinics of North America*. 2004; 33(4):839-854
341. Ellis I, Lerch MM, Whitcomb DC. Genetic testing for hereditary pancreatitis: guidelines for indications, counselling, consent and privacy issues. *Pancreatology*. 2001; 1(5):405-415
342. Endlicher E, Volk M, Feuerbach S, Scholmerich J, Schaffler A, Messmann H. Long-term follow-up of patients with necrotizing pancreatitis treated by percutaneous necrosectomy. *Hepato-Gastroenterology*. 2003; 50(54):2225-2228
343. Enya M, Yasuda I, Mukai T, Shinoda T, Otsuji K, Iwasa J et al. Endoscopic treatment for benign biliary strictures: Can placement of a covered metallic stent be an option in refractory cases? *Digestive Endoscopy*. 2004; 16(1):12-20
344. Epelboym I, Winner M, DiNorcia J, Lee MK, Lee JA, Schrope B et al. Quality of life in patients after total pancreatectomy is comparable with quality of life in patients who undergo a partial pancreatic resection. *Journal of Surgical Research*. 2014; 187(1):189-96
345. Erstad BL. Enteral nutrition support in acute pancreatitis. *Annals of Pharmacotherapy*. 2000; 34(4):514-21

346. Escourrou J, Shehab H, Buscail L, Bournet B, Andrau P, Moreau J et al. Peroral transgastric/transduodenal necrosectomy: success in the treatment of infected pancreatic necrosis. *Annals of Surgery*. 2008; 248(6):1074-80
347. Estruch R, Nicolas JM, Villegas E, Junque A, Urbano-Marquez A. Relationship between ethanol-related diseases and nutritional status in chronically alcoholic men. *Alcohol and Alcoholism*. 1993; 28(5):543-50
348. Falconi M, Ysebaert D. Acute necrotising pancreatitis and fistula treatment: The role of Somatostatin-14 and its analogues. *Research and Clinical Forums*. 2002; 24(2):31-43
349. Familiari P, Boskoski I, Bove V, Costamagna G. ERCP for biliary strictures associated with chronic pancreatitis. *Gastrointestinal Endoscopy Clinics of North America*. 2013; 23(4):833-45
350. Fan ST, Lai EC, Mok FP, Lo CM, Zheng SS, Wong J. Early treatment of acute biliary pancreatitis by endoscopic papillotomy. *New England Journal of Medicine*. 1993; 328(4):228-32
351. Farkas G, Leindler L, Farkas G, Jr., Daroczi M. Organ-preserving resection of the pancreatic head in patients with chronic pancreatitis. *Magyar Sebeszet*. 2004; 57(5):279-82
352. Farkas G, Marton J, Mandi Y, Leindler L. Surgical management and complex treatment of infected pancreatic necrosis: 18-Year experience at a single center. *Journal of Gastrointestinal Surgery*. 2006; 10(2):278-285
353. Farkas G, Marton J, Mandi Y, Szederkenyi E, Balogh A. Progress in the management and treatment of infected pancreatic necrosis. *Scandinavian Journal of Gastroenterology Supplement*. 1998; 228:31-7
354. Farnbacher MJ, Rabenstein T, Ell C, Hahn EG, Schneider HT. Is endoscopic drainage of common bile duct stenoses in chronic pancreatitis up-to-date? *American Journal of Gastroenterology*. 2000; 95(6):1466-1471
355. Farnbacher MJ, Schoen C, Rabenstein T, Benninger J, Hahn EG, Schneider HT. Pancreatic duct stones in chronic pancreatitis: Criteria for treatment intensity and success. *Gastrointestinal Endoscopy*. 2002; 56(4):501-6
356. Feig BW, Pomerantz RA, Vogelzang R, Rege RV, Nahrwold DL, Joehl RJ. Treatment of peripancreatic fluid collections in patients with complicated acute pancreatitis. *Surgery, Gynecology and Obstetrics*. 1992; 175(5):429-436
357. Felix K, Schuck A, Gaida MM, Hinz U, Dovzhanskiy D, Werner J. Objective parameters aid the prediction of fistulas in pancreatic surgery. *Experimental and Therapeutic Medicine*. 2014; 8(3):719-726
358. Fernandez-del Castillo C, Rattner DW, Makary MA, Mostafavi A, McGrath D, Warshaw AL. Debridement and closed packing for the treatment of necrotizing pancreatitis. *Annals of Surgery*. 1998; 228(5):676-84
359. Fitzsimmons D, Johnson CD, George S, Payne S, Sandberg AA, Bassi C et al. Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer. EORTC Study Group on Quality of Life. *European Journal of Cancer*. 1999; 35(6):939-41
360. Fitzsimmons D, Kahl S, Butturini G, van Wyk M, Bornman P, Bassi C et al. Symptoms and quality of life in chronic pancreatitis assessed by structured interview and the EORTC QLQ-C30 and QLQ-PAN26. *American Journal of Gastroenterology*. 2005; 100(4):918-26

361. Foitzik T, Klar E, Buhr HJ, Herfarth C. Improved survival in acute necrotizing pancreatitis despite limiting the indications for surgical debridement. *European Journal of Surgery, Acta Chirurgica*. 1995; 161(3):187-192
362. Folsch UR, Nitsche R, Ludtke R, Hilgers RA, Creutzfeldt W. Early ERCP and papillotomy compared with conservative treatment for acute biliary pancreatitis. The German Study Group on Acute Biliary Pancreatitis. *New England Journal of Medicine*. 1997; 336(4):237-42
363. Forsmark CE. Antibiotic prophylaxis for severe acute pancreatitis. *Current Gastroenterology Reports*. 2005; 7(2):87-89
364. Fotoohi M, D'Agostino HB, Wollman B, Chon K, Shahrokni S, vanSonnenberg E. Persistent pancreaticocutaneous fistula after percutaneous drainage of pancreatic fluid collections: Role of cause and severity of pancreatitis. *Radiology*. 1999; 213(2):573-8
365. Fotoohi M, Traverso LW. Management of severe pancreatic necrosis. *Current Treatment Options in Gastroenterology*. 2007; 10(5):341-346
366. Freeny PC, Hauptmann E, Althaus SJ, Traverso LW, Sinanan M. Percutaneous CT-guided catheter drainage of infected acute necrotizing pancreatitis: techniques and results. *American Journal of Roentgenology*. 1998; 170(4):969-75
367. French JJ, Charnley RM. Expandable metal stents in chronic pancreatitis. *HPB*. 2003; 5(1):58-61
368. Frey CF, Suzuki M, Isaji S. Treatment of chronic pancreatitis complicated by obstruction of the common bile duct or duodenum. *World Journal of Surgery*. 1990; 14(1):59-69
369. Friess H, Buchler MW. Efficacy of somatostatin and its analogues in pancreatic surgery and pancreatic disorders. *Digestion*. 1996; 57(Suppl 1):97-102
370. Friess H, Hofbauer B, Buchler MW. The role of somatostatin and octreotide in pancreatic surgery and in acute and chronic pancreatitis. *Digestive Surgery*. 1994; 11(3-6):445-50
371. Fritscher-Ravens A, Brand L, Knofel WT, Bobrowski C, Topalidis T, Thonke F et al. Comparison of endoscopic ultrasound-guided fine needle aspiration for focal pancreatic lesions in patients with normal parenchyma and chronic pancreatitis. *American Journal of Gastroenterology*. 2002; 97(11):2768-2775
372. Fugger R, Gotzinger P, Sautner T, Mittlbock M, Rogy M, Adamer K et al. Necrosectomy and laparostomy--a combined therapeutic concept in acute necrotising pancreatitis. *European Journal of Surgery*. 1995; 161(2):103-7
373. Fujino Y, Matsumoto I, Shinzeki M, Ajiki T, Kuroda Y. Impact of internal biliary drainage after pancreaticoduodenectomy. *Journal of Hepato-Biliary-Pancreatic Surgery*. 2009; 16(2):160-164
374. Fujisawa T, Kagawa K, Hisatomi K, Kubota K, Nakajima A, Matsuhashi N. Endoscopic papillary large-balloon dilation versus endoscopic papillary regular-balloon dilation for removal of large bile-duct stones. *Journal of Hepato-Biliary-Pancreatic Sciences*. 2014; 21(6):405-409
375. Fuller RK, Loveland JP, Frankel MH. An evaluation of the efficacy of nasogastric suction treatment in alcoholic pancreatitis. *American Journal of Gastroenterology*. 1981; 75(5):349-53
376. Funnell IC, Bornman PC, Krige JE, Beningfield SJ, Terblanche J. Endoscopic drainage of traumatic pancreatic pseudocyst. *British Journal of Surgery*. 1994; 81(6):879-81

377. Furuya N, Kawa S, Akamatsu T, Furihata K. Long-term follow-up of patients with chronic pancreatitis and K-ras gene mutation detected in pancreatic juice. *Gastroenterology*. 1997; 113(2):593-8
378. Furuya N, Kawa S, Hasebe O, Tokoo M, Mukawa K, Maejima S et al. Comparative study of CA242 and CA19-9 in chronic pancreatitis. *British Journal of Cancer*. 1996; 73(3):372-376
379. Futagawa Y, Imazu H, Mori N, Kanazawa K, Chiba M, Furukawa K et al. The effectiveness and feasibility of endoscopic ultrasound-guided transgastric drainage of postoperative fluid collections early after pancreatic surgery. *Surgical Laparoscopy, Endoscopy and Percutaneous Techniques*. 2017; 27(4):267-272
380. Gabbriellini A, Pandolfi M, Mutignani M, Spada C, Perri V, Petruzzello L et al. Efficacy of main pancreatic-duct endoscopic drainage in patients with chronic pancreatitis, continuous pain, and dilated duct. *Gastrointestinal Endoscopy*. 2005; 61(4):576-81
381. Gaitch N, Hubert D, Gameiro C, Burgel PR, Houriez F, Martinez B et al. CFTR and/or pancreatitis susceptibility genes mutations as risk factors of pancreatitis in cystic fibrosis patients? *Pancreatology*. 2016; 16(4):515-22
382. Galeiras R, Yanez L, Mourelo M. Severe acute pancreatitis and antibiotics. *The Journal of Trauma and Acute Care Surgery*. 2016; 81(2):401
383. Gambiez LP, Denimal FA, Porte HL, Saudemont A, Chambon JPM, Quandalle PA. Retroperitoneal approach and endoscopic management of peripancreatic necrosis collections. *Archives of Surgery*. 1998; 133(1):66-72
384. Garcia-Barrasa A, Borobia FG, Pallares R, Jorba R, Poves I, Busquets J et al. A double-blind, placebo-controlled trial of ciprofloxacin prophylaxis in patients with acute necrotizing pancreatitis. *Journal of Gastrointestinal Surgery*. 2009; 13(4):768-74
385. Garcia-Cano J, Taberna-Arana L, Jimeno-Ayllon C, Martinez-Fernandez R, Serrano-Sanchez L, Reyes-Guevara AK et al. Use of fully covered self-expanding metal stents for the management of benign biliary conditions. *Revista Española de Enfermedades Digestivas*. 2010; 102(9):526-532
386. Gardner TB, Chahal P, Papachristou GI, Vege SS, Petersen BT, Gostout CJ et al. A comparison of direct endoscopic necrosectomy with transmural endoscopic drainage for the treatment of walled-off pancreatic necrosis. *Gastrointestinal Endoscopy*. 2009; 69(6):1085-1094
387. Gardner TB, Coelho-Prabhu N, Gordon SR, Gelrud A, Maple JT, Papachristou GI et al. Direct endoscopic necrosectomy for the treatment of walled-off pancreatic necrosis: Results from a multicenter U.S. series. *Gastrointestinal Endoscopy*. 2011; 73(4):718-726
388. Gardner TB, Levy MJ. EUS diagnosis of chronic pancreatitis. *Gastrointestinal Endoscopy*. 2010; 71(7):1280-1289
389. Gardner TB, Vege SS, Chari ST, Petersen BT, Topazian MD, Clain JE et al. Faster rate of initial fluid resuscitation in severe acute pancreatitis diminishes in-hospital mortality. *Pancreatology*. 2009; 9(6):770-6
390. Gardner TB, Vege SS, Pearson RK, Chari ST. Fluid resuscitation in acute pancreatitis. *Clinical Gastroenterology and Hepatology*. 2008; 6(10):1070-6
391. Garg PK, Sharma M, Madan K, Sahni P, Banerjee D, Goyal R. Primary conservative treatment results in mortality comparable to surgery in patients with infected pancreatic necrosis. *Clinical Gastroenterology and Hepatology*. 2010; 8(12):1089-1094.e2

392. Garzya G. Pharmacologic action of 2 enzyme preparations in chronic pancreatitis: Double-blind comparison. *Clinica Europea*. 1985; 24(4):637-41
393. Gasiorowska A, Talar-Wojnarowska R, Czupryniak L, Smolarz B, Romanowicz-Makowska H, Kulig A et al. The prevalence of cationic trypsinogen (PRSS1) and serine protease inhibitor, kazal type 1 (SPINK1) gene mutations in polish patients with alcoholic and idiopathic chronic pancreatitis. *Digestive Diseases and Sciences*. 2011; 56(3):894-901
394. Gentile AT, Feliciano PD, Mullins RJ, Crass RA, Eidemiller LR, Sheppard BC. The utility of polyglycolic acid mesh for abdominal access in patients with necrotizing pancreatitis. *Journal of the American College of Surgeons*. 1998; 186(3):313-318
395. Giacino C, Grandval P, Laugier R. Fully covered self-expanding metal stents for refractory pancreatic duct strictures in chronic pancreatitis. *Endoscopy*. 2012; 44(9):874-877
396. Gianotti L, Meier R, Lobo DN, Bassi C, Dejong CH, Ockenga J et al. ESPEN Guidelines on Parenteral Nutrition: Pancreas. *Clinical Nutrition*. 2009; 28(4):428-35
397. Gibbons JC, Williams SJ. Progress in the endoscopic management of benign biliary strictures. *Journal of Gastroenterology and Hepatology*. 1998; 13(2):116-124
398. Giefer MJ, Lowe ME, Werlin SL, Zimmerman B, Wilschanski M, Troendle D et al. Early-Onset Acute Recurrent and Chronic Pancreatitis Is Associated with PRSS1 or CTSC Gene Mutations. *Journal of Pediatrics*. 2017; 186:95-100
399. Giovannini M. Endoscopic ultrasonography-guided pancreatic drainage. *Gastrointestinal Endoscopy Clinics of North America*. 2012; 22(2):221-30, viii
400. Giovannini M, Caillol F, Monges G, Poizat F, Lemaistre AI, Pujol B et al. Endoscopic ultrasound-guided needle-based confocal laser endomicroscopy in solid pancreatic masses. *Endoscopy*. 2016; 48(10):892-898
401. Girish BN, Rajesh G, Vaidyanathan K, Balakrishnan V. Fecal elastase1 and acid steatocrit estimation in chronic pancreatitis. *Indian Journal of Gastroenterology*. 2009; 28(6):201-5
402. Gjorup I, Roikjaer O, Andersen B, Burcharth F, Hovendal C, Pedersen SA et al. A double-blinded multicenter trial of somatostatin in the treatment of acute pancreatitis. *Surgery, Gynecology and Obstetrics*. 1992; 175(5):397-400
403. Glasbrenner B, Schon A, Klatt S, Beckh K, Adler G. Clinical evaluation of the faecal elastase test in the diagnosis and staging of chronic pancreatitis. *European Journal of Gastroenterology and Hepatology*. 1996; 8(11):1117-1120
404. Glaser J, Mann O, Pausch J. Diagnosis of chronic pancreatitis by means of a sonographic secretin test. *International journal of pancreatology : official journal of the International Association of Pancreatology*. 1994; 15(3):195-200
405. Gleeson FC, Topazian M. Endoscopic retrograde cholangiopancreatography and endoscopic ultrasound for diagnosis of chronic pancreatitis. *Current Gastroenterology Reports*. 2007; 9(2):123-129
406. Gluck M, Ross A, Irani S, Lin O, Gan SI, Fotoohi M et al. Dual modality drainage for symptomatic walled-off pancreatic necrosis reduces length of hospitalization, radiological procedures, and number of endoscopies compared to standard percutaneous drainage. *Journal of Gastrointestinal Surgery*. 2012; 16(2):248-257

407. Goenka MK, Bhasin DK, Kochhar R, Nagi B, Rungta U, Das K et al. Endoscopic nasobiliary drainage in the management of acute cholangitis: An experience in 143 patients. *Diagnostic and Therapeutic Endoscopy*. 1997; 3(3):161-170
408. Gomatos IP, Halloran CM, Ghaneh P, Raraty MGT, Polydoros F, Evans JC et al. Outcomes from minimal access retroperitoneal and open pancreatic necrosectomy in 394 patients with necrotizing pancreatitis. *Annals of Surgery*. 2016; 263(5):992-1001
409. Gonzalez-Sanchez V, Amrani R, Gonzalez V, Trigo C, Pico A, de-Madaria E. Diagnosis of exocrine pancreatic insufficiency in chronic pancreatitis: 13C-mixed triglyceride breath test versus fecal elastase. *Pancreatology*. 2017; 17(4):580-585
410. Gooshe M, Abdolghaffari AH, Nikfar S, Mahdavian P, Abdollahi M. Antioxidant therapy in acute, chronic and post-endoscopic retrograde cholangiopancreatography pancreatitis: An updated systematic review and meta-analysis. *World Journal of Gastroenterology*. 2015; 21(30):9189-208
411. Gotzinger P, Wamser P, Exner R, Schwanzer E, Jakesz R, Fugger R et al. Surgical treatment of severe acute pancreatitis: Timing of operation is crucial for survival. *Surgical Infections*. 2003; 4(2):205-11
412. Gou S, Xiong J, Wu H, Zhou F, Tao J, Liu T et al. Five-year cohort study of open pancreatic necrosectomy for necrotizing pancreatitis suggests it is a safe and effective operation. *Journal of Gastrointestinal Surgery*. 2013; 17(9):1634-1642
413. Gouma DJ. Stent versus surgery. *HPB*. 2007; 9(6):408-413
414. Gredal C, Madsen LG, Larsen S. The Lundh test and faecal elastase 1 determination in chronic pancreatitis: A comparative study. *Pancreatology*. 2003; 3(5):389-394
415. Gress F, Schmitt C, Sherman S, Ciaccia D, Ikenberry S, Lehman G. Endoscopic ultrasound-guided celiac plexus block for managing abdominal pain associated with chronic pancreatitis: a prospective single center experience. *American Journal of Gastroenterology*. 2001; 96(2):409-16
416. Guda NM, Partington S, Freeman ML. Extracorporeal shock wave lithotripsy in the management of chronic calcific pancreatitis: A meta-analysis. *Journal of the Pancreas*. 2005; 6(1):6-12
417. Gullo L, Pezzilli R, Ventrucchi M. Diagnostic value of the amino acid consumption test in pancreatic diseases. *Pancreas*. 1996; 12(1):64-67
418. Gullo L, Pezzilli R, Ventrucchi M, Barbara L. Caerulein induced plasma amino acid decrease: A simple, sensitive, and specific test of pancreatic function. *Gut*. 1990; 31(8):926-929
419. Gullo L, Ventrucchi M, Tomassetti P, Migliori M, Pezzilli R. Fecal elastase 1 determination in chronic pancreatitis. *Digestive Diseases and Sciences*. 1999; 44(1):210-213
420. Gumaste V, Singh V, Dave P. Significance of pleural effusion in patients with acute pancreatitis. *American Journal of Gastroenterology*. 1992; 87(7):871-4
421. Guo JH, Hu RX, Luo SC. Pancreaticobiliary duct drainage for the treatment of acute necrotizing pancreatitis. *Chinese Journal of General surgery*. 2001; 16(11):653-4
422. Guo Q, Li A, Xia Q, Lu H, Ke N, Du X et al. Timing of intervention in necrotizing pancreatitis. *Journal of Gastrointestinal Surgery*. 2014; 18(10):1770-1776

423. Guo Q, Lu H, Hu W, Zhang Z. A retroperitoneal approach for infected pancreatic necrosis. *Scandinavian Journal of Gastroenterology*. 2013; 48(2):225-30
424. Gupta K, Mallery S, Hunter D, Freeman ML. Endoscopic ultrasound and percutaneous access for endoscopic biliary and pancreatic drainage after initially failed ERCP. *Reviews in Gastroenterological Disorders*. 2007; 7(1):22-37
425. Gupta R, Patel K, Calder PC, Yaqoob P, Primrose JN, Johnson CD. A randomised clinical trial to assess the effect of total enteral and total parenteral nutritional support on metabolic, inflammatory and oxidative markers in patients with predicted severe acute pancreatitis (APACHE II > or =6). *Pancreatology*. 2003; 3(5):406-13
426. Gupta R, Rao GV, Reddy DN. Benign biliary stricture - Should they be dilated or treated surgically? *Indian Journal of Gastroenterology*. 2006; 25(4):202-205
427. Gupta R, Reddy DN. Stent selection for both biliary and pancreatic strictures caused by chronic pancreatitis: Multiple plastic stents or metallic stents? *Journal of Hepato-Biliary-Pancreatic Sciences*. 2011; 18(5):636-639
428. Gurusamy KS, Belgaumkar AP, Haswell A, Pereira SP, Davidson BR. Interventions for necrotising pancreatitis. *Cochrane Database of Systematic Reviews* 2016, Issue 4. Art. No.: CD011383. DOI: 10.1002/14651858.CD011383.pub2.
429. Gurusamy KS, Pallari E, Hawkins N, Pereira SP, Davidson BR. Management strategies for pancreatic pseudocysts. *Cochrane Database of Systematic Reviews* 2016, Issue 4. Art. No.: CD011392. DOI: 10.1002/14651858.CD011392.pub2.
430. Haapamäki C, Kylänpää L, Udd M, Lindström O, Grönroos J, Saarela A et al. Randomized multicenter study of multiple plastic stents vs. covered self-expandable metallic stent in the treatment of biliary stricture in chronic pancreatitis. *Endoscopy*. 2017; 47(7):605-610
431. Haber P, Nakamura M, Tsuchimoto K, Keogh GW, Apte MV, Moran CS et al. Alcohol and the pancreas. *Alcoholism: Clinical and Experimental Research*. 2001; 25(5 Suppl.):244S-250S
432. Haghshenasskashani A, Laurence JM, Kwan V, Johnston E, Hollands MJ, Richardson AJ et al. Endoscopic necrosectomy of pancreatic necrosis: A systematic review. *Surgical Endoscopy and Other Interventional Techniques*. 2011; 25(12):3724-3730
433. Halder SK, Bhattacharjee PK, Bhar P, Das C, Pandey P, Rakshit KP et al. A comparative study between longitudinal pancreaticojejunostomy v/s lateral pancreaticogastrostomy as a drainage procedure for pain relief in chronic pancreatitis done in a tertiary referral centre of Eastern India. *Indian Journal of Surgery*. 2015; 77(2):120-4
434. Halgreen H, Pedersen NT, Worning H. Symptomatic effect of pancreatic enzyme therapy in patients with chronic pancreatitis. *Scandinavian Journal of Gastroenterology*. 1986; 21(1):104-8
435. Halttunen J, Kylanpaa L. Treatment of pancreatic fistulas. *European Journal of Trauma and Emergency Surgery*. 2007; 33(3):227-30
436. Halttunen J, Weckman L, Kempainen E, Kylanpaa ML. The endoscopic management of pancreatic fistulas. *Surgical Endoscopy*. 2005; 19(4):559-62
437. Hammel P, Couvelard A, O'Toole D, Ratouis A, Sauvanet A, Flejou JF et al. Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. *New England Journal of Medicine*. 2001; 344(6):418-423

438. Hanck C, Whitcomb DC. Alcoholic pancreatitis. *Gastroenterology Clinics of North America*. 2004; 33(4):751-65
439. Hara T, Kanasaki H, Oride A, Ishihara T, Kyo S. A case of idiopathic acute pancreatitis in the first trimester of pregnancy. *Case Reports in Obstetrics and Gynecology*. 2015; 2015:469527
440. Hardt PD, Marzeion AM, Schnell-Kretschmer H, Wusten O, Nalop J, Zekorn T et al. Fecal elastase 1 measurement compared with endoscopic retrograde cholangiopancreatography for the diagnosis of chronic pancreatitis. *Pancreas*. 2002; 25(1):e6-9
441. Haritha J, Wilcox CM. Evaluation of patients' knowledge regarding smoking and chronic pancreatitis: A pilot study. *Journal of Gastroenterology, Pancreatology & Liver Disorders*. 2015; 1(2):1-4
442. Harris HW, Barcia A, Schell MT, Thoeni RF, Schechter WP. Necrotizing pancreatitis: A surgical approach independent of documented infection. *HPB*. 2004; 6(3):161-168
443. Hart PA, Bechtold ML, Marshall JB, Choudhary A, Puli SR, Roy PK. Prophylactic antibiotics in necrotizing pancreatitis: A meta-analysis. *Southern Medical Journal*. 2008; 101(11):1126-31
444. Hart PA, Kamisawa T, Brugge WR, Chung JB, Culver EL, Czako L et al. Long-term outcomes of autoimmune pancreatitis: A multicentre, international analysis. *Gut*. 2013; 62(12):1771-1776
445. Hassenpflug M, Hartwig W, Strobel O, Hinz U, Hackert T, Fritz S et al. Decrease in clinically relevant pancreatic fistula by coverage of the pancreatic remnant after distal pancreatectomy. *Surgery*. 2012; 152(3 Suppl 1):S164-71
446. Hausegger KA, Kugler C, Uggowitz M, Lammer J, Karaic R, Klein GE et al. Benign biliary obstruction: Is treatment with the wallstent advisable? *Radiology*. 1996; 200(2):437-441
447. Haydock MD, Mittal A, van den Heever M, Rossaak JI, Connor S, Rodgers M et al. National survey of fluid therapy in acute pancreatitis: Current practice lacks a sound evidence base. *World Journal of Surgery*. 2013; 37(10):2428-35
448. Haydock MD, Mittal A, Wilms HR, Phillips A, Petrov MS, Windsor JA. Fluid therapy in acute pancreatitis: anybody's guess *Annals of Surgery*. 2013; 257(2):182-188
449. He WH, Zhu Y, Liu P, Zeng H, Xia L, Yu C et al. The outcomes of initial endoscopic transluminal drainage are superior to percutaneous drainage for patients with infected pancreatic necrosis: A prospective cohort study. *Surgical Endoscopy and Other Interventional Techniques*. 2017; 31(7):3004-3013
450. He YM, Lv XS, Ai ZL, Liu ZS, Qian Q, Sun Q et al. Prevention and therapy of fungal infection in severe acute pancreatitis: A prospective clinical study. *World Journal of Gastroenterology*. 2003; 9(11):2619-21
451. Heider R, Meyer AA, Galanko JA, Behrns KE. Percutaneous drainage of pancreatic pseudocysts is associated with a higher failure rate than surgical treatment in unselected patients. *Annals of Surgery*. 1999; 229(6):781-789
452. Heo WG, Kim TH, Kim YJ, Chon HK, Woo YS, Sohn YW. Autoimmune pancreatitis complicated with pancreatic ascites, pancreatic ductal leakage, and multiple pseudocyst. *Pancreas*. 2017; 46(1):e10-e11
453. Hernandez LV, Catalano MF. EUS in the diagnosis of early-stage chronic pancreatitis. *Best Practice & Research: Clinical Gastroenterology*. 2010; 24(3):243-249

454. Hernandez N, Perez N, Patel S, Rosenkranz L. Antioxidant supplementation in chronic pancreatitis: Current evidence an overview. *Practical Gastroenterology*. 2011; 35(12):47-52
455. Herrerías JM, Gómez Parra M, García Montes JM, Petit MA, Valladolid León JM. A comparative cross-over study of pellet pancreatin and tablet pancreatin in chronic pancreatitis. *Revista Española de las Enfermedades del Aparato Digestivo*. 1989; 76(6 Pt 2):651-3
456. Heyries L, Jeanniard-Malet O, Lagrange X, Sahel J. Factors of pain recurrence after endoscopic stenting for painful chronic pancreatitis. *Pancreatology*. 2010; 10(2-3):294
457. Hirota M, Asakura T, Kanno A, Shimosegawa T. Endoscopic treatment for chronic pancreatitis: Indications, technique, results. *Journal of Hepato-Biliary-Pancreatic Sciences*. 2010; 17(6):770-5
458. Hiroyoshi M, Tateishi K, Yasunami Y, Maeshiro K, Ono J, Matsuoka Y et al. Elevated plasma levels of glucagon-like peptide-1 after oral glucose ingestion in patients with pancreatic diabetes. *American Journal of Gastroenterology*. 1999; 94(4):976-81
459. Ho HS, Frey CF. The role of antibiotic prophylaxis in severe acute pancreatitis. *Archives of Surgery*. 1997; 132(5):487-92; discussion 492-3
460. Hocke M, Ignee A, Dietrich CF. Advanced endosonographic diagnostic tools for discrimination of focal chronic pancreatitis and pancreatic carcinoma - Elastography, contrast enhanced high mechanical index (CEHMI) and low mechanical index (CELMI) endosonography in direct comparison. *Zeitschrift für Gastroenterologie*. 2012; 50(2):199-203
461. Hocke M, Will U, Gottschalk P, Settmacher U, Stallmach A. Transgastral retroperitoneal endoscopy in septic patients with pancreatic necrosis or infected pancreatic pseudocysts. *Zeitschrift für Gastroenterologie*. 2008; 46(12):1363-8
462. Hoki N, Mizuno N, Sawaki A, Tajika M, Takayama R, Shimizu Y et al. Diagnosis of autoimmune pancreatitis using endoscopic ultrasonography. *Journal of Gastroenterology*. 2009; 44(2):154-159
463. Hollemans RA, Bollen TL, van Brunschot S, Bakker OJ, Ahmed Ali U, van Goor H et al. Predicting success of catheter drainage in infected necrotizing pancreatitis. *Annals of Surgery*. 2016; 263(4):787-92
464. Hollerbach S, Klamann A, Topalidis T, Schmiegel WH. Endoscopic ultrasonography (EUS) and fine-needle aspiration (FNA) cytology for diagnosis of chronic pancreatitis. *Endoscopy*. 2001; 33(10):824-831
465. Holst T, Grille W, Asbeck F. Endoscopic therapy of a pancreatic effusion caused by chronic pancreatitis. *Zeitschrift für Gastroenterologie*. 1998; 36(10):893-6
466. Hoogerwerf WA. Pharmacological management of pancreatitis. *Current Opinion in Pharmacology*. 2005; 5(spec 6):578-582
467. Hookey LC, Debroux S, Delhaye M, Arvanitakis M, Le Moine O, Deviere J. Endoscopic drainage of pancreatic-fluid collections in 116 patients: A comparison of etiologies, drainage techniques, and outcomes. *Gastrointestinal Endoscopy*. 2006; 63(4):635-643
468. Horibe M, Egi M, Sasaki M, Sanui M. Continuous regional arterial infusion of protease inhibitors for treatment of severe acute pancreatitis: Systematic review and meta-analysis. *Pancreas*. 2015; 44(7):1017-23

469. Horibe M, Nishizawa T, Suzuki H, Minami K, Yahagi N, Iwasaki E et al. Timing of oral refeeding in acute pancreatitis: A systematic review and meta-analysis. *United European Gastroenterology Journal*. 2016; 4(6):725-732
470. Horvath K, Freeny P, Escallon J, Heagerty P, Comstock B, Glickerman DJ et al. Safety and efficacy of video-assisted retroperitoneal debridement for infected pancreatic collections: A multicenter, prospective, single-arm phase 2 study. *Archives of Surgery*. 2010; 145(9):817-825
471. Horvath KD, Kao LS, Ali A, Wherry KL, Pellegrini CA, Sinanan MN. Laparoscopic assisted percutaneous drainage of infected pancreatic necrosis. *Surgical Endoscopy*. 2001; 15(7):677-82
472. Houlihan MD, Bowyer BA, Barclay RL. Resolution of pancreatico-pleural fistula with endoscopic ultrasound-guided therapy. *Respiratory Medicine Case Reports*. 2013; 9:30-3
473. Howard JM. Delayed debridement and external drainage of massive pancreatic or peripancreatic necrosis. *Surgery, Gynecology and Obstetrics*. 1989; 168(1):25-9
474. Howard TJ, Swofford JB, Wagner DL, Sherman S, Lehman GA. Quality of life after bilateral thoracoscopic splanchnicectomy: Long-term evaluation in patients with chronic pancreatitis. *Journal of Gastrointestinal Surgery*. 2002; 6(6):845-52; discussion 853-4
475. Howard TJ, Temple MB. Prophylactic antibiotics alter the bacteriology of infected necrosis in severe acute pancreatitis. *Journal of the American College of Surgeons*. 2002; 195(6):759-67
476. Howell DA, Holbrook RF, Bosco JJ, Muggia RA, Biber BP. Endoscopic needle localization of pancreatic pseudocysts before transmural drainage. *Gastrointestinal Endoscopy*. 1993; 39(5):693-8
477. Hu B, Gao DJ, Wu J, Wang TT, Yang XM, Ye X. Intraductal radiofrequency ablation for refractory benign biliary stricture: Pilot feasibility study. *Digestive Endoscopy*. 2014; 26(4):581-585
478. Hu LH, Ye B, Yang YG, Ji JT, Zou WB, Du TT et al. Extracorporeal shock wave lithotripsy for chinese patients with pancreatic stones: A prospective study of 214 cases. *Pancreas*. 2016; 45(2):298-305
479. Huang YT, Liu Q, Zhang BS. Long-term results of surgical treatment for acute hemorrhagic necrotizing pancreatitis. *Chinese Medical Journal*. 1993; 106(7):500-3
480. Hubaczová M, Spicák J, Antós F, Bártová I, Cech P, Kasalický M et al. The role of antibiotic treatment in severe form of acute pancreatitis: A randomized prospective study. *Gut*. 2000; 47(Suppl 3):A142
481. Huggett MT, Oppong KW, Pereira SP, Keane MG, Mitra V, Charnley RM et al. Endoscopic drainage of walled-off pancreatic necrosis using a novel self-expanding metal stent. *Endoscopy*. 2015; 47(10):929-932
482. Hughes SJ, Papachristou GI, Federle MP, Lee KK. Necrotizing pancreatitis. *Gastroenterology Clinics of North America*. 2007; 36(2):313-323
483. Huizinga WK, Baker LW. Treatment of persistent and complicated pancreatic pseudocysts. *Journal of the Royal College of Surgeons of Edinburgh*. 1992; 37(6):373-6
484. Huizinga WKJ, Thomson SR, Spitaels JM, Simjee AE, Hoare EM. Chronic pancreatitis with biliary obstruction. *Annals of the Royal College of Surgeons of England*. 1992; 74(2):119-125

485. Hungness ES, Robb BW, Seeskin C, Hasselgren PO, Luchette FA. Early debridement for necrotizing pancreatitis: Is it worthwhile? *Journal of the American College of Surgeons*. 2002; 194(6):740-4; discussion 744-5
486. IAP/APA evidence-based guidelines for the management of acute pancreatitis. *Pancreatology*. 2013; 13(4 Suppl 2):e1-15
487. Igami T, Kamiya J, Yokoyama Y, Nishio H, Ebata T, Sugawara G et al. Treatment of pancreatic fistula after pancreatoduodenectomy using a hand-made T-tube. *Journal of Hepato-Biliary-Pancreatic Surgery*. 2009; 16(5):661-667
488. Igarashi Y, Okano N, Miura T, Iida K, Miki K. Endoscopic treatment for the benign biliary stricture in the patient with chronic pancreatitis. *Digestive Endoscopy*. 2004; 16(Suppl):S52-S53
489. Iglesias-Garcia J, Dominguez-Munoz JE, Castineira-Alvarino M, Luaces-Regueira M, Larino-Noia J. Quantitative elastography associated with endoscopic ultrasound for the diagnosis of chronic pancreatitis. *Endoscopy*. 2013; 45(10):781-8
490. Iglesias-Garcia J, Larino-Noia J, Lindkvist B, Enrique Dominguez-Munoz J. Endoscopic ultrasound in the diagnosis of chronic pancreatitis. *Revista Española de Enfermedades Digestivas*. 2015; 107(4):221-228
491. Ignatavicius P, Vitkauskiene A, Pundzius J, Dambrauskas Z, Barauskas G. Effects of prophylactic antibiotics in acute pancreatitis. *HPB*. 2012; 14(6):396-402
492. Ihse I, Larsson J, Lindstrom E. Surgical management of pure pancreatic fistulas. *Hepato-Gastroenterology*. 1994; 41(3):271-5
493. Ikeda M, Maetani I, Terada K, Ukita T, Tada T, Shigoka H et al. Usefulness of endoscopic retrograde biliary biopsy using large-capacity forceps for extrahepatic biliary strictures: A prospective randomized study. *Endoscopy*. 2010; 42(10):837-41
494. Inui K, Tazuma S, Yamaguchi T, Ohara H, Tsuji T, Miyagawa H et al. Treatment of pancreatic stones with extracorporeal shock wave lithotripsy: Results of a multicenter survey. *Pancreas*. 2005; 30(1):26-30
495. Iqbal CW, Moir CR, Ishitani MB. Management of chronic pancreatitis in the pediatric patient: Endoscopic retrograde cholangiopancreatography vs operative therapy. *Journal of Pediatric Surgery*. 2009; 44(1):139-43; discussion 143
496. Irani S, Baron TH, Akbar A, Lin OS, Gluck M, Gan I et al. Endoscopic treatment of benign biliary strictures using covered self-expandable metal stents (CSEMS). *Digestive Diseases and Sciences*. 2014; 59(1):152-160
497. Irani S, Gluck M, Ross A, Gan SI, Crane R, Brandabur JJ et al. Resolving external pancreatic fistulas in patients with disconnected pancreatic duct syndrome: Using rendezvous techniques to avoid surgery (with video). *Gastrointestinal Endoscopy*. 2012; 76(3):586-93.e1-3
498. Isaksson G, Ihse I. Pain reduction by an oral pancreatic enzyme preparation in chronic pancreatitis. *Digestive Diseases and Sciences*. 1983; 28(2):97-102
499. Isayama H, Nakai Y, Togawa O, Kogure H, Ito Y, Sasaki T et al. Covered metallic stents in the management of malignant and benign pancreatobiliary strictures. *Journal of Hepato-Biliary-Pancreatic Surgery*. 2009; 16(5):624-627

500. Isenmann R, Runzi M, Kron M, Kahl S, Kraus D, Jung N et al. Prophylactic antibiotic treatment in patients with predicted severe acute pancreatitis: A placebo-controlled, double-blind trial. *Gastroenterology*. 2004; 126(4):997-1004
501. Ishii Y, Kohno T, Ito A, Suzuki S, Kohno T, Takayama T et al. Measurement of extra-pancreatic secretory function by ¹³C-dipeptide breath test. *Translational Research*. 2007; 149(6):298-303
502. Issa Y, Kempeneers MA, van Santvoort HC, Bollen TL, Bipat S, Boermeester MA. Diagnostic performance of imaging modalities in chronic pancreatitis: a systematic review and meta-analysis. *European Radiology*. 2017; 27(9):3820-3844
503. Issa Y, van Santvoort HC, Fockens P, Besselink MG, Bollen TL, Bruno MJ et al. Diagnosis and treatment in chronic pancreatitis: an international survey and case vignette study. *HPB*. 2017; 19(11):978-985
504. Ito K, Fujita N, Noda Y, Kobayashi G, Horaguchi J. Endoscopic treatment for biliary stricture secondary to chronic pancreatitis. *Digestive Endoscopy*. 2012; 24(Suppl 1):17-21
505. Ito N, Yagi K, Kawano M, Mori Y, Okazaki S, Chujo D et al. Analysis of pancreatic endocrine function in patients with IgG4-related diseases, in whom autoimmune pancreatitis was ruled out by diagnostic imaging. *Endocrine Journal*. 2014; 61(8):765-772
506. Ito T, Otsuki M, Itoi T, Shimosegawa T, Funakoshi A, Shiratori K et al. Pancreatic diabetes in a follow-up survey of chronic pancreatitis in Japan. *Journal of Gastroenterology*. 2007; 42(4):291-7
507. Itoi T, Itokawa F, Sofuni A, Kurihara T, Tsuchiya T, Ishii K et al. Endoscopic sphincterotomy combined with large balloon dilation can reduce the procedure time and fluoroscopy time for removal of large bile duct stones. *American Journal of Gastroenterology*. 2009; 104(3):560-565
508. Itoi T, Khor CJL. Management of benign strictures of the extrahepatic bile duct due to chronic pancreatitis and surgical intervention. *Digestive Endoscopy*. 2012; 24(Suppl 1):8-16
509. Izbicki JR, Bloechle C, Broering DC, Knoefel WT, Kuechler T, Broelsch CE. Extended drainage versus resection in surgery for chronic pancreatitis: a prospective randomized trial comparing the longitudinal pancreaticojejunostomy combined with local pancreatic head excision with the pylorus-preserving pancreatoduodenectomy. *Annals of Surgery*. 1998; 228(6):771-9
510. Izbicki JR, Bloechle C, Broering DC, Kuechler T, Broelsch CE. Longitudinal V-shaped excision of the ventral pancreas for small duct disease in severe chronic pancreatitis: prospective evaluation of a new surgical procedure. *Annals of Surgery*. 1998; 227(2):213-9
511. Izbicki JR, Bloechle C, Knoefel WT, Broelsch CE. The Frey procedure for chronic pancreatitis with sclerosing pancreatic main duct. *International Journal of Pancreatology*. 1996; 19(3):232
512. Izbicki JR, Bloechle C, Knoefel WT, Kuechler T, Binmoeller KF, Soehendra N et al. Drainage versus resection in surgical therapy of chronic pancreatitis of the head of the pancreas: a randomized study. *Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizin*. 1997; 68(4):369-77
513. Izbicki JR, Bloechle C, Knoefel WT, Wilker DK, Dornschnieder G, Broelsch CE. Comparison of two techniques of duodenum-preserving resection of the head of the pancreas in chronic pancreatitis. *Digestive Surgery*. 1994; 11(3-6):331-337

514. Izbicki JR, Knoefel WT, Bloechle C, K uchler T, K uhn R, Limmer JC et al. The status of duodenum-preserving resection of the head of the pancreas in therapy of chronic pancreatitis. *Zentralblatt f ur Chirurgie*. 1995; 120(4):298-305
515. Jaakkola M, Frey T, Sillanaukee P, Koivula T, Nordback I. Acute pancreatic injury in asymptomatic individuals after heavy drinking over the long-term. *Hepato-Gastroenterology*. 1994; 41(5):477-82
516. Jacobson BC, Baron TH, Adler DG, Davila RE, Egan J, Hirota WK et al. ASGE guideline: The role of endoscopy in the diagnosis and the management of cystic lesions and inflammatory fluid collections of the pancreas. *Gastrointestinal Endoscopy*. 2005; 61(3):363-370
517. Jafari T, Feizi A, Askari G, Fallah AA. Parenteral immunonutrition in patients with acute pancreatitis: A systematic review and meta-analysis. *Clinical Nutrition*. 2015; 34(1):35-43
518. Jafri NS, Mahid SS, Idstein SR, Hornung CA, Galandiuk S. Antibiotic prophylaxis is not protective in severe acute pancreatitis: a systematic review and meta-analysis. *American Journal of Surgery*. 2009; 197(6):806-13
519. Jagielski M, Smoczynski M, Jablonska A, Adrych K. Endoscopic treatment of intraductal pancreatic stent fragmentation. *Digestive Endoscopy*. 2017; 29(7):798-805
520. Jagielski M, Smoczynski M, Jablonska A, Marek I, Dubowik M, Adrych K. The role of endoscopic ultrasonography in endoscopic debridement of walled-off pancreatic necrosis - A single center experience. *Pancreatology*. 2015; 15(5):503-507
521. Jain SK, Basra BK, Nanda G, Srivathsan R, Kaza RC. Rare case of internal pancreatic fistula in a young adult presenting with massive bilateral pleural effusion. *BMJ Case Reports*. 2009; published online 26 February 2009;doi:10.1136/bcr.06.2008.0341
522. Jalaly NY, Moran RA, Fargahi F, Khashab MA, Kamal A, Lennon AM et al. An evaluation of factors associated with pathogenic PRSS1, SPINK1, CTFR, and/or CTRC genetic variants in patients with idiopathic pancreatitis. *American Journal of Gastroenterology*. 2017; 112(8):1320-1329
523. Jang JY, Yoon CH, Kim KM. Endoscopic retrograde cholangiopancreatography in pancreatic and biliary tract disease in Korean children. *World Journal of Gastroenterology*. 2010; 16(4):490-495
524. Jarosz M, Orzeszko M, Rychlik E, Kozuch M. Antioxidants in the treatment of chronic pancreatitis. *Gastroenterologia Polska*. 2010; 17(1):41-46
525. Jazrawi SF, Barth BA, Sreenarasimhaiah J. Efficacy of endoscopic ultrasound-guided drainage of pancreatic pseudocysts in a pediatric population. *Digestive Diseases and Sciences*. 2011; 56(3):902-8
526. Jeejeebhoy KN. Enteral nutrition versus parenteral nutrition - The risks and benefits. *Nature Clinical Practice Gastroenterology and Hepatology*. 2007; 4(5):260-265
527. Jenkins SA, Berein A. Review article: the relative effectiveness of somatostatin and octreotide therapy in pancreatic disease. *Alimentary Pharmacology and Therapeutics*. 1995; 9(4):349-61
528. Jensen NM, Larsen S. A rapid, endoscopic exocrine pancreatic function test and the Lundh test: A comparative study. *Pancreatology*. 2008; 8(6):617-624
529. Jeppe CY, Becker P, Smith MD. Post-Frey procedure quality of life in South African patients with painful chronic pancreatitis. *Journal of the Pancreas*. 2013; 14(1):21-30

530. Jeppe CY, Bekker PJ, Omoshoro-Jones J, Smith MD. Post Frey procedure quality of life in South Africans with chronic pancreatitis. *HPB*. 2011; 13(Suppl 2):6-7
531. Jiaming Q, Jingnan LI, Zili T, Hong LU, Liping T. Etiological analysis of chronic pancreatitis in 215 cases. *Chinese Journal of Gastroenterology*. 2001; 6(3):153-155
532. Jiang K, Chen XZ, Xia Q, Tang WF, Wang L. Early nasogastric enteral nutrition for severe acute pancreatitis: A systematic review. *World Journal of Gastroenterology*. 2007; 13(39):5253-60
533. Jiang K, Huang W, Yang XN, Xia Q. Present and future of prophylactic antibiotics for severe acute pancreatitis. *World Journal of Gastroenterology*. 2012; 18(3):279-84
534. Jiang K, Liao Y, Tu B, Wu K. A meta-analysis of surgery treatment of chronic pancreatitis with an inflammatory mass in the head of pancreas: duodenum-preserving pancreatic head resection versus pancreatoduodenectomy. *Chinese Journal of Surgery*. 2014; 52(9):668-674
535. Jiang W, Tong Z, Yang D, Ke L, Shen X, Zhou J et al. Gastrointestinal fistulas in acute pancreatitis with infected pancreatic or peripancreatic necrosis: A 4-year single-center experience. *Medicine*. 2016; 95(14):e3318
536. Jimenez RE, Fernandez-del Castillo C, Rattner DW, Chang Y, Warshaw AL. Outcome of pancreaticoduodenectomy with pylorus preservation or with antrectomy in the treatment of chronic pancreatitis. *Annals of Surgery*. 2000; 231(3):293-300
537. Jin M, Zhang H, Lu B, Li Y, Wu D, Qian J et al. The optimal timing of enteral nutrition and its effect on the prognosis of acute pancreatitis: A propensity score matched cohort study. *Pancreatology*. 2017; 17(5):651-657
538. Joergensen M, Brusgaard K, Cruger DG, Gerdes AM, De Muckadell OBS. Incidence, prevalence, etiology, and prognosis of first-time chronic pancreatitis in young patients: A nationwide cohort study. *Digestive Diseases and Sciences*. 2010; 55(10):2988-2998
539. Joergensen M, Brusgaard K, Cruger DG, Gerdes AM, Schaffalitzky De Muckadell OB. Incidence, etiology and prognosis of first-time acute pancreatitis in young patients: A population-based cohort study. *Pancreatology*. 2010; 10(4):453-461
540. Johanns W, Jakobeit C, Greiner L, Janssen J. Ultrasound-guided extracorporeal shock wave lithotripsy of pancreatic ductal stones: six years' experience. *Canadian Journal of Gastroenterology*. 1996; 10(7):471-5
541. John GK, Singh V, Pasricha P, Makary M, Hirose K, Desai N et al. Modified clinical grading for postoperative dysmotility in chronic pancreatitis patients following total pancreatectomy with islet cell transplantation. *American Journal of Gastroenterology*. 2014; 109(Suppl 2):S76
542. John GK, Singh VK, Makary M, Hirose K, Desai N, Walsh C et al. Laparoscopic total pancreatectomy with islet autotransplantation (TP-IAT) reduces post-operative gastrointestinal dysmotility and length of hospital stay compared to open TP-IAT. *Pancreas*. 2014; 43(8):1371-1372
543. John GK, Singh VK, Makary M, Hirose K, Desai NM, Walsh C et al. Chronic pain and gastrointestinal dysmotility symptoms exist independent of each other in the post-operative period following total pancreatectomy with islet transplantation (TP-IAT). *Gastroenterology*. 2016; 150(4):S907
544. John GK, Singh VK, Moran RA, Warren D, Sun Z, Desai N et al. Chronic gastrointestinal dysmotility and pain following total pancreatectomy with islet autotransplantation for chronic pancreatitis. *Journal of Gastrointestinal Surgery*. 2017; 21(4):622-627

545. John GK, Singh VK, Pasricha PJ, Sinha A, Afghani E, Warren D et al. Delayed gastric emptying (DGE) following total pancreatectomy with islet auto transplantation in patients with chronic pancreatitis. *Journal of Gastrointestinal Surgery*. 2015; 19(7):1256-61
546. Johnson CD. Antibiotic prophylaxis in severe acute pancreatitis. *British Journal of Surgery*. 1996; 83(7):883-4
547. Johnson MD, Walsh RM, Henderson JM, Brown N, Ponsky J, Dumot J et al. Surgical versus nonsurgical management of pancreatic pseudocysts. *Journal of Clinical Gastroenterology*. 2009; 43(6):586-90
548. Joliat GR, Demartines N, Halkic N, Petermann D, Schafer M. Short-term outcomes after distal pancreatectomy: Laparotomy vs. laparoscopy - A single-center series. *Annals of Medicine and Surgery*. 2017; 13:1-5
549. Jordan PH, Jr., Pikoulis M. Operative treatment for chronic pancreatitis pain. *Journal of the American College of Surgeons*. 2001; 192(4):498-509
550. Jorge A, Diaz M, Lorenzo J, Jorge O. Choledochoduodenal fistulas. *Endoscopy*. 1991; 23(2):76-78
551. Jouannaud V, Coutarel P, Tossou H, Butel J, Vitte RL, Skinazi F et al. Cystic dystrophy of the duodenal wall associated with chronic alcoholic pancreatitis. Clinical features, diagnostic procedures and therapeutic management in a retrospective multicenter series of 23 patients. *Gastroenterologie Clinique et Biologique*. 2006; 30(4):580-6
552. Jung JG, Lee JK, Lee KH, Lee KT, Woo YS, Paik WH et al. Comparison of endoscopic retrograde cholangiopancreatography with papillary biopsy and endoscopic ultrasound-guided pancreatic biopsy in the diagnosis of autoimmune pancreatitis. *Pancreatology*. 2015; 15(3):259-264
553. Junming M, Peng L, Minqi Z, Yongfeng H, Qi W. Analysis of diagnosis and treatment of fifty-nine patients with chronic pancreatitis. *European Surgery - Acta Chirurgica Austriaca*. 2015; 47(Suppl 1):S106
554. Kaffes AJ. Management of benign biliary strictures: Current status and perspective. *Journal of Hepato-Biliary-Pancreatic Sciences*. 2015; 22(9):657-663
555. Kaffes AJ, Liu K. Fully covered self-expandable metal stents for treatment of benign biliary strictures. *Gastrointestinal Endoscopy*. 2013; 78(1):13-21
556. Kahaleh M, Brijbassie A, Sethi A, Degaetani M, Poneris JM, Loren DE et al. Multicenter trial evaluating the use of covered self-expanding metal stents in benign biliary strictures: Time to revisit our therapeutic options? *Journal of Clinical Gastroenterology*. 2013; 47(8):695-699
557. Kahaleh M, Shami VM, Conaway MR, Tokar J, Rockoff T, De La Rue SA et al. Endoscopic ultrasound drainage of pancreatic pseudocyst: A prospective comparison with conventional endoscopic drainage. *Endoscopy*. 2006; 38(4):355-9
558. Kahl S, Glasbrenner B, Leodolter A, Pross M, Schulz HU, Malfertheiner P. EUS in the diagnosis of early chronic pancreatitis: A prospective follow-up study. *Gastrointestinal Endoscopy*. 2002; 55(4):507-511
559. Kahl S, Schutte K, Glasbrenner B, Mayerle J, Simon P, Henniges F et al. The effect of oral pancreatic enzyme supplementation on the course and outcome of acute pancreatitis: A randomized, double-blind parallel-group study. *Journal of the Pancreas*. 2014; 15(2):165-74

560. Kahl S, Zimmermann S, Genz I, Glasbrenner B, Pross M, Schulz HU et al. Risk factors for failure of endoscopic stenting of biliary strictures in chronic pancreatitis: A prospective follow-up study. *American Journal of Gastroenterology*. 2003; 98(11):2448-2453
561. Kahl S, Zimmermann S, Genz I, Schmidt U, Pross M, Schulz HU et al. Biliary strictures are not the cause of pain in patients with chronic pancreatitis. *Pancreas*. 2004; 28(4):387-390
562. Kahl S, Zimmermann S, Glasbrenner B, Pross M, Schulz HU, McNamara D et al. Treatment of benign biliary strictures in chronic pancreatitis by self-expandable metal stents. *Digestive Diseases*. 2002; 20(2):199-203
563. Kaido T. Recent randomized controlled trials in pancreaticoduodenectomy. *Pancreas*. 2006; 33(3):228-232
564. Kale-Pradhan PB, Elnabity MH, Park NJ, Laus M. Enteral nutrition in patients with pancreatitis. *Pharmacotherapy*. 1999; 19(9):1036-41
565. Kalfarentzos F, Kehagias J, Mead N, Kokkinis K, Gogos CA. Enteral nutrition is superior to parenteral nutrition in severe acute pancreatitis: results of a randomized prospective trial. *British Journal of Surgery*. 1997; 84(12):1665-9
566. Kalfarentzos FE, Karavias DD, Karatzas TM, Alevizatos BA, Androulakis JA. Total parenteral nutrition in severe acute pancreatitis. *Journal of the American College of Nutrition*. 1991; 10(2):156-62
567. Kalfarentzos FE, Kehagias J, Kakkos SK, Petsas T, Kokkinis K, Gogos CA et al. Treatment of patients with severe acute necrotizing pancreatitis based on prospective evaluation. *Hepato-Gastroenterology*. 1999; 46(30):3249-3256
568. Kaman L, Behera A, Singh R, Katariya RN. Internal pancreatic fistulas with pancreatic ascites and pancreatic pleural effusions: recognition and management. *ANZ Journal of Surgery*. 2001; 71(4):221-5
569. Kamisawa T, Matsukawa M. Possibility of diagnosing early-stage chronic pancreatitis by endoscopic retrograde pancreatography. *Journal of Gastroenterology*. 2007; 42(Suppl 17):103-7
570. Kamisawa T, Ohara H, Kim MH, Kanno A, Okazaki K, Fujita N. Role of endoscopy in the diagnosis of autoimmune pancreatitis and immunoglobulin G4-related sclerosing cholangitis. *Digestive Endoscopy*. 2014; 26(5):627-635
571. Kamisawa T, Tu Y, Egawa N, Tsuruta K, Okamoto A. A new diagnostic endoscopic tool for autoimmune pancreatitis. *Gastrointestinal Endoscopy*. 2008; 68(2):358-61
572. Kandiah K, Neong SF, Vlavianos P, Bansi D, Hanna M, Westaby D. External shockwave lithotripsy (ESWL) of pancreatic calculi improves pain related to chronic calcific pancreatitis. *Gut*. 2014; 63(Suppl 1):A254
573. Kanneganti K, Srikakarlappudi S, Acharya B, Sindhaghatta V, Chilimuri S. Successful management of pancreatic ascites with both conservative management and pancreatic duct stenting. *Gastroenterology Research*. 2009; 2(4):245-247
574. Kanno A, Masamune A, Fujishima F, Iwashita T, Kodama Y, Katanuma A et al. Diagnosis of autoimmune pancreatitis by EUS-guided FNA using a 22-gauge needle: A prospective multicenter study. *Gastrointestinal Endoscopy*. 2016; 84(5):797-804.e1
575. Kanno A, Masamune A, Shimosegawa T. Endoscopic approaches for the diagnosis of autoimmune pancreatitis. *Digestive Endoscopy*. 2015; 27(2):250-258

576. Kapural L, Bensitel T. Spinal cord stimulation for pain management in chronic pancreatitis patients. *Pain Medicine*. 2010; 11(2):291
577. Kapural L, Cywinski JB, Sparks DA. Spinal cord stimulation for visceral pain from chronic pancreatitis. *Neuromodulation*. 2011; 14(5):423-6; discussion 426-7
578. Karamitsios N, Saltzman JR. Enteral nutrition in acute pancreatitis. *Nutrition Reviews*. 1997; 55(7):279-82
579. Karasawa Y, Kawa S, Aoki Y, Ochi Y, Unno H, Kiyosawa K et al. Extracorporeal shock wave lithotripsy of pancreatic duct stones and patient factors related to stone disintegration. *Journal of Gastroenterology*. 2002; 37(5):369-75
580. Karjula H, Saarela A, Vaarala A, Niemela J, Makela J. Endoscopic transpapillary stenting for pancreatic fistulas after necrosectomy with necrotizing pancreatitis. *Surgical Endoscopy*. 2015; 29(1):108-12
581. Kataoka K, Hosoda M, Yasuda H, Sakagami J, Kato M, Kashima K. Assessment of exocrine pancreatic dysfunction in chronic pancreatitis. *Digestion*. 1999; 60(Suppl 1):86-92
582. Kataoka K, Sakagami J, Hirota M, Masamune A, Shimosegawa T. Effects of oral ingestion of the elemental diet in patients with painful chronic pancreatitis in the real-life setting in Japan. *Pancreas*. 2014; 43(3):451-7
583. Kataoka K, Yamane Y, Kato M, Kashima K. Diagnosis of chronic pancreatitis using noninvasive tests of exocrine pancreatic function - Comparison to duodenal intubation tests. *Pancreas*. 1997; 15(4):409-415
584. Kaushik N, O'Keefe SJD. Nutritional support in acute pancreatitis. *Current Gastroenterology Reports*. 2004; 6(4):320-326
585. Kawakatsu S, Kaneoka Y, Maeda A, Fukami Y. Salvage anastomosis for postoperative chronic pancreatic fistula. *Updates in Surgery*. 2016; 68(4):413-417
586. Ke L, Li J, Hu P, Wang L, Chen H, Zhu Y. Percutaneous catheter drainage in infected pancreatitis necrosis: A systematic review. *Indian Journal of Surgery*. 2016; 78(3):221-8
587. Keane MG, Horsfall L, Rait G, Pereira SP. A case-control study comparing the incidence of early symptoms in pancreatic and biliary tract cancer. *BMJ Open*. 2014; 4(e005720)
588. Keck T, Wellner UF, Riediger H, Adam U, Sick O, Hopt UT et al. Long-term outcome after 92 duodenum-preserving pancreatic head resections for chronic pancreatitis: Comparison of Beger and Frey procedures. *Journal of Gastrointestinal Surgery*. 2010; 14(3):549-56
589. Keim V, Teich N, Moessner J. Clinical value of a new fecal elastase test for detection of chronic pancreatitis. *Clinical Laboratory*. 2003; 49(5-6):209-215
590. Keller J, Bruckel S, Jahr C, Layer P. A modified 13C-mixed triglyceride breath test detects moderate pancreatic exocrine insufficiency. *Pancreas*. 2011; 40(8):1201-1205
591. Ketwaroo G, Brown A, Young B, Kheraj R, Sawhney M, Morteale KJ et al. Defining the accuracy of secretin pancreatic function testing in patients with suspected early chronic pancreatitis. *American Journal of Gastroenterology*. 2013; 108(8):1360-1366
592. Ketwaroo GA, Freedman SD, Sheth SG. Approach to patients with suspected chronic pancreatitis: A comprehensive review. *Pancreas*. 2015; 44(2):173-80

593. Khreiss M, Zenati M, Clifford A, Lee KK, Hogg ME, Slivka A et al. Cyst gastrostomy and necrosectomy for the management of sterile walled-off pancreatic necrosis: A comparison of minimally invasive surgical and endoscopic outcomes at a high-volume pancreatic center. *Journal of Gastrointestinal Surgery*. 2015; 19(8):1441-1448
594. Kianicka B, Lata J, Novotny I, Dite P, Vanicek J. Single balloon enteroscopy for endoscopic retrograde cholangiography in patients with Roux-en-Y hepaticojejunostomy. *World Journal of Gastroenterology*. 2013; 19(44):8047-8055
595. Kiehne K, Folsch UR, Nitsche R. High complication rate of bile duct stents in patients with chronic alcoholic pancreatitis due to noncompliance. *Endoscopy*. 2000; 32(5):377-380
596. Kikuyama M, Itoi T, Sasada Y, Sofuni A, Ota Y, Itokawa F. Large-balloon technique for one-step endoscopic biliary stenting in patients with an inaccessible major papilla owing to difficult duodenal stricture (with video). *Gastrointestinal Endoscopy*. 2009; 70(3):568-72
597. Kikuyama M, Sasada Y, Matsushashi T, Ota Y, Nakahodo J. ERCP after Roux-en-Y reconstruction can be carried out using an oblique-viewing endoscope with an overtube. *Digestive Endoscopy*. 2009; 21(3):180-184
598. Kim JJ, Walia S, Lee SH, Patel B, Vetsa M, Zhao Y et al. Lower yield of endoscopic ultrasound-guided fine-needle aspiration in patients with pancreatic head mass with a biliary stent. *Digestive Diseases and Sciences*. 2015; 60(2):543-549
599. Kim MH, Myung SJ, Kim YS, Kim HJ, Seo DW, Nam SW et al. Routine biliary sphincterotomy may not be indispensable for endoscopic pancreatic sphincterotomy. *Endoscopy*. 1998; 30(8):697-701
600. King JC, Reber HA, Shiraga S, Hines OJ. Pancreatic-pleural fistula is best managed by early operative intervention. *Surgery*. 2010; 147(1):154-159
601. Kirk GR, White JS, McKie L, Stevenson M, Young I, Clements WD et al. Combined antioxidant therapy reduces pain and improves quality of life in chronic pancreatitis. *Journal of Gastrointestinal Surgery*. 2006; 10(4):499-503
602. Kirkegaard J, Mortensen FV, Cronin-Fenton D. Chronic pancreatitis and pancreatic cancer risk: A systematic review and meta-analysis. *American Journal of Gastroenterology*. 2017;
603. Kitagawa M, Naruse S, Ishiguro H, Nakae Y, Kondo T, Hayakawa T. Evaluating exocrine function tests for diagnosing chronic pancreatitis. *Pancreas*. 1997; 15(4):402-408
604. Klapdor S, Richter E, Klapdor R. Vitamin D status and per-oral vitamin D supplementation in patients suffering from chronic pancreatitis and pancreatic cancer disease. *Anticancer Research*. 2012; 32(5):1991-8
605. Klempa I, Spatny M, Menzel J, Baca I, Nustede R, Stöckmann F et al. Pancreatic function and quality of life after resection of the head of the pancreas in chronic pancreatitis. A prospective, randomized comparative study after duodenum preserving resection of the head of the pancreas versus Whipple's operation. *Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizin*. 1995; 66(4):350-9
606. Knill-Jones RP, Batten PJ, Williams R. [Comparative double blind experience of a polyenzymatic preparation in chronic pancreatic insufficiency]. *Acta Gastroenterologica Belgica*. 1973; 36(9):489-504
607. Knop FK, Vilsbøll T, Lund A, Krarup T, Holst JJ, Hornum M. The impact of pancreatic enzyme supplementation on postprandial responses of glucagon-like Peptide-2 in patients with

- chronic pancreatitis and pancreatic exocrine insufficiency. *Journal of the Pancreas*. 2010; 11(5):489-91
608. Kocher HM, Froeling FE. Chronic pancreatitis. *Clinical Evidence*. 2008; 2008:0417
609. Kocher HM, Kadaba R. Chronic pancreatitis. *Clinical Evidence*. 2011; 2011:0417
610. Koizumi M, Sata N, Yoshizawa K, Tsukahara M, Kurihara K, Yasuda Y et al. Post-ERCP pancreatogastric fistula associated with an intraductal papillary-mucinous neoplasm of the pancreas--a case report and literature review. *World Journal of Surgical Oncology*. 2005; 3:70
611. Kondo H, Naitoh I, Ohara H, Nakazawa T, Hayashi K, Okumura F et al. Efficacy of pancreatic stenting prior to extracorporeal shock wave lithotripsy for pancreatic stones. *Digestive and Liver Disease*. 2014; 46(7):639-44
612. Koninger J, Friess H, Muller M, Buchler MW. Duodenum preserving pancreatic head resection in the treatment of chronic pancreatitis. *Roczniki Akademii Medycznej w Białymstoku (1995)*. 2004; 49:53-60
613. Konzen KM, Perrault J, Moir C, Zinsmeister AR. Long-term follow-up of young patients with chronic hereditary or idiopathic pancreatitis. *Mayo Clinic Proceedings*. 1993; 68(5):449-53
614. Kothari D, Ketwaroo G, Freedman SD, Sheth SG. The impact of risk factors of chronic pancreatitis on secretin pancreatic function testing: Results of a 20-year study. *Pancreas*. 2017; 46(7):887-890
615. Kothari D, Ketwaroo G, Sawhney MS, Freedman SD, Sheth SG. Comparison of combined endoscopic ultrasonography and endoscopic secretin testing with the traditional secretin pancreatic function test in patients with suspected chronic pancreatitis: A prospective crossover study. *Pancreas*. 2017; 46(6):770-775
616. Kozarek RA, Ball TJ, Patterson DJ, Freeny PC, Ryan JA, Traverso LW. Endoscopic transpapillary therapy for disrupted pancreatic duct and peripancreatic fluid collections. *Gastroenterology*. 1991; 100(5 Pt 1):1362-70
617. Kozarek RA, Brayko CM, Harlan J, Sanowski RA, Cintora I, Kovac A. Endoscopic drainage of pancreatic pseudocysts. *Gastrointestinal Endoscopy*. 1985; 31(5):322-7
618. Krishnan K. Nutritional management of acute pancreatitis. *Current Opinion in Gastroenterology*. 2017; 33(2):102-106
619. Kulkarni CB, Pullara SK, Moorthy S, Prabhu NK, Nazar PK, Kannan RR. Percutaneous transhepatic balloon dilatation of benign bilioenteric strictures: Analysis of technique and long-term outcome. *Gastrointestinal Intervention*. 2015; 4(2):112-119
620. Kulkarni S, Bogart A, Buxbaum J, Matsuoka L, Selby R, Parekh D. Surgical transgastric debridement of walled off pancreatic necrosis: An option for patients with necrotizing pancreatitis. *Surgical Endoscopy and Other Interventional Techniques*. 2014; 29(3):575-582
621. Kumar A, Singh N, Prakash S, Saraya A, Joshi YK. Early enteral nutrition in severe acute pancreatitis: A prospective randomized controlled trial comparing nasojejunal and nasogastric routes. *Journal of Clinical Gastroenterology*. 2006; 40(5):431-4
622. Kumar N, Conwell DL, Thompson CC. Direct endoscopic necrosectomy versus step-up approach for walled-off pancreatic necrosis: Comparison of clinical outcome and health care utilization. *Pancreas*. 2014; 43(8):1334-9

623. Kumar R, Sharma BC, Singh J, Sarin SK. Endoscopic biliary drainage for severe acute cholangitis in biliary obstruction as a result of malignant and benign diseases. *Journal of Gastroenterology and Hepatology*. 2004; 19(9):994-997
624. Kumar S, Garipey CE. Nutrition and acute pancreatitis: Review of the literature and pediatric perspectives. *Current Gastroenterology Reports*. 2013; 15(8):338
625. Kume K, Masamune A, Ariga H, Shimosegawa T. Alcohol consumption and the risk for developing pancreatitis: A case-control study in Japan. *Pancreas*. 2015; 44(1):53-8
626. Kurumboor P, Varma D, Rajan M, Kamlesh NP, Paulose R, Narayanan RG et al. Outcome of pancreatic ascites in patients with tropical calcific pancreatitis managed using a uniform treatment protocol. *Indian Journal of Gastroenterology*. 2009; 28(3):102-6
627. Kuwabara K, Matsuda S, Fushimi K, Ishikawa KB, Horiguchi H, Fujimori K. Community-based appraisal of the effects of parenteral nutrition versus enteral nutrition on the quality of care for patients with acute pancreatitis. *Gastroenterology Research*. 2011; 4(1):1-8
628. Kuwabara K, Matsuda S, Fushimi K, Ishikawa KB, Horiguchi H, Fujimori K. Early crystalloid fluid volume management in acute pancreatitis: Association with mortality and organ failure. *Pancreatology*. 2011; 11(3):351-61
629. Kuwahara T, Hirooka Y, Kawashima H, Ohno E, Ishikawa T, Kawai M et al. Quantitative diagnosis of chronic pancreatitis using EUS elastography. *Journal of Gastroenterology*. 2017; 52(7):868-874
630. Kuwahara T, Hirooka Y, Kawashima H, Ohno E, Ishikawa T, Yamamura T et al. Usefulness of shear wave elastography as a quantitative diagnosis of chronic pancreatitis. *Journal of Gastroenterology and Hepatology*. 2017; Epublication
631. Kwek AB, Ang TL, Maydeo A. Current status of endotherapy for chronic pancreatitis. *Singapore Medical Journal*. 2014; 55(12):613-20
632. Kwon CI, Gromski MA, Sherman S, Easler JJ, El Hajj II, Watkins J et al. Time sequence evaluation of biliary stent occlusion by dissection analysis of retrieved stents. *Digestive Diseases and Sciences*. 2016; 61(8):2426-2435
633. Lang EK, Paolini RM, Pottmeyer A. The efficacy of palliative and definitive percutaneous versus surgical drainage of pancreatic abscesses and pseudocysts: A prospective study of 85 patients. *Southern Medical Journal*. 1991; 84(1):55-64
634. Lang MB, Segersvard R, Grundsten M, Segerdahl M, Arnelo U, Permert J et al. Management of alcohol use disorders in patients with chronic pancreatitis. *Journal of the Pancreas*. 2012; 13(6):654-9
635. Lankisch PG. Function tests in the diagnosis of chronic pancreatitis: Critical evaluation. *International Journal of Pancreatology*. 1993; 14(1):9-20
636. Lankisch PG, Schmidt I, Konig H, Lehnick D, Knollmann R, Lohr M et al. Faecal elastase 1: Not helpful in diagnosing chronic pancreatitis associated with mild to moderate exocrine pancreatic insufficiency. *Gut*. 1998; 42(4):551-554
637. Lara LF, Takita M, Burdick JS, DeMarco DC, Pimentel RR, Erim T et al. A study of the clinical utility of a 20-minute secretin-stimulated endoscopic pancreas function test and performance according to clinical variables. *Gastrointestinal Endoscopy*. 2017; 86(6):1048-1055.e2

638. Larino-Noia J, Lindkvist B, Iglesias-Garcia J, Seijo-Rios S, Iglesias-Canle J, Dominguez-Munoz JE. Early and/or immediately full caloric diet versus standard refeeding in mild acute pancreatitis: A randomized open-label trial. *Pancreatology*. 2014; 14(3):167-73
639. Larsen M, Kozarek R. Management of pancreatic ductal leaks and fistulae. *Journal of Gastroenterology and Hepatology*. 2014; 29(7):1360-70
640. Larvin M, McMahon MJ. Creon (enteric coated pancreatin microspheres) for the treatment of pain in chronic pancreatitis: a double-blind randomized placebo-controlled crossover study. *Gastroenterology*. 1991; 100(100):A283
641. Le Moine O, Matos C, Closset J, Deviere J. Endoscopic management of pancreatic fistula after pancreatic and other abdominal surgery. *Best Practice & Research: Clinical Gastroenterology*. 2004; 18(5):957-75
642. Lee JH. Self-expandable metal stents for malignant distal biliary strictures. *Gastrointestinal Endoscopy Clinics of North America*. 2011; 21(3):463-480
643. Lee JK, Kwak KK, Park JK, Yoon WJ, Lee SH, Ryu JK et al. The efficacy of nonsurgical treatment of infected pancreatic necrosis. *Pancreas*. 2007; 34(4):399-404
644. Lee SN, Lee KH, Chung S, Nam HS, Cho JH, Ryu JS et al. Pancreaticothoracic fistula presenting with hemoptysis and pneumothorax in a chronic alcoholic patient. *Tuberculosis & Respiratory Diseases*. 2014; 76(5):240-4
645. Lee VT, Chung AY, Chow PK, Thng CH, Low AS, Ooi LL et al. Infected pancreatic necrosis--an evaluation of the timing and technique of necrosectomy in a Southeast Asian population. *Annals of the Academy of Medicine, Singapore*. 2006; 35(8):523-30
646. Lei ZM, Li DY, Li J, Wang Q, He K, Zheng SL et al. Diagnostic value of amino acid consumption test on exocrine pancreatic insufficiency. *World Journal of Gastroenterology*. 2000; 6(2):290-292
647. Leksowski K, Tomaszewski S. Treatment of pain due to chronic pancreatitis. *Gastroenterologia Polska*. 2007; 14(5):372-376
648. Lerch MM, Mayerle J, Aghdassi AA, Budde C, Nitsche C, Sauter G et al. Advances in the etiology of chronic pancreatitis. *Digestive Diseases*. 2010; 28(2):324-329
649. Lerch MM, Stier A, Wahnschaffe U, Mayerle J. Pancreatic pseudocysts: Observation, endoscopic drainage, or resection? *Deutsches Arzteblatt International*. 2009; 106(38):614-621
650. Levy P, Bernades P, Belghiti J, Fekete F. Does elective pancreatic surgery modify the long-term mortality of patients with chronic pancreatitis? Comparison of operated and non-operated patients. *Gastroenterologie Clinique et Biologique*. 1989; 13(2 bis):A5
651. Li BR, Liao Z, Du TT, Ye B, Chen H, Ji JT et al. Extracorporeal shock wave lithotripsy is a safe and effective treatment for pancreatic stones coexisting with pancreatic pseudocysts. *Gastrointestinal Endoscopy*. 2016; 84(1):69-78
652. Li C, Zhang J, Zou Q, Chen J, Min Z. Management of biliary and pancreatic diseases using a new intraductal endoscope. *Journal of Laparoendoscopic and Advanced Surgical Techniques*. 2014; 24(3):130-133
653. Li CM, Liu ZH, Jiang GL, Zhang ZW. Clinical evaluation of endoscopic sphincterotomy and papillary balloon dilation for removal of common bile duct stones. *World Chinese Journal of Digestology*. 2006; 14(2):230-3

654. Li J, Xue GJ, Liu YL, Javed MA, Zhao XL, Wan MH et al. Early oral refeeding wisdom in patients with mild acute pancreatitis. *Pancreas*. 2013; 42(1):88-91
655. Li JN, Lai YM, Qian JM, Guo T, Lu H, Tang XY. Trends in etiologies of chronic pancreatitis within 20 years: Analysis of 636 cases. *Chinese Medical Journal*. 2011; 124(21):3556-3559
656. Li JY, Yu T, Chen GC, Yuan YH, Zhong W, Zhao LN et al. Enteral nutrition within 48 hours of admission improves clinical outcomes of acute pancreatitis by reducing complications: A meta-analysis. *PloS One*. 2013; 8(6):e64926
657. Li Q, Zhu B, Zhu X, Piao C, Cui W, Wang Y et al. Treatment of necrotizing acute pancreatitis with peritoneal lavage and dialysis by a new simplified technique insert catheters One retrospective study. *Medicine*. 2016; 95(23):e3821
658. Li QL, Gao WD, Zhang C, Zhou PH, Zhong YS, Chen WF et al. Is endoscopic sphincterotomy plus large-balloon dilation a better option than endoscopic large-balloon dilation alone in removal of large bile duct stones? A retrospective comparison study. *Indian Journal of Cancer*. 2015; 51(Suppl 2):e13-7
659. Li X, Ma F, Jia K. Early enteral nutrition within 24 hours or between 24 and 72 hours for acute pancreatitis: Evidence based on 12 RCTs. *Medical Science Monitor*. 2014; 20:2327-35
660. Liang TB, Bai XL, Zheng SS. Pancreatic fistula after pancreaticoduodenectomy: Diagnosed according to international study group pancreatic fistula (ISGPF) definition. *Pancreatology*. 2007; 7(4):325-331
661. Lillemoe KD, Pitt HA, Cameron JL. Current management of benign bile duct strictures. *Advances in Surgery*. 1992; 25:119-174
662. Lim CL, Lee W, Liew YX, Tang SS, Chlebicki MP, Kwa AL. Role of antibiotic prophylaxis in necrotizing pancreatitis: A meta-analysis. *Journal of Gastrointestinal Surgery*. 2015; 19(3):480-91
663. Lin SC, Shan YS, Lin PW. Adequate preoperative biliary drainage is determinative to decrease postoperative infectious complications after pancreaticoduodenectomy. *Hepato-Gastroenterology*. 2010; 57(101):698-705
664. Lipinski M, Rydzewska-Rosolowska A, Rydzewski A, Rydzewska G. Fluid resuscitation in acute pancreatitis: Normal saline or lactated Ringer's solution? *World Journal of Gastroenterology*. 2015; 21(31):9367-72
665. Lipsett PA, Cameron JL. Internal pancreatic fistula. *American Journal of Surgery*. 1992; 163(2):216-20
666. Lipsett PA, Cameron JL. Pancreatic ascites and pancreatic fistula in chronic pancreatitis. *Problems in General Surgery*. 1998; 15(1):116-122
667. Liu CL, Lo CM, Fan ST. Acute biliary pancreatitis: Diagnosis and management. *World Journal of Surgery*. 1997; 21(2):149-154
668. Liu M, Xia T, Zhang D, Hu L, Liao Z, Sun C et al. Genetic Background and Clinical Characters of Pediatric Chronic Pancreatitis: Data and Implications from the East. *Gastroenterology research & practice*. 2017; 2017:7548753
669. Liu WH, Ren LN, Chen T, Liu LY, Jiang JH, Wang T et al. Abdominal paracentesis drainage ahead of percutaneous catheter drainage benefits patients attacked by acute pancreatitis with fluid collections: A retrospective clinical cohort study. *Critical Care Medicine*. 2015; 43(1):109-119

670. Liu Y, Zheng X, Huang Z, Chen J, Song B. Secretin-stimulated magnetic resonance imaging/magnetic resonance cholangiopancreatography for the detection of chronic pancreatitis: A meta-analysis. *Pancreatology*. 2016; 16(3):365-371
671. Llamaza-Torres CJ, Fuentes-Pardo M, Alvarez-Higueras FJ, Alberca-De-Las-Parras F, Carballo-Alvarez F. Usefulness of percutaneous elastography by acoustic radiation force impulse for the non-invasive diagnosis of chronic pancreatitis. *Revista Española de Enfermedades Digestivas*. 2016; 108(8):450-456
672. Lock G, Kadow R, Messmann H, Zirngibl H, Scholmerich J, Holstege A. Modified serum pancreolauryl test in chronic pancreatitis: Evaluation in comparison to endoscopic retrograde pancreatography. *Hepato-Gastroenterology*. 1997; 44(16):1110-1116
673. Long DE, Axon ATR, Lintott DJ. The outcome of patients with an extrahepatic biliary stricture secondary to chronic pancreatitis. *International Journal of Pancreatology*. 1990; 7(4):331-341
674. Lopes CV, Pesenti C, Bories E, Caillol F, Giovannini M. Endoscopic-ultrasound-guided endoscopic transmural drainage of pancreatic pseudocysts and abscesses. *Scandinavian Journal of Gastroenterology*. 2007; 42(4):524-9
675. Lorenz D, Wolff H, Waclawiczek H. Pancreatic duct occlusion in resection treatment of chronic pancreatitis and cancer of the head of the pancreas. A 3-year follow-up study. *Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen*. 1988; 59(2):90-5
676. Loser C. Clinical relevance of fecal elastase 1 determination in the diagnosis of chronic pancreatitis. *Gastroenterology International*. 1997; 10(2):66-70
677. Loser C, Brauer C, Aygen S, Hennemann O, Folsch UR. Comparative clinical evaluation of the 13C-mixed triglyceride breath test as an indirect pancreatic function test. *Scandinavian Journal of Gastroenterology*. 1998; 33(3):327-334
678. Loser C, Folsch UR. A concept of treatment in acute pancreatitis--results of controlled trials, and future developments. *Hepato-Gastroenterology*. 1993; 40(6):569-73
679. Louie BE, Noseworthy T, Hailey D, Gramlich LM, Jacobs P, Warnock GL. 2004 MacLean-Mueller prize enteral or parenteral nutrition for severe pancreatitis: a randomized controlled trial and health technology assessment. *Canadian Journal of Surgery*. 2005; 48(4):298-306
680. Loveday BP, Mittal A, Phillips A, Windsor JA. Minimally invasive management of pancreatic abscess, pseudocyst, and necrosis: A systematic review of current guidelines. *World Journal of Surgery*. 2008; 32(11):2383-94
681. Lowenfels AB, Maisonneuve P, DiMagno EP, Elitsur Y, Gates Jr LK, Perrault J et al. Hereditary pancreatitis and the risk of pancreatic cancer. *Journal of the National Cancer Institute*. 1997; 89(6):442-446
682. Lu WP, Shi Q, Zhang WZ, Cai SW, Jiang K, Dong JH. A meta-analysis of the long-term effects of chronic pancreatitis surgical treatments: duodenum-preserving pancreatic head resection versus pancreatoduodenectomy *Chinese Medical Journal*. 2013; 126(1):147-153
683. Lu Y, Wu JC, Liu L, Bie LK, Gong B. Short-term and long-term outcomes after endoscopic sphincterotomy versus endoscopic papillary balloon dilation for bile duct stones. *European Journal of Gastroenterology and Hepatology*. 2014; 26(12):1367-73
684. Lucidi V, Alghisi F, Dall'Oglio L, D'Apice MR, Monti L, De Angelis P et al. The etiology of acute recurrent pancreatitis in children: A challenge for pediatricians. *Pancreas*. 2011; 40(4):517-21

685. Luiten EJ, Bruining HA. Antimicrobial prophylaxis in acute pancreatitis: selective decontamination versus antibiotics. *Best Practice & Research: Clinical Gastroenterology*. 1999; 13(2):317-30
686. Luiten EJ, Hop WC, Lange JF, Bruining HA. Controlled clinical trial of selective decontamination for the treatment of severe acute pancreatitis. *Annals of Surgery*. 1995; 222(1):57-65
687. Luiten EJ, Hop WC, Lange JF, Bruining HA. Differential prognosis of gram-negative versus gram-positive infected and sterile pancreatic necrosis: Results of a randomized trial in patients with severe acute pancreatitis treated with adjuvant selective decontamination. *Clinical Infectious Diseases*. 1997; 25(4):811-6
688. Lytras D, Olde Damink SW, Amin Z, Imber CJ, Malago M. Radical surgery in the presence of biliary metallic stents: Revising the palliative scenario. *Journal of Gastrointestinal Surgery*. 2011; 15(3):489-95
689. Ma J, Pendharkar SA, O'Grady G, Windsor JA, Petrov MS. Effect of nasogastric tube feeding vs nil per os on dysmotility in acute pancreatitis: Results of a randomized controlled trial. *Nutrition in Clinical Practice*. 2016; 31(1):99-104
690. Ma M, Zhai CX, Sun CX. Correlations Between LP-PLA2 Gene Polymorphisms and Susceptibility and Severity of Acute Pancreatitis in a Chinese Population. *Genetic Testing & Molecular Biomarkers*. 2017; 21(4):206-212
691. Madenci AL, Michailidou M, Chiou G, Thabet A, Fernandez-Del Castillo C, Fagenholz PJ. A contemporary series of patients undergoing open debridement for necrotizing pancreatitis. *American Journal of Surgery*. 2014; 208(3):324-331
692. Madsen P, Hansen E. Coeliac plexus block versus pancreaticogastrostomy for pain in chronic pancreatitis. A controlled randomized trial. *Scandinavian Journal of Gastroenterology*. 1985; 20(10):1217-20
693. Maejima S, Kawa S, Hasebe O, Homma T. The relationship between drinking status and serial changes of pancreatographic findings in patients with suspected early chronic alcoholic pancreatitis. *Pancreas*. 1996; 13(2):209-14
694. Maes B, Hastier P, Buckley MJM, Peten EP, Paolini O, Staccini P et al. Extensive aetiological investigations in acute pancreatitis: Results of a 1-year prospective study. *European Journal of Gastroenterology and Hepatology*. 1999; 11(8):891-896
695. Maeshiro K, Ikeda S, Yasunami Y, Nakayama Y, Hamada Y. Balloon-catheter endoscopic retrograde pancreatography-compression study for diagnosis of early-stage pancreatitis. *Journal of Gastroenterology*. 2007; 42(Suppl 17):95-102
696. Magyar A, Flautner L, Pulay I, Tihanyi TF, Harsanyi L. Pancreatic pseudocysts associated with chronic pancreatitis--early and late results of 1367 operations. *Acta Chirurgica Hungarica*. 1997; 36(1-4):215-8
697. Mahajan A, Ho H, Sauer B, Phillips MS, Shami VM, Ellen K et al. Temporary placement of fully covered self-expandable metal stents in benign biliary strictures: Midterm evaluation (with video). *Gastrointestinal Endoscopy*. 2009; 70(2):303-309
698. Mahajan R, Simon EG, Chacko A, Reddy DV, Kalyan PR, Joseph AJ et al. Endoscopic ultrasonography in pediatric patients--Experience from a tertiary care center in India. *Indian Journal of Gastroenterology*. 2016; 35(1):14-9

699. Maire F, Le Baleur Y, Rebours V, Vullierme MP, Couvelard A, Voitot H et al. Outcome of patients with type 1 or 2 autoimmune pancreatitis. *American Journal of Gastroenterology*. 2011; 106(1):151-6
700. Makin E, Harrison PM, Patel S, Davenport M. Pancreatic pseudocysts in children: Treatment by endoscopic cyst gastrostomy. *Journal of Pediatric Gastroenterology and Nutrition*. 2012; 55(5):556-8
701. Makola D, Krenitsky J, Parrish C, Dunston E, Shaffer HA, Yeaton P et al. Efficacy of enteral nutrition for the treatment of pancreatitis using standard enteral formula. *American Journal of Gastroenterology*. 2006; 101(10):2347-55
702. Makola D, Krenitsky J, Parrish CR. Enteral feeding in acute and chronic pancreatitis. *Gastrointestinal Endoscopy Clinics of North America*. 2007; 17(4):747-64
703. Malecka-Panas E, Gasiorowska A, Kropiwnicka A, Zlobinska A, Drzewoski J. Endocrine pancreatic function in patients after acute pancreatitis. *Hepato-Gastroenterology*. 2002; 49(48):1707-12
704. Malesci A, Gaia E, Fioretta A, Bocchia P, Ciravegna G, Cantor P et al. No effect of long-term treatment with pancreatic extract on recurrent abdominal pain in patients with chronic pancreatitis. *Scandinavian Journal of Gastroenterology*. 1995; 30(4):392-8
705. Malhotra S, Bhasin DK, Kumar R, Pandhi P, Rana S, Shafiq N. Pancreatic enzymes for chronic pancreatitis. *Cochrane Database of Systematic Reviews* 2007, Issue 1. Art. No.: CD006302. DOI: 10.1002/14651858.CD006302.
706. Mandal AK, Chaudhary S, Shrestha B, Paudel MS, Poudyal NS, Paudel BN et al. Efficacy of Prophylactic use of Ciprofloxacin and Metronidazole in Mild and Moderately Severe Acute Pancreatitis. *Jnma, Journal of the Nepal Medical Association*. 2017; 56(206):207-210
707. Manes G, Rabitti PG, Menchise A, Riccio E, Balzano A, Uomo G. Prophylaxis with meropenem of septic complications in acute pancreatitis: A randomized, controlled trial versus imipenem. *Pancreas*. 2003; 27(4):e79-83
708. Manes G, Uomo I, Menchise A, Rabitti PG, Ferrara EC, Uomo G. Timing of antibiotic prophylaxis in acute pancreatitis: a controlled randomized study with meropenem. *The American journal of gastroenterology*. 2006; 101(6):1348-53
709. Mangiavillano B, Manes G, Baron TH, Frego R, Dinelli M, Radaelli F et al. The use of double lasso, fully covered self-expandable metal stents with new "anchoring flap" system in the treatment of benign biliary diseases. *Digestive Diseases and Sciences*. 2014; 59(9):2308-13
710. Mao EQ, Tang YQ, Fei J, Qin S, Wu J, Li L et al. Fluid therapy for severe acute pancreatitis in acute response stage. *Chinese Medical Journal*. 2009; 122(2):169-73
711. Maraví-Poma E, Gener J, Alvarez-Lerma F, Olaechea P, Blanco A, Domínguez-Muñoz JE. Early antibiotic treatment (prophylaxis) of septic complications in severe acute necrotizing pancreatitis: A prospective, randomized, multicenter study comparing two regimens with imipenem-cilastatin. *Intensive Care Medicine*. 2003; 29(11):1974-80
712. Mariani A, Arcidiacono PG, Curioni S, Giussani A, Testoni PA. Diagnostic yield of ERCP and secretin-enhanced MRCP and EUS in patients with acute recurrent pancreatitis of unknown aetiology. *Digestive and Liver Disease*. 2009; 41(10):753-8
713. Marik PE, Zaloga GP. Meta-analysis of parenteral-nutrition versus enteral nutrition in patients with acute pancreatitis. *BMJ*. 2004; 328(7453):1407-1410

714. Marta K, Farkas N, Szabo I, Illes A, Vincze A, Par G et al. Meta-analysis of early nutrition: The benefits of enteral feeding compared to a nil per os diet not only in severe, but also in mild and moderate acute pancreatitis. *International Journal of Molecular Sciences*. 2016; 17(10):20
715. Marusic S, Sicaja M, Kujundzic M, Banic M, Jaksic O, Vrazic H. The utilization of antibiotics in the management of acute pancreatitis--experience from one transitional country university hospital. *Collegium Antropologicum*. 2008; 32(4):1189-94
716. Masson E, Chen JM, Audrezet MP, Cooper DN, Ferec C. A conservative assessment of the major genetic causes of idiopathic chronic pancreatitis: Data from a comprehensive analysis of PRSS1, SPINK1, CTSC and CFTR Genes in 253 young french patients. *PloS One*. 2013; 8(8):e73522
717. Mathew MJ, Parmar AK, Sahu D, Reddy PK. Laparoscopic necrosectomy in acute necrotizing pancreatitis: Our experience. *Journal of Minimal Access Surgery*. 2014; 10(3):126-31
718. Matlock J, Freeman ML. Endoscopic therapy of benign biliary strictures. *Reviews in Gastroenterological Disorders*. 2005; 5(4):206-214
719. Matsubayashi H, Kishida Y, Iwai T, Murai K, Yoshida M, Imai K et al. Transpapillary biliary stenting is a risk factor for pancreatic stones in patients with autoimmune pancreatitis. *Endoscopy International Open*. 2016; 4(8):E912-E917
720. Mattison LE, Coppage L, Alderman DF, Herlong JO, Sahn SA. Pleural effusions in the medical ICU: prevalence, causes, and clinical implications. *Chest*. 1997; 111(4):1018-23
721. Maurer C, Wagner JY, Schmid RM, Saugel B. Assessment of volume status and fluid responsiveness in the emergency department: A systematic approach. *Medizinische Klinik - Intensivmedizin und Notfallmedizin*. 2015; 112(4):326-333
722. Mauri G, Michelozzi C, Melchiorre F, Poretti D, Tramarin M, Pedicini V et al. Biodegradable biliary stent implantation in the treatment of benign bilioplastic-refractory biliary strictures: Preliminary experience. *European Radiology*. 2013; 23(12):3304-10
723. Mayerle J, Hoffmeister A, Werner J, Witt H, Lerch MM, Mossner J. Chronic pancreatitis - Definition, etiology, investigation and treatment. *Deutsches Arzteblatt International*. 2013; 110(22):387-393, 398-410
724. Mayerle J, Lerch MM. Is it necessary to distinguish between alcoholic and nonalcoholic chronic pancreatitis? *Journal of Gastroenterology*. 2007; 42(Suppl 17):127-130
725. Mayumi T, Ura H, Arata S, Kitamura N, Kiriya I, Shibuya K et al. Evidence-based clinical practice guidelines for acute pancreatitis: Proposals. *Journal of Hepato-Biliary-Pancreatic Surgery*. 2002; 9(4):413-22
726. Mayyas F, Fayers P, Kaasa S, Dale O. A systematic review of oxycodone in the management of chronic pain. *Journal of Pain and Symptom Management*. 2010; 39(2):296-308
727. Mazaki T, Ishii Y, Takayama T. Meta-analysis of prophylactic antibiotic use in acute necrotizing pancreatitis. *British Journal of Surgery*. 2006; 93(6):674-84
728. McClave SA, Chang WK, Dhaliwal R, Heyland DK. Nutrition support in acute pancreatitis: A systematic review of the literature. *Journal of Parenteral and Enteral Nutrition*. 2006; 30(2):143-56

729. McClave SA, Greene LM, Snider HL, Makk LJ, Cheadle WG, Owens NA et al. Comparison of the safety of early enteral vs parenteral nutrition in mild acute pancreatitis. *Journal of Parenteral and Enteral Nutrition*. 1997; 21(1):14-20
730. McClave SA, Spain DA, Snider HL. Nutritional management in acute and chronic pancreatitis. *Gastroenterology Clinics of North America*. 1998; 27(2):421-34
731. McClelland P, Murray A, Yaqoob M, Van Saene HK, Bone JM, Mostafa SM. Prevention of bacterial infection and sepsis in acute severe pancreatitis. *Annals of the Royal College of Surgeons of England*. 1992; 74(5):329-34
732. McCloy R. Chronic pancreatitis at Manchester, UK. Focus on antioxidant therapy. *Digestion*. 1998; 59(Suppl 4):36-48
733. McMahan MJ, Thomas WFG, Puntis MCA. Enteric coated microspheres of pancreatin (creon) in the treatment of pain associated with chronic pancreatitis: A double blind randomised placebo controlled crossover study. *Gut*. 1991; 32(Suppl 3):A344
734. Melman L, Azar R, Beddow K, Brunt LM, Halpin VJ, Eagon JC et al. Primary and overall success rates for clinical outcomes after laparoscopic, endoscopic, and open pancreatic cystgastrostomy for pancreatic pseudocysts. *Surgical Endoscopy*. 2009; 23(2):267-71
735. Menon K, Romagnuolo J, Barkun AN. Expandable metal biliary stenting in patients with recurrent premature polyethylene stent occlusion. *American Journal of Gastroenterology*. 2001; 96(5):1435-1440
736. Merdrignac A, Bergeat D, Rayar M, Harnoy Y, Turner K, Courtin-Tanguy L et al. Frey procedure combined with biliary diversion in chronic pancreatitis. *Surgery*. 2016; 160(5):1264-1270
737. Mergener K, Kozarek RA. Therapeutic pancreatic endoscopy. *Endoscopy*. 2005; 37(3):201-207
738. Midha S, Khajuria R, Shastri S, Kabra M, Garg PK. Idiopathic chronic pancreatitis in India: Phenotypic characterisation and strong genetic susceptibility due to SPINK1 and CFTR gene mutations. *Gut*. 2010; 59(6):800-807
739. Mier J, Luque-De Leon E, Castillo A, Robledo F, Blanco R. Early versus late necrosectomy in severe necrotizing pancreatitis. *American Journal of Surgery*. 1997; 173(2):71-75
740. Mikami Y, Takeda K, Omura N, Abe H, Fukuyama S, Motoi F et al. New strategy for acute necrotizing pancreatitis: Continuous Regional Arterial Infusion (CRAI) therapy. *Roczniki Akademii Medycznej w Białymstoku (1995)*. 2005; 50:101-105
741. Milek T, Ciostek P, Kielar M, Jarosz M, Slowik K, Petryka R et al. Multiple orifices are better than single in the endoscopic treatment of pancreatic pseudocysts. *Turkish Journal of Gastroenterology*. 2014; 25(1):59-62
742. Mirtallo JM, Forbes A, McClave SA, Jensen GL, Waitzberg DL, Davies AR et al. International consensus guidelines for nutrition therapy in pancreatitis. *Journal of Parenteral & Enteral Nutrition*. 2012; 36(3):284-91
743. Mitchell RMS, Byrne MF. Biliary emergencies: Pancreatitis, cholangitis, and more. *Seminars in Gastrointestinal Disease*. 2003; 14(2):77-86
744. Mithofer K, Mueller PR, Warshaw AL. Interventional and surgical treatment of pancreatic abscess. *World Journal of Surgery*. 1997; 21(2):162-168

745. Mittal R, Dangoor A. Paracentesis in the management of ascites. *British Journal of Hospital Medicine*. 2007; 68(9):M162-M165
746. Miyakawa H, Suga T, Okamura K. Usefulness of endoscopic ultrasonography for the diagnosis of chronic pancreatitis. *Journal of Gastroenterology*. 2007; 42(Suppl 17):85-89
747. Mizuno N, Bhatia V, Hosoda W, Sawaki A, Hoki N, Hara K et al. Histological diagnosis of autoimmune pancreatitis using EUS-guided trucut biopsy: A comparison study with EUS-FNA. *Journal of Gastroenterology*. 2009; 44(7):742-750
748. Mizushima T, Ochi K, Ichimura M, Kiura K, Harada H, Koide N. Pancreatic enzyme supplement improves dysmotility in chronic pancreatitis patients. *Journal of Gastroenterology and Hepatology*. 2004; 19(9):1005-9
749. Mobius C, Max D, Uhlmann D, Gump K, Behrbohm J, Horvath K et al. Five-year follow-up of a prospective non-randomised study comparing duodenum-preserving pancreatic head resection with classic Whipple procedure in the treatment of chronic pancreatitis. *Langenbecks Archives of Surgery*. 2007; 392(3):359-64
750. Moggia E, Koti R, Belgaumkar AP, Fazio F, Pereira SP, Davidson BR et al. Pharmacological interventions for acute pancreatitis. *Cochrane Database of Systematic Reviews* 2017, Issue Art. No.: 28431202. DOI: <https://dx.doi.org/10.1002/14651858.CD011384.pub2>.
751. Mohseni Salehi Monfared SS, Vahidi H, Abdolghaffari AH, Nikfar S, Abdollahi M. Antioxidant therapy in the management of acute, chronic and post-ERCP pancreatitis: a systematic review. *World Journal of Gastroenterology*. 2009; 15(36):4481-90
752. Mok SR, Ho HC, Shah P, Patel M, Gaughan JP, Elfant AB. Lactated ringer's solution in combination with rectal indomethacin for prevention of post-ERCP pancreatitis and readmission: A prospective randomized, double-blinded, placebo-controlled trial. *Gastrointestinal Endoscopy*. 2016; 85(5):1005-1013
753. Mole DJ, Hall A, McKeown D, Garden OJ, Parks RW. Detailed fluid resuscitation profiles in patients with severe acute pancreatitis. *HPB*. 2011; 13(1):51-8
754. Monkemuller KE, Kahl S, Malfertheiner P. Endoscopic therapy of chronic pancreatitis. *Digestive Diseases*. 2004; 22(3):280-91
755. Moole H, Jaeger A, Bechtold ML, Forcione D, Taneja D, Puli SR. Success of extracorporeal shock wave lithotripsy in chronic calcific pancreatitis management: A meta-analysis and systematic review. *Pancreas*. 2016; 45(5):651-8
756. Moorthy N, Raveesha A, Prabhakar K. Pancreaticopleural fistula and mediastinal pseudocyst: an unusual presentation of acute pancreatitis. *Annals of Thoracic Medicine*. 2007; 2(3):122-3
757. Morgan DE, Smith JK, Hawkins K, Wilcox CM. Endoscopic stent therapy in advanced chronic pancreatitis: relationships between ductal changes, clinical response, and stent patency. *American Journal of Gastroenterology*. 2003; 98(4):821-6
758. Morgan KA, Adams DB. Management of internal and external pancreatic fistulas. *Surgical Clinics of North America*. 2007; 87(6):1503-1513
759. Morishima T, Kawashima H, Ohno E, Yamamura T, Funasaka K, Nakamura M et al. Prospective multicenter study on the usefulness of EUS-guided FNA biopsy for the diagnosis of autoimmune pancreatitis. *Gastrointestinal Endoscopy*. 2016; 84(2):241-248
760. Morteale KJ, Girshman J, Szejnfeld D, Ashley SW, Erturk SM, Banks PA et al. CT-guided percutaneous catheter drainage of acute necrotizing pancreatitis: clinical experience and

- observations in patients with sterile and infected necrosis. *American Journal of Roentgenology*. 2009; 192(1):110-6
761. Morton JM, Brown A, Galanko JA, Norton JA, Grimm IS, Behrns KE. A national comparison of surgical versus percutaneous drainage of pancreatic pseudocysts: 1997-2001. *Journal of Gastrointestinal Surgery*. 2005; 9(1):15-20; discussion 20-1
762. Mossner J. Is there a place for pancreatic enzymes in the treatment of pain in chronic pancreatitis? *Digestion*. 1993; 54(Suppl 2):35-9
763. Mossner J, Secknus R, Meyer J, Niederau C, Adler G. Treatment of pain with pancreatic extracts in chronic pancreatitis: Results of a prospective placebo-controlled multicenter trial. *Digestion*. 1992; 53(1-2):54-66
764. Mosztbacher D, Farkas N, Solymar M, Par G, Bajor J, Szucs A et al. Restoration of energy level in the early phase of acute pediatric pancreatitis. *World Journal of Gastroenterology*. 2017; 23(6):957-963
765. Mouli VP, Sreenivas V, Garg PK. Efficacy of conservative treatment, without necrosectomy, for infected pancreatic necrosis: A systematic review and meta-analysis. *Gastroenterology*. 2013; 144(2):333-340.e2
766. Mourad MM, Evans R, Kalidindi V, Navaratnam R, Dvorkin L, Bramhall SR. Prophylactic antibiotics in acute pancreatitis: endless debate. *Annals of the Royal College of Surgeons of England*. 2017; 99(2):107-112
767. Moyshenyat I, Mandell E, Tenner S. Antibiotic prophylaxis of pancreatic infection in patients with necrotizing pancreatitis: Rationale, evidence, and recommendations. *Current Gastroenterology Reports*. 2006; 8(2):121-6
768. Muhl S, Wente MN, Schmidt J, Buchler MW. Evidence-based surgery in chronic pancreatitis. *European Surgery - Acta Chirurgica Austriaca*. 2009; 41(6):286-292
769. Mukai S, Itoi T, Baron TH, Sofuni A, Itokawa F, Kurihara T et al. Endoscopic ultrasound-guided placement of plastic vs. biflanged metal stents for therapy of walled-off necrosis: A retrospective single-center series. *Endoscopy*. 2015; 47(1):47-55
770. Mukai S, Itoi T, Sofuni A, Itokawa F, Kurihara T, Tsuchiya T et al. Expanding endoscopic interventions for pancreatic pseudocyst and walled-off necrosis. *Journal of Gastroenterology*. 2015; 50(2):211-20
771. Mukai S, Itoi T, Sofuni A, Itokawa F, Kurihara T, Tsuchiya T et al. Novel single transluminal gateway transcystic multiple drainages after EUS-guided drainage for complicated multilocular walled-off necrosis (with videos). *Gastrointestinal Endoscopy*. 2014; 79(3):531-5
772. Muller MW, Friess H, Martin DJ, Hinz U, Dahmen R, Buchler MW. Long-term follow-up of a randomized clinical trial comparing Beger with pylorus-preserving Whipple procedure for chronic pancreatitis. *British Journal of Surgery*. 2008; 95(3):350-6
773. Munene G, Dixon E, Sutherland F. Open transgastric debridement and internal drainage of symptomatic non-infected walled-off pancreatic necrosis. *HPB*. 2011; 13(4):234-239
774. Muniraj T, Jamidar PA. Fully covered metal biliary stents: Current and future uses. *Practical Gastroenterology*. 2013; 37(11):21-38
775. Munoz-Bongrand N, Sauvanet A, Denys A, Sibert A, Vilgrain V, Belghiti J. Conservative management of pancreatic fistula after pancreaticoduodenectomy with pancreaticogastrostomy. *Journal of the American College of Surgeons*. 2004; 199(2):198-203

776. Myburgh JA. The Hepp-Couinaud approach to strictures of the bile ducts: I. Injuries, choledochal cysts, and pancreatitis. *Annals of Surgery*. 1993; 218(5):615-620
777. Nabi Z, Basha J, Reddy DN. Endoscopic management of pancreatic fluid collections-revisited. *World Journal of Gastroenterology*. 2017; 23(15):2660-2672
778. Nair RR, Lowy AM, McIntyre B, Sussman JJ, Matthews JB, Ahmad SA. Fistulojejunostomy for the management of refractory pancreatic fistula. *Surgery*. 2007; 142(4):636-42; discussion 642.e1
779. Nakad A, Piessevaux H, Marot JC, Hoang P, Geubel A, Van Steenberg W et al. Is early enteral nutrition in acute pancreatitis dangerous? About 20 patients fed by an endoscopically placed nasogastrojejunal tube. *Pancreas*. 1998; 17(2):187-93
780. Nakahara K, Okuse C, Suetani K, Michikawa Y, Kobayashi S, Otsubo T et al. Covered metal stenting for malignant lower biliary stricture with pancreatic duct obstruction: Is endoscopic sphincterotomy needed? *Gastroenterology Research and Practice*. 2013; 2013:375613
781. Nakamura T, Sata M, Suzuki K, Moriwaki H, Fukui H, Fujiyama S et al. Open-labeled randomized controlled trial to compare diuretic therapy with recombinant human serum albumin and diuretic therapy for therapeutic treatment of ascites in patients with advanced liver cirrhosis: An exploratory trial. *Hepatology Research*. 2014; 44(5):502-514
782. Nakamura T, Takebe K, Kudoh K, Ishii M, Imamura K, Kikuchi H et al. Effects of pancreatic digestive enzymes, sodium bicarbonate, and a proton pump inhibitor on steatorrhea caused by pancreatic diseases. *Journal of International Medical Research*. 2012; 23(1):37-47
783. Nakanuma Y. A novel approach to biliary tract pathology based on similarities to pancreatic counterparts: Is the biliary tract an incomplete pancreas? *Pathology International*. 2010; 60(6):419-29
784. Nandi B, Garg P, Bhardwaj P, Prakash S, Tandon R. Efficacy of antioxidants for pain relief in patients with chronic pancreatitis: A randomized controlled trial. *Indian Journal of Gastroenterology*. 2002; 21:A43
785. Naoum E, Zavos A, Goudis K, Sarros C, Pitsargiotis E, Karamouti M et al. Pancreatic pseudocysts: 10 years of experience. *Journal of Hepato-Biliary-Pancreatic Surgery*. 2003; 10(5):373-6
786. National Clinical Guideline Centre. Intravenous fluid therapy in adults in hospital. NICE clinical guideline 174. London. National Clinical Guideline Centre, 2013. Available from: <http://guidance.nice.org.uk/CG174>
787. National Institute for Health and Care Excellence. Developing NICE guidelines: the manual. London. National Institute for Health and Care Excellence, 2014. Available from: <http://www.nice.org.uk/article/PMG20/chapter/1%20Introduction%20and%20overview>
788. Navalho M, Pires F, Duarte A, Goncalves A, Alexandrino P, Tavora I. Percutaneous drainage of infected pancreatic fluid collections in critically ill patients: correlation with C-reactive protein values. *Clinical Imaging*. 2006; 30(2):114-9
789. Navaneethan U, Jayanthi V. Nutritional support in acute pancreatitis: When to start oral feeds. *Minerva Gastroenterologica e Dietologica*. 2010; 56(1):65-9
790. Nealon WH, Urrutia F. Long-term follow-up after bilioenteric anastomosis for benign bile duct stricture. *Annals of Surgery*. 1996; 223(6):639-648

791. NHS Business Services Authority. NHS electronic drug tariff September 2016. Available from: <http://www.nhsbsa.nhs.uk/PrescriptionServices/4940.aspx> Last accessed: 28/09/2017.
792. NHS Supply Chain Catalogue. NHS Supply Chain, 2015. Available from: <http://www.supplychain.nhs.uk/>
793. Ni Q, Yun L, Roy M, Shang D. Advances in surgical treatment of chronic pancreatitis. *World Journal of Surgical Oncology*. 2015; 13:34
794. Nicholson LJ. Acute pancreatitis: Should we use antibiotics? *Current Gastroenterology Reports*. 2011; 13(4):336-43
795. Niederau C, Hippenstiel J. Conservative management of acute pancreatitis: Complications and outcome in a community-based hospital. *Pancreas*. 2006; 32(1):67-79
796. Niedergethmann M, Dusch N, Widyaningsih R, Weiss C, Kienle P, Post S. Risk-adapted anastomosis for partial pancreaticoduodenectomy reduces the risk of pancreatic fistula: A pilot study. *World Journal of Surgery*. 2010; 34(7):1579-86
797. Niemann T, Madsen LG, Larsen S, Thorsgaard N. Opioid treatment of painful chronic pancreatitis: Transdermal fentanyl versus sustained-release morphine. *International Journal of Pancreatology*. 2000; 27(3):235-240
798. Nieuwenhuijs VB, Besselink MG, van Minnen LP, Gooszen HG. Surgical management of acute necrotizing pancreatitis: A 13-year experience and a systematic review. *Scandinavian Journal of Gastroenterology Supplement*. 2003; 239:111-6
799. Nikkola J, Raty S, Laukkarinen J, Seppanen H, Lappalainen-Lehto R, Jarvinen S et al. Abstinence after first acute alcohol-associated pancreatitis protects against recurrent pancreatitis and minimizes the risk of pancreatic dysfunction. *Alcohol and Alcoholism*. 2013; 48(4):483-6
800. Nikou GC, Giamarellos-Bourboulis EJ, Grecka P, Toumpanakis C, Giannikopoulos G, Katsilambros N. Effect of octreotide administration on serum interleukin-6 (IL-6) levels of patients with acute edematous pancreatitis. *Hepato-Gastroenterology*. 2004; 51(56):599-602
801. Nitsche R, Fölsch UR, Lüdtker R, Hilgers RA, Creutzfeldt W. Urgent ERCP in all cases of acute biliary pancreatitis? A prospective randomized multicenter study. *European Journal of Medical Research*. 1995; 1(3):127-31
802. Noda A, Okuyama M, Murayama H, Takeuchi K, Yokota T, Kobayashi T et al. Dissolution of pancreatic stones by oral trimethadione in patients with chronic calcific pancreatitis. *Journal of Gastroenterology and Hepatology*. 1994; 9(5):478-85
803. Nordback I, Pelli H, Lappalainen-Lehto R, Jarvinen S, Raty S, Sand J. The recurrence of acute alcohol-associated pancreatitis can be reduced: A randomized controlled trial. *Gastroenterology*. 2009; 136(3):848-855
804. Nordback I, Pelli H, Lappalainen-Lehto R, Sand J. Is it long-term continuous drinking or the post-drinking withdrawal period that triggers the first acute alcoholic pancreatitis? *Scandinavian Journal of Gastroenterology*. 2005; 40(10):1235-9
805. Nordback I, Sand J. The value of the endoscopic pancreatogram in peritoneal or pleural pancreatic fistula. *International Surgery*. 1996; 81(2):184-6
806. Nordback I, Sand J, Saaristo R, Paajanen H. Early treatment with antibiotics reduces the need for surgery in acute necrotizing pancreatitis--a single-center randomized study. *Journal of Gastrointestinal Surgery*. 2001; 5(2):113-8; discussion 118-20

807. Nordeen N, Thomson A. QA and patient satisfaction in ERCP: The value of the day 14 phone call. *Journal of Gastroenterology and Hepatology*. 2012; 27(Suppl 4):131
808. Nussinson E, Cairns SR, Vaira D, Dowsett JF, Mason RR. A 10 year single centre experience of percutaneous and endoscopic extraction of bile duct stones with T tube in situ. *Gut*. 1991; 32(9):1040-3
809. Nwariaku FE, Terracina A, Mileski WJ, Minei JP, Carrico CJ. Is octreotide beneficial following pancreatic injury? *American Journal of Surgery*. 1995; 170(6):582-5
810. O'Brien SM, Hatfield ARW, Craig PI, Williams SP. A 5-year follow-up of self-expanding metal stents in the endoscopic management of patients with benign bile duct strictures. *European Journal of Gastroenterology and Hepatology*. 1998; 10(2):141-145
811. O'Keefe SJ, Cariem AK, Levy M. The exacerbation of pancreatic endocrine dysfunction by potent pancreatic exocrine supplements in patients with chronic pancreatitis. *Journal of Clinical Gastroenterology*. 2001; 32(4):319-23
812. O'Toole D, Vullierme MP, Ponsot P, Maire F, Calmels V, Hentic O et al. Diagnosis and management of pancreatic fistulae resulting in pancreatic ascites or pleural effusions in the era of helical CT and magnetic resonance imaging. *Gastroenterologie Clinique et Biologique*. 2007; 31(8-9 Pt 1):686-93
813. Ohwada M, Watanabe N, Maeda M, Gotoh M, Teramoto J, Moriya H et al. New endoscopic treatment for chronic pancreatitis, using contrast media containing ulinastatin and prednisolone. *Journal of Gastroenterology*. 1997; 32(2):216-221
814. Okabayashi T, Kobayashi M, Sugimoto T, Namikawa T, Okamoto K, Hokimoto N et al. Postoperative pancreatic fistula following distal pancreatectomy for pancreatic neoplasm; can pancreatic fistula be prevented? *Hepato-Gastroenterology*. 2004; 51(60):1838-41
815. Okamoto T, Gocho T, Futagawa Y, Fujioka S, Yanaga K, Ikeda K et al. Does preoperative pancreatic duct stenting prevent pancreatic fistula after surgery? A cohort study. *International Journal of Surgery*. 2008; 6(3):210-3
816. Olah A, Pardavi G, Belagy T, Nagy A, Issekutz A, Mohamed GE. Early nasojejunal feeding in acute pancreatitis is associated with a lower complication rate. *Nutrition*. 2002; 18(3):259-62
817. Olah A, Romics L, Jr. Evidence-based use of enteral nutrition in acute pancreatitis. *Langenbecks Archives of Surgery*. 2010; 395(4):309-16
818. Olah A, Romics L, Jr. Enteral nutrition in acute pancreatitis: a review of the current evidence. *World Journal of Gastroenterology*. 2014; 20(43):16123-31
819. Olakowski M, Mieczkowska-Palacz H, Olakowska E, Lampe P. Surgical management of pancreaticopleural fistulas. *Acta Chirurgica Belgica*. 2009; 109(6):735-40
820. Olazabal A, Fuller R. Failure of glucagon in the treatment of alcoholic pancreatitis. *Gastroenterology*. 1978; 74(3):489-91
821. Oldach D. Antibiotic prophylaxis for necrotising pancreatitis. *Lancet*. 1995; 346(8976):652
822. Ondrejka P, Faller J, Siket F, Toth G, Sugar I, Forgacs B et al. Isolated massive pleural effusion caused by pancreatico-pleural fistula. *Zeitschrift für Gastroenterologie*. 2000; 38(7):583-5
823. Oracz G, Pertkiewicz J, Oralewska B, Dadalski M, Kierkus J, Celinska-Cedro D et al. Pancreatic pseudocysts in children with chronic pancreatitis. *Pediatrics Wspolczesna*. 2010; 12(4):172-174

824. Organisation for Economic Co-operation and Development (OECD). Purchasing power parities (PPP). 2017. Available from: <https://data.oecd.org/conversion/purchasing-power-parities-ppp.htm> Last accessed: 25/08/2017.
825. Oria A, Cimmino D, Ocampo C, Silva W, Kohan G, Zandalazini H et al. Early endoscopic intervention versus early conservative management in patients with acute gallstone pancreatitis and biliopancreatic obstruction: a randomized clinical trial. *Annals of Surgery*. 2007; 245(1):10-7
826. Pai CG, Suvarna D, Bhat G. Endoscopic treatment as first-line therapy for pancreatic ascites and pleural effusion. *Journal of Gastroenterology and Hepatology*. 2009; 24(7):1198-202
827. Paisley P, Kinsella J. Pharmacological management of pain in chronic pancreatitis. *Scottish Medical Journal*. 2014; 59(1):71-9
828. Palani Velu LK, Chandrabalan VV, Jabbar S, McMillan DC, McKay CJ, Carter CR et al. Serum amylase on the night of surgery predicts clinically significant pancreatic fistula after pancreaticoduodenectomy. *HPB*. 2014; 16(7):610-619
829. Palermo JJ, Lin TK, Hornung L, Alexander Valencia C, Mathur A, Jackson K et al. Genophenotypic analysis of pediatric patients with acute recurrent and chronic pancreatitis. *Pancreas*. 2016; 45(9):1347-1352
830. Pandey S, Shetty SA, Janarthanan K, Balalakshmoji D, Sen KK, Leelakrishnan V. Pancreaticopleural and bronchial fistulae and associated pseudocysts: Case series. *Journal of the Pancreas*. 2014; 15(5):478-84
831. Pandey SK, Ahuja V, Joshi YK, Sharma MP. A randomized trial of oral refeeding compared with jejunal tube refeeding in acute pancreatitis. *Indian Journal of Gastroenterology*. 2004; 23(2):53-5
832. Pandya A, Xia XJ, Blanton SH, Landa B, Markello T, Nance WE. Implications of molecular diagnostic testing in families with hereditary pancreatitis. *Genetic testing*. 1997; 1(3):207-211
833. Papachristou GI, Takahashi N, Chahal P, Sarr MG, Baron TH. Peroral endoscopic drainage/debridement of walled-off pancreatic necrosis. *Annals of Surgery*. 2007; 245(6):943-951
834. Papakostas C, Smailis D, Avgerinos C, Sofianou K, Lytras D, Kolibiris C et al. Antibiotic prophylaxis in acute pancreatitis. *Annals of Gastroenterology*. 2000; 13(4):299-306
835. Parekh D. Laparoscopic-assisted pancreatic necrosectomy: A new surgical option for treatment of severe necrotizing pancreatitis. *Archives of Surgery*. 2006; 141(9):895-902; discussion 902-3
836. Parekh D, Segal I. Pancreatic ascites and effusion. Risk factors for failure of conservative therapy and the role of octreotide. *Archives of Surgery*. 1992; 127(6):707-12
837. Paris JC. A multicentre double-blind placebo-controlled study of the effect of a pancreatic enzyme formulation (Panzytrat 25 000) on impaired lipid digestion in adults with chronic pancreatitis. *Drug Investigation*. 1993; 5(4):229-237
838. Park A, Latif SU, Shah AU, Tian J, Werlin S, Hsiao A et al. Changing referral trends of acute pancreatitis in children: A 12-year single-center analysis. *Journal of Pediatric Gastroenterology and Nutrition*. 2009; 49(3):316-22
839. Park DE, Chae KM. Chylous ascites caused by acute pancreatitis with portal vein thrombosis. *Journal of the Korean Surgical Society*. 2011; 81(Suppl 1):S64-8

840. Park DH. A randomized controlled trial of antioxidant supplementation for pain relief in patients with chronic pancreatitis. *Korean Journal of Gastroenterology*. 2009; 53(5):331-2
841. Park DH, Kim MH, Moon SH, Lee SS, Seo DW, Lee SK. Feasibility and safety of placement of a newly designed, fully covered self-expandable metal stent for refractory benign pancreatic ductal strictures: A pilot study (with video). *Gastrointestinal Endoscopy*. 2008; 68(6):1182-1189
842. Park JS, Lee SS, Song TJ, Park DH, Seo DW, Lee SK et al. Long-term outcomes of covered self-expandable metal stents for treating benign biliary strictures. *Endoscopy*. 2016; 48(5):440-7
843. Pascual I, Sabater L, Anon R, Calvete J, Pacheco G, Munoz E et al. Surgical versus nonsurgical treatment of infected pancreatic necrosis: More arguments to change the paradigm. *Journal of Gastrointestinal Surgery*. 2013; 17(9):1627-1633
844. Patil V, Padhiyar R, Chavan S, Kamtalwar S. Pancreatitis presenting as a pleural effusion. *Journal of the Association of Physicians of India*. 2016; 64(1):104
845. Pausawasadi N, Soontornmanokul T, Rerknimitr R. Role of fully covered self-expandable metal stent for treatment of benign biliary strictures and bile leaks. *Korean Journal of Radiology*. 2012; 13(Suppl 1):S67-S73
846. Pearson EG, Scaife CL, Mulvihill SJ, Glasgow RE. Roux-en-Y drainage of a pancreatic fistula for disconnected pancreatic duct syndrome after acute necrotizing pancreatitis. *HPB*. 2012; 14(1):26-31
847. Pederzoli P, Bassi C, Vesentini S, Campedelli A. A randomized multicenter clinical trial of antibiotic prophylaxis of septic complications in acute necrotizing pancreatitis with imipenem. *Surgery, Gynecology and Obstetrics*. 1993; 176(5):480-3
848. Pelley JR, Gordon SR, Gardner TB. Abnormal duodenal [HCO₃⁻] following secretin stimulation develops sooner than endocrine insufficiency in minimal change chronic pancreatitis. *Pancreas*. 2012; 41(3):481-4
849. Pendharkar SA, Plank LD, Windsor JA, Petrov MS. Quality of life in a randomized trial of nasogastric tube feeding in acute pancreatitis. *Journal of Parenteral and Enteral Nutrition*. 2016; 40(5):693-8
850. Pericleous M, Sarnowski A, Moore A, Fijten R, Zaman M. The clinical management of abdominal ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: A review of current guidelines and recommendations. *European Journal of Gastroenterology and Hepatology*. 2016; 28(3):e10-8
851. Perri V, Boskoski I, Tringali A, Familiari P, Mutignani M, Marmo R et al. Fully covered self-expandable metal stents in biliary strictures caused by chronic pancreatitis not responding to plastic stenting: A prospective study with 2 years of follow-up. *Gastrointestinal Endoscopy*. 2012; 75(6):1271-1277
852. Perri V, Familiari P, Tringali A, Boskoski I, Costamagna G. Plastic biliary stents for benign biliary diseases. *Gastrointestinal Endoscopy Clinics of North America*. 2011; 21(3):405-33, viii
853. Petrov MS, Kukosh MV, Emelyanov NV. A randomized controlled trial of enteral versus parenteral feeding in patients with predicted severe acute pancreatitis shows a significant reduction in mortality and in infected pancreatic complications with total enteral nutrition. *Digestive Surgery*. 2006; 23(5-6):336-44; discussion 344-5

854. Petrov MS, McIlroy K, Grayson L, Phillips AR, Windsor JA. Early nasogastric tube feeding versus nil per os in mild to moderate acute pancreatitis: A randomized controlled trial. *Clinical Nutrition*. 2013; 32(5):697-703
855. Petrov MS, Pylypchuk RD, Emelyanov NV. Systematic review: nutritional support in acute pancreatitis. *Alimentary Pharmacology and Therapeutics*. 2008; 28(6):704-12
856. Petrov MS, Pylypchuk RD, Uchugina AF. A systematic review on the timing of artificial nutrition in acute pancreatitis. *British Journal of Nutrition*. 2009; 101(6):787-93
857. Petrov MS, van Santvoort HC, Besselink MG, van der Heijden GJ, Windsor JA, Gooszen HG. Enteral nutrition and the risk of mortality and infectious complications in patients with severe acute pancreatitis: a meta-analysis of randomized trials. *Archives of Surgery*. 2008; 143(11):1111-7
858. Petrov MS, Whelan K. Comparison of complications attributable to enteral and parenteral nutrition in predicted severe acute pancreatitis: a systematic review and meta-analysis. *British Journal of Nutrition*. 2010; 103(9):1287-95
859. Petrov MS, Zagainov VE. Influence of enteral versus parenteral nutrition on blood glucose control in acute pancreatitis: A systematic review. *Clinical Nutrition*. 2007; 26(5):514-23
860. Pezzilli R. Etiology of chronic pancreatitis: Has it changed in the last decade? *World Journal of Gastroenterology*. 2009; 15(38):4737-4740
861. Pezzilli R. Alcohol abuse and pancreatic diseases: An overview. *Recent Patents on Inflammation & Allergy Drug Discovery*. 2015; 9(2):102-6
862. Pezzilli R, Fantini L, Morselli-Labate AM. New approaches for the treatment of acute pancreatitis. *Journal of the Pancreas*. 2006; 7(1):79-91
863. Pezzilli R, Talamini G, Gullo L. Behaviour of serum pancreatic enzymes in chronic pancreatitis. *Digestive and Liver Disease*. 2000; 32(3):233-237
864. Phillips BJ, Fabrega AJ. Embolization of a mesenteric arteriovenous fistula following pancreatic allograft: The steal effect. *Transplantation*. 2000; 70(10):1529-31
865. Piascik M, Rydzewska G, Milewski J, Olszewski S, Furmanek M, Walecki J et al. The results of severe acute pancreatitis treatment with continuous regional arterial infusion of protease inhibitor and antibiotic: A randomized controlled study. *Pancreas*. 2010; 39(6):863-7
866. Piascik M, Rydzewska G, Wereszczynska-Siemiatkowska U, Milewski J, Madejska I, Skrodzka D et al. The efficacy of meropenem in the prevention of septic complications in severe acute pancreatitis in humans. *Gastroenterologia Polska*. 2004; 11(1):35-39
867. Piciocchi M, Merola E, Marignani M, Signoretti M, Valente R, Cocomello L et al. Nasogastric or nasointestinal feeding in severe acute pancreatitis. *World Journal of Gastroenterology*. 2010; 16(29):3692-6
868. Piette JD, Barnett PG, Moos RH. First-time admissions with alcohol-related medical problems: A 10-year follow-up of a national sample of alcoholic patients. *Journal of Studies on Alcohol*. 1998; 59(1):89-96
869. Pisters PWT, Ranson JHC. Nutritional support for acute pancreatitis. *Surgery, Gynecology and Obstetrics*. 1992; 175(3):275-284
870. Platell C, Cooper D, Hall JC. A meta-analysis of peritoneal lavage for acute pancreatitis. *Journal of Gastroenterology and Hepatology*. 2001; 16(6):689-93

871. Poddar U, Yachha SK, Borkar V, Srivastava A. Is acute recurrent pancreatitis in children a precursor of chronic pancreatitis? A long-term follow-up study of 93 cases. *Digestive and Liver Disease*. 2017; 49(7):796-801
872. Poddar U, Yachha SK, Borkar V, Srivastava A, Saraswat VA. Clinical profile and treatment outcome of chronic pancreatitis in children: a long-term follow-up study of 156 cases. *Scandinavian Journal of Gastroenterology*. 2017; 52(6-7):773-778
873. Poincloux L, Rouquette O, Buc E, Privat J, Pezet D, Dapoigny M et al. Endoscopic ultrasound-guided biliary drainage after failed ERCP: Cumulative experience of 101 procedures at a single center. *Endoscopy*. 2015; 47(9):794-801
874. Poley JW, Cahen DL, Metselaar HJ, van Buuren HR, Kazemier G, van Eijck CH et al. A prospective group sequential study evaluating a new type of fully covered self-expandable metal stent for the treatment of benign biliary strictures (with video). *Gastrointestinal Endoscopy*. 2012; 75(4):783-9
875. Powell JJ, Campbell E, Johnson CD, Siriwardena AK. Survey of antibiotic prophylaxis in acute pancreatitis in the UK and Ireland. *British Journal of Surgery*. 1999; 86(3):320-2
876. Powell JJ, Miles R, Siriwardena AK. Antibiotic prophylaxis in the initial management of severe acute pancreatitis. *British Journal of Surgery*. 1998; 85(5):582-7
877. Powell JJ, Murchison JT, Fearon KC, Ross JA, Siriwardena AK. Randomized controlled trial of the effect of early enteral nutrition on markers of the inflammatory response in predicted severe acute pancreatitis. *British Journal of Surgery*. 2000; 87(10):1375-81
878. Prabhudesai PP, Mahashur AA, Mehta N, Ajay R. Exudative pleural effusions in patients over forty years of age--an analysis of seventy-six patients. *Journal of Postgraduate Medicine*. 1993; 39(4):190-3
879. Pratt WB, Steinbrook RA, Maithel SK, Vanounou T, Callery MP, Vollmer CM, Jr. Epidural analgesia for pancreatoduodenectomy: A critical appraisal. *Journal of Gastrointestinal Surgery*. 2008; 12(7):1207-20
880. Puli SR, Reddy JB, Bechtold ML, Antillon MR, Brugge WR. EUS-guided celiac plexus neurolysis for pain due to chronic pancreatitis or pancreatic cancer pain: A meta-analysis and systematic review *Digestive Diseases and Sciences*. 2009; 54(11):2330-2337
881. Pungpapong S, Noh KW, Woodward TA, Wallace MB, Al-Haddad M, Raimondo M. Endoscopic ultrasound and IL-8 in pancreatic juice to diagnose chronic pancreatitis. *Pancreatology*. 2007; 7(5-6):491-496
882. Pungpapong S, Wallace MB, Woodward TA, Noh KW, Raimondo M. Accuracy of endoscopic ultrasonography and magnetic resonance cholangiopancreatography for the diagnosis of chronic pancreatitis: A prospective comparison study. *Journal of Clinical Gastroenterology*. 2007; 41(1):88-93
883. Pupelis G, Austrums E, Jansone A, Sprucs R, Wehbi H. Randomised trial of safety and efficacy of postoperative enteral feeding in patients with severe pancreatitis: Preliminary report. *European Journal of Surgery*. 2000; 166(5):383-7
884. Pupelis G, Fokin V, Zeiza K, Kazaka I, Pereca J, Skuja V et al. Ultrasound-assisted focused open necrosectomy in the treatment of necrotizing pancreatitis. *Journal of the Pancreas*. 2015; 16(2):150-158

885. Pupelis G, Snippe K, Plaudis H, Rudakovska M. Early oral feeding in acute pancreatitis: an alternative approach to tube feeding. Preliminary report. *Acta Chirurgica Belgica*. 2006; 106(2):181-6
886. Pupelis G, Zeiza K, Plaudis H, Suhova A. Conservative approach in the management of severe acute pancreatitis: Eight-year experience in a single institution. *HPB*. 2008; 10(5):347-55
887. Puylaert M, Kapural L, Van Zundert J, Peek D, Lataster A, Mekhail N et al. 26. Pain in chronic pancreatitis. *Pain Practice*. 2011; 11(5):492-505
888. Quan H, Wang X, Guo C. A meta-analysis of enteral nutrition and total parenteral nutrition in patients with acute pancreatitis. *Gastroenterology Research and Practice*. 2011; 2011:698248
889. Quartuccio M, Hall E, Singh V, Makary MA, Hirose K, Desai N et al. Glycemic predictors of insulin independence after total pancreatectomy with islet autotransplantation. *Journal of Clinical Endocrinology and Metabolism*. 2017; 102(3):801-809
890. Rada G, Pena J. Is antibiotic prophylaxis beneficial in acute pancreatitis?--First update. *Medwave*. 2015; 15(3):e6125
891. Raizner A, Phatak UP, Baker K, Patel MG, Husain SZ, Pashankar DS. Acute necrotizing pancreatitis in children. *Journal of Pediatrics*. 2013; 162(4):788-92
892. Ramesh H, Reddy N, Bhatia S, Rajkumar JS, Bapaye A, Kini D et al. A 51-week, open-label clinical trial in India to assess the efficacy and safety of pancreatin 40000 enteric-coated minimicrospheres in patients with pancreatic exocrine insufficiency due to chronic pancreatitis. *Pancreatology*. 2013; 13(2):133-9
893. Ramesh J, Bang JY, Trevino J, Varadarajulu S. Endoscopic ultrasound-guided drainage of pancreatic fluid collections in children. *Journal of Pediatric Gastroenterology and Nutrition*. 2013; 56(1):30-5
894. Ramos-De la Medina A, Sarr MG. Somatostatin analogues in the prevention of pancreas-related complications after pancreatic resection. *Journal of Hepato-Biliary-Pancreatic Surgery*. 2006; 13(3):190-3
895. Rana SS, Bhasin DK, Nanda M, Siyad I, Gupta R, Kang M et al. Endoscopic transpapillary drainage for external fistulas developing after surgical or radiological pancreatic interventions. *Journal of Gastroenterology and Hepatology*. 2010; 25(6):1087-92
896. Rana SS, Sharma V, Sharma R, Gupta R, Bhasin DK. Endoscopic ultrasound guided transmural drainage of walled off pancreatic necrosis using a "step - up" approach: A single centre experience. *Pancreatology*. 2017; 17(2):203-208
897. Rao CY, Hu CL, Zhao XY. Role of prophylactic antibiotics in the management of acute necrotizing pancreatitis: A meta-analysis. *World Chinese Journal of Digestology*. 2012; 20(14):1246-1251
898. Raptis SA, Ladas SD. Therapy of acute pancreatitis with somatostatin. *Scandinavian Journal of Gastroenterology Supplement*. 1994; 207:34-8
899. Raraty MG, Halloran CM, Dodd S, Ghaneh P, Connor S, Evans J et al. Minimal access retroperitoneal pancreatic necrosectomy: improvement in morbidity and mortality with a less invasive approach. *Annals of Surgery*. 2010; 251(5):787-93
900. Rasch S, Notzel B, Phillip V, Lahmer T, Schmid RM, Algul H. Management of pancreatic pseudocysts--A retrospective analysis. *PloS One*. 2017; Epublication

901. Rasch S, Phillip V, Reichel S, Rau B, Zapf C, Rosendahl J et al. Open surgical versus minimal invasive necrosectomy of the pancreas-a retrospective multicenter analysis of the german pancreatitis study group. *PloS One*. 2016; 11(9):e0163651
902. Rau B, Bothe A, Beger HG. Surgical treatment of necrotizing pancreatitis by necrosectomy and closed lavage: Changing patient characteristics and outcome in a 19-year, single-center series. *Surgery*. 2005; 138(1):28-39
903. Rau B, Uhl W, Buchler MW, Beger HG. Surgical treatment of infected necrosis. *World Journal of Surgery*. 1997; 21(2):155-61
904. Ray S, Ghatak S, Das K, Dasgupta J, Ray S, Khamrui S et al. Surgical management of benign biliary stricture in chronic pancreatitis: A single-center experience. *Indian Journal of Surgery*. 2015; 77(Suppl 2):608-13
905. Rebibo L, Yzet T, Cosse C, Delcenserie R, Bartoli E, Regimbeau JM. Frey procedure for the treatment of chronic pancreatitis associated with common bile duct stricture. *Hepatobiliary & Pancreatic Diseases International*. 2013; 12(6):637-644
906. Regimbeau JM, Fuks D, Bartoli E, Fumery M, Hanes A, Yzet T et al. A comparative study of surgery and endoscopy for the treatment of bile duct stricture in patients with chronic pancreatitis. *Surgical Endoscopy and Other Interventional Techniques*. 2012; 26(10):2902-2908
907. Reid GP, Williams EW, Francis DK, Lee MG. Acute pancreatitis: A 7 year retrospective cohort study of the epidemiology, aetiology and outcome from a tertiary hospital in Jamaica. *Annals of Medicine and Surgery*. 2017; 20:103-108
908. Repiso Ortega A, Gomez-Rodriguez R, Romero M, Fernandez-Zapardiel S, Del Mar Cespedes M, Carrobles JM. Prospective comparison of endoscopic ultrasonography and magnetic resonance cholangiopancreatography in the etiological diagnosis of "idiopathic" acute pancreatitis. *Pancreas*. 2011; 40(2):289-294
909. Reszetow J, Dobrowolski S, Smoczynski M. Pancreatic ascites - Surgical approach. *Polski Przegląd Chirurgiczny*. 2006; 78(12):1474-1482
910. Ridgeway MG, Stabile BE. Surgical management and treatment of pancreatic fistulas. *Surgical Clinics of North America*. 1996; 76(5):1159-73
911. Ridolfi C, Angiolini MR, Gavazzi F, Spaggiari P, Tinti MC, Uccelli F et al. Morphohistological features of pancreatic stump are the main determinant of pancreatic fistula after pancreatoduodenectomy. *BioMed Research International*. 2014; 2014:641239
912. Riediger H, Adam U, Fischer E, Keck T, Pfeffer F, Hopt UT et al. Long-term outcome after resection for chronic pancreatitis in 224 patients. *Journal of Gastrointestinal Surgery*. 2007; 11(8):949-59; discussion 959-60
913. Rische S, Riecken B, Degenkolb J, Kayser T, Caca K. Transmural endoscopic necrosectomy of infected pancreatic necroses and drainage of infected pseudocysts: A tailored approach. *Scandinavian Journal of Gastroenterology*. 2013; 48(2):231-240
914. Roberts KJ, Sheridan M, Morris-Stiff G, Smith AM. Pancreaticopleural fistula: Etiology, treatment and long-term follow-up. *Hepatobiliary & Pancreatic Diseases International*. 2012; 11(2):215-9
915. Rocca R, De Angelis C, Castellino F, Masoero G, Daperno M, Sostegni R et al. EUS diagnosis and simultaneous endoscopic retrograde cholangiography treatment of common bile duct

- stones by using an oblique-viewing echoendoscope. *Gastrointestinal Endoscopy*. 2006; 63(3):479-484
916. Rocha FG, Benoit E, Zinner MJ, Whang EE, Banks PA, Ashley SW et al. Impact of radiologic intervention on mortality in necrotizing pancreatitis the role of organ failure. *Archives of Surgery*. 2009; 144(3):261-265
917. Rockey DC, Cello JP. Pancreaticopleural fistula: Report of 7 patients and review of the literature. *Medicine*. 1990; 69(6):332-344
918. Roeyen G, Jansen M, Chapelle T, Bracke B, Hartman V, Ysebaert D et al. Diabetes mellitus and pre-diabetes are frequently undiagnosed and underreported in patients referred for pancreatic surgery. A prospective observational study. *Pancreatology*. 2016; 16(4):671-6
919. Røkke O, Harbitz TB, Liljedal J, Pettersen T, Fetvedt T, Heen L et al. Early treatment of severe pancreatitis with imipenem: A prospective randomized clinical trial. *Scandinavian Journal of Gastroenterology*. 2007; 42(6):771-6
920. Rolston RK, Kant JA. Genetic testing in acute and chronic pancreatitis. *Current Gastroenterology Reports*. 2001; 3(2):115-120
921. Romagnuolo J, Guda N, Freeman M, Durkalski V. Preferred designs, outcomes, and analysis strategies for treatment trials in idiopathic recurrent acute pancreatitis. *Gastrointestinal Endoscopy*. 2008; 68(5):966-974
922. Rosch T, Daniel S, Scholz M, Huibregtse K, Smits M, Schneider T et al. Endoscopic treatment of chronic pancreatitis: A multicenter study of 1000 patients with long-term follow-up. *Endoscopy*. 2002; 34(10):765-71
923. Rosenberg A, Steensma EA, Napolitano LM. Necrotizing pancreatitis: New definitions and a new era in surgical management. *Surgical Infections*. 2015; 16(1):1-13
924. Ross AS, Irani S, Gan SI, Rocha F, Siegal J, Fotoohi M et al. Dual-modality drainage of infected and symptomatic walled-off pancreatic necrosis: Long-term clinical outcomes. *Gastrointestinal Endoscopy*. 2014; 79(6):929-35
925. Rubenstein JN, Parsons WG, Kim SC, Weiser AC, Loor MM, Kube DS et al. Extracorporeal shock wave lithotripsy of pancreatic duct stones using the Healthtronics LithoTron lithotripter and the Dornier HM3 lithotripsy machine. *Journal of Urology*. 2002; 167(2 Pt 1):485-7
926. Rupasinghe SN, Siriwardena AK. Long-term outcome of patients with chronic pancreatitis treated with micronutrient antioxidant therapy. *Hepatobiliary & Pancreatic Diseases International*. 2017; 16(2):209-214
927. Russell KW, Barnhart DC, Madden J, Leeflang E, Jackson WD, Feola GP et al. Non-operative treatment versus percutaneous drainage of pancreatic pseudocysts in children. *Pediatric Surgery International*. 2013; 29(3):305-10
928. Rustagi T, Njei B. Antioxidant therapy for pain reduction in patients with chronic pancreatitis: A systematic review and meta-analysis. *Pancreas*. 2015; 44(5):812-8
929. Ruxer J, Mozdzan M, Loba J, Barański M, Ruxer M, Markuszewski L. Usefulness of continuous glucose monitoring system in detection of hypoglycaemic episodes in patients with diabetes in course of chronic pancreatitis. *Polskie Archiwum Medycyny Wewnętrznej*. 2012; 114(4):953-957

930. Ryu CH, Kim MH, Lee SS, Park DH, Seo DW, Lee SK. Temporary placement of fully covered self-expandable metal stents in benign biliary strictures. *Korean Journal of Gastroenterology*. 2013; 62(1):49-54
931. Safari MT, Miri MB, Ebadi S, Shahrokh S, Alizadeh AHM. Comparing the roles of EUS, ERCP and MRCP in idiopathic acute recurrent pancreatitis. *Clinical Medicine Insights: Gastroenterology*. 2016; 9:35-39
932. Safdi M, Bekal PK, Martin S, Saeed ZA, Burton F, Toskes PP. The effects of oral pancreatic enzymes (Creon 10 capsule) on steatorrhea: A multicenter, placebo-controlled, parallel group trial in subjects with chronic pancreatitis. *Pancreas*. 2006; 33(2):156-62
933. Saftoiu A, Vilmann P, Gorunescu F, Janssen J, Hocke M, Larsen M et al. Accuracy of endoscopic ultrasound elastography used for differential diagnosis of focal pancreatic masses: A multicenter study. *Endoscopy*. 2011; 43(7):596-603
934. Sagi SV, Schmidt S, Fogel E, Lehman GA, McHenry L, Sherman S et al. Association of greater intravenous volume infusion with shorter hospitalization for patients with post-ERCP pancreatitis. *Journal of Gastroenterology and Hepatology*. 2014; 29(6):1316-20
935. Sahai AV, Wyse J. EUS-guided celiac plexus block for chronic pancreatitis: a placebo-controlled trial should be the first priority. *Gastrointestinal Endoscopy*. 2010; 71(2):430-431
936. Sahai AV, Zimmerman M, Aabakken L, Tarnasky PR, Cunningham JT, Van Velse A et al. Prospective assessment of the ability of endoscopic ultrasound to diagnose, exclude, or establish the severity of chronic pancreatitis found by endoscopic retrograde cholangiopancreatography. *Gastrointestinal Endoscopy*. 1998; 48(1):18-25
937. Sahel J, Bastid C, Pellat B, Schurgers P, Sarles H. Endoscopic cystoduodenostomy of cysts of chronic calcifying pancreatitis: A report of 20 cases. *Pancreas*. 1987; 2(4):447-53
938. Sai JK, Suyama M, Kubokawa Y, Watanabe S. Diagnosis of mild chronic pancreatitis (Cambridge classification): Comparative study using secretin injection-magnetic resonance cholangiopancreatography and endoscopic retrograde pancreatography. *World Journal of Gastroenterology*. 2008; 14(8):1218-1221
939. Sainani NI, Kadiyala V, Morteale K, Lee L, Suleiman S, Rosenblum J et al. Evaluation of qualitative magnetic resonance imaging features for diagnosis of chronic pancreatitis. *Pancreas*. 2015; 44(8):1280-1289
940. Sainio V, Kemppainen E, Puolakkainen P, Taavitsainen M, Kivisaari L, Valtonen V et al. Early antibiotic treatment in acute necrotising pancreatitis. *Lancet*. 1995; 346(8976):663-7
941. Sakai Y, Tsuyuguchi T, Ishihara T, Yukisawa S, Sugiyama H, Miyakawa K et al. Long-term prognosis of patients with endoscopically treated postoperative bile duct stricture and bile duct stricture due to chronic pancreatitis. *Journal of Gastroenterology and Hepatology*. 2009; 24(7):1191-1197
942. Salim AS. Role of oxygen-derived free radical scavengers in the treatment of recurrent pain produced by chronic pancreatitis. A new approach. *Archives of Surgery*. 1991; 126(9):1109-14
943. Saluja SS, Kalayarsan R, Mishra PK, Srivastava S, Chandrasekar S, Godhi S. Chronic pancreatitis with benign biliary obstruction: Management issues. *World Journal of Surgery*. 2014; 38(9):2455-2459

944. Samokhvalov AV, Rehm J, Roerecke M. Alcohol consumption as a risk factor for acute and chronic pancreatitis: A systematic review and a series of meta-analyses. *EBioMedicine*. 2015; 2(12):1996-2002
945. Samuelson A, Zeligman B, Russ P, Austin GL, Yen R, Shah RJ. Pancreatic duct changes in patients with chronic pancreatitis treated with polyethylene and sof-flex material stents: A blinded comparison. *Pancreas*. 2016; 45(2):281-285
946. Sanchez A, Ramirez de la Piscina P, Duca IM, Estrada S, Salvador M, Campos A et al. Right pleural effusion secondary to a pancreaticopleural fistula in a patient with asymptomatic chronic pancreatitis. *Gastroenterología y Hepatología*. 2016; 39(8):529-531
947. Sand J, Lankisch PG, Nordback I. Alcohol consumption in patients with acute or chronic pancreatitis. *Pancreatology*. 2007; 7(2-3):147-56
948. Santos MA, Bose PS, Maher S, Desai M. Chylous ascites: An unusual complication of necrotizing pancreatitis. *American Journal of Medicine*. 2017; 31:31
949. Santosh D, Lakhtakia S, Gupta R, Reddy DN, Rao GV, Tandan M et al. Clinical trial: a randomized trial comparing fluoroscopy guided percutaneous technique vs. endoscopic ultrasound guided technique of coeliac plexus block for treatment of pain in chronic pancreatitis. *Alimentary Pharmacology and Therapeutics*. 2009; 29(9):979-84
950. Sarfeh IJ, Rypins EB, Jakowatz JG, Juler GL. A prospective, randomized clinical investigation of cholecystoenterostomy and choledochenterostomy. *American Journal of Surgery*. 1988; 155(3):411-4
951. Sarkaria S, Sethi A, Rondon C, Lieberman M, Srinivasan I, Weaver K et al. Pancreatic necrosectomy using covered esophageal stents: A novel approach. *Journal of Clinical Gastroenterology*. 2014; 48(2):145-152
952. Sarles H, Johnson CD. Alcoholic pancreatitis. *European Journal of Gastroenterology and Hepatology*. 1990; 2(6):422-425
953. Sato A, Irisawa A, Bhutani MS, Shibukawa G, Yamabe A, Fujisawa M et al. Significance of normal appearance on endoscopic ultrasonography in the diagnosis of early chronic pancreatitis. *Endoscopic Ultrasound*. 2017; Epublication
954. Saul A, Ramirez Luna MA, Chan C, Uscanga L, Valdovinos Andraca F, Hernandez Calleros J et al. EUS-guided drainage of pancreatic pseudocysts offers similar success and complications compared to surgical treatment but with a lower cost. *Surgical Endoscopy*. 2016; 30(4):1459-65
955. Sawai H, Okada Y, Funahashi H, Matsuo Y, Yamamoto M, Tanaka M et al. Surgical treatment for relief of severe pain with chronic pancreatitis that is resistant to conservative treatment. *Hepato-Gastroenterology*. 2006; 53(69):438-41
956. Saxena P, Diehl DL, Kumbhari V, Shieh F, Buscaglia JM, Sze W et al. A us multicenter study of safety and efficacy of fully covered self-expandable metallic stents in benign extrahepatic biliary strictures. *Digestive Diseases and Sciences*. 2015; 60(11):3442-3448
957. Schenker S, Montalvo R. Alcohol and the pancreas. *Recent Developments in Alcoholism*. 1998; 14:41-65
958. Schepers NJ, Bakker OJ, Besselink MG, Bollen TL, Dijkgraaf MG, Eijck CH et al. Early biliary decompression versus conservative treatment in acute biliary pancreatitis (APEC trial): Study protocol for a randomized controlled trial. *Trials*. 2017; 17:5

959. Schepers NJ, Besselink MG, van Santvoort HC, Bakker OJ, Bruno MJ, Dutch Pancreatitis Study G. Early management of acute pancreatitis. *Best Practice & Research: Clinical Gastroenterology*. 2013; 27(5):727-43
960. Schlaudraff E, Wagner HJ, Klose KJ, Heverhagen JT. Prospective evaluation of the diagnostic accuracy of secretin-enhanced magnetic resonance cholangiopancreatography in suspected chronic pancreatitis. *Magnetic Resonance Imaging*. 2008; 26(10):1367-1373
961. Schlosser W, Siech M, Gorich J, Beger HG. Common bile duct stenosis in complicated chronic pancreatitis. *Scandinavian Journal of Gastroenterology*. 2001; 36(2):214-219
962. Schmidt CM, Choi J, Powell ES, Yiannoutsos CT, Zyromski NJ, Nakeeb A et al. Pancreatic fistula following pancreaticoduodenectomy: Clinical predictors and patient outcomes. *HPB Surgery*. 2009; 2009:404520
963. Schneider A, Singer MV. Alcoholic pancreatitis. *Digestive Diseases*. 2005; 23(3-4):222-31
964. Schnelldorfer T, Adams DB. Outcome after lateral pancreaticojejunostomy in patients with chronic pancreatitis associated with pancreas divisum. *American Surgeon*. 2003; 69(12):1041-1044
965. Schofield D, Kay PM, Bottiglieri T, Uden S, Bilton D, Braganza JM. Placebo-controlled clinical trials of antioxidant therapy (AOT) in patients with recurrent non-gallstone pancreatitis: Essentiality of methionine plus ascorbate. *International Journal of Pancreatology*. 1994; 16(23):329
966. Schrader H, Menge BA, Zeidler C, Ritter PR, Tannapfel A, Uhl W et al. Determinants of glucose control in patients with chronic pancreatitis. *Diabetologia*. 2010; 53(6):1062-9
967. Schrover IM, Weusten BLAM, Besselink MGH, Bollen TL, Van Ramshorst B, Timmer R. EUS-guided endoscopic transgastric necrosectomy in patients with infected necrosis in acute pancreatitis. *Pancreatology*. 2008; 8(3):271-276
968. Schutz SM, Baillie J. Another treatment option for biliary strictures from chronic pancreatitis. *American Journal of Gastroenterology*. 1995; 90(6):1023-4
969. Schwarz M, Isenmann R, Meyer H, Beger HG. Antibiotic use in necrotizing pancreatitis. Results of a controlled study. *Deutsche Medizinische Wochenschrift*. 1997; 122(12):356-61
970. Schweigert M, Renz M, Dubecz A, Solymosi N, Ofner D, Stein HJ. Pancreaticopleural fistula-induced empyema thoracis: Principles and results of surgical management. *Thoracic and Cardiovascular Surgeon*. 2013; 61(7):619-25
971. Schweigert M, Solymosi N, Dubecz A, Ofner D, Stein HJ. Length of nonoperative treatment and risk of pleural empyema in the management of pancreatitis-induced pancreaticopleural fistula. *American Surgeon*. 2013; 79(6):614-9
972. Seewald S, Groth S, Omar S, Imazu H, Seitz U, De Weerth A et al. Aggressive endoscopic therapy for pancreatic necrosis and pancreatic abscess: A new safe and effective treatment algorithm (videos). *Gastrointestinal Endoscopy*. 2005; 62(1):92-100
973. Segarra-Newnham M, Geber JM. Antibiotic prophylaxis in acute necrotizing pancreatitis. *Journal of Pharmacy Technology*. 1998; 14(6):245-248
974. Segarra-Newnham M, Hough A. Antibiotic prophylaxis in acute necrotizing pancreatitis revisited. *Annals of Pharmacotherapy*. 2009; 43(9):1486-95

975. Seicean A, Badea R, Stan-luga R, Gulei I, Pop T, Pascu O. The added value of real-time harmonics contrast-enhanced endoscopic ultrasonography for the characterisation of pancreatic diseases in routine practice. *Journal of Gastrointestinal and Liver Diseases*. 2010; 19(1):99-104
976. Seifert H, Biermer M, Schmitt W, Jurgensen C, Will U, Gerlach R et al. Transluminal endoscopic necrosectomy after acute pancreatitis: A multicentre study with long-term follow-up (the GEPARD Study). *Gut*. 2009; 58(9):1260-1266
977. Seven G, Schreiner MA, Ross AS, Lin OS, Gluck M, Gan SI et al. Long-term outcomes associated with pancreatic extracorporeal shock wave lithotripsy for chronic calcific pancreatitis. *Gastrointestinal Endoscopy*. 2012; 75(5):997-1004.e1
978. Seza K, Yamaguchi T, Ishihara T, Tadenema H, Tawada K, Saisho H et al. A long-term controlled trial of endoscopic pancreatic stenting for treatment of main pancreatic duct stricture in chronic pancreatitis. *Hepato-Gastroenterology*. 2011; 58(112):2128-31
979. Shah N, Siriwardena AK. Cytokine profiles in patients receiving antioxidant therapy within the ANTICIPATE trial. *World Journal of Gastroenterology*. 2013; 19(25):4001-6
980. Shah NS, Makin AJ, Sheen AJ, Siriwardena AK. Quality of life assessment in patients with chronic pancreatitis receiving antioxidant therapy. *World Journal of Gastroenterology*. 2010; 16(32):4066-71
981. Shao D, Zhuang Y, Xu F, Chen JP. Endoscopic sphincterotomy plus balloon dilation for large bile duct stones: An analysis of 80 cases. *World Chinese Journal of Digestology*. 2012; 20(12):1057-60
982. Sharma SS, Bhargawa N, Govil A. Endoscopic management of pancreatic pseudocyst: A long-term follow-up. *Endoscopy*. 2002; 34(3):203-7
983. Sharma V, Rana SS, Sharma R, Chaudhary V, Gupta R, Bhasin DK. Naso-jejunal fluid resuscitation in predicted severe acute pancreatitis: Randomized comparative study with intravenous Ringer's lactate. *Journal of Gastroenterology and Hepatology*. 2016; 31(1):265-9
984. Sharma VK, Howden CW. Prophylactic antibiotic administration reduces sepsis and mortality in acute necrotizing pancreatitis: A meta-analysis. *Pancreas*. 2001; 22(1):28-31
985. Shaygan-Nejad A, Masjedizadeh AR, Ghavidel A, Ghojazadeh M, Khoshbaten M. Aggressive hydration with Lactated Ringer's solution as the prophylactic intervention for postendoscopic retrograde cholangiopancreatography pancreatitis: A randomized controlled double-blind clinical trial. *Journal of Research in Medical Sciences*. 2015; 20(9):838-43
986. Shen QX, Xu GX, Shen MH. Effect of early enteral nutrition (EN) on endotoxin in serum and intestinal permeability in patients with severe acute pancreatitis. *European Review for Medical and Pharmacological Sciences*. 2017; 21(11):2764-2768
987. Shen Y, Deng X, Jin W, Zhang C, Zhang X, Wang Y. Effect of pharmaconutrition-supplemented parenteral nutrition for severe acute pancreatitis: A meta-analysis of randomized controlled trials. *Journal of the Pancreas*. 2014; 15(4):371-377
988. Shen Y, Liu M, Chen M, Li Y, Lu Y, Zou X. Covered metal stent or multiple plastic stents for refractory pancreatic ductal strictures in chronic pancreatitis: A systematic review. *Pancreatology*. 2014; 14(2):87-90

989. Shenvi S, Gupta R, Kang M, Khullar M, Rana SS, Singh R et al. Timing of surgical intervention in patients of infected necrotizing pancreatitis not responding to percutaneous catheter drainage. *Pancreatology*. 2016; 16(5):778-787
990. Sheridan MB. Endoscopic retrograde cholangiopancreatography should no longer be used as a diagnostic test: The case in favour. *Digestive and Liver Disease*. 2002; 34(5):370-374
991. Sherman S. Idiopathic acute pancreatitis: role of ERCP in diagnosis and therapy. *ASGE Clinical Update*. 2004; 12(1):1-4
992. Shimizu T, Suzuki R, Yamashiro Y, Segawa O, Yamataka A, Kuwatsuru R. Magnetic resonance cholangiopancreatography in assessing the cause of acute pancreatitis in children. *Pancreas*. 2001; 22(2):196-9
993. Shrikhande SV, Kleeff J, Friess H, Buchler MW. Management of pain in small duct chronic pancreatitis. *Journal of Gastrointestinal Surgery*. 2006; 10(2):227-33
994. Sikora SS, Khare R, Srikanth G, Kumar A, Saxena R, Kapoor VK. External pancreatic fistula as a sequel to management of acute severe necrotizing pancreatitis. *Digestive Surgery*. 2005; 22(6):446-51; discussion 452
995. Simmons MZ, Miller JA, Zurlo JV, Levine CD. Pleural effusions associated with acute pancreatitis: Incidence and appearance based on computed tomography. *Emergency Radiology*. 1997; 4(5):287-289
996. Singh A, Chen M, Li T, Yang XL, Li JZ, Gong JP. Parenteral nutrition combined with enteral nutrition for severe acute pancreatitis. *ISRN Gastroenterology*. 2012; 2012:791383
997. Singh N, Sharma B, Sharma M, Sachdev V, Bhardwaj P, Mani K et al. Evaluation of early enteral feeding through nasogastric and nasojejunal tube in severe acute pancreatitis: A noninferiority randomized controlled trial. *Pancreas*. 2012; 41(1):153-9
998. Singh RP, Vrakas G, Hayek S, Hayek S, Anam S, Aqueel M et al. Clinically significant peripancreatic fluid collections after simultaneous pancreas-kidney transplantation. *Transplantation*. 2013; 95(10):1263-9
999. Singh VK, Gardner TB, Papachristou GI, Rey-Riveiro M, Faghieh M, Koutroumpakis E et al. An international multicenter study of early intravenous fluid administration and outcome in acute pancreatitis. *United European Gastroenterology Journal*. 2017; 5(4):491-498
1000. Siow E. Enteral versus parenteral nutrition for acute pancreatitis. *Critical Care Nurse*. 2008; 28(4):19-25, 27-2531; quiz 32
1001. Siriwardena AK, Mason JM, Sheen AJ, Makin AJ, Shah NS. Antioxidant therapy does not reduce pain in patients with chronic pancreatitis: The ANTICIPATE study. *Gastroenterology*. 2012; 143(3):655-63.e1
1002. Sisman G, Tugcu M, Ayla K, Sebati O, Senturk H. Mutation analysis of PRSS1, SPINK1 and CFTR gene in patients with alcoholic and idiopathic chronic pancreatitis: A single center study. *Turkish Journal of Gastroenterology*. 2015; 26(2):176-80
1003. Skipworth JR, Raptis DA, Wijesuriya S, Puthuchery Z, Olde Damink SW, Imber C et al. The use of nasojejunal nutrition in patients with chronic pancreatitis. *Journal of the Pancreas*. 2011; 12(6):574-80
1004. Slaff J, Jacobson D, Tillman CR, Curington C, Toskes P. Protease-specific suppression of pancreatic exocrine secretion. *Gastroenterology*. 1984; 87(1):44-52

1005. Slavin J, Neoptolemos JP. Antibiotic prophylaxis in severe acute pancreatitis--what are the facts? *Langenbecks Archives of Surgery*. 2001; 386(2):155-9
1006. Smith I, Ramesh J, Kyanam Kabir Baig KR, Monkemuller K, Wilcox CM. Emerging role of endoscopic ultrasound in the diagnostic evaluation of idiopathic pancreatitis. *American Journal of the Medical Sciences*. 2015; 350(3):229-234
1007. Smits ME, Rauws EA, Tytgat GN, Huibregtse K. The efficacy of endoscopic treatment of pancreatic pseudocysts. *Gastrointestinal Endoscopy*. 1995; 42(3):202-7
1008. Smits ME, Rauws EAJ, Van Gulik TM, Gouma DJ, Tytgat GNJ, Huibregtse K. Long-term results of endoscopic stenting and surgical drainage for biliary stricture due to chronic pancreatitis. *British Journal of Surgery*. 1996; 83(6):764-768
1009. Smoczynski M, Marek I, Dubowik M, Rompa G, Pienkowska J. Endoscopic treatment of external pancreatic fistulas. *Gastroenterologia Polska*. 2007; 14(3):191-195
1010. Solanki R, Thumma V, Sastry RA, Bheerappa N. The role of image guided percutaneous drainage in multidisciplinary management of necrotizing pancreatitis. *Tropical Gastroenterology*. 2013; 34(1):25-30
1011. Songur Y, Oguz D, Gurkaynak G, Demirci F, Sahin B. Endoscopic ultrasonography and endoscopic retrograde pancreatography in the diagnosis of chronic pancreatitis. *Digestive Endoscopy*. 2000; 12(1):37-41
1012. Soran A, Col C, Kocer B, Chelluri L, Lee KKW, Aydin D et al. Can the outcome of acute pancreatitis be improved in intensive care unit?: A collaborative study. *Turkish Journal of Gastroenterology*. 2001; 12(3):223-227
1013. Sorrentino L, Chiara O, Mutignani M, Sammartano F, Brioschi P, Cimbanassi S. Combined totally mini-invasive approach in necrotizing pancreatitis: a case report and systematic literature review. *World Journal of Emergency Surgery*. 2017; 12:16
1014. Spanier BW, Mathus-Vliegen EM, Tuynman HA, Van der Hulst RW, Dijkgraaf MG, Bruno MJ et al. Nutritional management of patients with acute pancreatitis: a Dutch observational multicentre study. *Alimentary Pharmacology and Therapeutics*. 2008; 28(9):1159-65
1015. Spanier BWM, Dijkgraaf MGW, Bruno MJ. Epidemiology, aetiology and outcome of acute and chronic pancreatitis: An update. *Best Practice & Research: Clinical Gastroenterology*. 2008; 22(1):45-63
1016. Spicak J. Antibiotic prophylaxis in large pancreatic necrosis: multicentre randomized trial with ciprofloxacin and metronidazole or meropenem. *Gastroenterology*. 2004; 2004(126):A-229
1017. Spicak J, Hejtmankova S, Hubaczova M, Antos F, Bartova J, Cech P et al. Antibiotic prophylaxis of infectious complications of acute pancreatitis - the results of randomised study by meropenem. *Ceska a Slovenska Gastroenterologie a Hepatologie*. 2003; 57(6):222-7
1018. Spicak J, Hubaczova M, Antos F, Bartova J, Cech P, Kasalicky M et al. Antibiotics in the treatment of acute pancreatitis - Findings from a randomized multi-centre prospective study. *Ceska a Slovenska Gastroenterologie a Hepatologie*. 2002; 56(5):183-9
1019. Srikanth G, Sikora SS, Baijal SS, Ayyagiri A, Kumar A, Saxena R et al. Pancreatic abscess: 10 years experience. *ANZ Journal of Surgery*. 2002; 72(12):881-6
1020. Sriskandarajah S, Carter-Storch R, Frydkjaer-Olsen U, Mogensen CB. High diagnostic value of general practitioners' presumptive diagnosis for pyelonephritis, meningitis and pancreatitis. *Danish Medical Journal*. 2016; 63(1):A5181

1021. Staahl C, Dimcevski G, Andersen SD, Thorsgaard N, Christrup LL, Arendt-Nielsen L et al. Differential effect of opioids in patients with chronic pancreatitis: An experimental pain study. *Scandinavian Journal of Gastroenterology*. 2007; 42(3):383-90
1022. Stabuc B, Drobne D, Ferkolj I, Gruden A, Jereb J, Kolar G et al. Acute biliary pancreatitis: Detection of common bile duct stones with endoscopic ultrasound. *European Journal of Gastroenterology and Hepatology*. 2008; 20(12):1171-1175
1023. Stanga Z, Giger U, Marx A, DeLegge MH. Effect of jejunal long-term feeding in chronic pancreatitis. *Journal of Parenteral & Enteral Nutrition*. 2005; 29(1):12-20
1024. Stefaniak T, Vingerhoets A, Makarewicz W, Kaska L, Kobiela J, Kwiecinska B et al. Opioid use determines success of videothoracoscopic splanchnicectomy in chronic pancreatic pain patients. *Langenbecks Archives of Surgery*. 2008; 393(2):213-8
1025. Stevens T, Costanzo A, Lopez R, Kapural L, Parsi MA, Vargo JJ. Adding triamcinolone to endoscopic ultrasound-guided celiac plexus blockade does not reduce pain in patients with chronic pancreatitis. *Clinical Gastroenterology and Hepatology*. 2012; 10(2):186-91, 191.e1
1026. Stevens T, Dumot JA, Parsi MA, Zuccaro G, Vargo JJ. Combined endoscopic ultrasound and secretin endoscopic pancreatic function test in patients evaluated for chronic pancreatitis. *Digestive Diseases and Sciences*. 2010; 55(9):2681-7
1027. Stevens T, Zuccaro G, Dumot JA, Vargo JJ, Parsi MA, Lopez R et al. Prospective comparison of radial and linear endoscopic ultrasound for diagnosis of chronic pancreatitis. *Endoscopy*. 2009; 41(10):836-841
1028. Stimac D, Poropat G, Hauser G, Licul V, Franjic N, Valkovic Zujic P et al. Early nasojejunal tube feeding versus nil-by-mouth in acute pancreatitis: A randomized clinical trial. *Pancreatology*. 2016; 16(4):523-8
1029. Strate T, Bachmann K, Busch P, Mann O, Schneider C, Bruhn JP et al. Resection vs drainage in treatment of chronic pancreatitis: Long-term results of a randomized trial. *Gastroenterology*. 2008; 134(5):1406-11
1030. Strate T, Busch P, Bruhn JP, Mann O, Schurr P, Bloechle C. Organ preservation or resection in chronic pancreatitis long-term results of a randomised study (Frey versus pylorus preserving Whipple). *Zeitschrift für Gastroenterologie*. 2006; 44(8):888-9
1031. Strate T, Knoefel WT, Yekebas E, Izbicki JR. Chronic pancreatitis: Etiology, pathogenesis, diagnosis, and treatment. *International Journal of Colorectal Disease*. 2003; 18(2):97-106
1032. Strate T, Taherpour Z, Bloechle C, Mann O, Bruhn JP, Schneider C et al. Beger versus Frey as organ-retaining therapy options in chronic pancreatitis - Long-term results of a randomised study. *Zeitschrift für Gastroenterologie*. 2005; 43(8):986-7
1033. Strum WB. Abstinence in alcoholic chronic pancreatitis. Effect on pain and outcome. *Journal of Clinical Gastroenterology*. 1995; 20(1):37-41
1034. Suc B, Escat J, Cherqui D, Fourtanier G, Hay JM, Fingerhut A et al. Surgery vs endoscopy as primary treatment in symptomatic patients with suspected common bile duct stones. A multicenter randomized trial. *Archives of Surgery*. 1998; 133(7):702-708
1035. Suc B, Msika S, Piccinini M, Fourtanier G, Hay JM, Flamant Y et al. Octreotide in the prevention of intra-abdominal complications following elective pancreatic resection: A prospective, multicenter randomized controlled trial. *Archives of Surgery*. 2004; 139(3):288-294

1036. Sudo T, Murakami Y, Uemura K, Hashimoto Y, Kondo N, Nakagawa N et al. Short- and long-term results of lateral pancreaticojejunostomy for chronic pancreatitis: A retrospective Japanese single-center study. *Journal of Hepato-Biliary-Pancreatic Sciences*. 2014; 21(6):426-432
1037. Sugimoto M, Takahashi S, Kobayashi T, Kojima M, Gotohda N, Satake M et al. Pancreatic perfusion data and post-pancreaticoduodenectomy outcomes. *Journal of Surgical Research*. 2015; 194(2):441-449
1038. Sugito K, Furuya T, Kaneda H, Masuko T, Ohashi K, Inoue M et al. Long-term follow-up of nutritional status, pancreatic function, and morphological changes of the pancreatic remnant after pancreatic tumor resection in children. *Pancreas*. 2012; 41(4):554-9
1039. Sugiyama M, Atomi Y. Acute biliary pancreatitis: The roles of endoscopic ultrasonography and endoscopic retrograde cholangiopancreatography. *Surgery*. 1998; 124(1):14-21
1040. Sugiyama M, Haradome H, Atomi Y. Magnetic resonance imaging for diagnosing chronic pancreatitis. *Journal of Gastroenterology*. 2007; 42(Suppl 17):108-112
1041. Sugumar A, Levy MJ, Kamisawa T, Webster GJ, G JMW, Kim MH et al. Endoscopic retrograde pancreatography criteria to diagnose autoimmune pancreatitis: an international multicentre study. *Gut*. 2011; 60(5):666-70
1042. Sukharamwala PB, Patel KD, Teta AF, Parikh S, Ross SB, Ryan CE et al. Long-term outcomes favor duodenum-preserving pancreatic head resection over pylorus-preserving pancreaticoduodenectomy for chronic pancreatitis: A meta-analysis and systematic review. *American Surgeon*. 2015; 81(9):909-14
1043. Sun B, Gao Y, Xu J, Zhou XL, Zhou ZQ, Liu C et al. Role of individually staged nutritional support in the management of severe acute pancreatitis. *Hepatobiliary & Pancreatic Diseases International*. 2004; 3(3):458-63
1044. Sun JK, Li WQ, Ke L, Tong ZH, Ni HB, Li G et al. Early enteral nutrition prevents intra-abdominal hypertension and reduces the severity of severe acute pancreatitis compared with delayed enteral nutrition: A prospective pilot study. *World Journal of Surgery*. 2013; 37(9):2053-60
1045. Sun JK, Mu XW, Li WQ, Tong ZH, Li J, Zheng SY. Effects of early enteral nutrition on immune function of severe acute pancreatitis patients. *World Journal of Gastroenterology*. 2013; 19(6):917-22
1046. Sun Y, Lu ZH, Zhang XS, Geng XP, Cao LJ, Yin L. The effects of fluid resuscitation according to PiCCO on the early stage of severe acute pancreatitis. *Pancreatology*. 2015; 15(5):497-502
1047. Swidnicka-Siergiejko A, Wereszczynska-Siemiakowska U, Dajbrowski A. The efficacy of different modes of antibiotic prophylaxis in the prevention of complications in severe acute pancreatitis. *Gastroenterologia Polska*. 2007; 14(3):179-183
1048. Symersky T, van Hoorn B, Masclee AAM. The outcome of a long-term follow-up of pancreatic function after recovery from acute pancreatitis. *Journal of the Pancreas*. 2006; 7(5):447-453
1049. Szabo FK, Fei L, Cruz LA, Abu-El-Haija M. Early enteral nutrition and aggressive fluid resuscitation are associated with improved clinical outcomes in acute pancreatitis. *Journal of Pediatrics*. 2015; 167(2):397-402.e1

1050. Szczygiel B, Pertkiewicz M, Wojcik Z. Lipid-associated total parenteral nutrition in the treatment of severe acute pancreatitis. *Journal of Clinical Nutrition and Gastroenterology*. 1991; 6(4):203-213
1051. Szeliga J, Jackowski M. Minimally invasive procedures in severe acute pancreatitis treatment - Assessment of benefits and possibilities of use. *Wideochirurgia I Inne Techniki Maloinwazyjne*. 2014; 9(2):170-8
1052. Tahir M, Mahmood Z, Imran M, Javed MA. Management of biliary and pancreatic fistulae by fistulojejunosomy. *Pakistan Journal of Medical and Health Sciences*. 2011; 5(3):487-488
1053. Tajima Y, Tsutsumi R, Kuroki T, Mishima T, Adachi T, Kitasato A et al. Evaluation and management of thoracopancreatic fistula. *Surgery*. 2006; 140(5):773-8
1054. Takuma K, Kamisawa T, Tabata T, Inaba Y, Egawa N, Igarashi Y. Short-term and long-term outcomes of autoimmune pancreatitis. *European Journal of Gastroenterology and Hepatology*. 2011; 23(2):146-52
1055. Talar-Wojnarowska R, Wozniak B, Pazurek M, Malecka-Panas E. Outcome of pseudocysts complicating chronic pancreatitis. *Hepato-Gastroenterology*. 2010; 57(99-100):631-4
1056. Talukdar R, Ingale P, Choudhury HP, Dhingra R, Shetty S, Joshi H et al. Antibiotic use in acute pancreatitis: An Indian multicenter observational study. *Indian Journal of Gastroenterology*. 2014; 33(5):458-65
1057. Talukdar R, Lakhtakia S, Nageshwar Reddy D, Rao GV, Pradeep R, Banerjee R et al. Ameliorating effect of antioxidants and pregabalin combination in pain recurrence after ductal clearance in chronic pancreatitis: Results of a randomized, double blind, placebo-controlled trial. *Journal of Gastroenterology and Hepatology*. 2016; 31(9):1654-62
1058. Talukdar R, Murthy HV, Reddy DN. Role of methionine containing antioxidant combination in the management of pain in chronic pancreatitis: A systematic review and meta-analysis. *Pancreatology*. 2015; 15(2):136-44
1059. Talukdar R, Swaroop Vege S. Early management of severe acute pancreatitis. *Current Gastroenterology Reports*. 2011; 13(2):123-30
1060. Tanaka M, Matsumoto I, Shinzeki M, Asari S, Goto T, Yamashita H et al. Short- and long-term results of modified Frey's procedure in patients with chronic pancreatitis: A retrospective Japanese single-center study. *Kobe Journal of Medical Sciences*. 2014; 60(2):E30-E36
1061. Tanaka T, Kuroki T, Kitasato A, Adachi T, Ono S, Hirabaru M et al. Endoscopic transpapillary pancreatic stenting for internal pancreatic fistula with the disruption of the pancreatic ductal system. *Pancreatology*. 2013; 13(6):621-4
1062. Tandan M, Nageshwar Reddy D, Santosh D, Vinod K, Ramchandani M, Rajesh G et al. Extracorporeal shock wave lithotripsy and endotherapy for pancreatic calculi-a large single center experience. *Indian Journal of Gastroenterology*. 2010; 29(4):143-8
1063. Tao Y, Tang C, Feng W, Bao Y, Yu H. Early nasogastric feeding versus parenteral nutrition in severe acute pancreatitis: A retrospective study. *Pakistan Journal of Medical Sciences*. 2016; 32(6):1517-1521
1064. Targarona EM, Ayuso RM, Bordas JM, Ros E, Pros I, Martinez J et al. Randomised trial of endoscopic sphincterotomy with gallbladder left in situ versus open surgery for common bile duct calculi in high-risk patients. *Lancet*. 1996; 347(9006):926-9

1065. Targarona Modena J, Barreda Cevalco L, Arroyo Basto C, Orellana Vicuna A, Portanova Ramirez M. Total enteral nutrition as prophylactic therapy for pancreatic necrosis infection in severe acute pancreatitis. *Pancreatology*. 2006; 6(1-2):58-64
1066. Tazelaar JP, Kant JA. Genetic testing in chronic pancreatitis. *Expert Review of Molecular Diagnostics*. 2003; 3(6):799-809
1067. Teh SH, Pham TH, Lee A, Stavlo PL, Hanna AM, Moir C. Pancreatic pseudocyst in children: The impact of management strategies on outcome. *Journal of Pediatric Surgery*. 2006; 41(11):1889-93
1068. Teich N, Aghdassi A, Fischer J, Walz B, Caca K, Wallochny T et al. Optimal timing of oral refeeding in mild acute pancreatitis: Results of an open randomized multicenter trial. *Pancreas*. 2010; 39(7):1088-92
1069. Tenner S, Baillie J, Dewitt J, Vege SS. American college of gastroenterology guideline: Management of acute pancreatitis. *American Journal of Gastroenterology*. 2013; 108(9):1400-1415
1070. Testoni PA. Acute recurrent pancreatitis: Etiopathogenesis, diagnosis and treatment. *World Journal of Gastroenterology*. 2014; 20(45):16891-16901
1071. Thomson A. Enteral versus parenteral nutritional support in acute pancreatitis: A clinical review. *Journal of Gastroenterology and Hepatology*. 2006; 21(1 Pt 1):22-5
1072. Thorat V, Reddy N, Bhatia S, Bapaye A, Rajkumar JS, Kini DD et al. Randomised clinical trial: the efficacy and safety of pancreatin enteric-coated minimicrospheres (Creon 40000 MMS) in patients with pancreatic exocrine insufficiency due to chronic pancreatitis--a double-blind, placebo-controlled study. *Alimentary Pharmacology and Therapeutics*. 2012; 36(5):426-36
1073. Toh SKC, Phillips S, Johnson CD. A prospective audit against national standards of the presentation and management of acute pancreatitis in the south of England. *Gut*. 2000; 46(2):239-243
1074. Tong Z, Li W, Yu W, Geng Y, Ke L, Nie Y et al. Percutaneous catheter drainage for infective pancreatic necrosis: Is it always the first choice for all patients? *Pancreas*. 2012; 41(2):302-5
1075. Toouli J, Brooke-Smith M, Bassi C, Carr-Locke D, Telford J, Freeny P et al. Guidelines for the management of acute pancreatitis. *Journal of Gastroenterology and Hepatology*. 2002; 17(Suppl 1):S15-S39
1076. Trespi E, Vecchi P, Vigoni R, Venturini A, Bottani L. Effects of Buprenorphine and Tramadol on recurrent pain and gastrointestinal transit time in patients with chronic pancreatitis. *Italian Journal of Gastroenterology and Hepatology*. 1997; 29(Suppl 1):A25
1077. Trevino JM, Tamhane A, Varadarajulu S. Successful stenting in ductal disruption favorably impacts treatment outcomes in patients undergoing transmural drainage of peripancreatic fluid collections. *Journal of Gastroenterology and Hepatology*. 2010; 25(3):526-31
1078. Trikudanathan G, Navaneethan U, Vege SS. Current controversies in fluid resuscitation in acute pancreatitis: A systematic review. *Pancreas*. 2012; 41(6):827-34
1079. Trikudanathan G, Vega-Peralta J, Malli A, Munigala S, Han Y, Bellin M et al. Diagnostic performance of Endoscopic Ultrasound (EUS) for Non-Calcific Chronic Pancreatitis (NCCP) based on histopathology. *American Journal of Gastroenterology*. 2016; 111(4):568-574
1080. Trikudanathan G, Walker SP, Munigala S, Spilseth B, Malli A, Han Y et al. Diagnostic performance of contrast-enhanced MRI with secretin-stimulated mrCP for non-calcific

- chronic pancreatitis: A comparison with histopathology. *American Journal of Gastroenterology*. 2015; 110(11):1598-1606
1081. Tsiotos GG, Sarr MG. Management of fluid collections and necrosis in acute pancreatitis. *Current Gastroenterology Reports*. 1999; 1(2):139-44
1082. Tsiotos GG, Smith CD, Sarr MG. Incidence and management of pancreatic and enteric fistulas after surgical management of severe necrotizing pancreatitis. *Archives of Surgery*. 1995; 130(1):48-52
1083. Uchikov AP, Shipkov HD, Markova DI. Pleural effusions in acute pancreatitis. *Folia Medica*. 2000; 42(3):34-6
1084. Uden S, Bilton D, Nathan L, Hunt LP, Main C, Braganza JM. Antioxidant therapy for recurrent pancreatitis: placebo-controlled trial. *Alimentary Pharmacology and Therapeutics*. 1990; 4(4):357-71
1085. Uden S, Main C. Placebo-controlled double-blind trial of antioxidant supplements in patients with recurrent pancreatitis. *Clin-sci*. 1989; 77 (Suppl 21):26-27
1086. Uden S, Schofield D, Miller PF, Day JP, Bottiglier T, Braganza JM. Antioxidant therapy for recurrent pancreatitis: biochemical profiles in a placebo-controlled trial. *Alimentary Pharmacology and Therapeutics*. 1992; 6(2):229-40
1087. Ukai T, Shikata S, Inoue M, Noguchi Y, Igarashi H, Isaji S et al. Early prophylactic antibiotics administration for acute necrotizing pancreatitis: A meta-analysis of randomized controlled trials. *Journal of Hepato-biliary-pancreatic Sciences*. 2015; 22(4):316-21
1088. Usatoff V, Brancatisano R, Williamson RC. Operative treatment of pseudocysts in patients with chronic pancreatitis. *British Journal of Surgery*. 2000; 87(11):1494-9
1089. Uskudar O, Oguz D, Akdogan M, Altiparmak E, Sahin B. Comparison of endoscopic retrograde cholangiopancreatography, endoscopic ultrasonography, and fecal elastase 1 in chronic pancreatitis and clinical correlation. *Pancreas*. 2009; 38(5):503-506
1090. Vallance AE, Wilson CH, Charnley RM. Minimal access drainage procedures for patients with necrotising pancreatitis. *Cochrane Database of Systematic Reviews* 2014, Issue 6. Art. No.: CD011081. DOI: 10.1002/14651858.CD011081.
1091. van Baal MC, van Santvoort HC, Bollen TL, Bakker OJ, Besselink MG, Gooszen HG et al. Systematic review of percutaneous catheter drainage as primary treatment for necrotizing pancreatitis. *British Journal of Surgery*. 2011; 98(1):18-27
1092. van Berkel AM, Cahen DL, van Westerlo DJ, Rauws EAJ, Huibregtse K, Bruno MJ. Self-expanding metal stents in benign biliary strictures due to chronic pancreatitis. *Endoscopy*. 2004; 36(5):381-384
1093. Van Boeckel PGA, Vleggaar FP, Siersema PD. Plastic or metal stents for benign extrahepatic biliary strictures: A systematic review. *BMC Gastroenterology*. 2009; 9 96
1094. van Brunschot S, Bakker OJ, Besselink MG, Bollen TL, Fockens P, Gooszen HG et al. Treatment of necrotizing pancreatitis. *Clinical Gastroenterology and Hepatology*. 2012; 10(11):1190-1201
1095. van Brunschot S, Fockens P, Bakker OJ, Besselink MG, Voermans RP, Poley JW et al. Endoscopic transluminal necrosectomy in necrotising pancreatitis: A systematic review. *Surgical Endoscopy and Other Interventional Techniques*. 2014; 28(5):1425-1438

1096. van Brunschot S, Hollemans RA, Bakker OJ, Besselink MG, Baron TH, Beger HG et al. Minimally invasive and endoscopic versus open necrosectomy for necrotising pancreatitis: a pooled analysis of individual data for 1980 patients. *Gut*. 2017; Epublication
1097. van Brunschot S, van Grinsven J, van Santvoort HC, Bakker OJ, Besselink MG, Boermeester MA et al. Endoscopic or surgical step-up approach for infected necrotising pancreatitis: a multicentre randomised trial. *Lancet*. 2017; 391(10115):51-58
1098. van Brunschot S, van Grinsven J, Voermans RP, Bakker OJ, Besselink MGH, Boermeester MA et al. Transluminal endoscopic step-up approach versus minimally invasive surgical step-up approach in patients with infected necrotising pancreatitis (TENSION trial): Design and rationale of a randomised controlled multicenter trial [ISRCTN09186711]. *BMC Gastroenterology*. 2013; 13:161
1099. Van Grinsven J, Timmerman P, Van Lienden KP, Haveman JW, Boerma D, Van Eijck CHJ et al. Proactive versus standard percutaneous catheter drainage for infected necrotizing pancreatitis. *Pancreas*. 2017; 46(4):518-523
1100. Van Grinsven J, Van Santvoort HC, Boermeester MA, Dejong CH, Van Eijck CH, Fockens P et al. Timing of catheter drainage in infected necrotizing pancreatitis. *Nature Reviews Gastroenterology and Hepatology*. 2016; 13(5):306-312
1101. Van Santvoort HC, Bakker OJ, Bollen TL, Besselink MG, Ahmed Ali U, Schrijver AM et al. A conservative and minimally invasive approach to necrotizing pancreatitis improves outcome. *Gastroenterology*. 2011; 141(4):1254-1263
1102. Van Santvoort HC, Besselink MG, Bakker OJ, Hofker HS, Boermeester MA, Dejong CH et al. A step-up approach or open necrosectomy for necrotizing pancreatitis. *New England Journal of Medicine*. 2010; 362(16):1491-1502
1103. Van Santvoort HC, Besselink MG, Bollen TL, Buskens E, Van Ramshorst B, Gooszen HG. Case-matched comparison of the retroperitoneal approach with laparotomy for necrotizing pancreatitis. *World Journal of Surgery*. 2007; 31(8):1635-1642
1104. Vansonnenberg E, Wittich GR, Chon KS, D'Agostino HB, Casola G, Easter D et al. Percutaneous radiologic drainage of pancreatic abscesses. *American Journal of Roentgenology*. 1997; 168(4):979-984
1105. Vantini I, Piubeilo W, Chioffi L, Fioretta A, Maso R, Talamini G et al. Oral citrate in chronic pancreatitis. *International Journal of Pancreatology*. 1990; 7(4):379
1106. Varadarajulu S, Bang JY, Sutton BS, Trevino JM, Christein JD, Wilcox CM. Equal efficacy of endoscopic and surgical cystogastrostomy for pancreatic pseudocyst drainage in a randomized trial. *Gastroenterology*. 2013; 145(3):583-90.e1
1107. Varadarajulu S, Lopes TL, Wilcox CM, Drelichman ER, Kilgore ML, Christein JD. EUS versus surgical cyst-gastrostomy for management of pancreatic pseudocysts. *Gastrointestinal Endoscopy*. 2008; 68(4):649-55
1108. Varadarajulu S, Wilcox CM, Latif S, Phadnis M, Christein JD. Management of pancreatic fluid collections: a changing of the guard from surgery to endoscopy. *American Surgeon*. 2011; 77(12):1650-5
1109. Varadarajulu S, Wilcox CM, Tamhane A, Eloubeidi MA, Blakely J, Canon CL. Role of EUS in drainage of peripancreatic fluid collections not amenable for endoscopic transmural drainage. *Gastrointestinal Endoscopy*. 2007; 66(6):1107-19

1110. Vaughn VM, Shuster D, Rogers MAM, Mann J, Conte ML, Saint S et al. Early versus delayed feeding in patients with acute pancreatitis: A systematic review. *Annals of Internal Medicine*. 2017; 166(12):883-892
1111. Velamati PG, Herlong HF. Treatment of refractory ascites. *Current Treatment Options in Gastroenterology*. 2006; 9(6):530-537
1112. Velanovich V, Kheibek T, Khan M. Relationship of postoperative complications from preoperative biliary stents after pancreaticoduodenectomy. A new cohort analysis and meta-analysis of modern studies. *Journal of the Pancreas*. 2009; 10(1):24-29
1113. Verhaegh BP, van Kleef M, Geurts JW, Puylaert M, van Zundert J, Kessels AG et al. Percutaneous radiofrequency ablation of the splanchnic nerves in patients with chronic pancreatitis: Results of single and repeated procedures in 11 patients. *Pain Practice*. 2013; 13(8):621-6
1114. Villatoro E, Bassi C, Larvin M. Antibiotic therapy for prophylaxis against infection of pancreatic necrosis in acute pancreatitis. *Cochrane Database of Systematic Reviews* 2003, Issue 4. Art. No.: CD002941. DOI: 10.1002/14651858.CD002941.
1115. Villatoro E, Mulla M, Larvin M. Antibiotic therapy for prophylaxis against infection of pancreatic necrosis in acute pancreatitis. *Cochrane Database of Systematic Reviews* 2010, Issue 5. Art. No.: CD002941. DOI: 10.1002/14651858.CD002941.pub3.
1116. Vitale GC, Reed Jr DN, Nguyen CT, Lawhon JC, Larson GM. Endoscopic treatment of distal bile duct stricture from chronic pancreatitis. *Surgical Endoscopy*. 2000; 14(3):227-231
1117. Vitas GJ, Sarr MG. Selected management of pancreatic pseudocysts: Operative versus expectant management. *Surgery*. 1992; 111(2):123-30
1118. Vitkomb D, Maleska-Panas E, Lekhman G, Vasil'eva N, Gubergrits N, Karas S et al. Efficacy and safety of pancrealipase delayed-release capsules (Creon) in patients with pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery. *Experimental & Clinical Gastroenterology*. 2010; (3):65-70
1119. Voermans RP, Veldkamp MC, Rauws EA, Bruno MJ, Fockens P. Endoscopic transmural debridement of symptomatic organized pancreatic necrosis (with videos). *Gastrointestinal Endoscopy*. 2007; 66(5):909-916
1120. Voss M, Ali A, Eubanks WS, Pappas TN. Surgical management of pancreaticocutaneous fistula. *Journal of Gastrointestinal Surgery*. 2003; 7(4):542-546
1121. Vries AC, Besselink MGH, Buskens E, Ridwan BU, Schipper M, Van Erpecum KJ et al. Randomized controlled trials of antibiotic prophylaxis in severe acute pancreatitis: Relationship between methodological quality and outcome. *Pancreatology*. 2007; 7(5-6):531-8
1122. Vue PM, McFann K, Narkewicz MR. Genetic mutations in pediatric pancreatitis. *Pancreas*. 2016; 45(7):992-6
1123. Wagh MS, Chavalitdhamrong D, Moezardalan K, Chauhan SS, Gupte AR, Nosler MJ et al. Effectiveness and safety of endoscopic treatment of benign biliary strictures using a new fully covered self expandable metal stent. *Diagnostic and Therapeutic Endoscopy*. 2013; 2013:183513
1124. Wakefield S, Tutty B, Britton J. Pancreaticopleural fistula: A rare complication of chronic pancreatitis. *Postgraduate Medical Journal*. 1996; 72(844):115-116

1125. Waldthaler A, Schutte K, Weigt J, Kropf S, Malfertheiner P, Kahl S. Long-term outcome of self expandable metal stents for biliary obstruction in chronic pancreatitis. *Journal of the Pancreas*. 2013; 14(1):57-62
1126. Wall I, Badalov N, Baradarian R, Iswara K, Li JJ, Tenner S. Decreased mortality in acute pancreatitis related to early aggressive hydration. *Pancreas*. 2011; 40(4):547-50
1127. Walter D, Laleman W, Jansen JM, Van Milligen De Wit AWM, Weusten BL, Van Boeckel PG et al. A fully covered self-expandable metal stent with antimigration features for benign biliary strictures: A prospective, multicenter cohort study. *Gastrointestinal Endoscopy*. 2015; 81(5):1197-1203
1128. Walter D, Van Boeckel PGA, Groenen MJ, Weusten BLAM, Witteman BJ, Tan G et al. Cost Efficacy of Metal Stents for Palliation of Extrahepatic Bile Duct Obstruction in a Randomized Controlled Trial. *Gastroenterology*. 2015; 149(1):130-138
1129. Wang C, Zhao X, You S. Efficacy of the prophylactic use of octreotide for the prevention of complications after pancreatic resection: An updated systematic review and meta-analysis of randomized controlled trials. *Medicine*. 2017; 96(29):e7500
1130. Wang MD, Ji Y, Xu J, Jiang DH, Luo L, Huang SW. Early goal-directed fluid therapy with fresh frozen plasma reduces severe acute pancreatitis mortality in the intensive care unit. *Chinese Medical Journal*. 2013; 126(10):1987-8
1131. Wang W, Liao Z, Li ZS, Shi XG, Wang LW, Liu F et al. Chronic pancreatitis in Chinese children: Etiology, clinical presentation and imaging diagnosis. *Journal of Gastroenterology and Hepatology*. 2009; 24(12):1862-1868
1132. Wang W, Sun XT, Weng XL, Zhou DZ, Sun C, Xia T et al. Comprehensive screening for PRSS1, SPINK1, CFTR, CTSC and CLDN2 gene mutations in Chinese paediatric patients with idiopathic chronic pancreatitis: a cohort study. *BMJ Open*. 2013; 3:e003150
1133. Wang YP, Li DB, Dong CL, Wu XA. Antibiotic prophylaxis in severe acute pancreatitis: a systematic review *Chinese Journal of Evidence-Based Medicine*. 2012; 12(4):477-483
1134. Warndorf MG, Kurtzman JT, Bartel MJ, Cox M, Mackenzie T, Robinson S et al. Early fluid resuscitation reduces morbidity among patients with acute pancreatitis. *Clinical Gastroenterology and Hepatology*. 2011; 9(8):705-9
1135. Wasan SM, Ross WA, Staerckel GA, Lee JH. Use of expandable metallic biliary stents in resectable pancreatic cancer. *American Journal of Gastroenterology*. 2005; 100(9):2056-61
1136. Weber A, Zellner S, Wagenpfeil S, Schneider J, Gerngross C, Baur DM et al. Long-term follow-up after endoscopic stent therapy for benign biliary strictures. *Journal of Clinical Gastroenterology*. 2014; 48(1):88-93
1137. Weigt J, Kandulski A, Malfertheiner P. Anatomy-shaped design of a fully-covered, biliary, self-expandable metal stent for treatment of benign distal biliary strictures. *Endoscopy International Open*. 2016; 4(1):E79-E82
1138. Weinberg L, Wong D, Karalapillai D, Pearce B, Tan CO, Tay S et al. The impact of fluid intervention on complications and length of hospital stay after pancreaticoduodenectomy (Whipple's procedure). *BMC Anesthesiology*. 2014; 14 35
1139. Weitz G, Woitalla J, Wellhoner P, Schmidt K, Buning J, Fellermann K. Detrimental effect of high volume fluid administration in acute pancreatitis - a retrospective analysis of 391 patients. *Pancreatology*. 2014; 14(6):478-83

1140. Wejnarska K, Kolodziejczyk E, Ryzko J, Oracz G. Comparison of 72-hour fecal fat quantification and the ¹³C-mixed triglyceride breath test in assessing pancreatic exocrine sufficiency in children with chronic pancreatitis. *Medycyna Wieku Rozwojowego*. 2016; 20(3):222-227
1141. Weniger M, D'Haese JG, Angele MK, Kleespies A, Werner J, Hartwig W. Treatment options for chylous ascites after major abdominal surgery: A systematic review *American Journal of Surgery*. 2016; 211(1):206-213
1142. Wereszczynska-Siemiakowska U, Swidnicka-Siergiejko A, Siemiakowski A, Dabrowski A. Early enteral nutrition is superior to delayed enteral nutrition for the prevention of infected necrosis and mortality in acute pancreatitis. *Pancreas*. 2013; 42(4):640-646
1143. Wilcox CM, Seay T, Kim H, Varadarajulu S. Prospective endoscopic ultrasound-based approach to the evaluation of idiopathic pancreatitis: causes, response to therapy, and long-term outcome. *American Journal of Gastroenterology*. 2016; 111(9):1339-1348
1144. Wilder-Smith CH, Hill L, Oshir W, O'Keefe S. Effect of tramadol and morphine on pain and gastrointestinal motor function in patients with chronic pancreatitis. *Digestive Diseases and Sciences*. 1999; 44(6):1107-1116
1145. Will U, Fuedner F, Thieme AK, Goldmann B, Gerlach R, Wanzar I et al. Transgastric pancreatography and EUS-guided drainage of the pancreatic duct. *Journal of Hepato-Biliary-Pancreatic Surgery*. 2007; 14(4):377-82
1146. Will U, Wanzar C, Gerlach R, Meyer F. Interventional ultrasound-guided procedures in pancreatic pseudocysts, abscesses and infected necroses - treatment algorithm in a large single-center study. *Ultraschall in der Medizin*. 2011; 32(2):176-83
1147. Will U, Wegener C, Graf KI, Wanzar I, Manger T, Meyer F. Differential treatment and early outcome in the interventional endoscopic management of pancreatic pseudocysts in 27 patients. *World Journal of Gastroenterology*. 2006; 12(26):4175-8
1148. Williams KJ, Fabian TC. Pancreatic pseudocyst: recommendations for operative and nonoperative management. *American Surgeon*. 1992; 58(3):199-205
1149. Windsor AC, Kanwar S, Li AG, Barnes E, Guthrie JA, Spark JI et al. Compared with parenteral nutrition, enteral feeding attenuates the acute phase response and improves disease severity in acute pancreatitis. *Gut*. 1998; 42(3):431-5
1150. Winstead NS, Wilcox CM. Clinical trials of pancreatic enzyme replacement for painful chronic pancreatitis--a review. *Pancreatology*. 2009; 9(4):344-50
1151. Wittau M, Hohl K, Mayer J, Henne-Bruns D, Isenmann R. The weak evidence base for antibiotic prophylaxis in severe acute pancreatitis. *Hepato-Gastroenterology*. 2008; 55(88):2233-7
1152. Wittau M, Mayer B, Scheele J, Henne-Bruns D, Dellinger EP, Isenmann R. Systematic review and meta-analysis of antibiotic prophylaxis in severe acute pancreatitis. *Scandinavian Journal of Gastroenterology*. 2011; 46(3):261-270
1153. Witzigmann H, Max D, Uhlmann D, Geissler F, Schwarz R, Ludwig S et al. Outcome after duodenum-preserving pancreatic head resection is improved compared with classic Whipple procedure in the treatment of chronic pancreatitis. *Surgery*. 2003; 134(1):53-62
1154. Wlochal M, Swora-Cwynar E, Karczewski J, Grzymislawski M. Assessment of nutritional knowledge of patients with pancreatitis. *Przegląd Gastroenterologiczny*. 2015; 10(4):229-33

1155. Wolf JS, Jr., Nakada SY, Aliperti G, Edmundowicz SA, Clayman RV. Washington University experience with extracorporeal shock-wave lithotripsy of pancreatic duct calculi. *Urology*. 1995; 46(5):638-42
1156. Wolfsen HC, Kozarek RA, Ball TJ, Patterson DJ, Traverso LW, Freeny PC. Pancreaticocenteric fistula: No longer a surgical disease? *Journal of Clinical Gastroenterology*. 1992; 14(2):117-21
1157. Wronski M, Cebulski W, Karkocha D, Slodkowski M, Wysocki L, Jankowski M et al. Ultrasound-guided percutaneous drainage of infected pancreatic necrosis. *Surgical Endoscopy and Other Interventional Techniques*. 2013; 27(8):2841-2848
1158. Wronski M, Slodkowski M, Cebulski W, Moronczyk D, Krasnodebski IW. Optimizing management of pancreaticopleural fistulas. *World Journal of Gastroenterology*. 2011; 17(42):4696-4703
1159. Wu BU. Editorial: Fluid resuscitation in acute pancreatitis: Striking the right balance. *American Journal of Gastroenterology*. 2011; 106(10):1851-1852
1160. Wu BU, Hwang JQ, Gardner TH, Repas K, Delee R, Yu S et al. Lactated Ringer's solution reduces systemic inflammation compared with saline in patients with acute pancreatitis. *Clinical Gastroenterology and Hepatology*. 2011; 9(8):710-717.e1
1161. Wu XM, Ji KQ, Wang HY, Li GF, Zang B, Chen WM. Total enteral nutrition in prevention of pancreatic necrotic infection in severe acute pancreatitis. *Pancreas*. 2010; 39(2):248-51
1162. Wu XM, Liao YW, Wang HY, Ji KQ, Li GF, Zang B. When to initialize enteral nutrition in patients with severe acute pancreatitis? A retrospective review in a single institution experience (2003-2013). *Pancreas*. 2015; 44(3):507-11
1163. Wyncoll DL. The management of severe acute necrotising pancreatitis: An evidence-based review of the literature. *Intensive Care Medicine*. 1999; 25(2):146-56
1164. Xiong GS, Wu SM, Wang ZH. Role of prophylactic antibiotic administration in severe acute pancreatitis: A meta-analysis. *Medical Principles and Practice*. 2006; 15(2):106-10
1165. Xu T, Cai Q. Prophylactic antibiotic treatment in acute necrotizing pancreatitis: Results from a meta-analysis. *Scandinavian Journal of Gastroenterology*. 2008; 43(10):1249-58
1166. Xu XF, Li JA, Lou WH. The impact of internal stenting of pancreatojejunostomy on the pancreatic fistula rate after pancreaticoduodenectomy. *American Surgeon*. 2014; 80(2):215-216
1167. Xue P, Deng LH, Zhang ZD, Yang XN, Wan MH, Song B et al. Effect of antibiotic prophylaxis on acute necrotizing pancreatitis: Results of a randomized controlled trial. *Journal of Gastroenterology and Hepatology*. 2009; 24(5):736-42
1168. Yaghoobi M, McNabb-Baltar J, Bijarchi R, Cotton PB. Pancreatic enzyme supplements are not effective for relieving abdominal pain in patients with chronic pancreatitis: meta-analysis and systematic review of randomized controlled trials. *Canadian Journal of Gastroenterology & Hepatology*. 2016; 2016:8541839
1169. Yamaguchi T, Ishihara T, Seza K, Nakagawa A, Sudo K, Tawada K et al. Long-term outcome of endoscopic metallic stenting for benign biliary stenosis associated with chronic pancreatitis. *World Journal of Gastroenterology*. 2006; 12(3):426-430
1170. Yanagisawa S, Fujinaga Y, Watanabe T, Maruyama M, Muraki T, Takahashi M et al. Usefulness of three-dimensional magnetic resonance cholangiopancreatography with partial maximum

- intensity projection for diagnosing autoimmune pancreatitis. *Pancreatology*. 2017; 17(4):567-571
1171. Yang D, Amin S, Gonzalez S, Mullady D, Hasak S, Gaddam S et al. Transpapillary drainage has no added benefit on treatment outcomes in patients undergoing EUS-guided transmural drainage of pancreatic pseudocysts: A large multicenter study. *Gastrointestinal Endoscopy*. 2016; 83(4):720-729
1172. Yang J, Huang Q, Lin XS, Liu CH, Xie F, Li RY. Endoscopic versus surgical treatment of chronic pancreatitis: A systematic review *World Chinese Journal of Digestology*. 2014; 2014(15):2183-2189
1173. Yang P, Feng KX, Luo H, Wang D, Hu ZH. Acute biliary pancreatitis treated by early endoscopic intervention. *Panminerva Medica*. 2012; 54(2):65-69
1174. Yang XN, Deng LH, Xue P, Zhao L, Jin T, Wan MH et al. Non-preventive use of antibiotics in patients with severe acute pancreatitis treated with integrated traditional Chinese and Western medicine therapy: A randomized controlled trial. *Zhong xi yi jie he xue bao [Journal of Chinese integrative medicine]*. 2009; 7(4):330-3
1175. Yanling N, Zhaoshen LI, Guoming XU, Xiaoping Z, Zhendong J. Endoscopic ultrasonography in the diagnosis of chronic pancreatitis. *Chinese Journal of Gastroenterology*. 2001; 6(3):151-152+155
1176. Yao L, Huang X, Li Y, Shi R, Zhang G. Prophylactic antibiotics reduce pancreatic necrosis in acute necrotizing pancreatitis: A meta-analysis of randomized trials. *Digestive Surgery*. 2010; 27(6):442-9
1177. Yi F, Ge L, Zhao J, Lei Y, Zhou F, Chen Z et al. Meta-analysis: Total parenteral nutrition versus total enteral nutrition in predicted severe acute pancreatitis. *Internal Medicine*. 2012; 51(6):523-30
1178. Yokoi Y, Kikuyama M, Kurokami T, Sato T. Early dual drainage combining transpapillary endotherapy and percutaneous catheter drainage in patients with pancreatic fistula associated with severe acute pancreatitis. *Pancreatology*. 2016; 16(4):497-507
1179. Zainutdinov AM, Malkov IS. Selective decontamination of the intestine and the interstitial electrophoresis in prevention and treatment of purulent complications in acute pancreatitis. *International Journal of Pharmacy and Technology*. 2016; 8(4):24572-24579
1180. Zambudio N, Muffak K, Villegas T, Becerra A, Fundora Y, Garrote D et al. Evidence-based management of pancreatitis. *Central European Journal of Medicine*. 2014; 9(4):594-600
1181. Zerem E, Imamovic G, Susic A, Haracic B. Step-up approach to infected necrotising pancreatitis: A 20-year experience of percutaneous drainage in a single centre. *Digestive and Liver Disease*. 2011; 43(6):478-483
1182. Zhan X, Guo X, Chen Y, Dong Y, Yu Q, Wang K et al. EUS in exploring the etiology of mild acute biliary pancreatitis with a negative finding of biliary origin by conventional radiological methods. *Journal of Gastroenterology and Hepatology*. 2011; 26(10):1500-1503
1183. Zhang MM, Cheng JQ, Lu YR, Yi ZH, Yang P, Wu XT. Use of pre-, pro- and synbiotics in patients with acute pancreatitis: A meta-analysis. *World Journal of Gastroenterology*. 2010; 16(31):3970-8

1184. Zhang SY, Liang ZY, Yu WQ, Wang ZE, Chen ZB, Zhang Y. Early enteral nutrition with polymeric feeds was associated with chylous ascites in patients with severe acute pancreatitis. *Pancreas*. 2014; 43(4):553-8
1185. Zhang XM, Shi H, Parker L, Dohke M, Holland GA, Mitchell DG. Suspected early or mild chronic pancreatitis: Enhancement patterns on gadolinium chelate dynamic MRI. *Journal of Magnetic Resonance Imaging*. 2003; 17(1):86-94
1186. Zhang YS, Shu XL, Zhong JX, Sheng Y, Meng BL. Total parenteral nutrition combined with enteral nutrition in treatment of severe acute pancreatitis. *Academic Journal of Second Military Medical University*. 2011; 32(7):737-40
1187. Zhao G, Wang CY, Wang F, Xiong JX. Clinical study on nutrition support in patients with severe acute pancreatitis. *World Journal of Gastroenterology*. 2003; 9(9):2105-8
1188. Zhao G, Zhang JG, Wu HS, Tao J, Qin Q, Deng SC et al. Effects of different resuscitation fluid on severe acute pancreatitis. *World Journal of Gastroenterology*. 2013; 19(13):2044-52
1189. Zhao XL, Zhu SF, Xue GJ, Li J, Liu YL, Wan MH et al. Early oral refeeding based on hunger in moderate and severe acute pancreatitis: A prospective controlled, randomized clinical trial. *Nutrition*. 2015; 31(1):171-5
1190. Zheng Y, Zhou Z, Li H, Li J, Li A, Ma B et al. A multicenter study on etiology of acute pancreatitis in Beijing during 5 years. *Pancreas*. 2015; 44(3):409-14
1191. Zhou D, Wang W, Cheng X, Wei J, Zheng S. Antioxidant therapy for patients with chronic pancreatitis: A systematic review and meta-analysis. *Clinical Nutrition*. 2015; 34(4):627-34
1192. Zhou J, Huang Z, Cheng L, Lin N, Liu W, Sun H et al. Abdominal paracentesis drainage (APD) attenuates acute pancreatitis-associated lung injury in patients with ascitic fluids: A retrospective study. *International Journal of Clinical and Experimental Medicine*. 2016; 9:18400-18409
1193. Zhou MQ, Li NP, Lu RD. Duodenoscopy in treatment of acute gallstone pancreatitis. *Hepatobiliary and Pancreatic Diseases International*. 2002; 1(4):608-10
1194. Zhou YM, Xue ZL, Li YM, Zhu YQ, Cao N. Antibiotic prophylaxis in patients with severe acute pancreatitis. *Hepatobiliary & Pancreatic Diseases International*. 2005; 4(1):23-7
1195. Zhu H, Jiang F, Zhu J, Du Y, Jin Z, Li Z. Assessment of morbidity and mortality associated with eus-guided fna for pancreatic cystic lesions: A system review and meta-analysis. *Digestive Endoscopy*. 2017; 29(6):667-675
1196. Zhu Y, Yin H, Zhang R, Ye X, Wei J. Nasogastric nutrition versus nasojejunal nutrition in patients with severe acute pancreatitis: A meta-analysis of randomized controlled trials. *Gastroenterology Research and Practice*. 2016; 2016:6430632
1197. Zou L, Ke L, Li W, Tong Z, Wu C, Chen Y et al. Enteral nutrition within 72 h after onset of acute pancreatitis vs delayed initiation. *European Journal of Clinical Nutrition*. 2014; 68(12):1288-93

© NICE 2018. All rights reserved. Subject to [Notice of rights](#).